

**NTP TECHNICAL REPORT**

**ON THE**

**TOXICOLOGY AND CARCINOGENESIS**

**STUDIES OF URETHANE, ETHANOL,**  
**AND URETHANE/ETHANOL**

**(URETHANE, CAS NO. 51-79-6; ETHANOL, CAS NO. 64-17-5)**

**IN B6C3F<sub>1</sub> MICE**

**(DRINKING WATER STUDIES)**

**Scheduled Peer Review Date: September 5, 2002**

**NOTICE**

This is a DRAFT Technical Report prepared for public review and comment. Until this DRAFT has been reviewed and approved by the NTP Board of Scientific Counselors' Technical Reports Review Subcommittee in public session, the interpretations described herein do not represent the official scientific position of the National Toxicology Program. Following peer review, readers should contact the NTP for the final version of this Technical Report.

**NTP TR 510**

**NIH Publication No. 02-4444**



**National Toxicology Program**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
**National Institutes of Health**

## FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. The interpretive conclusions presented in this Technical Report are based only on the results of these NTP studies. Extrapolation of these results to other species and quantitative risk analyses for humans require wider analyses beyond the purview of these studies. Selection *per se* is not an indicator of a chemical's carcinogenic potential.

Details about ongoing and completed NTP studies are available at the NTP's World Wide Web site: <http://ntp-server.niehs.nih.gov>. Abstracts of all NTP Technical Reports and full versions of the most recent reports and other publications are available from the NIEHS' Environmental Health Information Service (EHIS) <http://ehis.niehs.nih.gov> (800-315-3010 or 919-541-3841). In addition, printed copies of these reports are available from EHIS as supplies last.

**NTP TECHNICAL REPORT**

**ON THE**

**TOXICOLOGY AND CARCINOGENESIS**

**STUDIES OF URETHANE, ETHANOL,**  
**AND URETHANE/ETHANOL**

**(URETHANE, CAS NO. 51-79-6; ETHANOL, CAS NO. 64-17-5)**

**IN B6C3F<sub>1</sub> MICE**

**(DRINKING WATER STUDIES)**

**Scheduled Peer Review Date: September 5, 2002**

**NOTICE**

This is a DRAFT Technical Report prepared for public review and comment. Until this DRAFT has been reviewed and approved by the NTP Board of Scientific Counselors' Technical Reports Review Subcommittee in public session, the interpretations described herein do not represent the official scientific position of the National Toxicology Program. Following peer review, readers should contact the NTP for the final version of this Technical Report.

**NTP TR 510**

**NIH Publication No. 02-4444**



**National Toxicology Program**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
**National Institutes of Health**

## CONTRIBUTORS

The studies on urethane, ethanol, and urethane/ethanol were conducted at the FDA's National Center for Toxicological Research under an interagency agreement between the FDA and the NIEHS. The studies were designed and monitored by a Toxicology Study Selection and Review Committee, composed of representatives from the NCTR and other FDA product centers, NIEHS, and other *ad hoc* members from other government agencies and academia. The interagency agreement was designed to use the staff and facilities of the NCTR in testing of FDA priority chemicals and to provide FDA scientists and regulatory policymakers information for hazard identification and risk assessment.

### Toxicology Study Selection and Review Committee

J.R. Bucher, Ph.D., Chairperson  
National Institute of Environmental Health Sciences

D.A. Casciano, Ph.D., Chairperson  
National Center for Toxicological Research

W.T. Allaben, Ph.D., Vice Chairperson, Executive Secretary  
National Center for Toxicological Research

P.L. Chamberlain, D.V.M., Ph.D.  
Center for Veterinary Medicine, Food and Drug Administration

D.A. Dennis, Ph.D.  
Center for Food Safety and Applied Nutrition,  
Food and Drug Administration

J.K. Dunnick, Ph.D.  
National Institute of Environmental Health Sciences

J.G. Farrelly, Ph.D.  
Center for Devices and Radiological Health,  
Food and Drug Administration

P.D. Forbes, Ph.D.  
Charles River Laboratories

K.J. Greenlees, Ph.D.  
Center for Veterinary Medicine, Food and Drug Administration

R.J. Lorentzen, Ph.D.  
Center for Food Safety and Applied Nutrition,  
Food and Drug Administration

M.A. Miller, Ph.D.  
Office of Women's Health, Food and Drug Administration

R.R. Newbold  
National Institute of Environmental Health Sciences

M. Poirier, Ph.D.  
National Cancer Institute

F.D. Sistare, Ph.D.  
Center for Devices and Radiological Health,  
Food and Drug Administration

E.A. Yetley, Ph.D.  
Center for Food Safety and Applied Nutrition,  
Food and Drug Administration

W.G. Wamer  
Center for Food Safety and Applied Nutrition,  
Food and Drug Administration

### Bionetics

*Prepared animal feed and cared for mice*

J. Carson, B.S.  
J.H. Durrett, B.S.  
A. Matson, B.S.  
M. Moore  
M.L. Nichols  
E.S. Smith

### National Center for Toxicological Research, Food and Drug Administration

*Conducted studies, evaluated and interpreted results and pathology findings, and reported findings*

F.A. Beland, Ph.D., Study Scientist  
W.T. Allaben, Ph.D.  
J.R. Appleget, B.S.  
R.W. Benson, B.S.  
M.I. Churchwell, B.S.  
D.R. Doerge, Ph.D.  
J.-L. Fang, Ph.D.  
C.D. Jackson, Ph.D.  
R.L. Kodell, Ph.D.  
J.M. Reed, M.S.  
D.W. Roberts, Ph.D.  
K.L. Witt, M.S., ILS, Inc.  
W.M. Witt, D.V.M., Ph.D.

*Conducted chemical analyses of feed and water and purity of the agent*

W.M. Cooper, B.S.  
F.E. Evans, Ph.D.  
J.P. Freeman, Ph.D.  
T.A. Gehring, B.S.  
T.M. Heinze, M.S.  
P.H. Siitonen, B.S.

**Pathology Associates International**

*Evaluated pathology findings*

P.W. Mellick, D.V.M., Ph.D.

R.M. Kovatch, D.V.M.

**Experimental Pathology Laboratories, Inc.**

*Provided pathology quality assurance*

J.F. Hardisty, D.V.M., Principal Investigator

C.C. Shackelford, D.V.M., M.S., Ph.D.

**NTP Pathology Working Group**

*Evaluated slides and prepared pathology report  
(January 23-24, 2001)*

C.C. Shackelford, D.V.M., M.S., Ph.D., Chairperson  
Experimental Pathology Laboratories, Inc.

J.R. Hailey, D.V.M.  
National Toxicology Program

J.F. Hardisty, D.V.M.  
Experimental Pathology Laboratories, Inc.

R.A. Herbert, D.V.M., Ph.D.  
National Toxicology Program

R.M. Kovatch, D.V.M.  
Pathology Associates International

P.W. Mellick, D.V.M., Ph.D.  
Pathology Associates International

J.M. Ward, D.V.M., Ph.D.  
National Cancer Institute

**R.O.W. Sciences, Inc.**

*Provided experimental support and statistical analyses*

J. Armstrong, B.S.

M. Austen, M.S.

D.L. Barton, M.S.

B. Bryant

K. Carroll

X. Ding, M.S.

S. Goldman

J.M. Gossett, M.S.

C.C. McCarty, B.S.

W.A. McCracken, M.S.

B. Spadoni

B.T. Thorn, M.S.

**Biotechnical Services, Inc.**

*Prepared Technical Report*

S.R. Gunnels, M.A., Principal Investigator

L.M. Harper, B.S.

D.C. Serbus, Ph.D.

R.A. Willis, B.A., B.S.


# CONTENTS

|   |  |            |
|---|--|------------|
| <b>ABSTRACT</b>   |  | <b>7</b>   |
| <b>EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY</b> |  | <b>16</b>  |
| <b>TECHNICAL REPORTS REVIEW SUBCOMMITTEE</b>                      |  | <b>17</b>  |
| <b>SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS</b>  |  | <b>18</b>  |
| <b>INTRODUCTION</b>   |  | <b>19</b>  |
| <b>MATERIALS AND METHODS</b>                                      |  | <b>35</b>  |
| <b>RESULTS</b>  |  | <b>51</b>  |
| <b>DISCUSSION AND CONCLUSIONS</b>                                 |  | <b>109</b> |
| <b>REFERENCES</b>   |  | <b>123</b> |
| <b>APPENDIX A</b>   | <b>Summary of Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b>   | <b>A-1</b> |
| <b>APPENDIX B</b>   | <b>Summary of Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol</b>                 | <b>B-1</b> |
| <b>APPENDIX C</b>   | <b>Summary of Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol</b>                   | <b>C-1</b> |
| <b>APPENDIX D</b>   | <b>Summary of Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b> | <b>D-1</b> |
| <b>APPENDIX E</b>   | <b>Summary of Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol</b>               | <b>E-1</b> |
| <b>APPENDIX F</b>   | <b>Summary of Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol</b>                 | <b>F-1</b> |
| <b>APPENDIX G</b>   | <b>4-Week Study Results</b>  | <b>G-1</b> |
| <b>APPENDIX H</b>   | <b>Organ Weights and Organ-Weight-to-Body-Weight Ratios</b>  | <b>H-1</b> |
| <b>APPENDIX I</b>   | <b>Chemical Characterization and Dose Formulation Studies</b>  | <b>I-1</b> |
| <b>APPENDIX J</b>   | <b>Water and Urethane Consumption in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b>    | <b>J-1</b> |
| <b>APPENDIX K</b>   | <b>Feed Consumption in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b>                  | <b>K-1</b> |

|                   |   |            |
|-------------------|---|------------|
| <b>APPENDIX L</b> | <b>Ingredients, Nutrient Composition, and Contaminant Levels<br/>in NIH-31 Rat and Mouse Ration .....</b> | <b>L-1</b> |
| <b>APPENDIX M</b> | <b>Sentinel Animal Program .....</b>  | <b>M-1</b> |



## ABSTRACT




### URETHANE

CAS No. 51-79-6

Chemical Formula:  $C_3H_7NO_2$       Molecular Weight: 89.09

**Synonyms:** Carbamic acid ethyl ester; ethyl carbamate; ethylurethan; ethyl urethan; ethyl urethane; leucothane; pracobamin; urethan



### ETHANOL

CAS No. 64-17-5

Chemical Formula:  $C_2H_6O$       Molecular Weight: 46.07

**Synonyms:** Ethyl alcohol; ethyl hydrate; ethyl hydroxide; absolute alcohol; anhydrous alcohol; dehydrated alcohol; grain alcohol

Urethane (ethyl carbamate) is produced commercially for use in the preparation and modification of amino resins and as a cosolvent during the manufacture of pesticides, fumigants, and cosmetics. It has also been used as a chemical intermediate in the textile industry to impart wash and wear properties to fabrics, as a cosolvent with drugs, and, for a brief period, as an antineoplastic agent for the treatment of chronic leukemia and multiple myeloma. The major source of human exposure to urethane is from fermented foods and beverages. Urethane in combination with ethanol was nominated by the U.S. Food and Drug Administration for in-depth toxicological evaluation by the NTP because of the widespread exposure to urethane in alcoholic beverages and a lack of adequate dose-response carcinogenicity data to conduct meaningful risk assessments. Male and female B6C3F<sub>1</sub> mice were exposed to urethane (99% pure) and/or ethanol (92.6% ethanol, 7.4% water) in drinking water for 4 weeks or 2 years.

#### 4-WEEK MECHANISTIC STUDY

Groups of four male and four female mice were exposed to 0, 10, 30, or 90 ppm urethane in the presence of 0%, 2.5%, or 5% ethanol in drinking water *ad libitum* for 4 weeks. Concentrations of 10, 30, and 90 ppm urethane resulted in average daily consumption of approximately 35, 110, and 315  $\mu\text{g}$  urethane for males and 30, 80, and 245  $\mu\text{g}$  for females. Concentrations of 2.5% and 5% ethanol resulted in average daily consumption of approximately 85 and 170 mg ethanol for males and 70 and 130 mg for females. Liver and lung samples were collected for cell proliferation and apoptosis analyses. Additional groups of four male and four female mice were sacrificed after 4 weeks of exposure; liver and lung samples were collected for induction of glutathione, cytochromes P450 and P450 2E1, and DNA adduct formation, and blood was collected for measurement of urethane and ethanol serum concentrations.

Terminal group mean body weights were not affected by either urethane or ethanol. Increasing the urethane concentration had no effect on water consumption by mice. Increasing the ethanol concentration caused a significant decrease in water consumption by males and a significant ethanol-by-urethane interaction in males. Increasing the ethanol concentration caused a significant exposure-related decrease in feed consumption by males.

Urethane was detected in the serum of mice exposed to 30 or 90 ppm urethane and 5% ethanol; ethanol was not detected in any of the samples. The percentage of hepatocytes in the  $G_0$  phase was decreased and the percentage in the  $G_1$  phase was increased in females exposed to 30 or 90 ppm urethane; this effect was independent of the ethanol concentration. The percent of PCNA-labeling was decreased in the lung of mice exposed to 30 or 90 ppm urethane, and the effect was independent of the ethanol concentration. Increasing the concentration of ethanol caused an exposure-related increase in cytochrome P450 2E1 activity and an exposure-related decrease in glutathione content in the liver of females; these parameters in females exposed to 2.5% or 5% ethanol were significantly greater or less than those in the controls; the changes were independent of the urethane concentration. Etheno-dA adduct concentrations in hepatic DNA were significantly increased by exposure to urethane and decreased by exposure to ethanol.

## 2-YEAR STUDY

Groups of 48 male and 48 female mice were exposed to 0, 10, 30, or 90 ppm urethane in the presence of 0%, 2.5%, or 5% ethanol in drinking water *ad libitum* for 2 years. Concentrations of 10, 30, and 90 ppm urethane resulted in average daily consumption of approximately 40, 115, and 360  $\mu\text{g}$  urethane for males and 35, 105, and 325  $\mu\text{g}$  for females. Concentrations of 2.5% and 5% ethanol resulted in average daily consumption of approximately 100 and 180 mg ethanol for males and 80 and 155 mg for females.

### *Survival, Body Weights, and Water Consumption*

Urethane caused an exposure-related decrease in survival of mice; the decrease was significant in 30 and 90 ppm mice. Ethanol caused a marginal exposure-related increase in survival of males, but had no effect on survival of females. Mean body weights of mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol showed evidence of urethane-induced reductions in body weights, especially in female mice. Mean body weights of mice exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol were generally decreased during the last 24 weeks of the study; in addition, females exposed to 10 or 30 ppm urethane and 2.5% ethanol or 0, 10, or 30 ppm urethane and 5% ethanol had generally reduced body weights during this time period. Water consumption by mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol was unchanged throughout the study; water consumption by mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane was generally decreased throughout the studies. This ethanol-induced reduction in water consumption was more marked in males than in females.

### *Pathology Findings*

Exposure to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane caused an exposure-related decrease in liver weights of males. The incidences of hemangiosarcoma of the liver in mice exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol were significantly increased. The incidences of hepatocellular neoplasms were significantly increased in males exposed to 30 or 90 ppm urethane and 0% ethanol or 90 ppm urethane and 2.5% ethanol. In female mice, an increase in the concentration of urethane in the presence of 0%, 2.5%, or

5% ethanol caused an exposure-related increase in the incidences of hepatocellular neoplasms. The incidences of hepatocellular neoplasms occurred with positive trends in males exposed to increasing concentrations of ethanol and 0 ppm urethane (hepatocellular adenoma: 0% ethanol, 7/46; 2.5% ethanol, 12/47; 5% ethanol, 19/48; hepatocellular adenoma or carcinoma: 12/46, 16/47, 25/48). Nonneoplastic liver lesions related to urethane exposure occurred in male and female mice.

Incidences of alveolar/bronchiolar neoplasms increased with positive trends in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol. The incidences of alveolar/bronchiolar adenoma or carcinoma (combined) occurred with positive trends in females exposed to increasing concentrations of ethanol and 10 ppm urethane, and the incidence was significantly increased in females exposed to 5% ethanol. Incidences of alveolar/bronchiolar adenoma occurred with negative trends in males exposed to ethanol and 10 or 30 ppm urethane.

Incidences of harderian gland neoplasms increased with positive trends in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol. The incidences of harderian gland adenoma or carcinoma (combined) were significantly increased in all urethane-exposed groups except in females exposed to 10 ppm urethane and 2.5% ethanol. The incidences of harderian gland neoplasms were decreased in males exposed to ethanol and 30 ppm urethane.

Incidences of adenoacanthoma, adenocarcinoma, and adenoacanthoma or adenocarcinoma (combined) of the mammary gland increased with positive trends in females exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol. The incidences of these neoplasms were generally significantly increased in females exposed to 30 or 90 ppm urethane and 0%, 2.5%, or 5% ethanol.

The incidences of hemangiosarcoma of the heart were significantly increased in males exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol and in females exposed to 90 ppm urethane and 5% ethanol; the incidence of this

neoplasm in females exposed to 90 ppm urethane and 2.5% ethanol was also increased. Increasing the ethanol concentration in the 90 ppm female group caused an exposure-related increase in the incidence of this neoplasm. Incidences of endothelial hyperplasia and angiectasis of the heart increased with positive trends in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol.

The incidences of granulosa cell tumor (benign or malignant) of the ovary were significantly increased in females exposed to 90 ppm urethane and 0% ethanol, and the incidences of benign and benign or malignant (combined) granulosa cell tumor were significantly increased in females exposed to 30 ppm urethane and 5% ethanol. The incidences of angiectasis and thrombosis of the uterus in females exposed to 30 or 90 ppm urethane and 0% or 2.5% ethanol were significantly increased.

The incidences of squamous cell papilloma or carcinoma (combined) of the forestomach occurred with a positive trend in males exposed to increasing concentrations of urethane and 0% ethanol, and the incidence in the 90 ppm group was significantly increased.

Incidences of hemangiosarcoma of the spleen increased with positive trends in males exposed to increasing concentrations of urethane and 2.5% ethanol and in females exposed to increasing concentrations of urethane and 0% or 2.5% ethanol. The incidence of this neoplasm in females exposed to 90 ppm urethane and 0% ethanol was significantly increased. Urethane also caused slight increases in the incidences of hemangiosarcoma of the uterus and skin in females.

## CONCLUSIONS

Under the conditions of this 2-year drinking water study, there was *clear evidence of carcinogenic activity\** of urethane in male B6C3F<sub>1</sub> mice based on increased incidences of liver, lung, harderian gland, and forestomach neoplasms and of hemangiosarcoma, primarily of the liver and heart. There was *clear evidence of carcinogenic*

*activity* of urethane in female B6C3F<sub>1</sub> mice based on increased incidences of liver, lung, harderian gland, mammary gland, and ovarian neoplasms and of hemangiosarcoma, primarily of the liver, heart, and spleen. The occurrences of hemangiosarcoma of the spleen in males and of the uterus and skin in females were also considered to be exposure related.

Exposure to urethane resulted in increased incidences of nonneoplastic lesions of the liver and heart in males and females and of the uterus in females.

Under the conditions of this 2-year drinking water study, there was *equivocal evidence of carcinogenic activity* of ethanol in male B6C3F<sub>1</sub> mice based on increased incidences of hepatocellular neoplasms. There was *no evidence of carcinogenic activity* of ethanol in female B6C3F<sub>1</sub> mice exposed to 2.5% or 5%.

The coadministration of urethane and ethanol resulted in marginal changes in the incidences of some neoplasms that were attributed to urethane alone. In males, increasing the ethanol concentration may have decreased the alveolar/bronchiolar and harderian gland adenoma or carcinoma responses to urethane. In females, increasing the ethanol concentration may have increased the hemangiosarcoma of the heart and alveolar/bronchiolar adenoma or carcinoma responses to urethane. Overall, the findings were insufficient to establish a definitive effect of ethanol on the carcinogenicity of urethane in B6C3F<sub>1</sub> mice.

---

\* Explanation of Levels of Evidence of Carcinogenic Activity is on page 16.

---

**Summary of the 2-Year Carcinogenesis Study of Urethane and Urethane/Ethanol**


---

|   | <b>Male B6C3F<sub>1</sub> Mice</b>   |  |   |
|---|--|--|---|
|   | <b>Urethane and 0% Ethanol</b>   | <b>Urethane and 2.5% Ethanol</b>   | <b>Urethane and 5% Ethanol</b>  |
| <b>Urethane concentrations in drinking water</b>  | 0, 10, 30, or 90 ppm   | 0, 10, 30, or 90 ppm   | 0, 10, 30, or 90 ppm  |
| <b>Survival rates</b>                             | 27/48, 26/48, 26/48, 8/48  | 32/48, 30/48, 25/48, 16/48   | 36/48, 29/48, 25/48, 12/48  |
| <b>Body weights</b>                               | 90 ppm group less than the control group   | 90 ppm group less than the control group   | 90 ppm group less than the control group  |
| <b>Nonneoplastic effects</b>                      | <p><u>Liver</u>: eosinophilic focus (6/46, 7/47, 19/46, 28/44); angiectasis (0/46, 4/47, 6/46, 17/44)</p> <p><u>Heart</u>: hyperplasia, endothelium (0/48, 0/48, 4/47, 9/48); angiectasis (0/48, 1/48, 2/47, 11/48)</p>  | <p><u>Liver</u>: eosinophilic focus (6/47, 3/48, 17/46, 22/48); angiectasis (0/47, 0/48, 7/46, 16/48); regeneration (0/47, 1/48, 1/46, 9/48)</p> <p><u>Heart</u>: hyperplasia, endothelium (0/48, 1/48, 4/47, 9/48); angiectasis (0/48, 0/48, 7/47, 13/48)</p>   | <p><u>Liver</u>: eosinophilic focus (10/48, 9/46, 18/48, 25/48); angiectasis (1/48, 1/46, 8/48, 19/48); regeneration (0/48, 0/46, 3/48, 5/48)</p> <p><u>Heart</u>: hyperplasia, endothelium (0/47, 0/48, 0/48, 2/48); angiectasis (0/47, 0/48, 1/48, 5/48)</p>  |
| <b>Neoplastic effects</b>                         | <p><u>Liver</u>: hemangiosarcoma (1/46, 2/47, 5/46, 13/44); hepatocellular adenoma (7/46, 13/47, 17/46, 17/44); hepatocellular adenoma or carcinoma (12/46, 18/47, 24/46, 23/44)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (4/48, 17/48, 22/47, 34/48); alveolar/bronchiolar carcinoma (1/48, 1/48, 9/47, 9/48); alveolar/bronchiolar adenoma or carcinoma (5/48, 18/48, 29/47, 37/48)</p> <p><u>Harderian gland</u>: adenoma (3/47, 11/47, 25/47, 28/47); carcinoma (0/47, 1/47, 7/47, 16/47); adenoma or carcinoma (3/47, 12/47, 30/47, 38/47)</p> <p><u>Heart</u>: hemangiosarcoma (0/48, 0/48, 1/47, 5/48)</p> <p><u>Forestomach</u>: squamous cell papilloma or squamous cell carcinoma (0/46, 2/47, 3/44, 5/45)</p> | <p><u>Liver</u>: hemangiosarcoma (3/47, 4/48, 3/46, 11/48); hepatocellular adenoma (12/47, 15/48, 16/46, 24/48); hepatocellular adenoma or carcinoma (16/47, 19/48, 17/46, 24/48)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (10/48, 16/48, 19/47, 35/48); alveolar/bronchiolar carcinoma (2/48, 3/48, 8/47, 24/48); alveolar/bronchiolar adenoma or carcinoma (11/48, 19/48, 24/47, 43/48)</p> <p><u>Harderian gland</u>: adenoma (6/48, 14/48, 21/47, 27/48); carcinoma (0/48, 0/48, 1/47, 16/48); adenoma or carcinoma (6/48, 14/48, 21/47, 38/48)</p> <p><u>Heart</u>: hemangiosarcoma (0/48, 0/48, 2/47, 4/48)</p> <p><u>Spleen</u>: hemangiosarcoma (0/46, 0/46, 1/46, 3/46)</p> | <p><u>Liver</u>: hemangiosarcoma (2/48, 1/46, 4/48, 13/48)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (6/48, 8/48, 9/48, 33/48); alveolar/bronchiolar carcinoma (5/48, 4/48, 5/48, 17/48); alveolar/bronchiolar adenoma or carcinoma (11/48, 11/48, 14/48, 40/48)</p> <p><u>Harderian gland</u>: adenoma (5/47, 12/48, 15/48, 26/45); carcinoma (0/47, 2/48, 2/48, 10/45); adenoma or carcinoma (5/47, 14/48, 17/48, 35/45)</p> <p><u>Heart</u>: hemangiosarcoma (0/47, 0/48, 1/48, 4/48)</p> |
| <b>Level of evidence of carcinogenic activity</b> |  | Clear evidence of urethane   |   |

---

---

**Summary of the 2-Year Carcinogenesis Study of Urethane and Urethane/Ethanol**


---

|  | <b>Female B6C3F<sub>1</sub> Mice</b>  |   |   |
|--|---|---|---|
|  | <b>Urethane and 0% Ethanol</b>  | <b>Urethane and 2.5% Ethanol</b>  | <b>Urethane and 5% Ethanol</b>  |
| <b>Urethane concentrations in drinking water</b> | 0, 10, 30, or 90 ppm  | 0, 10, 30, or 90 ppm  | 0, 10, 30, or 90 ppm  |
| <b>Survival rates</b>                            | 38/48, 37/48, 27/48, 1/48   | 39/48, 33/48, 19/48, 8/48   | 31/48, 32/48, 27/48, 4/48   |
| <b>Body weights</b>                              | 90 ppm group less than the control group  | 10, 30, and 90 ppm groups less than the control group   | 0, 10, 30, and 90 ppm groups less than the control group  |
| <b>Nonneoplastic effects</b>                     | <p><u>Liver</u>: eosinophilic focus (3/48, 14/47, 32/47, 20/47); angiectasis (0/48, 3/47, 10/47, 24/47); thrombosis (0/48, 1/47, 1/47, 11/47)</p> <p><u>Heart</u>: hyperplasia, endothelium (1/48, 0/48, 3/48, 6/48)</p> <p><u>Uterus</u>: angiectasis (0/48, 4/47, 6/48, 7/46); thrombosis (0/48, 1/47, 4/48, 4/46)</p>  | <p><u>Liver</u>: eosinophilic focus (2/47, 20/47, 21/47, 28/46); angiectasis (2/47, 5/47, 7/47, 20/46); thrombosis (1/47, 0/47, 4/47, 9/46); regeneration (0/47, 0/47, 0/47, 2/46)</p> <p><u>Heart</u>: hyperplasia, endothelium (0/47, 0/47, 3/48, 8/48); angiectasis (0/47, 0/47, 1/48, 4/48)</p> <p><u>Uterus</u>: angiectasis (1/47, 2/47, 7/48, 9/48); thrombosis (0/47, 0/47, 5/48, 6/48)</p>   | <p><u>Liver</u>: eosinophilic focus (2/48, 26/47, 25/48, 21/48); angiectasis (2/48, 1/47, 5/48, 22/48); thrombosis (0/48, 0/47, 1/48, 8/48); regeneration (0/48, 0/47, 0/48, 3/48)</p> <p><u>Heart</u>: hyperplasia, endothelium (0/47, 1/48, 3/48, 14/47); angiectasis (0/47, 0/48, 3/48, 4/47)</p>  |
| <b>Neoplastic effects</b>                        | <p><u>Liver</u>: hemangiosarcoma (0/48, 0/47, 1/47, 7/47); hepatocellular adenoma (5/48, 10/47, 19/47, 18/47); hepatocellular adenoma or carcinoma (5/48, 11/47, 20/47, 19/47)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (4/48, 6/48, 17/48, 29/47); alveolar/bronchiolar carcinoma (2/48, 4/48, 13/48, 19/47); alveolar/bronchiolar adenoma or carcinoma (6/48, 8/48, 28/48, 39/47)</p> <p><u>Harderian gland</u>: adenoma (3/48, 10/48, 8/48, 21/48); carcinoma (0/48, 1/48, 11/48, 11/48); adenoma or carcinoma (3/48, 11/48, 19/48, 30/48)</p> | <p><u>Liver</u>: hemangiosarcoma (1/47, 2/47, 0/47, 7/46); hepatocellular adenoma (6/47, 5/47, 15/47, 23/46); hepatocellular adenoma or carcinoma (7/47, 5/47, 16/47, 23/46)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (5/47, 10/47, 16/48, 28/48); alveolar/bronchiolar carcinoma (0/47, 2/47, 6/48, 23/48); alveolar/bronchiolar adenoma or carcinoma (5/47, 11/47, 21/48, 38/48)</p> <p><u>Harderian gland</u>: adenoma (2/47, 3/47, 9/46, 19/47); carcinoma (1/47, 3/47, 6/46, 16/47); adenoma or carcinoma (3/47, 5/47, 15/46, 35/47)</p> | <p><u>Liver</u>: hemangiosarcoma (0/48, 0/47, 0/48, 6/48); hepatocellular adenoma (3/48, 6/47, 16/48, 16/48); hepatocellular adenoma or carcinoma (3/48, 7/47, 16/48, 17/48)</p> <p><u>Lung</u>: alveolar/bronchiolar adenoma (5/48, 10/48, 18/48, 30/48); alveolar/bronchiolar carcinoma (1/48, 7/48, 9/48, 23/48); alveolar/bronchiolar adenoma or carcinoma (5/48, 17/48, 24/48, 37/48)</p> <p><u>Harderian gland</u>: adenoma (4/48, 7/48, 6/46, 20/46); carcinoma (1/48, 11/48, 7/46, 10/46); adenoma or carcinoma (5/48, 18/48, 13/46, 29/46)</p> |

---

**Summary of the 2-Year Carcinogenesis Study of Urethane and Urethane/Ethanol**

|   | Female B6C3F <sub>1</sub> Mice   |  |   |
|---|--|--|---|
|   | Urethane and 0% Ethanol  | Urethane and 2.5% Ethanol  | Urethane and 5% Ethanol   |
| <b>Neoplastic effects (continued)</b>             | <p><u>Mammary gland</u>:<br/>                     adenoacanthoma (0/47, 1/46, 1/46, 11/48); adenocarcinoma (4/47, 3/46, 3/46, 11/48);<br/>                     adenoacanthoma or adenocarcinoma (4/47, 4/46, 4/46, 22/48)</p> <p><u>Ovary</u>: benign granulosa cell tumor (0/48, 0/46, 2/46, 3/39); malignant granulosa cell tumor (0/48, 0/46, 0/46, 3/39); benign or malignant granulosa cell tumor (0/48, 0/46, 2/46, 5/39)</p> <p><u>Spleen</u>: hemangiosarcoma (0/48, 0/45, 1/47, 4/46)</p> <p><u>Uterus</u>: hemangiosarcoma (0/48, 0/47, 0/48, 2/46)</p> <p><u>Skin</u>: hemangiosarcoma (0/48, 0/48, 0/46, 2/48)</p> | <p><u>Mammary gland</u>:<br/>                     adenoacanthoma (0/47, 0/45, 2/48, 3/47); adenocarcinoma (4/47, 3/45, 11/48, 14/47);<br/>                     adenoacanthoma or adenocarcinoma (4/47, 3/45, 12/48, 16/47)</p> <p><u>Heart</u>: hemangiosarcoma (0/47, 0/47, 0/48, 3/48)</p> <p><u>Spleen</u>: hemangiosarcoma (0/47, 0/46, 0/46, 3/46)</p> <p><u>Skin</u>: hemangiosarcoma (0/47, 0/47, 0/48, 2/47)</p> | <p><u>Mammary gland</u>:<br/>                     adenoacanthoma (0/47, 0/48, 1/48, 9/45); adenocarcinoma (3/47, 4/48, 6/48, 15/45);<br/>                     adenoacanthoma or adenocarcinoma (3/47, 4/48, 7/48, 23/45)</p> <p><u>Heart</u>: hemangiosarcoma (0/47, 0/48, 0/48, 6/47)</p> <p><u>Ovary</u>: benign granulosa cell tumor (0/46, 0/47, 5/46, 3/45); benign or malignant granulosa cell tumor (0/46, 0/47, 6/46, 3/45)</p> |
| <b>Level of evidence of carcinogenic activity</b> | Clear evidence of urethane   |  |   |

## EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (**clear evidence and some evidence**); one category for uncertain findings (**equivocal evidence**); one category for no observable effects (**no evidence**); and one category for experiments that cannot be evaluated because of major flaws (**inadequate study**). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- **Clear evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- **Some evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- **Equivocal evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemical related.
- **No evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
- **Inadequate study** of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

For studies showing multiple chemical-related neoplastic effects that if considered individually would be assigned to different levels of evidence categories, the following convention has been adopted to convey completely the study results. In a study with clear evidence of carcinogenic activity at some tissue sites, other responses that alone might be deemed some evidence are indicated as “were also related” to chemical exposure. In studies with clear or some evidence of carcinogenic activity, other responses that alone might be termed equivocal evidence are indicated as “may have been” related to chemical exposure.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- adequacy of the experimental design and conduct;
- occurrence of common versus uncommon neoplasia;
- progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
- latency in tumor induction;
- multiplicity in site-specific neoplasia;
- metastases;
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- presence or absence of dose relationships;
- statistical significance of the observed tumor increase;
- concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- survival-adjusted analyses and false positive or false negative concerns;
- structure-activity correlations; and
- in some cases, genetic toxicology.

**NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS  
TECHNICAL REPORTS REVIEW SUBCOMMITTEE**

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on urethane, ethanol, and urethane/ethanol on September 5, 2002, are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing the NTP studies:

- to ascertain that all relevant literature data have been adequately cited and interpreted,
- to determine if the design and conditions of the NTP studies were appropriate,
- to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- to judge the significance of the experimental results by scientific criteria, and
- to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

**Norman R. Drinkwater, Ph.D., Chairperson**  
McArdle Laboratory for Cancer Research  
University of Wisconsin-Madison  
Madison, WI

**Walter W. Piegorsch, Ph.D.**  
Department of Statistics  
University of South Carolina  
Columbia, SC

**Kim Boekelheide, M.D., Ph.D.**  
Division of Biology and Medicine  
Department of Pathology and Laboratory Medicine  
Brown University  
Providence, RI

**Stephen M. Roberts, Ph.D.**  
Department of Physiological Sciences  
College of Veterinary Medicine  
University of Florida  
Gainesville, FL

**Michael R. Elwell, D.V.M., Ph.D.**  
Pfizer, Inc.  
Groton, CT

**Richard D. Storer, M.P.H., Ph.D.**  
Department of Genetic and Cellular Toxicology  
Merck Research Laboratories  
West Point, PA

**Shuk-Mei Ho, Ph.D.**  
Department of Surgery, Division of Urology  
University of Massachusetts Medical School  
Worcester, MA

**Mary Anna Thrall, D.V.M.**  
Department of Pathology  
College of Veterinary Medicine and Biomedical Sciences  
Colorado State University  
Fort Collins, CO

**James E. Klaunig, Ph.D.**  
Division of Toxicology  
Department of Pharmacology and Toxicology  
Indiana University School of Medicine  
Indianapolis, IN

**Mary Vore, Ph.D.**  
Graduate Center for Toxicology  
University of Kentucky  
Lexington, KY

**David E. Malarkey, D.V.M., Ph.D.**  
Department of Microbiology, Pathology, and Parasitology  
College of Veterinary Medicine  
North Carolina State University  
Raleigh, NC

**Cheryl Lyn Walker, Ph.D.**  
M.D. Anderson Cancer Center  
The University of Texas  
Smithville, TX


**Ad Hoc Expert Consultant**

**David H. Phillips, D.Sc., Ph.D.**  
Institute of Cancer Research  
Haddow Laboratories  
Sutton, England

**SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS**

**NOTE:** A summary of the Technical Reports Review Subcommittee's remarks will appear in a future draft of this report.

## INTRODUCTION




**URETHANE**

CAS No. 51-79-6

Chemical Formula:  $C_3H_7NO_2$       Molecular Weight: 89.09

**Synonyms:** Carbamic acid ethyl ester; ethyl carbamate; ethylurethan; ethyl urethan; ethyl urethane; leucothane; pracobamin; urethan



**ETHANOL**

CAS No. 64-17-5

Chemical Formula:  $C_2H_6O$       Molecular Weight: 46.07

**Synonyms:** Ethyl alcohol; ethyl hydrate; ethyl hydroxide; absolute alcohol; anhydrous alcohol; dehydrated alcohol; grain alcohol

### CHEMICAL AND PHYSICAL PROPERTIES OF URETHANE, AND PRODUCTION, USE, AND HUMAN EXPOSURE

Urethane (ethyl carbamate), the ethyl ester of carbamic acid, is an odorless, white crystalline powder that is produced commercially for use in the preparation and modification of amino resins and as a cosolvent during the manufacture of pesticides, fumigants, and cosmetics (IARC, 1974). It has also been used as a chemical intermediate in the textile industry to impart wash and wear properties to fabrics (IARC, 1974), as a cosolvent with drugs (Nomura, 1975), and, for a brief period, as an antineoplastic agent for the treatment of chronic leukemia and multiple myeloma (IARC, 1974). Urethane has also been identified in the food supply as an inadvertent by-product of fermentation (IARC, 1974).

The major source of human exposure to urethane is from fermented foods and beverages, and it is estimated that the average daily intake for adults is 10 to 20 mg urethane/kg body weight, assuming the major source of urethane is from bread (Schlatter and Lutz, 1990; Zimmerli and Schlatter, 1991). Smoking twenty cigarettes per day can double this amount, while the consumption of 30 mL of some stone-fruit brandies can increase daily intake

60-fold. Surveys of urethane concentrations in various food products have been presented by Clegg *et al.* (1988), Canas *et al.* (1989), Dennis *et al.* (1989), Battaglia *et al.* (1990), Dunn *et al.* (1991), Vahl (1993), and Haddon *et al.* (1994).

## PHARMACODYNAMICS OF URETHANE

In early pharmacodynamic studies of urethane, rats and mice were typically treated intravenously, intraperitoneally, or dermally instead of orally, the usual route of human exposure. Regardless of the route of administration, urethane underwent a rapid systemic distribution, including to the fetuses of pregnant mice (Boyland and Nery, 1965; IARC, 1974). In mice, an estimated 90% of the administered dose of [carboxy-<sup>14</sup>C]-urethane and [methylene-<sup>14</sup>C]-urethane was excreted as exhaled <sup>14</sup>CO<sub>2</sub> within 24 hours. During the same time period, approximately 6% of the total <sup>14</sup>C remained in the body, and a similar amount was excreted in the urine (Mirvish, 1968; IARC, 1974); less than 1% was eliminated in the feces (Mirvish, 1968).

In subsequent studies, Fossa *et al.* (1985) compared the distribution and binding of [ethyl-1-<sup>14</sup>C]-urethane in male SENCAR and BALB/c mice. Mice were fasted 24 hours and treated with 100 mg/kg urethane either orally in water or dermally in acetone. Total tissue radioactivity in the skin, liver, lung, and stomach was measured at selected times. Peak absorption occurred at the first sampling (1 hour) regardless of strain or route of administration. One hour after oral dosing, SENCAR mice absorbed two to three times more [<sup>14</sup>C]-urethane than did BALB/c mice; however, this difference was not evident at the later time periods (6, 12, 24, and 48 hours). When [<sup>14</sup>C]-urethane was applied dermally, there was a consistently greater binding of urethane to protein, RNA, and DNA in the skin of BALB/c mice than in the skin of SENCAR mice. Because SENCAR mice are more susceptible to urethane-initiated skin papillomas than BALB/c mice, it suggests that factors in addition to macromolecular binding contribute to the carcinogenic response.

Nomeir *et al.* (1989) compared the absorption, distribution, and excretion of urethane in male F344 rats that received 475 µg/kg to 475 mg/kg [carbonyl-<sup>14</sup>C]-urethane orally by gavage or by intravenous injection to that in

male B6C3F<sub>1</sub> mice. Tissues, including blood, lung, liver, skin, fat, muscle, and kidneys were assayed for radioactivity 15 minutes to 72 hours after treatment. In rats dosed intravenously with 47.5 mg/kg [carbonyl-<sup>14</sup>C]-urethane, the highest levels of radioactivity were found in the kidneys, the lowest in fat, and radioactivity in all other tissues was similar. The maximum levels of radioactivity in fat and skin occurred 2 hours after dosing; in all other tissues, the peak levels were observed 15 minutes after treatment. At 475 mg/kg, maximum levels of radioactivity in all tissues occurred 2 hours after dosing; again, the kidneys had the greatest amount of radioactivity and fat the least. At both 47.5 and 475 mg/kg, radioactivity rapidly decreased in all the tissues. Mice treated intravenously with 47.5 mg/kg [carbonyl-<sup>14</sup>C]-urethane had lower peak levels of radioactivity than did rats, and the radioactivity was eliminated at a faster rate in mice. The initial radioactivity levels in the tissues of mice administered 475 mg/kg [carbonyl-<sup>14</sup>C]-urethane intravenously were similar to the levels in rats; but as with the 47.5 mg/kg dose, the radioactivity was eliminated at a faster rate by mice. The faster elimination of urethane by mice was also observed by Mirvish (1968), who reported elimination rates of 50, 60, 25, and 4 μg/mL per hour for rats, adult Swiss mice, rabbits, and humans, respectively, based on the disappearance of urethane from the blood.

Twenty-four hours after treatment, rats administered 47.5 mg/kg [carbonyl-<sup>14</sup>C]-urethane intravenously had similar tissue levels of radioactivity as those treated orally (Nomeir *et al.*, 1989). At 475 mg/kg, higher levels occurred in rats treated orally, which presumably reflects impaired absorption. Regardless of the route of administration, species, or dose, a minimum of 90% of the <sup>14</sup>C derived from urethane was exhaled as <sup>14</sup>CO<sub>2</sub>, 2% to 8% was excreted in the urine, 0.3% to 2% was exhaled as volatiles other than carbon dioxide, and 0.3% to 1% was eliminated in the feces. Other than CO<sub>2</sub> and urethane, no metabolite was identified. Saturation of metabolism and elimination occurred after intravenous doses greater than 4.75 mg/kg in rats and 47.5 mg/kg in mice. Urethane elimination was saturated in male outbred Swiss mice at 400 to 1,800 mg/kg (O'Flaherty and Sichak, 1983), and in female NMRI mice at 37.5 mg/kg (Kristiansen *et al.*, 1994). Based on these data, it appears that early investigations of the carcinogenicity of urethane using high-dose, single-treatment protocols probably used doses of urethane that saturated metabolism and clearance.

Neonatal and weanling mice eliminate urethane at a much slower rate than adult mice (Cividalli *et al.*, 1965); the rate of elimination in neonates increases slowly for the first 10 days, then more rapidly from days 15 to 20. The longer retention times in very young mouse liver have been attributed to the lack of an esterase capable of metabolizing urethane to CO<sub>2</sub>; this enzyme is active in adult mouse liver (Kaye, 1960; IARC, 1974). Urethane is a far more potent carcinogen to very young mice than to adult mice (Mirvish, 1968), which suggests that the esterase-catalyzed metabolism of urethane is a detoxification pathway.

## METABOLISM OF URETHANE

Ninety to ninety-five percent of urethane is metabolized by an esterase to ethanol, CO<sub>2</sub>, and NH<sub>3</sub> before it is eliminated (IARC, 1974; Nomeir *et al.*, 1989), while 3% to 4% is excreted in the urine as parent compound or as *N*-hydroxyurethane, *N*-acetyl-*N*-hydroxyurethane, *N*-acetyl-*S*-ethylcysteine, and *N*-acetyl-*S*-carbethoxycysteine (Boyland and Nery, 1965). Because Cramer *et al.* (1960) demonstrated that metabolic activation of carcinogenic aromatic amines and amides was mediated via an *N*-hydroxylation pathway, finding *N*-hydroxyl urethane metabolites in the urine (Boyland and Nery, 1965) suggests that urethane might be metabolically activated by the same pathway. However, carcinogenicity studies conducted by Kaye and Trainin (1966) showed that *N*-hydroxyurethane had only half the carcinogenic potency of urethane in weanling mice and less than half the potency in neonatal mice. In addition, Mirvish (1968) estimated that 70% of the administered dose of *N*-hydroxyurethane was metabolized by reduction to the parent compound, urethane. Because the majority of *N*-hydroxyurethane is converted to urethane, and because the carcinogenicity of urethane is approximately twice that of its *N*-hydroxy metabolite, it is unlikely that the *N*-hydroxylation pathway plays a major role in the carcinogenicity of urethane.

Studies of structure-activity relationships of urethane and congeners indicated that small structural changes produced large changes in carcinogenicity (Mirvish, 1968). For example, structurally similar alkyl carbamates such as methyl, *n*-propyl, *iso*-propyl, and *n*-butyl carbamate were either not carcinogenic or only weakly carcinogenic. Furthermore, Lawson and Pound (1973) showed that only the ethyl carbons of ethyl carbamate

became covalently bound to mouse DNA *in vivo*, and that significant amounts of methyl, *n*-propyl, and *n*-butyl carbamate did not bind to liver DNA. These data, plus observations on the carcinogenicity of vinyl chloride, led Dahl *et al.* (1978) to postulate that urethane was metabolically activated via a C-oxidation pathway, with vinyl carbamate being the proximate carcinogenic metabolite (Figure 1). They further postulated that if vinyl carbamate was formed, it would be further oxidized to the ultimate carcinogen, vinyl carbamate epoxide. In accord with this hypothesis, these investigators reported that vinyl carbamate was 10 to 50 times more carcinogenic than urethane in the skin and lungs of female CD-1 mice. Similar results were subsequently obtained in F344 rats and B6C3F<sub>1</sub> mice (Dahl *et al.*, 1980).

Using an approach analogous to that for identifying the presence of the epoxide derivative of vinyl chloride, Ribovich *et al.* (1982) injected B6C3F<sub>1</sub> and A/Jax mice with either [ethyl-1,2-<sup>3</sup>H]-urethane or [ethyl-1-<sup>14</sup>C]-urethane and demonstrated the presence of 1,*N*<sup>6</sup>-ethenoadenosine and 3,*N*<sup>4</sup>-ethenocytidine in hepatic RNA (Figure 1). They further noted that these adducts were derived from metabolic activation of urethane and not the hydrolysis product ethanol, and thus concluded that vinyl carbamate and its epoxide were the carcinogenic metabolites of urethane. This interpretation was supported by the fact that the target tissue levels of RNA adducts derived from vinyl carbamate were greater than those obtained from urethane (Miller and Miller, 1983). In addition, Scherer *et al.* (1986) showed that 7-(2-oxoethyl)deoxyguanosine, isolated from the liver of rats or mice, was formed to a 100-fold greater extent from vinyl carbamate than from urethane.

The synthesis of vinyl carbamate epoxide was first reported by Park *et al.* (1990), who demonstrated its reactivity with adenosine to form 1,*N*<sup>6</sup>-ethenoadenosine. When injected intraperitoneally into 12-day-old male B6C3F<sub>1</sub> mice, vinyl carbamate epoxide resulted in more of this etheno nucleoside in hepatic RNA than in mice treated similarly with vinyl carbamate. Vinyl carbamate epoxide was also a direct mutagen in *Salmonella typhimurium* TA1535, whereas vinyl carbamate required a metabolic system (Leithauser *et al.*, 1990; Park *et al.*, 1990). In subsequent studies, vinyl carbamate epoxide reacted with DNA *in vitro* and *in vivo* to form 7-(2-oxoethyl)-deoxyguanosine, *N*<sup>2</sup>,3-ethenodeoxyguanosine, and 1,*N*<sup>6</sup>-ethenodeoxyadenosine (Park *et al.*, 1993) (Figure 1). It was also a stronger tumor initiator than urethane or vinyl carbamate on the skin of CD-1 mice and in the liver of B6C3F<sub>1</sub> mice. More




FIGURE 1  
Metabolism of Urethane

recently, Fernando *et al.* (1996) used immunoaffinity chromatography and <sup>32</sup>P-postlabeling analyses to demonstrate the presence of 3,*N*<sup>4</sup>-ethenodeoxycytidine and 1,*N*<sup>6</sup>-ethenodeoxyadenosine (Figure 1) in DNA from the lungs and liver of neonatal and adult mice treated with urethane, vinyl carbamate, and vinyl carbamate epoxide. The binding of urethane and vinyl carbamate to hepatic DNA was greater in neonatal mice than in adults, which was consistent with the greater susceptibility of neonatal mice to the carcinogenicity of urethane.

By using competitive substrates, Guengerich and Kim (1991) demonstrated that human liver cytochrome P450 IIE1 was a major isoform responsible for the oxidation of urethane and vinyl carbamate. They further showed that the microsomal oxidation of both urethane and vinyl carbamate in the presence of adenosine would lead to the formation of 1,*N*<sup>6</sup>-ethenoadenosine, and that the rate of conversion was 500 times faster for vinyl carbamate than for urethane. The difference in rate appeared to be the reason for the failure to detect vinyl carbamate as a metabolite of urethane in earlier metabolic studies.

## CARCINOGENICITY AND METABOLISM OF ETHANOL

The carcinogenicity of ethanol was evaluated in rats (Gibel, 1967; Schmähl, 1976; Mendenhall and Chedid, 1980; Radike *et al.*, 1981; Gričiute *et al.*, 1986; Takahashi *et al.*, 1986), mice (Horie *et al.*, 1965; Schrauzer *et al.*, 1979; Gričiute *et al.*, 1981; Schmidt *et al.*, 1987), and hamsters (McCoy *et al.*, 1981, 1986; Pour *et al.*, 1983). The International Agency for Research on Cancer (IARC, 1988) reviewed these data and concluded that the results were inadequate for the classification of ethanol as a carcinogen in experimental animals. The IARC did feel, however, that there was clear evidence that the consumption of alcoholic beverages by humans was causally related to the occurrence of malignant tumors of the oral cavity, pharynx, larynx, esophagus, and liver. Accordingly, alcoholic beverages were classified as carcinogenic to humans (Group 1). More recently, Holmberg and Ekström (1995) assessed the carcinogenicity of ethanol in Sprague-Dawley rats exposed to 1% or 3% ethanol in the diet and compared them to rats exposed to an isocaloric amount of glucose in a semisynthetic liquid diet. Although there was an increase in mammary tumors in the 1% females, there was no exposure-related increase in tumorigenicity in either sex or in any organ.

The absorption and metabolism of ethanol have been reviewed (IARC, 1988). It is absorbed by simple diffusion and then sequential oxidation to acetaldehyde and acetic acid (Figure 2). The metabolism of ethanol occurs primarily in the liver, where the oxidation to acetaldehyde is catalyzed primarily by alcohol dehydrogenase, and to a lesser extent, by cytochrome P450 and catalase. The carcinogenicity of acetaldehyde has been assessed in rats exposed by inhalation (Woutersen *et al.*, 1986) and in hamsters exposed by inhalation (Feron *et al.*, 1982) and intratracheal instillation (Feron, 1979). Exposure by inhalation resulted in respiratory tract tumors in both species; tumors were not induced after intratracheal administration in hamsters. After considering these results and reviewing epidemiological data, the IARC concluded that acetaldehyde is a carcinogen in experimental animals and possibly carcinogenic in humans (Group 2B) (IARC, 1985, 1987).

Acetaldehyde reacts with the *N*<sup>2</sup> position of deoxyguanosine to form a Schiff's base that can be detected following reduction to *N*<sup>2</sup>-ethyldeoxyguanosine (Figure 2). *N*<sup>2</sup>-Ethyldeoxyguanosine was found in liver DNA of mice administered ethanol (Fang and Vaca, 1995), in granulocyte and lymphocyte DNA of alcoholic and control human patients (Fang and Vaca, 1997), and in the urine of individuals who had abstained from alcohol consumption (Matsuda *et al.*, 1999). When incorporated into DNA, *N*<sup>2</sup>-ethyldeoxyguanosine led to the misincorporation of deoxyguanosine opposite the lesion (Terashima *et al.*, 2001). This suggests that tumors that arise from acetaldehyde and, by extension ethanol, could result from G to C transversion mutations. More recently, additional DNA adducts of acetaldehyde were characterized (Wang *et al.*, 2000); however, it is not known if these were formed *in vivo*.

## **METABOLIC INTERACTIONS OF URETHANE AND ETHANOL**

The oxidation of urethane to vinyl carbamate and vinyl carbamate epoxide (Figure 1) is catalyzed by cytochrome P450 IIE1 (Guengerich and Kim, 1991; Guengerich *et al.*, 1991), an isoform that is induced 5- to 20-fold by ethanol in rats, mice, and humans (Lieber, 1988, 1990; Kurata *et al.*, 1991a; Ingelman-Sundberg *et al.*, 1993). This suggests that chronic ethanol treatment could increase the oxidation of urethane to its epoxide derivative.




FIGURE 2  
Metabolism of Ethanol

Waddell *et al.* (1987) treated fasted adult A/Jax male mice orally with [ethyl-1-<sup>14</sup>C]-urethane and demonstrated with whole-body autoradiography that concurrent ethanol administration inhibited the localization of urethane 1 hour after treatment. Because more than 90% of the urethane dose in mice was eliminated by metabolism, they postulated that ethanol was interfering with urethane metabolism. The interpretation of these experiments is complicated to some extent by the use of fasted mice because fasting induces cytochrome P450 IIE1 (Imaoka *et al.*, 1990), the principal isoform responsible for the metabolism of urethane (Guengerich and Kim, 1991). In a later study, fasted adult male A/Jax mice were dosed orally with [ethyl-1-<sup>14</sup>C]-urethane dissolved in water or 10% ethanol (Yamamoto *et al.*, 1988). In this study, ethanol inhibited the initial metabolism of urethane and delayed covalent binding of the reactive metabolites for 8 hours, after which urethane metabolism proceeded normally. In addition, blood ethanol concentrations of 15 mg/mL produced complete inhibition of urethane metabolism *in vivo*. This contrasted with *in vitro* experiments in which liver homogenates were only inhibited 50% by 35 mg/mL ethanol, and suggested that extrahepatic urethane metabolism may occur *in vivo*. The inhibition of urethane metabolism by ethanol was released when the ethanol concentration in blood decreased to approximately 10 mg/mL, at which the metabolism proceeded at apparently normal rates (Kurata *et al.*, 1991b).

To characterize the enzyme systems responsible for the metabolism of urethane, Kurata *et al.* (1990) focused on acetaldehyde as a possible inhibitor of urethane metabolism. Adult male A/Jax mice were treated orally with urethane and immediately given an intraperitoneal injection of acetaldehyde, paraldehyde, or sodium acetate. Additional mice were injected with disulfiram prior to receiving the urethane or with D-penicillamine before and after the urethane treatment. Acetaldehyde and ethanol inhibited urethane metabolism approximately equally for the first 2 hours, and then the effect of acetaldehyde rapidly diminished. The diminution in inhibition by acetaldehyde (compared to ethanol) was attributed to its rapid metabolism (i.e., 3  $\mu\text{mol/g}$  liver per minute). This interpretation was supported by the fact that sodium acetate (the second oxidation product of ethanol metabolism) did not inhibit urethane metabolism, while paraldehyde, which is hydrolyzed to acetaldehyde, produced a more prolonged inhibition than acetaldehyde itself. In addition, D-penicillamine, a compound that sequesters acetaldehyde, abolished the inhibitory effects of acetaldehyde, as did a combination of ethanol and

D-penicillamine. Finally, disulfiram, a nonspecific inhibitor of aldehyde dehydrogenase, produced prolonged and stable concentrations of urethane in blood, indicating that urethane may be metabolized by this enzyme.

Disulfiram is also an inhibitor of cytochrome P450 IIE1 (Parkinson, 1996), which suggests that the oxidation of urethane would also be inhibited.

The temporal relationship between ethanol and urethane administration can result in marked differences in urethane metabolism. For example, when ethanol was given concurrently with urethane, urethane metabolism was inhibited (Waddell *et al.*, 1987); however, when a single dose of urethane was given to adult male A/Jax mice 48 hours after they received 10% ethanol in the drinking water continuously for 36 hours and followed by water without ethanol for the next 12 hours, the metabolism of urethane was enhanced by 50% (Kurata *et al.*, 1991b). In contrast, when 5% ethanol was given for 7 consecutive days and then water without ethanol for 24 hours prior to oral treatment with urethane, the metabolism of urethane was not altered; the same was true when 5 g/kg ethanol was given by gavage 24 and 48 hours prior to an oral dose of urethane. In another study (Carlson, 1994), one group of male adult Sprague-Dawley rats was dosed with ethanol by gavage 1 hour prior to an intraperitoneal dose of urethane. A second group received 10% ethanol in the drinking water for 3 weeks, water without ethanol for the next day, and then an intraperitoneal injection of urethane. The group that received a bolus dose of ethanol 1 hour prior to the urethane dose had greatly diminished urethane metabolism, while the 3-week administration of ethanol had no effect on urethane metabolism measured as exhaled  $^{14}\text{CO}_2$ .

Plasma levels of urethane have been determined in male and female B6C3F<sub>1</sub> mice administered 110, 330, or 1,100 ppm urethane in drinking water in the presence or absence of 5% ethanol (NTP, 1996). The average half-life for urethane elimination in male mice was 0.77 hours (range, 0.6 to 0.9 hours) and was not affected by the presence of ethanol. Kinetic values could not be calculated for female mice. In nearly all the plasma samples, the ethanol concentration was below the limit of detection.

## EFFECTS OF ETHANOL ON URETHANE CARCINOGENICITY

The effect of ethanol on the tumorigenicity of urethane has been evaluated in three studies. Kristiansen *et al.* (1990) exposed adult female A/Ph mice to 0, 200, 500, or 1,000 ppm urethane in 5%, 10%, or 20% ethanol for 12 weeks. All mice treated with urethane developed lung adenomas, and the multiplicity of these increased in a dose-dependent manner. The coadministration of ethanol decreased the tumor multiplicity in a dose-related manner, and the differences were significant in the 10% and 20% ethanol groups.

Altmann *et al.* (1991) treated groups of adult female NMRI mice daily for 8 weeks by gavage with urethane in water or 20% ethanol. The treatment was discontinued and, after an additional 8 weeks, the mice were killed to assess the extent of lung tumor induction. As with the Kristiansen *et al.* (1990) study, urethane treatment increased the incidence of lung tumors in mice as well as the tumor multiplicity; however, as opposed to the results of Kristiansen *et al.* (1990), the coadministration of ethanol did not decrease the tumor incidence or tumor multiplicity. The failure of Altmann *et al.* (1991) to detect an ethanol effect may have been due to the fact that the animals were treated by gavage with very small amounts of ethanol compared to studies in which ethanol was given in the drinking water.

In a drinking water study, Stoewsand *et al.* (1991) exposed weanling male C3H/HeJ mice to 0, 10, or 20 mg urethane/kg body weight in either water or 12% ethanol for 41 weeks. Urethane caused an increase in the incidences of hepatocellular adenoma or carcinoma (combined), hemangioendothelioma, and hemangiosarcoma in the liver, and Clara cell and alveolar adenoma in the lungs. The coadministration of urethane with 12% ethanol significantly decreased the incidence of hepatocellular adenoma in the 10 mg/kg urethane group, but increased (although not significantly) the incidences in the 0 and 20 mg/kg groups. Ethanol also decreased the incidences of hepatocellular carcinoma in the 10 and 20 mg/kg groups, although the decrease was not significant. Ethanol treatment did not affect the incidence of hemangioendothelioma but did decrease the incidence of hemangiosarcoma, although the difference was not statistically significant except for the 20 mg/kg group. In the lung, ethanol coadministration decreased tumor incidence, and the incidence of Clara cell adenoma was significantly decreased in the 10 mg/kg group.

Urethane was evaluated in a 13-week toxicity study (NTP, 1996). Male and female F344/N rats and B6C3F<sub>1</sub> mice were exposed to 0, 110, 330, 1,100, 3,300, or 10,000 ppm urethane in drinking water or in 5% ethanol. Thirty percent of the male rats and 60% of the female rats exposed to 10,000 ppm urethane survived the entire treatment period. All of the male rats and 90% of the female rats also survived the 3,300 ppm treatment. When 10,000 ppm urethane was coadministered with 5% ethanol, 80% of the male rats and none of the female rats survived.

Urethane at concentrations of 1,100 ppm or greater caused lymphoid cell depletion, liver lesions, and increased severity of nephropathy and cardiomyopathy in male and/or female rats. None of the mice exposed to 10,000 ppm urethane or 10,000 ppm urethane in 5% ethanol survived. Ninety percent of the male mice and 60% of the female mice given 3,300 ppm urethane in 5% ethanol survived the entire treatment period, whereas none of the mice exposed to 3,300 ppm urethane in water survived. Although ethanol appeared to protect the mice from the toxicities of urethane, the difference in mortality may have been due to a decreased intake of urethane by mice coadministered ethanol. Urethane administered in drinking water to mice induced lung inflammation, alveolar and bronchiolar hyperplasia, nephropathy, cardiomyopathy, lymphoid and bone marrow cell depletion, seminiferous tubule degeneration, ovarian atrophy, and follicular degeneration. In female mice, exposure to 5% ethanol appeared to exacerbate ovarian atrophy. The incidences and severities of alveolar epithelial hyperplasia were slightly increased in mice exposed to urethane in 5% ethanol compared to mice exposed to urethane in drinking water. One 330 ppm male mouse exposed to urethane in drinking water had an alveolar/bronchiolar adenoma; males exposed to 110, 1,100, or 3,300 ppm urethane in 5% ethanol had alveolar/bronchiolar adenomas.

## GENETIC TOXICITY

Urethane is a demonstrated mutagen. A review of the extensive published studies of urethane genotoxicity was presented by NTP (1996), along with results of NTP studies. Results from *in vivo* somatic cell assays with urethane were generally positive, with the strongest responses seen in mouse bone marrow micronucleus tests. The results of *in vitro* tests varied among assays; the infrequent positive responses appeared most often with high doses of urethane tested with exogenous metabolic activation in specific cell types under stringent conditions. No

mammalian germ cell mutagenicity has been demonstrated for urethane in classical assays, including mouse specific locus and dominant lethal assays (Bateman, 1967; Tutikawa, 1969; Epstein *et al.*, 1972; Russell *et al.*, 1987; NTP, unpublished data). However, there was one report in which mice were exposed to urethane prior to mating, and significantly increased tumor incidences were observed in the F<sub>1</sub> offspring (Nomura, 1982). The heritability of these presumed parental germline tumor mutations was demonstrated by breeding the F<sub>1</sub> mice and then observing increased tumor incidences in the F<sub>2</sub> offspring.

Urethane was mutagenic in *Salmonella typhimurium* strain TA1535 with induced liver S9 enzymes (Zeiger *et al.*, 1992), and it induced sister chromatid exchanges, but not chromosomal aberrations, in Chinese hamster ovary cells with and without S9 enzymes (NTP, 1996). *In vivo*, urethane induced sex-linked recessive lethal mutations and reciprocal translocations in germ cells of male *Drosophila melanogaster* (Foureman *et al.*, 1994). Significantly increased frequencies of micronucleated erythrocytes were observed in peripheral blood obtained from male and female B6C3F<sub>1</sub> mice after 45 days of exposure and in bone marrow and peripheral blood obtained after 13 weeks of exposure to urethane in drinking water (Witt *et al.*, 2000).

In contrast to urethane, ethanol is generally considered to be nonmutagenic. It showed little, if any, indication of mutagenic activity in bacterial assays (Zeiger *et al.*, 1992). Chromosomal breakage and aneuploidy have occasionally been reported in eukaryotic cells exposed *in vitro* (Meisner *et al.*, 1970; Badr *et al.*, 1977; Alvarez *et al.*, 1980; de Raat *et al.*, 1983) or *in vivo* (Baraona *et al.*, 1981), particularly when experimental conditions permit generation of the genetically active metabolite acetaldehyde, but most tests for somatic cell chromosomal damage by ethanol were negative (Chaubey *et al.*, 1977; Korte *et al.*, 1979; Jansson, 1982; Banduhn and Obe, 1985). However, there are several reports of ethanol-induced dominant lethal mutations in germ cells of male rats (Klassen and Persaud, 1976; Mankes *et al.*, 1982) and mice (Badr and Badr, 1975; Anderson and Beyler, 1978; James and Smith, 1982; Berryman *et al.*, 1992). The mutagenicity data for ethanol (IARC, 1988; Phillips and Jenkinson, 2001) and for acetaldehyde (Obe and Anderson, 1987) have been reviewed.

Only two experiments investigating genotoxicity after coadministration of urethane and ethanol have been identified, and both were mouse micronucleus tests. Significant increases in micronucleated erythrocytes were observed in male and female mice treated with urethane in 5% ethanol for 13 weeks (NTP, 1996). Choy *et al.* (1996) reported that coadministration of ethanol produced a transient inhibition of micronucleus induction by urethane in mice, but they concluded that there was no reduction in the final magnitude of the urethane response. The NTP (1996) data are consistent with those of Choy *et al.* (1996) in that there appeared to be little difference in the magnitude of the response between mice administered urethane in drinking water and mice administered urethane in 5% ethanol. In both instances, the increases in micronucleus frequencies were highly significant.

## STUDY DESIGN AND DOSE SELECTION RATIONALE

Urethane is carcinogenic in a number of species including rats, mice, hamsters, and monkeys (Mirvish, 1968; Salmon *et al.*, 1991; Thorgeirsson *et al.*, 1994), which suggests a potential carcinogenic risk to humans. Based on experimental and epidemiological data, urethane is classified as a possible human carcinogen (Group 2B) by the IARC (1987). Because of the widespread exposure to urethane in alcoholic beverages and a lack of adequate dose-response carcinogenicity data to conduct meaningful risk assessments, urethane in combination with ethanol was nominated by the U.S. Food and Drug Administration for in-depth toxicological evaluation by the NTP.

The most comprehensive dose-response study of urethane in mice was conducted by Inai *et al.* (1991); male B6C3F<sub>1</sub> mice were exposed to 0, 0.6, 3, 6, 60, or 600 ppm urethane in the drinking water for 70 weeks. Treatment-related tumors included lung alveolar/bronchiolar adenomas, and the incidence was significantly increased at 60 ppm; incidences of lung carcinomas and liver hemangiomas and angiosarcomas were significantly increased at 600 ppm. In the 13-week toxicity study conducted by the NTP (1996), the no-observed-adverse-effect level was 110 and 330 ppm for male and female B6C3F<sub>1</sub> mice, respectively; this suggested that female mice may be less sensitive to the toxicities of urethane. C57Bl/10F mice tolerated lifetime exposures of up to 7.5% ethanol in the drinking water with no effects on body weight or survival (Schmidt *et al.*, 1987).

The present evaluation of urethane and ethanol consisted of a bioassay and ancillary studies to provide mechanistic information. Since results from the 13-week toxicity study indicated that urethane was less toxic to rats (NTP, 1996), the present studies were conducted in male and female B6C3F<sub>1</sub> mice and consisted of three exposure concentrations of urethane (10, 30, and 90 ppm) and two exposure concentrations of ethanol (2.5% and 5%).

Since ethanol may increase (NTP, 1996), decrease (Kristiansen *et al.*, 1990; Stoewsand *et al.*, 1991), or not affect (Altmann *et al.*, 1991) the tumorigenicity of urethane, it was necessary to select doses for the present studies that would give a range of tumor incidences, and doses of 10, 60, and 90 ppm urethane were anticipated to allow the description of a urethane dose response. A minimum of two doses of ethanol was necessary to determine a dose response for ethanol. The 2.5% ethanol dose was chosen because higher doses (10% or 20%) may have resulted in a decreased intake of urethane or in significant differences in body weight. The 5% ethanol dose was selected because it is comparable to the concentration of alcohol in the average alcoholic drink consumed by humans.

## MATERIALS AND METHODS

### PROCUREMENT AND CHARACTERIZATION OF URETHANE AND ETHANOL

Urethane was obtained from Aldrich Chemical Company (Milwaukee, WI) in one lot (09101PN), and ethanol was obtained from AAPER Alcohol (Shelbyville, KY) in one lot (961730BB). Identity, purity, and stability analyses were conducted by the study laboratory (Appendix I).

Lot 09101PN, a white crystalline solid, was identified as urethane by  $^1\text{H}$ - and  $^{13}\text{C}$ -nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Lot 961730BB, a clear liquid, was identified as ethanol by  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectroscopy. The purity of lots 09101PN and 961730BB were determined by  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR and gas chromatography (GC)/MS (lot 09101PN). The water content of urethane and ethanol was determined by Karl Fischer titration. For urethane, the results of  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectroscopy indicated a purity of 99% or greater, and GC/MS indicated a purity of greater than 95% with no minor impurity peaks detected. For ethanol, no impurities other than water were detected;  $^1\text{H}$ -NMR spectroscopy indicated 92.6% ethanol and 7.4% water. Karl Fischer titration indicated 0.1% water in urethane and 7.4% water in ethanol.

The bulk urethane was stored in sealed plastic bags in glass dessicators under phosphorus pentoxide at ambient temperature. The bulk ethanol was stored in glass containers at ambient temperature. Stability of urethane and ethanol in aqueous solutions was monitored for 56 (urethane) or 35 (ethanol) days using GC with a flame ionization detector. Concentrations of 10 ppm urethane and 0%, 2.5%, and 5% ethanol and 1% urethane were used to monitor the stability of urethane; concentrations of 2.5% ethanol and water and 2.5% ethanol and 90 ppm urethane were used to monitor the stability of ethanol. No degradation of the bulk chemical was detected.

## PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

The dose formulations were prepared once weekly during the 4-week study and approximately every 8 weeks during the 2-year study by mixing urethane with deionized water, ethanol with Millipore-filtered tap water, and then urethane with Millipore-filtered tap water or Millipore-filtered tap water containing ethanol (Table I1).

Periodic analyses of the dose formulations were conducted by the study laboratory using GC as described above.

The dose formulations were analyzed once weekly during the 4-week study (Table I2) and approximately every 8 weeks during the 2-year study (Table I3). During the 2-year study, animal room samples of the dose formulations were analyzed approximately every 6 months. Of the urethane dose formulations used during the 4-week study, 90 of 90 were within the target concentrations ( $\pm 20\%$  for the 10 ppm or  $\pm 10\%$  for the 30 and 90 ppm dose formulations); of the ethanol dose formulations, 80 of 80 were within the target concentrations ( $\pm 20\%$  for the 2.5% or  $\pm 10\%$  for the 5% dose formulations). Of the urethane dose formulations used during the 2-year study, 223 of 228 were within the target concentrations; of the animal room samples analyzed, 35 of 36 were within the target concentrations. Of the ethanol dose formulations, 200 of 203 were within the target concentrations; of the animal room samples analyzed, 31 of 32 were within the target concentrations.

## 2-YEAR STUDY

### Study Design

Groups of 48 male and 48 female mice received 0, 10, 30, or 90 ppm urethane in the presence of 0%, 2.5%, or 5% ethanol in drinking water *ad libitum* for 105 weeks. A 4-week study was conducted separately and consisted of additional groups of four male and four female mice designated for cell proliferation and apoptosis analyses; additional groups of four male and four female mice were also designated for measurement of induction of liver microsomal cytochromes (P450 and P450 2E1) and glutathione, liver and lung DNA adduct formation, and serum concentrations of urethane and ethanol. Liver, lung, and body weights were measured in four mice per group, and feed and water consumption were measured for all 4-week study mice; the results were combined.

## Source and Specification of Animals

Male and female B6C3F<sub>1</sub>/Nctr BR (C57BL/6N × C3H/HeN MTV<sup>-</sup>) mice were obtained from the study laboratory's breeding colony. Mice were quarantined for 7 days before the beginning of the study and were approximately 5 weeks old on the first day of the study. The health of the mice was monitored during the studies according to the protocols of the study laboratory's Sentinel Animal Program (Appendix M).

## Animal Maintenance

Mice were housed four per cage. Feed and water were available *ad libitum*. Feed and water consumption were measured once per week. Cages were changed once weekly, and racks were changed once monthly. Further details of animal maintenance are given in Table 1. Information on feed composition and contaminants is provided in Appendix L.

## Cell Proliferation and Apoptosis Analyses: 4-Week Mechanistic Study

Liver and lung slices (approximately 5 mm thick) were fixed in 10% neutral buffered formalin for 24 hours, processed for 8 hours on a Shandon Pathcenter Tissue+ Processor (Shandon, Inc., Pittsburgh, PA), embedded in paraffin, sectioned to a thickness of 4 μm, and mounted on positive-charged slides. Cell proliferation indices were determined by immunohistochemical localization of proliferating cell nuclear antigen (PCNA), slightly modified from Foley *et al.* (1991). Tissue sections were deparaffinized in xylene and rehydrated with decreasing concentrations of ethanol into phosphate-buffered saline. Endogenous peroxidase was quenched with 3% hydrogen peroxide containing 0.1% sodium azide. The sections were placed in an antigen-retrieval solution consisting of 1% zinc sulfate in deionized water and heated for 7.5 minutes in a 700-watt microwave oven set to full power. A routine streptavidin procedure was performed, beginning with application of 0.5% casein to block nonspecific binding of subsequent antibody and sequential incubation of sections in a mouse monoclonal anti-PCNA antibody (clone PC10, Dako Corp., Carpinteria, CA), biotinylated goat anti-mouse IgG (Boehringer-Mannheim, Indianapolis, IN), and streptavidin-conjugated horseradish peroxidase (Jackson Immunoresearch Laboratories, West Grove, PA). The PCNA-positive cells were visualized by incubating the sections in 3,3'-diaminobenzidine

hydrochloride chromogen followed by counterstaining with Mayer's hematoxylin. The stained slides were analyzed with the point counting feature of an image analysis system (Optimas Corporation, Bothell, WA). Approximately 2,000 cells per liver were analyzed to determine the percentage of cells in the G<sub>0</sub>, G<sub>1</sub>, G<sub>2</sub>, S, and M phases of the cell cycle. A similar number of cells were analyzed in the lung, and the data were reported as percentage of PCNA-labeled cells.

Apoptotic cell indices were determined with an Apoptag detection system (Oncor, Gaithersburg, MD), which measures *in situ* end-labeling of 3'-hydroxy DNA strand breaks localized in apoptotic bodies (Gavrieli *et al.*, 1992). Permeabilized tissue sections were enzymatically labeled with digoxigenin-nucleotide via terminal deoxynucleotidyl transferase and subsequently exposed to horseradish peroxidase-conjugated anti-digoxigenin antibody. Staining was developed with 3,3'-diaminobenzidine, and sections were counterstained with methyl green. Approximately 2,000 cells per liver were analyzed.

### **Induction of Cytochromes P450 and P450 2E1: 4-Week Mechanistic Study**

Liver samples were rinsed in ice-cold saline, blotted, weighed, and homogenized in five volumes of 100 mM Tris-hydrochloride (pH 7.2) buffer containing 50 mM potassium chloride. A 400  $\mu$ L aliquot of the homogenate was removed, 20  $\mu$ L of 20% sulfosalicylic acid was added, and the mixture was vortexed and centrifuged at 2,000  $\times$  g for 20 minutes at 4° C. The clear supernatant was stored at -70° C for glutathione determinates. Microsomes were prepared from the homogenate by differential centrifugation described by Leakey *et al.* (1989). The washed microsomal pellets were suspended in 50 mM Tris-hydrochloride (pH 7.2) buffer, without the addition of glycerol, a known substrate for cytochrome P450 2E1, and stored at -80° C. Microsomal protein concentrations were determined using the method of Lowry *et al.* (1951), with bovine serum albumin as the standard. Differential spectrophotometric determinations of liver microsomal total cytochrome P450 were conducted according to Omura and Sato (1964). Liver microsomal cytochrome P450 2E1 activity was assessed by measuring the oxidation of *p*-nitrophenol to 4-nitrocatechol. Incubation conditions were essentially as described by Mishin *et al.* (1996), except that incubation volumes were reduced to 575  $\mu$ L. Final concentrations in the reaction mixtures were

magnesium chloride, 2.5 mM; NADPH, 1 mM; *p*-nitrophenol, 0.1 mM; and microsomal protein, 0.14 mg/mL.

Reactions were stopped by addition of trifluoroacetic acid, the pH was raised by addition of 10 N sodium hydroxide as described by Reinke and Moyer (1985), and the reactions were read in duplicate on a Thermomax<sup>®</sup> (Molecular Devices Corp., Sunnyvale, CA) plate reader at 340 nm. Under these conditions, the conversion of *p*-nitrophenol to 4-nitrocatechol was linear with regard to both incubation time and the concentration of microsomal protein.

Glutathione was measured by a modification of the spectrophotometric method of Sedlak and Lindsay (1968), which is based on the reductive cleavage of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). Aliquots (60  $\mu$ L) were mixed with 682  $\mu$ L 100 mM sodium phosphate buffer (pH 8), and 200  $\mu$ L portions were assayed in triplicate on a Thermomax<sup>®</sup> plate reader at 412 nm after the addition of 25  $\mu$ L 1 mM DTNB.

#### **DNA Adduct Formation: 4-Week Mechanistic Study**

Ethenodeoxyadenosine (etheno-dA) and [<sup>15</sup>N<sub>5</sub>]etheno-dA were synthesized according to the procedure of Green and Hathway (1978) using 1 M sodium acetate (pH 4.5). After the reaction, the solvent was evaporated under reduced pressure, the residue was dissolved in water, and the adducts were purified by high-performance liquid chromatography (HPLC) and quantified by ultraviolet (UV) spectrometry (Barrio *et al.*, 1972).

Ethenodeoxycytidine (etheno-dC) and [<sup>15</sup>N<sub>3</sub>]etheno-dC were prepared in a similar manner using 200 mM ammonium acetate (pH 3.5). HPLC purifications were conducted by reversed-phase HPLC using a  $\mu$ Bondapak C18 column (0.39 cm  $\times$  30 cm; Waters Associates, Milford, MA) with an HPLC system consisting of two Waters Model 510 pumps, a Rheodyne Model 7125 injector (Rheodyne, Cotati, CA), and a Waters Model 660 automated gradient controller. The peaks were monitored at 280 nm with a Hewlett-Packard 1050 diode array spectrophotometric detector (Hewlett-Packard, Wilmington, DE). Samples were eluted with a 30-minute linear gradient of 0% to 20% solvent B; solvent A was 10 mM ammonium acetate (pH 5.3), and solvent B was methanol. The flow rate was 2 mL per minute. Etheno-dA eluted at 25 minutes, and etheno-dC eluted at 22 minutes.

The *in vitro*- and *in vivo*-modified DNA samples (100  $\mu$ g in 100 to 200  $\mu$ L total volume) were spiked with the internal standards (10 to 20 pg). Initially, the DNA was hydrolyzed enzymatically to nucleosides with DNase I,

followed by snake venom phosphodiesterase and alkaline phosphatase (Heflich *et al.*, 1986). Because unsatisfactory results were obtained, subsequent hydrolyses were conducted with micrococcal nuclease, spleen phosphodiesterase, and nuclease P1. Specifically, the samples were incubated with 2 U micrococcal nuclease (Sigma Chemical Co., St. Louis, MO) and 0.2 U spleen phosphodiesterase (Sigma) for 4 hours at 37° C in 20 mM sodium succinate buffer (pH 6) containing 10 mM calcium chloride. These enzymes were previously dialyzed against water (Randerath *et al.*, 1981). Nuclease P1 (5 µg, Sigma) was then added, and the hydrolysis was continued an additional 2 hours.

The deoxyadenosine present in each hydrolysate was converted to deoxyinosine by the action of adenosine deaminase; more than 99% of the deoxyadenosine was hydrolyzed after 30 minutes using 0.01 units per sample. Etheno-dA and etheno-dC were stable under these conditions. Complete hydrolysis of the DNA to nucleosides was verified using HPLC-UV spectrometry.

Liver and lung etheno DNA adducts were determined by liquid chromatography-electrospray mass spectrometry/mass spectrometry (LC-ES MS/MS) by direct injection of incubations into the LC system. The liquid handling system consisted of an autosampler (AS3500, Dionex, Sunnyvale, CA), two automated switching valves (TPMV, Rheodyne, Cotati, CA), and two HPLC pumps (a Dionex GP40 quaternary gradient pump and a Hewlett Packard 1050 pump, Palo Alto, CA). Valve 1 allowed the gradient pump eluent to either load a sample onto the trap column and then wash it or bypass the trap column and clean the analytical column (Doerge *et al.*, 1999). Valve 2 was used to divert the trap column effluent to either waste or to the analytical column. The gradient pump was used for sample injection, cleanup, and regeneration of the trap and analytical columns; the isocratic pump, containing water:acetonitrile (90:10), was used to backflush the trap column to the analytical column during the analysis and to keep a constant flow of mobile phase going into the mass spectrometer during sample loading and preparation periods. The sample was loaded and washed for 4.5 minutes at 1 mL per minute with 100% water onto a reverse phase trap column (Luna C18, 2 mm × 30 mm, 5 µm, Phenomenex, Torrance, CA), and then the trap column was washed with water:acetonitrile (95:5) for 1.5 minutes at 1 mL per minute to waste. After switching

valve 2, the concentrated sample zone was backflushed from the trap column onto the analytical column (Luna C18, 2 mm × 150 mm, 3 μm, Phenomenex) at 200 μL per minute with water:acetonitrile (90:10), and sample components were eluted into the mass spectrometer. When the 12-minute run was finished, valve 2 was switched, and the trap column was cleaned with water:acetonitrile (5:95) for 2 minutes at 1 mL per minute to waste. Valve 1 was then switched, and the analytical column was cleaned with water:acetonitrile (5:95) for 2 minutes at 200 μL/minute. Both valves were switched to their initial positions to equilibrate the trap and analytical columns at the starting mobile phase compositions, and the process was repeated.

Analyses were conducted with a Quattro LC triple quadrupole mass spectrometer (Micromass, Manchester, England) equipped with an ES interface with a source block temperature of 150° C and desolvation temperature of 450° C. Nitrogen gas was used as the desolvation gas (750 L/hour) and nebulizing gas (90 L/hour). Argon was used as the collision gas at a collision cell pressure of  $1.5 \times 10^{-3}$  mBar. Positive ions were acquired in multiple reaction monitoring mode (dwell time = 0.3 seconds, span = 0.02 Da, and interchannel delay = 0.03 seconds) for the (M+H)<sup>+</sup> to BH<sub>2</sub><sup>+</sup> transitions for both etheno-dA (m/z 276/160) and etheno-dC (m/z 252/136) and the internal standards, <sup>15</sup>N<sub>3</sub>-etheno-dA (m/z 281/165) and <sup>15</sup>N<sub>3</sub>-etheno-dC (m/z 255/139). The cone voltage was 25 V for the etheno-dA transitions and 20 V for the etheno-dC transitions. The collision energy was 15 eV for all four transitions.

### **Urethane and Ethanol Serum Concentrations: 4-Week Mechanistic Study**

Serum urethane was quantified by isotope dilution gas chromatography (GC)/MS according to Hurst *et al.* (1990). Isotopically labeled (99 atom% <sup>13</sup>C, <sup>15</sup>N) urethane was used as the internal standard. Serum ethanol was measured spectrophotometrically using Sigma Diagnostics Ethanol Procedure No. 332-UV and reagents (Sigma). This procedure measures the ethanol concentration by assessing the reduction of NAD to NADH during the alcohol dehydrogenase-catalyzed oxidation of ethanol to acetaldehyde (Poklis and Mackell, 1982). The serum ethanol assays were conducted in quartz 96-well microtiter plates (Molecular Devices Corp.) and NADH was quantified at 340 nm using a Thermomax<sup>®</sup> microplate reader.

## Clinical Examinations and Pathology

All animals were observed twice daily. Clinical findings were recorded weekly. Body weights were recorded weekly and at the end of the study.

Complete necropsies and microscopic examinations were performed on all mice. The liver and lung were weighed, and all organs and tissues were examined for grossly visible lesions. All major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in Tissue-Prep II, sectioned to a thickness of 4 to 6  $\mu\text{m}$ , and stained with hematoxylin and eosin for microscopic examination. Tissues examined microscopically are listed in Table 1.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the study laboratory's Micropath Data Collection System. The slides, paraffin blocks, and residual wet tissues were sent to the study laboratory's Block and Slide Laboratory for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assurance group. The individual animal records and tables were compared for accuracy, the slide and tissue counts were verified, and the histotechnique was evaluated. For the 2-year study, a quality assessment pathologist evaluated slides from all tumors and all potential target organs, which included the heart and liver of males and females. In addition, slides from the lung, harderian gland, spleen, and thymus of males and females, the adrenal, coagulating, and preputial glands of males, and the ovary and uterus of females were examined.

Differences of opinion were reconciled between the study and quality assessment pathologists. The quality assessment pathologist served as the Pathology Working Group (PWG) chairperson and presented histopathology slides containing the diagnoses made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologists, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist,

the study pathologist, and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Final diagnoses for reviewed lesions represent a consensus between the laboratory pathologist, reviewing pathologist, and the PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman *et al.* (1985). For subsequent analyses of the pathology data, the decision of whether to evaluate the diagnosed lesions for each tissue type separately or combined was generally based on the guidelines of McConnell *et al.* (1986).

**TABLE 1**  
**Experimental Design and Materials and Methods in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

---

**Study Laboratory**

National Center for Toxicological Research (NCTR) (Jefferson, AR)

**Strain and Species**

B6C3F<sub>1</sub>/Nctr BR (C57BL/6N × C3H/HeN MTV<sup>-</sup>) mice

**Animal Source**

NCTR breeding colony (Jefferson, AR)

**Time Held Before Study**

7 days

**Average Age When Study Began**

5 weeks

**Date of First Exposure**

March 10-June 9, 1997

**Duration of Exposure**

105 weeks

**Date of Last Exposure**

March 8-June 7, 1999

**Necropsy Dates**

March 9-June 8, 1999

**Average Age at Necropsy**

110 weeks

**Size of Study Groups**

48 males and 48 females

**Method of Distribution**

Animals were distributed randomly into groups of approximately equal initial mean body weights.

**Animals per Cage**

4

**Method of Animal Identification**

Ear clip and cage number

**Diet**

NIH-31 autoclaved pelleted diet (Purina Mills, Richmond, IN), available *ad libitum*

**Water**

Millipore-filtered water (Jefferson municipal supply) via water bottle, available *ad libitum*

---

**TABLE 1**  
**Experimental Design and Materials and Methods in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

---

**Cages**

Polycarbonate (Lab Products, Seaford, DE), changed once weekly

**Bedding**

Hardwood chips (Northeastern Products, Warrensburg, NY), changed once weekly

**Racks**

Stainless steel (Allentown Caging Equipment Co., Inc., Allentown, NJ), changed once monthly

**Animal Room Environment**

Temperature: 72° ± 3° F

Relative humidity: 50% ± 20%

Room fluorescent light: 12 hours/day

Room air changes: 10/hour

**Exposure Concentrations**

0, 10, 30, or 90 ppm urethane and 0%, 2.5%, or 5% ethanol in drinking water

**Type and Frequency of Observation**

Observed twice daily; clinical findings and food and water consumption were recorded weekly; mice were weighed once weekly and at the end of the study

**Method of Sacrifice**

Carbon dioxide asphyxiation

**Necropsy**

Necropsy was performed on all animals. The liver and lung were weighed.

**Histopathology**

Complete histopathology was performed on all 2-year study mice. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone with marrow, brain, clitoral gland, coagulating gland, ear canal, esophagus, eye, gallbladder, hardierian gland, heart with aorta, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, lacrimal gland, larynx, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland (females only), mesentery, muscle, nose, ovary, pancreas, pancreatic islets, parathyroid gland, pharynx, pituitary gland, preputial gland, prostate gland, salivary gland, sciatic nerve, skin, spinal cord, spleen, stomach (forestomach and glandular), testis with epididymus and seminal vesicle, thymus, thyroid gland, tongue, trachea, urinary bladder, uterus, vagina, and Zymbal's gland.

**4-Week Mechanistic Study*****Cell Proliferation and Apoptosis Analyses***

Additional groups of four male and four female mice were sacrificed after 4 weeks of exposure (October 7-November 5, 1996) to urethane, ethanol, and urethane/ethanol, and liver and lung samples were collected for cell proliferation analyses; liver samples were also used for apoptosis analyses.

***Induction of Cytochromes P450 and P450 2E1, Glutathione Concentration, DNA Adduct Formation, and Urethane and Ethanol Serum Concentrations***

Additional groups of four male and four female mice were sacrificed after 4 weeks of exposure (November 4-December 13, 1996) to urethane, ethanol, and urethane/ethanol. Liver and lung samples were collected for measurements of induction of cytochromes (P450 and P450 2E1) and glutathione; liver and lung samples were collected for measurements of DNA adduct concentrations; blood was collected from the retroorbital sinus for measurements of serum concentrations of urethane and ethanol.

Liver, lung, and body weights were measured in four mice per group, and feed and water consumption were measured in all 4-week study mice; results were combined.

---

## STATISTICAL METHODS

### Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals found dead of other than natural causes were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival effects of urethane are one sided, and those for ethanol and the effect of ethanol on the carcinogenicity of urethane are two sided; the P values are unadjusted.

### Calculation of Incidence

The incidences of neoplasms or nonneoplastic lesions are presented in Tables A1, A4, B1, B3, C1, C3, D1, D4, E1, E3, F1, and F3 as the numbers of animals bearing such lesions at a specific anatomic site and the numbers of animals with that site examined microscopically. For calculation of statistical significance, the incidences of most neoplasms (Tables A2a through A2e, B2, C2, D2a through D2e, E2, and F2) and all nonneoplastic lesions are given as the numbers of animals affected at each site examined microscopically. Tables A2a through A2e, B2, C2, D2a through D2e, E2, and F2 also give the survival-adjusted neoplasm rate for each group and each site-specific neoplasm. This survival-adjusted rate (based on the Poly-3 method described below) accounts for differential mortality by assigning a reduced risk of neoplasm, proportional to the third power of the fraction of time on study, to animals that do not reach terminal sacrifice.

### Analysis of Neoplasm and Nonneoplastic Lesion Incidences

The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. This test is a survival-adjusted quantal-response procedure that modifies the Cochran-Armitage linear trend test to take survival differences into account. More specifically, this method modifies the denominator in the quantal estimate of lesion incidence to approximate more closely the total number of animal years at risk. For analysis of a given site, each animal is assigned a risk weight. This value is

one if the animal had a lesion at that site or if it survived until terminal sacrifice; if the animal died prior to terminal sacrifice and did not have a lesion at that site, its risk weight is the fraction of the entire study time that it survived, raised to the  $k$ th power.

This method yields a lesion prevalence rate that depends only upon the choice of a shape parameter for a Weibull hazard function describing cumulative lesion incidence over time (Bailer and Portier, 1988). Unless otherwise specified, a value of  $k=3$  was used in the analysis of site-specific lesions. This value was recommended by Bailer and Portier (1988) following an evaluation of neoplasm onset time distributions for a variety of site-specific neoplasms in control F344 rats and B6C3F<sub>1</sub> mice (Portier *et al.*, 1986). Bailer and Portier (1988) showed that the Poly-3 test gave valid results if the true value of  $k$  was anywhere in the range from 1 to 5. A further advantage of the Poly-3 method is that it does not require lesion lethality assumptions. Variation introduced by the use of risk weights, which reflect differential mortality, was accommodated by adjusting the variance of the Poly-3 statistic as recommended by Bieler and Williams (1993).

Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall exposure-related trend. Continuity-corrected Poly-3 tests were used in the analysis of neoplasm incidence, and reported P values are one sided for urethane and two sided for ethanol and the effect of ethanol on the carcinogenicity of urethane. Positive trends are reported with right-tailed P values. Negative trends are reported with left-tailed P values, with the letter N added to indicate a lower incidence as exposure increases.

The relationship between treatment and nonneoplastic lesion severity was analyzed by the Jonckheere-Terpstra test (Jonckheere, 1954). This test looks for monotonic trends. Unlike the Poly-3 test, it is not age adjusted, and animals that died early without nonneoplastic lesions or with less severe lesions were counted as though they had full opportunity to develop a more severe nonneoplastic lesion. The P values are one tailed (i.e., only increasing severity with dose will be significant). Pairwise comparisons were conducted using Williams' modification (Williams, 1986) of Shirley's test (Shirley, 1977). As with the Jonckheere-Terpstra test, this analysis detects

monotonic differences and is not age adjusted. Because the test is monotonic, a mid-dose comparison cannot be significant unless all of the doses greater than it are also significant.

### **Analysis of Continuous Variables**

For the 2-year study, body weights and feed and water consumption comparisons were made on a per cage basis on a subset of measurements sampled at 3-month intervals and were analyzed by analysis of variance (ANOVA); the cage body weight was calculated by averaging the individual animal weights. A mixed model approach to repeated measures analysis was used with the following fixed effects: urethane concentration, ethanol concentration, and urethane-ethanol interaction. ANOVA was also used to analyze liver and lung weight, terminal body weight, and the ratio of liver and lung weight to the terminal body weight. Only terminal sacrifice animals were included in this analysis.

For the 4-week study, the same two-way ANOVA procedure was used to analyze weekly mean body weights and feed and water consumption, terminal mean body and organ weights, cell proliferation indexes, concentrations of apoptosis, hepatic cytochromes (P450 and P450 2E1) and glutathione content, etheno DNA adduct concentrations, and serum urethane and ethanol. With the exception of terminal body and organ weights, all data from the 4-week study were analyzed with Dunnett's (1955) two-sided test to compare exposed group means to the control means. When necessary, data were transformed before the analysis to maintain an equal variance, normal distribution, or both.

### **QUALITY ASSURANCE METHODS**

The studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). The Quality Assurance Unit of the National Center for Toxicological Research performed audits and inspections of protocols, procedures, data, and reports throughout the course of the studies. Separate audits covered completeness and accuracy of the pathology data, pathology specimens, final pathology

tables, and a draft of this NTP Technical Report. Audit procedures and findings are presented in the reports and are on file at the NCTR. The audit findings were reviewed and assessed by the NCTR staff, and all comments were resolved or otherwise addressed during the preparation of this Technical Report.



## RESULTS

### 4-WEEK MECHANISTIC STUDY

Results of the 4-week study are presented in Appendix G. Terminal group mean body weights were not affected by exposure to either urethane or ethanol (Table G1). Increasing the urethane concentration had no effect on water consumption by mice (Table G2). Increasing the ethanol concentration caused a significant decrease in water consumption by males; a significant ethanol-by-urethane interaction occurred in males (Table G2). Concentrations of 10, 30, and 90 ppm urethane resulted in average daily consumption of approximately 35, 110, and 315  $\mu\text{g}$  urethane for males and 30, 80, and 245  $\mu\text{g}$  for females. Concentrations of 2.5% and 5% ethanol resulted in average daily consumption of approximately 85 and 170 mg ethanol for males and 70 and 130 mg for females. Increasing the urethane concentration had no effect on feed consumption by mice (Table G3); increasing the ethanol concentration caused a significant exposure-related decrease in feed consumption by males.

Serum concentrations of urethane and ethanol were assessed. Urethane was detected in the serum of males and females exposed to 30 or 90 ppm urethane and 5% ethanol (Table G4); the concentration of urethane in other groups was similar to the detection limit of the assay. Ethanol was not detected in any of the samples. Liver and lung weights were not affected by either urethane or ethanol (Table G5). Increasing the ethanol concentration had no effect on the cell cycle distribution in the liver of males or females (Table G6). The percentage of  $G_0$  cells was decreased and the percentage of  $G_1$  cells was increased in the liver of females exposed to 30 or 90 ppm urethane (Table G6); the percentage of these cells were unchanged in males. The percent of apoptotic cells in the liver was affected by urethane in males, and the effect was significant in the 10 and 30 ppm groups (Table G6); ethanol had no effect on apoptosis in either sex. The percent of PCNA-labeling was decreased in the lung of males and females exposed to 30 or 90 ppm urethane; increasing the ethanol concentration had no effect on the percent of PCNA-labeling in males or females (Table G7). Total cytochrome P450 content, cytochrome P450 2E1 activity,

and glutathione content in the liver of males and females were not affected by urethane (Table G8). Increasing the concentration of ethanol caused an exposure-related increase in cytochrome P450 2E1 activity and an exposure-related decrease in glutathione content in females (Table G8); these parameters in females exposed to 2.5% or 5% ethanol were significantly greater or less than those in the controls. Etheno-dA adduct concentrations in hepatic DNA were significantly increased by exposure to urethane and decreased by exposure to ethanol (Table G9); in lung DNA, neither urethane nor ethanol affected etheno-dA or etheno-dC adduct concentrations.

## 2-YEAR STUDY

### *Survival*

Estimates of 2-year survival probabilities for male and female mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol are shown in Tables 2, 3, and 4 and in Kaplan-Meier survival curves (Figures 3 and 4). Urethane caused an exposure-related decrease in survival of mice, and the decrease was significant in 30 and 90 ppm males and females and marginally significant in females exposed to 10 ppm urethane (statistical analyses not presented). When analyses were conducted within each exposure concentration of ethanol, significant exposure-related decreases in survival were observed as a function of urethane concentration (Tables 2, 3, and 4). Pairwise comparisons indicated that survival of males exposed to 90 ppm and females exposed to 30 or 90 ppm urethane and 0% ethanol was significantly less than that of the controls (Table 2). In addition, survival of males exposed to 90 ppm and females exposed to 10 ppm or greater urethane and 2.5% ethanol was significantly less than that of the controls (Table 3); survival of males exposed to 30 or 90 ppm and females exposed to 90 ppm urethane and 5% ethanol was significantly less (Table 4).

Estimates of 2-year survival probabilities for male and female mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane are shown in Table 5 and in Kaplan-Meier survival curves (Figures 5 and 6). Ethanol caused a marginal exposure-related increase in survival of males, but had no effect on the survival of females. When analyses were conducted within each exposure concentration of urethane, a significant exposure-related increase in survival occurred in males exposed to 0 ppm urethane (Table 5). Pairwise comparisons indicated that survival of mice exposed to 2.5% ethanol and 90 ppm urethane and of males exposed to 5% ethanol and 0 ppm urethane was significantly greater than that of the controls (Table 5).

**TABLE 2**  
**Survival of Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm  |
|--|---------|---------|---------|---------|
| <b>Male</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Moribund   | 2       | 8       | 4       | 11      |
| Natural deaths   | 19      | 14      | 18      | 29      |
| Animals surviving to study termination                       | 27      | 26      | 26      | 8       |
| Percent probability of survival at end of study <sup>a</sup> | 56      | 54      | 54      | 17      |
| Mean survival (days) <sup>b</sup>                            | 667     | 655     | 697     | 626     |
| Survival analysis <sup>c</sup>                               | P=0.001 | P=0.375 | P=0.460 | P=0.001 |
| <b>Female</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Moribund   | 1       | 3       | 5       | 18      |
| Natural deaths   | 9       | 8       | 16      | 29      |
| Animals surviving to study termination                       | 38      | 37      | 27      | 1       |
| Percent probability of survival at end of study              | 79      | 77      | 56      | 2       |
| Mean survival (days)   | 747     | 740     | 706     | 628     |
| Survival analysis  | P=0.001 | P=0.390 | P=0.006 | P=0.001 |

<sup>a</sup> Kaplan-Meier determinations

<sup>b</sup> Mean of all deaths (uncensored and terminal sacrifice)

<sup>c</sup> The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed group columns.

**TABLE 3**  
**Survival of Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm  |
|--|---------|---------|---------|---------|
| <b>Male</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Moribund   | 10      | 5       | 7       | 9       |
| Natural deaths   | 6       | 13      | 16      | 23      |
| Animals surviving to study termination                       | 32      | 30      | 25      | 16      |
| Percent probability of survival at end of study <sup>a</sup> | 67      | 62      | 52      | 33      |
| Mean survival (days) <sup>b</sup>                            | 703     | 711     | 657     | 673     |
| Survival analysis <sup>c</sup>                               | P=0.001 | P=0.390 | P=0.078 | P=0.002 |
| <b>Female</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Accidental deaths <sup>d</sup>                               | 4       | 4       | 0       | 0       |
| Moribund   | 1       | 4       | 11      | 9       |
| Natural deaths   | 4       | 7       | 18      | 31      |
| Animals surviving to study termination                       | 39      | 33      | 19      | 8       |
| Percent probability of survival at end of study              | 89      | 75      | 40      | 17      |
| Mean survival (days)   | 758     | 733     | 681     | 663     |
| Survival analysis  | P=0.001 | P=0.043 | P=0.001 | P=0.001 |

<sup>a</sup> Kaplan-Meier determinations

<sup>b</sup> Mean of all deaths (uncensored, censored, and terminal sacrifice)

<sup>c</sup> The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed group columns.

<sup>d</sup> Censored from survival analyses

**TABLE 4**  
**Survival of Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm  |
|--|---------|---------|---------|---------|
| <b>Male</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Moribund   | 5       | 6       | 6       | 15      |
| Natural deaths   | 7       | 13      | 17      | 21      |
| Animals surviving to study termination                       | 36      | 29      | 25      | 12      |
| Percent probability of survival at end of study <sup>a</sup> | 75      | 62      | 52      | 25      |
| Mean survival (days) <sup>b</sup>                            | 736     | 687     | 676     | 654     |
| Survival analysis <sup>c</sup>                               | P=0.001 | P=0.062 | P=0.007 | P=0.001 |
| <b>Female</b>  |         |         |         |         |
| Animals initially in study                                   | 48      | 48      | 48      | 48      |
| Accidental deaths <sup>d</sup>                               | 4       | 0       | 0       | 0       |
| Moribund   | 6       | 4       | 4       | 11      |
| Natural deaths   | 7       | 12      | 17      | 33      |
| Animals surviving to study termination                       | 31      | 32      | 27      | 4       |
| Percent probability of survival at end of study              | 70      | 67      | 56      | 8       |
| Mean survival (days)   | 741     | 713     | 712     | 645     |
| Survival analysis  | P=0.001 | P=0.330 | P=0.064 | P=0.001 |

<sup>a</sup> Kaplan-Meier determinations

<sup>b</sup> Mean of all deaths (uncensored, censored, and terminal sacrifice)

<sup>c</sup> The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed group columns.

<sup>d</sup> Censored from survival analyses




FIGURE 3  
Kaplan-Meier Survival Curves for Male Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol  
in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)




FIGURE 4  
Kaplan-Meier Survival Curves for Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)

**TABLE 5**  
**Survival Analysis of Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane**  
**in Drinking Water for 2 Years<sup>a</sup>**

|                                | Urethane (ppm) | 0% Ethanol | 2.5% Ethanol | 5% Ethanol |
|--------------------------------|----------------|------------|--------------|------------|
| <b>Male</b>                    |                |            |              |            |
| Survival analysis <sup>b</sup> |                |            |              |            |
|                                | 0              | P=0.043N   | P=0.315N     | P=0.043N   |
|                                | 10             | P=0.408N   | P=0.330N     | P=0.422N   |
|                                | 30             | P=0.732N   | P=0.651      | P=0.739    |
|                                | 90             | P=0.147N   | P=0.023N     | P=0.151N   |
| <b>Female</b>                  |                |            |              |            |
| Survival analysis              |                |            |              |            |
|                                | 0              | P=0.311    | P=0.215N     | P=0.329    |
|                                | 10             | P=0.265    | P=0.774      | P=0.271    |
|                                | 30             | P=0.916N   | P=0.101      | P=0.917N   |
|                                | 90             | P=0.273N   | P=0.023N     | P=0.221N   |

<sup>a</sup> The number of animals initially in study; the number of accidental deaths, moribund, and natural deaths; animals surviving to study termination; percent probability of survival at end of study; and mean survival are presented in Tables 2, 3, and 4; P values are two sided.

<sup>b</sup> The result of the life table trend test (Tarone, 1975) is in the 0% ethanol column, and the results of the life table pairwise comparisons (Cox, 1972) with 0% ethanol are in the 2.5% and 5% ethanol columns. A negative trend or a lower mortality in an exposure group is indicated by N.





FIGURE 5  
Kaplan-Meier Survival Curves for Male Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)




**FIGURE 6**  
**Kaplan-Meier Survival Curves for Female Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)**

***Body Weights, Water and Compound Consumption, Feed Consumption, and Clinical Findings***


Mean body weights of mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol showed evidence of urethane-induced reductions in body weights, especially in female mice (Figures 7 and 8). Mean body weights of mice exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol were generally decreased during the last 24 weeks of the study; in addition, females exposed to 10 or 30 ppm urethane and 2.5% ethanol or 0, 10, or 30 ppm urethane and 5% ethanol also had generally reduced body weights during this time period. Urethane, but not ethanol, caused an exposure-related decrease in terminal body weights of mice; terminal body weights were significantly decreased in males and females exposed to 90 ppm and in females exposed to 30 ppm urethane and 2.5% or 5% ethanol. Mean body weights of mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane were generally unchanged throughout the study (Figures 9 and 10).

Water consumption by mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol was unchanged throughout the study (Tables J1 through J6; Figures 11 and 12). Concentrations of 10, 30, and 90 ppm urethane resulted in average daily consumption of approximately 40, 115, and 360  $\mu\text{g}$  urethane for males and 35, 105, and 325  $\mu\text{g}$  for females. Water consumption by mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane was generally decreased throughout the study (Figures 13 and 14). This ethanol-induced reduction in water consumption was more marked in males than in females. Concentrations of 2.5% and 5% ethanol resulted in average daily consumption of approximately 100 and 180 mg ethanol for males and 80 and 155 mg for females.

Feed consumption by mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol was unchanged (Tables K1 through K6; Figures 15 and 16). Feed consumption by mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane was generally decreased, and a negative trend occurred in males and females (Figures 17 and 18). There were no clinical findings related to exposure to urethane or ethanol.



**FIGURE 7**  
**Growth Curves for Male Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol**  
**in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)**



**FIGURE 8**  
Growth Curves for Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol  
in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)





FIGURE 9  
 Growth Curves for Male Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane  
 in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)



**FIGURE 10**  
**Growth Curves for Female Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane**  
**in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)**




FIGURE 11  
Water Consumption by Male Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol  
in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)







FIGURE 12  
Water Consumption by Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol  
in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)




**FIGURE 13**  
**Water Consumption by Male Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane**  
**in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)**



**FIGURE 14**  
**Water Consumption by Female Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane**  
**in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)**



**FIGURE 15**  
**Feed Consumption by Male Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol**  
**in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)**



**FIGURE 16**  
**Feed Consumption by Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol**  
**in Drinking Water for 2 Years (■=0 ppm; ▲=10 ppm; ◆=30 ppm; ●=90 ppm)**





FIGURE 17  
 Feed Consumption by Male Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane  
 in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)



**FIGURE 18**  
**Feed Consumption by Female Mice Exposed to Ethanol and 0, 10, 30, or 90 ppm Urethane**  
**in Drinking Water for 2 Years (■=0%; ▲=2.5%; ◆=5%)**

### *Pathology and Statistical Analyses*

This section describes the statistically significant or biologically noteworthy changes in the incidences of hemangiosarcoma (all sites) and neoplasms and/or nonneoplastic lesions of the liver, lung, harderian gland, mammary gland, heart, ovary, uterus, forestomach, spleen, and skin. Summaries of the incidences of neoplasms and nonneoplastic lesions, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for most neoplasms mentioned in this section are presented in Appendixes A, B, and C for male mice and Appendixes D, E, and F for female mice.

*Liver:* Exposure to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol yielded no evidence that urethane affected liver weights in exposed mice; however, exposure to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane caused an exposure-related decrease in liver weights of males (Table H1). The incidences of hemangiosarcoma of the liver in mice exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol were significantly greater than those in mice exposed to 0 ppm urethane (Tables 6, A2a, B2, C2, D2a, E2, and F2; Figure 19) and exceeded the historical control ranges for hemangiosarcoma (all sites) [male: 7/474 (1.5%), range 0%-4%; female: 6/518 (1.2%), range 0%-2%; Tables A3a and D3a]. The incidences of hemangiosarcoma in mice exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane were not affected by exposure to ethanol (Tables A2b through A2e and D2b through D2e; Figure 19). The diagnosis of hemangiosarcoma was based on the proliferation of elongated, flattened, spindle-shaped or polyhedral endothelial cells that formed vascular spaces, solid nodules, or sheets of cells that replaced hepatic parenchyma. In organizing thrombi, normal-appearing endothelial cells penetrated only the superficial layers of fibrin in the thrombus and did not invade or replace hepatic parenchyma. In livers having large thrombi in areas of angiectasis, it was difficult to differentiate hemangiosarcoma from organizing thrombi.

In mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol, the incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) in males and females exposed to 30 or 90 ppm urethane and 0% ethanol, in males exposed to 90 ppm urethane and 2.5% ethanol, and in females

**TABLE 6**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Liver in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm        |
|---|---------------|---------------|---------------|---------------|
| <b>Male</b>   |               |               |               |               |
| <b>0% Ethanol</b>   |               |               |               |               |
| Number Examined Microscopically                           | 46            | 47            | 46            | 44            |
| Eosinophilic Focus <sup>a</sup>                           | 6             | 7             | 19**          | 28**          |
| Angiectasis   | 0             | 4*            | 6**           | 17**          |
| Regeneration  | 0             | 1             | 2             | 1             |
| Hemangiosarcoma   |               |               |               |               |
| Overall rate <sup>b</sup>                                 | 1/46 (2.2%)   | 2/47 (4.3%)   | 5/46 (10.9%)  | 13/44 (29.5%) |
| Poly-3 test <sup>c</sup>                                  | P=0.001       | P=0.489       | P=0.118       | P=0.001       |
| Hepatocellular Adenoma, Multiple                          | 2             | 3             | 4             | 7             |
| Hepatocellular Adenoma (includes multiple) <sup>d</sup>   |               |               |               |               |
| Overall rate  | 7/46 (15.2%)  | 13/47 (27.7%) | 17/46 (37.0%) | 17/44 (38.6%) |
| Poly-3 test   | P=0.009       | P=0.077       | P=0.025       | P=0.003       |
| Hepatocellular Carcinoma, Multiple                        | 1             | 0             | 1             | 1             |
| Hepatocellular Carcinoma (includes multiple) <sup>e</sup> | 7             | 6             | 9             | 9             |
| Hepatocellular Adenoma or Carcinoma <sup>f</sup>          |               |               |               |               |
| Overall rate  | 12/46 (26.1%) | 18/47 (38.3%) | 24/46 (52.2%) | 23/44 (52.3%) |
| Poly-3 test   | P=0.007       | P=0.095       | P=0.020       | P=0.002       |
| <b>2.5% Ethanol</b>                                       |               |               |               |               |
| Number Examined Microscopically                           | 47            | 48            | 46            | 48            |
| Eosinophilic Focus  | 6             | 3             | 17**          | 22**          |
| Angiectasis   | 0             | 0             | 7**           | 16**          |
| Regeneration  | 0             | 1             | 1             | 9**           |
| Hemangiosarcoma   |               |               |               |               |
| Overall rate  | 3/47 (6.4%)   | 4/48 (8.3%)   | 3/46 (6.5%)   | 11/48 (22.9%) |
| Poly-3 test   | P=0.002       | P=0.514       | P=0.604       | P=0.013       |
| Hepatocellular Adenoma, Multiple                          | 2             | 2             | 4             | 11*           |
| Hepatocellular Adenoma (includes multiple)                | 12            | 15            | 16            | 24**          |
| Hepatocellular Carcinoma, Multiple                        | 1             | 2             | 0             | 0             |
| Hepatocellular Carcinoma (includes multiple)              | 6             | 5             | 5             | 4             |
| Hepatocellular Adenoma or Carcinoma                       |               |               |               |               |
| Overall rate  | 16/47 (34.0%) | 19/48 (39.6%) | 17/46 (37.0%) | 24/48 (50.0%) |
| Poly-3 test   | P=0.019       | P=0.339       | P=0.294       | P=0.023       |

**TABLE 6**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Liver in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm                 | 10 ppm         | 30 ppm        | 90 ppm        |
|---|-----------------------|----------------|---------------|---------------|
| <b>Male (continued)</b>                                 |                       |                |               |               |
| <b>5% Ethanol</b>                                       |                       |                |               |               |
| Number Examined Microscopically                         | 48                    | 46             | 48            | 48            |
| Eosinophilic Focus                                      | 10                    | 9              | 18*           | 25**          |
| Angiectasis   | 1                     | 1              | 8**           | 19**          |
| Regeneration  | 0                     | 0              | 3*            | 5**           |
| Hemangiosarcoma   |                       |                |               |               |
| Overall rate  | 2/48 (4.2%)           | 2/46 (4.3%)    | 4/48 (8.3%)   | 13/48 (27.1%) |
| Poly-3 test   | P=0.001               | P=0.638        | P=0.260       | P=0.001       |
| Hepatocellular Adenoma, Multiple                        | 2                     | 3              | 3             | 3             |
| Hepatocellular Adenoma (includes multiple)              | 19                    | 9              | 16            | 12            |
| Hepatocellular Carcinoma                                | 7                     | 9              | 2             | 9             |
| Hepatocellular Adenoma or Carcinoma                     |                       |                |               |               |
| Overall rate  | 25/48 (52.1%)         | 16/46 (34.8%)  | 17/48 (35.4%) | 18/48 (37.5%) |
| Poly-3 test   | P=0.482N              | P=0.140N       | P=0.227N      | P=0.365N      |
| <b>Female</b>   |                       |                |               |               |
| <b>0% Ethanol</b>                                       |                       |                |               |               |
| Number Examined Microscopically                         | 48                    | 47             | 47            | 47            |
| Eosinophilic Focus                                      | 3                     | 14**           | 32**          | 20**          |
| Angiectasis   | 0                     | 3*             | 10**          | 24**          |
| Thrombosis  | 0                     | 1              | 1             | 11**          |
| Necrosis  |                       |                |               |               |
| Minimal   | 0 (0.0%) <sup>h</sup> | 1 (2.1%)       | 2 (4.3%)      | 0 (0.0%)      |
| Mild  | 3 (6.3%)              | 1 (2.1%)       | 1 (2.1%)      | 5 (10.6%)     |
| Moderate  | 1 (2.1%)              | 2 (4.3%)       | 2 (4.3%)      | 8 (17.0%)     |
| Monotonic trend test <sup>g</sup>                       | P=0.003               | P=0.485        | P=0.423       | P=0.003       |
| Regeneration  | 0                     | 0              | 1             | 2             |
| Hemangiosarcoma   |                       |                |               |               |
| Overall rate  | 0/48 (0.0%)           | 0/47 (0.0%)    | 1/47 (2.1%)   | 7/47 (14.9%)  |
| Poly-3 test   | P=0.001               | — <sup>i</sup> | P=0.471       | P=0.001       |
| Hepatocellular Adenoma, Multiple                        | 2                     | 2              | 9*            | 16**          |
| Hepatocellular Adenoma (includes multiple) <sup>j</sup> | 5                     | 10             | 19**          | 18**          |
| Hepatocellular Carcinoma                                | 0                     | 1              | 2             | 1             |
| Hepatocellular Adenoma or Carcinoma <sup>k</sup>        |                       |                |               |               |
| Overall rate  | 5/48 (10.4%)          | 11/47 (23.4%)  | 20/47 (42.6%) | 19/47 (40.4%) |
| Poly-3 test   | P=0.001               | P=0.071        | P=0.001       | P=0.001       |

**TABLE 6**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Liver in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|  | 0 ppm        | 10 ppm       | 30 ppm        | 90 ppm        |
|--|--------------|--------------|---------------|---------------|
| <b>Female (continued)</b>                  |              |              |               |               |
| <b>2.5% Ethanol</b>                        |              |              |               |               |
| Number Examined Microscopically            | 47           | 47           | 47            | 46            |
| Eosinophilic Focus                         | 2            | 20**         | 21**          | 28**          |
| Angiectasis                                | 2            | 5            | 7*            | 20**          |
| Thrombosis                                 | 1            | 0            | 4             | 9**           |
| Necrosis                                   |              |              |               |               |
| Minimal                                    | 3 (6.4%)     | 2 (4.3%)     | 1 (2.1%)      | 2 (4.3%)      |
| Mild                                       | 2 (4.3%)     | 1 (2.1%)     | 2 (4.3%)      | 9 (19.6%)     |
| Moderate                                   | 0 (0.0%)     | 0 (0.0%)     | 2 (4.3%)      | 6 (13.0%)     |
| Marked                                     | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%)      | 1 (2.2%)      |
| Monotonic trend test                       | P<0.001      | P=0.771      | P=0.554       | P<0.001       |
| Regeneration                               | 0            | 0            | 0             | 2*            |
| Hemangiosarcoma                            |              |              |               |               |
| Overall rate                               | 1/47 (2.1%)  | 2/47 (4.3%)  | 0/47 (0.0%)   | 7/46 (15.2%)  |
| Poly-3 test                                | P=0.001      | P=0.470      | P=0.553N      | P=0.007       |
| Hepatocellular Adenoma, Multiple           | 2            | 5            | 9*            | 14**          |
| Hepatocellular Adenoma (includes multiple) | 6            | 5            | 15**          | 23**          |
| Hepatocellular Carcinoma                   | 1            | 0            | 3             | 1             |
| Hepatocellular Adenoma or Carcinoma        |              |              |               |               |
| Overall rate                               | 7/47 (14.9%) | 5/47 (10.6%) | 16/47 (34.0%) | 23/46 (50.0%) |
| Poly-3 test                                | P=0.001      | P=0.441N     | P=0.003       | P=0.001       |
| <b>5% Ethanol</b>                          |              |              |               |               |
| Number Examined Microscopically            | 48           | 47           | 48            | 48            |
| Eosinophilic Focus                         | 2            | 26**         | 25**          | 21**          |
| Angiectasis                                | 2            | 1            | 5             | 22**          |
| Thrombosis                                 | 0            | 0            | 1             | 8**           |
| Necrosis                                   |              |              |               |               |
| Minimal                                    | 0 (0.0%)     | 1 (2.1%)     | 1 (2.1%)      | 2 (4.2%)      |
| Mild                                       | 0 (0.0%)     | 1 (2.1%)     | 2 (4.2%)      | 8 (16.7%)     |
| Moderate                                   | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%)      | 6 (12.5%)     |
| Marked                                     | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%)      | 1 (2.1%)      |
| Monotonic trend test                       | P<0.001      | P=0.075      | P=0.056       | P<0.001       |
| Regeneration                               | 0            | 0            | 0             | 3**           |

**TABLE 6**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Liver in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|  | 0 ppm       | 10 ppm       | 30 ppm        | 90 ppm        |
|--|-------------|--------------|---------------|---------------|
| <b>Female (continued)</b>                    |             |              |               |               |
| <b>5% Ethanol (continued)</b>                |             |              |               |               |
| Number Examined Microscopically              | 48          | 47           | 48            | 48            |
| Hemangiosarcoma                              |             |              |               |               |
| Overall rate                                 | 0/48 (0.0%) | 0/47 (0.0%)  | 0/48 (0.0%)   | 6/48 (12.5%)  |
| Poly-3 test                                  | P=0.001     | —            | —             | P=0.004       |
| Hepatocellular Adenoma, Multiple             | 0           | 2            | 11**          | 14**          |
| Hepatocellular Adenoma (includes multiple)   | 3           | 6            | 16**          | 16**          |
| Hepatocellular Carcinoma, Multiple           | 0           | 0            | 0             | 1             |
| Hepatocellular Carcinoma (includes multiple) | 0           | 1            | 0             | 1             |
| Hepatocellular Adenoma or Carcinoma          |             |              |               |               |
| Overall rate                                 | 3/48 (6.3%) | 7/47 (14.9%) | 16/48 (33.3%) | 17/48 (35.4%) |
| Poly-3 test                                  | P=0.001     | P=0.127      | P=0.001       | P=0.001       |

\* Significantly different ( $P \leq 0.05$ ) from the control group by the Poly-3 (neoplasms) or Williams' (nonneoplastic lesions) test

\*\*  $P \leq 0.01$

<sup>a</sup> Number of animals with lesion

<sup>b</sup> Number of animals with neoplasm per number of animals with liver examined microscopically

<sup>c</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>d</sup> Historical incidence for control groups in NCTR studies (mean): 89/470 (18.9%), range 13%-38%

<sup>e</sup> Historical incidence: 50/470 (10.6%), range 7%-21%

<sup>f</sup> Historical incidence: 129/470 (27.4%), range 19%-50%


<sup>g</sup> Beneath the control incidence is the overall monotonic trend in severity with exposure level tested using the Jonckheere-Terpstra test statistic. Beneath the exposed group incidence are the P values corresponding to pairwise monotonic tests of severity with exposure concentration using the Williams' modification of Shirley's nonparametric test for a monotonic dose response.

<sup>h</sup> Percentage of animals with lesion of given severity

<sup>i</sup> Value of statistic cannot be computed.

<sup>j</sup> Historical incidence: 21/515 (4.1%), range 0%-11%

<sup>k</sup> Historical incidence: 29/515 (5.6%), range 0%-11%



**FIGURE 19**  
**Incidences of Hemangiosarcoma of the Liver in Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**  
 [\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol]

exposed to 30 or 90 ppm urethane and 2.5% or 5% ethanol were significantly increased (Tables 6, A2a, B2, D2a, E2, and F2; Figure 20). The incidences of hepatocellular adenoma and hepatocellular carcinoma in males exposed to 30 or 90 ppm urethane and 0% ethanol were at the upper end of the historical control ranges; the incidences of hepatocellular adenoma or carcinoma (combined) in these groups slightly exceeded the historical range (Tables 6 and A3b). The incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) in females exposed to urethane and 0% ethanol exceeded the historical control ranges (Tables 6 and D3b).

The incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) occurred with positive trends in males exposed to increasing concentrations of ethanol and 0 ppm urethane, and the incidence of hepatocellular adenoma was significantly increased in the 5% ethanol group (Figure 20; Table A2b).

Hepatocellular adenomas were nodular lesions that obviously compressed adjacent parenchyma. Hepatocytes comprising these adenomas were larger than normal hepatocytes and were arranged without a lobular pattern. In some adenomas, there were a few small bile ducts, but in most adenomas, bile ducts were absent. A distinctive feature of the adenomas was sinusoidal ectasia that varied greatly in severity. Increased numbers of hematopoietic cells were usually present in the dilated vascular spaces. In severe cases of angiectasis within adenomas, there was often thrombus formation and necrosis of hepatocytes both within the adenoma and sometimes in adjacent nonneoplastic parenchyma. Differentiation between hepatocellular adenoma and a large eosinophilic focus (also induced by urethane administration and characterized by angiectasis) was made on the basis of size, the severity of compression of adjacent parenchyma, absence of lobular architecture and bile ducts from adenomas, and slight cellular atypia and pleomorphism in adenomas. The histomorphology of these adenomas differed from spontaneous-occurring hepatocellular adenomas in B6C3F<sub>1</sub> mice described by Harada *et al.* (1999). Spontaneous hepatocellular adenomas lack angiectasis with hematopoietic cell infiltration, and the hepatocytes are usually slightly smaller with more cytoplasmic basophilia.




FIGURE 20

**Incidences of Hepatocellular Adenoma or Carcinoma of the Liver in Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**

[\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol; \*\*=Significantly increased compared to group exposed to 0 ppm urethane and 0% ethanol]

Incidences of several nonneoplastic lesions were significantly increased in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol (Tables 6, A4, B3, C3, D4, E3, and F3).

Eosinophilic foci consisted of focal areas in which hepatocytes were larger than normal because of increased amounts of eosinophilic cytoplasm. The eosinophilic foci differed from eosinophilic foci usually seen in B6C3F<sub>1</sub> mice (Harada *et al.*, 1999) because the sinusoids within the foci were often dilated and contained increased numbers of hematopoietic cells. In a few foci, the cytoplasm of hepatocytes was vacuolated (clear cell focus) and in others, cells with both vacuolated and eosinophilic cytoplasm were present (mixed cell foci).

While sinusoidal dilatation was a consistent component of hepatocellular adenomas and eosinophilic foci, the vascular component of these lesions was not documented separately. However, in a number of animals, foci of angiectasis consisting of focal areas of sinusoidal dilatation lined by a single layer of essentially normal endothelial cells were present without morphologic alteration of adjacent hepatocytes. In these cases, angiectasis was coded. Hematopoietic cells were usually numerous and prominent within foci of angiectasis. Often the hepatic parenchyma adjacent to larger areas of angiectasis was either atrophic, necrotic, or there was a complete absence of hepatocytes. In areas lacking hepatocytes, there were orderly sinusoidal channels composed of condensed reticular hepatic framework lined by viable essentially normal endothelial cells. Thrombus formation was frequently present in larger areas of angiectasis. At the periphery of large thrombi, there were usually increased numbers of plump spindle-shaped endothelial cells and a few fibroblasts infiltrating the superficial layers of fibrin. There were often large, irregular areas of hepatocellular necrosis adjacent to large areas of angiectasis and thrombosis. Liver necrosis that had no lobular orientation was most likely due to intrahepatic circulatory disturbances caused by lesions in the microvasculature rather than to direct chemical toxicity.

Regeneration was present in some animals with extensive areas of liver necrosis. It was often difficult to differentiate areas of regeneration from hepatocellular adenoma. Regeneration usually accompanied large areas of hepatocellular necrosis and consisted of nodular proliferations of slightly enlarged hepatocytes. Angiectasis, which

was very prominent in urethane-induced eosinophilic foci and hepatocellular adenomas, was not a prominent feature in regenerative nodules. In areas of regeneration, the lobular architecture was usually present but distorted. Portal areas were fewer and less distinct than in normal livers, and the hepatocytes lacked the atypia and pleomorphism that was usually present in hepatocellular adenomas.

*Lung:* Lung weights of mice exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol were generally greater than those of mice exposed to 0 ppm urethane; the increases were significant in 90 ppm males and females exposed to 0% and 2.5% ethanol, respectively (Table H1). Incidences of alveolar/bronchiolar neoplasms increased with positive trends in males and females exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol, and the incidences of these neoplasms in the 30 and 90 ppm urethane groups were significantly increased except in males exposed to 30 ppm urethane and 5% ethanol (Tables 7, A2a, B2, C2, D2a, E2, and F2; Figure 21). The incidences of alveolar/bronchiolar neoplasms were also significantly increased in males exposed to 10 ppm urethane and 0% ethanol and in females exposed to 10 ppm urethane and 5% ethanol. Both single and multiple alveolar/bronchiolar neoplasms occurred. In mice exposed to increasing concentrations of urethane and 0% ethanol, the incidences of these lesions generally exceeded the historical control ranges in males exposed to 10, 30, or 90 ppm and in females exposed to 0, 10, 30, or 90 ppm urethane (Tables 7, A3c, and D3c).

The incidences of alveolar/bronchiolar adenoma or carcinoma (combined) occurred with positive trends in females exposed to increasing concentrations of ethanol and 10 ppm urethane, and the incidence was significantly increased in females exposed to 5% ethanol (Figure 21 and Table D2c). Incidences of alveolar/bronchiolar adenoma occurred with negative trends in males exposed to increasing concentrations of ethanol and 10 or 30 ppm urethane, and the incidences were significantly decreased in males exposed to 5% ethanol (Figure 21; Tables A2c and A2d). In addition, the incidence of alveolar/bronchiolar adenoma or carcinoma (combined) was significantly decreased in males exposed to 5% ethanol and 30 ppm urethane (Figure 21 and Table A2d).

**TABLE 7**  
**Incidences of Neoplasms of the Lung in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm        |
|---|---------------|---------------|---------------|---------------|
| <b>Male</b>   |               |               |               |               |
| <b>0% Ethanol</b>   |               |               |               |               |
| Number Examined Microscopically                                 | 48            | 48            | 47            | 48            |
| Alveolar/bronchiolar Adenoma, Multiple <sup>a</sup>             | 1             | 2             | 7*            | 20**          |
| Alveolar/bronchiolar Adenoma (includes multiple) <sup>b</sup>   |               |               |               |               |
| Overall rate <sup>c</sup>                                       | 4/48 (8.3%)   | 17/48 (35.4%) | 22/47 (46.8%) | 34/48 (70.8%) |
| Poly-3 test <sup>d</sup>  | P=0.001       | P=0.001       | P=0.001       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple                        | 0             | 0             | 1             | 1             |
| Alveolar/bronchiolar Carcinoma (includes multiple) <sup>e</sup> |               |               |               |               |
| Overall rate  | 1/48 (2.1%)   | 1/48 (2.1%)   | 9/47 (19.1%)  | 9/48 (18.8%)  |
| Poly-3 test   | P=0.001       | P=0.753       | P=0.010       | P=0.002       |
| Alveolar/bronchiolar Adenoma or Carcinoma <sup>f</sup>          |               |               |               |               |
| Overall rate  | 5/48 (10.4%)  | 18/48 (37.5%) | 29/47 (61.7%) | 37/48 (77.1%) |
| Poly-3 test   | P=0.001       | P=0.001       | P=0.001       | P=0.001       |
| <b>2.5% Ethanol</b>   |               |               |               |               |
| Number Examined Microscopically                                 | 48            | 48            | 47            | 48            |
| Alveolar/bronchiolar Adenoma, Multiple                          | 1             | 2             | 8*            | 24**          |
| Alveolar/bronchiolar Adenoma (includes multiple)                |               |               |               |               |
| Overall rate  | 10/48 (20.8%) | 16/48 (33.3%) | 19/47 (40.4%) | 35/48 (72.9%) |
| Poly-3 test   | P=0.001       | P=0.124       | P=0.010       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple                        | 0             | 0             | 1             | 4*            |
| Alveolar/bronchiolar Carcinoma (includes multiple)              |               |               |               |               |
| Overall rate  | 2/48 (4.2%)   | 3/48 (6.3%)   | 8/47 (17.0%)  | 24/48 (50.0%) |
| Poly-3 test   | P=0.001       | P=0.513       | P=0.029       | P=0.001       |
| Alveolar/bronchiolar Adenoma or Carcinoma                       |               |               |               |               |
| Overall rate  | 11/48 (22.9%) | 19/48 (39.6%) | 24/47 (51.1%) | 43/48 (89.6%) |
| Poly-3 test   | P=0.001       | P=0.062       | P=0.001       | P=0.001       |

**TABLE 7**  
**Incidences of Neoplasms of the Lung in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm        |
|---|---------------|---------------|---------------|---------------|
| <b>Male (continued)</b>   |               |               |               |               |
| <b>5% Ethanol</b>   |               |               |               |               |
| Number Examined Microscopically                                 | 48            | 48            | 48            | 48            |
| Alveolar/bronchiolar Adenoma, Multiple                          | 1             | 1             | 3             | 14**          |
| Alveolar/bronchiolar Adenoma (includes multiple)                |               |               |               |               |
| Overall rate  | 6/48 (12.5%)  | 8/48 (16.7%)  | 9/48 (18.8%)  | 33/48 (68.8%) |
| Poly-3 test   | P=0.001       | P=0.288       | P=0.189       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple                        | 0             | 0             | 0             | 2             |
| Alveolar/bronchiolar Carcinoma (includes multiple)              |               |               |               |               |
| Overall rate  | 5/48 (10.4%)  | 4/48 (8.3%)   | 5/48 (10.4%)  | 17/48 (35.4%) |
| Poly-3 test   | P=0.001       | P=0.578       | P=0.531       | P=0.001       |
| Alveolar/bronchiolar Adenoma or Carcinoma                       |               |               |               |               |
| Overall rate  | 11/48 (22.9%) | 11/48 (22.9%) | 14/48 (29.2%) | 40/48 (83.3%) |
| Poly-3 test   | P=0.001       | P=0.457       | P=0.190       | P=0.001       |
| <b>Female</b>   |               |               |               |               |
| <b>0% Ethanol</b>   |               |               |               |               |
| Number Examined Microscopically                                 | 48            | 48            | 48            | 47            |
| Alveolar/bronchiolar Adenoma, Multiple                          | 0             | 0             | 4*            | 17*           |
| Alveolar/bronchiolar Adenoma (includes multiple) <sup>g</sup>   |               |               |               |               |
| Overall rate  | 4/48 (8.3%)   | 6/48 (12.5%)  | 17/48 (35.4%) | 29/47 (61.7%) |
| Poly-3 test   | P=0.001       | P=0.356       | P=0.001       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple                        | 0             | 0             | 3             | 13**          |
| Alveolar/bronchiolar Carcinoma (includes multiple) <sup>h</sup> |               |               |               |               |
| Overall rate  | 2/48 (4.2%)   | 4/48 (8.3%)   | 13/48 (27.1%) | 19/47 (40.4%) |
| Poly-3 test   | P=0.001       | P=0.324       | P=0.001       | P=0.001       |
| Alveolar/bronchiolar Adenoma or Carcinoma <sup>i</sup>          |               |               |               |               |
| Overall rate  | 6/48 (12.5%)  | 8/48 (16.7%)  | 28/48 (58.3%) | 39/47 (83.0%) |
| Poly-3 test   | P=0.001       | P=0.365       | P=0.001       | P=0.001       |

**TABLE 7**  
**Incidences of Neoplasms of the Lung in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|  | 0 ppm        | 10 ppm        | 30 ppm        | 90 ppm        |
|--|--------------|---------------|---------------|---------------|
| <b>Female (continued)</b>                          |              |               |               |               |
| <b>2.5% Ethanol</b>                                |              |               |               |               |
| Number Examined Microscopically                    | 47           | 47            | 48            | 48            |
| Alveolar/bronchiolar Adenoma, Multiple             | 0            | 3             | 4*            | 18**          |
| Alveolar/bronchiolar Adenoma (includes multiple)   |              |               |               |               |
| Overall rate                                       | 5/47 (10.6%) | 10/47 (21.3%) | 16/48 (33.3%) | 28/48 (58.3%) |
| Poly-3 test  | P=0.001      | P=0.103       | P=0.001       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple           | 0            | 0             | 2             | 12**          |
| Alveolar/bronchiolar Carcinoma (includes multiple) |              |               |               |               |
| Overall rate                                       | 0/47 (0.0%)  | 2/47 (4.3%)   | 6/48 (12.5%)  | 23/48 (47.9%) |
| Poly-3 test  | P=0.001      | P=0.219       | P=0.007       | P=0.001       |
| Alveolar/bronchiolar Adenoma or Carcinoma          |              |               |               |               |
| Overall rate                                       | 5/47 (10.6%) | 11/47 (23.4%) | 21/48 (43.8%) | 38/48 (79.2%) |
| Poly-3 test  | P=0.001      | P=0.064       | P=0.001       | P=0.001       |
| <b>5% Ethanol</b>                                  |              |               |               |               |
| Number Examined Microscopically                    | 48           | 48            | 48            | 48            |
| Alveolar/bronchiolar Adenoma, Multiple             | 1            | 2             | 3             | 22**          |
| Alveolar/bronchiolar Adenoma (includes multiple)   |              |               |               |               |
| Overall rate                                       | 5/48 (10.4%) | 10/48 (20.8%) | 18/48 (37.5%) | 30/48 (62.5%) |
| Poly-3 test  | P=0.001      | P=0.103       | P=0.001       | P=0.001       |
| Alveolar/bronchiolar Carcinoma, Multiple           | 0            | 2             | 2             | 15**          |
| Alveolar/bronchiolar Carcinoma (includes multiple) |              |               |               |               |
| Overall rate                                       | 1/48 (2.1%)  | 7/48 (14.6%)  | 9/48 (18.8%)  | 23/48 (47.9%) |
| Poly-3 test  | P=0.001      | P=0.024       | P=0.005       | P=0.001       |
| Alveolar/bronchiolar Adenoma or Carcinoma          |              |               |               |               |
| Overall rate                                       | 5/48 (10.4%) | 17/48 (35.4%) | 24/48 (50.0%) | 37/48 (77.1%) |
| Poly-3 test  | P=0.001      | P=0.001       | P=0.001       | P=0.001       |

\* Significantly different ( $P \leq 0.05$ ) from the control group by the Poly-3 test

\*\*  $P \leq 0.01$

a

Number of animals with neoplasm

b

Historical incidence for control groups in NCTR studies (mean): 71/473 (15.0%), range 8%-27%

c

Number of animals with neoplasm per number of animals with lung examined microscopically

d

Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice.

e

Historical incidence: 11/473 (2.3%), range 0%-8%

f

Historical incidence: 82/473 (17.3%), range 11%-31%

g


Historical incidence: 22/515 (4.3%), range 2%-6%

h

Historical incidence: 3/515 (0.6%), range 0%-4%

i

Historical incidence: 25/515 (4.9%), range 2%-11%



**FIGURE 21**

**Incidences of Alveolar/bronchiolar Adenoma or Carcinoma (Combined) in Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**

[\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol; \*\*=Significantly different from the group exposed to the same concentration of urethane and 0% ethanol]

Multiple alveolar/bronchiolar adenomas were coded when more than one alveolar/bronchiolar adenoma was present in the lung of a mouse. Multiple alveolar/bronchiolar carcinoma was coded when alveolar/bronchiolar carcinomas were present in different lung lobes and situated in a way that local invasion or intrapulmonary metastasis appeared unlikely. The histomorphology of urethane-induced benign and malignant lung tumors was similar to that of spontaneously occurring lung tumors in mice (Dixon *et al.*, 1999).

*Harderian Gland:* Incidences of harderian gland neoplasms increased with positive trends in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol (Tables 8, A2a, B2, C2, D2a, E2, and F2; Figure 22). The incidences of harderian gland adenoma and carcinoma were generally increased in mice exposed to 10, 30, or 90 ppm urethane and 0%, 2.5%, or 5% ethanol; in addition, the incidences of harderian gland adenoma or carcinoma (combined) were significantly increased in all urethane-exposed groups except in females exposed to 10 ppm urethane and 2.5% ethanol. The incidences of these harderian gland neoplasms in mice exposed to 10, 30, or 90 ppm urethane and 0% ethanol exceeded the historical control ranges (Tables 8, A3d, and D3d). Multiplicity in the case of harderian gland neoplasms was indicated by the occurrence of adenomas or carcinomas in both harderian glands (bilateral) in the same animal.

In males exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane, exposure-related decreased incidences of harderian gland adenoma and adenoma or carcinoma (combined) were noted in the 30 ppm groups; the decrease was significant for the combined neoplasm incidence in males exposed to 30 ppm urethane and 5% ethanol (Tables A2b through A2e). In females, no consistent effect of ethanol on harderian gland neoplasms was noted (Tables D2b through D2e).

**TABLE 8**  
**Incidences of Neoplasms of the Harderian Gland in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm        | 10 ppm         | 30 ppm        | 90 ppm        |
|---|--------------|----------------|---------------|---------------|
| <b>Male</b>                                 |              |                |               |               |
| <b>0% Ethanol</b>                           |              |                |               |               |
| Number Examined Microscopically             | 47           | 47             | 47            | 47            |
| Adenoma, Bilateral <sup>a</sup>             | 0            | 1              | 4*            | 7*            |
| Adenoma (includes bilateral) <sup>b</sup>   |              |                |               |               |
| Overall rate <sup>c</sup>                   | 3/47 (6.4%)  | 11/47 (23.4%)  | 25/47 (53.2%) | 28/47 (59.6%) |
| Poly-3 test <sup>d</sup>                    | P=0.001      | P=0.013        | P=0.001       | P=0.001       |
| Carcinoma, Bilateral                        | 0            | 0              | 1             | 2             |
| Carcinoma (includes bilateral) <sup>e</sup> |              |                |               |               |
| Overall rate                                | 0/47 (0.0%)  | 1/47 (2.1%)    | 7/47 (14.9%)  | 16/47 (34.0%) |
| Poly-3 test                                 | P=0.001      | P=0.493        | P=0.011       | P=0.001       |
| Adenoma or Carcinoma <sup>b</sup>           |              |                |               |               |
| Overall rate                                | 3/47 (6.4%)  | 12/47 (25.5%)  | 30/47 (63.8%) | 38/47 (80.9%) |
| Poly-3 test                                 | P=0.001      | P=0.006        | P=0.001       | P=0.001       |
| <b>2.5% Ethanol</b>                         |              |                |               |               |
| Number Examined Microscopically             | 48           | 48             | 47            | 48            |
| Adenoma, Bilateral                          | 0            | 1              | 4*            | 8*            |
| Adenoma (includes bilateral)                |              |                |               |               |
| Overall rate                                | 6/48 (12.5%) | 14/48 (29.2%)  | 21/47 (44.7%) | 27/48 (56.3%) |
| Poly-3 test                                 | P=0.001      | P=0.034        | P=0.001       | P=0.001       |
| Carcinoma, Bilateral                        | 0            | 0              | 0             | 3             |
| Carcinoma (includes bilateral)              |              |                |               |               |
| Overall rate                                | 0/48 (0.0%)  | 0/48 (0.0%)    | 1/47 (2.1%)   | 16/48 (33.3%) |
| Poly-3 test                                 | P=0.001      | — <sup>f</sup> | P=0.476       | P=0.001       |
| Adenoma or Carcinoma                        |              |                |               |               |
| Overall rate                                | 6/48 (12.5%) | 14/48 (29.2%)  | 21/47 (44.7%) | 38/48 (79.2%) |
| Poly-3 test                                 | P=0.001      | P=0.034        | P=0.001       | P=0.001       |

**TABLE 8**  
**Incidences of Neoplasms of the Harderian Gland in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm        | 10 ppm        | 30 ppm        | 90 ppm        |
|---|--------------|---------------|---------------|---------------|
| <b>Male (continued)</b>                     |              |               |               |               |
| <b>5% Ethanol</b>                           |              |               |               |               |
| Number Examined Microscopically             | 47           | 48            | 48            | 45            |
| Adenoma, Bilateral                          | 0            | 0             | 3             | 10**          |
| Adenoma (includes bilateral)                |              |               |               |               |
| Overall rate                                | 5/47 (10.6%) | 12/48 (25.0%) | 15/48 (31.3%) | 26/45 (57.8%) |
| Poly-3 test                                 | P=0.001      | P=0.034       | P=0.004       | P=0.001       |
| Carcinoma, Bilateral                        | 0            | 0             | 0             | 3             |
| Carcinoma (includes bilateral)              |              |               |               |               |
| Overall rate                                | 0/47 (0.0%)  | 2/48 (4.2%)   | 2/48 (4.2%)   | 10/45 (22.2%) |
| Poly-3 test                                 | P=0.001      | P=0.215       | P=0.210       | P=0.001       |
| Adenoma or Carcinoma                        |              |               |               |               |
| Overall rate                                | 5/47 (10.6%) | 14/48 (29.2%) | 17/48 (35.4%) | 35/45 (77.8%) |
| Poly-3 test                                 | P=0.001      | P=0.010       | P=0.001       | P=0.001       |
| <b>Female</b>                               |              |               |               |               |
| <b>0% Ethanol</b>                           |              |               |               |               |
| Number Examined Microscopically             | 48           | 48            | 48            | 48            |
| Adenoma, Bilateral                          | 0            | 0             | 0             | 1             |
| Adenoma (includes bilateral) <sup>g</sup>   |              |               |               |               |
| Overall rate                                | 3/48 (6.3%)  | 10/48 (20.8%) | 8/48 (16.7%)  | 21/48 (43.8%) |
| Poly-3 test                                 | P=0.001      | P=0.033       | P=0.070       | P=0.001       |
| Carcinoma, Bilateral                        | 0            | 0             | 0             | 4*            |
| Carcinoma (includes bilateral) <sup>h</sup> |              |               |               |               |
| Overall rate                                | 0/48 (0.0%)  | 1/48 (2.1%)   | 11/48 (22.9%) | 11/48 (22.9%) |
| Poly-3 test                                 | P=0.001      | P=0.495       | P=0.001       | P=0.001       |
| Adenoma or Carcinoma <sup>i</sup>           |              |               |               |               |
| Overall rate                                | 3/48 (6.3%)  | 11/48 (22.9%) | 19/48 (39.6%) | 30/48 (62.5%) |
| Poly-3 test                                 | P=0.001      | P=0.018       | P=0.001       | P=0.001       |

**TABLE 8**  
**Incidences of Neoplasms of the Harderian Gland in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|                                 | 0 ppm        | 10 ppm        | 30 ppm        | 90 ppm        |
|---------------------------------|--------------|---------------|---------------|---------------|
| <b>Female (continued)</b>       |              |               |               |               |
| <b>2.5% Ethanol</b>             |              |               |               |               |
| Number Examined Microscopically | 47           | 47            | 46            | 47            |
| Adenoma, Bilateral              | 0            | 0             | 0             | 3             |
| Adenoma (includes bilateral)    |              |               |               |               |
| Overall rate                    | 2/47 (4.3%)  | 3/47 (6.4%)   | 9/46 (19.6%)  | 19/47 (40.4%) |
| Poly-3 test                     | P=0.001      | P=0.461       | P=0.007       | P=0.001       |
| Carcinoma, Bilateral            | 0            | 0             | 0             | 4*            |
| Carcinoma (includes bilateral)  |              |               |               |               |
| Overall rate                    | 1/47 (2.1%)  | 3/47 (6.4%)   | 6/46 (13.0%)  | 16/47 (34.0%) |
| Poly-3 test                     | P=0.001      | P=0.276       | P=0.024       | P=0.001       |
| Adenoma or Carcinoma            |              |               |               |               |
| Overall rate                    | 3/47 (6.4%)  | 5/47 (10.6%)  | 15/46 (32.6%) | 35/47 (74.5%) |
| Poly-3 test                     | P=0.001      | P=0.311       | P=0.001       | P=0.001       |
| <b>5% Ethanol</b>               |              |               |               |               |
| Number Examined Microscopically | 48           | 48            | 46            | 46            |
| Adenoma, Bilateral              | 0            | 0             | 0             | 6*            |
| Adenoma (includes bilateral)    |              |               |               |               |
| Overall rate                    | 4/48 (8.3%)  | 7/48 (14.6%)  | 6/46 (13.0%)  | 20/46 (43.5%) |
| Poly-3 test                     | P=0.001      | P=0.226       | P=0.294       | P=0.001       |
| Carcinoma, Bilateral            | 0            | 1             | 1             | 0             |
| Carcinoma (includes bilateral)  |              |               |               |               |
| Overall rate                    | 1/48 (2.1%)  | 11/48 (22.9%) | 7/46 (15.2%)  | 10/46 (21.7%) |
| Poly-3 test                     | P=0.011      | P=0.001       | P=0.017       | P=0.001       |
| Adenoma or Carcinoma            |              |               |               |               |
| Overall rate                    | 5/48 (10.4%) | 18/48 (37.5%) | 13/46 (28.3%) | 29/46 (63.0%) |
| Poly-3 test                     | P=0.001      | P=0.001       | P=0.013       | P=0.001       |

\* Significantly different ( $P \leq 0.05$ ) from the control group by the Poly-3 test

\*\*  $P \leq 0.01$

<sup>a</sup> Number of animals with neoplasm

<sup>b</sup> Historical incidence for control groups in NCTR studies (mean): 25/325 (7.7%), range 2%-11%

<sup>c</sup> Number of animals with neoplasm per number of animals with harderian gland examined microscopically

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice.


<sup>e</sup> Historical incidence: 0/325

<sup>f</sup> Value of statistic cannot be computed.

<sup>g</sup> Historical incidence: 21/368 (5.7%), range 3%-9%

<sup>h</sup> Historical incidence: 3/368 (0.8%), range 1%-2%

<sup>i</sup> Historical incidence: 23/368 (6.3%), range 4%-9%



**FIGURE 22**  
**Incidences of Adenoma or Carcinoma (Combined) of the Harderian Gland in Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**  
 [\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol; \*\*=Significantly decreased compared to group exposed to 30 ppm urethane and 0% ethanol)

*Mammary Gland:* Incidences of adenoacanthoma, adenocarcinoma, and adenoacanthoma or adenocarcinoma (combined) increased with positive trends in females exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol (Tables 9, D2a, E2, and F2; Figure 23). The incidences of these neoplasms were significantly increased in females exposed to 90 ppm urethane and 0% or 5% ethanol. The incidences of adenocarcinoma and adenoacanthoma or adenocarcinoma (combined) in females exposed to 30 or 90 ppm urethane and 2.5% ethanol were significantly increased. Adenoacanthoma occurred only in females exposed to urethane or to urethane and ethanol. The incidences of these neoplasms in females exposed to increasing concentrations of urethane and 0% ethanol exceeded the historical control ranges (Tables 9 and D3e); the incidence of adenocarcinoma in females exposed to 0 ppm urethane and 0% ethanol also exceeded the historical range.

In females exposed to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane, the incidences of adenoacanthoma and adenocarcinoma were similar to those in females exposed to 0% ethanol (Figure 23; Tables D2b through D2e).

Growth patterns of the adenocarcinomas were either the tubular or tubulo-alveolar type. In adenoacanthomas, the growth pattern was similar to the adenocarcinomas, but at least 25% or more of the tumor consisted of squamous metaplasia. The adenoacanthomas and adenocarcinomas were malignant; a few neoplasms of each type metastasized to the lung.

**TABLE 9**  
**Incidences of Neoplasms of the Mammary Gland in Female Mice in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm       | 10 ppm         | 30 ppm        | 90 ppm        |
|---|-------------|----------------|---------------|---------------|
| <b>0% Ethanol</b>                             |             |                |               |               |
| Adenoacanthoma <sup>a</sup>                   |             |                |               |               |
| Overall rate <sup>b</sup>                     | 0/47 (0.0%) | 1/46 (2.2%)    | 1/46 (2.2%)   | 11/48 (22.9%) |
| Poly-3 test <sup>c</sup>                      | P=0.001     | P=0.492        | P=0.476       | P=0.001       |
| Adenocarcinoma <sup>d</sup>                   |             |                |               |               |
| Overall rate                                  | 4/47 (8.5%) | 3/46 (6.5%)    | 3/46 (6.5%)   | 11/48 (22.9%) |
| Poly-3 test                                   | P=0.001     | P=0.524N       | P=0.564N      | P=0.007       |
| Adenoacanthoma or Adenocarcinoma <sup>d</sup> |             |                |               |               |
| Overall rate                                  | 4/47 (8.5%) | 4/46 (8.7%)    | 4/46 (8.7%)   | 22/48 (45.8%) |
| Poly-3 test                                   | P=0.001     | P=0.622        | P=0.582       | P=0.001       |
| <b>2.5% Ethanol</b>                           |             |                |               |               |
| Adenoacanthoma                                |             |                |               |               |
| Overall rate                                  | 0/47 (0.0%) | 0/45 (0.0%)    | 2/48 (4.2%)   | 3/47 (6.4%)   |
| Poly-3 test                                   | P=0.017     | — <sup>e</sup> | P=0.188       | P=0.071       |
| Adenocarcinoma                                |             |                |               |               |
| Overall rate                                  | 4/47 (8.5%) | 3/45 (6.7%)    | 11/48 (22.9%) | 14/47 (29.8%) |
| Poly-3 test                                   | P=0.001     | P=0.568N       | P=0.015       | P=0.001       |
| Adenoacanthoma or Adenocarcinoma              |             |                |               |               |
| Overall rate                                  | 4/47 (8.5%) | 3/45 (6.7%)    | 12/48 (25.0%) | 16/47 (34.0%) |
| Poly-3 test                                   | P=0.001     | P=0.568N       | P=0.007       | P=0.001       |
| <b>5% Ethanol</b>                             |             |                |               |               |
| Adenoacanthoma                                |             |                |               |               |
| Overall rate                                  | 0/47 (0.0%) | 0/48 (0.0%)    | 1/48 (2.1%)   | 9/45 (20.0%)  |
| Poly-3 test                                   | P=0.001     | —              | P=0.483       | P=0.001       |
| Adenocarcinoma                                |             |                |               |               |
| Overall rate                                  | 3/47 (6.4%) | 4/48 (8.3%)    | 6/48 (12.5%)  | 15/45 (33.3%) |
| Poly-3 test                                   | P=0.001     | P=0.476        | P=0.214       | P=0.001       |
| Adenoacanthoma or Adenocarcinoma              |             |                |               |               |
| Overall rate                                  | 3/47 (6.4%) | 4/48 (8.3%)    | 7/48 (14.6%)  | 23/45 (51.1%) |
| Poly-3 test                                   | P=0.001     | P=0.476        | P=0.134       | P=0.001       |

<sup>a</sup> Historical incidence for control groups in NCTR studies: 0/179

<sup>b</sup> Number of animals with neoplasm per number of animals with mammary gland examined microscopically

<sup>c</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A lower incidence in an exposed group is indicated by N.

<sup>d</sup> Historical incidence (mean): 2/179 (1.1%), range 1%-2%

<sup>e</sup> Value of statistic cannot be computed.




FIGURE 23

**Incidences of Adenoacanthoma and Adenocarcinoma of the Mammary Gland in Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**

[\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol]

*Heart:* The incidences of hemangiosarcoma were significantly increased in males exposed to 90 ppm urethane and 0%, 2.5%, or 5% ethanol (Tables 10, A2a, B2, and C2; Figure 24). The incidence of hemangiosarcoma was increased in females exposed to 90 ppm urethane and 2.5% ethanol and significantly increased in females exposed to 90 ppm urethane and 5% ethanol (Tables 10 and F2; Figure 24) and exceeded the historical control ranges for hemangiosarcoma (all sites) [male: 7/474 (1.5%), range 0%-4%; female: 6/518 (1.2%), range 0%-2%; Tables A3a and D3a]. The incidences of hemangiosarcoma of the heart occurred only in groups exposed to urethane.

Increasing the concentration of ethanol had no effect on the incidences of hemangiosarcoma of the heart in males exposed to 0, 10, 30, or 90 ppm urethane or in females exposed to 0, 10, or 30 ppm urethane (Tables A1, A2e, B1, C1, D1, E1, and F1). In females, increasing the ethanol concentration in the 90 ppm urethane group caused an exposure-related increase in the incidence of hemangiosarcoma, and the increase in the 5% ethanol group was significant (Figure 24 and Table D2e).

Incidences of endothelial hyperplasia and angiectasis increased with positive trends in mice exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol (Tables 10, A4, B3, C3, D4, E3, and F3). Endothelial hyperplasia in males and angiectasis in males and females occurred only in urethane-exposed groups.

Exposure to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane generally had no effect on the incidence of endothelial hyperplasia or angiectasis in males or females (Tables 10, A4, B3, C3, D4, E3, and F3).

The endothelial hyperplasia and angiectasis were morphologically different, though possibly related, and involved the microvasculature of the heart. Endothelial hyperplasia was characterized by increased numbers of slightly enlarged hyperchromatic nuclei in the capillary endothelium between individual cardiac muscle fibers. Most endothelial hyperplastic lesions were focal changes that varied greatly in size, and the size of the lesion was the

**TABLE 10**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Heart in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|                                   | 0 ppm                 | 10 ppm         | 30 ppm      | 90 ppm       |
|-----------------------------------|-----------------------|----------------|-------------|--------------|
| <b>Male</b>                       |                       |                |             |              |
| <b>0% Ethanol</b>                 |                       |                |             |              |
| Number Examined Microscopically   | 48                    | 48             | 47          | 48           |
| Hyperplasia, Endothelium          |                       |                |             |              |
| Minimal <sup>a</sup>              | 0 (0.0%) <sup>c</sup> | 0 (0.0%)       | 2 (4.3%)    | 5 (10.4%)    |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 2 (4.3%)    | 3 (6.3%)     |
| Moderate                          | 0 (0.0%)              | 0 (0.0%)       | 0 (0.0%)    | 1 (2.1%)     |
| Monotonic trend test <sup>b</sup> | P<0.001               | — <sup>d</sup> | P=0.007     | P<0.001      |
| Angiectasis                       |                       |                |             |              |
| Minimal                           | 0 (0.0%)              | 1 (2.1%)       | 1 (2.1%)    | 8 (16.7%)    |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 3 (6.3%)     |
| Monotonic trend test              | P<0.001               | P=0.159        | P=0.087     | P<0.001      |
| Hemangiosarcoma                   |                       |                |             |              |
| Overall rate <sup>e</sup>         | 0/48 (0.0%)           | 0/48 (0.0%)    | 1/47 (2.1%) | 5/48 (10.4%) |
| Poly-3 test <sup>f</sup>          | P=0.001               | —              | P=0.508     | P=0.016      |
| <b>2.5% Ethanol</b>               |                       |                |             |              |
| Number Examined Microscopically   | 48                    | 48             | 47          | 48           |
| Hyperplasia, Endothelium          |                       |                |             |              |
| Minimal                           | 0 (0.0%)              | 1 (2.1%)       | 1 (2.1%)    | 5 (10.4%)    |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 2 (4.3%)    | 4 (8.3%)     |
| Moderate                          | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 0 (0.0%)     |
| Monotonic trend test              | P<0.001               | P=0.159        | P=0.013     | P<0.001      |
| Angiectasis                       |                       |                |             |              |
| Minimal                           | 0 (0.0%)              | 0 (0.0%)       | 3 (6.4%)    | 5 (10.4%)    |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 4 (8.3%)     |
| Moderate                          | 0 (0.0%)              | 0 (0.0%)       | 3 (6.4%)    | 2 (4.2%)     |
| Marked                            | 0 (0.0%)              | 0 (0.0%)       | 0 (0.0%)    | 2 (4.2%)     |
| Monotonic trend test              | P<0.001               | —              | P<0.001     | P<0.001      |
| Hemangiosarcoma                   |                       |                |             |              |
| Overall rate                      | 0/48 (0.0%)           | 0/48 (0.0%)    | 2/47 (4.3%) | 4/48 (8.3%)  |
| Poly-3 test                       | P=0.007               | —              | P=0.211     | P=0.049      |
| <b>5% Ethanol</b>                 |                       |                |             |              |
| Number Examined Microscopically   | 47                    | 48             | 48          | 48           |
| Hyperplasia, Endothelium          |                       |                |             |              |
| Minimal                           | 0 (0.0%)              | 0 (0.0%)       | 0 (0.0%)    | 1 (2.1%)     |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 0 (0.0%)    | 1 (2.1%)     |
| Monotonic trend test              | P=0.029               | —              | —           | P=0.028      |
| Angiectasis                       |                       |                |             |              |
| Minimal                           | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 3 (6.3%)     |
| Mild                              | 0 (0.0%)              | 0 (0.0%)       | 0 (0.0%)    | 2 (4.2%)     |
| Monotonic trend test              | P=0.002               | —              | P=0.133     | P=0.002      |
| Hemangiosarcoma                   |                       |                |             |              |
| Overall rate                      | 0/47 (0.0%)           | 0/48 (0.0%)    | 1/48 (2.1%) | 4/48 (8.3%)  |
| Poly-3 test                       | P=0.003               | —              | P=0.470     | P=0.035      |

**TABLE 10**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Heart in Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|                                 | 0 ppm       | 10 ppm      | 30 ppm      | 90 ppm       |
|---------------------------------|-------------|-------------|-------------|--------------|
| <b>Female</b>                   |             |             |             |              |
| <b>0% Ethanol</b>               |             |             |             |              |
| Number Examined Microscopically | 48          | 48          | 48          | 48           |
| Hyperplasia, Endothelium        |             |             |             |              |
| Minimal                         | 0 (0.0%)    | 0 (0.0%)    | 1 (2.1%)    | 3 (6.3%)     |
| Mild                            | 1 (2.1%)    | 0 (0.0%)    | 2 (4.2%)    | 3 (6.3%)     |
| Monotonic trend test            | P=0.005     | P=0.841     | P=0.130     | P=0.014      |
| Hemangiosarcoma                 | 0           | 0           | 1           | 0            |
| <b>2.5% Ethanol</b>             |             |             |             |              |
| Number Examined Microscopically | 47          | 47          | 48          | 48           |
| Hyperplasia, Endothelium        |             |             |             |              |
| Minimal                         | 0 (0.0%)    | 0 (0.0%)    | 3 (6.3%)    | 4 (8.3%)     |
| Mild                            | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)    | 3 (6.3%)     |
| Moderate                        | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)    | 1 (2.1%)     |
| Monotonic trend test            | P<0.001     | —           | P=0.020     | P<0.001      |
| Angiectasis                     |             |             |             |              |
| Minimal                         | 0 (0.0%)    | 0 (0.0%)    | 1 (2.1%)    | 2 (4.2%)     |
| Mild                            | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)    | 2 (4.2%)     |
| Monotonic trend test            | P=0.004     | —           | P=0.134     | P=0.006      |
| Hemangiosarcoma                 | 0           | 0           | 0           | 3            |
| <b>5% Ethanol</b>               |             |             |             |              |
| Number Examined Microscopically | 47          | 48          | 48          | 47           |
| Hyperplasia, Endothelium        |             |             |             |              |
| Minimal                         | 0 (0.0%)    | 0 (0.0%)    | 2 (4.2%)    | 5 (10.6%)    |
| Mild                            | 0 (0.0%)    | 0 (0.0%)    | 1 (2.1%)    | 7 (14.9%)    |
| Moderate                        | 0 (0.0%)    | 1 (2.1%)    | 0 (0.0%)    | 2 (4.3%)     |
| Monotonic trend test            | P<0.001     | P=0.161     | P=0.039     | P<0.001      |
| Angiectasis                     |             |             |             |              |
| Minimal                         | 0 (0.0%)    | 0 (0.0%)    | 1 (2.1%)    | 1 (2.1%)     |
| Mild                            | 0 (0.0%)    | 0 (0.0%)    | 2 (4.2%)    | 3 (6.4%)     |
| Monotonic trend test            | P=0.005     | —           | P=0.019     | P=0.017      |
| Hemangiosarcoma                 |             |             |             |              |
| Overall rate                    | 0/47 (0.0%) | 0/48 (0.0%) | 0/48 (0.0%) | 6/47 (12.8%) |
| Poly-3 test                     | P=0.001     | —           | —           | P=0.004      |

<sup>a</sup> Number of animals with lesion

<sup>b</sup> Beneath the control incidence is the overall monotonic trend in severity with exposure level tested using the Jonckheere-Terpstra test statistic. Beneath the exposed group incidence are the P values corresponding to pairwise monotonic tests of severity with exposure concentration using the Williams' modification of Shirley's nonparametric test for a monotonic dose response.

<sup>c</sup> Percentage of animals with lesion of given severity

<sup>d</sup> Value of statistic cannot be computed.

<sup>e</sup> Number of animals with neoplasm per number of animals with heart examined microscopically

<sup>f</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice.




FIGURE 24

**Incidences of Hemangiosarcoma of the Heart in Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**

[\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol; \*\*=Significantly increased compared to group exposed to 90 ppm urethane and 0% ethanol; #=Marginally increased compared to group exposed to 0 ppm urethane and 2.5% ethanol]

primary determination for severity grades. Angiectasis consisted of focal dilatation of vascular spaces in the myocardium. The dilated spaces were lined by a single layer of essentially normal endothelial cells, and the size of the angiectatic foci was the basis for severity grade.

*Ovary and Uterus:* The incidences of granulosa cell tumors (benign or malignant) occurred with positive trends in females exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol (Tables 11, D2a, E2, and F2; Figure 25). The incidences of these neoplasms were significantly increased in females exposed to 90 ppm urethane and 0% ethanol and in females exposed to 30 ppm urethane and 5% ethanol. Marginally increased incidences occurred in females exposed to 30 or 90 ppm urethane and 2.5% ethanol and in females exposed to 90 ppm urethane and 5% ethanol. The incidences of these ovarian tumors generally exceeded the historical control ranges in females exposed to 30 or 90 ppm urethane and 0%, 2.5%, or 5% ethanol (Tables 11 and D3f).

In females exposed to increasing concentrations of urethane and 0%, 2.5%, or 5% ethanol, hemangiosarcoma of the uterus occurred in eight urethane-exposed females. None of the increased incidences were significant (Tables 11, D1, E1, F1), but the incidence in females exposed to 90 ppm urethane and 0% ethanol exceeded the historical control range for hemangiosarcoma (all sites) [6/518 (1.2%), range 0%-2%; Table D3a].

Incidences of ovarian and uterine neoplasms were not affected by exposure to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane (Tables 11, D1, D2d, and D2e).

In the uterus of females exposed to increasing concentrations of urethane and 0% or 2.5% ethanol, incidences of angiectasis (dilated vascular spaces lined by a single layer of essentially normal endothelial cells) and thrombosis occurred with positive trends, and the incidences in females exposed to 30 or 90 ppm urethane were significantly increased (Tables 11, D4, and E3). Hemorrhage from large areas of uterine angiectasis was the cause of death in five females (one exposed to 30 ppm and four exposed to 90 ppm urethane).

**TABLE 11**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Reproductive System in Female Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|   | 0 ppm                 | 10 ppm         | 30 ppm      | 90 ppm       |
|---|-----------------------|----------------|-------------|--------------|
| <b>0% Ethanol</b>                                     |                       |                |             |              |
| Ovary <sup>a</sup>                                    | 48                    | 46             | 46          | 39           |
| Benign Granulosa Cell Tumor <sup>b,c</sup>            | 0                     | 0              | 2           | 3*           |
| Malignant Granulosa Cell Tumor <sup>d</sup>           | 0                     | 0              | 0           | 3*           |
| Benign or Malignant Granulosa Cell Tumor <sup>d</sup> |                       |                |             |              |
| Overall rate <sup>e</sup>                             | 0/48 (0.0%)           | 0/46 (0.0%)    | 2/46 (4.3%) | 5/39 (12.8%) |
| Poly-3 test <sup>f</sup>                              | P=0.001               | — <sup>g</sup> | P=0.203     | P=0.004      |
| Uterus  | 48                    | 47             | 48          | 46           |
| Angiectasis   |                       |                |             |              |
| Minimal   | 0 (0.0%) <sup>i</sup> | 2 (4.3%)       | 0 (0.0%)    | 0 (0.0%)     |
| Mild  | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 2 (4.3%)     |
| Moderate  | 0 (0.0%)              | 1 (2.1%)       | 4 (8.3%)    | 2 (4.3%)     |
| Marked  | 0 (0.0%)              | 1 (2.1%)       | 1 (2.1%)    | 3 (6.5%)     |
| Monotonic trend test <sup>h</sup>                     | P=0.003               | P=0.020        | P=0.009     | P=0.005      |
| Thrombosis  |                       |                |             |              |
| Moderate  | 0 (0.0%)              | 0 (0.0%)       | 3 (6.3%)    | 1 (2.2%)     |
| Marked  | 0 (0.0%)              | 1 (2.1%)       | 1 (2.1%)    | 3 (6.5%)     |
| Monotonic trend test                                  | P=0.010               | P=0.156        | P=0.016     | P=0.028      |
| Hemangiosarcoma                                       | 0                     | 0              | 0           | 2            |
| <b>2.5% Ethanol</b>                                   |                       |                |             |              |
| Ovary   |                       |                |             |              |
| Benign Granulosa Cell Tumor                           |                       |                |             |              |
| Overall rate  | 0/47 (0.0%)           | 0/46 (0.0%)    | 3/47 (6.4%) | 3/48 (6.3%)  |
| Poly-3 test   | P=0.023               | —              | P=0.080     | P=0.073      |
| Uterus  | 47                    | 47             | 48          | 48           |
| Angiectasis   |                       |                |             |              |
| Mild  | 1 (2.1%)              | 2 (4.3%)       | 2 (4.2%)    | 5 (10.4%)    |
| Moderate  | 0 (0.0%)              | 0 (0.0%)       | 4 (8.3%)    | 3 (6.3%)     |
| Marked  | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 1 (2.1%)     |
| Monotonic trend test                                  | P<0.001               | P=0.280        | P=0.009     | P=0.004      |
| Thrombosis  |                       |                |             |              |
| Mild  | 0 (0.0%)              | 0 (0.0%)       | 2 (4.2%)    | 0 (0.0%)     |
| Moderate  | 0 (0.0%)              | 0 (0.0%)       | 2 (4.2%)    | 4 (8.3%)     |
| Marked  | 0 (0.0%)              | 0 (0.0%)       | 1 (2.1%)    | 2 (4.2%)     |
| Monotonic trend test                                  | P=0.001               | —              | P=0.003     | P=0.005      |
| Hemangiosarcoma                                       | 0                     | 0              | 1           | 1            |

**TABLE 11**  
**Incidences of Neoplasms and Nonneoplastic Lesions of the Reproductive System in Female Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|  | 0 ppm       | 10 ppm      | 30 ppm         | 90 ppm      |
|--|-------------|-------------|----------------|-------------|
| <b>5% Ethanol</b>                        |             |             |                |             |
| Ovary                                    | 46          | 47          | 46             | 45          |
| Benign Granulosa Cell Tumor              | 0           | 0           | 5 <sup>a</sup> | 3           |
| Malignant Granulosa Cell Tumor           | 0           | 0           | 1              | 0           |
| Benign or Malignant Granulosa Cell Tumor |             |             |                |             |
| Overall rate                             | 0/46 (0.0%) | 0/47 (0.0%) | 6/46 (13.0%)   | 3/45 (6.7%) |
| Poly-3 test                              | P=0.022     | —           | P=0.011        | P=0.064     |
| Uterus                                   | 48          | 48          | 47             | 45          |
| Angiectasis                              |             |             |                |             |
| Mild                                     | 1 (2.1%)    | 0 (0.0%)    | 6 (12.8%)      | 2 (4.4%)    |
| Moderate                                 | 1 (2.1%)    | 0 (0.0%)    | 2 (4.3%)       | 3 (6.7%)    |
| Marked                                   | 2 (4.2%)    | 2 (4.2%)    | 0 (0.0%)       | 1 (2.2%)    |
| Monotonic trend test                     | P=0.093     | P=0.789     | P=0.116        | P=0.207     |
| Thrombosis                               |             |             |                |             |
| Moderate                                 | 0 (0.0%)    | 0 (0.0%)    | 2 (4.3%)       | 3 (6.7%)    |
| Marked                                   | 1 (2.1%)    | 2 (4.2%)    | 0 (0.0%)       | 1 (2.2%)    |
| Monotonic trend test                     | P=0.080     | P=0.280     | P=0.347        | P=0.083     |
| Hemangiosarcoma                          | 0           | 2           | 1              | 1           |

<sup>a</sup> Number of animals with ovary or uterus examined microscopically

<sup>b</sup> Number of animals with lesion

<sup>c</sup> Historical incidence for control groups in NCTR studies: 0/504

<sup>d</sup> Historical incidence (mean): 1/504 (0.2%), range 0%-1%


<sup>e</sup> Number of animals with neoplasm per number of animals with ovary examined microscopically

<sup>f</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice.

<sup>g</sup> Value of statistic cannot be computed.

<sup>h</sup> Beneath the control incidence is the overall monotonic trend in severity with exposure level tested using the Jonckheere-Terpstra test statistic. Beneath the exposed group incidence are the P values corresponding to pairwise monotonic tests of severity with exposure concentration using the Williams' modification of Shirley's nonparametric test for a monotonic dose response.

<sup>i</sup> Percentage of animals with lesion of given severity



**FIGURE 25**


**Incidences of Granulosa Cell Tumor of the Ovary in Female Mice Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**

[\*=Significantly increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol; #=Marginally increased compared to group exposed to 0 ppm urethane and the same (i.e., 0%, 2.5%, or 5%) concentration of ethanol]

The incidences of uterine angiectasis and thrombosis were generally not affected by increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane except for a slight ethanol-induced increase in females exposed to 0 ppm urethane (Tables 11, D4, E3, and F3).

Angiectasis was differentiated from hemangiosarcoma by the presence of proliferating endothelial cells that formed irregular vascular spaces in hemangiosarcomas. In angiectasis, endothelial cells were sometimes slightly enlarged but were arranged in orderly fashion forming a single cell layer that lined dilated vascular spaces. Thrombus formation was frequent in larger areas of angiectasis. At the periphery of large thrombi, there were usually increased numbers of plump spindle-shaped endothelial cells and a few fibroblasts infiltrating the superficial layers of fibrin.

*Forestomach:* The incidences of squamous cell papilloma or carcinoma (combined) occurred with a positive trend in males exposed to increasing concentrations of urethane and 0% ethanol, and the incidence in the 90 ppm group was significantly increased (0 ppm, 0/46; 10 ppm, 2/47; 30 ppm, 3/44; 90 ppm, 5/45) (Figure 26 and Table A2a). The incidences of this neoplasm in males were not affected by exposure to increasing concentrations of ethanol and 0, 10, 30, or 90 ppm urethane (Tables A2b through A2e). The incidences of this neoplasm in all urethane-exposed groups of males exceeded the historical control range [2/458 (0.4%), range 0%-2%].



**FIGURE 26**  
**Incidences of Squamous Cell Papilloma or Carcinoma (Combined) of the Forestomach in Male Mice**  
**Exposed to Urethane and 0%, 2.5%, or 5% Ethanol in Drinking Water for 2 Years**  
 (\*=Significantly increased compared to group exposed to 0 ppm urethane and 0% ethanol)

*Spleen:* Incidences of hemangiosarcoma of the spleen increased with positive trends in males exposed to increasing concentrations of urethane and 2.5% ethanol and in females exposed to increasing concentrations of urethane and 0% or 2.5% ethanol (Tables 12, A2a, B2, D2a, and E2). The incidence of this neoplasm in females exposed to 90 ppm urethane and 0% ethanol was significantly increased, and the incidences in males and females were considered to be exposure-related. The incidences of this neoplasm in mice exposed to 90 ppm urethane and 0% or 2.5% ethanol exceeded the historical control ranges for hemangiosarcoma (all sites) [male: 7/474 (1.5%), range 0%-4%; female: 6/518 (1.2%), range 0%-2%; Tables A3a and D3a].

*Skin:* Urethane caused slight increases in the incidences of hemangiosarcoma of the skin in females exposed to 0% ethanol (0 ppm, 0/48; 10 ppm, 0/48; 30 ppm, 0/46; 90 ppm, 2/48) or 2.5% ethanol (0/47, 0/47, 0/48, 2/47) (Tables D1 and E1); these increases were considered to be exposure-related. The incidences of this neoplasm in females exposed to 90 ppm urethane and 0% or 2.5% ethanol exceeded the historical control range for hemangiosarcoma (all sites) [6/518 (1.2%), range 0%-2%; Table D3a]

In addition to the liver, heart, and spleen in males and females and the uterus and skin in females, incidences of hemangiosarcoma occurred in many different organs in mice including the bone, bone marrow, mesentery, lung, and kidney of males and females, the pancreas, forestomach, preputial gland, seminal vesicle, and mandibular, mesenteric, and inguinal lymph node of males, and the adrenal cortex, skeletal muscle, and ovary of females (Tables A1, B1, C1, D1, E1, and F1). However, the incidences of this neoplasm in these organs were not exposure concentration related.

**TABLE 12**  
**Incidence of Hemangiosarcoma of the Spleen in Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

|                           | 0 ppm       | 10 ppm         | 30 ppm      | 90 ppm       |
|---------------------------|-------------|----------------|-------------|--------------|
| <b>Male</b>               |             |                |             |              |
| <b>0% Ethanol</b>         |             |                |             |              |
| Hemangiosarcoma           |             |                |             |              |
| Overall rate <sup>a</sup> | 2/44 (4.5%) | 2/46 (4.3%)    | 2/45 (4.4%) | 5/42 (11.9%) |
| Poly-3 test <sup>b</sup>  | P=0.051     | P=0.692        | P=0.681N    | P=0.120      |
| <b>2.5% Ethanol</b>       |             |                |             |              |
| Hemangiosarcoma           |             |                |             |              |
| Overall rate              | 0/46 (0.0%) | 0/46 (0.0%)    | 1/46 (2.2%) | 3/46 (6.5%)  |
| Poly-3 test               | P=0.015     | — <sup>c</sup> | P=0.478     | P=0.099      |
| <b>5% Ethanol</b>         |             |                |             |              |
| Hemangiosarcoma           | 0/48        | 1/46           | 0/46        | 1/45         |
| <b>Female</b>             |             |                |             |              |
| <b>0% Ethanol</b>         |             |                |             |              |
| Hemangiosarcoma           |             |                |             |              |
| Overall rate              | 0/48 (0.0%) | 0/45 (0.0%)    | 1/47 (2.1%) | 4/46 (8.7%)  |
| Poly-3 test               | P=0.001     | —              | P=0.471     | P=0.021      |
| <b>2.5% Ethanol</b>       |             |                |             |              |
| Hemangiosarcoma           |             |                |             |              |
| Overall rate              | 0/47 (0.0%) | 0/46 (0.0%)    | 0/46 (0.0%) | 3/46 (6.5%)  |
| Poly-3 test               | P=0.005     | —              | —           | P=0.069      |
| <b>5% Ethanol</b>         |             |                |             |              |
| Hemangiosarcoma           | 0/48        | 1/47           | 0/48        | 1/45         |

<sup>a</sup> Number of animals with neoplasm per number of animals examined microscopically

<sup>b</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A lower incidence in an exposed group is indicated by N.

<sup>c</sup> Value of statistic cannot be computed.

## DISCUSSION AND CONCLUSIONS

### *Survival, Body Weights, and Water and Feed Consumption*

In the current 2-year study, survival of mice significantly decreased as the urethane content of the drinking water was increased, and the decrease was more pronounced in females than in males. In a drinking water study conducted by Inai *et al.* (1991), survival of male B6C3F<sub>1</sub> mice exposed to 600 ppm urethane for 70 weeks was decreased, but survival of those exposed to 0.6, 3, 6, or 60 ppm urethane was not decreased; the mice were killed after 70 weeks of exposure. In the present study, decreases in survival were evident after approximately 80 weeks of exposure. A similar decrease in survival of NMRI mice exposed to concentrations up to 12.5 mg urethane/kg body weight per day in drinking water began at approximately 85 weeks into the study (Schmähl *et al.*, 1977); that exposure concentration is similar to the 90 ppm urethane concentration used in the current 2-year study.

Survival of female mice was not affected by ethanol in the current 2-year study. However, in male mice, there was a marginal exposure-related increase in survival as a function of the ethanol concentration, and male mice exposed to 5% ethanol in the absence of urethane survived significantly longer than males that did not receive ethanol. Schmidt *et al.* (1987) also reported an increase in survival of male C57BL/10J mice administered 7.5% ethanol, but there was no effect on survival at 3.5% ethanol, and there was a decrease in survival of mice at 15% ethanol.

In the current 2-year study, water consumption was affected by ethanol, but not urethane. Specifically, as the concentration of ethanol increased, the fluid intake by mice decreased. Concomitant with the decrease in fluid intake, there was a decrease in feed consumption as the ethanol concentration (but not urethane) in drinking water increased, which resulted in similar caloric intake among the exposed groups. Based upon a caloric content of 4.5 kcal/g for NIH-31 diet (Lewis, 1996, personal communication) and 7.11 kcal/g for ethanol (Mayes, 1996), male mice that received 0%, 2.5%, or 5% ethanol in the current 2-year study consumed 25.5, 24.7, or 24.2 kcal/day, respectively, while female mice consumed 21.8, 21.3, or 21.2 kcal/day, respectively.

A decrease in the mean fluid intake occurred in 14- to 160-week-old male C57BL/10J mice administered 12% ethanol in drinking water (Schmidt *et al.*, 1987); however, no decrease occurred in mice given 3.5% or 7.5% ethanol. The Schmidt *et al.* (1987) study differed from the current 2-year study in a number of ways, including the strain of mouse, exposure period, and number of mice per cage. In another study, feed consumption by Sprague-Dawley rats was not affected by 1% ethanol in a semisynthetic liquid diet (Holmberg and Ekström, 1995). When the ethanol content was increased to 3%, exposed male rats decreased their feed intake compared to the control rats that received an isocaloric glucose diet, whereas the opposite trend occurred in female rats.

In the current 2-year study, mean body weights of mice were affected by urethane beginning at approximately 92 weeks (males) and 56 weeks (females). These changes probably reflected the exposure-related changes in survival due to the induction of neoplasia that occurred after increasing the urethane content of the drinking water. Body weights were not affected by ethanol, which is similar to what occurred in male C57BL/10J mice during lifetime exposure of up to 12% ethanol (Schmidt *et al.*, 1987). In contrast, there was a significant decrease in the body weights of Sprague-Dawley rats exposed to 3% ethanol in a semisynthetic liquid diet (Holmberg and Ekström, 1995).

Mice in the current 2-year study adjusted their caloric intake by decreasing their feed consumption as the ethanol content of the drinking water increased. This observation is important because the spontaneous incidence of certain tumors in mice is related to body weight (Seilkop, 1995; Haseman *et al.*, 1997); it should be noted, however, that while the total calories consumed were nearly identical among the groups in the current study, there was a linear decreasing trend in males and females as the ethanol content increased. This suggests that the mice utilized the calories obtained from ethanol more efficiently than those obtained from the NIH-31 diet, an interpretation supported by the fact that only about 80% of the NIH-31 diet is metabolically available (Lewis, 1996, personal communication).

Although ethanol did not affect the body weights of mice in the current 2-year study, the body weights of mice in all exposure groups were substantially greater than those of B6C3F<sub>1</sub> mice typically used at the National Center for Toxicological Research (NCTR). This was particularly true for female mice, which weighed nearly 50 g at the end of the study compared to the typical 35 g in other NCTR studies (Turturro and Hart, 1986; Culp *et al.*, 1998; Culp, personal communication). This trend was less pronounced in males; nonetheless, males in the current 2-year study weighed approximately 10% more than that typically seen in NCTR studies. Comparisons to current study results to historical control results must be conducted with caution because of the relationship between the spontaneous incidences of certain tumors to body weight (Seilkop, 1995; Haseman *et al.*, 1997).

The mice in the current 2-year study were fed pelleted NIH-31 diet. When compared to another bioassay conducted at the NCTR using the same feed (experiment E-0503) (Turturro and Hart, 1986), the amount of feed consumed by the mice in the two studies was nearly identical. A major difference between these two studies is that while the mice in the current study were housed four per cage, the mice in study E-0503 were housed singly. In other recent NCTR bioassays (studies E2127 and E6722) (Culp *et al.*, 1998; Culp, personal communication), group-housed female B6C3F<sub>1</sub> mice also received NIH-31 meal. The mice in those studies showed weight gains similar to those in study E-0503; however, feed consumption in studies E2127 and E6722 was only 75% of that observed in the current 2-year study and study E-0503. From these data, we concluded that singly-housed mice have greater energy requirements than group-housed mice, and thus require more food to maintain the same weight. It also appears that feed consumption by group-housed mice fed pelleted NIH-31 diet in the current 2-year study was greater than that by group-housed mice fed NIH-31 meal in previous NCTR studies, and that this greater feed consumption by mice in the current 2-year study was responsible for the increased body weight.

In Schmidt *et al.* (1987), water consumption by the group-housed males was substantially less than that by the males housed singly. Body weights of both groups were nearly identical; however, because feed consumption was not reported, it is difficult to make comparisons to the current 2-year study. As noted earlier, mice in the Schmidt

*et al.* (1987) study did not decrease fluid intake even after they received 3.5% or 7% ethanol in contrast to the decrease that occurred in the current 2-year study. This difference may be due to the greater energy requirements to maintain the body weight of the singly housed mice.

### ***Urethane Carcinogenesis***

The liver in mice is a common tumor target of urethane (Mirvish, 1968; IARC, 1974; Dragani *et al.*, 1984), although this is not always the case (Inai *et al.*, 1991). Hepatocellular adenomas and carcinomas are thought to arise from the sequential metabolism of urethane to vinyl carbamate and vinyl carbamate epoxide (Ribovich *et al.*, 1982). To support this, vinyl carbamate has been shown to induce more hepatocellular carcinomas than urethane (Dahl *et al.*, 1980), and vinyl carbamate epoxide is more hepatocarcinogenic than vinyl carbamate (Park *et al.*, 1993). DNA adducts indicative of vinyl carbamate epoxide have been detected in liver DNA of mice treated with urethane, vinyl carbamate, and vinyl carbamate epoxide (Fernando *et al.*, 1996). In addition, hepatocellular adenomas and carcinomas induced by urethane and vinyl carbamate in B6C3F<sub>1</sub> mice have a characteristic increase in CAA to CTA mutations at codon 61 of the H-*ras* oncogene when compared to the CAA to AAA mutations typically found in spontaneous tumors (Wiseman *et al.*, 1986; Dragani *et al.*, 1991; Maronpot *et al.*, 1995; Watson *et al.*, 1995). Such a mutation is consistent with the formation of 1,N<sup>6</sup>-ethenodeoxyadenosine, which is known to lead to dA to dT transversion mutations (Levine *et al.*, 2000).

In the absence of urethane and ethanol in the current 2-year study, the incidences of hepatocellular adenoma or carcinoma (combined) were 26.1% in males and 10.4% in females. The incidence in these control males was similar to the incidences in other studies conducted at the NCTR. However, the incidence of this neoplasm in control females was greater than the historical mean, but still within the historical control range. The high spontaneous liver neoplasm incidence in female mice was probably a reflection of their increased body weight (Seilkop, 1995; Haseman *et al.*, 1997).

Urethane, in the absence of ethanol, caused exposure-related increases in the incidences of hepatocellular adenoma or carcinoma (combined) in males and females in the current 2-year study. These increased incidences could have been due to increases in the concentrations of 1,*N*<sup>6</sup>-ethenodeoxyadenosine in hepatic DNA, such as that recorded in the current 4-week study. Compared to other carcinogens administered chronically (Beland and Poirier, 1993), however, the increase in 1,*N*<sup>6</sup>-ethenodeoxyadenosine was rather modest (approximately 25%); nonetheless, it was consistent with that reported by Fernando *et al.*, (1996) who administered 250 nmol urethane/g body weight per day to adult B6C3F<sub>1</sub> mice. Mice given 90 ppm urethane in the current 2-year study consumed approximately 90 nmol/g per day.

The LC-ES MS/MS method used to conduct the DNA adduct analyses in current 4-week study was designed to detect 1,*N*<sup>6</sup>-ethenodeoxyadenosine and 3,*N*<sup>4</sup>-ethenodeoxycytidine. Two other DNA adducts, *N*<sup>2</sup>,3-ethenodeoxyguanosine and 7-(2-oxoethyl)deoxyguanosine, are also formed upon the metabolic activation of urethane. While these adducts could be involved in the tumorigenicity of urethane, the fact that a CAA to CTA transversion in codon 61 of the *H-ras* protooncogene, which is typically observed in hepatocellular tumors induced by urethane (Dragani *et al.*, 1991), suggests that 1,*N*<sup>6</sup>-ethenodeoxyadenosine would make a substantially greater contribution.

Female mice exposed to urethane in the current 4-week study had a fourfold increase in the percentage of hepatocytes in the G1 phase of the cell cycle; this change did not occur in males. The fact that female mice had a greater relative increase in the incidence of hepatocellular neoplasms suggests that the formation of 1,*N*<sup>6</sup>-ethenodeoxyadenosine, coupled with the greater rate of cell replication, contributed to the neoplasm response.

In addition to the increased incidences of hepatocellular adenoma and hepatocellular carcinoma, urethane caused exposure-related increases in the incidences of liver hemangiosarcoma in the current 2-year study; the increases were significant in mice exposed to 90 ppm urethane. Urethane also caused significant increases in the incidences of hemangiosarcoma of the heart. Hemangiosarcomas are rare in B6C3F<sub>1</sub> mice; the control incidences in all organs

in studies conducted at the NCTR are 1.5% in males and 1.2% in females. The mechanism for the induction of hemangiosarcoma is not known, but liver and heart hemangiosarcomas were also observed by Inai *et al.* (1991), who found a significant increase in the incidence in male mice exposed to 600 ppm urethane in the drinking water. In the current 2-year study and in the Inai *et al.* (1991) study, the formation of hemangiosarcoma appeared to be markedly nonlinear. In the Inai *et al.* (1991) study, a significantly increased incidence of hemangiosarcoma occurred only in the 600 ppm group; in the current 2-year study, a substantial increase occurred in the 90 ppm group. With other carcinogens, similar exposure-responses have been attributed to carcinogen-induced toxicity at higher concentrations, with a concomitant increase in cell replication (Cohen and Ellwein, 1990, 1992, 1995; Culp *et al.*, 2000). In preliminary NCTR studies, the levels of 8-oxodeoxyguanosine, 1,*N*<sup>6</sup>-ethenodeoxyadenosine, and 3,*N*<sup>4</sup>-ethenodeoxycytidine were substantially higher in liver endothelial cells than in hepatocytes; however, the levels were not dramatically affected by the presence of urethane (Hamilton, Doerge, and Beland, unpublished data). Although these data need to be confirmed, they support the concept that the incidence of hemangiosarcoma may result from enhanced cell proliferation due to toxicity that occurs at high doses of urethane.

In the absence of urethane and ethanol in the current 2-year study, the incidences of alveolar/bronchiolar adenoma or carcinoma (combined) were 10.4% in males and 12.5% in females. The incidence in males was at the low end of the historical control range in studies conducted at the NCTR; the incidence in females exceeded the historical control range. The occurrence of lung tumors in female B6C3F<sub>1</sub> mice is not related to body weight (Seilkop, 1995; Haseman *et al.*, 1997); thus, the increased spontaneous incidence of these neoplasms cannot be explained by the increased body weights of female control mice in the current 2-year study.

Urethane caused a linear, exposure-related increase in the incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in males and females. In the absence of ethanol, a statistically significant increase in alveolar/bronchiolar adenoma or carcinoma (combined) occurred in 10 ppm males (37.5%) and 30 ppm females (59.3%), and the incidences were 77.1% and 83.0% in 90 ppm males and females, respectively. Inai *et al.* (1991) also found an increase in the incidences of alveolar/bronchiolar adenoma or carcinoma in male B6C3F<sub>1</sub> mice; the

incidences were 68.0% and 95.5% at 60 and 600 ppm urethane, respectively. They did not detect an increase in tumors at 6 ppm; in addition, no carcinomas occurred in mice exposed to 60 ppm urethane and only a low incidence (13.6%) in mice exposed to 600 ppm. In contrast, the incidences of alveolar/bronchiolar carcinoma were only slightly less than those of alveolar/bronchiolar adenoma in males and females in the current 2-year study.

A urethane-induced formation of alveolar/bronchiolar adenoma or carcinoma (combined) in male B6C3F<sub>1</sub> mice was associated with activation of the *K-ras* protooncogene, which occurs in approximately 50% of the tumors (Kawano *et al.*, 1995). A CAA to CTA transversion in codon 61 was the major mutation detected (62% of the mutations). Codon 61 CAA to CGA transversion (21%) and codon 12 GGT to GAT (18%) transition mutations were detected to a lesser extent. *K-ras* mutations were found in approximately 30% of spontaneous tumors in male B6C3F<sub>1</sub> mice, and the majority of mutations (73%) involved dG transitions and transversions at codons 12 and 13 (Sills *et al.*, 1999; Hayashi *et al.*, 2001). A comparison of these data suggests that the interaction of urethane metabolites with dA is involved in lung tumor initiation. This interpretation is supported by the high prevalence of *K-ras* mutations in lung tumors induced by vinyl carbamate in various C57BL/6J hybrids; the majority involved codon 61 CAA to CGA transition and CAA to CTA transversion mutations (Massey *et al.*, 1995). Nonetheless, the administration of urethane did not affect the levels of 1,*N*<sup>6</sup>-ethenodeoxyadenosine or 3,*N*<sup>4</sup>-ethenodeoxycytidine in lung DNA. Furthermore, Fernando *et al.* (1996) reported only a modest (and probably statistically insignificant) increase in 1,*N*<sup>6</sup>-ethenodeoxyadenosine and no change in the levels of 3,*N*<sup>4</sup>-ethenodeoxycytidine in adult male B6C3F<sub>1</sub> mice treated with urethane. Although the levels of 1,*N*<sup>6</sup>-ethenodeoxyadenosine and 3,*N*<sup>4</sup>-ethenodeoxycytidine were not increased after treatment with urethane in the current 4-week study, there was a significant decrease in PCNA labeling. This suggests that there was urethane-induced DNA damage and that progression through the cell cycle was arrested until the damage could be repaired.

In the current 2-year study, urethane caused increased incidences of adenocarcinoma and adenoacanthoma of the mammary gland in females; these are rare neoplasms in B6C3F<sub>1</sub> mice. In studies conducted at the NCTR, the spontaneous incidences were 1.1% for adenocarcinoma and 0% for adenoacanthoma. Similar to the NCTR

historical control data, mammary gland adenoacanthoma did not occur in control mice (0 ppm urethane and 0% ethanol) in the current study; however, the incidence of adenocarcinoma (8.5%) exceeded the historical control incidence. As noted previously, female mice in the current 2-year study weighed considerably more than B6C3F<sub>1</sub> mice used at the NCTR. The incidence of mammary gland neoplasms is related to body weight in F344 rats; although, this does not appear to be the case with B6C3F<sub>1</sub> mice (Seilkop, 1995; Haseman *et al.*, 1997). Nonetheless, the incidence of mammary gland adenocarcinoma in 90 ppm females in the current study exceeded the control incidence by a factor of three, which is a clear indication of the carcinogenicity of urethane in this tissue, and supports the observations of Tannenbaum and Silverstone (1958) and Della Porta *et al.* (1967), who reported the induction of mammary gland carcinoma in female B6C3F<sub>1</sub> mice after administration of urethane by various routes. Adenocarcinomas and adenoacanthomas were also reported in other strains of mice (Tannenbaum and Silverstone, 1958; Tannenbaum and Maltoni, 1962; Della Porta *et al.*, 1967; Imai *et al.*, 1982, 1984).

In the current 2-year study, urethane induced high incidences of harderian gland adenoma and carcinoma in males and females, and the increases occurred in a relatively linear manner. In control mice, the incidences of adenoma or carcinoma (combined) (6.4% in males and 6.3% in females) were similar to those in controls from other studies conducted at the NCTR. The induction of harderian gland neoplasms was previously reported in B6C3F<sub>1</sub> mice (Tannenbaum and Silverstone, 1958; Della Porta *et al.*, 1967; Vesselinovitch *et al.*, 1971) as well as in other strains of mice (Della Porta *et al.*, 1963, 1967; Deringer, 1965; Klein, 1966) exposed to urethane.

In the current 2-year study, urethane also caused significant increases in the incidences of granulosa cell tumors of the ovary in female mice and of squamous cell papilloma or carcinoma (combined) of the forestomach in males. The incidence of granulosa cell tumor of the ovary in 30 ppm females exceeded the incidence in historical controls, as did the forestomach neoplasm incidence in 10 ppm males.

### *Ethanol Carcinogenesis*

Equivocal results have been obtained in previous studies that assessed the carcinogenicity of ethanol in mice. Horie *et al.* (1965) administered 14% or 43% ethanol in the drinking water to CF<sub>1</sub> mice for 5 days per week and found low incidences of forestomach papilloma, malignant lymphoma, and lung adenoma in the 43% ethanol group; however, the lack of a control group make these data difficult to interpret. The same criticism applies to studies in which ddN mice were exposed to 19.5% ethanol in the drinking water 5 days per week (Kuratsune *et al.*, 1971) and C57Bl mice were treated with 200  $\mu$ l of 40% ethanol by gavage twice weekly (Griciute *et al.*, 1981). In other studies, exposure to 12% ethanol in the drinking water decreased the latency of mammary gland tumors in female C3H/St mice (Schrauzer *et al.*, 1979). Likewise, the incidence of liver sarcoma was increased in C57Bl/10J mice exposed to 7.5% or 12% ethanol in the drinking water compared to those exposed to 0% or 3.5% ethanol (Schmidt *et al.*, 1987). In the current 2-year study, male B6C3F<sub>1</sub> mice exposed to ethanol had exposure-related increases in the incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined); the incidences were significantly increased in the 5% ethanol group. A similar trend did not occur in female mice.

As noted in the Introduction of this Technical Report, ethanol is metabolized through oxidation to acetaldehyde, a process that is catalyzed primarily by alcohol dehydrogenase, and to a lesser extent, cytochrome P450 and catalase (IARC, 1988). Acetaldehyde reacts with the exocyclic amine of deoxyguanosine to form a Schiff base, which can be reduced to give *N*<sup>2</sup>-ethyldeoxyguanosine (Fang and Vaca, 1995, 1997; Matsuda *et al.*, 1999; Terashima *et al.*, 2001). *N*<sup>2</sup>-Ethyldeoxyguanosine has been detected in hepatic DNA from male C57Bl/6 mice administered 10% ethanol in drinking water for 5 weeks (Fang and Vaca, 1995); a potential criticism of this study is a lack of control mice, therefore, it is not clear whether the adduct detected was due solely to the oxidation of ethanol to acetaldehyde. In another study, female BD<sub>6</sub> rats were given 5% ethanol in the drinking water for 8 months (Izzotti *et al.*, 1998). When assessed by <sup>32</sup>P-postlabeling analyses, treatment-related DNA adducts were not detected in the esophagus, liver, lung, or heart after exposure to ethanol; however, the chromatographic conditions were such that the detection of *N*<sup>2</sup>-ethyldeoxyguanosine would be quite unlikely. In the current 4-week study, the presence of *N*<sup>2</sup>-ethyldeoxyguanosine in hepatic DNA was assessed using the method described by Fang and Vaca (1995).

*N*<sup>2</sup>-Ethyldeoxyguanosine was not detected in any of the samples with a detection limit of 6 adducts/10<sup>8</sup> nucleotides (Fang and Beland, unpublished observation).

### ***The Effect of Ethanol on the Carcinogenicity of Urethane***

Ethanol increased the activity of certain carcinogens in mice; for example, treating male and female C57Bl mice with ethanol and *N*-nitrosodimethylamine by gavage resulted in the induction of aesthesioneuroepithelioma, a tumor that does not occur in the absence of ethanol (Griciute *et al.*, 1981). Likewise, the coadministration of ethanol and *N*-nitrosodimethylamine in male strain A mice increased the incidence and multiplicity of lung tumors (Anderson, 1988; Anderson *et al.*, 1992). A similar ethanol-induced enhancement of tumorigenicity occurred with other *N*-nitrosamines, including *N*-nitrosodiethylamine (Griciute *et al.*, 1984; Anderson *et al.*, 1993), *N*-nitrosodipropylamine (Griciute *et al.*, 1984), and *N*-nitrosopyrrolidine (Anderson *et al.*, 1993). The mechanism for the enhancement in carcinogenicity has been attributed to ethanol inhibiting the hepatic first-pass metabolism of the carcinogen, which increases exposure to extrahepatic organs, the sites of increased tumorigenesis (Anderson *et al.*, 1995). This mechanism is supported by the decreased rates of carcinogen clearance and increased DNA adduct formation in extrahepatic tissues (Anderson *et al.*, 1986, 1994). In addition, ethanol induces cytochrome P450 2E1 (Forkert *et al.*, 1991), the enzyme responsible for the metabolism of many low molecular-weight compounds and for the activation of *N*-nitrosamines. These concepts appear to have a direct bearing on the results obtained in the current 2-year study.

In the current 4-week study, female mice exposed to ethanol (in the presence or absence of urethane) for 4 weeks had a significant increase in hepatic cytochrome P450 2E1, and the increase was 1.3- and 1.6-fold at 2.5% and 5% ethanol, respectively. Although somewhat modest, a similar magnitude of induction was reported by Forkert *et al.* (1991) who exposed male CD-1 mice to 10% ethanol in the drinking water for 2 weeks. Because urethane is metabolized to a reactive electrophile by cytochrome P450 2E1, these results suggest there could be an increased activation of the carcinogen upon coadministration of ethanol, at least in female B6C3F<sub>1</sub> mice.

Urethane was detected only in the serum from mice exposed to ethanol in the current 4-week study; thus, as with *N*-nitrosamines (Anderson *et al.*, 1986, 1994), the coadministration of ethanol appeared to decrease the first-pass hepatic clearance of urethane, with a concomitant increase in its systemic distribution. Consistent with a decrease in hepatic metabolism of urethane, there was a decrease in the level of etheno dA in liver DNA of mice treated with ethanol.

Furthermore, as was observed with *N*-nitrosodimethylamine (Anderson, 1988; Anderson *et al.*, 1992) and *N*-nitrosopyrrolidine (Anderson *et al.*, 1993), in female B6C3F<sub>1</sub> mice administered 10 ppm urethane, ethanol caused exposure-related increases in the incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in the current 2-year study, and the increase was significant in females exposed to 10 ppm urethane and 5% ethanol. This trend was not evident in females exposed to 30 or 90 ppm urethane; however, these exposure concentrations resulted in appreciably higher neoplasm incidences in the absence of ethanol. In the current 2-year study in males, ethanol caused an exposure-related decrease in the incidence of alveolar/bronchiolar adenoma at 10 ppm urethane, and the decrease was significant in the 5% ethanol group. In males exposed to 30 ppm urethane, ethanol caused exposure-related decreases in the incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined), and the decreases were, again, significant in males exposed to 5% ethanol.

In the current 2-year study, ethanol also increased the incidence of hemangiosarcoma of the heart in females exposed to 90 ppm urethane, but not in males. This finding is of interest because heart hemangiosarcomas are very rare in B6C3F<sub>1</sub> mice. Ethanol also caused exposure-related decreases in the incidences of harderian gland adenoma or carcinoma (combined) in males exposed to 30 ppm urethane; the decrease was significant in the 5% ethanol group. The reason for these sex-related differences in response in the lung, heart, and harderian gland is not known, but may be related to the fact that ethanol induced cytochrome P450 2E1 in females, but not males. It should also be noted that the changes in tumorigenicity of ethanol were modest and could have been due to normal biological variation; therefore, the current studies do not establish a definitive effect of ethanol on the carcinogenicity of urethane.

Ethanol increased the incidences of forestomach tumors in C55Bl mice treated with *N*-nitrosodiethylamine and *N*-nitrosodi-*n*-propylamine (Griciute *et al.*, 1984). Although forestomach neoplasms occurred in male B6C3F<sub>1</sub> mice exposed to urethane in the current 2-year study, the occurrence of these neoplasms was not affected by ethanol.

## CONCLUSIONS

Under the conditions of this 2-year drinking water study, there was *clear evidence of carcinogenic activity\** of urethane in male B6C3F<sub>1</sub> mice based on increased incidences of liver, lung, harderian gland, and forestomach neoplasms and of hemangiosarcoma, primarily of the liver and heart. There was *clear evidence of carcinogenic activity* of urethane in female B6C3F<sub>1</sub> mice based on increased incidences of liver, lung, harderian gland, mammary gland, and ovarian neoplasms and of hemangiosarcoma, primarily of the liver, heart, and spleen. The occurrences of hemangiosarcoma of the spleen in males and of the uterus and skin in females were also considered to be exposure related.

Exposure to urethane resulted in increased incidences of nonneoplastic lesions of the liver and heart in males and females and of the uterus in females.

Under the conditions of this 2-year drinking water study, there was *equivocal evidence of carcinogenic activity* of ethanol in male B6C3F<sub>1</sub> mice based on increased incidences of hepatocellular neoplasms. There was *no evidence of carcinogenic activity* of ethanol in female B6C3F<sub>1</sub> mice exposed to 2.5% or 5%.

The coadministration of urethane and ethanol resulted in marginal changes in the incidences of some neoplasms that were attributed to urethane alone. In males, increasing the ethanol concentration may have decreased the alveolar/bronchiolar and harderian gland adenoma or carcinoma responses to urethane. In females, increasing the

ethanol concentration may have increased the hemangiosarcoma of the heart and alveolar/bronchiolar adenoma or carcinoma responses to urethane. Overall, the findings were insufficient to establish a definitive effect of ethanol on the carcinogenicity of urethane in B6C3F<sub>1</sub> mice.

---

\* Explanation of Levels of Evidence of Carcinogenic Activity is on page 16.



## REFERENCES

- Altmann, H.-J., Dusemund, B., Goll, M., and Grunow, W. (1991). Effect of ethanol on the induction of lung tumours by ethyl carbamate in mice. *Toxicology* **68**, 195-201.
- Alvarez, M.R., Cimino, L.E., Jr., Cory, M.J., and Gordon, R.E. (1980). Ethanol induction of sister chromatid exchanges in human cells in vitro. *Cytogenet. Cell Genet.* **27**, 66-69.
- Anderson, L.M. (1988). Increased numbers of *N*-nitrosodimethylamine-initiated lung tumors in mice by chronic co-administration of ethanol. *Carcinogenesis* **9**, 1717-1719.
- Anderson, L.M., Harrington, G.W., Pylypiw, H.M., Jr., Hagiwara, A., and Magee, P.N. (1986). Tissue levels and biological effects of *N*-nitrosodimethylamine in mice during chronic low or high dose exposure with or without ethanol. *Drug Metab. Dispos.* **14**, 733-739.
- Anderson, L.M., Carter, J.P., Logsdon, D.L., Driver, C.L., and Kovatch, R.M. (1992). Characterization of ethanol's enhancement of tumorigenesis by *N*-nitrosodimethylamine in mice. *Carcinogenesis* **13**, 2107-2111.
- Anderson, L.M., Carter, J.P., Driver, C.L., Logsdon, D.L., Kovatch, R.M., and Giner-Sorolla, A. (1993). Enhancement of tumorigenesis by *N*-nitrosodiethylamine, *N*-nitrosopyrrolidine and *N*<sup>6</sup>(methylnitroso)-adenosine by ethanol. *Cancer Lett.* **68**, 61-66.
- Anderson, L.M., Koseniauskas, R., Burak, E.S., Logsdon, D.L., Carter, J.P., Driver, C.L., Gombar, C.T., Magee, P.N., and Harrington, G.W. (1994). Suppression of *in vivo* clearance of *N*-nitrosodimethylamine in mice by cotreatment with ethanol. *Drug Metab. Dispos.* **22**, 43-49.
- Anderson, L.M., Chhabra, S.K., Nerurkar, P.V., Souliotis, V.L., and Kyrtopoulos, S.A. (1995). Alcohol-related cancer risk: a toxicokinetic hypothesis. *Alcohol* **12**, 97-104.
- Anderson, R.A., Jr., and Beyler, S.A. (1978). Reduced litter size and survival of offspring sired by ethanol treated male mice. *Biol. Reprod.* **18** (Suppl. 1), p. 49A (Abstr.).
- Badr, F.M., and Badr, R.S. (1975). Induction of dominant lethal mutation in male mice by ethyl alcohol. *Nature* **253**, 134-136.
- Badr, F.M., Badr, R.S., Asker, R.L., and Hussain, F.H. (1977). Evaluation of the mutagenic effects of ethyl alcohol by different techniques. In *Alcohol Intoxication and Withdrawal-IIIa. Biological Aspects of Ethanol* (M.M. Gross, Ed.), pp. 25-46. Plenum Press, New York.
- Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. *Biometrics* **44**, 417-431.
- Banduhn, N., and Obe, G. (1985). Mutagenicity of methyl 2-benzimidazolecarbamate, diethylstilbestrol and estradiol: Structural chromosomal aberrations, sister-chromatid exchanges, C-mitoses, polyploidies and micronuclei. *Mutat. Res.* **156**, 199-218.

- Baraona, E., Guerra, M., and Lieber, C.S. (1981). Cytogenetic damage of bone marrow cells produced by chronic alcohol consumption. *Life Sci.* **29**, 1797-1802.
- Barrio, J.R., Secrist, J.A., III, and Leonard, N.J. (1972). Fluorescent adenosine and cytidine derivatives. *Biochem. Biophys. Res. Commun.* **46**, 597-604.
- Bateman, A.J. (1967). A failure to detect any mutagenic action of urethane in the mouse. *Mutat. Res.* **4**, 710-712.
- Battaglia, R., Conacher, H.B.S, and Page, B.D. (1990). Ethyl carbamate (urethane) in alcoholic beverages and foods: A review. *Food Addit. Contam.* **7**, 477-496
- Beland, F.A., and Poirier, M.C. (1993). Significance of DNA adduct studies in animal models for cancer molecular dosimetry and risk assessment. *Environ. Health Perspect.* **99**, 5-10.
- Berryman, S.H., Anderson, R.A., Jr., Weis, J., and Bartke, A. (1992). Evaluation of the co-mutagenicity of ethanol and  $\Delta^9$ -tetrahydrocannabinol with Trenimon. *Mutat. Res.* **278**, 47-60.
- Bieler, G.S., and Williams, R.L. (1993). Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. *Biometrics* **49**, 793-801.
- Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.
- Boyland, E., and Nery, R. (1965). The metabolism of urethane and related compounds. *Biochem. J.* **94**, 198-208.
- Canas, B.J., Havery, D.C., Robinson, L.R., Sullivan, M.P., Joe, F.L., Jr., and Diachenko, G.W. (1989). Ethyl carbamate levels in selected fermented foods and beverages. *J. Assoc. Off. Anal. Chem.* **72**, 873-876.
- Carlson, G.P. (1994). The effect of inducers and inhibitors of urethane metabolism on its in vitro and in vivo metabolism in rats. *Cancer Lett.* **87**, 145-150.
- Chaubey, R.C., Kavi, B.R., Chauhan, P.S., and Sundaram, K. (1977). Evaluation of the effect of ethanol on the frequency of micronuclei in the bone marrow of Swiss mice *Mutat. Res.* **43**, 441-444.
- Choy, W.N., Mandakas, G., and Paradisin, W. (1996). Co-administration of ethanol transiently inhibits urethane genotoxicity as detected by a kinetic study of micronuclei induction in mice. *Mutat. Res.* **367**, 237-244.
- Cividalli, G., Mirvish, S.S., and Berenblum, I. (1965). The catabolism of urethan in young mice of varying age and strain, and in X-irradiated mice, in relation to urethan carcinogenesis. *Cancer Res.* **25**, 855-858.
- Clegg, B.S., Frank, R., Ripley, B.D., Chapman, N.D., Braun, H.E., Sobolov, M., and Wright, S.A. (1988). Contamination of alcoholic products by trace quantities of ethyl carbamate (urethane). *Bull. Environ. Contam. Toxicol.* **41**, 832-837.
- Code of Federal Regulations (CFR) **21**, Part 58.
- Cohen, S.M., and Ellwein, L.B. (1990). Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: Biological modeling of the ED01 study. *Toxicol. Appl. Pharmacol.* **104**, 79-93.
- Cohen, S.M., and Ellwein, L.B. (1992). Risk assessment based on high-dose animal exposure experiments. *Chem. Res. Toxicol.* **5**, 742-748.

- Cohen, S.M., and Ellwein, L.B. (1995). Relationship of DNA adducts derived from 2-acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. *Toxicol. Pathol.* **23**, 136-142.
- Cox, D.R. (1972). Regression models and life-tables. *J. R. Stat. Soc.* **B34**, 187-220.
- Cramer, J.W., Miller, J.A., and Miller, E.C. (1960). *N*-Hydroxylation: A new metabolic reaction observed in the rat with the carcinogen 2-acetylaminofluorene. *J. Biol. Chem.* **235**, 885-888.
- Culp, S.J., Gaylor, D.W., Sheldon, W.G., Goldstein, L.S., and Beland, F.A. (1998). A comparison of the tumors induced by coal tar and benzo[*a*]pyrene in a 2-year bioassay. *Carcinogenesis* **19**, 117-124.
- Culp, S.J., Warbritton, A.R., Smith, B.A., Li, E.E., and Beland, F.A. (2000). DNA adduct measurements, cell proliferation and tumor mutation induction in relation to tumor formation in B6C3F1 mice fed coal tar or benzo[*a*]pyrene. *Carcinogenesis* **21**, 1433-1440.
- Dahl, G.A., Miller, J.A., and Miller, E.C. (1978). Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. *Cancer Res.* **38**, 3793-3804.
- Dahl, G.A., Miller, E.C., and Miller, J.A. (1980). Comparative carcinogenicities and mutagenicities of vinyl carbamate, ethyl carbamate, and ethyl *N*-hydroxycarbamate. *Cancer Res.* **40**, 1194-1203.
- Della Porta, G., Capitano, J., Montipò, W., and Parmi, L. (1963). A study of the carcinogenic action of urethan in mice [in Italian, English summary]. *Tumori* **49**, 413-428.
- Della Porta, G., Capitano, J., Parmi, L., and Colnaghi, M.I. (1967). Urethan carcinogenesis in newborn, suckling, and adult mice of C57BL, C3H, BC3F<sub>1</sub>, C3Hf, and SWR strains [in Italian, English summary]. *Tumori* **53**, 81-102.
- Dennis, M.J., Howarth, N., Key, P.E., Pointer, M., and Massey, R.C. (1989). Investigation of ethyl carbamate levels in some fermented foods and alcoholic beverages. *Food Addit. Contam.* **6**, 383-389.
- de Raat, W.K., Davis, P.B., and Bakker, G.L. (1983). Induction of sister-chromatid exchanges by alcohol and alcoholic beverages after metabolic activation by rat-liver homogenate. *Mutat. Res.* **124**, 85-90.
- Deringer, M.K. (1965). Response of strain DBA/2eBDe mice to treatment with urethan. *J. Natl. Cancer Inst.* **34**, 841-847.
- Dixon, D., Herbert, R.A., Sills, R.C., and Boorman, G.A. (1999). Lungs, pleura, and mediastinum. In *Pathology of the Mouse* (R.R. Maronpot, Ed.), pp. 293-332. Cache River Press, Vienna, IL.
- Doerge, D.R., Churchwell, M.I., Marques, M.M., and Beland, F.A. (1999). Quantitative analysis of 4-aminobiphenyl-C8-deoxyguanosyl DNA adducts produced *in vitro* and *in vivo* using HPLC-ES-MS. *Carcinogenesis* **20**, 1055-1061.
- Dragani, T.A., Sozzi, G., and Della Porta, G. (1984). Spontaneous and urethan-induced tumor incidence in B6C3F1 versus B6CF1 mice. *Tumori* **70**, 485-490.
- Dragani, T.A., Manenti, G., Colombo, B.M., Falvella, F.S., Gariboldi, M., Pierotti, M.A., and Della Porta, G. (1991). Incidence of mutations at codon 61 of the Ha-*ras* gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. *Oncogene* **6**, 333-338.

- Dunn, A.J., Salmon, A.G., and Zeise, L. (1991). Background. In *Risks of Carcinogenesis from Urethane Exposure* (A.G. Salmon and L. Zeise, Eds.), pp. 4-9. CRC Press, Boca Raton, FL.
- Dunnnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1096-1121.
- Epstein, S.S., Arnold, E., Andrea, J., Bass, W., and Bishop, Y. (1972). Detection of chemical mutagens by the dominant lethal assay in the mouse. *Toxicol. Appl. Pharmacol.* **23**, 288-325.
- Fang, J.-L., and Vaca, C.E. (1995). Development of a <sup>32</sup>P-postlabelling method for the analysis of adducts arising through the reaction of acetaldehyde with 2'-deoxyguanosine-3'-monophosphate and DNA. *Carcinogenesis* **16**, 2177-2185.
- Fang, J.-L., and Vaca, C.E. (1997). Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. *Carcinogenesis* **18**, 627-632.
- Fernando, R.C., Nair, J., Barbin, A., Miller, J.A., and Bartsch, H. (1996). Detection of 1,N<sup>6</sup>-ethenodeoxyadenosine and 3,N<sup>4</sup>-ethenodeoxycytidine by immunoaffinity/<sup>32</sup>P-postlabelling in liver and lung DNA of mice treated with ethyl carbamate (urethane) or its metabolites. *Carcinogenesis* **17**, 1711-1718.
- Feron, V.J. (1979). Effects of exposure to acetaldehyde in Syrian hamsters simultaneously treated with benzo(a)pyrene or diethylnitrosamine. *Prog. Exp. Tumor Res.* **24**, 162-176.
- Feron, V.J., Kruijse, A., and Woutersen, R.A. (1982). Respiratory tract tumours in hamsters exposed to acetaldehyde vapour alone or simultaneously to benzo(a)pyrene or diethylnitrosamine. *Eur. J. Cancer Clin. Oncol.* **18**, 13-31.
- Foley, J.F., Dietrich, D.R., Swenberg, J.A., and Maronpot, R.R. (1991). Detection and evaluation of proliferating cell nuclear antigen (PCNA) in rat tissue by an improved immunohistochemical procedure. *J. Histotechnol.* **14**, 237-241.
- Forkert, P.G., Massey, T.E., Jones, A.B., Park, S.S., Gelboin, H.V., and Anderson, L.M. (1991). Distribution of cytochrome CYP2E1 in murine liver after ethanol and acetone administration. *Carcinogenesis* **12**, 2259-2268.
- Fossa, A.A., Baird, W.M., and Carlson, G.P. (1985). Distribution of urethane and its binding to DNA, RNA, and protein in SENCAR and BALB/c mice following oral and dermal administration. *J. Toxicol. Environ. Health* **15**, 635-654.
- Foureman, P., Mason, J.M., Valencia, R., and Zimmering, S. (1994). Chemical mutagenesis testing in *Drosophila*. IX. Results of 50 coded compounds tested for the National Toxicology Program. *Environ. Mol. Mutagen* **23**, 51-63.
- Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J. Cell Biol.* **119**, 493-501.
- Gibel, W. (1967). Experimentelle Untersuchungen zur Synkarzinogenese beim Ösophaguskarzinom. *Arch. Geschwulstforsch.* **30**, 181-189.
- Griciute, L., Castegnaro, M., and Béréziat, J.-C. (1981). Influence of ethyl alcohol on carcinogenesis with N-nitrosodimethylamine. *Cancer Lett.* **13**, 345-352.

- Griciute, L., Castegnaro, M., and Béréziat, J.-C. (1984). Influence of ethyl alcohol on carcinogenesis induced with *N*-nitrosodi-*n*-propylamine. In *Models, Mechanisms and Etiology of Tumour Promotion* (IARC Scientific Publications No. 56). (M. Börzsönyi, N.E. Day, K. Lapis, and H. Yamasaki, Eds.), pp. 413-417. IARC Scientific Publications, Lyon.
- Griciute, L., Castegnaro, M., Béréziat, J.-C., and Cabral, J.R.P. (1986). Influence of ethyl alcohol on carcinogenic activity of *N*-nitrosornicotine. *Cancer Lett.* **31**, 267-275.
- Guengerich, F.P., and Kim, D.-H. (1991). Enzymatic oxidation of ethyl carbamate to vinyl carbamate and its role as an intermediate in the formation of 1,*N*<sup>6</sup>-ethenoadenosine. *Chem. Res. Toxicol.* **4**, 413-421.
- Guengerich, F.P., Kim, D.-H., and Iwasaki, M. (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. *Chem. Res. Toxicol.* **4**, 168-179.
- Haddon, W.F., Mancini, M.L., McLaren, M., Effio, A., Harden, L.A., Degre, R.L., and Bradford, J.L. (1994). Occurrence of ethyl carbamate (urethane) in U.S. and Canadian breads: Measurements by gas chromatography-mass spectrometry. *Cereal Chem.* **71**, 207-215.
- Harada, T., Enomoto, A., Boorman, G.A., and Maronpot, R.R. (1999). Liver and gall bladder. In *Pathology of the Mouse* (R.R. Maronpot, Ed.), pp. 119-183. Cache River Press, Vienna, IL.
- Haseman, J.K., Young, E., Eustis, S.L., and Hailey, J.R. (1997). Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. *Toxicol. Pathol.* **25**, 256-263.
- Hayashi, S.-M., Hong, H.-H.L., Toyoda, K., Ton, T.-V.T., Devereux, T.R., Maronpot, R.R., Huff, J., and Sills, R.C. (2001). High frequency of *ras* mutations in forestomach and lung tumors of B6C3F1 mice exposed to 1-amino-2,4-dibromoanthraquinone for 2 years. *Toxicol. Pathol.* **29**, 422-429.
- Heflich, R.H., Morris, S.M., Beranek, D.T., McGarrity, L.J., Chen, J.J., and Beland, F.A. (1986). Relationships between the DNA adducts and the mutations and sister-chromatid exchanges produced in Chinese hamster ovary cells by *N*-hydroxy-2-aminofluorene, *N*-hydroxy-*N'*-acetylbenzidine and 1-nitrosopyrene. *Mutagenesis* **1**, 201-206.
- Holmberg, B., and Ekström, T. (1995). The effects of long-term oral administration of ethanol on Sprague-Dawley rats – a condensed report. *Toxicology* **96**, 133-145.
- Horie, A., Kohchi, S., and Kuratsune, M. (1965). Carcinogenesis in the esophagus. II. Experimental production of esophageal cancer by administration of ethanolic solution of carcinogens. *Gann* **56**, 429-441.
- Hurst, H.E., Kemper, R.A., and Kurata, N. (1990). Measurement of ethyl carbamate in blood by capillary gas chromatography/mass spectrometry using selected ion monitoring. *Biomed. Environ. Mass Spectrom.* **19**, 27-31.
- Imai, S., Morimoto, J., Tsubura, Y., and Hilgers, J. (1982). Mammary tumor induction in inbred mouse strains with urethane is not accompanied by changes in expression of B- and C-type retroviral structural proteins. *Int. J. Cancer* **30**, 101-106.
- Imai, S., Tsubura, Y., and Hilgers, J. (1984). Urethane-induced mammary tumorigenesis in a murine mammary tumor virus (MuMTV)-positive mouse strain: Evidence for a keratinized nodule as an MuMTV-negative precursor lesion for squamous cell tumors. *J. Natl. Cancer Inst.* **73**, 935-941.
- Imaoka, S., Terano, Y., and Funae, Y. (1990). Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. *Arch. Biochem. Biophys.* **278**, 168-178.

- Inai, K., Arihiro, K., Takeshima, Y., Yonehara, S., Tachiyama, Y., Khatun, N., and Nishisaka, T. (1991). Quantitative risk assessment of carcinogenicity of urethane (ethyl carbamate) on the basis of long-term oral administration to B6C3F<sub>1</sub> mice. *Jpn. J. Cancer Res.* **82**, 380-385.
- Ingelman-Sundberg, M., Johansson, I., Yin, H., Terelius, Y., Eliasson, E., Clot, P., and Albano, E. (1993). Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. *Alcohol* **10**, 447-452.
- International Agency for Research on Cancer (IARC) (1974). *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Anti-thyroid and Related Substances, Nitrofurans and Industrial Chemicals*, Vol. 7, pp. 111-140. IARC, Lyon, France.
- International Agency for Research on Cancer (IARC) (1985). *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Allyl Compounds, Aldehydes, Epoxides and Peroxides*, Vol. 36, pp. 101-132. IARC, Lyon, France.
- International Agency for Research on Cancer (IARC) (1987). *IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, Volumes 1 to 42 (Suppl. 7)*, pp. 1-440. IARC, Lyon, France.
- International Agency for Research on Cancer (IARC) (1988). *IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans: Alcohol Drinking*, Vol. 44, pp. 1-378. IARC, Lyon, France.
- Izzotti, A., Balansky, R.M., Blagoeva, P.M., Mircheva, Z.I., Tulimiero, L., Cartiglia, C., and De Flora, S. (1998). DNA alterations in rat organs after chronic exposure to cigarette smoke and/or ethanol ingestion. *FASEB J.* **12**, 753-758.
- James, D.A., and Smith, D.M. (1982). Analysis of results from a collaborative study of the dominant lethal assay. *Mutat. Res.* **97**, 303-314.
- Jansson, T. (1982). The frequency of sister chromatid exchanges in human lymphocytes treated with ethanol and acetaldehyde. *Hereditas* **97**, 301-303.
- Jonckheere, A.R. (1954). A distribution-free *k*-sample test against ordered alternatives. *Biometrika* **41**, 133-145.
- Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **53**, 457-481.
- Kawano, R., Nishisaka, T., Takeshima, Y., Yonehara, S., and Inai, K. (1995). Role of point mutation of the *K-ras* gene in tumorigenesis of B6C3F<sub>1</sub> mouse lung lesions induced by urethane. *Jpn. J. Cancer Res.* **86**, 802-810.
- Kaye, A.M. (1960). A study of the relationship between the rate of ethyl carbamate (urethan) catabolism and urethan carcinogenesis. *Cancer Res.* **20**, 237-241.
- Kaye, A.M., and Trainin, N. (1966). Urethan carcinogenesis and nucleic acid metabolism: Factors influencing lung adenoma induction. *Cancer Res.* **26**, 2206-2212.
- Klassen, R.W., and Persaud, T.V.N. (1976). Experimental studies on the influence of male alcoholism on pregnancy and progeny. *Exp. Pathol.* **12**, 38-45.
- Klien, M. (1966). Influence of age on induction with urethan of hepatomas and other tumors in infant mice. *J. Natl. Cancer Inst.* **36**, 1111-1120.

- Korte, A., Slacik-Erben, R., and Obe, G. (1979). The influence of ethanol treatment on cytogenetic effects in bone marrow cells of Chinese hamsters by cyclophosphamide, aflatoxin B1 and patulin. *Toxicology* **12**, 53-61.
- Kristiansen, E., Clemmensen, S., and Meyer, O. (1990). Chronic ethanol intake and reduction of lung tumours from urethane in strain A mice. *Food Chem. Toxicol.* **28**, 35-38.
- Kristiansen, E., Vahl, M., Ladefoged, O., Meyer, O., Østergaard, G., and Lam, H.R. (1994). The area under the plasma concentration curve (AUC) of urethane in mice and the influence of concomitant administration of ethanol. *Pharmacol. Toxicol.* **75**, 324-326.
- Kurata, N., Kemper, R., Hurst, H.E., and Waddell, W.J. (1990). Inhibition of the metabolism of ethyl carbamate by acetaldehyde. *Drug Metab. Dispos.* **18**, 504-507.
- Kurata, N., Hurst, H.E., Benz, F.W., Kemper, R.A., and Waddell, W.J. (1991a). Studies on inhibition and induction of metabolism of ethyl carbamate by acetone and related compounds. Evidence for metabolism by cytochromes P-450. *Drug Metab. Dispos.* **19**, 388-393.
- Kurata, N., Hurst, H.E., Kemper, R.A., and Waddell, W.J. (1991b). Studies on induction of metabolism of ethyl carbamate in mice by ethanol. *Drug Metab. Dispos.* **19**, 239-240.
- Kuratsune, M., Kochi, S., Horie, A., and Nishizumi, M. (1971). Test of alcoholic beverages and ethanol solutions for carcinogenicity and tumor-promoting activity. *Gann* **62**, 395-405.
- Lawson, T.A., and Pound, A.W. (1973). The interaction of carbon-14-labelled alkyl carbamates, labelled in the alkyl and carbonyl positions, with DNA *in vivo*. *Chem. Biol. Interact.* **6**, 99-105.
- Leakey, J.E.A., Cunny, H.C., Bazare, J., Jr., Webb, P.J., Feuers, R.J., Duffy, P.H., and Hart, R.W. (1989). Effects of aging and caloric restriction on hepatic drug metabolizing enzymes in the Fischer 344 rat. I: The cytochrome P-450 dependent monooxygenase system. *Mech. Ageing Dev.* **48**, 145-155.
- Leithauser, M.T., Liem, A., Stewart, B.C., Miller, E.C., and Miller, J.A. (1990). 1,*N*<sup>6</sup>-Ethenoadenosine formation, mutagenicity and murine tumor induction as indicators of the generation of an electrophilic epoxide metabolite of the closely related carcinogens ethyl carbamate (urethane) and vinyl carbamate. *Carcinogenesis* **11**, 463-473.
- Levine, R.L., Yang, I.-Y., Hossain, M., Pandya, G.A., Grollman, A.P., and Moriya, M. (2000). Mutagenesis induced by a single 1,*N*<sup>6</sup>-ethenodeoxyadenosine adduct in human cells. *Cancer Res.* **60**, 4098-4104.
- Lieber, C.S. (1988). Biochemical and molecular basis of alcohol-induced injury to liver and other tissues. *N. Engl. J. Med.* **319**, 1639-1650.
- Lieber, C.S. (1990). Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease. *Drugs* **40**, 23-44.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951). Protein measurement with the folin phenol reagent. *J. Biol. Chem.* **193**, 265-275.
- McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* **76**, 283-289.
- McCoy, G.D., Hecht, S.S., Katayama, S., and Wynder, E.L. (1981). Differential effect of chronic ethanol consumption on the carcinogenicity of *N*-nitrosopyrrolidine and *N*'-nitrosornicotine in male Syrian golden hamsters. *Cancer Res.* **41**, 2849-2854.

- McCoy, G.D., Hecht, S.S., and Furuya, K. (1986). The effect of chronic ethanol consumption on the tumorigenicity of *N*-nitrosopyrrolidine in male Syrian golden hamsters. *Cancer Lett.* **33**, 151-159.
- Mankes, R.F., LeFevre, R., Benitz, K.-F., Rosenblum, I., Bates, H., Walker, A.I.T., and Abraham, R. (1982). Paternal effects of ethanol in the Long-Evans rat. *J. Toxicol. Environ. Health* **10**, 871-878.
- Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.
- Maronpot, R.R., Fox, T., Malarkey, D.E., and Goldsworthy, T.L. (1995). Mutations in the *ras* proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. *Toxicology* **101**, 125-156.
- Massey, T.E., Devereux, T.R., Maronpot, R.R., Foley, J.F., and Anderson, M.W. (1995). High frequency of *K-ras* mutations in spontaneous and vinyl carbamate-induced lung tumors of relatively resistant B6CF<sub>1</sub> (C57BL/6J × BALB/cJ) mice. *Carcinogenesis* **16**, 1065-1069.
- Matsuda, T., Terashima, I., Matsumoto, Y., Yabushita, H., Matsui, S., and Shibutani, S. (1999). Effective utilization of *N*<sup>2</sup>-ethyl-2'-deoxyguanosine triphosphate during DNA synthesis catalyzed by mammalian replicative DNA polymerases. *Biochemistry* **38**, 929-935.
- Mayes, P.A. (1996). Nutrition. In *Harper's Biochemistry*. (R.K. Murray, D.K. Granner, P.A. Mayes, and V.W. Rodwell, Eds.), 24th ed., p. 626. Appleton and Lange, A Simon & Schuster Company, Stamford, CT.
- Meisner, L.F., Inhorn, S.L., and Nielson, P.M. (1970). Chemically-induced chromatid breaks: Toxicogenic or mutagenic. *Mamm. Chromos. Newslett.* **11**, 69-70 (Abstr.).
- Mendenhall, C.L., and Chedid, A. (1980). Peliosis hepatis. Its relationship to chronic alcoholism, aflatoxin B<sub>1</sub>, and carcinogenesis in male Holtzman rats. *Dig. Dis. Sci.* **25**, 587-592.
- Miller, J.A., and Miller, E.C. (1983). The metabolic activation and nucleic acid adducts of naturally-occurring carcinogens: Recent results with ethyl carbamate and the spice flavors safrole and estragole. *Br. J. Cancer* **48**, 1-15.
- Mirvish, S.S. (1968). The carcinogenic action and metabolism of urethan and *N*-hydroxyurethan. *Adv. Cancer Res.* **11**, 1-42.
- Mishin, V.M., Koivisto, T., and Lieber, C.S. (1996). The determination of cytochrome P450 2E1-dependent *p*-nitrophenol hydroxylation by high-performance liquid chromatography with electrochemical detection. *Anal. Biochem.* **233**, 212-215.
- National Toxicology Program (NTP) (1996). NTP Technical Report on Toxicity Studies of Urethane in Drinking Water and Urethane in 5% Ethanol Administered to F344/N Rats and B6C3F<sub>1</sub> Mice. Toxicity Report Series No. 52. NIH Publication No. 96-3937. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
- Nomeir, A.A., Ioannou, Y.M., Sanders, J.M., and Matthews, H.B. (1989). Comparative metabolism and disposition of ethyl carbamate (urethane) in male Fischer 344 rats and male B6C3F<sub>1</sub> mice. *Toxicol. Appl. Pharmacol.* **97**, 203-215.
- Nomura, T. (1975). Urethan (ethyl carbamate) as a cosolvent of drugs commonly used parenterally in humans. *Cancer Res.* **35**, 2895-2899.

- Nomura, T. (1982). Parental exposure to X rays and chemicals induces heritable tumours and anomalies in mice. *Nature* **296**, 575-577.
- Obe, G., and Anderson, D. (1987). Genetic effects of ethanol. *Mutat. Res.* **186**, 177-200.
- O'Flaherty, E.J., and Sichak, S.P. (1983). The kinetics of urethane elimination in the mouse. *Toxicol. Appl. Pharmacol.* **68**, 354-358.
- Omura, T., and Sato, R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. *J. Biol. Chem.* **239**, 2370-2378.
- Park, K.-K., Surh, Y.-J., Stewart, B.C., and Miller, J.A. (1990). Synthesis and properties of vinyl carbamate epoxide, a possible ultimate electrophilic and carcinogenic metabolite of vinyl carbamate and ethyl carbamate. *Biochem. Biophys. Res. Commun.* **169**, 1094-1098.
- Park, K.-K., Liem, A., Stewart, B.C., and Miller, J.A. (1993). Vinyl carbamate epoxide, a major strong electrophilic, mutagenic and carcinogenic metabolite of vinyl carbamate and ethyl carbamate (urethane). *Carcinogenesis* **14**, 441-450.
- Parkinson, A. (1996). Biotransformation of xenobiotics. In *Casarett & Doull's Toxicology. The Basic Science of Poisons* (C.D. Klaassen, Ed.), 5th ed., pp. 113-186. McGraw-Hill, New York.
- Phillips, B.J., and Jenkinson, P. (2001). Is ethanol genotoxic? A review of the published data. *Mutagenesis* **16**, 91-101.
- Piegorsch, W.W., and Bailer, A.J. (1997). *Statistics for Environmental Biology and Toxicology*, Section 6.3.2. Chapman and Hall, London.
- Poklis, A., and Mackell, M.A. (1982). Evaluation of a modified alcohol dehydrogenase assay for the determination of ethanol in blood. *Clin. Chem.* **28**, 2125-2127.
- Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. *Fundam. Appl. Toxicol.* **12**, 731-737.
- Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. *Cancer Res.* **46**, 4372-4378.
- Pour, P.M., Reber, H.A., and Stepan, K. (1983). Modification of pancreatic carcinogenesis in the hamster model. XII. Dose-related effect of ethanol. *JNCI* **71**, 1085-1087.
- Radike, M.J., Stemmer, K.L., and Bingham, E. (1981). Effect of ethanol on vinyl chloride carcinogenesis. *Environ. Health Perspect.* **41**, 59-62.
- Randerath, K., Reddy, M.V., and Gupta, R.C. (1981). <sup>32</sup>P-Labeling test for DNA damage. *Proc. Natl. Acad. Sci. USA* **78**, 6126-6129.
- Reinke, L.A., and Moyer, M.J. (1985). *p*-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. *Drug Metab. Dispos.* **13**, 548-552.
- Ribovich, M.L., Miller, J.A., Miller, E.C., and Timmins, L.G. (1982). Labeled 1,*N*<sup>6</sup>-ethenoadenosine and 3,*N*<sup>4</sup>-ethenocytidine in hepatic RNA of mice given [ethyl-1,2-<sup>3</sup>H or ethyl-1-<sup>14</sup>C] ethyl carbamate (urethan). *Carcinogenesis* **3**, 539-546.

- Russell, L.B., Hunsicker, P.R., Oakberg, E.F., Cummings, C.C., and Schmoyer, R.L. (1987). Tests for urethane induction of germ-cell mutations and germ-cell killing in the mouse. *Mutat. Res.* **188**, 335-342.
- Salmon, A.G., Painter, P., Dunn, A.J., Wu-Williams, A., Monserrat, L., and Zeise, L. (1991). Carcinogenic effects. In *Risks of Carcinogenesis from Urethane Exposure* (A.G. Salmon and L. Zeise, Eds.), pp. 48-77. CRC Press, Boca Raton, FL.
- Scherer, E., Winterwerp, H., and Emmelot, P. (1986). Modification of DNA and metabolism of ethyl carbamate *in vivo*: Formation of 7-(2-oxoethyl)guanine and its sensitive determination by reductive tritiation using <sup>3</sup>H-sodium borohydride. In *The Role of Cyclic Nucleic Acid Adducts in Carcinogenesis and Mutagenesis*, No. 70 (B. Singer and H. Bartsch, Eds.), pp. 109-125. International Agency for Research on Cancer, Lyon, France.
- Schlatter, J., and Lutz, W.K. (1990). The carcinogenic potential of ethyl carbamate (urethane): Risk assessment at human dietary exposure levels. *Food Chem. Toxicol.* **28**, 205-211.
- Schmähl, D. (1976). Investigations on esophageal carcinogenicity by methyl-phenyl-nitrosamine and ethyl alcohol in rats. *Cancer Lett.* **1**, 215-218.
- Schmähl, D., Port, R., and Wahrendorf, J. (1977). A dose-response study on urethane carcinogenesis in rats and mice. *Int. J. Cancer* **19**, 77-80.
- Schmidt, W., Popham, R.E., and Israel, Y. (1987). Dose-specific effects of alcohol on the lifespan of mice and the possible relevance to man. *Br. J. Addict.* **82**, 775-788.
- Schrauzer, G.N., McGinness, J.E., Ishmael, D., and Bell, L.J. (1979). Alcoholism and cancer. I. Effects of long-term exposure to alcohol on spontaneous mammary adenocarcinoma and prolactin levels in C3H/St mice. *J. Stud. Alcohol* **40**, 240-246.
- Sedlak, J., and Lindsay, R.H. (1968). Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal. Biochem.* **25**, 192-205.
- Seilkop, S.K. (1995). The effect of body weight on tumor incidence and carcinogenicity testing in B6C3F<sub>1</sub> mice and F344 rats. *Fundam. Appl. Toxicol.* **24**, 247-259.
- Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* **33**, 386-389.
- Sills, R.C., Hong, H.L., Melnick, R.L., Boorman, G.A., and Devereux, T.R. (1999). High frequency of codon 61 K-ras A to T transversions in lung and hardierian gland neoplasms of B6C3F<sub>1</sub> mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. *Carcinogenesis* **20**, 657-662.
- Stoewsand, G.S., Anderson, J.L., and Munson, L. (1991). Inhibition by wine of tumorigenesis induced by ethyl carbamate (urethane) in mice. *Food Chem. Toxicol.* **29**, 291-295.
- Takahashi, M., Hasegawa, R., Furukawa, F., Toyada, K., Sato, H., and Hayashi, Y. (1986). Effects of ethanol, potassium metabisulfite, formaldehyde and hydrogen peroxide on gastric carcinogenesis in rats after initiation with N-methyl-N'-nitro-N-nitrosoguanidine. *Jpn. J. Cancer Res.* **77**, 118-124.
- Tannenbaum, A., and Maltoni, C. (1962). Neoplastic response of various tissues to the administration of urethan. *Cancer Res.* **22**, 1105-1112.

- Tannenbaum, A., and Silverstone, H. (1958). Urethan (ethyl carbamate) as a multipotential carcinogen. *Cancer Res.* **15**, 1225-1231.
- Tarone, R.E. (1975). Tests for trend in life table analysis. *Biometrika* **62**, 679-682.
- Terashima, I., Matsuda, T., Fang, T.-W., Suzuki, N., Kobayashi, J., Kohda, K., and Shibutani, S. (2001). Miscoding potential of the N<sup>2</sup>-ethyl-2'-deoxyguanosine DNA adduct by the exonuclease-free Klenow fragment of *Escherichia coli* DNA polymerase I. *Biochemistry* **40**, 4106-4114.
- Thorgeirsson, U.P., Dalgard, D.W., Reeves, J., and Adamson, R.H. (1994). Tumor incidence in a chemical carcinogenesis study of nonhuman primates. *Regul. Toxicol. Pharmacol.* **19**, 130-151.
- Turturro, A., and Hart, R.W. (1986). Normal versus caloric restriction of B6C3F1 (hybrid-NTP) mice fed NIH31 or NIH31 plus 1.67× vitamin supplement at 60% of *ab libitum* diet. NCTR Experiment E-0503. National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR.
- Tutikawa, K. (1969). Lack of effect of urethane on the induction of dominant lethal mutations in male mice. In *Annual Report of the National Institute of Genetics*, No. 19, pp. 69-70. The National Institute of Genetics, Misima, Japan.
- Vahl, M. (1993). A survey of ethyl carbamate in beverages, bread and acidified milks sold in Denmark. *Food Addit. Contam.* **10**, 585-592.
- Vesselinovich, S.D., Mihailovich, N., Rao, K.V.N., and Itze, L. (1971). Perinatal carcinogenesis by urethan. *Cancer Res.* **32**, 2143-2147.
- Waddell, W.J., Marlowe, C., and Pierce, W.M., Jr. (1987). Inhibition of the localization of urethane in mouse tissues by ethanol. *Food Chem. Toxicol.* **25**, 527-531.
- Wang, M., McIntee, E.J., Cheng, G., Shi, Y., Villalta, P.W., and Hecht, S.S. (2000). Identification of DNA adducts of acetaldehyde. *Chem. Res. Toxicol.* **13**, 1149-1157.
- Watson, M.A., Devereux, T.R., Malarkey, D.E., Anderson, M.W., and Maronpot, R.R. (1995). H-ras oncogene mutation spectra in B6C3F1 and C57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. *Carcinogenesis* **16**, 1705-1710.
- Williams, D.A. (1986). A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. *Biometrics* **42**, 183-186.
- Wiseman, R.W., Stowers, S.J., Miller, E.C., Anderson, M.W., and Miller, J.A. (1986). Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3F1 mouse. *Proc. Natl. Acad. Sci. USA* **83**, 5825-5829.
- Witt, K.L., Knapton, A., Wehr, C.M., Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. (2000). Micronucleated erythrocyte frequency in peripheral blood of B6C3F<sub>1</sub> Mice from short-term, prechronic, and chronic studies of the NTP Carcinogenesis Bioassay Program. *Environ. Mol. Mutagen.* **36**, 163-194.
- Woutersen, R.A., Appelman, L.M., van Garderen-Hoetmer, A., and Feron, V.J. (1986). Inhalation toxicity of acetaldehyde in rats. III. Carcinogenicity study. *Toxicology* **41**, 213-231.

Yamamoto, T., Pierce, W.M. Jr., Hurst, H.E., Chen, D., and Waddell, W.J. (1988). Inhibition of the metabolism of urethane by ethanol. *Drug Metab. Dispos.* **16**, 355-358.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

Zimmerli, B., and Schlatter, J. (1991). Ethyl carbamate: Analytical methodology, occurrence, formation, biological activity and risk assessment. *Mutat. Res.* **259**, 325-350.

**APPENDIX A**  
**SUMMARY OF LESIONS IN MALE MICE**  
**IN THE 2-YEAR DRINKING WATER STUDY**  
**OF URETHANE, ETHANOL, AND URETHANE/ETHANOL**

|                  |   |             |
|------------------|---|-------------|
| <b>TABLE A1</b>  | <b>Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> .....             | <b>A-2</b>  |
| <b>TABLE A2a</b> | <b>Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> .....         | <b>A-8</b>  |
| <b>TABLE A2b</b> | <b>Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years</b> .....   | <b>A-13</b> |
| <b>TABLE A2c</b> | <b>Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>A-16</b> |
| <b>TABLE A2d</b> | <b>Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>A-20</b> |
| <b>TABLE A2e</b> | <b>Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>A-25</b> |
| <b>TABLE A3a</b> | <b>Historical Incidence of Hemangiosarcoma (All Sites) in Control Male B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                           | <b>A-31</b> |
| <b>TABLE A3b</b> | <b>Historical Incidence of Hepatocellular Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                              | <b>A-31</b> |
| <b>TABLE A3c</b> | <b>Historical Incidence of Alveolar/bronchiolar Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                        | <b>A-32</b> |
| <b>TABLE A3d</b> | <b>Historical Incidence of Harderian Gland Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                             | <b>A-32</b> |
| <b>TABLE A4</b>  | <b>Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> ..... | <b>A-33</b> |

**TABLE A1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol<sup>a</sup>**

|                                    | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|------------------------------------|---------|----------|----------|----------|
| <b>Disposition Summary</b>         |         |          |          |          |
| Animals initially in study         | 48      | 48       | 48       | 48       |
| Early deaths                       |         |          |          |          |
| Moribund                           | 2       | 8        | 4        | 11       |
| Natural deaths                     | 19      | 14       | 18       | 29       |
| Survivors                          |         |          |          |          |
| Terminal sacrifice                 | 27      | 26       | 26       | 8        |
| Animals examined microscopically   | 48      | 48       | 47       | 48       |
| <b>Alimentary System</b>           |         |          |          |          |
| Esophagus                          | (47)    | (47)     | (46)     | (46)     |
| Lymphoma malignant                 | 2 (4%)  |          |          |          |
| Gallbladder                        | (35)    | (38)     | (36)     | (23)     |
| Lymphoma malignant                 |         |          | 1 (3%)   |          |
| Intestine large, cecum             | (39)    | (37)     | (40)     | (31)     |
| Lymphoma malignant                 |         |          | 1 (3%)   |          |
| Intestine small, ileum             | (37)    | (37)     | (35)     | (26)     |
| Lymphoma malignant                 |         | 1 (3%)   | 2 (6%)   |          |
| Intestine small, jejunum           | (39)    | (39)     | (37)     | (24)     |
| Carcinoma                          |         |          | 1 (3%)   |          |
| Liver                              | (46)    | (47)     | (46)     | (44)     |
| Hemangiosarcoma                    | 1 (2%)  | 2 (4%)   | 5 (11%)  | 13 (30%) |
| Hepatoblastoma                     |         | 1 (2%)   |          |          |
| Hepatocellular adenoma             | 5 (11%) | 10 (21%) | 13 (28%) | 10 (23%) |
| Hepatocellular adenoma, multiple   | 2 (4%)  | 3 (6%)   | 4 (9%)   | 7 (16%)  |
| Hepatocellular carcinoma           | 6 (13%) | 6 (13%)  | 8 (17%)  | 8 (18%)  |
| Hepatocellular carcinoma, multiple | 1 (2%)  |          | 1 (2%)   | 1 (2%)   |
| Histiocytic sarcoma                | 1 (2%)  | 2 (4%)   | 5 (11%)  | 2 (5%)   |
| Leukemia granulocytic              |         |          |          | 1 (2%)   |
| Lymphoma malignant                 | 3 (7%)  | 2 (4%)   | 3 (7%)   | 1 (2%)   |
| Sarcoma, metastatic, skin          |         |          |          | 2 (5%)   |
| Mesentery                          | (1)     | (1)      | (1)      | (1)      |
| Sarcoma, metastatic, skin          |         |          |          | 1 (100%) |
| Pancreas                           | (45)    | (44)     | (44)     | (42)     |
| Hemangiosarcoma                    |         |          | 1 (2%)   |          |
| Histiocytic sarcoma                | 1 (2%)  |          |          |          |
| Leukemia granulocytic              |         |          |          | 1 (2%)   |
| Lymphoma malignant                 | 2 (4%)  | 1 (2%)   | 2 (5%)   |          |
| Salivary glands                    | (47)    | (48)     | (46)     | (46)     |
| Leukemia granulocytic              |         |          |          | 1 (2%)   |
| Lymphoma malignant                 | 3 (6%)  | 1 (2%)   | 3 (7%)   |          |
| Neoplasm NOS, metastatic, thymus   | 1 (2%)  |          |          |          |
| Sarcoma, metastatic, skin          | 1 (2%)  |          |          |          |
| Stomach, forestomach               | (46)    | (47)     | (44)     | (45)     |
| Hemangiosarcoma                    |         |          |          | 1 (2%)   |
| Hemangiosarcoma, serosa            |         |          |          | 1 (2%)   |
| Lymphoma malignant                 | 1 (2%)  |          |          |          |
| Squamous cell carcinoma            |         | 1 (2%)   |          | 2 (4%)   |
| Squamous cell papilloma            |         | 1 (2%)   | 3 (7%)   | 3 (7%)   |
| Stomach, glandular                 | (43)    | (43)     | (44)     | (42)     |
| Carcinoma                          |         | 1 (2%)   |          |          |
| Lymphoma malignant                 | 1 (2%)  |          | 1 (2%)   |          |
| Sarcoma, metastatic, serosa, skin  |         |          |          | 1 (2%)   |
| Tongue                             | (47)    | (48)     | (47)     | (48)     |
| Lymphoma malignant                 | 2 (4%)  |          |          |          |

**TABLE A1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm  | 10 ppm | 30 ppm | 90 ppm  |
|--|--------|--------|--------|---------|
| <b>Cardiovascular System</b>                     |        |        |        |         |
| Blood vessel                                     | (47)   | (46)   | (47)   | (45)    |
| Lymphoma malignant                               |        | 1 (2%) |        |         |
| Heart  | (48)   | (48)   | (47)   | (48)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung |        |        | 1 (2%) |         |
| Hemangioma                                       |        | 1 (2%) | 1 (2%) |         |
| Hemangiosarcoma                                  |        |        | 1 (2%) | 5 (10%) |
| Lymphoma malignant                               | 2 (4%) |        | 1 (2%) |         |
| Neoplasm NOS, metastatic, thymus                 | 1 (2%) |        |        |         |
| Schwannoma malignant                             |        |        |        | 1 (2%)  |
| <b>Endocrine System</b>                          |        |        |        |         |
| Adrenal gland, cortex                            | (44)   | (44)   | (44)   | (44)    |
| Adenoma  | 1 (2%) | 1 (2%) |        |         |
| Adenoma, subcapsular                             | 1 (2%) | 1 (2%) | 1 (2%) |         |
| Lymphoma malignant                               |        |        | 2 (5%) |         |
| Adrenal gland, medulla                           | (44)   | (43)   | (42)   | (43)    |
| Lymphoma malignant                               |        |        | 1 (2%) |         |
| Pheochromocytoma benign                          |        |        | 2 (5%) | 5 (12%) |
| Pheochromocytoma benign, bilateral               |        |        |        | 1 (2%)  |
| Islets, pancreatic                               | (45)   | (44)   | (44)   | (42)    |
| Adenoma  |        |        |        | 1 (2%)  |
| Pituitary gland                                  | (35)   | (42)   | (39)   | (38)    |
| Lymphoma malignant                               |        |        | 1 (3%) |         |
| Thyroid gland                                    | (46)   | (46)   | (46)   | (45)    |
| Adenoma, follicular cell                         | 2 (4%) | 2 (4%) |        |         |
| Lymphoma malignant                               | 2 (4%) |        | 1 (2%) |         |
| <b>General Body System</b>                       |        |        |        |         |
| None   |        |        |        |         |
| <b>Genital System</b>                            |        |        |        |         |
| Coagulating gland                                | (46)   | (48)   | (46)   | (46)    |
| Lymphoma malignant                               | 2 (4%) |        | 1 (2%) |         |
| Epididymis                                       | (47)   | (48)   | (46)   | (44)    |
| Leukemia granulocytic                            |        |        |        | 1 (2%)  |
| Lymphoma malignant                               | 2 (4%) |        | 1 (2%) |         |
| Neoplasm NOS, metastatic, thymus                 | 1 (2%) |        |        |         |
| Preputial gland                                  | (45)   | (44)   | (43)   | (43)    |
| Carcinoma  |        |        | 1 (2%) |         |
| Lymphoma malignant                               | 1 (2%) |        | 1 (2%) |         |
| Prostate   | (46)   | (45)   | (45)   | (45)    |
| Lymphoma malignant                               | 2 (4%) |        | 2 (4%) |         |
| Neoplasm NOS, metastatic, thymus                 | 1 (2%) |        |        |         |
| Seminal vesicle                                  | (46)   | (48)   | (46)   | (46)    |
| Leukemia granulocytic                            |        |        |        | 1 (2%)  |
| Lymphoma malignant                               | 2 (4%) |        | 1 (2%) |         |
| Testes   | (47)   | (48)   | (46)   | (46)    |
| Lymphoma malignant                               |        |        | 1 (2%) | 1 (2%)  |

**TABLE A1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm   | 10 ppm | 30 ppm  | 90 ppm   |
|---|---------|--------|---------|----------|
| <b>Hematopoietic System</b>                                   |         |        |         |          |
| Bone marrow   | (46)    | (47)   | (45)    | (45)     |
| Hemangiosarcoma   | 1 (2%)  | 1 (2%) |         |          |
| Histiocytic sarcoma   | 1 (2%)  | 1 (2%) |         | 1 (2%)   |
| Leukemia granulocytic   |         |        |         | 1 (2%)   |
| Lymphoma malignant  | 1 (2%)  |        | 1 (2%)  |          |
| Lymph node  | (47)    | (47)   | (46)    | (46)     |
| Alveolar/bronchiolar carcinoma, metastatic, mediastinal, lung |         |        | 1 (2%)  |          |
| Carcinoma, metastatic, pancreatic, stomach                    |         | 1 (2%) |         |          |
| Hepatoblastoma, metastatic, mediastinal, liver                |         | 1 (2%) |         |          |
| Histiocytic sarcoma, lumbar                                   |         | 1 (2%) |         |          |
| Leukemia granulocytic, iliac                                  |         |        |         | 1 (2%)   |
| Leukemia granulocytic, inguinal                               |         |        |         | 1 (2%)   |
| Lymphoma malignant, axillary                                  |         |        | 2 (4%)  |          |
| Lymphoma malignant, inguinal                                  |         |        | 2 (4%)  |          |
| Lymphoma malignant, lumbar                                    |         |        | 2 (4%)  |          |
| Lymphoma malignant, mediastinal                               |         | 1 (2%) |         |          |
| Lymphoma malignant, pancreatic                                |         | 1 (2%) |         |          |
| Lymphoma malignant, renal                                     |         | 2 (4%) | 3 (7%)  |          |
| Sarcoma, metastatic, axillary, skin                           | 1 (2%)  |        |         |          |
| Lymph node, mandibular  | (46)    | (46)   | (46)    | (45)     |
| Hemangiosarcoma   | 1 (2%)  |        |         |          |
| Leukemia granulocytic   |         |        |         | 1 (2%)   |
| Lymphoma malignant  | 3 (7%)  | 1 (2%) | 3 (7%)  | 1 (2%)   |
| Neoplasm NOS  | 1 (2%)  |        |         |          |
| Lymph node, mesenteric  | (43)    | (47)   | (43)    | (38)     |
| Hemangiosarcoma   |         |        |         | 1 (3%)   |
| Histiocytic sarcoma   | 1 (2%)  | 2 (4%) | 2 (5%)  | 1 (3%)   |
| Leukemia granulocytic   |         |        |         | 1 (3%)   |
| Lymphoma malignant  | 6 (14%) | 3 (6%) | 5 (12%) | 2 (5%)   |
| Neoplasm NOS, metastatic, thymus                              | 1 (2%)  |        |         |          |
| Sarcoma   |         | 1 (2%) |         |          |
| Spleen  | (44)    | (46)   | (45)    | (42)     |
| Hemangioma  |         |        | 1 (2%)  | 1 (2%)   |
| Hemangiosarcoma   | 2 (5%)  | 2 (4%) | 2 (4%)  | 5 (12%)  |
| Histiocytic sarcoma   | 1 (2%)  | 3 (7%) | 3 (7%)  | 2 (5%)   |
| Leukemia granulocytic   |         |        |         | 1 (2%)   |
| Lymphoma malignant  | 9 (20%) | 4 (9%) | 5 (11%) | 3 (7%)   |
| Thymus  | (32)    | (29)   | (35)    | (27)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung              |         |        | 1 (3%)  |          |
| Lymphoma malignant  | 2 (6%)  | 2 (7%) | 3 (9%)  |          |
| Neoplasm NOS  | 1 (3%)  |        |         |          |
| Sarcoma, metastatic, skin                                     |         |        |         | 1 (4%)   |
| Sarcoma, metastatic, uncertain primary site                   | 1 (3%)  |        |         |          |
| <b>Integumentary System</b>                                   |         |        |         |          |
| Mammary gland   |         | (2)    | (5)     | (1)      |
| Carcinoma   |         |        |         | 1 (100%) |
| Lymphoma malignant  |         |        | 1 (20%) |          |

TABLE A1

## Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol

|   | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|---|---------|----------|----------|----------|
| <b>Integumentary System</b> (continued)                     |         |          |          |          |
| Skin  | (47)    | (48)     | (47)     | (48)     |
| Basal cell adenoma  |         |          | 2 (4%)   | 1 (2%)   |
| Basal cell carcinoma  |         | 1 (2%)   |          | 1 (2%)   |
| Fibroma   |         | 2 (4%)   | 3 (6%)   |          |
| Fibroma, multiple   | 1 (2%)  |          |          |          |
| Fibroma, tail   |         |          |          | 1 (2%)   |
| Hemangioma  |         | 1 (2%)   |          | 1 (2%)   |
| Hemangiosarcoma   | 1 (2%)  |          |          | 2 (4%)   |
| Histiocytic sarcoma   | 1 (2%)  |          | 1 (2%)   |          |
| Histiocytic sarcoma, multiple                               | 1 (2%)  |          |          |          |
| Lipoma  |         |          |          | 1 (2%)   |
| Lymphoma malignant  | 1 (2%)  |          | 1 (2%)   | 1 (2%)   |
| Neoplasm NOS  |         |          |          | 1 (2%)   |
| Rhabdomyosarcoma, metastatic, skeletal muscle               |         | 1 (2%)   |          |          |
| Sarcoma   | 9 (19%) | 7 (15%)  | 5 (11%)  | 9 (19%)  |
| Sarcoma, multiple   | 1 (2%)  | 2 (4%)   |          | 5 (10%)  |
| Squamous cell carcinoma                                     |         |          | 2 (4%)   | 1 (2%)   |
| Squamous cell papilloma                                     |         | 1 (2%)   | 1 (2%)   | 3 (6%)   |
| Squamous cell papilloma, multiple                           |         |          |          | 2 (4%)   |
| <b>Musculoskeletal System</b>                               |         |          |          |          |
| Bone  | (48)    | (48)     | (47)     | (48)     |
| Hemangiosarcoma, cranium                                    |         |          |          | 1 (2%)   |
| Sarcoma, metastatic, sternum, uncertain primary site        | 1 (2%)  |          |          |          |
| Skeletal muscle   | (48)    | (48)     | (47)     | (48)     |
| Alveolar/bronchiolar carcinoma, metastatic                  |         |          |          | 1 (2%)   |
| Alveolar/bronchiolar carcinoma, metastatic, diaphragm, lung |         |          |          | 1 (2%)   |
| Lymphoma malignant  | 1 (2%)  |          | 1 (2%)   |          |
| Neoplasm NOS, metastatic, thymus                            | 1 (2%)  |          |          |          |
| Rhabdomyosarcoma  | 1 (2%)  | 1 (2%)   |          |          |
| Sarcoma   |         |          |          | 1 (2%)   |
| <b>Nervous System</b>                                       |         |          |          |          |
| Brain, cerebellum   | (48)    | (47)     | (44)     | (46)     |
| Lymphoma malignant  | 1 (2%)  |          | 1 (2%)   |          |
| Brain, cerebrum   | (48)    | (48)     | (47)     | (47)     |
| Lymphoma malignant  | 1 (2%)  |          | 1 (2%)   |          |
| <b>Respiratory System</b>                                   |         |          |          |          |
| Larynx  | (45)    | (45)     | (46)     | (45)     |
| Lymphoma malignant  | 2 (4%)  |          |          |          |
| Lung  | (48)    | (48)     | (47)     | (48)     |
| Alveolar/bronchiolar adenoma                                | 3 (6%)  | 15 (31%) | 15 (32%) | 14 (29%) |
| Alveolar/bronchiolar adenoma, multiple                      | 1 (2%)  | 2 (4%)   | 7 (15%)  | 20 (42%) |
| Alveolar/bronchiolar carcinoma                              | 1 (2%)  | 1 (2%)   | 8 (17%)  | 8 (17%)  |
| Alveolar/bronchiolar carcinoma, multiple                    |         |          | 1 (2%)   | 1 (2%)   |
| Basal cell carcinoma, metastatic, skin                      |         | 1 (2%)   |          |          |

**TABLE A1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm  | 10 ppm   | 30 ppm   | 90 ppm   |
|---|--------|----------|----------|----------|
| <b>Respiratory System (continued)</b>                 |        |          |          |          |
| Lung (continued)                                      | (48)   | (48)     | (47)     | (48)     |
| Hemangiosarcoma                                       |        |          |          | 1 (2%)   |
| Hepatoblastoma, metastatic, liver                     |        | 1 (2%)   |          |          |
| Hepatocellular carcinoma, metastatic, liver           | 4 (8%) |          | 2 (4%)   | 1 (2%)   |
| Hepatocellular carcinoma, metastatic, multiple, liver |        |          |          | 1 (2%)   |
| Histiocytic sarcoma                                   |        | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Leukemia granulocytic                                 |        |          |          | 1 (2%)   |
| Lymphoma malignant                                    | 3 (6%) |          | 3 (6%)   |          |
| Neoplasm NOS  | 1 (2%) |          |          |          |
| Neoplasm NOS, metastatic, thymus                      | 1 (2%) |          |          |          |
| Sarcoma, metastatic, skin                             | 1 (2%) | 2 (4%)   | 1 (2%)   | 3 (6%)   |
| Schwannoma malignant, metastatic, lung                |        |          |          | 1 (2%)   |
| Schwannoma malignant, metastatic, nose                |        | 1 (2%)   |          |          |
| Nose  | (47)   | (48)     | (47)     | (47)     |
| Hemangioma, mucosa                                    |        |          |          | 1 (2%)   |
| Lymphoma malignant                                    | 1 (2%) |          | 1 (2%)   |          |
| Schwannoma malignant                                  |        | 1 (2%)   |          |          |
| Trachea   | (47)   | (47)     | (46)     | (46)     |
| Lymphoma malignant                                    | 1 (2%) |          | 1 (2%)   |          |
| <b>Special Senses System</b>                          |        |          |          |          |
| Eye   | (47)   | (47)     | (47)     | (47)     |
| Lymphoma malignant                                    | 1 (2%) |          |          |          |
| Harderian gland                                       | (47)   | (47)     | (47)     | (47)     |
| Adenoma   | 3 (6%) | 10 (21%) | 21 (45%) | 21 (45%) |
| Adenoma, bilateral                                    |        | 1 (2%)   | 4 (9%)   | 7 (15%)  |
| Carcinoma   |        | 1 (2%)   | 6 (13%)  | 14 (30%) |
| Carcinoma, bilateral                                  |        |          | 1 (2%)   | 2 (4%)   |
| Lymphoma malignant                                    | 2 (4%) |          | 1 (2%)   |          |
| Lacrimal gland  | (47)   | (47)     | (44)     | (47)     |
| Leukemia granulocytic                                 |        |          |          | 1 (2%)   |
| Lymphoma malignant                                    | 2 (4%) |          | 1 (2%)   |          |
| Zymbal's gland  | (45)   | (45)     | (45)     | (45)     |
| Basosquamous tumor benign                             |        |          | 1 (2%)   |          |
| Lymphoma malignant                                    | 2 (4%) |          | 1 (2%)   |          |
| <b>Urinary System</b>                                 |        |          |          |          |
| Kidney  | (46)   | (47)     | (46)     | (45)     |
| Adenoma, renal tubule                                 |        |          | 1 (2%)   | 1 (2%)   |
| Hemangiosarcoma                                       |        |          |          | 1 (2%)   |
| Leukemia granulocytic                                 |        |          |          | 1 (2%)   |
| Lymphoma malignant                                    | 2 (4%) | 2 (4%)   | 2 (4%)   | 2 (4%)   |
| Urinary bladder                                       | (46)   | (46)     | (46)     | (40)     |
| Lymphoma malignant                                    | 1 (2%) | 1 (2%)   | 1 (2%)   |          |

**TABLE A1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|--|-------|--------|--------|--------|
| <b>Neoplasm Summary</b>  |       |        |        |        |
| Total animals with primary neoplasms <sup>b</sup>              | 33    | 39     | 46     | 47     |
| Total primary neoplasms  | 123   | 114    | 204    | 221    |
| Total animals with benign neoplasms                            | 17    | 29     | 41     | 45     |
| Total benign neoplasms   | 19    | 51     | 80     | 101    |
| Total animals with malignant neoplasms                         | 27    | 30     | 37     | 43     |
| Total malignant neoplasms                                      | 101   | 63     | 124    | 119    |
| Total animals with metastatic neoplasms                        | 7     | 6      | 5      | 8      |
| Total metastatic neoplasms                                     | 16    | 8      | 6      | 12     |
| Total animals with uncertain neoplasms-<br>benign or malignant | 2     |        |        | 1      |
| Total uncertain neoplasms                                      | 3     |        |        | 1      |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE A2a**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm         | 10 ppm          | 30 ppm          | 90 ppm          |
|---|---------------|-----------------|-----------------|-----------------|
| <b>Adrenal Medulla: Benign Pheochromocytoma</b>                   |               |                 |                 |                 |
| Overall rate <sup>a</sup>   | 0/44 (0.0%)   | 0/43 (0.0%)     | 2/42 (4.8%)     | 6/43 (14.0%)    |
| Adjusted rate <sup>b</sup>  | 0/35.9 (0.0%) | 0/32.7 (0.0%)   | 2/36.1 (5.5%)   | 6/29.4 (20.4%)  |
| Terminal rate <sup>c</sup>  | 0/27 (0.0%)   | 0/23 (0.0%)     | 0/23 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days) <sup>e</sup>                               | —             | — <sup>f</sup>  | 432             | 453             |
| Poly-3 test <sup>d</sup>  | P=0.001       | — <sup>f</sup>  | P=0.238         | P=0.006         |
| <b>Harderian Gland: Adenoma</b>                                   |               |                 |                 |                 |
| Overall rate  | 3/47 (6.4%)   | 11/47 (23.4%)   | 25/47 (53.2%)   | 28/47 (59.6%)   |
| Adjusted rate   | 3/38.0 (7.9%) | 11/36.5 (30.1%) | 25/41.2 (60.7%) | 28/36.0 (77.8%) |
| Terminal rate   | 1/27 (3.7%)   | 7/26 (26.9%)    | 17/26 (65.4%)   | 8/8 (100.0%)    |
| First incidence (days)  | 599           | 691             | 456             | 466             |
| Poly-3 test   | P=0.001       | P=0.013         | P=0.001         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>                                 |               |                 |                 |                 |
| Overall rate  | 0/47 (0.0%)   | 1/47 (2.1%)     | 7/47 (14.9%)    | 16/47 (34.0%)   |
| Adjusted rate   | 0/37.2 (0.0%) | 1/35.9 (2.8%)   | 7/41.2 (17.0%)  | 16/35.7 (44.9%) |
| Terminal rate   | 0/27 (0.0%)   | 1/26 (3.8%)     | 2/26 (7.7%)     | 3/8 (37.5%)     |
| First incidence (days)  | —             | 765 (T)         | 510             | 453             |
| Poly-3 test   | P=0.001       | P=0.493         | P=0.011         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>                      |               |                 |                 |                 |
| Overall rate  | 3/47 (6.4%)   | 12/47 (25.5%)   | 30/47 (63.8%)   | 38/47 (80.9%)   |
| Adjusted rate   | 3/38.0 (7.9%) | 12/36.5 (32.8%) | 30/43.3 (69.2%) | 38/42.0 (90.6%) |
| Terminal rate   | 1/27 (3.7%)   | 8/26 (30.8%)    | 17/26 (65.4%)   | 8/8 (100.0%)    |
| First incidence (days)  | 599           | 691             | 456             | 453             |
| Poly-3 test   | P=0.001       | P=0.006         | P=0.001         | P=0.001         |
| <b>Heart: Hemangiosarcoma</b>                                     |               |                 |                 |                 |
| Overall rate  | 0/48 (0.0%)   | 0/48 (0.0%)     | 1/47 (2.1%)     | 5/48 (10.4%)    |
| Adjusted rate   | 0/37.6 (0.0%) | 0/36.3 (0.0%)   | 1/39.1 (2.6%)   | 5/31.0 (16.1%)  |
| Terminal rate   | 0/27 (0.0%)   | 0/26 (0.0%)     | 0/26 (0.0%)     | 1/8 (12.5%)     |
| First incidence (days)  | —             | —               | 754             | 453             |
| Poly-3 test   | P=0.001       | —               | P=0.508         | P=0.016         |
| <b>Heart: Hemangioma or Hemangiosarcoma</b>                       |               |                 |                 |                 |
| Overall rate  | 0/48 (0.0%)   | 1/48 (2.1%)     | 2/47 (4.3%)     | 5/48 (10.4%)    |
| Adjusted rate   | 0/37.6 (0.0%) | 1/36.3 (2.8%)   | 2/39.2 (5.1%)   | 5/31.0 (16.1%)  |
| Terminal rate   | 0/27 (0.0%)   | 0/26 (0.0%)     | 0/26 (0.0%)     | 1/8 (12.5%)     |
| First incidence (days)  | —             | 754             | 724             | 453             |
| Poly-3 test   | P=0.004       | P=0.493         | P=0.246         | P=0.016         |
| <b>Kidney: Adenoma, Hemangiosarcoma, or Leukemia Granulocytic</b> |               |                 |                 |                 |
| Overall rate  | 0/46 (0.0%)   | 0/47 (0.0%)     | 1/46 (2.2%)     | 3/45 (6.7%)     |
| Adjusted rate   | 0/36.8 (0.0%) | 0/36.3 (0.0%)   | 1/38.9 (2.6%)   | 3/29.5 (10.2%)  |
| Terminal rate   | 0/27 (0.0%)   | 0/26 (0.0%)     | 1/26 (3.8%)     | 0/8 (0.0%)      |
| First incidence (days)  | —             | —               | 765 (T)         | 493             |
| Poly-3 test   | P=0.012       | —               | P=0.511         | P=0.082         |
| <b>Liver: Hemangiosarcoma</b>                                     |               |                 |                 |                 |
| Overall rate  | 1/46 (2.2%)   | 2/47 (4.3%)     | 5/46 (10.9%)    | 13/44 (29.5%)   |
| Adjusted rate   | 1/36.8 (2.7%) | 2/35.6 (5.6%)   | 5/39.6 (12.6%)  | 13/31.1 (41.8%) |
| Terminal rate   | 1/27 (3.7%)   | 1/26 (3.8%)     | 3/26 (11.5%)    | 2/8 (25.0%)     |
| First incidence (days)  | 765 (T)       | 754             | 510             | 493             |
| Poly-3 test   | P=0.001       | P=0.489         | P=0.118         | P=0.001         |

TABLE A2a

## Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>Liver: Histiocytic Sarcoma</b>                      |                 |                 |                 |                 |
| Overall rate   | 1/46 (2.2%)     | 2/47 (4.3%)     | 5/46 (10.9%)    | 2/44 (4.5%)     |
| Adjusted rate  | 1/36.8 (2.7%)   | 2/36.1 (5.5%)   | 5/39.3 (12.7%)  | 2/28.4 (7.1%)   |
| Terminal rate  | 0/27 (0.0%)     | 0/26 (0.0%)     | 2/26 (7.7%)     | 0/8 (0.0%)      |
| First incidence (days)                                 | 756             | 614             | 668             | 680             |
| Poly-3 test  | P=0.347         | P=0.493         | P=0.115         | P=0.410         |
| <b>Liver: Hepatocellular Adenoma</b>                   |                 |                 |                 |                 |
| Overall rate   | 7/46 (15.2%)    | 13/47 (27.7%)   | 17/46 (37.0%)   | 17/44 (38.6%)   |
| Adjusted rate  | 7/37.4 (18.7%)  | 13/36.1 (36.0%) | 17/41.3 (41.2%) | 17/33.8 (50.3%) |
| Terminal rate  | 6/27 (22.2%)    | 11/26 (42.3%)   | 9/26 (34.6%)    | 4/8 (50.0%)     |
| First incidence (days)                                 | 541             | 662             | 456             | 453             |
| Poly-3 test  | P=0.009         | P=0.077         | P=0.025         | P=0.003         |
| <b>Liver: Hepatocellular Carcinoma</b>                 |                 |                 |                 |                 |
| Overall rate   | 7/46 (15.2%)    | 6/47 (12.8%)    | 9/46 (19.6%)    | 9/44 (20.5%)    |
| Adjusted rate  | 7/37.0 (18.9%)  | 6/36.0 (16.7%)  | 9/40.3 (22.3%)  | 9/30.0 (30.0%)  |
| Terminal rate  | 5/27 (18.5%)    | 3/26 (11.5%)    | 5/26 (19.2%)    | 2/8 (25.0%)     |
| First incidence (days)                                 | 712             | 665             | 542             | 580             |
| Poly-3 test  | P=0.135         | P=0.521N        | P=0.464         | P=0.221         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                 |                 |                 |                 |
| Overall rate   | 12/46 (26.1%)   | 18/47 (38.3%)   | 24/46 (52.2%)   | 23/44 (52.3%)   |
| Adjusted rate  | 12/37.6 (31.9%) | 18/36.6 (49.2%) | 24/42.5 (56.5%) | 23/35.2 (65.3%) |
| Terminal rate  | 9/27 (33.3%)    | 13/26 (50.0%)   | 13/26 (50.0%)   | 5/8 (62.5%)     |
| First incidence (days)                                 | 541             | 662             | 456             | 453             |
| Poly-3 test  | P=0.007         | P=0.095         | P=0.020         | P=0.002         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)     | 17/48 (35.4%)   | 22/47 (46.8%)   | 34/48 (70.8%)   |
| Adjusted rate  | 4/37.6 (10.6%)  | 17/38.4 (44.3%) | 22/41.2 (53.4%) | 34/39.5 (86.2%) |
| Terminal rate  | 4/27 (14.8%)    | 11/26 (42.3%)   | 16/26 (61.5%)   | 8/8 (100.0%)    |
| First incidence (days)                                 | 765 (T)         | 511             | 456             | 293             |
| Poly-3 test  | P=0.001         | P=0.001         | P=0.001         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)     | 1/48 (2.1%)     | 9/47 (19.1%)    | 9/48 (18.8%)    |
| Adjusted rate  | 1/37.7 (2.7%)   | 1/36.3 (2.8%)   | 9/40.5 (22.2%)  | 9/30.8 (29.2%)  |
| Terminal rate  | 0/27 (0.0%)     | 1/26 (3.8%)     | 5/26 (19.2%)    | 3/8 (37.5%)     |
| First incidence (days)                                 | 739             | 765 (T)         | 542             | 521             |
| Poly-3 test  | P=0.001         | P=0.753         | P=0.010         | P=0.002         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)    | 18/48 (37.5%)   | 29/47 (61.7%)   | 37/48 (77.1%)   |
| Adjusted rate  | 5/37.7 (13.3%)  | 18/38.4 (46.9%) | 29/42.2 (68.8%) | 37/40.4 (91.7%) |
| Terminal rate  | 4/27 (14.8%)    | 12/26 (46.2%)   | 20/26 (76.9%)   | 8/8 (100.0%)    |
| First incidence (days)                                 | 739             | 511             | 456             | 293             |
| Poly-3 test  | P=0.001         | P=0.001         | P=0.001         | P=0.001         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                 |                 |                 |                 |
| Overall rate   | 1/43 (2.3%)     | 2/47 (4.3%)     | 2/43 (4.7%)     | 1/38 (2.6%)     |
| Adjusted rate  | 1/35.2 (2.8%)   | 2/36.8 (5.4%)   | 2/36.8 (5.4%)   | 1/25.5 (3.9%)   |
| Terminal rate  | 0/26 (0.0%)     | 0/26 (0.0%)     | 0/25 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                                 | 756             | 614             | 668             | 729             |
| Poly-3 test  | P=0.614         | P=0.515         | P=0.515         | P=0.685         |

TABLE A2a

## Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol

|  | 0 ppm           | 10 ppm          | 30 ppm         | 90 ppm          |
|--|-----------------|-----------------|----------------|-----------------|
| <b>Skin: Squamous Cell Papilloma</b>   |                 |                 |                |                 |
| Overall rate   | 0/47 (0.0%)     | 1/48 (2.1%)     | 1/47 (2.1%)    | 5/48 (10.4%)    |
| Adjusted rate  | 0/37.2 (0.0%)   | 1/36.6 (2.7%)   | 1/39.1 (2.6%)  | 5/30.4 (16.4%)  |
| Terminal rate  | 0/27 (0.0%)     | 0/26 (0.0%)     | 0/26 (0.0%)    | 2/8 (25.0%)     |
| First incidence (days)   | —               | 662             | 762            | 453             |
| Poly-3 test  | P=0.002         | P=0.497         | P=0.510        | P=0.016         |
| <b>Skin: Squamous Cell Papilloma or Squamous Cell Carcinoma</b>  |                 |                 |                |                 |
| Overall rate   | 0/47 (0.0%)     | 1/48 (2.1%)     | 3/47 (6.4%)    | 6/48 (12.5%)    |
| Adjusted rate  | 0/37.2 (0.0%)   | 1/36.6 (2.7%)   | 3/39.1 (7.7%)  | 6/31.0 (19.4%)  |
| Terminal rate  | 0/27 (0.0%)     | 0/26 (0.0%)     | 2/26 (7.7%)    | 2/8 (25.0%)     |
| First incidence (days)   | —               | 662             | 762            | 453             |
| Poly-3 test  | P=0.001         | P=0.497         | P=0.127        | P=0.007         |
| <b>Skin: Squamous Cell Papilloma, Squamous Cell Carcinoma, Basal Cell Adenoma, or Basal Cell Carcinoma</b> |                 |                 |                |                 |
| Overall rate   | 0/47 (0.0%)     | 1/48 (2.1%)     | 5/47 (10.6%)   | 8/48 (16.7%)    |
| Adjusted rate  | 0/37.2 (0.0%)   | 1/36.6 (2.7%)   | 5/39.1 (12.8%) | 8/31.8 (25.2%)  |
| Terminal rate  | 0/27 (0.0%)     | 0/26 (0.0%)     | 3/26 (11.5%)   | 2/8 (25.0%)     |
| First incidence (days)   | —               | 662             | 746            | 453             |
| Poly-3 test  | P=0.001         | P=0.497         | P=0.034        | P=0.001         |
| <b>Skin: Sarcoma</b>   |                 |                 |                |                 |
| Overall rate   | 10/47 (21.3%)   | 9/48 (18.8%)    | 5/47 (10.6%)   | 14/48 (29.2%)   |
| Adjusted rate  | 10/38.7 (25.8%) | 9/37.8 (23.8%)  | 5/39.9 (12.5%) | 14/34.7 (40.3%) |
| Terminal rate  | 6/27 (22.2%)    | 5/26 (19.2%)    | 3/26 (11.5%)   | 1/8 (12.5%)     |
| First incidence (days)   | 536             | 520             | 432            | 453             |
| Poly-3 test  | P=0.064         | P=0.526N        | P=0.111N       | P=0.137         |
| <b>Skin: Fibroma or Sarcoma</b>  |                 |                 |                |                 |
| Overall rate   | 10/47 (21.3%)   | 11/48 (22.9%)   | 8/47 (17.0%)   | 15/48 (31.3%)   |
| Adjusted rate  | 10/38.7 (25.8%) | 11/37.8 (29.1%) | 8/39.9 (20.0%) | 15/35.0 (42.9%) |
| Terminal rate  | 6/27 (22.2%)    | 7/26 (26.9%)    | 6/26 (23.1%)   | 1/8 (12.5%)     |
| First incidence (days)   | 536             | 520             | 432            | 453             |
| Poly-3 test  | P=0.064         | P=0.472         | P=0.366N       | P=0.092         |
| <b>Skin: Hemangioma or Hemangiosarcoma</b>   |                 |                 |                |                 |
| Overall rate   | 1/47 (2.1%)     | 1/48 (2.1%)     | 0/47 (0.0%)    | 3/48 (6.3%)     |
| Adjusted rate  | 1/37.2 (2.7%)   | 1/36.3 (2.8%)   | 0/39.0 (0.0%)  | 3/30.3 (9.9%)   |
| Terminal rate  | 0/27 (0.0%)     | 1/26 (3.8%)     | 0/26 (0.0%)    | 1/8 (12.5%)     |
| First incidence (days)   | 764             | 765 (T)         | —              | 576             |
| Poly-3 test  | P=0.103         | P=0.756         | P=0.490N       | P=0.235         |
| <b>Spleen: Hemangiosarcoma</b>   |                 |                 |                |                 |
| Overall rate   | 2/44 (4.5%)     | 2/46 (4.3%)     | 2/45 (4.4%)    | 5/42 (11.9%)    |
| Adjusted rate  | 2/36.7 (5.4%)   | 2/36.5 (5.5%)   | 2/38.1 (5.2%)  | 5/28.1 (17.8%)  |
| Terminal rate  | 1/27 (3.7%)     | 1/26 (3.8%)     | 1/26 (3.8%)    | 1/8 (12.5%)     |
| First incidence (days)   | 757             | 691             | 724            | 548             |
| Poly-3 test  | P=0.051         | P=0.692         | P=0.681N       | P=0.120         |
| <b>Spleen: Hemangioma or Hemangiosarcoma</b>   |                 |                 |                |                 |
| Overall rate   | 2/44 (4.5%)     | 2/46 (4.3%)     | 3/45 (6.7%)    | 6/42 (14.3%)    |
| Adjusted rate  | 2/36.7 (5.4%)   | 2/36.5 (5.5%)   | 3/38.1 (7.9%)  | 6/28.9 (20.8%)  |
| Terminal rate  | 1/27 (3.7%)     | 1/26 (3.8%)     | 2/26 (7.7%)    | 1/8 (12.5%)     |
| First incidence (days)   | 757             | 691             | 724            | 483             |
| Poly-3 test  | P=0.021         | P=0.692         | P=0.517        | P=0.065         |

TABLE A2a

## Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol

|  | 0 ppm          | 10 ppm         | 30 ppm         | 90 ppm          |
|--|----------------|----------------|----------------|-----------------|
| <b>Spleen: Histiocytic Sarcoma</b>   |                |                |                |                 |
| Overall rate   | 1/44 (2.3%)    | 3/46 (6.5%)    | 3/45 (6.7%)    | 2/42 (4.8%)     |
| Adjusted rate  | 1/36.7 (2.7%)  | 3/36.7 (8.2%)  | 3/38.7 (7.8%)  | 2/27.5 (7.3%)   |
| Terminal rate  | 0/27 (0.0%)    | 1/26 (3.8%)    | 0/26 (0.0%)    | 0/8 (0.0%)      |
| First incidence (days)   | 756            | 614            | 643            | 680             |
| Poly-3 test  | P=0.423        | P=0.304        | P=0.324        | P=0.401         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                            |                |                |                |                 |
| Overall rate   | 0/46 (0.0%)    | 1/47 (2.1%)    | 3/44 (6.8%)    | 3/45 (6.7%)     |
| Adjusted rate  | 0/36.8 (0.0%)  | 1/36.5 (2.7%)  | 3/37.7 (7.9%)  | 3/29.3 (10.2%)  |
| Terminal rate  | 0/27 (0.0%)    | 0/26 (0.0%)    | 3/26 (11.5%)   | 0/8 (0.0%)      |
| First incidence (days)   | —              | 691            | 765 (T)        | 646             |
| Poly-3 test  | P=0.058        | P=0.499        | P=0.122        | P=0.081         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                |                |                |                 |
| Overall rate   | 0/46 (0.0%)    | 2/47 (4.3%)    | 3/44 (6.8%)    | 5/45 (11.1%)    |
| Adjusted rate  | 0/36.8 (0.0%)  | 2/37.2 (5.4%)  | 3/37.7 (7.9%)  | 5/29.6 (16.9%)  |
| Terminal rate  | 0/27 (0.0%)    | 0/26 (0.0%)    | 3/26 (11.5%)   | 1/8 (12.5%)     |
| First incidence (days)   | —              | 537            | 765 (T)        | 646             |
| Poly-3 test  | P=0.011        | P=0.239        | P=0.122        | P=0.015         |
| <b>All Organs: Hemangioma</b>  |                |                |                |                 |
| Overall rate   | 0/48 (0.0%)    | 2/48 (4.2%)    | 2/47 (4.3%)    | 3/48 (6.3%)     |
| Adjusted rate  | 0/37.6 (0.0%)  | 2/36.3 (5.5%)  | 2/39.2 (5.1%)  | 3/30.1 (10.0%)  |
| Terminal rate  | 0/27 (0.0%)    | 1/26 (3.8%)    | 1/26 (3.8%)    | 1/8 (12.5%)     |
| First incidence (days)   | —              | 754            | 724            | 483             |
| Poly-3 test  | P=0.097        | P=0.229        | P=0.246        | P=0.082         |
| <b>All Organs: Hemangiosarcoma</b>   |                |                |                |                 |
| Overall rate   | 4/48 (8.3%)    | 4/48 (8.3%)    | 7/47 (14.9%)   | 19/48 (39.6%)   |
| Adjusted rate  | 4/37.7 (10.6%) | 4/36.6 (10.9%) | 7/39.9 (17.5%) | 19/34.5 (55.2%) |
| Terminal rate  | 1/27 (3.7%)    | 2/26 (7.7%)    | 4/26 (15.4%)   | 3/8 (37.5%)     |
| First incidence (days)   | 739            | 691            | 510            | 453             |
| Poly-3 test  | P=0.001        | P=0.628        | P=0.292        | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                 |                |                |                |                 |
| Overall rate   | 4/48 (8.3%)    | 5/48 (10.4%)   | 9/47 (19.1%)   | 21/48 (43.8%)   |
| Adjusted rate  | 4/37.7 (10.6%) | 5/36.6 (13.7%) | 9/40.1 (22.4%) | 21/35.2 (59.7%) |
| Terminal rate  | 1/27 (3.7%)    | 3/26 (11.5%)   | 5/26 (19.2%)   | 4/8 (50.0%)     |
| First incidence (days)   | 739            | 691            | 510            | 453             |
| Poly-3 test  | P=0.001        | P=0.480        | P=0.135        | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>   |                |                |                |                 |
| Overall rate   | 3/48 (6.3%)    | 3/48 (6.3%)    | 6/47 (12.8%)   | 2/48 (4.2%)     |
| Adjusted rate  | 3/38.3 (7.8%)  | 3/36.8 (8.1%)  | 6/39.9 (15.1%) | 2/29.7 (6.7%)   |
| Terminal rate  | 1/27 (3.7%)    | 1/26 (3.8%)    | 2/26 (7.7%)    | 0/8 (0.0%)      |
| First incidence (days)   | 515            | 614            | 643            | 680             |
| Poly-3 test  | P=0.560N       | P=0.645        | P=0.259        | P=0.615N        |
| <b>All Organs: Malignant Lymphoma</b>  |                |                |                |                 |
| Overall rate   | 9/48 (18.8%)   | 7/48 (14.6%)   | 6/47 (12.8%)   | 4/48 (8.3%)     |
| Adjusted rate  | 9/37.7 (23.8%) | 7/36.7 (19.1%) | 6/40.3 (14.9%) | 4/29.8 (13.4%)  |
| Terminal rate  | 7/27 (25.9%)   | 6/26 (23.1%)   | 3/26 (11.5%)   | 2/8 (25.0%)     |
| First incidence (days)   | 739            | 642            | 410            | 600             |
| Poly-3 test  | P=0.200N       | P=0.414N       | P=0.236N       | P=0.222N        |

**TABLE A2a**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Uncertain or Benign Neoplasms</b>             |                 |                 |                 |                 |
| Overall rate   | 19/48 (39.6%)   | 29/48 (60.4%)   | 41/47 (87.2%)   | 45/48 (93.8%)   |
| Adjusted rate  | 19/40.2 (47.2%) | 29/39.0 (74.4%) | 41/44.1 (92.9%) | 45/45.8 (98.3%) |
| Terminal rate  | 14/27 (51.9%)   | 19/26 (73.1%)   | 25/26 (96.2%)   | 8/8 (100.0%)    |
| First incidence (days)                                       | 541             | 511             | 432             | 293             |
| Poly-3 test  | P=0.001         | P=0.009         | P=0.001         | P=0.001         |
| <b>All Organs: Malignant Neoplasms</b>                       |                 |                 |                 |                 |
| Overall rate   | 27/48 (56.3%)   | 30/48 (62.5%)   | 37/47 (78.7%)   | 43/48 (89.6%)   |
| Adjusted rate  | 27/40.3 (67.1%) | 30/40.4 (74.2%) | 37/45.3 (81.7%) | 43/44.0 (97.8%) |
| Terminal rate  | 17/27 (63.0%)   | 17/26 (65.4%)   | 19/26 (73.1%)   | 8/8 (100.0%)    |
| First incidence (days)                                       | 515             | 520             | 410             | 453             |
| Poly-3 test  | P=0.001         | P=0.319         | P=0.090         | P=0.001         |
| <b>All Organs: Uncertain, Benign, or Malignant Neoplasms</b> |                 |                 |                 |                 |
| Overall rate   | 33/48 (68.8%)   | 39/48 (81.3%)   | 46/47 (97.9%)   | 47/48 (97.9%)   |
| Adjusted rate  | 33/42.1 (78.5%) | 39/41.3 (94.3%) | 46/46.1 (99.7%) | 47/47.1 (99.8%) |
| Terminal rate  | 20/27 (74.1%)   | 24/26 (92.3%)   | 26/26 (100.0%)  | 8/8 (100.0%)    |
| First incidence (days)                                       | 515             | 511             | 410             | 293             |
| Poly-3 test  | P=0.001         | P=0.031         | P=0.001         | P=0.001         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE A2b**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|   | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|---|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>                    |                 |                 |                 |
| Overall rate <sup>a</sup>                         | 2/44 (4.5%)     | 3/46 (6.5%)     | 3/46 (6.5%)     |
| Adjusted rate <sup>b</sup>                        | 2/35.9 (5.6%)   | 3/38.9 (7.7%)   | 3/41.9 (7.2%)   |
| Terminal rate <sup>c</sup>                        | 2/27 (7.4%)     | 3/31 (9.7%)     | 3/35 (8.6%)     |
| First incidence (days)                            | 765 (T)         | 765 (T)         | 765 (T)         |
| Poly-3 test <sup>d</sup>                          | P=0.986         | P=1.000         | P=1.000         |
| <b>Adrenal Medulla: Benign Pheochromocytoma</b>   |                 |                 |                 |
| Overall rate                                      | 0/44 (0.0%)     | 2/44 (4.5%)     | 2/46 (4.3%)     |
| Adjusted rate                                     | 0/35.9 (0.0%)   | 2/36.9 (5.4%)   | 2/41.9 (4.8%)   |
| Terminal rate                                     | 0/27 (0.0%)     | 2/29 (6.9%)     | 2/35 (5.7%)     |
| First incidence (days)                            | — <sup>e</sup>  | 765 (T)         | 765 (T)         |
| Poly-3 test                                       | P=0.449         | P=0.485         | P=0.556         |
| <b>Harderian Gland: Adenoma</b>                   |                 |                 |                 |
| Overall rate                                      | 3/47 (6.4%)     | 6/48 (12.5%)    | 5/47 (10.6%)    |
| Adjusted rate                                     | 3/38.0 (7.9%)   | 6/41.1 (14.6%)  | 5/42.9 (11.7%)  |
| Terminal rate                                     | 1/27 (3.7%)     | 4/32 (12.5%)    | 5/35 (14.3%)    |
| First incidence (days)                            | 599             | 582             | 765 (T)         |
| Poly-3 test                                       | P=0.772         | P=0.560         | P=0.848         |
| <b>Liver: Hemangiosarcoma</b>                     |                 |                 |                 |
| Overall rate                                      | 1/46 (2.2%)     | 3/47 (6.4%)     | 2/48 (4.2%)     |
| Adjusted rate                                     | 1/36.8 (2.7%)   | 3/40.0 (7.5%)   | 2/44.6 (4.5%)   |
| Terminal rate                                     | 1/27 (3.7%)     | 2/32 (6.3%)     | 1/36 (2.8%)     |
| First incidence (days)                            | 765 (T)         | 719             | 464             |
| Poly-3 test                                       | P=1.000         | P=0.670         | P=1.000         |
| <b>Liver: Hepatocellular Adenoma</b>              |                 |                 |                 |
| Overall rate                                      | 7/46 (15.2%)    | 12/47 (25.5%)   | 19/48 (39.6%)   |
| Adjusted rate                                     | 7/37.4 (18.7%)  | 12/41.1 (29.2%) | 19/44.6 (42.6%) |
| Terminal rate                                     | 6/27 (22.2%)    | 9/32 (28.1%)    | 16/36 (44.4%)   |
| First incidence (days)                            | 541             | 582             | 607             |
| Poly-3 test                                       | P=0.024         | P=0.411         | P=0.034         |
| <b>Liver: Hepatocellular Carcinoma</b>            |                 |                 |                 |
| Overall rate                                      | 7/46 (15.2%)    | 6/47 (12.8%)    | 7/48 (14.6%)    |
| Adjusted rate                                     | 7/37.0 (18.9%)  | 6/40.9 (14.7%)  | 7/44.9 (15.6%)  |
| Terminal rate                                     | 5/27 (18.5%)    | 3/32 (9.4%)     | 3/36 (8.3%)     |
| First incidence (days)                            | 712             | 607             | 447             |
| Poly-3 test                                       | P=0.835         | P=0.843         | P=0.918         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate                                      | 12/46 (26.1%)   | 16/47 (34.0%)   | 25/48 (52.1%)   |
| Adjusted rate                                     | 12/37.6 (31.9%) | 16/41.9 (38.2%) | 25/45.6 (54.8%) |
| Terminal rate                                     | 9/27 (33.3%)    | 11/32 (34.4%)   | 19/36 (52.8%)   |
| First incidence (days)                            | 541             | 582             | 447             |
| Poly-3 test                                       | P=0.038         | P=0.724         | P=0.056         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>         |                 |                 |                 |
| Overall rate                                      | 4/48 (8.3%)     | 10/48 (20.8%)   | 6/48 (12.5%)    |
| Adjusted rate                                     | 4/37.6 (10.6%)  | 10/40.8 (24.5%) | 6/44.1 (13.6%)  |
| Terminal rate                                     | 4/27 (14.8%)    | 8/32 (25.0%)    | 5/36 (13.9%)    |
| First incidence (days)                            | 765 (T)         | 614             | 710             |
| Poly-3 test                                       | P=0.966         | P=0.187         | P=0.944         |

**TABLE A2b**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)     | 2/48 (4.2%)     | 5/48 (10.4%)    |
| Adjusted rate  | 1/37.7 (2.7%)   | 2/40.1 (5.0%)   | 5/43.9 (11.4%)  |
| Terminal rate  | 0/27 (0.0%)     | 2/32 (6.3%)     | 5/36 (13.9%)    |
| First incidence (days)                                 | 739             | 765 (T)         | 765 (T)         |
| Poly-3 test  | P=0.165         | P=1.000         | P=0.280         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)    | 11/48 (22.9%)   | 11/48 (22.9%)   |
| Adjusted rate  | 5/37.7 (13.3%)  | 11/40.8 (27.0%) | 11/44.1 (25.0%) |
| Terminal rate  | 4/27 (14.8%)    | 9/32 (28.1%)    | 10/36 (27.8%)   |
| First incidence (days)                                 | 739             | 614             | 710             |
| Poly-3 test  | P=0.296         | P=0.216         | P=0.294         |
| <b>Skin: Sarcoma</b>                                   |                 |                 |                 |
| Overall rate   | 10/47 (21.3%)   | 16/48 (33.3%)   | 12/48 (25.0%)   |
| Adjusted rate  | 10/38.7 (25.8%) | 16/43.1 (37.1%) | 12/44.8 (26.8%) |
| Terminal rate  | 6/27 (22.2%)    | 9/32 (28.1%)    | 6/36 (16.7%)    |
| First incidence (days)                                 | 536             | 582             | 607             |
| Poly-3 test  | P=1.000         | P=0.389         | P=1.000         |
| <b>Skin: Fibroma or Sarcoma</b>                        |                 |                 |                 |
| Overall rate   | 10/47 (21.3%)   | 18/48 (37.5%)   | 13/48 (27.1%)   |
| Adjusted rate  | 10/38.7 (25.8%) | 18/43.1 (41.8%) | 13/44.8 (29.0%) |
| Terminal rate  | 6/27 (22.2%)    | 11/32 (34.4%)   | 7/36 (19.4%)    |
| First incidence (days)                                 | 536             | 582             | 607             |
| Poly-3 test  | P=0.953         | P=0.195         | P=0.935         |
| <b>Spleen: Hemangiosarcoma</b>                         |                 |                 |                 |
| Overall rate   | 2/44 (4.5%)     | 0/46 (0.0%)     | 0/48 (0.0%)     |
| Adjusted rate  | 2/36.7 (5.4%)   | 0/39.2 (0.0%)   | 0/43.9 (0.0%)   |
| Terminal rate  | 1/27 (3.7%)     | 0/32 (0.0%)     | 0/36 (0.0%)     |
| First incidence (days)                                 | 757             | —               | —               |
| Poly-3 test  | P=0.168         | P=0.445         | P=0.398         |
| <b>All Organs: Hemangioma</b>                          |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)     | 0/48 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/37.6 (0.0%)   | 0/40.1 (0.0%)   | 3/43.9 (6.8%)   |
| Terminal rate  | 0/27 (0.0%)     | 0/32 (0.0%)     | 3/36 (8.3%)     |
| First incidence (days)                                 | —               | — <sup>f</sup>  | 765 (T)         |
| Poly-3 test  | P=0.086         | — <sup>f</sup>  | P=0.297         |
| <b>All Organs: Hemangiosarcoma</b>                     |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)     | 3/48 (6.3%)     | 3/48 (6.3%)     |
| Adjusted rate  | 4/37.7 (10.6%)  | 3/40.3 (7.4%)   | 3/44.6 (6.7%)   |
| Terminal rate  | 1/27 (3.7%)     | 2/32 (6.3%)     | 2/36 (5.6%)     |
| First incidence (days)                                 | 739             | 719             | 464             |
| Poly-3 test  | P=0.690         | P=0.929         | P=0.819         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>       |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)     | 3/48 (6.3%)     | 6/48 (12.5%)    |
| Adjusted rate  | 4/37.7 (10.6%)  | 3/40.3 (7.4%)   | 6/44.6 (13.4%)  |
| Terminal rate  | 1/27 (3.7%)     | 2/32 (6.3%)     | 5/36 (13.9%)    |
| First incidence (days)                                 | 739             | 719             | 464             |
| Poly-3 test  | P=0.767         | P=0.929         | P=0.956         |

**TABLE A2b**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |
| Overall rate                                     | 3/48 (6.3%)     | 1/48 (2.1%)     | 2/48 (4.2%)     |
| Adjusted rate                                    | 3/38.3 (7.8%)   | 1/40.1 (2.5%)   | 2/44.9 (4.5%)   |
| Terminal rate                                    | 1/27 (3.7%)     | 1/32 (3.1%)     | 0/36 (0.0%)     |
| First incidence (days)                           | 515             | 765 (T)         | 542             |
| Poly-3 test                                      | P=0.719         | P=0.577         | P=0.858         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |
| Overall rate                                     | 9/48 (18.8%)    | 11/48 (22.9%)   | 12/48 (25.0%)   |
| Adjusted rate                                    | 9/37.7 (23.8%)  | 11/41.0 (26.8%) | 12/44.5 (27.0%) |
| Terminal rate                                    | 7/27 (25.9%)    | 9/32 (28.1%)    | 11/36 (30.6%)   |
| First incidence (days)                           | 739             | 614             | 542             |
| Poly-3 test                                      | P=0.866         | P=0.965         | P=0.945         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 19/48 (39.6%)   | 27/48 (56.3%)   | 30/48 (62.5%)   |
| Adjusted rate                                    | 19/40.2 (47.2%) | 27/42.4 (63.6%) | 30/45.0 (66.6%) |
| Terminal rate                                    | 14/27 (51.9%)   | 21/32 (65.6%)   | 25/36 (69.4%)   |
| First incidence (days)                           | 541             | 582             | 607             |
| Poly-3 test                                      | P=0.088         | P=0.190         | P=0.103         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 27/48 (56.3%)   | 31/48 (64.6%)   | 31/48 (64.6%)   |
| Adjusted rate                                    | 27/40.3 (67.1%) | 31/44.7 (69.4%) | 31/47.5 (65.2%) |
| Terminal rate                                    | 17/27 (63.0%)   | 19/32 (59.4%)   | 20/36 (55.6%)   |
| First incidence (days)                           | 515             | 513             | 447             |
| Poly-3 test                                      | P=0.924         | P=1.000         | P=1.000         |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 33/48 (68.8%)   | 41/48 (85.4%)   | 42/48 (87.5%)   |
| Adjusted rate                                    | 33/42.1 (78.5%) | 41/44.7 (91.8%) | 42/47.5 (88.4%) |
| Terminal rate                                    | 20/27 (74.1%)   | 29/32 (90.6%)   | 31/36 (86.1%)   |
| First incidence (days)                           | 515             | 513             | 447             |
| Poly-3 test                                      | P=0.251         | P=0.133         | P=0.317         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE A2c**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|   | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|---|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>                  |                 |                 |                 |
| Overall rate <sup>a</sup>                       | 2/44 (4.5%)     | 1/45 (2.2%)     | 3/47 (6.4%)     |
| Adjusted rate <sup>b</sup>                      | 2/33.6 (6.0%)   | 1/38.5 (2.6%)   | 3/38.6 (7.8%)   |
| Terminal rate <sup>c</sup>                      | 1/23 (4.3%)     | 1/28 (3.6%)     | 3/29 (10.3%)    |
| First incidence (days)                          | 665             | 765 (T)         | 765 (T)         |
| Poly-3 test <sup>d</sup>                        | P=0.897         | P=0.905         | P=1.000         |
| <b>Adrenal Medulla: Benign Pheochromocytoma</b> |                 |                 |                 |
| Overall rate                                    | 0/43 (0.0%)     | 2/42 (4.8%)     | 6/46 (13.0%)    |
| Adjusted rate                                   | 0/32.7 (0.0%)   | 2/35.5 (5.6%)   | 6/37.7 (15.9%)  |
| Terminal rate                                   | 0/23 (0.0%)     | 2/25 (8.0%)     | 5/28 (17.9%)    |
| First incidence (days)                          | — <sup>e</sup>  | 765 (T)         | 739             |
| Poly-3 test                                     | P=0.020         | P=0.510         | P=0.045         |
| <b>Harderian Gland: Adenoma</b>                 |                 |                 |                 |
| Overall rate                                    | 11/47 (23.4%)   | 14/48 (29.2%)   | 12/48 (25.0%)   |
| Adjusted rate                                   | 11/36.5 (30.1%) | 14/41.4 (33.8%) | 12/40.0 (30.0%) |
| Terminal rate                                   | 7/26 (26.9%)    | 12/30 (40.0%)   | 10/29 (34.5%)   |
| First incidence (days)                          | 691             | 628             | 517             |
| Poly-3 test                                     | P=1.000         | P=0.912         | P=1.000         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>    |                 |                 |                 |
| Overall rate                                    | 12/47 (25.5%)   | 14/48 (29.2%)   | 14/48 (29.2%)   |
| Adjusted rate                                   | 12/36.5 (32.8%) | 14/41.4 (33.8%) | 14/40.1 (34.9%) |
| Terminal rate                                   | 8/26 (30.8%)    | 12/30 (40.0%)   | 11/29 (37.9%)   |
| First incidence (days)                          | 691             | 628             | 517             |
| Poly-3 test                                     | P=0.946         | P=1.000         | P=1.000         |
| <b>Liver: Hemangiosarcoma</b>                   |                 |                 |                 |
| Overall rate                                    | 2/47 (4.3%)     | 4/48 (8.3%)     | 2/46 (4.3%)     |
| Adjusted rate                                   | 2/35.6 (5.6%)   | 4/41.0 (9.8%)   | 2/38.4 (5.2%)   |
| Terminal rate                                   | 1/26 (3.8%)     | 3/30 (10.0%)    | 1/29 (3.4%)     |
| First incidence (days)                          | 754             | 681             | 620             |
| Poly-3 test                                     | P=1.000         | P=0.808         | P=1.000         |
| <b>Liver: Hemangioma or Hemangiosarcoma</b>     |                 |                 |                 |
| Overall rate                                    | 2/47 (4.3%)     | 4/48 (8.3%)     | 4/46 (8.7%)     |
| Adjusted rate                                   | 2/35.6 (5.6%)   | 4/41.0 (9.8%)   | 4/38.4 (10.4%)  |
| Terminal rate                                   | 1/26 (3.8%)     | 3/30 (10.0%)    | 3/29 (10.3%)    |
| First incidence (days)                          | 754             | 681             | 620             |
| Poly-3 test                                     | P=0.625         | P=0.808         | P=0.743         |
| <b>Liver: Histiocytic Sarcoma</b>               |                 |                 |                 |
| Overall rate                                    | 2/47 (4.3%)     | 4/48 (8.3%)     | 0/46 (0.0%)     |
| Adjusted rate                                   | 2/36.1 (5.5%)   | 4/41.4 (9.7%)   | 0/37.9 (0.0%)   |
| Terminal rate                                   | 0/26 (0.0%)     | 1/30 (3.3%)     | 0/29 (0.0%)     |
| First incidence (days)                          | 614             | 638             | —               |
| Poly-3 test                                     | P=0.393         | P=0.804         | P=0.451         |
| <b>Liver: Hepatocellular Adenoma</b>            |                 |                 |                 |
| Overall rate                                    | 13/47 (27.7%)   | 15/48 (31.3%)   | 9/46 (19.6%)    |
| Adjusted rate                                   | 13/36.1 (36.0%) | 15/41.6 (36.1%) | 9/38.1 (23.7%)  |
| Terminal rate                                   | 11/26 (42.3%)   | 13/30 (43.3%)   | 7/29 (24.1%)    |
| First incidence (days)                          | 662             | 620             | 747             |
| Poly-3 test                                     | P=0.301         | P=1.000         | P=0.359         |

**TABLE A2c**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol                 | 2.5% Ethanol    | 5% Ethanol      |
|--|----------------------------|-----------------|-----------------|
| <b>Liver: Hepatocellular Carcinoma</b>                 |                            |                 |                 |
| Overall rate   | 6/47 (12.8%)               | 5/48 (10.4%)    | 9/46 (19.6%)    |
| Adjusted rate  | 6/36.0 (16.7%)             | 5/41.4 (12.1%)  | 9/39.2 (23.0%)  |
| Terminal rate  | 3/26 (11.5%)               | 4/30 (13.3%)    | 6/29 (20.7%)    |
| First incidence (days)                                 | 665                        | 523             | 542             |
| Poly-3 test  | P=0.535                    | P=0.804         | P=0.693         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                            |                 |                 |
| Overall rate   | 18/47 (38.3%) <sup>f</sup> | 19/48 (39.6%)   | 16/46 (34.8%)   |
| Adjusted rate  | 18/36.6 (49.2%)            | 19/42.2 (45.0%) | 16/39.2 (40.8%) |
| Terminal rate  | 13/26 (50.0%)              | 16/30 (53.3%)   | 12/29 (41.4%)   |
| First incidence (days)                                 | 662                        | 523             | 542             |
| Poly-3 test  | P=0.538                    | P=0.881         | P=0.608         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                            |                 |                 |
| Overall rate   | 17/48 (35.4%)              | 16/48 (33.3%)   | 8/48 (16.7%)    |
| Adjusted rate  | 17/38.4 (44.3%)            | 16/41.4 (38.6%) | 8/38.7 (20.7%)  |
| Terminal rate  | 11/26 (42.3%)              | 13/30 (43.3%)   | 8/29 (27.6%)    |
| First incidence (days)                                 | 511                        | 617             | 765 (T)         |
| Poly-3 test  | P=0.037                    | P=0.773         | P=0.042         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                            |                 |                 |
| Overall rate   | 1/48 (2.1%)                | 3/48 (6.3%)     | 4/48 (8.3%)     |
| Adjusted rate  | 1/36.3 (2.8%)              | 3/41.3 (7.3%)   | 4/38.7 (10.3%)  |
| Terminal rate  | 1/26 (3.8%)                | 1/30 (3.3%)     | 4/29 (13.8%)    |
| First incidence (days)                                 | 765 (T)                    | 620             | 765 (T)         |
| Poly-3 test  | P=0.301                    | P=0.705         | P=0.394         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                            |                 |                 |
| Overall rate   | 18/48 (37.5%)              | 19/48 (39.6%)   | 11/48 (22.9%)   |
| Adjusted rate  | 18/38.4 (46.9%)            | 19/42.0 (45.3%) | 11/38.7 (28.4%) |
| Terminal rate  | 12/26 (46.2%)              | 14/30 (46.7%)   | 11/29 (37.9%)   |
| First incidence (days)                                 | 511                        | 617             | 765 (T)         |
| Poly-3 test  | P=0.121                    | P=1.000         | P=0.141         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                            |                 |                 |
| Overall rate   | 2/47 (4.3%)                | 4/48 (8.3%)     | 0/44 (0.0%)     |
| Adjusted rate  | 2/36.8 (5.4%)              | 4/41.4 (9.7%)   | 0/36.6 (0.0%)   |
| Terminal rate  | 0/26 (0.0%)                | 1/30 (3.3%)     | 0/28 (0.0%)     |
| First incidence (days)                                 | 614                        | 638             | —               |
| Poly-3 test  | P=0.425                    | P=0.785         | P=0.475         |
| <b>Skin: Sarcoma</b>                                   |                            |                 |                 |
| Overall rate   | 9/48 (18.8%)               | 10/48 (20.8%)   | 10/47 (21.3%)   |
| Adjusted rate  | 9/37.8 (23.8%)             | 10/42.3 (23.6%) | 10/40.8 (24.5%) |
| Terminal rate  | 5/26 (19.2%)               | 5/30 (16.7%)    | 2/29 (6.9%)     |
| First incidence (days)                                 | 520                        | 617             | 517             |
| Poly-3 test  | P=1.000                    | P=1.000         | P=1.000         |
| <b>Skin: Fibroma or Sarcoma</b>                        |                            |                 |                 |
| Overall rate   | 11/48 (22.9%)              | 13/48 (27.1%)   | 12/47 (25.5%)   |
| Adjusted rate  | 11/37.8 (29.1%)            | 13/42.3 (30.7%) | 12/40.8 (29.4%) |
| Terminal rate  | 7/26 (26.9%)               | 8/30 (26.7%)    | 4/29 (13.8%)    |
| First incidence (days)                                 | 520                        | 617             | 517             |
| Poly-3 test  | P=1.000                    | P=1.000         | P=1.000         |

**TABLE A2c**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol      |
|--|----------------|----------------|-----------------|
| <b>Spleen: Histiocytic Sarcoma</b>   |                |                |                 |
| Overall rate   | 3/46 (6.5%)    | 3/46 (6.5%)    | 0/46 (0.0%)     |
| Adjusted rate  | 3/36.7 (8.2%)  | 3/40.9 (7.3%)  | 0/37.9 (0.0%)   |
| Terminal rate  | 1/26 (3.8%)    | 1/30 (3.3%)    | 0/29 (0.0%)     |
| First incidence (days)   | 614            | 638            | —               |
| Poly-3 test  | P=0.186        | P=1.000        | P=0.224         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                            |                |                |                 |
| Overall rate   | 1/47 (2.1%)    | 4/47 (8.5%)    | 2/47 (4.3%)     |
| Adjusted rate  | 1/36.5 (2.7%)  | 4/41.4 (9.7%)  | 2/38.0 (5.3%)   |
| Terminal rate  | 0/26 (0.0%)    | 2/30 (6.7%)    | 2/29 (6.9%)     |
| First incidence (days)   | 691            | 523            | 765 (T)         |
| Poly-3 test  | P=0.861        | P=0.437        | P=1.000         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                |                |                 |
| Overall rate   | 2/47 (4.3%)    | 4/47 (8.5%)    | 2/47 (4.3%)     |
| Adjusted rate  | 2/37.2 (5.4%)  | 4/41.4 (9.7%)  | 2/38.0 (5.3%)   |
| Terminal rate  | 0/26 (0.0%)    | 2/30 (6.7%)    | 2/29 (6.9%)     |
| First incidence (days)   | 537            | 523            | 765 (T)         |
| Poly-3 test  | P=1.000        | P=0.776        | P=1.000         |
| <b>All Organs: Hemangioma</b>  |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 0/48 (0.0%)    | 3/48 (6.3%)     |
| Adjusted rate  | 2/36.3 (5.5%)  | 0/40.7 (0.0%)  | 3/38.7 (7.8%)   |
| Terminal rate  | 1/26 (3.8%)    | 0/30 (0.0%)    | 3/29 (10.3%)    |
| First incidence (days)   | 754            | —              | 765 (T)         |
| Poly-3 test  | P=0.804        | P=0.424        | P=1.000         |
| <b>All Organs: Hemangiosarcoma</b>   |                |                |                 |
| Overall rate   | 4/48 (8.3%)    | 5/48 (10.4%)   | 3/48 (6.3%)     |
| Adjusted rate  | 4/36.6 (10.9%) | 5/41.0 (12.2%) | 3/39.1 (7.7%)   |
| Terminal rate  | 2/26 (7.7%)    | 4/30 (13.3%)   | 2/29 (6.9%)     |
| First incidence (days)   | 691            | 681            | 620             |
| Poly-3 test  | P=0.774        | P=1.000        | P=0.926         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                 |                |                |                 |
| Overall rate   | 5/48 (10.4%)   | 5/48 (10.4%)   | 6/48 (12.5%)    |
| Adjusted rate  | 5/36.6 (13.7%) | 5/41.0 (12.2%) | 6/39.1 (15.3%)  |
| Terminal rate  | 3/26 (11.5%)   | 4/30 (13.3%)   | 5/29 (17.2%)    |
| First incidence (days)   | 691            | 681            | 620             |
| Poly-3 test  | P=0.960        | P=1.000        | P=1.000         |
| <b>All Organs: Histiocytic Sarcoma</b>   |                |                |                 |
| Overall rate   | 3/48 (6.3%)    | 4/48 (8.3%)    | 0/48 (0.0%)     |
| Adjusted rate  | 3/36.8 (8.1%)  | 4/41.4 (9.7%)  | 0/38.7 (0.0%)   |
| Terminal rate  | 1/26 (3.8%)    | 1/30 (3.3%)    | 0/29 (0.0%)     |
| First incidence (days)   | 614            | 638            | —               |
| Poly-3 test  | P=0.205        | P=1.000        | P=0.218         |
| <b>All Organs: Malignant Lymphoma</b>  |                |                |                 |
| Overall rate   | 7/48 (14.6%)   | 6/48 (12.5%)   | 10/48 (20.8%)   |
| Adjusted rate  | 7/36.7 (19.1%) | 6/41.2 (14.6%) | 10/38.9 (25.7%) |
| Terminal rate  | 6/26 (23.1%)   | 5/30 (16.7%)   | 9/29 (31.0%)    |
| First incidence (days)   | 642            | 622            | 701             |
| Poly-3 test  | P=0.545        | P=0.821        | P=0.679         |

**TABLE A2c**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 29/48 (60.4%)   | 33/48 (68.8%)   | 29/48 (60.4%)   |
| Adjusted rate                                    | 29/39.0 (74.4%) | 33/43.7 (75.4%) | 29/40.6 (71.4%) |
| Terminal rate                                    | 19/26 (73.1%)   | 24/30 (80.0%)   | 23/29 (79.3%)   |
| First incidence (days)                           | 511             | 523             | 517             |
| Poly-3 test                                      | P=0.850         | P=1.000         | P=0.958         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 30/48 (62.5%)   | 32/48 (66.7%)   | 30/48 (62.5%)   |
| Adjusted rate                                    | 30/40.4 (74.2%) | 32/45.9 (69.7%) | 30/42.9 (70.0%) |
| Terminal rate                                    | 17/26 (65.4%)   | 18/30 (60.0%)   | 18/29 (62.1%)   |
| First incidence (days)                           | 520             | 382             | 421             |
| Poly-3 test                                      | P=0.771         | P=0.822         | P=0.849         |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 39/48 (81.3%)   | 45/48 (93.8%)   | 41/48 (85.4%)   |
| Adjusted rate                                    | 39/41.3 (94.3%) | 45/46.3 (97.2%) | 41/43.2 (94.8%) |
| Terminal rate                                    | 24/26 (92.3%)   | 29/30 (96.7%)   | 28/29 (96.6%)   |
| First incidence (days)                           | 511             | 382             | 421             |
| Poly-3 test                                      | P=1.000         | P=0.885         | P=1.000         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> A single incidence of hepatoblastoma occurred in an animal that also had a carcinoma.

**TABLE A2d**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|   | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|---|-----------------|-----------------|-----------------|
| <b>Adrenal Medulla: Benign Pheochromocytoma</b> |                 |                 |                 |
| Overall rate <sup>a</sup>                       | 2/42 (4.8%)     | 2/45 (4.4%)     | 3/46 (6.5%)     |
| Adjusted rate <sup>b</sup>                      | 2/36.1 (5.5%)   | 2/34.1 (5.9%)   | 3/36.6 (8.2%)   |
| Terminal rate <sup>c</sup>                      | 0/23 (0.0%)     | 1/24 (4.2%)     | 1/24 (4.2%)     |
| First incidence (days)                          | 432             | 734             | 507             |
| Poly-3 test <sup>d</sup>                        | P=0.833         | P=1.000         | P=1.000         |
| <b>Harderian Gland: Adenoma</b>                 |                 |                 |                 |
| Overall rate                                    | 25/47 (53.2%)   | 21/47 (44.7%)   | 15/48 (31.3%)   |
| Adjusted rate                                   | 25/41.2 (60.7%) | 21/37.2 (56.4%) | 15/39.1 (38.4%) |
| Terminal rate                                   | 17/26 (65.4%)   | 17/25 (68.0%)   | 10/25 (40.0%)   |
| First incidence (days)                          | 456             | 426             | 507             |
| Poly-3 test                                     | P=0.050         | P=0.875         | P=0.064         |
| <b>Harderian Gland: Carcinoma</b>               |                 |                 |                 |
| Overall rate                                    | 7/47 (14.9%)    | 1/47 (2.1%)     | 2/48 (4.2%)     |
| Adjusted rate                                   | 7/41.2 (17.0%)  | 1/35.5 (2.8%)   | 2/37.7 (5.3%)   |
| Terminal rate                                   | 2/26 (7.7%)     | 1/25 (4.0%)     | 1/25 (4.0%)     |
| First incidence (days)                          | 510             | 765 (T)         | 539             |
| Poly-3 test                                     | P=0.080         | P=0.095         | P=0.199         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>    |                 |                 |                 |
| Overall rate                                    | 30/47 (63.8%)   | 21/47 (44.7%)   | 17/48 (35.4%)   |
| Adjusted rate                                   | 30/43.3 (69.2%) | 21/37.2 (56.4%) | 17/39.7 (42.8%) |
| Terminal rate                                   | 17/26 (65.4%)   | 17/25 (68.0%)   | 11/25 (44.0%)   |
| First incidence (days)                          | 456             | 426             | 507             |
| Poly-3 test                                     | P=0.014         | P=0.323         | P=0.020         |
| <b>Liver: Hemangiosarcoma</b>                   |                 |                 |                 |
| Overall rate                                    | 5/46 (10.9%)    | 3/46 (6.5%)     | 4/48 (8.3%)     |
| Adjusted rate                                   | 5/39.6 (12.6%)  | 3/35.2 (8.5%)   | 4/37.4 (10.7%)  |
| Terminal rate                                   | 3/26 (11.5%)    | 2/25 (8.0%)     | 3/25 (12.0%)    |
| First incidence (days)                          | 510             | 684             | 660             |
| Poly-3 test                                     | P=0.919         | P=0.844         | P=1.000         |
| <b>Liver: Hemangioma or Hemangiosarcoma</b>     |                 |                 |                 |
| Overall rate                                    | 5/46 (10.9%)    | 3/46 (6.5%)     | 6/48 (12.5%)    |
| Adjusted rate                                   | 5/39.6 (12.6%)  | 3/35.2 (8.5%)   | 6/37.4 (16.0%)  |
| Terminal rate                                   | 3/26 (11.5%)    | 2/25 (8.0%)     | 5/25 (20.0%)    |
| First incidence (days)                          | 510             | 684             | 660             |
| Poly-3 test                                     | P=0.811         | P=0.844         | P=0.918         |
| <b>Liver: Histiocytic Sarcoma</b>               |                 |                 |                 |
| Overall rate                                    | 5/46 (10.9%)    | 3/46 (6.5%)     | 4/48 (8.3%)     |
| Adjusted rate                                   | 5/39.3 (12.7%)  | 3/36.2 (8.3%)   | 4/37.8 (10.6%)  |
| Terminal rate                                   | 2/26 (7.7%)     | 0/25 (0.0%)     | 1/25 (4.0%)     |
| First incidence (days)                          | 668             | 514             | 625             |
| Poly-3 test                                     | P=0.894         | P=0.802         | P=1.000         |
| <b>Liver: Hepatocellular Adenoma</b>            |                 |                 |                 |
| Overall rate                                    | 17/46 (37.0%)   | 16/46 (34.8%)   | 16/48 (33.3%)   |
| Adjusted rate                                   | 17/41.3 (41.2%) | 16/36.3 (44.0%) | 16/38.2 (41.9%) |
| Terminal rate                                   | 9/26 (34.6%)    | 10/25 (40.0%)   | 12/25 (48.0%)   |
| First incidence (days)                          | 456             | 528             | 570             |
| Poly-3 test                                     | P=1.000         | P=0.981         | P=1.000         |

**TABLE A2d**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Liver: Hepatocellular Carcinoma</b>                 |                 |                 |                 |
| Overall rate   | 9/46 (19.6%)    | 5/46 (10.9%)    | 2/48 (4.2%)     |
| Adjusted rate  | 9/40.3 (22.3%)  | 5/35.4 (14.1%)  | 2/37.9 (5.3%)   |
| Terminal rate  | 5/26 (19.2%)    | 2/25 (8.0%)     | 0/25 (0.0%)     |
| First incidence (days)                                 | 542             | 711             | 570             |
| Poly-3 test  | P=0.041         | P=0.537         | P=0.060         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                 |                 |                 |
| Overall rate   | 24/46 (52.2%)   | 17/46 (37.0%)   | 17/48 (35.4%)   |
| Adjusted rate  | 24/42.5 (56.5%) | 17/36.3 (46.8%) | 17/38.4 (44.3%) |
| Terminal rate  | 13/26 (50.0%)   | 11/25 (44.0%)   | 12/25 (48.0%)   |
| First incidence (days)                                 | 456             | 528             | 570             |
| Poly-3 test  | P=0.299         | P=0.519         | P=0.372         |
| <b>Lung: Histiocytic Sarcoma</b>                       |                 |                 |                 |
| Overall rate   | 2/47 (4.3%)     | 3/47 (6.4%)     | 3/48 (6.3%)     |
| Adjusted rate  | 2/39.1 (5.1%)   | 3/36.8 (8.2%)   | 3/37.8 (7.9%)   |
| Terminal rate  | 0/26 (0.0%)     | 0/25 (0.0%)     | 0/25 (0.0%)     |
| First incidence (days)                                 | 752             | 514             | 625             |
| Poly-3 test  | P=0.794         | P=0.944         | P=0.970         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |
| Overall rate   | 22/47 (46.8%)   | 19/47 (40.4%)   | 9/48 (18.8%)    |
| Adjusted rate  | 22/41.2 (53.4%) | 19/36.7 (51.8%) | 9/38.1 (23.6%)  |
| Terminal rate  | 16/26 (61.5%)   | 15/25 (60.0%)   | 6/25 (24.0%)    |
| First incidence (days)                                 | 456             | 593             | 507             |
| Poly-3 test  | P=0.008         | P=1.000         | P=0.009         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |
| Overall rate   | 9/47 (19.1%)    | 8/47 (17.0%)    | 5/48 (10.4%)    |
| Adjusted rate  | 9/40.5 (22.2%)  | 8/36.4 (22.0%)  | 5/37.6 (13.3%)  |
| Terminal rate  | 5/26 (19.2%)    | 5/25 (20.0%)    | 3/25 (12.0%)    |
| First incidence (days)                                 | 542             | 640             | 671             |
| Poly-3 test  | P=0.403         | P=1.000         | P=0.463         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 29/47 (61.7%)   | 24/47 (51.1%)   | 14/48 (29.2%)   |
| Adjusted rate  | 29/42.2 (68.8%) | 24/37.3 (64.4%) | 14/38.6 (36.2%) |
| Terminal rate  | 20/26 (76.9%)   | 18/25 (72.0%)   | 9/25 (36.0%)    |
| First incidence (days)                                 | 456             | 593             | 507             |
| Poly-3 test  | P=0.003         | P=0.852         | P=0.004         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                 |                 |                 |
| Overall rate   | 2/43 (4.7%)     | 4/45 (8.9%)     | 3/42 (7.1%)     |
| Adjusted rate  | 2/36.8 (5.4%)   | 4/36.3 (11.0%)  | 3/34.8 (8.6%)   |
| Terminal rate  | 0/25 (0.0%)     | 0/25 (0.0%)     | 1/25 (4.0%)     |
| First incidence (days)                                 | 668             | 514             | 678             |
| Poly-3 test  | P=0.772         | P=0.660         | P=0.948         |
| <b>Skin: Sarcoma</b>                                   |                 |                 |                 |
| Overall rate   | 5/47 (10.6%)    | 10/46 (21.7%)   | 15/48 (31.3%)   |
| Adjusted rate  | 5/39.9 (12.5%)  | 10/37.7 (26.5%) | 15/42.4 (35.4%) |
| Terminal rate  | 3/26 (11.5%)    | 5/24 (20.8%)    | 3/25 (12.0%)    |
| First incidence (days)                                 | 432             | 362             | 368             |
| Poly-3 test  | P=0.020         | P=0.197         | P=0.026         |

**TABLE A2d**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol    | 5% Ethanol      |
|--|----------------|-----------------|-----------------|
| <b>Skin: Fibroma or Sarcoma</b>  |                |                 |                 |
| Overall rate   | 8/47 (17.0%)   | 11/46 (23.9%)   | 16/48 (33.3%)   |
| Adjusted rate  | 8/39.9 (20.0%) | 11/37.7 (29.2%) | 16/42.4 (37.7%) |
| Terminal rate  | 6/26 (23.1%)   | 6/24 (25.0%)    | 4/25 (16.0%)    |
| First incidence (days)   | 432            | 362             | 368             |
| Poly-3 test  | P=0.093        | P=0.498         | P=0.121         |
| <b>Skin: Hemangiosarcoma</b>   |                |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 4/46 (8.7%)     | 0/48 (0.0%)     |
| Adjusted rate  | 0/39.0 (0.0%)  | 4/34.9 (11.5%)  | 0/37.1 (0.0%)   |
| Terminal rate  | 0/26 (0.0%)    | 2/24 (8.3%)     | 0/25 (0.0%)     |
| First incidence (days)   | — <sup>e</sup> | 710             | — <sup>f</sup>  |
| Poly-3 test  | P=1.000        | P=0.092         | —               |
| <b>Skin: Squamous Cell Papilloma or Squamous Cell Carcinoma</b>                      |                |                 |                 |
| Overall rate   | 3/47 (6.4%)    | 4/46 (8.7%)     | 0/48 (0.0%)     |
| Adjusted rate  | 3/39.1 (7.7%)  | 4/35.0 (11.4%)  | 0/37.1 (0.0%)   |
| Terminal rate  | 2/26 (7.7%)    | 3/24 (12.5%)    | 0/25 (0.0%)     |
| First incidence (days)   | 762            | 642             | —               |
| Poly-3 test  | P=0.272        | P=0.878         | P=0.254         |
| <b>Skin: Squamous Cell Papilloma, Basal Cell Adenoma, or Squamous Cell Carcinoma</b> |                |                 |                 |
| Overall rate   | 5/47 (10.6%)   | 4/46 (8.7%)     | 0/48 (0.0%)     |
| Adjusted rate  | 5/39.1 (12.8%) | 4/35.0 (11.4%)  | 0/37.1 (0.0%)   |
| Terminal rate  | 3/26 (11.5%)   | 3/24 (12.5%)    | 0/25 (0.0%)     |
| First incidence (days)   | 746            | 642             | —               |
| Poly-3 test  | P=0.067        | P=1.000         | P=0.068         |
| <b>Spleen: Hemangioma or Hemangiosarcoma</b>   |                |                 |                 |
| Overall rate   | 3/45 (6.7%)    | 2/46 (4.3%)     | 0/46 (0.0%)     |
| Adjusted rate  | 3/38.1 (7.9%)  | 2/35.1 (5.7%)   | 0/36.4 (0.0%)   |
| Terminal rate  | 2/26 (7.7%)    | 1/25 (4.0%)     | 0/25 (0.0%)     |
| First incidence (days)   | 724            | 733             | —               |
| Poly-3 test  | P=0.179        | P=1.000         | P=0.252         |
| <b>Spleen: Histiocytic Sarcoma</b>   |                |                 |                 |
| Overall rate   | 3/45 (6.7%)    | 2/46 (4.3%)     | 3/46 (6.5%)     |
| Adjusted rate  | 3/38.7 (7.8%)  | 2/36.0 (5.6%)   | 3/37.1 (8.1%)   |
| Terminal rate  | 0/26 (0.0%)    | 0/25 (0.0%)     | 0/25 (0.0%)     |
| First incidence (days)   | 643            | 514             | 625             |
| Poly-3 test  | P=1.000        | P=1.000         | P=1.000         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                                |                |                 |                 |
| Overall rate   | 3/44 (6.8%)    | 1/46 (2.2%)     | 3/45 (6.7%)     |
| Adjusted rate  | 3/37.7 (7.9%)  | 1/35.0 (2.9%)   | 3/36.6 (8.2%)   |
| Terminal rate  | 3/26 (11.5%)   | 1/25 (4.0%)     | 2/25 (8.0%)     |
| First incidence (days)   | 765 (T)        | 765 (T)         | 614             |
| Poly-3 test  | P=1.000        | P=0.665         | P=1.000         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b>     |                |                 |                 |
| Overall rate   | 3/44 (6.8%)    | 1/46 (2.2%)     | 4/45 (8.9%)     |
| Adjusted rate  | 3/37.7 (7.9%)  | 1/35.0 (2.9%)   | 4/36.6 (10.9%)  |
| Terminal rate  | 3/26 (11.5%)   | 1/25 (4.0%)     | 2/25 (8.0%)     |
| First incidence (days)   | 765 (T)        | 765 (T)         | 614             |
| Poly-3 test  | P=0.809        | P=0.665         | P=0.966         |

**TABLE A2d**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Hemangioma</b>                    |                 |                 |                 |
| Overall rate                                     | 2/47 (4.3%)     | 3/47 (6.4%)     | 2/48 (4.2%)     |
| Adjusted rate                                    | 2/39.2 (5.1%)   | 3/35.9 (8.3%)   | 2/37.1 (5.4%)   |
| Terminal rate                                    | 1/26 (3.8%)     | 1/25 (4.0%)     | 2/25 (8.0%)     |
| First incidence (days)                           | 724             | 710             | 765 (T)         |
| Poly-3 test                                      | P=1.000         | P=0.921         | P=1.000         |
| <b>All Organs: Hemangiosarcoma</b>               |                 |                 |                 |
| Overall rate                                     | 7/47 (14.9%)    | 9/47 (19.1%)    | 5/48 (10.4%)    |
| Adjusted rate                                    | 7/39.9 (17.5%)  | 9/36.2 (24.8%)  | 5/37.4 (13.4%)  |
| Terminal rate                                    | 4/26 (15.4%)    | 5/25 (20.0%)    | 4/25 (16.0%)    |
| First incidence (days)                           | 510             | 684             | 660             |
| Poly-3 test                                      | P=0.784         | P=0.616         | P=0.848         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                 |                 |                 |
| Overall rate                                     | 9/47 (19.1%)    | 11/47 (23.4%)   | 7/48 (14.6%)    |
| Adjusted rate                                    | 9/40.1 (22.4%)  | 11/36.4 (30.2%) | 7/37.4 (18.7%)  |
| Terminal rate                                    | 5/26 (19.2%)    | 6/25 (24.0%)    | 6/25 (24.0%)    |
| First incidence (days)                           | 510             | 684             | 660             |
| Poly-3 test                                      | P=0.840         | P=0.609         | P=0.900         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |
| Overall rate                                     | 6/47 (12.8%)    | 5/47 (10.6%)    | 4/48 (8.3%)     |
| Adjusted rate                                    | 6/39.9 (15.1%)  | 5/37.1 (13.5%)  | 4/37.8 (10.6%)  |
| Terminal rate                                    | 2/26 (7.7%)     | 1/25 (4.0%)     | 1/25 (4.0%)     |
| First incidence (days)                           | 643             | 514             | 625             |
| Poly-3 test                                      | P=0.682         | P=1.000         | P=0.802         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |
| Overall rate                                     | 6/47 (12.8%)    | 10/47 (21.3%)   | 8/48 (16.7%)    |
| Adjusted rate                                    | 6/40.3 (14.9%)  | 10/36.2 (27.6%) | 8/37.1 (21.6%)  |
| Terminal rate                                    | 3/26 (11.5%)    | 8/25 (32.0%)    | 8/25 (32.0%)    |
| First incidence (days)                           | 410             | 655             | 765 (T)         |
| Poly-3 test                                      | P=0.520         | P=0.274         | P=0.639         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 41/47 (87.2%)   | 37/47 (78.7%)   | 32/48 (66.7%)   |
| Adjusted rate                                    | 41/44.1 (92.9%) | 37/39.5 (93.7%) | 32/41.2 (77.7%) |
| Terminal rate                                    | 25/26 (96.2%)   | 25/25 (100.0%)  | 21/25 (84.0%)   |
| First incidence (days)                           | 432             | 426             | 368             |
| Poly-3 test                                      | P=0.022         | P=1.000         | P=0.056         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 37/47 (78.7%)   | 33/47 (70.2%)   | 37/48 (77.1%)   |
| Adjusted rate                                    | 37/45.3 (81.7%) | 33/42.2 (78.1%) | 37/44.8 (82.6%) |
| Terminal rate                                    | 19/26 (73.1%)   | 16/25 (64.0%)   | 18/25 (72.0%)   |
| First incidence (days)                           | 410             | 362             | 368             |
| Poly-3 test                                      | P=1.000         | P=0.881         | P=1.000         |

**TABLE A2d**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 46/47 (97.9%)   | 42/47 (89.4%)   | 44/48 (91.7%)   |
| Adjusted rate                                    | 46/46.1 (99.7%) | 42/42.2 (99.4%) | 44/45.2 (97.4%) |
| Terminal rate                                    | 26/26 (100.0%)  | 25/25 (100.0%)  | 24/25 (96.0%)   |
| First incidence (days)                           | 410             | 362             | 368             |
| Poly-3 test                                      | P=0.522         | P=1.000         | P=0.951         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Adrenal Medulla: Benign Pheochromocytoma</b>              |                 |                 |                 |
| Overall rate <sup>a</sup>                                    | 6/43 (14.0%)    | 4/46 (8.7%)     | 2/45 (4.4%)     |
| Adjusted rate <sup>b</sup>                                   | 6/29.4 (20.4%)  | 4/35.2 (11.4%)  | 2/31.6 (6.3%)   |
| Terminal rate <sup>c</sup>                                   | 0/8 (0.0%)      | 2/16 (12.5%)    | 1/12 (8.3%)     |
| First incidence (days)                                       | 453             | 524             | 753             |
| Poly-3 test <sup>d</sup>                                     | P=0.149         | P=0.512         | P=0.205         |
| <b>Adrenal Medulla: Benign or Malignant Pheochromocytoma</b> |                 |                 |                 |
| Overall rate   | 6/43 (14.0%)    | 4/46 (8.7%)     | 3/45 (6.7%)     |
| Adjusted rate  | 6/29.4 (20.4%)  | 4/35.2 (11.4%)  | 3/31.8 (9.4%)   |
| Terminal rate  | 0/8 (0.0%)      | 2/16 (12.5%)    | 1/12 (8.3%)     |
| First incidence (days)                                       | 453             | 524             | 691             |
| Poly-3 test  | P=0.299         | P=0.512         | P=0.390         |
| <b>Harderian Gland: Adenoma</b>                              |                 |                 |                 |
| Overall rate   | 28/47 (59.6%)   | 27/48 (56.3%)   | 26/45 (57.8%)   |
| Adjusted rate  | 28/36.0 (77.8%) | 27/41.2 (65.6%) | 26/38.3 (67.9%) |
| Terminal rate  | 8/8 (100.0%)    | 10/16 (62.5%)   | 6/12 (50.0%)    |
| First incidence (days)                                       | 466             | 395             | 444             |
| Poly-3 test  | P=0.415         | P=0.301         | P=0.439         |
| <b>Harderian Gland: Carcinoma</b>                            |                 |                 |                 |
| Overall rate   | 16/47 (34.0%)   | 16/48 (33.3%)   | 10/45 (22.2%)   |
| Adjusted rate  | 16/35.7 (44.9%) | 16/41.6 (38.4%) | 10/33.8 (29.6%) |
| Terminal rate  | 3/8 (37.5%)     | 2/16 (12.5%)    | 4/12 (33.3%)    |
| First incidence (days)                                       | 453             | 395             | 478             |
| Poly-3 test  | P=0.233         | P=0.729         | P=0.266         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>                 |                 |                 |                 |
| Overall rate   | 38/47 (80.9%)   | 38/48 (79.2%)   | 35/45 (77.8%)   |
| Adjusted rate  | 38/42.0 (90.6%) | 38/45.2 (84.1%) | 35/39.8 (87.9%) |
| Terminal rate  | 8/8 (100.0%)    | 12/16 (75.0%)   | 10/12 (83.3%)   |
| First incidence (days)                                       | 453             | 395             | 444             |
| Poly-3 test  | P=0.816         | P=0.530         | P=0.969         |
| <b>Heart: Hemangiosarcoma</b>                                |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)    | 4/48 (8.3%)     | 4/48 (8.3%)     |
| Adjusted rate  | 5/31.0 (16.1%)  | 4/37.0 (10.8%)  | 4/33.9 (11.8%)  |
| Terminal rate  | 1/8 (12.5%)     | 1/16 (6.3%)     | 2/12 (16.7%)    |
| First incidence (days)                                       | 453             | 552             | 670             |
| Poly-3 test  | P=0.770         | P=0.777         | P=0.886         |
| <b>Kidney: Hemangiosarcoma</b>                               |                 |                 |                 |
| Overall rate   | 1/45 (2.2%)     | 2/47 (4.3%)     | 3/48 (6.3%)     |
| Adjusted rate  | 1/28.4 (3.5%)   | 2/35.9 (5.6%)   | 3/34.0 (8.8%)   |
| Terminal rate  | 0/8 (0.0%)      | 0/16 (0.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                       | 761             | 569             | 643             |
| Poly-3 test  | P=0.559         | P=1.000         | P=0.741         |
| <b>Liver: Hemangiosarcoma</b>                                |                 |                 |                 |
| Overall rate   | 13/44 (29.5%)   | 11/48 (22.9%)   | 13/48 (27.1%)   |
| Adjusted rate  | 13/31.1 (41.8%) | 11/38.3 (28.7%) | 13/35.2 (36.9%) |
| Terminal rate  | 2/8 (25.0%)     | 4/16 (25.0%)    | 5/12 (41.7%)    |
| First incidence (days)                                       | 493             | 488             | 507             |
| Poly-3 test  | P=0.818         | P=0.363         | P=0.872         |

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Liver: Histiocytic Sarcoma</b>                        |                 |                 |                 |
| Overall rate   | 2/44 (4.5%)     | 6/48 (12.5%)    | 5/48 (10.4%)    |
| Adjusted rate  | 2/28.4 (7.1%)   | 6/37.1 (16.2%)  | 5/35.2 (14.2%)  |
| Terminal rate  | 0/8 (0.0%)      | 2/16 (12.5%)    | 1/12 (8.3%)     |
| First incidence (days)                                   | 680             | 536             | 577             |
| Poly-3 test  | P=0.585         | P=0.465         | P=0.616         |
| <b>Liver: Hepatocellular Adenoma</b>                     |                 |                 |                 |
| Overall rate   | 17/44 (38.6%)   | 24/48 (50.0%)   | 12/48 (25.0%)   |
| Adjusted rate  | 17/33.8 (50.3%) | 24/38.8 (61.9%) | 12/35.1 (34.2%) |
| Terminal rate  | 4/8 (50.0%)     | 13/16 (81.3%)   | 6/12 (50.0%)    |
| First incidence (days)                                   | 453             | 395             | 570             |
| Poly-3 test  | P=0.197         | P=0.420         | P=0.241         |
| <b>Liver: Hepatocellular Carcinoma</b>                   |                 |                 |                 |
| Overall rate   | 9/44 (20.5%)    | 4/48 (8.3%)     | 9/48 (18.8%)    |
| Adjusted rate  | 9/30.0 (30.0%)  | 4/35.6 (11.2%)  | 9/36.5 (24.7%)  |
| Terminal rate  | 2/8 (25.0%)     | 4/16 (25.0%)    | 1/12 (8.3%)     |
| First incidence (days)                                   | 580             | 765 (T)         | 553             |
| Poly-3 test  | P=0.843         | P=0.104         | P=0.835         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>        |                 |                 |                 |
| Overall rate   | 23/44 (52.3%)   | 24/48 (50.0%)   | 18/48 (37.5%)   |
| Adjusted rate  | 23/35.2 (65.3%) | 24/38.8 (61.9%) | 18/37.1 (48.6%) |
| Terminal rate  | 5/8 (62.5%)     | 13/16 (81.3%)   | 7/12 (58.3%)    |
| First incidence (days)                                   | 453             | 395             | 553             |
| Poly-3 test  | P=0.156         | P=0.944         | P=0.198         |
| <b>Liver: Hepatocellular Carcinoma or Hepatoblastoma</b> |                 |                 |                 |
| Overall rate   | 9/44 (20.5%)    | 4/48 (8.3%)     | 10/48 (20.8%)   |
| Adjusted rate  | 9/30.0 (30.0%)  | 4/35.6 (11.2%)  | 10/36.5 (27.4%) |
| Terminal rate  | 2/8 (25.0%)     | 4/16 (25.0%)    | 2/12 (16.7%)    |
| First incidence (days)                                   | 580             | 765 (T)         | 553             |
| Poly-3 test  | P=1.000         | P=0.104         | P=1.000         |
| <b>Lung: Histiocytic Sarcoma</b>                         |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)     | 4/48 (8.3%)     | 3/48 (6.3%)     |
| Adjusted rate  | 1/29.4 (3.4%)   | 4/37.1 (10.8%)  | 3/34.4 (8.7%)   |
| Terminal rate  | 0/8 (0.0%)      | 0/16 (0.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                   | 729             | 536             | 593             |
| Poly-3 test  | P=0.666         | P=0.512         | P=0.723         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>                |                 |                 |                 |
| Overall rate   | 34/48 (70.8%)   | 35/48 (72.9%)   | 33/48 (68.8%)   |
| Adjusted rate  | 34/39.5 (86.2%) | 35/43.3 (80.9%) | 33/42.2 (78.2%) |
| Terminal rate  | 8/8 (100.0%)    | 14/16 (87.5%)   | 9/12 (75.0%)    |
| First incidence (days)                                   | 293             | 395             | 355             |
| Poly-3 test  | P=0.389         | P=0.690         | P=0.460         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>              |                 |                 |                 |
| Overall rate   | 9/48 (18.8%)    | 24/48 (50.0%)   | 17/48 (35.4%)   |
| Adjusted rate  | 9/30.8 (29.2%)  | 24/39.6 (60.7%) | 17/37.1 (45.9%) |
| Terminal rate  | 3/8 (37.5%)     | 9/16 (56.3%)    | 5/12 (41.7%)    |
| First incidence (days)                                   | 521             | 569             | 478             |
| Poly-3 test  | P=0.320         | P=0.010         | P=0.228         |

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 37/48 (77.1%)   | 43/48 (89.6%)   | 40/48 (83.3%)   |
| Adjusted rate  | 37/40.4 (91.7%) | 43/45.1 (95.3%) | 40/44.5 (89.9%) |
| Terminal rate  | 8/8 (100.0%)    | 15/16 (93.8%)   | 11/12 (91.7%)   |
| First incidence (days)                                 | 293             | 395             | 355             |
| Poly-3 test  | P=0.871         | P=0.746         | P=1.000         |
| <b>Lymph Node (Mesenteric): Hemangiosarcoma</b>        |                 |                 |                 |
| Overall rate   | 1/38 (2.6%)     | 3/44 (6.8%)     | 1/43 (2.3%)     |
| Adjusted rate  | 1/25.4 (3.9%)   | 3/33.2 (9.0%)   | 1/30.7 (3.3%)   |
| Terminal rate  | 0/8 (0.0%)      | 1/15 (6.7%)     | 0/12 (0.0%)     |
| First incidence (days)                                 | 761             | 569             | 691             |
| Poly-3 test  | P=1.000         | P=0.809         | P=1.000         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                 |                 |                 |
| Overall rate   | 1/38 (2.6%)     | 4/44 (9.1%)     | 4/43 (9.3%)     |
| Adjusted rate  | 1/25.5 (3.9%)   | 4/33.7 (11.9%)  | 4/31.8 (12.6%)  |
| Terminal rate  | 0/8 (0.0%)      | 1/15 (6.7%)     | 1/12 (8.3%)     |
| First incidence (days)                                 | 729             | 536             | 577             |
| Poly-3 test  | P=0.430         | P=0.541         | P=0.496         |
| <b>Preputial Gland: Hemangioma</b>                     |                 |                 |                 |
| Overall rate   | 0/43 (0.0%)     | 3/46 (6.5%)     | 0/44 (0.0%)     |
| Adjusted rate  | 0/26.6 (0.0%)   | 3/34.4 (8.7%)   | 0/31.3 (0.0%)   |
| Terminal rate  | 0/7 (0.0%)      | 2/15 (13.3%)    | 0/12 (0.0%)     |
| First incidence (days)                                 | — <sup>e</sup>  | 620             | — <sup>f</sup>  |
| Poly-3 test  | P=1.000         | P=0.337         | —               |
| <b>Preputial Gland: Hemangioma or Hemangiosarcoma</b>  |                 |                 |                 |
| Overall rate   | 0/43 (0.0%)     | 4/46 (8.7%)     | 0/44 (0.0%)     |
| Adjusted rate  | 0/26.6 (0.0%)   | 4/34.4 (11.6%)  | 0/31.3 (0.0%)   |
| Terminal rate  | 0/7 (0.0%)      | 2/15 (13.3%)    | 0/12 (0.0%)     |
| First incidence (days)                                 | —               | 620             | —               |
| Poly-3 test  | P=1.000         | P=0.194         | —               |
| <b>Skin: Sarcoma</b>                                   |                 |                 |                 |
| Overall rate   | 14/48 (29.2%)   | 8/47 (17.0%)    | 12/45 (26.7%)   |
| Adjusted rate  | 14/34.7 (40.3%) | 8/36.8 (21.7%)  | 12/34.4 (34.9%) |
| Terminal rate  | 1/8 (12.5%)     | 2/16 (12.5%)    | 4/12 (33.3%)    |
| First incidence (days)                                 | 453             | 395             | 467             |
| Poly-3 test  | P=0.737         | P=0.133         | P=0.822         |
| <b>Skin: Fibroma or Sarcoma</b>                        |                 |                 |                 |
| Overall rate   | 15/48 (31.3%)   | 8/47 (17.0%)    | 13/45 (28.9%)   |
| Adjusted rate  | 15/35.0 (42.9%) | 8/36.8 (21.7%)  | 13/34.4 (37.8%) |
| Terminal rate  | 1/8 (12.5%)     | 2/16 (12.5%)    | 4/12 (33.3%)    |
| First incidence (days)                                 | 453             | 395             | 467             |
| Poly-3 test  | P=0.758         | P=0.083         | P=0.846         |
| <b>Skin: Hemangioma or Hemangiosarcoma</b>             |                 |                 |                 |
| Overall rate   | 3/48 (6.3%)     | 1/47 (2.1%)     | 1/45 (2.2%)     |
| Adjusted rate  | 3/30.3 (9.9%)   | 1/34.9 (2.9%)   | 1/32.4 (3.1%)   |
| Terminal rate  | 1/8 (12.5%)     | 1/16 (6.3%)     | 0/12 (0.0%)     |
| First incidence (days)                                 | 576             | 765 (T)         | 623             |
| Poly-3 test  | P=0.394         | P=0.507         | P=0.558         |

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol      |
|--|----------------|----------------|-----------------|
| <b>Skin: Squamous Cell Papilloma</b>   |                |                |                 |
| Overall rate   | 5/48 (10.4%)   | 3/47 (6.4%)    | 6/45 (13.3%)    |
| Adjusted rate  | 5/30.4 (16.4%) | 3/35.7 (8.4%)  | 6/32.4 (18.5%)  |
| Terminal rate  | 2/8 (25.0%)    | 2/16 (12.5%)   | 2/12 (16.7%)    |
| First incidence (days)   | 453            | 453            | 710             |
| Poly-3 test  | P=0.906        | P=0.534        | P=1.000         |
| <b>Skin: Squamous Cell Papilloma or Squamous Cell Carcinoma</b>  |                |                |                 |
| Overall rate   | 6/48 (12.5%)   | 7/47 (14.9%)   | 7/45 (15.6%)    |
| Adjusted rate  | 6/31.0 (19.4%) | 7/37.6 (18.6%) | 7/32.4 (21.6%)  |
| Terminal rate  | 2/8 (25.0%)    | 2/16 (12.5%)   | 2/12 (16.7%)    |
| First incidence (days)   | 453            | 453            | 710             |
| Poly-3 test  | P=0.949        | P=1.000        | P=1.000         |
| <b>Skin: Basal Cell Carcinoma or Squamous Cell Carcinoma</b>   |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 4/47 (8.5%)    | 1/45 (2.2%)     |
| Adjusted rate  | 2/30.5 (6.6%)  | 4/36.8 (10.9%) | 1/32.0 (3.1%)   |
| Terminal rate  | 0/8 (0.0%)     | 0/16 (0.0%)    | 0/12 (0.0%)     |
| First incidence (days)   | 530            | 524            | 753             |
| Poly-3 test  | P=0.749        | P=0.854        | P=0.966         |
| <b>Skin: Squamous Cell Papilloma, Basal Cell Adenoma, Basal Cell Carcinoma, or Squamous Cell Carcinoma</b> |                |                |                 |
| Overall rate   | 8/48 (16.7%)   | 7/47 (14.9%)   | 10/45 (22.2%)   |
| Adjusted rate  | 8/31.8 (25.2%) | 7/37.6 (18.6%) | 10/32.9 (30.4%) |
| Terminal rate  | 2/8 (25.0%)    | 2/16 (12.5%)   | 3/12 (25.0%)    |
| First incidence (days)   | 453            | 453            | 691             |
| Poly-3 test  | P=0.706        | P=0.711        | P=0.847         |
| <b>Spleen: Hemangiosarcoma</b>   |                |                |                 |
| Overall rate   | 5/42 (11.9%)   | 3/46 (6.5%)    | 1/45 (2.2%)     |
| Adjusted rate  | 5/28.1 (17.8%) | 3/35.2 (8.5%)  | 1/32.4 (3.1%)   |
| Terminal rate  | 1/8 (12.5%)    | 1/16 (6.3%)    | 0/12 (0.0%)     |
| First incidence (days)   | 548            | 552            | 753             |
| Poly-3 test  | P=0.091        | P=0.472        | P=0.134         |
| <b>Spleen: Hemangioma or Hemangiosarcoma</b>   |                |                |                 |
| Overall rate   | 6/42 (14.3%)   | 3/46 (6.5%)    | 1/45 (2.2%)     |
| Adjusted rate  | 6/28.9 (20.8%) | 3/35.2 (8.5%)  | 1/32.4 (3.1%)   |
| Terminal rate  | 1/8 (12.5%)    | 1/16 (6.3%)    | 0/12 (0.0%)     |
| First incidence (days)   | 483            | 552            | 753             |
| Poly-3 test  | P=0.042        | P=0.294        | P=0.069         |
| <b>Spleen: Histiocytic Sarcoma</b>   |                |                |                 |
| Overall rate   | 2/42 (4.8%)    | 3/46 (6.5%)    | 3/45 (6.7%)     |
| Adjusted rate  | 2/27.5 (7.3%)  | 3/35.6 (8.4%)  | 3/33.1 (9.1%)   |
| Terminal rate  | 0/8 (0.0%)     | 0/16 (0.0%)    | 1/12 (8.3%)     |
| First incidence (days)   | 680            | 536            | 593             |
| Poly-3 test  | P=1.000        | P=1.000        | P=1.000         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>  |                |                |                 |
| Overall rate   | 3/45 (6.7%)    | 2/46 (4.3%)    | 5/48 (10.4%)    |
| Adjusted rate  | 3/29.3 (10.2%) | 2/34.5 (5.8%)  | 5/33.8 (14.8%)  |
| Terminal rate  | 0/8 (0.0%)     | 2/16 (12.5%)   | 2/12 (16.7%)    |
| First incidence (days)   | 646            | 765 (T)        | 697             |
| Poly-3 test  | P=0.658        | P=0.850        | P=0.873         |

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                 |                 |                 |
| Overall rate   | 5/45 (11.1%)    | 3/46 (6.5%)     | 5/48 (10.4%)    |
| Adjusted rate  | 5/29.6 (16.9%)  | 3/34.5 (8.7%)   | 5/33.8 (14.8%)  |
| Terminal rate  | 1/8 (12.5%)     | 3/16 (18.8%)    | 2/12 (16.7%)    |
| First incidence (days)   | 646             | 765 (T)         | 697             |
| Poly-3 test  | P=1.000         | P=0.541         | P=1.000         |
| <b>All Organs: Hemangioma</b>  |                 |                 |                 |
| Overall rate   | 3/48 (6.3%)     | 4/48 (8.3%)     | 2/48 (4.2%)     |
| Adjusted rate  | 3/30.1 (10.0%)  | 4/36.0 (11.1%)  | 2/33.6 (6.0%)   |
| Terminal rate  | 1/8 (12.5%)     | 3/16 (18.8%)    | 1/12 (8.3%)     |
| First incidence (days)   | 483             | 620             | 748             |
| Poly-3 test  | P=0.722         | P=1.000         | P=0.898         |
| <b>All Organs: Hemangiosarcoma</b>   |                 |                 |                 |
| Overall rate   | 19/48 (39.6%)   | 21/48 (43.8%)   | 18/48 (37.5%)   |
| Adjusted rate  | 19/34.5 (55.2%) | 21/39.5 (53.1%) | 18/36.2 (49.7%) |
| Terminal rate  | 3/8 (37.5%)     | 8/16 (50.0%)    | 7/12 (58.3%)    |
| First incidence (days)   | 453             | 488             | 507             |
| Poly-3 test  | P=0.726         | P=1.000         | P=0.815         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                 |                 |                 |                 |
| Overall rate   | 21/48 (43.8%)   | 22/48 (45.8%)   | 19/48 (39.6%)   |
| Adjusted rate  | 21/35.2 (59.7%) | 22/39.5 (55.6%) | 19/36.3 (52.4%) |
| Terminal rate  | 4/8 (50.0%)     | 9/16 (56.3%)    | 7/12 (58.3%)    |
| First incidence (days)   | 453             | 488             | 507             |
| Poly-3 test  | P=0.601         | P=0.900         | P=0.681         |
| <b>All Organs: Histiocytic Sarcoma</b>   |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)     | 7/48 (14.6%)    | 5/48 (10.4%)    |
| Adjusted rate  | 2/29.7 (6.7%)   | 7/37.1 (18.8%)  | 5/35.2 (14.2%)  |
| Terminal rate  | 0/8 (0.0%)      | 3/16 (18.8%)    | 1/12 (8.3%)     |
| First incidence (days)   | 680             | 536             | 577             |
| Poly-3 test  | P=0.595         | P=0.279         | P=0.574         |
| <b>All Organs: Malignant Lymphoma</b>  |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)     | 7/48 (14.6%)    | 14/48 (29.2%)   |
| Adjusted rate  | 4/29.8 (13.4%)  | 7/36.6 (19.1%)  | 14/37.1 (37.7%) |
| Terminal rate  | 2/8 (25.0%)     | 5/16 (31.3%)    | 4/12 (33.3%)    |
| First incidence (days)   | 600             | 588             | 296             |
| Poly-3 test  | P=0.022         | P=0.772         | P=0.043         |
| <b>All Organs: Benign Neoplasms</b>  |                 |                 |                 |
| Overall rate   | 45/48 (93.8%)   | 46/48 (95.8%)   | 40/48 (83.3%)   |
| Adjusted rate  | 45/45.8 (98.3%) | 46/46.3 (99.2%) | 40/42.8 (93.5%) |
| Terminal rate  | 8/8 (100.0%)    | 16/16 (100.0%)  | 12/12 (100.0%)  |
| First incidence (days)   | 293             | 395             | 355             |
| Poly-3 test  | P=0.156         | P=1.000         | P=0.385         |
| <b>All Organs: Malignant Neoplasms</b>   |                 |                 |                 |
| Overall rate   | 43/48 (89.6%)   | 45/48 (93.8%)   | 45/48 (93.8%)   |
| Adjusted rate  | 43/44.0 (97.8%) | 45/46.2 (97.4%) | 45/45.5 (98.9%) |
| Terminal rate  | 8/8 (100.0%)    | 15/16 (93.8%)   | 12/12 (100.0%)  |
| First incidence (days)   | 453             | 395             | 296             |
| Poly-3 test  | P=0.998         | P=1.000         | P=1.000         |

**TABLE A2e**  
**Statistical Analysis of Primary Neoplasms in Male Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol     | 5% Ethanol      |
|--|-----------------|------------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                  |                 |
| Overall rate                                     | 47/48 (97.9%)   | 47/48 (97.9%)    | 46/48 (95.8%)   |
| Adjusted rate                                    | 47/47.1 (99.8%) | 47/47.0 (100.0%) | 46/46.3 (99.4%) |
| Terminal rate                                    | 8/8 (100.0%)    | 16/16 (100.0%)   | 12/12 (100.0%)  |
| First incidence (days)                           | 293             | 395              | 296             |
| Poly-3 test                                      | P=1.000         | P=1.000          | P=1.000         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE A3a**  
**Historical Incidence of Hemangiosarcoma (All Sites) in Control Male B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |              |
|--------------------------|-----------------------|--------------|
|                          |                       |              |
| Chloral hydrate (gavage) |                       | 2/48         |
| Chloral hydrate (feed)   |                       | 1/48         |
| Doxylamine               |                       | 0/48         |
| Fumonisin B <sub>1</sub> |                       | 0/48         |
| Pyrilamine               |                       | 0/47         |
| Sulfamethazine           |                       | 3/187        |
| Triprolidine             |                       | 1/48         |
| Total (mean)             |                       | 7/474 (1.5%) |
| Range                    |                       | 0%-4%        |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE A3b**  
**Historical Incidence of Hepatocellular Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |                |                      |
|--------------------------|-----------------------|----------------|----------------------|
|                          | Adenoma               | Carcinoma      | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 18/48                 | 10/48          | 24/48                |
| Chloral hydrate (feed)   | 12/48                 | 4/48           | 16/48                |
| Doxylamine               | 6/48                  | 4/48           | 9/48                 |
| Fumonisin B <sub>1</sub> | 9/47                  | 4/47           | 12/47                |
| Pyrilamine               | 10/46                 | 3/46           | 13/46                |
| Sulfamethazine           | 25/185                | 20/185         | 42/185               |
| Triprolidine             | 9/48                  | 5/48           | 13/48                |
| Total (mean)             | 89/470 (18.9%)        | 50/470 (10.6%) | 129/470 (27.4%)      |
| Range                    | 13%-38%               | 7%-21%         | 19%-50%              |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE A3c**  
**Historical Incidence of Alveolar/bronchiolar Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |               |                      |
|--------------------------|-----------------------|---------------|----------------------|
|                          | Adenoma               | Carcinoma     | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 4/48                  | 4/48          | 8/48                 |
| Chloral hydrate (feed)   | 13/48                 | 2/48          | 15/48                |
| Doxylamine               | 9/48                  | 0/48          | 9/48                 |
| Fumonisin B <sub>1</sub> | 6/48                  | 0/48          | 6/48                 |
| Pyrilamine               | 5/47                  | 0/47          | 5/47                 |
| Sulfamethazine           | 25/186                | 3/186         | 28/186               |
| Triprolidine             | 9/48                  | 2/48          | 11/48                |
| Total (mean)             | 71/473 (15.0%)        | 11/473 (2.3%) | 82/473 (17.3%)       |
| Range                    | 8%-27%                | 0%-8%         | 11%-31%              |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE A3d**  
**Historical Incidence of Harderian Gland Neoplasms in Control Male B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |           |                      |
|--------------------------|-----------------------|-----------|----------------------|
|                          | Adenoma               | Carcinoma | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 4/48                  | 0/48      | 4/48                 |
| Chloral hydrate (feed)   | 5/47                  | 0/47      | 5/47                 |
| Fumonisin B <sub>1</sub> | 1/46                  | 0/46      | 1/46                 |
| Sulfamethazine           | 15/184                | 0/184     | 15/184               |
| Total (mean)             | 25/325 (7.7%)         | 0/325     | 25/325 (7.7%)        |
| Range                    | 2%-11%                |           | 2%-11%               |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol<sup>a</sup>**

|  | 0 ppm   | 10 ppm  | 30 ppm   | 90 ppm   |
|--|---------|---------|----------|----------|
| <b>Disposition Summary</b>                         |         |         |          |          |
| Animals initially in study                         | 48      | 48      | 48       | 48       |
| Early deaths                                       |         |         |          |          |
| Moribund   | 2       | 8       | 4        | 11       |
| Natural deaths                                     | 19      | 14      | 18       | 29       |
| Survivors  |         |         |          |          |
| Terminal sacrifice                                 | 27      | 26      | 26       | 8        |
| Animals examined microscopically                   | 48      | 48      | 47       | 48       |
| <b>Alimentary System</b>                           |         |         |          |          |
| Gallbladder  | (35)    | (38)    | (36)     | (23)     |
| Concretion   | 1 (3%)  |         |          |          |
| Cytoplasmic alteration, moderate, epithelium       |         |         | 1 (3%)   |          |
| Infiltration cellular, lymphocytic, mild           | 2 (6%)  |         |          |          |
| Inflammation, acute, mild                          |         | 1 (3%)  | 1 (3%)   |          |
| Inflammation, acute, minimal                       |         | 1 (3%)  |          |          |
| Inflammation, acute, moderate                      |         |         | 1 (3%)   |          |
| Intestine large, rectum                            | (45)    | (47)    | (45)     | (44)     |
| Cyst, minimal                                      | 1 (2%)  |         |          |          |
| Erosion, moderate                                  |         | 1 (2%)  |          |          |
| Infiltration cellular, lymphocytic, marked, serosa | 1 (2%)  |         |          |          |
| Inflammation, chronic active, moderate             |         | 3 (6%)  |          |          |
| Necrosis, marked                                   | 1 (2%)  |         |          |          |
| Intestine small, duodenum                          | (35)    | (38)    | (36)     | (26)     |
| Inflammation, chronic active, mild                 |         |         |          | 1 (4%)   |
| Intestine small, ileum                             | (37)    | (37)    | (35)     | (26)     |
| Inflammation, chronic active, minimal              |         |         |          | 1 (4%)   |
| Intestine small, jejunum                           | (39)    | (39)    | (37)     | (24)     |
| Inflammation, chronic active, minimal              |         |         |          | 1 (4%)   |
| Liver  | (46)    | (47)    | (46)     | (44)     |
| Amyloid deposition, minimal                        |         | 1 (2%)  |          |          |
| Angiectasis  |         | 4 (9%)  | 6 (13%)  | 17 (39%) |
| Basophilic focus                                   | 1 (2%)  | 1 (2%)  | 2 (4%)   | 1 (2%)   |
| Clear cell focus                                   | 3 (7%)  |         | 5 (11%)  | 2 (5%)   |
| Cyst, marked, bile duct                            | 1 (2%)  |         |          |          |
| Cyst, mild, bile duct                              |         |         | 1 (2%)   |          |
| Cyst, minimal, bile duct                           |         |         | 1 (2%)   |          |
| Eosinophilic focus                                 | 6 (13%) | 6 (13%) | 19 (41%) | 28 (64%) |
| Eosinophilic focus, multiple                       |         | 1 (2%)  |          |          |
| Hematopoietic cell proliferation, marked           |         |         | 1 (2%)   |          |
| Hematopoietic cell proliferation, mild             | 1 (2%)  | 1 (2%)  | 3 (7%)   | 2 (5%)   |
| Hematopoietic cell proliferation, minimal          |         | 2 (4%)  | 4 (9%)   | 7 (16%)  |
| Hematopoietic cell proliferation, moderate         |         | 2 (4%)  | 1 (2%)   | 2 (5%)   |
| Hyperplasia, marked, Kupffer cell                  |         | 1 (2%)  |          | 2 (5%)   |
| Hyperplasia, mild, Kupffer cell                    | 2 (4%)  | 3 (6%)  | 5 (11%)  | 4 (9%)   |
| Hyperplasia, minimal, bile duct                    |         |         | 1 (2%)   |          |
| Hyperplasia, minimal, Kupffer cell                 | 2 (4%)  | 3 (6%)  | 2 (4%)   | 1 (2%)   |
| Hyperplasia, minimal, oval cell                    |         | 1 (2%)  |          |          |
| Hyperplasia, moderate, Kupffer cell                | 1 (2%)  | 3 (6%)  | 3 (7%)   | 5 (11%)  |
| Hypertrophy, hepatocyte                            | 1 (2%)  |         |          |          |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Alimentary System (continued)</b>           |          |          |          |          |
| Liver (continued)                              | (46)     | (47)     | (46)     | (44)     |
| Infiltration cellular, lymphocytic, marked     |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal    | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, moderate   |          | 1 (2%)   |          |          |
| Infiltration cellular, mixed cell, mild        |          | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, mixed cell, minimal     | 1 (2%)   | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Inflammation, subacute, moderate               |          | 1 (2%)   |          |          |
| Mixed cell focus                               | 1 (2%)   | 1 (2%)   | 3 (7%)   |          |
| Necrosis, marked                               | 1 (2%)   |          |          | 2 (5%)   |
| Necrosis, marked, hepatocyte                   |          | 1 (2%)   |          |          |
| Necrosis, mild                                 | 1 (2%)   |          |          | 2 (5%)   |
| Necrosis, mild, hepatocyte                     |          |          | 2 (4%)   | 2 (5%)   |
| Necrosis, minimal                              |          | 1 (2%)   | 1 (2%)   |          |
| Necrosis, minimal, hepatocyte                  | 3 (7%)   | 3 (6%)   | 2 (4%)   |          |
| Necrosis, moderate                             | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Necrosis, moderate, hepatocyte                 |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Nuclear alteration, mild, hepatocyte           | 2 (4%)   |          |          |          |
| Nuclear alteration, minimal, hepatocyte        | 1 (2%)   |          |          |          |
| Regeneration                                   |          | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Syncytial alteration, mild, hepatocyte         | 3 (7%)   | 3 (6%)   | 2 (4%)   |          |
| Syncytial alteration, minimal, hepatocyte      | 5 (11%)  | 3 (6%)   | 6 (13%)  | 1 (2%)   |
| Tension lipodosis                              | 1 (2%)   |          |          |          |
| Vacuolization cytoplasmic, mild, hepatocyte    |          | 2 (4%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, minimal, hepatocyte | 2 (4%)   | 1 (2%)   |          |          |
| Mesentery                                      | (1)      | (1)      | (1)      | (1)      |
| Cyst, moderate                                 |          |          | 1 (100%) |          |
| Necrosis, fat                                  | 1 (100%) | 1 (100%) |          |          |
| Pancreas                                       | (45)     | (44)     | (44)     | (42)     |
| Atrophy, marked, acinar cell                   | 1 (2%)   |          |          |          |
| Atrophy, moderate, acinar cell                 |          |          |          | 1 (2%)   |
| Basophilic focus                               |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal    | 4 (9%)   | 3 (7%)   | 5 (11%)  | 2 (5%)   |
| Necrosis, mild                                 |          |          |          | 1 (2%)   |
| Vacuolization cytoplasmic, mild, acinar cell   |          | 1 (2%)   |          |          |
| Salivary glands                                | (47)     | (48)     | (46)     | (46)     |
| Atrophy, mild                                  | 2 (4%)   | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Atrophy, minimal                               |          | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Atrophy, moderate                              |          | 2 (4%)   |          |          |
| Hyperplasia, lymphoid, moderate                | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild       | 18 (38%) | 19 (40%) | 22 (48%) | 7 (15%)  |
| Infiltration cellular, lymphocytic, minimal    | 12 (26%) | 17 (35%) | 16 (35%) | 19 (41%) |
| Infiltration cellular, lymphocytic, moderate   | 2 (4%)   | 1 (2%)   | 1 (2%)   |          |
| Stomach, forestomach                           | (46)     | (47)     | (44)     | (45)     |
| Cyst, marked                                   |          |          | 1 (2%)   |          |
| Cytoplasmic alteration, minimal, epithelium    |          |          |          | 1 (2%)   |
| Diverticulum                                   |          |          |          | 1 (2%)   |
| Hyperplasia, marked, epithelium                |          |          | 2 (5%)   |          |
| Hyperplasia, mild, epithelium                  |          |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, minimal, epithelium               | 1 (2%)   |          | 1 (2%)   |          |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm  | 10 ppm | 30 ppm | 90 ppm  |
|---|--------|--------|--------|---------|
| <b>Alimentary System</b> (continued)                |        |        |        |         |
| Stomach, glandular                                  | (43)   | (43)   | (44)   | (42)    |
| Cyst, minimal                                       | 1 (2%) | 2 (5%) | 3 (7%) | 1 (2%)  |
| Cyst, moderate                                      |        | 1 (2%) |        |         |
| Ectopic tissue                                      |        | 1 (2%) |        |         |
| Erosion, mild                                       |        |        | 1 (2%) | 1 (2%)  |
| Erosion, minimal                                    | 1 (2%) |        |        |         |
| Hyperplasia, mild, epithelium                       |        | 1 (2%) |        |         |
| Infiltration cellular, lymphocytic, minimal         | 1 (2%) | 1 (2%) |        |         |
| Inflammation, acute, mild                           | 1 (2%) |        |        |         |
| Inflammation, acute, minimal                        | 1 (2%) |        |        |         |
| Inflammation, chronic, minimal                      |        | 1 (2%) |        |         |
| Inflammation, subacute, mild                        | 1 (2%) |        |        |         |
| Inflammation, subacute, minimal                     |        |        |        | 1 (2%)  |
| Mineralization, minimal                             |        | 1 (2%) |        |         |
| Tongue  | (47)   | (48)   | (47)   | (48)    |
| Infiltration cellular, lymphocytic, mild            | 1 (2%) |        |        |         |
| Necrosis, minimal                                   | 1 (2%) |        |        |         |
| <b>Cardiovascular System</b>                        |        |        |        |         |
| Heart   | (48)   | (48)   | (47)   | (48)    |
| Angiectasis, mild                                   |        |        | 1 (2%) | 3 (6%)  |
| Angiectasis, minimal                                |        | 1 (2%) | 1 (2%) | 8 (17%) |
| Bacterium   |        |        | 1 (2%) |         |
| Cardiomyopathy, minimal                             |        | 1 (2%) |        |         |
| Hyperplasia, mild, endothelium                      |        |        | 2 (4%) | 3 (6%)  |
| Hyperplasia, minimal, endothelium                   |        |        | 2 (4%) | 5 (10%) |
| Hyperplasia, moderate, endothelium                  |        |        |        | 1 (2%)  |
| Hypertrophy, minimal, parenchymal cell              |        | 2 (4%) |        | 1 (2%)  |
| Infiltration cellular, lymphocytic, minimal, atrium | 1 (2%) |        |        |         |
| Inflammation, acute, mild, myocardium               | 1 (2%) |        | 1 (2%) |         |
| Inflammation, acute, mild, valve                    |        |        | 1 (2%) | 1 (2%)  |
| Inflammation, acute, minimal, myocardium            | 1 (2%) |        |        |         |
| Inflammation, chronic, mild, myocardium             |        |        | 1 (2%) |         |
| Inflammation, chronic, mild, valve                  |        |        | 1 (2%) |         |
| Inflammation, chronic, minimal, epicardium          |        |        | 1 (2%) |         |
| Inflammation, chronic, minimal, myocardium          |        | 2 (4%) | 1 (2%) | 1 (2%)  |
| Inflammation, chronic, minimal, valve               |        |        | 1 (2%) |         |
| Mineralization, mild                                |        | 1 (2%) | 1 (2%) |         |
| Mineralization, minimal                             |        | 1 (2%) |        |         |
| Mineralization, moderate                            |        |        | 1 (2%) |         |
| Necrosis, mild                                      |        |        | 1 (2%) |         |
| Necrosis, minimal                                   |        | 1 (2%) |        |         |
| Thrombosis, marked, atrium                          |        |        |        | 1 (2%)  |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Endocrine System</b>                      |          |          |          |          |
| Adrenal gland, cortex                        | (44)     | (44)     | (44)     | (44)     |
| Angiectasis, moderate                        |          |          | 1 (2%)   |          |
| Cyst, mild                                   | 1 (2%)   |          |          |          |
| Degeneration, minimal                        |          |          | 1 (2%)   |          |
| Hyperplasia, focal, mild                     |          | 1 (2%)   |          | 1 (2%)   |
| Hyperplasia, focal, moderate                 | 1 (2%)   |          | 4 (9%)   | 1 (2%)   |
| Hyperplasia, marked, subcapsular             | 1 (2%)   | 1 (2%)   | 2 (5%)   |          |
| Hyperplasia, mild, subcapsular               | 12 (27%) | 7 (16%)  | 9 (20%)  | 12 (27%) |
| Hyperplasia, minimal, subcapsular            | 23 (52%) | 25 (57%) | 22 (50%) | 23 (52%) |
| Hyperplasia, moderate, subcapsular           | 2 (5%)   | 2 (5%)   |          | 1 (2%)   |
| Hypertrophy, mild                            | 4 (9%)   | 5 (11%)  | 1 (2%)   | 1 (2%)   |
| Hypertrophy, minimal                         | 3 (7%)   | 2 (5%)   | 2 (5%)   | 1 (2%)   |
| Hypertrophy, moderate                        | 1 (2%)   |          |          |          |
| Adrenal gland, medulla                       | (44)     | (43)     | (42)     | (43)     |
| Amyloid deposition, mild                     |          |          | 1 (2%)   |          |
| Fibrosis, mild                               |          |          |          | 1 (2%)   |
| Hyperplasia, mild                            |          |          | 1 (2%)   |          |
| Hyperplasia, minimal                         |          |          | 1 (2%)   |          |
| Hyperplasia, moderate                        |          |          | 1 (2%)   | 1 (2%)   |
| Pigmentation, mild                           |          |          | 1 (2%)   |          |
| Islets, pancreatic                           | (45)     | (44)     | (44)     | (42)     |
| Hyperplasia, marked                          |          |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild                            | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, minimal                         | 3 (7%)   | 2 (5%)   |          |          |
| Parathyroid gland                            | (42)     | (33)     | (30)     | (28)     |
| Cyst, mild                                   |          | 1 (3%)   |          |          |
| Cyst, minimal                                | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild     |          | 1 (3%)   |          |          |
| Infiltration cellular, lymphocytic, minimal  |          |          |          | 1 (4%)   |
| Inflammation, acute, mild                    | 1 (2%)   |          |          |          |
| Pituitary gland                              | (35)     | (42)     | (39)     | (38)     |
| Cyst, mild, pars distalis                    |          | 1 (2%)   |          |          |
| Cyst, minimal, pars distalis                 |          |          |          | 1 (3%)   |
| Hyperplasia, focal, minimal, pars distalis   |          |          |          | 1 (3%)   |
| Thyroid gland                                | (46)     | (46)     | (46)     | (45)     |
| Crystals                                     | 1 (2%)   | 1 (2%)   |          |          |
| Cyst, mild, follicle                         |          | 1 (2%)   |          | 2 (4%)   |
| Cyst, minimal, follicle                      |          |          |          | 1 (2%)   |
| Hyperplasia, focal, minimal, follicular cell |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  |          | 1 (2%)   |          |          |
| Inflammation, chronic, minimal               | 1 (2%)   |          |          |          |
| Ultimobranchial cyst                         | 8 (17%)  | 10 (22%) | 12 (26%) | 9 (20%)  |

**General Body System**

None

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|---|---------|----------|----------|----------|
| <b>Genital System</b>                       |         |          |          |          |
| Coagulating gland                           | (46)    | (48)     | (46)     | (46)     |
| Atrophy, marked                             |         |          | 1 (2%)   |          |
| Atrophy, mild                               | 1 (2%)  | 1 (2%)   | 2 (4%)   | 5 (11%)  |
| Atrophy, minimal                            |         | 1 (2%)   | 2 (4%)   |          |
| Dilatation, mild                            |         | 3 (6%)   |          |          |
| Dilatation, minimal                         |         |          | 1 (2%)   |          |
| Dilatation, moderate                        | 1 (2%)  |          |          |          |
| Infiltration cellular, lymphocytic, mild    |         | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal | 9 (20%) | 4 (8%)   | 3 (7%)   |          |
| Inflammation, acute, moderate               | 2 (4%)  |          |          |          |
| Epididymis                                  | (47)    | (48)     | (46)     | (44)     |
| Infiltration cellular, lymphocytic, mild    |         | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal | 5 (11%) | 3 (6%)   | 10 (22%) | 3 (7%)   |
| Infiltration cellular, mixed cell, mild     |         | 1 (2%)   |          |          |
| Inflammation, chronic, mild                 | 2 (4%)  | 3 (6%)   |          |          |
| Inflammation, chronic, minimal              | 1 (2%)  |          |          | 1 (2%)   |
| Inflammation, subacute, minimal             | 1 (2%)  |          |          | 1 (2%)   |
| Mineralization, minimal                     | 1 (2%)  |          |          | 1 (2%)   |
| Necrosis, minimal                           | 1 (2%)  |          |          |          |
| Penis                                       |         | (1)      | (1)      | (2)      |
| Cyst, minimal                               |         |          | 1 (100%) |          |
| Hyperplasia, mild                           |         |          |          | 1 (50%)  |
| Inflammation, chronic active, mild          |         |          |          | 1 (50%)  |
| Inflammation, chronic active, moderate      |         | 1 (100%) |          |          |
| Inflammation, chronic, mild                 |         |          | 1 (100%) |          |
| Preputial gland                             | (45)    | (44)     | (43)     | (43)     |
| Angiectasis, marked                         | 1 (2%)  |          |          |          |
| Angiectasis, minimal                        |         | 1 (2%)   |          |          |
| Atrophy, marked                             | 3 (7%)  | 4 (9%)   | 5 (12%)  | 11 (26%) |
| Atrophy, mild                               | 5 (11%) | 3 (7%)   | 4 (9%)   | 7 (16%)  |
| Atrophy, minimal                            | 2 (4%)  | 4 (9%)   | 2 (5%)   | 1 (2%)   |
| Atrophy, moderate                           | 8 (18%) | 3 (7%)   | 3 (7%)   | 9 (21%)  |
| Cyst, moderate                              |         | 1 (2%)   |          |          |
| Dilatation, marked                          |         | 1 (2%)   | 2 (5%)   |          |
| Dilatation, mild                            | 4 (9%)  | 12 (27%) | 7 (16%)  | 4 (9%)   |
| Dilatation, minimal                         | 1 (2%)  | 5 (11%)  | 1 (2%)   | 1 (2%)   |
| Dilatation, moderate                        | 2 (4%)  | 2 (5%)   | 6 (14%)  | 5 (12%)  |
| Inflammation, acute, marked                 | 1 (2%)  |          |          |          |
| Inflammation, acute, mild                   | 1 (2%)  | 2 (5%)   |          |          |
| Inflammation, acute, minimal                |         | 1 (2%)   |          |          |
| Inflammation, acute, moderate               | 1 (2%)  |          |          |          |
| Inflammation, chronic active, marked        | 3 (7%)  | 2 (5%)   | 1 (2%)   |          |
| Inflammation, chronic active, mild          | 2 (4%)  | 4 (9%)   | 3 (7%)   | 6 (14%)  |
| Inflammation, chronic active, moderate      | 5 (11%) | 6 (14%)  | 5 (12%)  | 4 (9%)   |
| Inflammation, chronic, marked               |         |          |          | 1 (2%)   |
| Inflammation, chronic, mild                 | 1 (2%)  | 1 (2%)   | 7 (16%)  | 2 (5%)   |
| Inflammation, chronic, minimal              | 6 (13%) | 5 (11%)  | 2 (5%)   | 6 (14%)  |
| Inflammation, subacute, mild                |         |          |          | 1 (2%)   |
| Inflammation, subacute, minimal             |         |          | 1 (2%)   |          |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm  |
|--|----------|----------|----------|---------|
| <b>Genital System (continued)</b>            |          |          |          |         |
| Prostate                                     | (46)     | (45)     | (45)     | (45)    |
| Atrophy, mild                                | 1 (2%)   |          |          | 2 (4%)  |
| Atrophy, minimal                             |          | 1 (2%)   | 1 (2%)   | 2 (4%)  |
| Atrophy, moderate                            |          |          |          | 1 (2%)  |
| Dilatation, mild                             |          | 1 (2%)   |          |         |
| Hyperplasia, marked, epithelium              |          |          | 1 (2%)   |         |
| Infiltration cellular, lymphocytic, mild     | 1 (2%)   |          |          |         |
| Infiltration cellular, lymphocytic, minimal  |          | 2 (4%)   | 1 (2%)   | 1 (2%)  |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   |          |          |         |
| Inflammation, acute, marked                  | 1 (2%)   |          |          |         |
| Inflammation, acute, mild                    | 1 (2%)   | 1 (2%)   |          | 2 (4%)  |
| Inflammation, acute, moderate                | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)  |
| Inflammation, chronic, moderate, artery      | 1 (2%)   |          |          |         |
| Inflammation, subacute, mild                 | 2 (4%)   |          |          | 1 (2%)  |
| Inflammation, subacute, minimal              | 13 (28%) | 16 (36%) | 13 (29%) | 4 (9%)  |
| Seminal vesicle                              | (46)     | (48)     | (46)     | (46)    |
| Atrophy, mild                                | 2 (4%)   | 3 (6%)   | 2 (4%)   | 2 (4%)  |
| Atrophy, minimal                             |          |          | 2 (4%)   | 3 (7%)  |
| Dilatation, mild                             | 3 (7%)   | 1 (2%)   | 3 (7%)   |         |
| Dilatation, minimal                          | 1 (2%)   |          | 1 (2%)   |         |
| Dilatation, moderate                         | 1 (2%)   | 1 (2%)   |          |         |
| Infiltration cellular, lymphocytic, minimal  |          |          | 1 (2%)   | 1 (2%)  |
| Inflammation, acute, marked                  |          | 1 (2%)   |          |         |
| Inflammation, acute, mild                    |          | 1 (2%)   |          | 1 (2%)  |
| Inflammation, acute, minimal                 | 1 (2%)   |          |          |         |
| Inflammation, chronic, mild                  |          |          | 1 (2%)   |         |
| Testes                                       | (47)     | (48)     | (46)     | (46)    |
| Atrophy, mild, germinal epithelium           | 1 (2%)   | 2 (4%)   | 1 (2%)   | 2 (4%)  |
| Atrophy, minimal, germinal epithelium        | 1 (2%)   |          |          |         |
| Atrophy, moderate, germinal epithelium       |          | 2 (4%)   | 2 (4%)   |         |
| Degeneration, mild, germinal epithelium      |          | 3 (6%)   |          |         |
| Degeneration, minimal, germinal epithelium   | 3 (6%)   | 1 (2%)   | 3 (7%)   | 1 (2%)  |
| Developmental malformation                   |          |          | 1 (2%)   |         |
| Hemorrhage, mild                             |          |          |          | 1 (2%)  |
| Mineralization, minimal                      | 1 (2%)   | 1 (2%)   |          | 2 (4%)  |
| Ovotestis                                    |          |          | 1 (2%)   |         |
| <b>Hematopoietic System</b>                  |          |          |          |         |
| Bone marrow                                  | (46)     | (47)     | (45)     | (45)    |
| Angiectasis, moderate                        |          |          | 2 (4%)   |         |
| Hyperplasia, mild                            | 3 (7%)   | 5 (11%)  | 4 (9%)   | 4 (9%)  |
| Hyperplasia, minimal                         | 3 (7%)   | 1 (2%)   | 2 (4%)   | 5 (11%) |
| Hyperplasia, moderate                        |          |          |          | 1 (2%)  |
| Necrosis, marked                             | 1 (2%)   |          |          |         |
| Thrombosis                                   |          |          | 1 (2%)   |         |
| Lymph node                                   | (47)     | (47)     | (46)     | (46)    |
| Autolysis, renal                             |          |          | 1 (2%)   |         |
| Degeneration, cystic, inguinal               |          | 1 (2%)   |          |         |
| Hemorrhage, moderate, inguinal               |          |          |          | 1 (2%)  |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Hematopoietic System</b> (continued)      |          |          |          |          |
| Lymph node (continued)                       | (47)     | (47)     | (46)     | (46)     |
| Hyperplasia, lymphoid, marked, renal         |          |          | 1 (2%)   |          |
| Hyperplasia, lymphoid, mild, axillary        |          |          |          | 1 (2%)   |
| Hyperplasia, lymphoid, mild, inguinal        |          |          |          | 1 (2%)   |
| Hyperplasia, lymphoid, mild, lumbar          | 1 (2%)   |          |          |          |
| Hyperplasia, lymphoid, mild, renal           |          |          |          | 1 (2%)   |
| Hyperplasia, lymphoid, moderate, inguinal    |          | 1 (2%)   |          | 1 (2%)   |
| Hyperplasia, lymphoid, moderate, renal       |          |          | 1 (2%)   | 1 (2%)   |
| Lymph node, mandibular                       | (46)     | (46)     | (46)     | (45)     |
| Angiectasis, marked                          |          |          | 1 (2%)   |          |
| Hemorrhage, minimal                          |          | 1 (2%)   |          | 1 (2%)   |
| Hyperplasia, lymphoid, marked                | 1 (2%)   | 2 (4%)   |          | 1 (2%)   |
| Hyperplasia, lymphoid, mild                  | 5 (11%)  | 2 (4%)   | 6 (13%)  | 6 (13%)  |
| Hyperplasia, lymphoid, minimal               | 4 (9%)   | 4 (9%)   | 9 (20%)  | 3 (7%)   |
| Hyperplasia, lymphoid, moderate              | 2 (4%)   | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, histiocytic, mild     | 2 (4%)   | 1 (2%)   |          | 1 (2%)   |
| Infiltration cellular, histiocytic, minimal  | 2 (4%)   | 2 (4%)   | 2 (4%)   | 3 (7%)   |
| Mineralization, minimal                      | 1 (2%)   |          |          |          |
| Pigmentation, mild                           |          |          | 1 (2%)   |          |
| Pigmentation, minimal                        | 1 (2%)   |          |          |          |
| Lymph node, mesenteric                       | (43)     | (47)     | (43)     | (38)     |
| Angiectasis                                  | 1 (2%)   |          |          |          |
| Angiectasis, marked                          | 1 (2%)   | 2 (4%)   |          | 3 (8%)   |
| Angiectasis, mild                            | 11 (26%) | 11 (23%) | 11 (26%) | 10 (26%) |
| Angiectasis, minimal                         | 3 (7%)   | 6 (13%)  | 9 (21%)  | 2 (5%)   |
| Angiectasis, moderate                        | 6 (14%)  | 2 (4%)   | 5 (12%)  | 2 (5%)   |
| Hematopoietic cell proliferation, minimal    |          |          |          | 1 (3%)   |
| Hemorrhage, mild                             |          | 1 (2%)   |          |          |
| Hemorrhage, minimal                          |          |          |          | 1 (3%)   |
| Hemorrhage, moderate                         |          |          |          | 1 (3%)   |
| Hyperplasia, lymphoid, marked                |          | 1 (2%)   | 1 (2%)   |          |
| Hyperplasia, lymphoid, mild                  | 2 (5%)   | 7 (15%)  | 5 (12%)  | 1 (3%)   |
| Hyperplasia, lymphoid, minimal               | 4 (9%)   | 5 (11%)  | 3 (7%)   | 4 (11%)  |
| Hyperplasia, lymphoid, moderate              |          |          | 2 (5%)   |          |
| Infiltration cellular, histiocytic, mild     | 1 (2%)   |          |          |          |
| Infiltration cellular, histiocytic, minimal  | 1 (2%)   |          |          | 2 (5%)   |
| Infiltration cellular, lymphocytic, moderate |          | 1 (2%)   |          |          |
| Necrosis, mild                               |          | 1 (2%)   |          |          |
| Spleen                                       | (44)     | (46)     | (45)     | (42)     |
| Angiectasis, mild                            |          |          | 1 (2%)   |          |
| Angiectasis, moderate                        |          |          | 1 (2%)   |          |
| Atrophy, mild, lymphoid follicle             | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Atrophy, minimal, lymphoid follicle          |          | 1 (2%)   |          |          |
| Atrophy, moderate, lymphoid follicle         | 2 (5%)   | 1 (2%)   |          |          |
| Hematopoietic cell proliferation, marked     | 5 (11%)  | 6 (13%)  | 5 (11%)  | 9 (21%)  |
| Hematopoietic cell proliferation, mild       | 6 (14%)  | 7 (15%)  | 4 (9%)   | 6 (14%)  |
| Hematopoietic cell proliferation, minimal    |          |          | 5 (11%)  | 3 (7%)   |
| Hematopoietic cell proliferation, moderate   | 8 (18%)  | 9 (20%)  | 3 (7%)   | 14 (33%) |
| Hyperplasia, marked, lymphoid follicle       | 5 (11%)  | 3 (7%)   | 6 (13%)  | 1 (2%)   |
| Hyperplasia, mild, lymphoid follicle         | 3 (7%)   | 8 (17%)  | 7 (16%)  |          |
| Hyperplasia, minimal, lymphoid follicle      | 2 (5%)   | 3 (7%)   | 3 (7%)   |          |
| Hyperplasia, moderate, lymphoid follicle     |          | 2 (4%)   | 4 (9%)   |          |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm  |
|--|---------|---------|---------|---------|
| <b>Hematopoietic System</b> (continued)      |         |         |         |         |
| Spleen (continued)                           | (44)    | (46)    | (45)    | (42)    |
| Infiltration cellular, lymphocytic, moderate |         | 1 (2%)  |         |         |
| Inflammation, chronic active, mild           |         |         |         | 1 (2%)  |
| Necrosis, moderate                           |         |         |         | 1 (2%)  |
| Pigmentation, mild                           |         |         | 1 (2%)  |         |
| Thymus                                       | (32)    | (29)    | (35)    | (27)    |
| Atrophy, marked                              | 6 (19%) | 6 (21%) | 4 (11%) | 7 (26%) |
| Atrophy, mild                                | 4 (13%) | 1 (3%)  | 4 (11%) | 3 (11%) |
| Atrophy, minimal                             | 1 (3%)  | 2 (7%)  | 4 (11%) | 3 (11%) |
| Atrophy, moderate                            | 4 (13%) | 2 (7%)  | 2 (6%)  | 5 (19%) |
| Cyst, mild                                   |         |         | 1 (3%)  |         |
| Cyst, minimal                                | 3 (9%)  |         | 1 (3%)  | 1 (4%)  |
| Hyperplasia, mild, medulla                   |         | 1 (3%)  |         |         |
| Hyperplasia, minimal, cortex                 |         |         | 1 (3%)  |         |
| Hyperplasia, minimal, epithelial cell        |         |         | 1 (3%)  |         |
| Hyperplasia, minimal, medulla                | 1 (3%)  |         |         |         |
| <b>Integumentary System</b>                  |         |         |         |         |
| Mammary gland                                |         | (2)     | (5)     | (1)     |
| Cyst, mild                                   |         |         | 1 (20%) |         |
| Skin   | (47)    | (48)    | (47)    | (48)    |
| Edema, mild                                  |         |         | 2 (4%)  | 1 (2%)  |
| Erosion, marked                              |         |         |         | 1 (2%)  |
| Erosion, minimal                             | 1 (2%)  |         |         |         |
| Hyperplasia, marked, epithelium              | 1 (2%)  |         |         |         |
| Hyperplasia, mild, epithelium                | 1 (2%)  | 2 (4%)  |         |         |
| Hyperplasia, moderate, sebaceous gland       |         |         |         | 1 (2%)  |
| Inflammation, acute, minimal                 | 1 (2%)  |         |         |         |
| Inflammation, chronic active, marked         |         | 1 (2%)  |         |         |
| Inflammation, chronic active, mild           |         | 1 (2%)  |         | 1 (2%)  |
| Inflammation, chronic active, minimal        |         | 1 (2%)  |         |         |
| Inflammation, chronic active, moderate       | 1 (2%)  |         |         |         |
| Inflammation, chronic, mild                  | 4 (9%)  | 2 (4%)  |         | 1 (2%)  |
| Inflammation, chronic, minimal               |         | 2 (4%)  |         |         |
| Inflammation, chronic, moderate              |         |         |         | 2 (4%)  |
| Metaplasia, osseous, mild                    | 1 (2%)  | 1 (2%)  |         |         |
| Metaplasia, osseous, moderate                |         | 1 (2%)  |         |         |
| Ulcer, marked                                | 1 (2%)  | 1 (2%)  |         |         |
| Ulcer, mild                                  |         | 1 (2%)  |         |         |
| Ulcer, moderate                              | 2 (4%)  | 1 (2%)  |         |         |
| <b>Musculoskeletal System</b>                |         |         |         |         |
| Bone   | (48)    | (48)    | (47)    | (48)    |
| Hyperostosis, mild, sternum                  | 1 (2%)  |         |         |         |
| Hyperostosis, minimal, sternum               | 1 (2%)  |         |         | 1 (2%)  |
| Osteomalacia, mild, sternum                  |         |         |         | 1 (2%)  |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Musculoskeletal System (continued)</b>        |          |          |          |          |
| Bone, femur                                      | (48)     | (48)     | (47)     | (48)     |
| Degeneration, marked, joint, cartilage           |          | 1 (2%)   |          |          |
| Degeneration, mild, joint, cartilage             | 2 (4%)   | 3 (6%)   | 1 (2%)   | 1 (2%)   |
| Degeneration, minimal, joint, cartilage          | 1 (2%)   | 6 (13%)  | 8 (17%)  |          |
| Degeneration, moderate, joint, cartilage         |          | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Hyperostosis, mild                               |          |          |          | 1 (2%)   |
| Hyperostosis, moderate, joint                    |          |          |          | 1 (2%)   |
| Osteomalacia, mild                               | 1 (2%)   |          |          |          |
| Skeletal muscle                                  | (48)     | (48)     | (47)     | (48)     |
| Infiltration cellular, lymphocytic, mild         |          | 1 (2%)   |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal      | 2 (4%)   | 2 (4%)   | 4 (9%)   | 1 (2%)   |
| Inflammation, subacute, minimal                  |          |          | 1 (2%)   |          |
| Mineralization, minimal                          |          |          | 1 (2%)   |          |
| Necrosis, minimal                                | 1 (2%)   |          |          |          |
| <b>Nervous System</b>                            |          |          |          |          |
| Brain, cerebellum                                | (48)     | (47)     | (44)     | (46)     |
| Inflammation, acute, mild, meninges              |          |          | 1 (2%)   |          |
| Brain, cerebrum                                  | (48)     | (48)     | (47)     | (47)     |
| Cyst epithelial inclusion                        |          | 1 (2%)   |          |          |
| Inflammation, acute, mild                        |          |          | 1 (2%)   |          |
| Mineralization, mild, thalamus                   | 2 (4%)   | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Mineralization, minimal, thalamus                | 23 (48%) | 23 (48%) | 22 (47%) | 15 (32%) |
| Necrosis, mild                                   |          |          |          | 1 (2%)   |
| Peripheral nerve                                 | (47)     | (48)     | (47)     | (48)     |
| Degeneration, mild                               |          |          |          | 1 (2%)   |
| Degeneration, minimal                            | 6 (13%)  | 7 (15%)  | 5 (11%)  | 1 (2%)   |
| <b>Respiratory System</b>                        |          |          |          |          |
| Larynx   | (45)     | (45)     | (46)     | (45)     |
| Inflammation, acute, minimal                     |          |          |          | 1 (2%)   |
| Inflammation, chronic, minimal                   |          | 1 (2%)   |          |          |
| Lung   | (48)     | (48)     | (47)     | (48)     |
| Hemorrhage, minimal                              |          |          |          | 1 (2%)   |
| Hyperplasia, marked, alveolar epithelium         |          | 1 (2%)   |          | 4 (8%)   |
| Hyperplasia, mild, alveolar epithelium           | 1 (2%)   |          | 3 (6%)   | 4 (8%)   |
| Hyperplasia, minimal, alveolar epithelium        | 1 (2%)   |          | 3 (6%)   | 1 (2%)   |
| Hyperplasia, moderate, alveolar epithelium       |          |          |          | 2 (4%)   |
| Infiltration cellular, histiocytic, minimal      |          |          | 1 (2%)   | 2 (4%)   |
| Infiltration cellular, histiocytic, moderate     |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild         | 3 (6%)   | 1 (2%)   | 2 (4%)   |          |
| Infiltration cellular, lymphocytic, mild, pleura | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, minimal      | 3 (6%)   | 5 (10%)  | 4 (9%)   |          |
| Infiltration cellular, lymphocytic, moderate     |          | 1 (2%)   |          |          |
| Inflammation, chronic active, minimal            | 1 (2%)   |          |          |          |
| Inflammation, chronic active, moderate           |          | 1 (2%)   |          |          |
| Inflammation, chronic, minimal                   | 2 (4%)   | 1 (2%)   |          | 1 (2%)   |
| Inflammation, subacute, mild, vein               |          |          | 1 (2%)   |          |
| Parasite protozoan                               |          | 1 (2%)   |          |          |
| Pigmentation, mild                               |          |          | 1 (2%)   | 1 (2%)   |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm  |
|--|----------|----------|----------|---------|
| <b>Respiratory System (continued)</b>                    |          |          |          |         |
| Nose   | (47)     | (48)     | (47)     | (47)    |
| Cyst, minimal, mucosa                                    | 1 (2%)   |          |          |         |
| Cytoplasmic alteration, mild, olfactory epithelium       | 10 (21%) | 12 (25%) | 12 (26%) | 8 (17%) |
| Cytoplasmic alteration, mild, respiratory epithelium     | 18 (38%) | 15 (31%) | 14 (30%) | 9 (19%) |
| Cytoplasmic alteration, minimal, olfactory epithelium    | 11 (23%) | 14 (29%) | 9 (19%)  | 8 (17%) |
| Cytoplasmic alteration, minimal, respiratory epithelium  | 8 (17%)  | 9 (19%)  | 6 (13%)  | 8 (17%) |
| Cytoplasmic alteration, moderate, olfactory epithelium   |          | 1 (2%)   |          |         |
| Cytoplasmic alteration, moderate, respiratory epithelium |          | 1 (2%)   | 2 (4%)   |         |
| Inflammation, mild                                       |          |          |          | 1 (2%)  |
| Inflammation, minimal                                    |          |          | 2 (4%)   |         |
| <b>Special Senses System</b>                             |          |          |          |         |
| Eye  | (47)     | (47)     | (47)     | (47)    |
| Atrophy, marked  |          |          |          | 1 (2%)  |
| Cataract, mild, lens                                     |          |          | 2 (4%)   |         |
| Cataract, minimal, lens                                  |          | 1 (2%)   | 1 (2%)   |         |
| Degeneration, mild, cornea                               |          |          |          | 1 (2%)  |
| Hyperplasia, mild, cornea                                |          |          | 1 (2%)   |         |
| Inflammation, acute, mild, cornea                        | 1 (2%)   |          |          | 1 (2%)  |
| Inflammation, acute, mild, iris                          |          |          |          | 1 (2%)  |
| Inflammation, chronic active, mild, cornea               |          |          |          | 1 (2%)  |
| Inflammation, chronic active, minimal, lids              |          |          | 1 (2%)   |         |
| Inflammation, chronic active, moderate, cornea           |          | 1 (2%)   |          | 1 (2%)  |
| Inflammation, chronic, marked, cornea                    |          |          |          | 1 (2%)  |
| Inflammation, chronic, mild, cornea                      |          |          | 4 (9%)   | 2 (4%)  |
| Inflammation, chronic, minimal, cornea                   |          |          | 1 (2%)   |         |
| Inflammation, chronic, moderate, cornea                  |          |          | 1 (2%)   | 3 (6%)  |
| Harderian gland  | (47)     | (47)     | (47)     | (47)    |
| Hyperplasia, focal, marked                               |          |          | 1 (2%)   |         |
| Hyperplasia, focal, mild                                 |          | 1 (2%)   | 1 (2%)   |         |
| Hyperplasia, focal, moderate                             |          |          | 2 (4%)   | 2 (4%)  |
| Infiltration cellular, lymphocytic, mild                 | 2 (4%)   | 1 (2%)   | 2 (4%)   |         |
| Infiltration cellular, lymphocytic, minimal              | 16 (34%) | 17 (36%) | 9 (19%)  | 5 (11%) |
| Inflammation, chronic, mild                              |          |          |          | 1 (2%)  |
| Inflammation, chronic, minimal                           |          | 1 (2%)   |          |         |
| Lacrimal gland   | (47)     | (47)     | (44)     | (47)    |
| Atrophy, focal, mild                                     |          |          |          | 1 (2%)  |
| Atrophy, marked  | 1 (2%)   |          |          |         |
| Atrophy, mild  | 2 (4%)   | 5 (11%)  | 1 (2%)   | 4 (9%)  |
| Atrophy, minimal   | 4 (9%)   | 5 (11%)  | 4 (9%)   | 1 (2%)  |
| Atrophy, moderate  |          |          |          | 3 (6%)  |
| Hyperplasia, focal, minimal                              |          |          | 1 (2%)   |         |
| Infiltration cellular, lymphocytic, mild                 | 3 (6%)   | 4 (9%)   | 4 (9%)   | 2 (4%)  |
| Infiltration cellular, lymphocytic, minimal              | 17 (36%) | 10 (21%) | 7 (16%)  | 9 (19%) |
| Infiltration cellular, lymphocytic, moderate             |          | 1 (2%)   |          |         |
| Mineralization, minimal                                  |          |          |          | 1 (2%)  |
| Zymbal's gland   | (45)     | (45)     | (45)     | (45)    |
| Dilatation, mild   |          |          |          | 1 (2%)  |
| Dilatation, moderate                                     |          |          | 1 (2%)   |         |
| Hyperplasia, mild  |          |          | 2 (4%)   |         |

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Urinary System</b>                                 |          |          |          |          |
| Kidney  | (46)     | (47)     | (46)     | (45)     |
| Accumulation, hyaline droplet, moderate, renal tubule |          |          | 1 (2%)   |          |
| Amyloid deposition, mild                              |          | 1 (2%)   |          |          |
| Amyloid deposition, minimal                           |          | 4 (9%)   |          |          |
| Cyst, mild  | 1 (2%)   |          | 2 (4%)   |          |
| Cyst, minimal   | 3 (7%)   | 2 (4%)   | 3 (7%)   | 3 (7%)   |
| Degeneration, marked, renal tubule                    |          | 1 (2%)   |          |          |
| Degeneration, mild, renal tubule                      | 4 (9%)   | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Degeneration, minimal, renal tubule                   | 14 (30%) | 18 (38%) | 9 (20%)  | 4 (9%)   |
| Degeneration, moderate, renal tubule                  |          |          |          | 1 (2%)   |
| Dilatation, minimal, pelvis                           |          | 1 (2%)   |          |          |
| Glomerulosclerosis, mild                              | 7 (15%)  | 12 (26%) | 10 (22%) | 9 (20%)  |
| Glomerulosclerosis, minimal                           | 22 (48%) | 23 (49%) | 23 (50%) | 16 (36%) |
| Glomerulosclerosis, moderate                          | 1 (2%)   |          | 2 (4%)   | 2 (4%)   |
| Hematopoietic cell proliferation, mild                |          |          | 1 (2%)   |          |
| Hyperplasia, focal, mild, renal tubule                |          |          |          | 1 (2%)   |
| Hyperplasia, focal, minimal, renal tubule             | 1 (2%)   | 2 (4%)   |          |          |
| Hypoplasia, focal, mild                               |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild              | 3 (7%)   | 2 (4%)   | 6 (13%)  | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal           | 11 (24%) | 15 (32%) | 15 (33%) | 17 (38%) |
| Infiltration cellular, lymphocytic, moderate          | 1 (2%)   |          |          |          |
| Inflammation, acute, marked, pelvis                   | 1 (2%)   |          |          |          |
| Inflammation, acute, mild, pelvis                     | 3 (7%)   | 1 (2%)   |          |          |
| Inflammation, chronic, minimal                        |          |          |          | 1 (2%)   |
| Inflammation, chronic, minimal, pelvis                |          | 1 (2%)   | 2 (4%)   |          |
| Inflammation, chronic, moderate                       | 1 (2%)   |          |          |          |
| Inflammation, subacute, mild, pelvis                  |          | 1 (2%)   |          |          |
| Mineralization, mild                                  | 1 (2%)   | 1 (2%)   |          |          |
| Mineralization, minimal                               | 7 (15%)  | 7 (15%)  | 7 (15%)  | 3 (7%)   |
| Necrosis, mild, papilla                               |          | 1 (2%)   |          |          |
| Nephropathy, minimal                                  |          | 1 (2%)   |          |          |
| Pigmentation, mild                                    | 1 (2%)   |          |          |          |
| Pigmentation, moderate                                |          |          |          | 1 (2%)   |
| Thrombosis, mild, glomerulus                          |          |          |          | 1 (2%)   |
| Thrombosis, mild, vein                                |          |          |          | 1 (2%)   |
| Urethra   |          | (1)      |          | (1)      |
| Congestion, marked, bulbourethral gland               |          | 1 (100%) |          |          |
| Urinary bladder                                       | (46)     | (46)     | (46)     | (40)     |
| Dilatation, marked                                    | 1 (2%)   |          |          |          |
| Dilatation, mild                                      |          | 1 (2%)   |          |          |
| Dilatation, moderate                                  |          |          |          | 2 (5%)   |
| Edema, mild   |          |          | 1 (2%)   | 1 (3%)   |
| Edema, minimal  | 1 (2%)   |          |          |          |
| Edema, moderate                                       |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild              | 3 (7%)   | 3 (7%)   | 3 (7%)   | 3 (8%)   |
| Infiltration cellular, lymphocytic, minimal           | 16 (35%) | 18 (39%) | 17 (37%) | 6 (15%)  |
| Inflammation, acute, marked                           |          | 1 (2%)   |          |          |
| Inflammation, acute, mild                             | 2 (4%)   |          |          | 3 (8%)   |
| Inflammation, acute, minimal                          | 1 (2%)   |          | 1 (2%)   | 1 (3%)   |
| Inflammation, acute, moderate                         | 1 (2%)   |          |          |          |
| Inflammation, chronic active, moderate                | 2 (4%)   | 1 (2%)   |          |          |



**APPENDIX B**  
**SUMMARY OF LESIONS IN MALE MICE**  
**IN THE 2-YEAR DRINKING WATER STUDY**  
**OF URETHANE AND 2.5% ETHANOL**

**TABLE B1** Summary of the Incidence of Neoplasms in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... B-2

**TABLE B2** Statistical Analysis of Primary Neoplasms in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... B-8

**TABLE B3** Summary of the Incidence of Nonneoplastic Lesions in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... B-14

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol<sup>a</sup>**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Disposition Summary</b>                       |          |          |          |          |
| Animals initially in study                       | 48       | 48       | 48       | 48       |
| Early deaths                                     |          |          |          |          |
| Moribund   | 10       | 5        | 7        | 9        |
| Natural deaths                                   | 6        | 13       | 16       | 23       |
| Survivors  |          |          |          |          |
| Terminal sacrifice                               | 32       | 30       | 25       | 16       |
| Animals examined microscopically                 | 48       | 48       | 47       | 48       |
| <b>Alimentary System</b>                         |          |          |          |          |
| Gallbladder                                      | (39)     | (41)     | (40)     | (39)     |
| Lymphoma malignant                               |          |          | 1 (3%)   | 1 (3%)   |
| Sarcoma, metastatic, skin                        |          |          |          | 1 (3%)   |
| Intestine large, cecum                           | (46)     | (40)     | (42)     | (43)     |
| Lymphoma malignant                               |          |          | 1 (2%)   |          |
| Intestine small, duodenum                        | (43)     | (42)     | (40)     | (42)     |
| Lymphoma malignant                               |          |          | 2 (5%)   |          |
| Polyp adenomatous                                |          |          |          | 1 (2%)   |
| Intestine small, ileum                           | (42)     | (42)     | (41)     | (41)     |
| Histiocytic sarcoma                              |          |          | 1 (2%)   |          |
| Lymphoma malignant                               |          | 1 (2%)   | 2 (5%)   | 1 (2%)   |
| Intestine small, jejunum                         | (42)     | (41)     | (41)     | (37)     |
| Histiocytic sarcoma                              |          | 1 (2%)   |          |          |
| Lymphoma malignant                               |          | 1 (2%)   | 1 (2%)   | 1 (3%)   |
| Liver  | (47)     | (48)     | (46)     | (48)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          |          |          | 1 (2%)   |
| Hemangiosarcoma                                  | 3 (6%)   | 4 (8%)   | 3 (7%)   | 11 (23%) |
| Hepatocellular adenoma                           | 10 (21%) | 13 (27%) | 12 (26%) | 13 (27%) |
| Hepatocellular adenoma, multiple                 | 2 (4%)   | 2 (4%)   | 4 (9%)   | 11 (23%) |
| Hepatocellular carcinoma                         | 5 (11%)  | 3 (6%)   | 5 (11%)  | 4 (8%)   |
| Hepatocellular carcinoma, multiple               | 1 (2%)   | 2 (4%)   |          |          |
| Histiocytic sarcoma                              | 1 (2%)   | 4 (8%)   | 3 (7%)   | 6 (13%)  |
| Lymphoma malignant                               | 1 (2%)   | 2 (4%)   | 2 (4%)   | 3 (6%)   |
| Mesothelioma malignant, metastatic, pancreas     | 1 (2%)   |          |          |          |
| Sarcoma, metastatic, skin                        | 1 (2%)   |          |          | 3 (6%)   |
| Mesentery  |          | (3)      | (2)      | (3)      |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          | 1 (33%)  |          |          |
| Histiocytic sarcoma                              |          |          | 1 (50%)  | 1 (33%)  |
| Lymphoma malignant                               |          |          |          | 1 (33%)  |
| Mesothelioma NOS                                 |          | 1 (33%)  |          |          |
| Sarcoma  |          |          | 1 (50%)  |          |
| Pancreas   | (47)     | (45)     | (46)     | (46)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          | 1 (2%)   |          |          |
| Hemangiosarcoma                                  |          | 1 (2%)   |          |          |
| Histiocytic sarcoma                              |          |          |          | 1 (2%)   |
| Lymphoma malignant                               | 1 (2%)   |          | 1 (2%)   | 2 (4%)   |
| Mesothelioma malignant                           | 1 (2%)   |          |          |          |
| Mesothelioma NOS, metastatic, mesentery          |          | 1 (2%)   |          |          |
| Sarcoma, metastatic, skin                        |          |          |          | 1 (2%)   |
| Salivary glands                                  | (48)     | (48)     | (46)     | (48)     |
| Lymphoma malignant                               | 1 (2%)   |          | 2 (4%)   | 2 (4%)   |
| Sarcoma, metastatic, skin                        | 1 (2%)   |          |          |          |

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm | 30 ppm | 90 ppm |
|--|----------|--------|--------|--------|
| <b>Alimentary System</b> (continued)             |          |        |        |        |
| Stomach, forestomach                             | (47)     | (47)   | (46)   | (46)   |
| Lymphoma malignant                               | 1 (2%)   |        |        | 1 (2%) |
| Sarcoma, metastatic, skin                        |          |        |        | 1 (2%) |
| Squamous cell carcinoma                          | 1 (2%)   |        |        | 2 (4%) |
| Squamous cell papilloma                          |          | 4 (9%) | 1 (2%) | 2 (4%) |
| Stomach, glandular                               | (47)     | (45)   | (45)   | (46)   |
| Adenoma  |          |        |        | 1 (2%) |
| Lymphoma malignant                               | 1 (2%)   |        |        | 1 (2%) |
| Tongue   | (47)     | (48)   | (46)   | (48)   |
| Lymphoma malignant                               |          |        |        | 1 (2%) |
| <b>Cardiovascular System</b>                     |          |        |        |        |
| Heart  | (48)     | (48)   | (47)   | (48)   |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          | 1 (2%) |        | 1 (2%) |
| Hemangiosarcoma                                  |          |        | 2 (4%) | 4 (8%) |
| Lymphoma malignant                               |          |        |        | 1 (2%) |
| Mesothelioma NOS, metastatic, mesentery          |          | 1 (2%) |        |        |
| Sarcoma, metastatic, skin                        |          |        |        | 1 (2%) |
| <b>Endocrine System</b>                          |          |        |        |        |
| Adrenal gland, cortex                            | (46)     | (45)   | (46)   | (46)   |
| Adenoma  | 2 (4%)   | 1 (2%) |        |        |
| Adenoma, subcapsular                             | 1 (2%)   |        | 1 (2%) |        |
| Histiocytic sarcoma                              |          |        | 1 (2%) |        |
| Lymphoma malignant                               |          |        |        | 1 (2%) |
| Mesothelioma malignant, metastatic, pancreas     | 1 (2%)   |        |        |        |
| Sarcoma, metastatic, skin                        |          |        |        | 1 (2%) |
| Adrenal gland, medulla                           | (44)     | (42)   | (45)   | (46)   |
| Histiocytic sarcoma                              |          |        | 1 (2%) |        |
| Pheochromocytoma benign                          | 2 (5%)   | 2 (5%) | 2 (4%) | 3 (7%) |
| Pheochromocytoma benign, bilateral               |          |        |        | 1 (2%) |
| Sarcoma, metastatic, skin                        |          |        |        | 1 (2%) |
| Islets, pancreatic                               | (47)     | (45)   | (46)   | (46)   |
| Adenoma  |          |        |        | 2 (4%) |
| Lymphoma malignant                               |          |        |        | 1 (2%) |
| Pituitary gland                                  | (46)     | (42)   | (41)   | (42)   |
| Adenoma, pars distalis                           | 1 (2%)   |        |        |        |
| Thyroid gland                                    | (46)     | (48)   | (46)   | (47)   |
| Adenoma, follicular cell                         | 1 (2%)   | 2 (4%) | 1 (2%) | 2 (4%) |
| Lymphoma malignant                               |          |        |        | 1 (2%) |
| <b>General Body System</b>                       |          |        |        |        |
| Tissue NOS                                       | (1)      |        |        |        |
| Mesothelioma malignant, metastatic, pancreas     | 1 (100%) |        |        |        |

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm  | 10 ppm | 30 ppm | 90 ppm |
|---|--------|--------|--------|--------|
| <b>Genital System</b>                               |        |        |        |        |
| Coagulating gland                                   | (46)   | (48)   | (45)   | (46)   |
| Lymphoma malignant                                  |        |        | 1 (2%) | 2 (4%) |
| Mesothelioma NOS, metastatic, mesentery             |        | 1 (2%) |        |        |
| Epididymis  | (48)   | (48)   | (46)   | (48)   |
| Hemangioma  |        |        | 1 (2%) | 1 (2%) |
| Histiocytic sarcoma                                 |        |        | 1 (2%) | 1 (2%) |
| Lymphoma malignant                                  |        |        | 1 (2%) | 3 (6%) |
| Mesothelioma malignant                              |        |        | 1 (2%) |        |
| Mesothelioma malignant, metastatic, pancreas        | 1 (2%) |        |        |        |
| Mesothelioma NOS, metastatic, mesentery             |        | 1 (2%) |        |        |
| Preputial gland                                     | (46)   | (45)   | (45)   | (46)   |
| Adenoma   |        | 1 (2%) |        |        |
| Hemangioma  |        |        | 1 (2%) | 3 (7%) |
| Hemangiosarcoma                                     |        |        | 1 (2%) | 1 (2%) |
| Lymphoma malignant                                  |        |        | 1 (2%) | 1 (2%) |
| Sarcoma, metastatic, skin                           | 1 (2%) |        |        |        |
| Prostate  | (46)   | (47)   | (43)   | (48)   |
| Histiocytic sarcoma                                 |        |        |        | 1 (2%) |
| Lymphoma malignant                                  |        | 2 (4%) | 1 (2%) | 2 (4%) |
| Seminal vesicle                                     | (47)   | (48)   | (46)   | (47)   |
| Hemangiosarcoma                                     |        |        |        | 1 (2%) |
| Histiocytic sarcoma                                 |        |        |        | 1 (2%) |
| Lymphoma malignant                                  |        |        | 2 (4%) | 2 (4%) |
| Mesothelioma NOS, metastatic, mesentery             |        | 1 (2%) |        |        |
| Sarcoma, metastatic, mesentery                      |        |        | 1 (2%) |        |
| Testes  | (48)   | (48)   | (47)   | (47)   |
| Histiocytic sarcoma                                 |        |        |        | 1 (2%) |
| Lipoma, bilateral                                   |        |        | 1 (2%) |        |
| <b>Hematopoietic System</b>                         |        |        |        |        |
| Bone marrow   | (48)   | (48)   | (47)   | (46)   |
| Histiocytic sarcoma                                 |        | 1 (2%) | 2 (4%) |        |
| Lymphoma malignant                                  |        |        | 1 (2%) | 2 (4%) |
| Lymph node  | (48)   | (48)   | (47)   | (47)   |
| Hemangiosarcoma, inguinal                           |        |        |        | 1 (2%) |
| Lymphoma malignant, axillary                        |        |        | 1 (2%) |        |
| Lymphoma malignant, inguinal                        |        |        | 2 (4%) | 2 (4%) |
| Lymphoma malignant, lumbar                          | 1 (2%) |        | 1 (2%) | 1 (2%) |
| Lymphoma malignant, renal                           | 1 (2%) | 2 (4%) | 2 (4%) | 3 (6%) |
| Lymphoma malignant, thoracic                        |        | 1 (2%) |        |        |
| Mesothelioma malignant, metastatic, renal, pancreas | 1 (2%) |        |        |        |
| Sarcoma, metastatic, axillary, skin                 |        |        |        | 1 (2%) |
| Sarcoma, metastatic, mediastinal, skin              |        | 1 (2%) |        |        |
| Squamous cell carcinoma, metastatic, skin           |        |        | 1 (2%) |        |
| Lymph node, mandibular                              | (48)   | (48)   | (45)   | (47)   |
| Carcinoma, metastatic, harderian gland              |        |        |        | 1 (2%) |
| Hemangiosarcoma                                     |        |        |        | 1 (2%) |
| Histiocytic sarcoma                                 |        | 2 (4%) | 1 (2%) | 2 (4%) |
| Lymphoma malignant                                  | 2 (4%) | 2 (4%) | 4 (9%) | 3 (6%) |
| Sarcoma, metastatic, skin                           | 1 (2%) |        |        |        |

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm  | 30 ppm  | 90 ppm  |
|---|----------|---------|---------|---------|
| <b>Hematopoietic System (continued)</b>                     |          |         |         |         |
| Lymph node, mesenteric                                      | (48)     | (48)    | (45)    | (44)    |
| Carcinoma, metastatic, harderian gland                      |          |         |         | 1 (2%)  |
| Hemangiosarcoma   |          |         |         | 3 (7%)  |
| Histiocytic sarcoma   |          | 4 (8%)  | 4 (9%)  | 4 (9%)  |
| Lymphoma malignant  | 9 (19%)  | 4 (8%)  | 6 (13%) | 6 (14%) |
| Mesothelioma malignant, metastatic, pancreas                | 1 (2%)   |         |         |         |
| Mesothelioma NOS, metastatic, mesentery                     |          | 1 (2%)  |         |         |
| Sarcoma, metastatic, skin                                   |          |         |         | 1 (2%)  |
| Spleen  | (46)     | (46)    | (46)    | (46)    |
| Hemangioma  |          |         | 1 (2%)  |         |
| Hemangiosarcoma   |          |         | 1 (2%)  | 3 (7%)  |
| Histiocytic sarcoma   |          | 3 (7%)  | 2 (4%)  | 3 (7%)  |
| Lymphoma malignant  | 7 (15%)  | 4 (9%)  | 5 (11%) | 5 (11%) |
| Mesothelioma malignant, metastatic, pancreas                | 1 (2%)   |         |         |         |
| Thymus  | (35)     | (32)    | (28)    | (32)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung            |          | 1 (3%)  |         | 2 (6%)  |
| Lymphoma malignant  | 1 (3%)   | 1 (3%)  | 3 (11%) | 3 (9%)  |
| Sarcoma, metastatic, skin                                   |          |         |         | 1 (3%)  |
| <b>Integumentary System</b>                                 |          |         |         |         |
| Skin  | (48)     | (48)    | (46)    | (47)    |
| Basal cell adenoma  |          | 1 (2%)  |         |         |
| Fibroma   | 2 (4%)   | 3 (6%)  |         |         |
| Fibroma, multiple   |          |         | 1 (2%)  |         |
| Fibroma, prepuce  |          | 1 (2%)  |         |         |
| Fibroma, tail   |          | 1 (2%)  |         |         |
| Hemangiosarcoma   |          |         | 4 (9%)  | 1 (2%)  |
| Lymphoma malignant  | 1 (2%)   |         |         | 1 (2%)  |
| Rhabdomyosarcoma, metastatic, skeletal muscle               | 1 (2%)   |         |         |         |
| Sarcoma   | 16 (33%) | 9 (19%) | 9 (20%) | 7 (15%) |
| Sarcoma, multiple   |          | 1 (2%)  | 1 (2%)  | 1 (2%)  |
| Squamous cell carcinoma                                     |          | 1 (2%)  | 2 (4%)  | 4 (9%)  |
| Squamous cell papilloma                                     |          |         | 2 (4%)  | 3 (6%)  |
| <b>Musculoskeletal System</b>                               |          |         |         |         |
| Bone  | (48)     | (48)    | (47)    | (48)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung            |          |         |         | 1 (2%)  |
| Alveolar/bronchiolar carcinoma, metastatic, vertebra, lung  |          |         |         | 1 (2%)  |
| Skeletal muscle   | (48)     | (48)    | (47)    | (48)    |
| Alveolar/bronchiolar carcinoma, metastatic                  |          |         |         | 1 (2%)  |
| Alveolar/bronchiolar carcinoma, metastatic, diaphragm, lung |          |         |         | 1 (2%)  |
| Alveolar/bronchiolar carcinoma, metastatic, lung            |          | 1 (2%)  |         |         |
| Fibrosarcoma  | 1 (2%)   |         |         |         |
| Histiocytic sarcoma   |          |         |         | 1 (2%)  |
| Lymphoma malignant  |          |         | 1 (2%)  |         |
| Rhabdomyosarcoma  | 1 (2%)   |         |         |         |
| Sarcoma, metastatic, skin                                   | 1 (2%)   |         |         | 1 (2%)  |

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|--|---------|----------|----------|----------|
| <b>Nervous System</b>                            |         |          |          |          |
| Brain, cerebellum                                | (47)    | (48)     | (47)     | (48)     |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| Brain, cerebrum                                  | (48)    | (48)     | (47)     | (48)     |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| Oligodendroglioma malignant                      |         | 1 (2%)   |          |          |
| Spinal cord, thoracic                            | (48)    | (48)     | (47)     | (48)     |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| <b>Respiratory System</b>                        |         |          |          |          |
| Larynx   | (44)    | (47)     | (46)     | (47)     |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| Lung   | (48)    | (48)     | (47)     | (48)     |
| Alveolar/bronchiolar adenoma                     | 9 (19%) | 14 (29%) | 11 (23%) | 11 (23%) |
| Alveolar/bronchiolar adenoma, multiple           | 1 (2%)  | 2 (4%)   | 8 (17%)  | 24 (50%) |
| Alveolar/bronchiolar carcinoma                   | 2 (4%)  | 3 (6%)   | 7 (15%)  | 20 (42%) |
| Alveolar/bronchiolar carcinoma, multiple         |         |          | 1 (2%)   | 4 (8%)   |
| Carcinoma, metastatic, harderian gland           |         |          |          | 1 (2%)   |
| Hepatocellular carcinoma, metastatic, liver      | 2 (4%)  | 1 (2%)   | 2 (4%)   | 3 (6%)   |
| Histiocytic sarcoma                              |         | 2 (4%)   | 3 (6%)   | 4 (8%)   |
| Lymphoma malignant                               | 1 (2%)  |          | 2 (4%)   | 2 (4%)   |
| Mesothelioma malignant, metastatic, pancreas     | 1 (2%)  |          |          |          |
| Mesothelioma NOS, metastatic, mesentery          |         | 1 (2%)   |          |          |
| Sarcoma, metastatic, skin                        | 1 (2%)  |          |          | 3 (6%)   |
| Nose   | (48)    | (48)     | (47)     | (48)     |
| Lymphoma malignant                               |         |          | 1 (2%)   | 1 (2%)   |
| <b>Special Senses System</b>                     |         |          |          |          |
| Eye  | (47)    | (47)     | (47)     | (46)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |         | 1 (2%)   |          |          |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| Harderian gland                                  | (48)    | (48)     | (47)     | (48)     |
| Adenoma  | 6 (13%) | 13 (27%) | 17 (36%) | 19 (40%) |
| Adenoma, bilateral                               |         | 1 (2%)   | 4 (9%)   | 8 (17%)  |
| Carcinoma  |         |          | 1 (2%)   | 13 (27%) |
| Carcinoma, bilateral                             |         |          |          | 3 (6%)   |
| Lymphoma malignant                               |         |          | 1 (2%)   | 1 (2%)   |
| Lacrimal gland                                   | (48)    | (47)     | (45)     | (46)     |
| Lymphoma malignant                               | 1 (2%)  |          | 1 (2%)   | 1 (2%)   |
| Zymbal's gland                                   | (47)    | (45)     | (46)     | (43)     |
| Lymphoma malignant                               |         |          |          | 1 (2%)   |
| Sarcoma, metastatic, skin                        |         |          | 1 (2%)   |          |
| <b>Urinary System</b>                            |         |          |          |          |
| Kidney   | (48)    | (48)     | (47)     | (47)     |
| Adenoma, multiple, renal tubule                  |         |          |          | 1 (2%)   |
| Alveolar/bronchiolar carcinoma, metastatic, lung |         | 1 (2%)   |          |          |
| Hemangiosarcoma                                  |         |          |          | 2 (4%)   |
| Histiocytic sarcoma                              |         | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Lymphoma malignant                               | 1 (2%)  | 1 (2%)   | 2 (4%)   | 3 (6%)   |
| Mesothelioma malignant, metastatic, pancreas     | 1 (2%)  |          |          |          |
| Sarcoma, metastatic, skin                        |         |          |          | 1 (2%)   |

**TABLE B1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|--|-------|--------|--------|--------|
| <b>Urinary System</b> (continued)                              |       |        |        |        |
| Urinary bladder  | (47)  | (46)   | (45)   | (46)   |
| Histiocytic sarcoma  |       | 1 (2%) |        |        |
| Lymphoma malignant   |       |        | 1 (2%) | 1 (2%) |
| <b>Neoplasm Summary</b>  |       |        |        |        |
| Total animals with primary neoplasms <sup>b</sup>              | 41    | 45     | 42     | 47     |
| Total primary neoplasms  | 99    | 127    | 181    | 289    |
| Total animals with benign neoplasms                            | 27    | 33     | 37     | 46     |
| Total benign neoplasms   | 37    | 61     | 68     | 106    |
| Total animals with malignant neoplasms                         | 31    | 32     | 33     | 45     |
| Total malignant neoplasms                                      | 62    | 65     | 113    | 183    |
| Total animals with metastatic neoplasms                        | 10    | 4      | 5      | 11     |
| Total metastatic neoplasms                                     | 18    | 16     | 5      | 30     |
| Total animals with uncertain neoplasms-<br>benign or malignant |       | 1      |        |        |
| Total uncertain neoplasms                                      |       | 1      |        |        |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|---|----------------|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>                  |                |                 |                 |                 |
| Overall rate <sup>a</sup>                       | 3/46 (6.5%)    | 1/45 (2.2%)     | 1/46 (2.2%)     | 0/46 (0.0%)     |
| Adjusted rate <sup>b</sup>                      | 3/38.9 (7.7%)  | 1/38.5 (2.6%)   | 1/35.0 (2.9%)   | 0/34.5 (0.0%)   |
| Terminal rate <sup>c</sup>                      | 3/31 (9.7%)    | 1/28 (3.6%)     | 1/25 (4.0%)     | 0/16 (0.0%)     |
| First incidence (days)                          | 765 (T)        | 765 (T)         | 765 (T)         | — <sup>e</sup>  |
| Poly-3 test <sup>d</sup>                        | P=0.130N       | P=0.308N        | P=0.344N        | P=0.141N        |
| <b>Adrenal Cortex: Adenoma or Carcinoma</b>     |                |                 |                 |                 |
| Overall rate                                    | 3/46 (6.5%)    | 1/45 (2.2%)     | 1/46 (2.2%)     | 0/46 (0.0%)     |
| Adjusted rate                                   | 3/38.9 (7.7%)  | 1/38.5 (2.6%)   | 1/35.0 (2.9%)   | 0/34.5 (0.0%)   |
| Terminal rate                                   | 3/31 (9.7%)    | 1/28 (3.6%)     | 1/25 (4.0%)     | 0/16 (0.0%)     |
| First incidence (days)                          | 765 (T)        | 765 (T)         | 765 (T)         | —               |
| Poly-3 test                                     | P=0.130N       | P=0.308N        | P=0.344N        | P=0.141N        |
| <b>Adrenal Medulla: Benign Pheochromocytoma</b> |                |                 |                 |                 |
| Overall rate                                    | 2/44 (4.5%)    | 2/42 (4.8%)     | 2/45 (4.4%)     | 4/46 (8.7%)     |
| Adjusted rate                                   | 2/36.9 (5.4%)  | 2/35.5 (5.6%)   | 2/34.1 (5.9%)   | 4/35.2 (11.4%)  |
| Terminal rate                                   | 2/29 (6.9%)    | 2/25 (8.0%)     | 1/24 (4.2%)     | 2/16 (12.5%)    |
| First incidence (days)                          | 765 (T)        | 765 (T)         | 734             | 524             |
| Poly-3 test                                     | P=0.204        | P=0.681         | P=0.666         | P=0.314         |
| <b>Harderian Gland: Adenoma</b>                 |                |                 |                 |                 |
| Overall rate                                    | 6/48 (12.5%)   | 14/48 (29.2%)   | 21/47 (44.7%)   | 27/48 (56.3%)   |
| Adjusted rate                                   | 6/41.1 (14.6%) | 14/41.4 (33.8%) | 21/37.2 (56.4%) | 27/41.2 (65.6%) |
| Terminal rate                                   | 4/32 (12.5%)   | 12/30 (40.0%)   | 17/25 (68.0%)   | 10/16 (62.5%)   |
| First incidence (days)                          | 582            | 628             | 426             | 395             |
| Poly-3 test                                     | P=0.001        | P=0.034         | P=0.001         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>               |                |                 |                 |                 |
| Overall rate                                    | 0/48 (0.0%)    | 0/48 (0.0%)     | 1/47 (2.1%)     | 16/48 (33.3%)   |
| Adjusted rate                                   | 0/40.1 (0.0%)  | 0/40.7 (0.0%)   | 1/35.5 (2.8%)   | 16/41.6 (38.4%) |
| Terminal rate                                   | 0/32 (0.0%)    | 0/30 (0.0%)     | 1/25 (4.0%)     | 2/16 (12.5%)    |
| First incidence (days)                          | —              | — <sup>f</sup>  | 765 (T)         | 395             |
| Poly-3 test                                     | P=0.001        | —               | P=0.476         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>    |                |                 |                 |                 |
| Overall rate                                    | 6/48 (12.5%)   | 14/48 (29.2%)   | 21/47 (44.7%)   | 38/48 (79.2%)   |
| Adjusted rate                                   | 6/41.1 (14.6%) | 14/41.4 (33.8%) | 21/37.2 (56.4%) | 38/45.2 (84.1%) |
| Terminal rate                                   | 4/32 (12.5%)   | 12/30 (40.0%)   | 17/25 (68.0%)   | 12/16 (75.0%)   |
| First incidence (days)                          | 582            | 628             | 426             | 395             |
| Poly-3 test                                     | P=0.001        | P=0.034         | P=0.001         | P=0.001         |
| <b>Heart: Hemangiosarcoma</b>                   |                |                 |                 |                 |
| Overall rate                                    | 0/48 (0.0%)    | 0/48 (0.0%)     | 2/47 (4.3%)     | 4/48 (8.3%)     |
| Adjusted rate                                   | 0/40.1 (0.0%)  | 0/40.7 (0.0%)   | 2/35.6 (5.6%)   | 4/37.0 (10.8%)  |
| Terminal rate                                   | 0/32 (0.0%)    | 0/30 (0.0%)     | 1/25 (4.0%)     | 1/16 (6.3%)     |
| First incidence (days)                          | —              | —               | 743             | 552             |
| Poly-3 test                                     | P=0.007        | —               | P=0.211         | P=0.049         |
| <b>Liver: Hemangiosarcoma</b>                   |                |                 |                 |                 |
| Overall rate                                    | 3/47 (6.4%)    | 4/48 (8.3%)     | 3/46 (6.5%)     | 11/48 (22.9%)   |
| Adjusted rate                                   | 3/40.0 (7.5%)  | 4/41.0 (9.8%)   | 3/35.2 (8.5%)   | 11/38.3 (28.7%) |
| Terminal rate                                   | 2/32 (6.3%)    | 3/30 (10.0%)    | 2/25 (8.0%)     | 4/16 (25.0%)    |
| First incidence (days)                          | 719            | 681             | 684             | 488             |
| Poly-3 test                                     | P=0.002        | P=0.514         | P=0.604         | P=0.013         |

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>Liver: Histiocytic Sarcoma</b>                      |                 |                 |                 |                 |
| Overall rate   | 1/47 (2.1%)     | 4/48 (8.3%)     | 3/46 (6.5%)     | 6/48 (12.5%)    |
| Adjusted rate  | 1/39.8 (2.5%)   | 4/41.4 (9.7%)   | 3/36.2 (8.3%)   | 6/37.1 (16.2%)  |
| Terminal rate  | 1/32 (3.1%)     | 1/30 (3.3%)     | 0/25 (0.0%)     | 2/16 (12.5%)    |
| First incidence (days)                                 | 765 (T)         | 638             | 514             | 536             |
| Poly-3 test  | P=0.053         | P=0.190         | P=0.271         | P=0.044         |
| <b>Liver: Hepatocellular Adenoma</b>                   |                 |                 |                 |                 |
| Overall rate   | 12/47 (25.5%)   | 15/48 (31.3%)   | 16/46 (34.8%)   | 24/48 (50.0%)   |
| Adjusted rate  | 12/41.1 (29.2%) | 15/41.6 (36.1%) | 16/36.3 (44.0%) | 24/38.8 (61.9%) |
| Terminal rate  | 9/32 (28.1%)    | 13/30 (43.3%)   | 10/25 (40.0%)   | 13/16 (81.3%)   |
| First incidence (days)                                 | 582             | 620             | 528             | 395             |
| Poly-3 test  | P=0.001         | P=0.332         | P=0.129         | P=0.002         |
| <b>Liver: Hepatocellular Carcinoma</b>                 |                 |                 |                 |                 |
| Overall rate   | 6/47 (12.8%)    | 5/48 (10.4%)    | 5/46 (10.9%)    | 4/48 (8.3%)     |
| Adjusted rate  | 6/40.9 (14.7%)  | 5/41.4 (12.1%)  | 5/35.4 (14.1%)  | 4/35.6 (11.2%)  |
| Terminal rate  | 3/32 (9.4%)     | 4/30 (13.3%)    | 2/25 (8.0%)     | 4/16 (25.0%)    |
| First incidence (days)                                 | 607             | 523             | 711             | 765 (T)         |
| Poly-3 test  | P=0.443N        | P=0.492N        | P=0.603N        | P=0.460N        |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                 |                 |                 |                 |
| Overall rate   | 16/47 (34.0%)   | 19/48 (39.6%)   | 17/46 (37.0%)   | 24/48 (50.0%)   |
| Adjusted rate  | 16/41.9 (38.2%) | 19/42.2 (45.0%) | 17/36.3 (46.8%) | 24/38.8 (61.9%) |
| Terminal rate  | 11/32 (34.4%)   | 16/30 (53.3%)   | 11/25 (44.0%)   | 13/16 (81.3%)   |
| First incidence (days)                                 | 582             | 523             | 528             | 395             |
| Poly-3 test  | P=0.019         | P=0.339         | P=0.294         | P=0.023         |
| <b>Lung: Histiocytic Sarcoma</b>                       |                 |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)     | 2/48 (4.2%)     | 3/47 (6.4%)     | 4/48 (8.3%)     |
| Adjusted rate  | 0/40.1 (0.0%)   | 2/41.0 (4.9%)   | 3/36.8 (8.2%)   | 4/37.1 (10.8%)  |
| Terminal rate  | 0/32 (0.0%)     | 0/30 (0.0%)     | 0/25 (0.0%)     | 0/16 (0.0%)     |
| First incidence (days)                                 | —               | 713             | 514             | 536             |
| Poly-3 test  | P=0.057         | P=0.242         | P=0.103         | P=0.050         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |                 |
| Overall rate   | 10/48 (20.8%)   | 16/48 (33.3%)   | 19/47 (40.4%)   | 35/48 (72.9%)   |
| Adjusted rate  | 10/40.8 (24.5%) | 16/41.4 (38.6%) | 19/36.7 (51.8%) | 35/43.3 (80.9%) |
| Terminal rate  | 8/32 (25.0%)    | 13/30 (43.3%)   | 15/25 (60.0%)   | 14/16 (87.5%)   |
| First incidence (days)                                 | 614             | 617             | 593             | 395             |
| Poly-3 test  | P=0.001         | P=0.124         | P=0.010         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)     | 3/48 (6.3%)     | 8/47 (17.0%)    | 24/48 (50.0%)   |
| Adjusted rate  | 2/40.1 (5.0%)   | 3/41.3 (7.3%)   | 8/36.4 (22.0%)  | 24/39.6 (60.7%) |
| Terminal rate  | 2/32 (6.3%)     | 1/30 (3.3%)     | 5/25 (20.0%)    | 9/16 (56.3%)    |
| First incidence (days)                                 | 765 (T)         | 620             | 640             | 569             |
| Poly-3 test  | P=0.001         | P=0.513         | P=0.029         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |                 |
| Overall rate   | 11/48 (22.9%)   | 19/48 (39.6%)   | 24/47 (51.1%)   | 43/48 (89.6%)   |
| Adjusted rate  | 11/40.8 (27.0%) | 19/42.0 (45.3%) | 24/37.3 (64.4%) | 43/45.1 (95.3%) |
| Terminal rate  | 9/32 (28.1%)    | 14/30 (46.7%)   | 18/25 (72.0%)   | 15/16 (93.8%)   |
| First incidence (days)                                 | 614             | 617             | 593             | 395             |
| Poly-3 test  | P=0.001         | P=0.062         | P=0.001         | P=0.001         |

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm         |
|---|-----------------|-----------------|-----------------|----------------|
| <b>Lymph Node (Mesenteric): Hemangiosarcoma</b>                 |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 0/48 (0.0%)     | 0/45 (0.0%)     | 3/44 (6.8%)    |
| Adjusted rate   | 0/40.1 (0.0%)   | 0/40.7 (0.0%)   | 0/34.8 (0.0%)   | 3/33.2 (9.0%)  |
| Terminal rate   | 0/32 (0.0%)     | 0/30 (0.0%)     | 0/25 (0.0%)     | 1/15 (6.7%)    |
| First incidence (days)  | —               | —               | —               | 569            |
| Poly-3 test   | P=0.005         | —               | —               | P=0.086        |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>             |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 4/48 (8.3%)     | 4/45 (8.9%)     | 4/44 (9.1%)    |
| Adjusted rate   | 0/40.1 (0.0%)   | 4/41.4 (9.7%)   | 4/36.3 (11.0%)  | 4/33.7 (11.9%) |
| Terminal rate   | 0/32 (0.0%)     | 1/30 (3.3%)     | 0/25 (0.0%)     | 1/15 (6.7%)    |
| First incidence (days)  | —               | 638             | 514             | 536            |
| Poly-3 test   | P=0.121         | P=0.064         | P=0.047         | P=0.040        |
| <b>Skin: Sarcoma</b>  |                 |                 |                 |                |
| Overall rate  | 16/48 (33.3%)   | 10/48 (20.8%)   | 10/46 (21.7%)   | 8/47 (17.0%)   |
| Adjusted rate   | 16/43.1 (37.1%) | 10/42.3 (23.6%) | 10/37.7 (26.5%) | 8/36.8 (21.7%) |
| Terminal rate   | 9/32 (28.1%)    | 5/30 (16.7%)    | 5/24 (20.8%)    | 2/16 (12.5%)   |
| First incidence (days)  | 582             | 617             | 362             | 395            |
| Poly-3 test   | P=0.159N        | P=0.129N        | P=0.218N        | P=0.102N       |
| <b>Skin: Fibroma or Sarcoma</b>                                 |                 |                 |                 |                |
| Overall rate  | 18/48 (37.5%)   | 13/48 (27.1%)   | 11/46 (23.9%)   | 8/47 (17.0%)   |
| Adjusted rate   | 18/43.1 (41.8%) | 13/42.3 (30.7%) | 11/37.7 (29.2%) | 8/36.8 (21.7%) |
| Terminal rate   | 11/32 (34.4%)   | 8/30 (26.7%)    | 6/24 (25.0%)    | 2/16 (12.5%)   |
| First incidence (days)  | 582             | 617             | 362             | 395            |
| Poly-3 test   | P=0.058N        | P=0.200N        | P=0.172N        | P=0.044N       |
| <b>Skin: Hemangiosarcoma</b>                                    |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 0/48 (0.0%)     | 4/46 (8.7%)     | 1/47 (2.1%)    |
| Adjusted rate   | 0/40.1 (0.0%)   | 0/40.7 (0.0%)   | 4/34.9 (11.5%)  | 1/34.9 (2.9%)  |
| Terminal rate   | 0/32 (0.0%)     | 0/30 (0.0%)     | 2/24 (8.3%)     | 1/16 (6.3%)    |
| First incidence (days)  | —               | —               | 710             | 765 (T)        |
| Poly-3 test   | P=0.324         | —               | P=0.043         | P=0.473        |
| <b>Skin: Squamous Cell Papilloma</b>                            |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 0/48 (0.0%)     | 2/46 (4.3%)     | 3/47 (6.4%)    |
| Adjusted rate   | 0/40.1 (0.0%)   | 0/40.7 (0.0%)   | 2/34.5 (5.8%)   | 3/35.7 (8.4%)  |
| Terminal rate   | 0/32 (0.0%)     | 0/30 (0.0%)     | 2/24 (8.3%)     | 2/16 (12.5%)   |
| First incidence (days)  | —               | —               | 765 (T)         | 453            |
| Poly-3 test   | P=0.026         | —               | P=0.205         | P=0.098        |
| <b>Skin: Squamous Cell Carcinoma</b>                            |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 1/48 (2.1%)     | 2/46 (4.3%)     | 4/47 (8.5%)    |
| Adjusted rate   | 0/40.1 (0.0%)   | 1/40.7 (2.5%)   | 2/35.0 (5.7%)   | 4/36.8 (10.9%) |
| Terminal rate   | 0/32 (0.0%)     | 1/30 (3.3%)     | 1/24 (4.2%)     | 0/16 (0.0%)    |
| First incidence (days)  | —               | 765 (T)         | 642             | 524            |
| Poly-3 test   | P=0.021         | P=0.503         | P=0.207         | P=0.049        |
| <b>Skin: Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                 |                 |                 |                |
| Overall rate  | 0/48 (0.0%)     | 1/48 (2.1%)     | 4/46 (8.7%)     | 7/47 (14.9%)   |
| Adjusted rate   | 0/40.1 (0.0%)   | 1/40.7 (2.5%)   | 4/35.0 (11.4%)  | 7/37.6 (18.6%) |
| Terminal rate   | 0/32 (0.0%)     | 1/30 (3.3%)     | 3/24 (12.5%)    | 2/16 (12.5%)   |
| First incidence (days)  | —               | 765 (T)         | 642             | 453            |
| Poly-3 test   | P=0.001         | P=0.503         | P=0.043         | P=0.005        |

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm         | 10 ppm        | 30 ppm         | 90 ppm         |
|--|---------------|---------------|----------------|----------------|
| <b>Skin: Basal Cell Adenoma, Squamous Cell Papilloma, or Squamous Cell Carcinoma</b> |               |               |                |                |
| Overall rate   | 0/48 (0.0%)   | 2/48 (4.2%)   | 4/46 (8.7%)    | 7/47 (14.9%)   |
| Adjusted rate  | 0/40.1 (0.0%) | 2/40.7 (4.9%) | 4/35.0 (11.4%) | 7/37.6 (18.6%) |
| Terminal rate  | 0/32 (0.0%)   | 2/30 (6.7%)   | 3/24 (12.5%)   | 2/16 (12.5%)   |
| First incidence (days)   | —             | 765 (T)       | 642            | 453            |
| Poly-3 test  | P=0.003       | P=0.240       | P=0.043        | P=0.005        |
| <b>Spleen: Hemangiosarcoma</b>   |               |               |                |                |
| Overall rate   | 0/46 (0.0%)   | 0/46 (0.0%)   | 1/46 (2.2%)    | 3/46 (6.5%)    |
| Adjusted rate  | 0/39.2 (0.0%) | 0/40.4 (0.0%) | 1/35.1 (2.9%)  | 3/35.2 (8.5%)  |
| Terminal rate  | 0/32 (0.0%)   | 0/30 (0.0%)   | 0/25 (0.0%)    | 1/16 (6.3%)    |
| First incidence (days)   | —             | —             | 733            | 552            |
| Poly-3 test  | P=0.015       | —             | P=0.478        | P=0.099        |
| <b>Spleen: Hemangioma or Hemangiosarcoma</b>   |               |               |                |                |
| Overall rate   | 0/46 (0.0%)   | 0/46 (0.0%)   | 2/46 (4.3%)    | 3/46 (6.5%)    |
| Adjusted rate  | 0/39.2 (0.0%) | 0/40.4 (0.0%) | 2/35.1 (5.7%)  | 3/35.2 (8.5%)  |
| Terminal rate  | 0/32 (0.0%)   | 0/30 (0.0%)   | 1/25 (4.0%)    | 1/16 (6.3%)    |
| First incidence (days)   | —             | —             | 733            | 552            |
| Poly-3 test  | P=0.026       | —             | P=0.213        | P=0.099        |
| <b>Spleen: Histiocytic Sarcoma</b>   |               |               |                |                |
| Overall rate   | 0/46 (0.0%)   | 3/46 (6.5%)   | 2/46 (4.3%)    | 3/46 (6.5%)    |
| Adjusted rate  | 0/39.2 (0.0%) | 3/40.9 (7.3%) | 2/36.0 (5.6%)  | 3/35.6 (8.4%)  |
| Terminal rate  | 0/32 (0.0%)   | 1/30 (3.3%)   | 0/25 (0.0%)    | 0/16 (0.0%)    |
| First incidence (days)   | —             | 638           | 514            | 536            |
| Poly-3 test  | P=0.194       | P=0.126       | P=0.218        | P=0.101        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                                |               |               |                |                |
| Overall rate   | 0/47 (0.0%)   | 4/47 (8.5%)   | 1/46 (2.2%)    | 2/46 (4.3%)    |
| Adjusted rate  | 0/39.8 (0.0%) | 4/41.4 (9.7%) | 1/35.0 (2.9%)  | 2/34.5 (5.8%)  |
| Terminal rate  | 0/32 (0.0%)   | 2/30 (6.7%)   | 1/25 (4.0%)    | 2/16 (12.5%)   |
| First incidence (days)   | —             | 523           | 765 (T)        | 765 (T)        |
| Poly-3 test  | P=0.466       | P=0.065       | P=0.474        | P=0.206        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b>     |               |               |                |                |
| Overall rate   | 1/47 (2.1%)   | 4/47 (8.5%)   | 1/46 (2.2%)    | 3/46 (6.5%)    |
| Adjusted rate  | 1/40.0 (2.5%) | 4/41.4 (9.7%) | 1/35.0 (2.9%)  | 3/34.5 (8.7%)  |
| Terminal rate  | 0/32 (0.0%)   | 2/30 (6.7%)   | 1/25 (4.0%)    | 3/16 (18.8%)   |
| First incidence (days)   | 719           | 523           | 765 (T)        | 765 (T)        |
| Poly-3 test  | P=0.360       | P=0.189       | P=0.730        | P=0.253        |
| <b>Preputial Gland: Hemangioma</b>   |               |               |                |                |
| Overall rate   | 0/46 (0.0%)   | 0/45 (0.0%)   | 1/45 (2.2%)    | 3/46 (6.5%)    |
| Adjusted rate  | 0/38.9 (0.0%) | 0/38.2 (0.0%) | 1/33.9 (2.9%)  | 3/34.4 (8.7%)  |
| Terminal rate  | 0/32 (0.0%)   | 0/28 (0.0%)   | 0/24 (0.0%)    | 2/15 (13.3%)   |
| First incidence (days)   | —             | —             | 710            | 620            |
| Poly-3 test  | P=0.016       | —             | P=0.473        | P=0.097        |
| <b>Preputial Gland: Hemangioma or Hemangiosarcoma</b>                                |               |               |                |                |
| Overall rate   | 0/46 (0.0%)   | 0/45 (0.0%)   | 2/45 (4.4%)    | 4/46 (8.7%)    |
| Adjusted rate  | 0/38.9 (0.0%) | 0/38.2 (0.0%) | 2/33.9 (5.9%)  | 4/34.4 (11.6%) |
| Terminal rate  | 0/32 (0.0%)   | 0/28 (0.0%)   | 1/24 (4.2%)    | 2/15 (13.3%)   |
| First incidence (days)   | —             | —             | 710            | 620            |
| Poly-3 test  | P=0.006       | —             | P=0.207        | P=0.045        |

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Hemangioma</b>                    |                 |                 |                 |                 |
| Overall rate                                     | 0/48 (0.0%)     | 0/48 (0.0%)     | 3/47 (6.4%)     | 4/48 (8.3%)     |
| Adjusted rate                                    | 0/40.1 (0.0%)   | 0/40.7 (0.0%)   | 3/35.9 (8.3%)   | 4/36.0 (11.1%)  |
| Terminal rate                                    | 0/32 (0.0%)     | 0/30 (0.0%)     | 1/25 (4.0%)     | 3/16 (18.8%)    |
| First incidence (days)                           | —               | —               | 710             | 620             |
| Poly-3 test                                      | P=0.010         | —               | P=0.099         | P=0.047         |
| <b>All Organs: Hemangiosarcoma</b>               |                 |                 |                 |                 |
| Overall rate                                     | 3/48 (6.3%)     | 5/48 (10.4%)    | 9/47 (19.1%)    | 21/48 (43.8%)   |
| Adjusted rate                                    | 3/40.3 (7.4%)   | 5/41.0 (12.2%)  | 9/36.2 (24.8%)  | 21/39.5 (53.1%) |
| Terminal rate                                    | 2/32 (6.3%)     | 4/30 (13.3%)    | 5/25 (20.0%)    | 8/16 (50.0%)    |
| First incidence (days)                           | 719             | 681             | 684             | 488             |
| Poly-3 test                                      | P=0.001         | P=0.365         | P=0.035         | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                 |                 |                 |                 |
| Overall rate                                     | 3/48 (6.3%)     | 5/48 (10.4%)    | 11/47 (23.4%)   | 22/48 (45.8%)   |
| Adjusted rate                                    | 3/40.3 (7.4%)   | 5/41.0 (12.2%)  | 11/36.4 (30.2%) | 22/39.5 (55.6%) |
| Terminal rate                                    | 2/32 (6.3%)     | 4/30 (13.3%)    | 6/25 (24.0%)    | 9/16 (56.3%)    |
| First incidence (days)                           | 719             | 681             | 684             | 488             |
| Poly-3 test                                      | P=0.001         | P=0.365         | P=0.009         | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 4/48 (8.3%)     | 5/47 (10.6%)    | 7/48 (14.6%)    |
| Adjusted rate                                    | 1/40.1 (2.5%)   | 4/41.4 (9.7%)   | 5/37.1 (13.5%)  | 7/37.1 (18.8%)  |
| Terminal rate                                    | 1/32 (3.1%)     | 1/30 (3.3%)     | 1/25 (4.0%)     | 3/16 (18.8%)    |
| First incidence (days)                           | 765 (T)         | 638             | 514             | 536             |
| Poly-3 test                                      | P=0.027         | P=0.187         | P=0.083         | P=0.021         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |                 |
| Overall rate                                     | 11/48 (22.9%)   | 6/48 (12.5%)    | 10/47 (21.3%)   | 7/48 (14.6%)    |
| Adjusted rate                                    | 11/41.0 (26.8%) | 6/41.2 (14.6%)  | 10/36.2 (27.6%) | 7/36.6 (19.1%)  |
| Terminal rate                                    | 9/32 (28.1%)    | 5/30 (16.7%)    | 8/25 (32.0%)    | 5/16 (31.3%)    |
| First incidence (days)                           | 614             | 622             | 655             | 588             |
| Poly-3 test                                      | P=0.435N        | P=0.134N        | P=0.570         | P=0.297N        |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |                 |
| Overall rate                                     | 27/48 (56.3%)   | 33/48 (68.8%)   | 37/47 (78.7%)   | 46/48 (95.8%)   |
| Adjusted rate                                    | 27/42.4 (63.6%) | 33/43.7 (75.4%) | 37/39.5 (93.7%) | 46/46.3 (99.2%) |
| Terminal rate                                    | 21/32 (65.6%)   | 24/30 (80.0%)   | 25/25 (100.0%)  | 16/16 (100.0%)  |
| First incidence (days)                           | 582             | 523             | 426             | 395             |
| Poly-3 test                                      | P=0.001         | P=0.159         | P=0.001         | P=0.001         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |                 |
| Overall rate                                     | 31/48 (64.6%)   | 32/48 (66.7%)   | 33/47 (70.2%)   | 45/48 (93.8%)   |
| Adjusted rate                                    | 31/44.7 (69.4%) | 32/45.9 (69.7%) | 33/42.2 (78.1%) | 45/46.2 (97.4%) |
| Terminal rate                                    | 19/32 (59.4%)   | 18/30 (60.0%)   | 16/25 (64.0%)   | 15/16 (93.8%)   |
| First incidence (days)                           | 513             | 382             | 362             | 395             |
| Poly-3 test                                      | P=0.001         | P=0.577         | P=0.246         | P=0.001         |

**TABLE B2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm           |
|--|-----------------|-----------------|-----------------|------------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |                  |
| Overall rate                                     | 41/48 (85.4%)   | 45/48 (93.8%)   | 42/47 (89.4%)   | 47/48 (97.9%)    |
| Adjusted rate                                    | 41/44.7 (91.8%) | 45/46.3 (97.2%) | 42/42.2 (99.4%) | 47/47.0 (100.0%) |
| Terminal rate                                    | 29/32 (90.6%)   | 29/30 (96.7%)   | 25/25 (100.0%)  | 16/16 (100.0%)   |
| First incidence (days)                           | 513             | 382             | 362             | 395              |
| Poly-3 test                                      | P=0.045         | P=0.231         | P=0.090         | P=0.054          |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol<sup>a</sup>**

|  | 0 ppm   | 10 ppm  | 30 ppm   | 90 ppm   |
|--|---------|---------|----------|----------|
| <b>Disposition Summary</b>                   |         |         |          |          |
| Animals initially in study                   | 48      | 48      | 48       | 48       |
| Early deaths                                 |         |         |          |          |
| Moribund                                     | 10      | 5       | 7        | 9        |
| Natural deaths                               | 6       | 13      | 16       | 23       |
| Survivors                                    |         |         |          |          |
| Terminal sacrifice                           | 32      | 30      | 25       | 16       |
| Animals examined microscopically             | 48      | 48      | 47       | 48       |
| <b>Alimentary System</b>                     |         |         |          |          |
| Gallbladder                                  | (39)    | (41)    | (40)     | (39)     |
| Cyst, minimal                                |         | 1 (2%)  |          |          |
| Inflammation, acute, minimal                 |         | 1 (2%)  |          |          |
| Pigmentation, moderate                       |         |         | 1 (3%)   |          |
| Intestine large, cecum                       | (46)    | (40)    | (42)     | (43)     |
| Hemorrhage, marked                           |         |         |          | 1 (2%)   |
| Intestine large, colon                       | (47)    | (43)    | (44)     | (46)     |
| Hyperplasia, minimal, lymphoid tissue        |         | 1 (2%)  |          |          |
| Intestine large, rectum                      | (47)    | (47)    | (47)     | (47)     |
| Erosion, focal, mild, anus                   |         |         | 1 (2%)   |          |
| Inflammation, acute, moderate, serosa        | 1 (2%)  |         |          |          |
| Inflammation, chronic active, marked, serosa |         |         | 1 (2%)   |          |
| Inflammation, chronic active, moderate       | 1 (2%)  |         |          |          |
| Ulcer, mild                                  | 1 (2%)  |         |          |          |
| Intestine small, ileum                       | (42)    | (42)    | (41)     | (41)     |
| Hyperplasia, mild, lymphoid tissue           |         | 1 (2%)  |          |          |
| Inflammation, chronic active, mild           | 1 (2%)  |         |          |          |
| Liver  | (47)    | (48)    | (46)     | (48)     |
| Amyloid deposition, moderate                 |         |         | 1 (2%)   |          |
| Angiectasis                                  |         |         | 7 (15%)  | 16 (33%) |
| Basophilic focus                             | 2 (4%)  | 1 (2%)  | 1 (2%)   | 2 (4%)   |
| Clear cell focus                             |         | 3 (6%)  | 5 (11%)  |          |
| Cyst, moderate, bile duct                    | 1 (2%)  |         |          |          |
| Eosinophilic focus                           | 6 (13%) | 3 (6%)  | 17 (37%) | 22 (46%) |
| Hematopoietic cell proliferation, marked     | 1 (2%)  |         | 1 (2%)   | 1 (2%)   |
| Hematopoietic cell proliferation, mild       | 1 (2%)  | 1 (2%)  |          | 6 (13%)  |
| Hematopoietic cell proliferation, minimal    | 2 (4%)  |         | 3 (7%)   | 1 (2%)   |
| Hematopoietic cell proliferation, moderate   | 2 (4%)  |         | 1 (2%)   | 3 (6%)   |
| Hyperplasia, mild, Kupffer cell              | 2 (4%)  | 6 (13%) | 5 (11%)  | 6 (13%)  |
| Hyperplasia, mild, oval cell                 |         | 1 (2%)  |          |          |
| Hyperplasia, minimal, Kupffer cell           | 4 (9%)  | 6 (13%) | 2 (4%)   |          |
| Hyperplasia, moderate, Kupffer cell          | 1 (2%)  |         | 2 (4%)   | 7 (15%)  |
| Infiltration cellular, lymphocytic, minimal  |         | 2 (4%)  |          |          |
| Infiltration cellular, mixed cell, mild      | 1 (2%)  | 2 (4%)  |          |          |
| Infiltration cellular, mixed cell, minimal   | 4 (9%)  | 1 (2%)  | 5 (11%)  |          |
| Inflammation, chronic active, moderate       |         |         | 1 (2%)   |          |
| Mixed cell focus                             |         | 3 (6%)  | 4 (9%)   | 1 (2%)   |
| Necrosis, marked                             | 1 (2%)  |         | 1 (2%)   |          |
| Necrosis, mild                               |         | 1 (2%)  | 1 (2%)   |          |
| Necrosis, mild, hepatocyte                   |         | 2 (4%)  | 2 (4%)   | 2 (4%)   |
| Necrosis, minimal                            | 1 (2%)  | 2 (4%)  | 1 (2%)   |          |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System (continued)</b>            |          |          |          |          |
| Liver (continued)                               | (47)     | (48)     | (46)     | (48)     |
| Necrosis, minimal, hepatocyte                   | 3 (6%)   | 3 (6%)   | 2 (4%)   | 1 (2%)   |
| Necrosis, moderate                              | 1 (2%)   | 1 (2%)   | 1 (2%)   | 4 (8%)   |
| Necrosis, moderate, hepatocyte                  | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Nuclear alteration, mild, hepatocyte            |          | 2 (4%)   |          |          |
| Nuclear alteration, minimal, hepatocyte         | 1 (2%)   |          | 1 (2%)   |          |
| Pigmentation, mild                              | 1 (2%)   |          |          |          |
| Regeneration                                    |          | 1 (2%)   | 1 (2%)   | 9 (19%)  |
| Syncytial alteration, mild, hepatocyte          | 2 (4%)   | 3 (6%)   | 1 (2%)   | 1 (2%)   |
| Syncytial alteration, minimal, hepatocyte       | 6 (13%)  | 3 (6%)   | 4 (9%)   | 3 (6%)   |
| Syncytial alteration, moderate, hepatocyte      | 1 (2%)   |          |          |          |
| Vacuolization cytoplasmic, mild, hepatocyte     | 1 (2%)   | 2 (4%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, minimal, hepatocyte  | 3 (6%)   | 2 (4%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, moderate, hepatocyte | 1 (2%)   |          |          | 1 (2%)   |
| Mesentery                                       |          | (3)      | (2)      | (3)      |
| Necrosis, fat                                   |          | 1 (33%)  | 1 (50%)  | 1 (33%)  |
| Pancreas  | (47)     | (45)     | (46)     | (46)     |
| Amyloid deposition, minimal                     |          | 1 (2%)   |          |          |
| Atrophy, minimal, acinar cell                   |          | 1 (2%)   |          |          |
| Basophilic focus                                |          |          | 1 (2%)   |          |
| Degeneration, mild, acinar cell                 |          |          | 1 (2%)   |          |
| Eosinophilic focus                              |          | 1 (2%)   |          |          |
| Hyperplasia, focal, mild, acinar cell           |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild        |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal     | 2 (4%)   | 4 (9%)   | 2 (4%)   | 1 (2%)   |
| Inflammation, chronic, minimal                  |          |          | 1 (2%)   |          |
| Vacuolization cytoplasmic, mild, acinar cell    | 1 (2%)   |          |          |          |
| Vacuolization cytoplasmic, minimal, acinar cell | 2 (4%)   | 1 (2%)   |          | 1 (2%)   |
| Salivary glands                                 | (48)     | (48)     | (46)     | (48)     |
| Atrophy, mild                                   |          |          |          | 1 (2%)   |
| Atrophy, minimal                                | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Atrophy, moderate                               | 1 (2%)   |          | 2 (4%)   | 1 (2%)   |
| Atrophy, moderate, parotid gland                |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild        | 18 (38%) | 18 (38%) | 10 (22%) | 12 (25%) |
| Infiltration cellular, lymphocytic, minimal     | 11 (23%) | 18 (38%) | 17 (37%) | 17 (35%) |
| Infiltration cellular, lymphocytic, moderate    | 4 (8%)   | 1 (2%)   | 1 (2%)   |          |
| Infiltration cellular, mixed cell, moderate     | 1 (2%)   |          |          |          |
| Inflammation, chronic active, moderate          |          |          | 1 (2%)   |          |
| Mineralization, minimal                         |          |          | 1 (2%)   |          |
| Stomach, forestomach                            | (47)     | (47)     | (46)     | (46)     |
| Cyst, minimal                                   |          | 2 (4%)   | 1 (2%)   |          |
| Erosion, minimal                                |          | 1 (2%)   |          |          |
| Hyperplasia, marked, epithelium                 |          | 1 (2%)   |          |          |
| Hyperplasia, mild, epithelium                   | 1 (2%)   | 2 (4%)   |          | 3 (7%)   |
| Hyperplasia, minimal, epithelium                |          |          |          | 2 (4%)   |
| Inflammation, mild                              |          |          | 1 (2%)   |          |
| Stomach, glandular                              | (47)     | (45)     | (45)     | (46)     |
| Angiectasis, minimal, mucosa                    |          |          |          | 1 (2%)   |
| Angiectasis, moderate, serosa                   |          |          |          | 1 (2%)   |
| Cyst, minimal                                   | 1 (2%)   | 2 (4%)   |          |          |
| Erosion, mild                                   |          |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, marked, epithelium                 |          | 1 (2%)   |          |          |
| Hyperplasia, mild, epithelium                   |          |          | 2 (4%)   |          |
| Hyperplasia, minimal, epithelium                |          |          | 1 (2%)   |          |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System (continued)</b>        |          |          |          |          |
| Stomach, glandular (continued)              | (47)     | (45)     | (45)     | (46)     |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   | 2 (4%)   |          |          |
| Inflammation, acute, minimal                | 1 (2%)   |          |          |          |
| Inflammation, chronic, minimal              | 1 (2%)   |          |          |          |
| Tongue                                      | (47)     | (48)     | (46)     | (48)     |
| Foreign body                                |          |          | 1 (2%)   |          |
| Hyperplasia, focal, marked, epithelium      |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal |          | 1 (2%)   |          |          |
| Inflammation, chronic active, minimal       |          |          |          | 1 (2%)   |
| Inflammation, chronic, minimal              |          | 1 (2%)   | 2 (4%)   |          |
| <b>Cardiovascular System</b>                |          |          |          |          |
| Blood vessel                                | (48)     | (48)     | (45)     | (48)     |
| Mineralization, mild                        |          |          | 1 (2%)   |          |
| Heart                                       | (48)     | (48)     | (47)     | (48)     |
| Angiectasis, marked                         |          |          |          | 2 (4%)   |
| Angiectasis, mild                           |          |          | 1 (2%)   | 4 (8%)   |
| Angiectasis, minimal                        |          |          | 3 (6%)   | 5 (10%)  |
| Angiectasis, moderate                       |          |          | 3 (6%)   | 2 (4%)   |
| Bacterium, valve                            |          |          |          | 1 (2%)   |
| Cardiomyopathy, minimal                     |          |          |          | 2 (4%)   |
| Hyperplasia, mild, endothelium              |          |          | 2 (4%)   | 4 (8%)   |
| Hyperplasia, minimal, endothelium           |          | 1 (2%)   | 1 (2%)   | 5 (10%)  |
| Hyperplasia, moderate, endothelium          |          |          | 1 (2%)   |          |
| Hypertrophy, minimal, parenchymal cell      | 4 (8%)   |          | 1 (2%)   |          |
| Inflammation, acute, mild, epicardium       |          | 1 (2%)   |          |          |
| Inflammation, acute, moderate, valve        |          |          | 1 (2%)   |          |
| Inflammation, chronic active, marked, valve |          |          |          | 1 (2%)   |
| Inflammation, chronic, mild, artery         | 2 (4%)   |          |          |          |
| Inflammation, chronic, mild, epicardium     |          |          | 1 (2%)   |          |
| Inflammation, chronic, mild, myocardium     |          |          |          | 2 (4%)   |
| Inflammation, chronic, mild, valve          | 1 (2%)   |          |          |          |
| Inflammation, chronic, minimal, artery      |          | 1 (2%)   |          |          |
| Inflammation, chronic, minimal, myocardium  |          |          | 1 (2%)   | 1 (2%)   |
| Inflammation, subacute, minimal, epicardium |          |          | 1 (2%)   |          |
| Mineralization, mild                        |          | 1 (2%)   |          |          |
| Necrosis, minimal                           | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| <b>Endocrine System</b>                     |          |          |          |          |
| Adrenal gland, cortex                       | (46)     | (45)     | (46)     | (46)     |
| Cyst, minimal                               |          |          | 1 (2%)   |          |
| Hyperplasia, focal, marked                  | 1 (2%)   |          |          |          |
| Hyperplasia, focal, mild                    |          | 1 (2%)   | 1 (2%)   |          |
| Hyperplasia, focal, minimal                 |          | 1 (2%)   |          | 1 (2%)   |
| Hyperplasia, marked, subcapsular            |          |          | 1 (2%)   |          |
| Hyperplasia, mild, subcapsular              | 8 (17%)  | 7 (16%)  | 14 (30%) | 10 (22%) |
| Hyperplasia, minimal, subcapsular           | 24 (52%) | 26 (58%) | 22 (48%) | 32 (70%) |
| Hyperplasia, moderate, subcapsular          | 3 (7%)   | 5 (11%)  | 1 (2%)   |          |
| Hypertrophy, marked                         |          |          |          | 2 (4%)   |
| Hypertrophy, mild                           | 4 (9%)   | 2 (4%)   | 4 (9%)   | 5 (11%)  |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm  | 30 ppm   | 90 ppm   |
|---|----------|---------|----------|----------|
| <b>Endocrine System (continued)</b>         |          |         |          |          |
| Adrenal gland, cortex (continued)           | (46)     | (45)    | (46)     | (46)     |
| Hypertrophy, minimal                        | 2 (4%)   | 3 (7%)  | 2 (4%)   | 4 (9%)   |
| Hypertrophy, moderate                       |          |         | 1 (2%)   |          |
| Vacuolization cytoplasmic, focal, mild      |          |         |          | 1 (2%)   |
| Adrenal gland, medulla                      | (44)     | (42)    | (45)     | (46)     |
| Hyperplasia, mild                           | 1 (2%)   |         |          |          |
| Hyperplasia, minimal                        | 1 (2%)   | 1 (2%)  |          |          |
| Hyperplasia, moderate                       | 1 (2%)   |         |          | 1 (2%)   |
| Islets, pancreatic                          | (47)     | (45)    | (46)     | (46)     |
| Hyperplasia, mild                           | 2 (4%)   | 2 (4%)  | 2 (4%)   | 1 (2%)   |
| Hyperplasia, minimal                        |          | 1 (2%)  | 1 (2%)   |          |
| Hyperplasia, moderate                       |          |         |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal |          |         |          | 1 (2%)   |
| Parathyroid gland                           | (37)     | (40)    | (43)     | (38)     |
| Cyst, mild                                  | 1 (3%)   | 1 (3%)  | 1 (2%)   | 1 (3%)   |
| Cyst, minimal                               | 1 (3%)   |         |          |          |
| Infiltration cellular, lymphocytic, mild    |          |         | 1 (2%)   |          |
| Pituitary gland                             | (46)     | (42)    | (41)     | (42)     |
| Cyst, mild, pars distalis                   | 1 (2%)   |         | 1 (2%)   | 1 (2%)   |
| Cyst, minimal, pars distalis                | 1 (2%)   | 1 (2%)  | 1 (2%)   |          |
| Thyroid gland                               | (46)     | (48)    | (46)     | (47)     |
| Crystals                                    | 1 (2%)   |         |          |          |
| Cyst, mild, follicle                        |          | 1 (2%)  |          |          |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   | 1 (2%)  | 1 (2%)   |          |
| Inflammation, chronic, mild                 |          | 1 (2%)  |          |          |
| Inflammation, chronic, minimal              | 1 (2%)   |         |          |          |
| Ultimobranchial cyst                        | 11 (24%) | 7 (15%) | 13 (28%) | 14 (30%) |
| <b>General Body System</b>                  |          |         |          |          |
| None  |          |         |          |          |
| <b>Genital System</b>                       |          |         |          |          |
| Coagulating gland                           | (46)     | (48)    | (45)     | (46)     |
| Atrophy, mild                               |          | 4 (8%)  | 1 (2%)   | 3 (7%)   |
| Atrophy, minimal                            | 4 (9%)   | 2 (4%)  | 3 (7%)   | 5 (11%)  |
| Dilatation, mild                            | 1 (2%)   |         |          |          |
| Infiltration cellular, lymphocytic, mild    | 1 (2%)   |         |          |          |
| Infiltration cellular, lymphocytic, minimal | 3 (7%)   | 6 (13%) | 1 (2%)   | 2 (4%)   |
| Infiltration cellular, mixed cell, mild     | 1 (2%)   |         |          |          |
| Inflammation, acute, moderate               | 1 (2%)   |         |          |          |
| Inflammation, chronic active, mild          |          | 1 (2%)  |          |          |
| Inflammation, chronic, mild                 |          |         | 1 (2%)   |          |
| Inflammation, subacute, minimal             |          | 1 (2%)  |          |          |
| Epididymis                                  | (48)     | (48)    | (46)     | (48)     |
| Fibrosis, mild                              |          |         |          | 1 (2%)   |
| Granuloma sperm, mild                       |          | 1 (2%)  |          |          |
| Hyperplasia, focal, minimal, epithelium     |          |         |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild    | 1 (2%)   |         |          | 2 (4%)   |
| Infiltration cellular, lymphocytic, minimal | 8 (17%)  | 7 (15%) | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, mixed cell, marked   | 1 (2%)   |         |          |          |
| Inflammation, chronic, mild                 |          | 1 (2%)  | 1 (2%)   | 1 (2%)   |
| Inflammation, chronic, minimal              |          |         |          | 1 (2%)   |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Genital System (continued)</b>           |          |          |          |          |
| Penis                                       |          |          | (2)      | (2)      |
| Inflammation, acute, moderate               |          |          |          | 1 (50%)  |
| Inflammation, chronic active, marked        |          |          | 1 (50%)  |          |
| Inflammation, chronic, mild                 |          |          |          | 1 (50%)  |
| Inflammation, chronic, minimal              |          |          | 1 (50%)  |          |
| Preputial gland                             | (46)     | (45)     | (45)     | (46)     |
| Atrophy, marked                             | 1 (2%)   | 4 (9%)   | 6 (13%)  | 8 (17%)  |
| Atrophy, mild                               | 1 (2%)   | 3 (7%)   | 1 (2%)   | 5 (11%)  |
| Atrophy, minimal                            | 1 (2%)   |          | 2 (4%)   | 1 (2%)   |
| Atrophy, moderate                           | 11 (24%) | 12 (27%) | 11 (24%) | 10 (22%) |
| Cyst, mild                                  |          | 2 (4%)   | 2 (4%)   |          |
| Cyst, minimal                               | 1 (2%)   |          |          |          |
| Dilatation, marked                          | 1 (2%)   | 2 (4%)   | 1 (2%)   | 1 (2%)   |
| Dilatation, mild                            | 8 (17%)  | 12 (27%) | 10 (22%) | 7 (15%)  |
| Dilatation, minimal                         | 4 (9%)   |          | 2 (4%)   | 2 (4%)   |
| Dilatation, moderate                        | 2 (4%)   |          | 2 (4%)   | 7 (15%)  |
| Inflammation, acute, moderate               | 1 (2%)   |          |          | 1 (2%)   |
| Inflammation, chronic active, marked        | 4 (9%)   | 1 (2%)   | 2 (4%)   |          |
| Inflammation, chronic active, mild          | 2 (4%)   | 1 (2%)   | 3 (7%)   | 2 (4%)   |
| Inflammation, chronic active, moderate      | 3 (7%)   | 1 (2%)   | 3 (7%)   | 2 (4%)   |
| Inflammation, chronic, mild                 | 3 (7%)   | 4 (9%)   | 5 (11%)  | 6 (13%)  |
| Inflammation, chronic, minimal              | 8 (17%)  | 4 (9%)   | 1 (2%)   | 5 (11%)  |
| Inflammation, subacute, mild                |          |          | 1 (2%)   | 1 (2%)   |
| Inflammation, subacute, minimal             |          | 1 (2%)   |          |          |
| Prostate                                    | (46)     | (47)     | (43)     | (48)     |
| Atrophy, mild                               |          | 2 (4%)   |          |          |
| Atrophy, minimal                            |          |          |          | 2 (4%)   |
| Hyperplasia, marked, epithelium             |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal |          | 1 (2%)   |          | 1 (2%)   |
| Infiltration cellular, mixed cell, moderate | 1 (2%)   |          |          |          |
| Inflammation, acute, mild                   |          |          | 1 (2%)   |          |
| Inflammation, acute, minimal                |          |          | 1 (2%)   |          |
| Inflammation, acute, moderate               | 2 (4%)   |          |          |          |
| Inflammation, chronic active, minimal       |          |          | 1 (2%)   |          |
| Inflammation, subacute, mild                | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Inflammation, subacute, minimal             | 13 (28%) | 9 (19%)  | 7 (16%)  | 7 (15%)  |
| Seminal vesicle                             | (47)     | (48)     | (46)     | (47)     |
| Atrophy, mild                               | 3 (6%)   | 3 (6%)   | 2 (4%)   | 5 (11%)  |
| Atrophy, minimal                            | 3 (6%)   | 3 (6%)   | 4 (9%)   | 5 (11%)  |
| Atrophy, moderate                           |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal |          | 1 (2%)   |          |          |
| Inflammation, acute, marked                 | 1 (2%)   |          |          |          |
| Inflammation, acute, mild                   |          |          | 1 (2%)   |          |
| Inflammation, chronic active, moderate      |          | 1 (2%)   |          |          |
| Inflammation, chronic, minimal              |          | 1 (2%)   |          |          |
| Inflammation, chronic, moderate             |          | 1 (2%)   | 1 (2%)   |          |
| Testes                                      | (48)     | (48)     | (47)     | (47)     |
| Atrophy, marked, germinal epithelium        | 1 (2%)   |          |          |          |
| Atrophy, mild, germinal epithelium          | 1 (2%)   | 2 (4%)   | 1 (2%)   | 4 (9%)   |
| Atrophy, moderate, germinal epithelium      |          | 1 (2%)   |          |          |
| Cyst, moderate                              |          |          |          | 1 (2%)   |
| Degeneration, mild, germinal epithelium     | 1 (2%)   |          |          | 3 (6%)   |
| Degeneration, minimal, germinal epithelium  | 1 (2%)   | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Degeneration, moderate, germinal epithelium |          | 1 (2%)   |          | 1 (2%)   |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm  | 30 ppm  | 90 ppm   |
|---|----------|---------|---------|----------|
| <b>Genital System (continued)</b>                   |          |         |         |          |
| Testes (continued)                                  | (48)     | (48)    | (47)    | (47)     |
| Hemorrhage, mild                                    |          | 1 (2%)  |         |          |
| Mineralization, mild                                |          |         | 2 (4%)  | 1 (2%)   |
| Mineralization, minimal                             | 2 (4%)   | 2 (4%)  |         | 3 (6%)   |
| Mineralization, moderate                            | 1 (2%)   |         |         |          |
| <b>Hematopoietic System</b>                         |          |         |         |          |
| Bone marrow   | (48)     | (48)    | (47)    | (46)     |
| Angiectasis, mild                                   |          | 2 (4%)  |         |          |
| Hemorrhage, marked                                  |          |         | 1 (2%)  |          |
| Hyperplasia, marked                                 |          |         |         | 1 (2%)   |
| Hyperplasia, mild                                   | 9 (19%)  | 2 (4%)  | 5 (11%) | 1 (2%)   |
| Hyperplasia, minimal                                | 3 (6%)   | 2 (4%)  | 1 (2%)  | 7 (15%)  |
| Necrosis, mild                                      |          | 1 (2%)  |         |          |
| Lymph node  | (48)     | (48)    | (47)    | (47)     |
| Hemorrhage, moderate, axillary                      |          |         |         | 1 (2%)   |
| Hyperplasia, lymphoid, mild, axillary               | 1 (2%)   |         |         |          |
| Hyperplasia, lymphoid, mild, inguinal               | 1 (2%)   |         |         |          |
| Hyperplasia, lymphoid, mild, thoracic               |          |         | 1 (2%)  |          |
| Hyperplasia, lymphoid, moderate, lumbar             |          |         | 1 (2%)  |          |
| Infiltration cellular, mixed cell, moderate, lumbar | 1 (2%)   |         |         |          |
| Lymph node, mandibular                              | (48)     | (48)    | (45)    | (47)     |
| Angiectasis, mild                                   |          |         |         | 1 (2%)   |
| Congestion, mild                                    |          |         |         | 1 (2%)   |
| Depletion lymphoid, mild                            |          | 1 (2%)  |         |          |
| Hemorrhage, mild                                    |          |         |         | 2 (4%)   |
| Hyperplasia, lymphoid, marked                       |          | 1 (2%)  | 1 (2%)  | 1 (2%)   |
| Hyperplasia, lymphoid, mild                         | 6 (13%)  | 3 (6%)  | 5 (11%) | 6 (13%)  |
| Hyperplasia, lymphoid, minimal                      | 7 (15%)  | 4 (8%)  | 3 (7%)  | 3 (6%)   |
| Hyperplasia, lymphoid, moderate                     |          | 1 (2%)  | 2 (4%)  | 3 (6%)   |
| Infiltration cellular, histiocytic, mild            | 2 (4%)   | 3 (6%)  | 2 (4%)  | 2 (4%)   |
| Infiltration cellular, histiocytic, minimal         |          | 1 (2%)  |         | 2 (4%)   |
| Infiltration cellular, histiocytic, moderate        |          |         | 1 (2%)  |          |
| Infiltration cellular, mixed cell, minimal          | 1 (2%)   |         |         |          |
| Pigmentation, minimal                               | 2 (4%)   |         |         | 1 (2%)   |
| Lymph node, mesenteric                              | (48)     | (48)    | (45)    | (44)     |
| Angiectasis, marked                                 | 1 (2%)   |         | 3 (7%)  | 1 (2%)   |
| Angiectasis, mild                                   | 5 (10%)  | 9 (19%) | 5 (11%) | 11 (25%) |
| Angiectasis, minimal                                | 10 (21%) | 6 (13%) | 7 (16%) | 2 (5%)   |
| Angiectasis, moderate                               | 2 (4%)   | 5 (10%) | 7 (16%) | 4 (9%)   |
| Hemorrhage, minimal                                 |          |         |         | 1 (2%)   |
| Hemorrhage, moderate                                | 1 (2%)   |         |         | 1 (2%)   |
| Hyperplasia, lymphoid, marked                       | 1 (2%)   |         |         |          |
| Hyperplasia, lymphoid, mild                         | 3 (6%)   | 2 (4%)  | 4 (9%)  | 1 (2%)   |
| Hyperplasia, lymphoid, minimal                      | 7 (15%)  | 9 (19%) | 2 (4%)  | 1 (2%)   |
| Hyperplasia, lymphoid, moderate                     | 2 (4%)   | 1 (2%)  |         | 1 (2%)   |
| Infiltration cellular, histiocytic, minimal         |          | 2 (4%)  |         | 1 (2%)   |
| Infiltration cellular, mixed cell, moderate         | 1 (2%)   |         |         |          |
| Inflammation, acute, mild                           | 1 (2%)   |         |         |          |
| Inflammation, acute, moderate                       |          |         | 1 (2%)  |          |
| Inflammation, chronic active, mild                  |          |         | 1 (2%)  |          |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm   | 90 ppm   |
|--|---------|---------|----------|----------|
| <b>Hematopoietic System (continued)</b>      |         |         |          |          |
| Spleen                                       | (46)    | (46)    | (46)     | (46)     |
| Angiectasis, mild                            | 1 (2%)  |         |          |          |
| Angiectasis, minimal                         |         | 1 (2%)  | 1 (2%)   |          |
| Atrophy, mild, lymphoid follicle             |         | 1 (2%)  |          | 2 (4%)   |
| Congestion, marked                           | 1 (2%)  |         |          |          |
| Hematopoietic cell proliferation, marked     | 8 (17%) | 5 (11%) | 10 (22%) | 12 (26%) |
| Hematopoietic cell proliferation, mild       | 2 (4%)  | 3 (7%)  | 4 (9%)   | 7 (15%)  |
| Hematopoietic cell proliferation, minimal    | 2 (4%)  | 2 (4%)  | 2 (4%)   | 3 (7%)   |
| Hematopoietic cell proliferation, moderate   | 8 (17%) | 6 (13%) | 6 (13%)  | 10 (22%) |
| Hyperplasia, marked, lymphoid follicle       | 6 (13%) | 7 (15%) | 6 (13%)  | 1 (2%)   |
| Hyperplasia, mild, lymphoid follicle         | 3 (7%)  | 6 (13%) | 9 (20%)  | 3 (7%)   |
| Hyperplasia, minimal, lymphoid follicle      | 2 (4%)  | 3 (7%)  | 3 (7%)   | 3 (7%)   |
| Hyperplasia, moderate, lymphoid follicle     | 8 (17%) | 5 (11%) | 3 (7%)   | 4 (9%)   |
| Infiltration cellular, histiocytic, mild     |         | 1 (2%)  |          |          |
| Infiltration cellular, histiocytic, moderate |         |         | 1 (2%)   |          |
| Pigmentation, mild                           |         | 1 (2%)  |          |          |
| Thymus                                       | (35)    | (32)    | (28)     | (32)     |
| Atrophy, marked                              | 4 (11%) | 5 (16%) | 6 (21%)  | 8 (25%)  |
| Atrophy, mild                                | 1 (3%)  | 1 (3%)  | 1 (4%)   | 4 (13%)  |
| Atrophy, minimal                             | 2 (6%)  | 6 (19%) | 1 (4%)   | 1 (3%)   |
| Atrophy, moderate                            | 5 (14%) | 1 (3%)  | 5 (18%)  | 9 (28%)  |
| Cyst, mild                                   | 1 (3%)  |         |          |          |
| Cyst, minimal                                | 7 (20%) | 4 (13%) | 2 (7%)   | 1 (3%)   |
| Infiltration cellular, mixed cell, moderate  | 1 (3%)  |         |          |          |
| Necrosis, mild                               |         | 1 (3%)  |          |          |
| <b>Integumentary System</b>                  |         |         |          |          |
| Skin   | (48)    | (48)    | (46)     | (47)     |
| Edema, mild                                  |         | 1 (2%)  |          | 2 (4%)   |
| Edema, minimal                               |         |         | 1 (2%)   |          |
| Edema, moderate                              | 1 (2%)  |         |          |          |
| Erosion, mild                                | 1 (2%)  | 1 (2%)  | 1 (2%)   |          |
| Erosion, moderate                            |         |         | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild, epithelium                |         | 3 (6%)  |          | 1 (2%)   |
| Hyperplasia, moderate, epithelium            |         | 1 (2%)  |          | 1 (2%)   |
| Inflammation, acute, minimal                 |         |         | 1 (2%)   |          |
| Inflammation, acute, minimal, prepuce        |         | 1 (2%)  |          |          |
| Inflammation, chronic active, marked         | 1 (2%)  |         | 1 (2%)   |          |
| Inflammation, chronic active, mild           | 1 (2%)  |         |          | 2 (4%)   |
| Inflammation, chronic active, moderate       |         |         | 1 (2%)   | 3 (6%)   |
| Inflammation, chronic, mild                  | 1 (2%)  | 2 (4%)  | 1 (2%)   | 1 (2%)   |
| Inflammation, chronic, minimal               |         |         | 1 (2%)   | 3 (6%)   |
| Inflammation, chronic, moderate              |         | 3 (6%)  |          |          |
| Metaplasia, osseous, moderate                | 1 (2%)  |         |          |          |
| Ulcer, marked                                |         |         | 1 (2%)   |          |
| Ulcer, mild                                  | 1 (2%)  |         |          | 3 (6%)   |
| Ulcer, moderate                              |         |         | 1 (2%)   | 2 (4%)   |
| <b>Musculoskeletal System</b>                |         |         |          |          |
| Bone   | (48)    | (48)    | (47)     | (48)     |
| Hyperostosis, mild, cranium                  |         |         |          | 1 (2%)   |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Musculoskeletal System (continued)</b>     |          |          |          |          |
| Bone, femur                                   | (48)     | (48)     | (47)     | (48)     |
| Degeneration, marked, joint, cartilage        |          |          | 1 (2%)   |          |
| Degeneration, mild, joint, cartilage          | 3 (6%)   | 6 (13%)  | 6 (13%)  | 6 (13%)  |
| Degeneration, minimal, joint, cartilage       | 5 (10%)  | 3 (6%)   | 2 (4%)   | 3 (6%)   |
| Degeneration, moderate, joint, cartilage      | 1 (2%)   |          |          |          |
| Inflammation, acute, mild, joint              |          |          |          | 1 (2%)   |
| Inflammation, chronic active, moderate, joint |          | 1 (2%)   |          |          |
| Skeletal muscle                               | (48)     | (48)     | (47)     | (48)     |
| Infiltration cellular, lymphocytic, mild      | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, minimal   | 1 (2%)   | 2 (4%)   | 1 (2%)   | 1 (2%)   |
| Mineralization, mild                          |          | 1 (2%)   |          |          |
| <b>Nervous System</b>                         |          |          |          |          |
| Brain, cerebellum                             | (47)     | (48)     | (47)     | (48)     |
| Hemorrhage, minimal                           |          |          |          | 1 (2%)   |
| Necrosis, marked                              |          |          | 1 (2%)   |          |
| Brain, cerebrum                               | (48)     | (48)     | (47)     | (48)     |
| Mineralization, mild, thalamus                | 1 (2%)   |          | 1 (2%)   |          |
| Mineralization, minimal, thalamus             | 26 (54%) | 25 (52%) | 21 (45%) | 23 (48%) |
| Necrosis, moderate                            |          |          | 1 (2%)   |          |
| Peripheral nerve                              | (48)     | (48)     | (47)     | (48)     |
| Degeneration, mild                            |          |          |          | 2 (4%)   |
| Degeneration, minimal                         | 3 (6%)   | 5 (10%)  | 6 (13%)  | 5 (10%)  |
| Spinal cord, thoracic                         | (48)     | (48)     | (47)     | (48)     |
| Necrosis, mild                                |          | 1 (2%)   |          |          |
| Necrosis, minimal                             |          |          |          | 1 (2%)   |
| <b>Respiratory System</b>                     |          |          |          |          |
| Larynx  | (44)     | (47)     | (46)     | (47)     |
| Cyst, mild                                    |          |          |          | 1 (2%)   |
| Cyst, minimal                                 |          | 2 (4%)   |          |          |
| Inflammation, acute, minimal                  |          |          |          | 1 (2%)   |
| Inflammation, subacute, minimal               |          | 1 (2%)   | 1 (2%)   |          |
| Lung  | (48)     | (48)     | (47)     | (48)     |
| Foreign body                                  | 1 (2%)   | 1 (2%)   |          |          |
| Hyperplasia, mild, alveolar epithelium        |          | 2 (4%)   | 3 (6%)   | 3 (6%)   |
| Hyperplasia, minimal, alveolar epithelium     |          |          |          | 1 (2%)   |
| Hyperplasia, moderate, alveolar epithelium    |          | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Infiltration cellular, histiocytic, mild      |          | 1 (2%)   |          |          |
| Infiltration cellular, histiocytic, minimal   |          | 1 (2%)   |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild      | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal   | 5 (10%)  | 4 (8%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, moderate  |          |          | 1 (2%)   |          |
| Infiltration cellular, mixed cell, moderate   | 1 (2%)   |          |          |          |
| Inflammation, acute, mild, vein               |          |          |          | 1 (2%)   |
| Inflammation, chronic active, mild            | 1 (2%)   |          |          |          |
| Inflammation, chronic active, moderate        |          | 1 (2%)   |          |          |
| Inflammation, chronic, mild                   | 1 (2%)   |          | 4 (9%)   |          |
| Inflammation, chronic, minimal                | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Inflammation, chronic, moderate               |          |          | 1 (2%)   |          |
| Parasite protozoan                            |          |          | 1 (2%)   |          |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm  |
|---|----------|----------|----------|---------|
| <b>Respiratory System (continued)</b>                   |          |          |          |         |
| Lung (continued)  | (48)     | (48)     | (47)     | (48)    |
| Pigmentation, marked                                    |          |          | 1 (2%)   |         |
| Pigmentation, mild                                      |          | 1 (2%)   |          |         |
| Pigmentation, minimal                                   |          |          |          | 1 (2%)  |
| Nose  | (48)     | (48)     | (47)     | (48)    |
| Cyst, mild, mucosa                                      | 1 (2%)   |          |          |         |
| Cytoplasmic alteration, mild, olfactory epithelium      | 8 (17%)  | 7 (15%)  | 1 (2%)   | 3 (6%)  |
| Cytoplasmic alteration, mild, respiratory epithelium    | 6 (13%)  | 4 (8%)   | 2 (4%)   |         |
| Cytoplasmic alteration, minimal, olfactory epithelium   | 5 (10%)  | 5 (10%)  | 3 (6%)   | 4 (8%)  |
| Cytoplasmic alteration, minimal, respiratory epithelium | 9 (19%)  | 5 (10%)  | 3 (6%)   | 3 (6%)  |
| Foreign body  |          | 1 (2%)   |          |         |
| Hyperplasia, moderate, glands                           | 1 (2%)   |          |          |         |
| Inflammation, minimal                                   |          |          | 1 (2%)   | 1 (2%)  |
| Trachea   | (47)     | (48)     | (45)     | (48)    |
| Inflammation, acute, minimal                            | 1 (2%)   |          |          |         |
| <b>Special Senses System</b>                            |          |          |          |         |
| Ear   |          |          | (1)      |         |
| Inflammation, chronic active, moderate                  |          |          | 1 (100%) |         |
| Ulcer, moderate   |          |          | 1 (100%) |         |
| Eye   | (47)     | (47)     | (47)     | (46)    |
| Atrophy, marked   |          |          | 1 (2%)   |         |
| Cataract, marked, lens                                  |          |          |          | 1 (2%)  |
| Cataract, mild, lens                                    |          |          | 3 (6%)   |         |
| Cataract, minimal, lens                                 |          | 1 (2%)   |          | 2 (4%)  |
| Cataract, moderate, lens                                |          |          |          | 3 (7%)  |
| Inflammation, acute, mild, cornea                       |          |          |          | 1 (2%)  |
| Inflammation, acute, minimal, cornea                    |          |          |          | 1 (2%)  |
| Inflammation, acute, moderate, cornea                   |          |          |          | 1 (2%)  |
| Inflammation, chronic active, marked                    |          | 1 (2%)   |          |         |
| Inflammation, chronic active, marked, cornea            |          |          | 1 (2%)   | 1 (2%)  |
| Inflammation, chronic active, mild, cornea              |          |          | 2 (4%)   | 1 (2%)  |
| Inflammation, chronic active, moderate, cornea          |          |          | 1 (2%)   | 1 (2%)  |
| Inflammation, chronic, mild, cornea                     |          |          | 1 (2%)   | 3 (7%)  |
| Inflammation, chronic, minimal, cornea                  |          |          | 1 (2%)   |         |
| Inflammation, chronic, moderate, cornea                 |          |          |          | 2 (4%)  |
| Mineralization, minimal                                 |          |          | 1 (2%)   |         |
| Harderian gland   | (48)     | (48)     | (47)     | (48)    |
| Hyperplasia, focal, marked                              |          |          | 1 (2%)   |         |
| Hyperplasia, focal, mild                                |          |          |          | 1 (2%)  |
| Infiltration cellular, lymphocytic, mild                | 3 (6%)   | 2 (4%)   | 1 (2%)   | 1 (2%)  |
| Infiltration cellular, lymphocytic, minimal             | 13 (27%) | 16 (33%) | 7 (15%)  | 5 (10%) |
| Infiltration cellular, mixed cell, moderate             | 1 (2%)   |          |          |         |
| Inflammation, chronic active, mild                      |          |          | 1 (2%)   |         |
| Inflammation, chronic, minimal                          |          |          |          | 1 (2%)  |
| Lacrimal gland  | (48)     | (47)     | (45)     | (46)    |
| Atrophy, marked   |          |          |          | 1 (2%)  |
| Atrophy, mild   | 3 (6%)   | 4 (9%)   | 3 (7%)   | 5 (11%) |
| Atrophy, minimal  | 4 (8%)   | 3 (6%)   | 7 (16%)  | 6 (13%) |
| Atrophy, moderate                                       |          | 1 (2%)   |          | 2 (4%)  |
| Cyst, mild  |          |          | 1 (2%)   |         |
| Hyperplasia, moderate, duct                             |          | 1 (2%)   |          |         |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Special Senses System (continued)</b>             |          |          |          |          |
| Lacrimal gland (continued)                           | (48)     | (47)     | (45)     | (46)     |
| Infiltration cellular, lymphocytic, mild             |          | 2 (4%)   | 4 (9%)   | 2 (4%)   |
| Infiltration cellular, lymphocytic, minimal          | 9 (19%)  | 10 (21%) | 8 (18%)  | 13 (28%) |
| Infiltration cellular, mast cell, moderate           |          |          |          | 1 (2%)   |
| Infiltration cellular, mixed cell, moderate          | 1 (2%)   |          |          |          |
| Inflammation, chronic active, mild                   |          |          | 1 (2%)   |          |
| Zymbal's gland                                       | (47)     | (45)     | (46)     | (43)     |
| Cyst, moderate                                       | 1 (2%)   | 1 (2%)   |          |          |
| Dilatation, mild                                     |          |          |          | 1 (2%)   |
| Hyperplasia, minimal                                 | 1 (2%)   |          |          |          |
| <b>Urinary System</b>                                |          |          |          |          |
| Kidney   | (48)     | (48)     | (47)     | (47)     |
| Accumulation, hyaline droplet, minimal, renal tubule |          | 1 (2%)   |          |          |
| Amyloid deposition, mild                             | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Amyloid deposition, minimal                          | 3 (6%)   | 3 (6%)   |          | 1 (2%)   |
| Atrophy, marked                                      |          |          |          | 1 (2%)   |
| Atrophy, minimal                                     | 1 (2%)   |          |          |          |
| Bacterium  | 1 (2%)   |          |          | 1 (2%)   |
| Cyst, mild   | 3 (6%)   |          | 1 (2%)   | 1 (2%)   |
| Cyst, minimal  | 3 (6%)   | 5 (10%)  | 2 (4%)   | 2 (4%)   |
| Degeneration, mild, renal tubule                     |          | 2 (4%)   | 2 (4%)   |          |
| Degeneration, minimal, renal tubule                  | 19 (40%) | 11 (23%) | 13 (28%) | 6 (13%)  |
| Degeneration, moderate, renal tubule                 | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Dilatation, mild, pelvis                             | 2 (4%)   |          |          | 1 (2%)   |
| Dilatation, minimal, pelvis                          |          |          | 2 (4%)   |          |
| Dilatation, moderate, pelvis                         |          | 1 (2%)   |          | 1 (2%)   |
| Glomerulosclerosis, marked                           |          | 1 (2%)   |          |          |
| Glomerulosclerosis, mild                             | 13 (27%) | 5 (10%)  | 9 (19%)  | 11 (23%) |
| Glomerulosclerosis, minimal                          | 22 (46%) | 24 (50%) | 23 (49%) | 21 (45%) |
| Glomerulosclerosis, moderate                         |          | 2 (4%)   | 2 (4%)   | 2 (4%)   |
| Hyperplasia, focal, mild, renal tubule               | 2 (4%)   |          | 2 (4%)   | 2 (4%)   |
| Hyperplasia, focal, minimal, renal tubule            | 1 (2%)   |          |          | 1 (2%)   |
| Hyperplasia, focal, moderate, renal tubule           |          | 1 (2%)   |          |          |
| Hypoplasia, focal, minimal                           |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild             | 4 (8%)   | 8 (17%)  | 1 (2%)   | 3 (6%)   |
| Infiltration cellular, lymphocytic, minimal          | 23 (48%) | 20 (42%) | 18 (38%) | 11 (23%) |
| Infiltration cellular, lymphocytic, moderate         | 2 (4%)   |          |          |          |
| Infiltration cellular, mixed cell, moderate          | 1 (2%)   |          |          |          |
| Inflammation, acute, mild, pelvis                    | 1 (2%)   |          |          |          |
| Inflammation, acute, minimal                         | 1 (2%)   |          |          |          |
| Inflammation, acute, minimal, pelvis                 |          | 1 (2%)   | 1 (2%)   |          |
| Inflammation, chronic active, marked                 | 1 (2%)   |          |          |          |
| Inflammation, chronic active, marked, pelvis         |          |          |          | 1 (2%)   |
| Inflammation, chronic active, mild, pelvis           |          | 1 (2%)   | 1 (2%)   |          |
| Inflammation, chronic, minimal                       |          |          | 1 (2%)   |          |
| Inflammation, chronic, moderate, pelvis              |          |          |          | 1 (2%)   |
| Inflammation, mild, pelvis                           | 1 (2%)   |          |          |          |
| Metaplasia, osseous, minimal                         | 1 (2%)   |          |          |          |
| Mineralization, mild                                 |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Mineralization, mild, pelvis                         |          | 1 (2%)   |          |          |
| Mineralization, minimal                              | 7 (15%)  | 6 (13%)  | 7 (15%)  | 2 (4%)   |
| Mineralization, moderate                             |          |          |          | 1 (2%)   |

**TABLE B3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Urinary System</b> (continued)            |          |          |          |          |
| Kidney (continued)                           | (48)     | (48)     | (47)     | (47)     |
| Necrosis, marked, renal tubule               |          |          |          | 1 (2%)   |
| Necrosis, mild, papilla                      |          | 1 (2%)   |          |          |
| Necrosis, moderate, papilla                  |          |          |          | 1 (2%)   |
| Nephropathy, minimal                         |          |          |          | 1 (2%)   |
| Urinary bladder                              | (47)     | (46)     | (45)     | (46)     |
| Dilatation, moderate                         |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Edema, mild                                  |          |          | 1 (2%)   | 2 (4%)   |
| Edema, minimal                               |          |          |          | 1 (2%)   |
| Edema, moderate                              |          |          |          | 1 (2%)   |
| Hyperplasia, mild, transitional epithelium   |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild     | 4 (9%)   | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  | 19 (40%) | 21 (46%) | 17 (38%) | 16 (35%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   |          |          |          |
| Infiltration cellular, mixed cell, moderate  | 1 (2%)   |          |          |          |
| Inflammation, acute, marked                  | 1 (2%)   |          |          |          |
| Inflammation, acute, mild                    | 1 (2%)   |          |          |          |
| Inflammation, acute, moderate                |          |          |          | 1 (2%)   |
| Inflammation, chronic active, marked         |          |          | 1 (2%)   |          |
| Inflammation, chronic active, moderate       |          |          |          | 1 (2%)   |
| Inflammation, chronic, mild                  |          |          |          | 1 (2%)   |

**APPENDIX C**  
**SUMMARY OF LESIONS IN MALE MICE**  
**IN THE 2-YEAR DRINKING WATER STUDY**  
**OF URETHANE AND 5% ETHANOL**

**TABLE C1** Summary of the Incidence of Neoplasms in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... C-2

**TABLE C2** Statistical Analysis of Primary Neoplasms in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... C-8

**TABLE C3** Summary of the Incidence of Nonneoplastic Lesions in Male Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... C-13

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol<sup>a</sup>**

|                                  | 0 ppm    | 10 ppm  | 30 ppm   | 90 ppm   |
|----------------------------------|----------|---------|----------|----------|
| <b>Disposition Summary</b>       |          |         |          |          |
| Animals initially in study       | 48       | 48      | 48       | 48       |
| Early deaths                     |          |         |          |          |
| Moribund                         | 5        | 6       | 6        | 15       |
| Natural deaths                   | 7        | 13      | 17       | 21       |
| Survivors                        |          |         |          |          |
| Terminal sacrifice               | 36       | 29      | 25       | 12       |
| Animals examined microscopically | 48       | 48      | 48       | 48       |
| <b>Alimentary System</b>         |          |         |          |          |
| Esophagus                        | (47)     | (46)    | (48)     | (48)     |
| Lymphoma malignant               |          |         |          | 1 (2%)   |
| Intestine large                  | (48)     | (47)    | (48)     | (46)     |
| Squamous cell carcinoma, anus    |          |         |          | 1 (2%)   |
| Intestine large, cecum           | (45)     | (45)    | (38)     | (39)     |
| Carcinoma                        | 1 (2%)   |         |          |          |
| Histiocytic sarcoma              |          |         |          | 1 (3%)   |
| Lymphoma malignant               |          |         |          | 1 (3%)   |
| Intestine large, rectum          | (47)     | (46)    | (48)     | (46)     |
| Carcinoma                        |          | 1 (2%)  |          |          |
| Sarcoma, metastatic, skin        |          |         | 1 (2%)   |          |
| Intestine small, duodenum        | (46)     | (43)    | (36)     | (38)     |
| Hemangioma                       |          |         |          | 1 (3%)   |
| Leukemia granulocytic            |          | 1 (2%)  |          |          |
| Lymphoma malignant               |          | 1 (2%)  |          | 1 (3%)   |
| Polyp adenomatous                | 1 (2%)   |         | 1 (3%)   |          |
| Intestine small, ileum           | (42)     | (43)    | (36)     | (39)     |
| Histiocytic sarcoma              |          |         |          | 1 (3%)   |
| Lymphoma malignant               | 1 (2%)   | 1 (2%)  | 1 (3%)   | 4 (10%)  |
| Intestine small, jejunum         | (45)     | (46)    | (38)     | (36)     |
| Leukemia granulocytic            |          | 1 (2%)  |          |          |
| Lymphoma malignant               | 1 (2%)   | 1 (2%)  | 1 (3%)   | 1 (3%)   |
| Liver                            | (48)     | (46)    | (48)     | (48)     |
| Hemangioma                       |          | 2 (4%)  | 2 (4%)   |          |
| Hemangiosarcoma                  | 2 (4%)   | 2 (4%)  | 4 (8%)   | 13 (27%) |
| Hepatoblastoma                   |          |         |          | 1 (2%)   |
| Hepatocellular adenoma           | 17 (35%) | 6 (13%) | 13 (27%) | 9 (19%)  |
| Hepatocellular adenoma, multiple | 2 (4%)   | 3 (7%)  | 3 (6%)   | 3 (6%)   |
| Hepatocellular carcinoma         | 7 (15%)  | 9 (20%) | 2 (4%)   | 9 (19%)  |
| Histiocytic sarcoma              | 2 (4%)   |         | 4 (8%)   | 5 (10%)  |
| Ito cell tumor malignant         |          |         | 1 (2%)   |          |
| Leukemia granulocytic            |          | 1 (2%)  |          |          |
| Lymphoma malignant               | 1 (2%)   | 1 (2%)  | 3 (6%)   | 8 (17%)  |
| Sarcoma, metastatic, skin        | 1 (2%)   |         | 1 (2%)   |          |
| Mesentery                        | (4)      | (1)     | (2)      |          |
| Hemangiosarcoma                  | 1 (25%)  |         | 1 (50%)  |          |
| Pancreas                         | (48)     | (46)    | (45)     | (44)     |
| Hemangioma                       |          |         | 1 (2%)   |          |
| Histiocytic sarcoma              |          |         | 1 (2%)   | 1 (2%)   |
| Leukemia granulocytic            |          | 1 (2%)  |          |          |
| Lymphoma malignant               | 1 (2%)   |         | 3 (7%)   | 8 (18%)  |

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm  | 10 ppm  | 30 ppm | 90 ppm  |
|--|--------|---------|--------|---------|
| <b>Alimentary System (continued)</b>             |        |         |        |         |
| Salivary glands                                  | (48)   | (48)    | (48)   | (48)    |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Lymphoma malignant                               |        |         | 1 (2%) | 1 (2%)  |
| Rhabdomyosarcoma, metastatic, skeletal muscle    |        |         |        | 1 (2%)  |
| Sarcoma, metastatic, skin                        | 1 (2%) |         |        |         |
| Stomach, forestomach                             | (48)   | (47)    | (45)   | (48)    |
| Hemangioma                                       |        |         |        | 1 (2%)  |
| Histiocytic sarcoma                              |        |         |        | 1 (2%)  |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Squamous cell carcinoma                          |        | 1 (2%)  | 1 (2%) | 1 (2%)  |
| Squamous cell papilloma                          | 2 (4%) | 2 (4%)  | 3 (7%) | 5 (10%) |
| Stomach, glandular                               | (48)   | (46)    | (45)   | (45)    |
| Adenoma  | 1 (2%) |         |        |         |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Lymphoma malignant                               | 1 (2%) |         |        | 2 (4%)  |
| Tongue   | (48)   | (48)    | (48)   | (48)    |
| Lymphoma malignant                               |        |         |        | 1 (2%)  |
| Squamous cell carcinoma                          |        | 1 (2%)  |        | 1 (2%)  |
| <b>Cardiovascular System</b>                     |        |         |        |         |
| Blood vessel                                     | (47)   | (46)    | (47)   | (47)    |
| Lymphoma malignant                               |        |         |        | 1 (2%)  |
| Heart  | (47)   | (48)    | (48)   | (48)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung |        |         |        | 2 (4%)  |
| Hemangiosarcoma                                  |        |         | 1 (2%) | 4 (8%)  |
| Histiocytic sarcoma                              | 1 (2%) |         | 1 (2%) | 1 (2%)  |
| Lymphoma malignant                               | 1 (2%) |         |        | 4 (8%)  |
| Sarcoma, metastatic, thymus                      |        |         |        | 1 (2%)  |
| <b>Endocrine System</b>                          |        |         |        |         |
| Adrenal gland                                    | (46)   | (47)    | (47)   | (45)    |
| Rhabdomyosarcoma, metastatic, skeletal muscle    |        |         |        | 1 (2%)  |
| Adrenal gland, cortex                            | (46)   | (47)    | (47)   | (45)    |
| Adenoma  | 2 (4%) | 3 (6%)  | 1 (2%) |         |
| Adenoma, subcapsular                             | 1 (2%) |         |        |         |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Lymphoma malignant                               |        |         | 1 (2%) |         |
| Adrenal gland, medulla                           | (46)   | (46)    | (46)   | (45)    |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Lymphoma malignant                               |        |         | 1 (2%) |         |
| Pheochromocytoma benign                          | 2 (4%) | 6 (13%) | 3 (7%) | 2 (4%)  |
| Pheochromocytoma malignant                       |        |         |        | 1 (2%)  |
| Islets, pancreatic                               | (48)   | (46)    | (46)   | (44)    |
| Adenoma  |        | 1 (2%)  |        |         |
| Carcinoma  |        |         | 1 (2%) |         |
| Leukemia granulocytic                            |        | 1 (2%)  |        |         |
| Lymphoma malignant                               |        |         |        | 1 (2%)  |
| Pituitary gland                                  | (39)   | (39)    | (42)   | (42)    |
| Lymphoma malignant                               |        |         |        | 1 (2%)  |
| Thyroid gland                                    | (45)   | (47)    | (48)   | (47)    |
| Adenoma, follicular cell                         | 1 (2%) |         |        |         |
| Lymphoma malignant                               |        |         |        | 3 (6%)  |

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm   |
|---|---------|---------|---------|----------|
| <b>General Body System</b>                              |         |         |         |          |
| Tissue NOS  |         |         |         | (1)      |
| Alveolar/bronchiolar carcinoma, metastatic, lung        |         |         |         | 1 (100%) |
| <b>Genital System</b>                                   |         |         |         |          |
| Coagulating gland                                       | (47)    | (47)    | (48)    | (44)     |
| Lymphoma malignant                                      |         |         |         | 2 (5%)   |
| Epididymis  | (48)    | (48)    | (48)    | (47)     |
| Histiocytic sarcoma                                     |         |         | 1 (2%)  | 1 (2%)   |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      |         |         |         | 5 (11%)  |
| Preputial gland   | (45)    | (46)    | (45)    | (44)     |
| Hemangioma  |         |         | 1 (2%)  |          |
| Lymphoma malignant                                      |         |         |         | 1 (2%)   |
| Prostate  | (46)    | (46)    | (45)    | (48)     |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      | 1 (2%)  |         | 2 (4%)  | 6 (13%)  |
| Seminal vesicle   | (47)    | (47)    | (48)    | (45)     |
| Adenoma   |         |         | 1 (2%)  |          |
| Histiocytic sarcoma                                     |         |         |         | 1 (2%)   |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      |         |         |         | 3 (7%)   |
| Testes  | (48)    | (48)    | (48)    | (48)     |
| Adenoma, interstitial cell                              |         | 1 (2%)  |         |          |
| Hemangioma  | 1 (2%)  |         |         |          |
| <b>Hematopoietic System</b>                             |         |         |         |          |
| Bone marrow   | (48)    | (46)    | (46)    | (46)     |
| Hemangiosarcoma   |         | 1 (2%)  |         |          |
| Histiocytic sarcoma                                     |         |         | 1 (2%)  | 2 (4%)   |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      |         |         |         | 4 (9%)   |
| Lymph node  | (48)    | (47)    | (48)    | (47)     |
| Alveolar/bronchiolar carcinoma, metastatic, renal, lung |         |         |         | 1 (2%)   |
| Histiocytic sarcoma, axillary                           | 1 (2%)  |         |         |          |
| Histiocytic sarcoma, lumbar                             |         |         | 1 (2%)  | 1 (2%)   |
| Lymphoma malignant, axillary                            |         |         | 1 (2%)  | 2 (4%)   |
| Lymphoma malignant, inguinal                            |         | 1 (2%)  | 1 (2%)  | 4 (9%)   |
| Lymphoma malignant, lumbar                              |         |         | 2 (4%)  | 1 (2%)   |
| Lymphoma malignant, pancreatic                          |         |         |         | 1 (2%)   |
| Lymphoma malignant, renal                               | 1 (2%)  | 1 (2%)  | 3 (6%)  | 4 (9%)   |
| Lymphoma malignant, thoracic                            |         |         | 1 (2%)  |          |
| Lymph node, mandibular                                  | (48)    | (47)    | (48)    | (47)     |
| Histiocytic sarcoma                                     |         |         | 1 (2%)  | 2 (4%)   |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      | 2 (4%)  | 5 (11%) | 5 (10%) | 8 (17%)  |
| Sarcoma, metastatic, skin                               | 2 (4%)  | 1 (2%)  |         |          |
| Lymph node, mesenteric                                  | (46)    | (44)    | (42)    | (43)     |
| Hemangiosarcoma   |         |         |         | 1 (2%)   |
| Histiocytic sarcoma                                     |         |         | 3 (7%)  | 4 (9%)   |
| Leukemia granulocytic                                   |         | 1 (2%)  |         |          |
| Lymphoma malignant                                      | 6 (13%) | 5 (11%) | 7 (17%) | 12 (28%) |

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm  | 30 ppm   | 90 ppm   |
|--|----------|---------|----------|----------|
| <b>Hematopoietic System (continued)</b>          |          |         |          |          |
| Spleen   | (48)     | (46)    | (46)     | (45)     |
| Hemangiosarcoma                                  |          | 1 (2%)  |          | 1 (2%)   |
| Histiocytic sarcoma                              | 2 (4%)   |         | 3 (7%)   | 3 (7%)   |
| Leukemia granulocytic                            |          | 1 (2%)  |          |          |
| Lymphoma malignant                               | 9 (19%)  | 9 (20%) | 6 (13%)  | 10 (22%) |
| Sarcoma, metastatic, skin                        |          |         | 1 (2%)   |          |
| Thymus   | (34)     | (33)    | (32)     | (35)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          |         |          | 2 (6%)   |
| Leukemia granulocytic                            |          | 1 (3%)  |          |          |
| Lymphoma malignant                               |          | 2 (6%)  |          | 10 (29%) |
| Sarcoma  |          |         |          | 1 (3%)   |
| Thymoma benign                                   |          |         | 1 (3%)   | 1 (3%)   |
| <b>Integumentary System</b>                      |          |         |          |          |
| Skin   | (48)     | (47)    | (48)     | (45)     |
| Adenoma, sebaceous gland                         |          |         |          | 1 (2%)   |
| Basal cell adenoma                               |          |         |          | 2 (4%)   |
| Fibroma  | 2 (4%)   | 2 (4%)  | 1 (2%)   | 1 (2%)   |
| Fibroma, multiple                                |          |         | 1 (2%)   |          |
| Hemangiosarcoma                                  |          |         |          | 1 (2%)   |
| Lipoma   |          |         |          | 1 (2%)   |
| Lymphoma malignant                               |          |         | 1 (2%)   | 2 (4%)   |
| Osteosarcoma                                     |          |         | 1 (2%)   |          |
| Sarcoma  | 10 (21%) | 8 (17%) | 12 (25%) | 11 (24%) |
| Sarcoma, multiple                                | 2 (4%)   | 2 (4%)  | 3 (6%)   | 1 (2%)   |
| Squamous cell carcinoma                          |          |         |          | 1 (2%)   |
| Squamous cell papilloma                          |          | 2 (4%)  |          | 6 (13%)  |
| <b>Musculoskeletal System</b>                    |          |         |          |          |
| Bone   | (48)     | (48)    | (47)     | (48)     |
| Carcinoma, metastatic, sternum, harderian gland  |          |         |          | 1 (2%)   |
| Skeletal muscle                                  | (48)     | (48)    | (48)     | (47)     |
| Lymphoma malignant                               |          |         |          | 1 (2%)   |
| Rhabdomyosarcoma                                 |          |         | 1 (2%)   | 1 (2%)   |
| Sarcoma  |          | 1 (2%)  |          |          |
| Sarcoma, metastatic, skin                        |          | 1 (2%)  |          |          |
| <b>Nervous System</b>                            |          |         |          |          |
| Brain, cerebrum                                  | (48)     | (48)    | (48)     | (48)     |
| Leukemia granulocytic, meninges                  |          | 1 (2%)  |          |          |
| Lymphoma malignant                               |          |         |          | 2 (4%)   |
| Peripheral nerve                                 | (47)     | (48)    | (48)     | (47)     |
| Schwannoma malignant                             | 1 (2%)   |         |          |          |
| <b>Respiratory System</b>                        |          |         |          |          |
| Larynx   | (46)     | (47)    | (45)     | (47)     |
| Leukemia granulocytic                            |          | 1 (2%)  |          |          |
| Lymphoma malignant                               |          |         |          | 3 (6%)   |

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|--|---------|----------|----------|----------|
| <b>Respiratory System (continued)</b>              |         |          |          |          |
| Lung   | (48)    | (48)     | (48)     | (48)     |
| Alveolar/bronchiolar adenoma                       | 5 (10%) | 7 (15%)  | 6 (13%)  | 19 (40%) |
| Alveolar/bronchiolar adenoma, multiple             | 1 (2%)  | 1 (2%)   | 3 (6%)   | 14 (29%) |
| Alveolar/bronchiolar carcinoma                     | 5 (10%) | 4 (8%)   | 5 (10%)  | 15 (31%) |
| Alveolar/bronchiolar carcinoma, multiple           |         |          |          | 2 (4%)   |
| Carcinoma, metastatic, harderian gland             |         |          |          | 1 (2%)   |
| Hemangiosarcoma                                    |         |          |          | 1 (2%)   |
| Hepatocellular carcinoma, metastatic, liver        |         | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Histiocytic sarcoma                                |         |          | 3 (6%)   | 3 (6%)   |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 | 2 (4%)  | 1 (2%)   | 2 (4%)   | 4 (8%)   |
| Rhabdomyosarcoma, metastatic, skeletal muscle      |         |          |          | 1 (2%)   |
| Sarcoma, metastatic, skin                          | 1 (2%)  | 4 (8%)   | 2 (4%)   |          |
| Sarcoma, metastatic, thymus                        |         |          |          | 1 (2%)   |
| Nose   | (48)    | (48)     | (48)     | (46)     |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          |          | 4 (9%)   |
| Trachea  | (47)    | (48)     | (48)     | (48)     |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          |          | 2 (4%)   |
| <b>Special Senses System</b>                       |         |          |          |          |
| Eye  | (48)    | (48)     | (48)     | (46)     |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Schwannoma malignant, metastatic, peripheral nerve | 1 (2%)  |          |          |          |
| Harderian gland                                    | (47)    | (48)     | (48)     | (45)     |
| Adenoma  | 5 (11%) | 12 (25%) | 12 (25%) | 16 (36%) |
| Adenoma, bilateral                                 |         |          | 3 (6%)   | 10 (22%) |
| Carcinoma  |         | 2 (4%)   | 2 (4%)   | 7 (16%)  |
| Carcinoma, bilateral                               |         |          |          | 3 (7%)   |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          |          | 1 (2%)   |
| Lacrimal gland                                     | (47)    | (47)     | (48)     | (47)     |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          | 1 (2%)   | 1 (2%)   |
| Zymbal's gland                                     | (46)    | (45)     | (47)     | (42)     |
| Carcinoma  |         |          |          | 1 (2%)   |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          |          | 1 (2%)   |
| <b>Urinary System</b>                              |         |          |          |          |
| Kidney   | (48)    | (47)     | (48)     | (48)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung   |         |          |          | 1 (2%)   |
| Carcinoma, renal tubule                            |         |          |          | 1 (2%)   |
| Hemangiosarcoma                                    |         |          |          | 3 (6%)   |
| Histiocytic sarcoma                                |         |          | 1 (2%)   | 1 (2%)   |
| Leukemia granulocytic                              |         | 1 (2%)   |          |          |
| Lymphoma malignant                                 |         |          | 4 (8%)   | 7 (15%)  |
| Sarcoma, metastatic, skin                          |         |          | 2 (4%)   |          |

**TABLE C1**  
**Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm  | 10 ppm | 30 ppm | 90 ppm |
|---|--------|--------|--------|--------|
| <b>Urinary System</b> (continued)                 |        |        |        |        |
| Urinary bladder                                   | (48)   | (47)   | (48)   | (45)   |
| Carcinoma   |        |        |        | 1 (2%) |
| Hemangioma  | 2 (4%) | 1 (2%) |        |        |
| Leukemia granulocytic                             |        | 1 (2%) |        |        |
| Lymphoma malignant                                | 1 (2%) |        |        | 3 (7%) |
| <b>Neoplasm Summary</b>                           |        |        |        |        |
| Total animals with primary neoplasms <sup>b</sup> | 42     | 40     | 44     | 46     |
| Total primary neoplasms                           | 108    | 138    | 158    | 345    |
| Total animals with benign neoplasms               | 30     | 29     | 32     | 40     |
| Total benign neoplasms                            | 45     | 49     | 56     | 92     |
| Total animals with malignant neoplasms            | 31     | 29     | 37     | 45     |
| Total malignant neoplasms                         | 63     | 89     | 102    | 253    |
| Total animals with metastatic neoplasms           | 5      | 6      | 4      | 8      |
| Total metastatic neoplasms                        | 6      | 8      | 8      | 16     |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE C2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|--|----------------|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>                               |                |                 |                 |                 |
| Overall rate <sup>a</sup>                                    | 3/46 (6.5%)    | 3/47 (6.4%)     | 1/47 (2.1%)     | 0/45 (0.0%)     |
| Adjusted rate <sup>b</sup>                                   | 3/41.9 (7.2%)  | 3/38.6 (7.8%)   | 1/36.7 (2.7%)   | 0/31.5 (0.0%)   |
| Terminal rate <sup>c</sup>                                   | 3/35 (8.6%)    | 3/29 (10.3%)    | 0/25 (0.0%)     | 0/12 (0.0%)     |
| First incidence (days)                                       | 765 (T)        | 765 (T)         | 763             | — <sup>e</sup>  |
| Poly-3 test <sup>d</sup>                                     | P=0.095N       | P=0.624         | P=0.354N        | P=0.178N        |
| <b>Adrenal Medulla: Benign Pheochromocytoma</b>              |                |                 |                 |                 |
| Overall rate   | 2/46 (4.3%)    | 6/46 (13.0%)    | 3/46 (6.5%)     | 2/45 (4.4%)     |
| Adjusted rate  | 2/41.9 (4.8%)  | 6/37.7 (15.9%)  | 3/36.6 (8.2%)   | 2/31.6 (6.3%)   |
| Terminal rate  | 2/35 (5.7%)    | 5/28 (17.9%)    | 1/24 (4.2%)     | 1/12 (8.3%)     |
| First incidence (days)                                       | 765 (T)        | 739             | 507             | 753             |
| Poly-3 test  | P=0.456N       | P=0.100         | P=0.438         | P=0.587         |
| <b>Adrenal Medulla: Benign or Malignant Pheochromocytoma</b> |                |                 |                 |                 |
| Overall rate   | 2/46 (4.3%)    | 6/46 (13.0%)    | 3/46 (6.5%)     | 3/45 (6.7%)     |
| Adjusted rate  | 2/41.9 (4.8%)  | 6/37.7 (15.9%)  | 3/36.6 (8.2%)   | 3/31.8 (9.4%)   |
| Terminal rate  | 2/35 (5.7%)    | 5/28 (17.9%)    | 1/24 (4.2%)     | 1/12 (8.3%)     |
| First incidence (days)                                       | 765 (T)        | 739             | 507             | 691             |
| Poly-3 test  | P=0.535        | P=0.100         | P=0.438         | P=0.377         |
| <b>Harderian Gland: Adenoma</b>                              |                |                 |                 |                 |
| Overall rate   | 5/47 (10.6%)   | 12/48 (25.0%)   | 15/48 (31.3%)   | 26/45 (57.8%)   |
| Adjusted rate  | 5/42.9 (11.7%) | 12/40.0 (30.0%) | 15/39.1 (38.4%) | 26/38.3 (67.9%) |
| Terminal rate  | 5/35 (14.3%)   | 10/29 (34.5%)   | 10/25 (40.0%)   | 6/12 (50.0%)    |
| First incidence (days)                                       | 765 (T)        | 517             | 507             | 444             |
| Poly-3 test  | P=0.001        | P=0.034         | P=0.004         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>                            |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 2/48 (4.2%)     | 2/48 (4.2%)     | 10/45 (22.2%)   |
| Adjusted rate  | 0/42.9 (0.0%)  | 2/38.7 (5.2%)   | 2/37.7 (5.3%)   | 10/33.8 (29.6%) |
| Terminal rate  | 0/35 (0.0%)    | 1/29 (3.4%)     | 1/25 (4.0%)     | 4/12 (33.3%)    |
| First incidence (days)                                       | —              | 748             | 539             | 478             |
| Poly-3 test  | P=0.001        | P=0.215         | P=0.210         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>                 |                |                 |                 |                 |
| Overall rate   | 5/47 (10.6%)   | 14/48 (29.2%)   | 17/48 (35.4%)   | 35/45 (77.8%)   |
| Adjusted rate  | 5/42.9 (11.7%) | 14/40.1 (34.9%) | 17/39.7 (42.8%) | 35/39.8 (87.9%) |
| Terminal rate  | 5/35 (14.3%)   | 11/29 (37.9%)   | 11/25 (44.0%)   | 10/12 (83.3%)   |
| First incidence (days)                                       | 765 (T)        | 517             | 507             | 444             |
| Poly-3 test  | P=0.001        | P=0.010         | P=0.001         | P=0.001         |
| <b>Heart: Hemangiosarcoma</b>                                |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/48 (0.0%)     | 1/48 (2.1%)     | 4/48 (8.3%)     |
| Adjusted rate  | 0/43.5 (0.0%)  | 0/38.7 (0.0%)   | 1/37.4 (2.7%)   | 4/33.9 (11.8%)  |
| Terminal rate  | 0/36 (0.0%)    | 0/29 (0.0%)     | 0/25 (0.0%)     | 2/12 (16.7%)    |
| First incidence (days)                                       | —              | — <sup>f</sup>  | 660             | 670             |
| Poly-3 test  | P=0.003        | —               | P=0.470         | P=0.035         |
| <b>Kidney: Hemangiosarcoma</b>                               |                |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)    | 0/47 (0.0%)     | 0/48 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/43.9 (0.0%)  | 0/38.6 (0.0%)   | 0/37.1 (0.0%)   | 3/34.0 (8.8%)   |
| Terminal rate  | 0/36 (0.0%)    | 0/29 (0.0%)     | 0/25 (0.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                       | —              | —               | —               | 643             |
| Poly-3 test  | P=0.006        | —               | —               | P=0.079         |

**TABLE C2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>Liver: Hemangiosarcoma</b>                            |                 |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)     | 2/46 (4.3%)     | 4/48 (8.3%)     | 13/48 (27.1%)   |
| Adjusted rate  | 2/44.6 (4.5%)   | 2/38.4 (5.2%)   | 4/37.4 (10.7%)  | 13/35.2 (36.9%) |
| Terminal rate  | 1/36 (2.8%)     | 1/29 (3.4%)     | 3/25 (12.0%)    | 5/12 (41.7%)    |
| First incidence (days)                                   | 464             | 620             | 660             | 507             |
| Poly-3 test  | P=0.001         | P=0.638         | P=0.260         | P=0.001         |
| <b>Liver: Hemangioma or Hemangiosarcoma</b>              |                 |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)     | 4/46 (8.7%)     | 6/48 (12.5%)    | 13/48 (27.1%)   |
| Adjusted rate  | 2/44.6 (4.5%)   | 4/38.4 (10.4%)  | 6/37.4 (16.0%)  | 13/35.2 (36.9%) |
| Terminal rate  | 1/36 (2.8%)     | 3/29 (10.3%)    | 5/25 (20.0%)    | 5/12 (41.7%)    |
| First incidence (days)                                   | 464             | 620             | 660             | 507             |
| Poly-3 test  | P=0.001         | P=0.270         | P=0.083         | P=0.001         |
| <b>Liver: Histiocytic Sarcoma</b>                        |                 |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)     | 0/46 (0.0%)     | 4/48 (8.3%)     | 5/48 (10.4%)    |
| Adjusted rate  | 2/44.6 (4.5%)   | 0/37.9 (0.0%)   | 4/37.8 (10.6%)  | 5/35.2 (14.2%)  |
| Terminal rate  | 0/36 (0.0%)     | 0/29 (0.0%)     | 1/25 (4.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                   | 542             | —               | 625             | 577             |
| Poly-3 test  | P=0.029         | P=0.276N        | P=0.262         | P=0.131         |
| <b>Liver: Hepatocellular Adenoma</b>                     |                 |                 |                 |                 |
| Overall rate   | 19/48 (39.6%)   | 9/46 (19.6%)    | 16/48 (33.3%)   | 12/48 (25.0%)   |
| Adjusted rate  | 19/44.6 (42.6%) | 9/38.1 (23.7%)  | 16/38.2 (41.9%) | 12/35.1 (34.2%) |
| Terminal rate  | 16/36 (44.4%)   | 7/29 (24.1%)    | 12/25 (48.0%)   | 6/12 (50.0%)    |
| First incidence (days)                                   | 607             | 747             | 570             | 570             |
| Poly-3 test  | P=0.475N        | P=0.054N        | P=0.563N        | P=0.296N        |
| <b>Liver: Hepatocellular Carcinoma</b>                   |                 |                 |                 |                 |
| Overall rate   | 7/48 (14.6%)    | 9/46 (19.6%)    | 2/48 (4.2%)     | 9/48 (18.8%)    |
| Adjusted rate  | 7/44.9 (15.6%)  | 9/39.2 (23.0%)  | 2/37.9 (5.3%)   | 9/36.5 (24.7%)  |
| Terminal rate  | 3/36 (8.3%)     | 6/29 (20.7%)    | 0/25 (0.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                   | 447             | 542             | 570             | 553             |
| Poly-3 test  | P=0.264         | P=0.281         | P=0.127N        | P=0.229         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>        |                 |                 |                 |                 |
| Overall rate   | 25/48 (52.1%)   | 16/46 (34.8%)   | 17/48 (35.4%)   | 18/48 (37.5%)   |
| Adjusted rate  | 25/45.6 (54.8%) | 16/39.2 (40.8%) | 17/38.4 (44.3%) | 18/37.1 (48.6%) |
| Terminal rate  | 19/36 (52.8%)   | 12/29 (41.4%)   | 12/25 (48.0%)   | 7/12 (58.3%)    |
| First incidence (days)                                   | 447             | 542             | 570             | 553             |
| Poly-3 test  | P=0.482N        | P=0.140N        | P=0.227N        | P=0.365N        |
| <b>Liver: Hepatocellular Carcinoma or Hepatoblastoma</b> |                 |                 |                 |                 |
| Overall rate   | 7/48 (14.6%)    | 9/46 (19.6%)    | 2/48 (4.2%)     | 10/48 (20.8%)   |
| Adjusted rate  | 7/44.9 (15.6%)  | 9/39.2 (23.0%)  | 2/37.9 (5.3%)   | 10/36.5 (27.4%) |
| Terminal rate  | 3/36 (8.3%)     | 6/29 (20.7%)    | 0/25 (0.0%)     | 2/12 (16.7%)    |
| First incidence (days)                                   | 447             | 542             | 570             | 553             |
| Poly-3 test  | P=0.168         | P=0.281         | P=0.127N        | P=0.152         |
| <b>Lung: Histiocytic Sarcoma</b>                         |                 |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)     | 0/48 (0.0%)     | 3/48 (6.3%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/43.9 (0.0%)   | 0/38.7 (0.0%)   | 3/37.8 (7.9%)   | 3/34.4 (8.7%)   |
| Terminal rate  | 0/36 (0.0%)     | 0/29 (0.0%)     | 0/25 (0.0%)     | 1/12 (8.3%)     |
| First incidence (days)                                   | —               | —               | 625             | 593             |
| Poly-3 test  | P=0.029         | —               | P=0.094         | P=0.081         |

**TABLE C2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|---|-----------------|-----------------|-----------------|-----------------|
| <b>Lung: Alveolar/bronchiolar Adenoma</b>                       |                 |                 |                 |                 |
| Overall rate  | 6/48 (12.5%)    | 8/48 (16.7%)    | 9/48 (18.8%)    | 33/48 (68.8%)   |
| Adjusted rate   | 6/44.1 (13.6%)  | 8/38.7 (20.7%)  | 9/38.1 (23.6%)  | 33/42.2 (78.2%) |
| Terminal rate   | 5/36 (13.9%)    | 8/29 (27.6%)    | 6/25 (24.0%)    | 9/12 (75.0%)    |
| First incidence (days)  | 710             | 765 (T)         | 507             | 355             |
| Poly-3 test   | P=0.001         | P=0.288         | P=0.189         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>                     |                 |                 |                 |                 |
| Overall rate  | 5/48 (10.4%)    | 4/48 (8.3%)     | 5/48 (10.4%)    | 17/48 (35.4%)   |
| Adjusted rate   | 5/43.9 (11.4%)  | 4/38.7 (10.3%)  | 5/37.6 (13.3%)  | 17/37.1 (45.9%) |
| Terminal rate   | 5/36 (13.9%)    | 4/29 (13.8%)    | 3/25 (12.0%)    | 5/12 (41.7%)    |
| First incidence (days)  | 765 (T)         | 765 (T)         | 671             | 478             |
| Poly-3 test   | P=0.001         | P=0.578N        | P=0.531         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b>          |                 |                 |                 |                 |
| Overall rate  | 11/48 (22.9%)   | 11/48 (22.9%)   | 14/48 (29.2%)   | 40/48 (83.3%)   |
| Adjusted rate   | 11/44.1 (25.0%) | 11/38.7 (28.4%) | 14/38.6 (36.2%) | 40/44.5 (89.9%) |
| Terminal rate   | 10/36 (27.8%)   | 11/29 (37.9%)   | 9/25 (36.0%)    | 11/12 (91.7%)   |
| First incidence (days)  | 710             | 765 (T)         | 507             | 355             |
| Poly-3 test   | P=0.001         | P=0.457         | P=0.190         | P=0.001         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>             |                 |                 |                 |                 |
| Overall rate  | 0/46 (0.0%)     | 0/44 (0.0%)     | 3/42 (7.1%)     | 4/43 (9.3%)     |
| Adjusted rate   | 0/42.0 (0.0%)   | 0/36.6 (0.0%)   | 3/34.8 (8.6%)   | 4/31.8 (12.6%)  |
| Terminal rate   | 0/36 (0.0%)     | 0/28 (0.0%)     | 1/25 (4.0%)     | 1/12 (8.3%)     |
| First incidence (days)  | —               | —               | 678             | 577             |
| Poly-3 test   | P=0.007         | —               | P=0.087         | P=0.032         |
| <b>Skin: Sarcoma</b>  |                 |                 |                 |                 |
| Overall rate  | 12/48 (25.0%)   | 10/47 (21.3%)   | 15/48 (31.3%)   | 12/45 (26.7%)   |
| Adjusted rate   | 12/44.8 (26.8%) | 10/40.8 (24.5%) | 15/42.4 (35.4%) | 12/34.4 (34.9%) |
| Terminal rate   | 6/36 (16.7%)    | 2/29 (6.9%)     | 3/25 (12.0%)    | 4/12 (33.3%)    |
| First incidence (days)  | 607             | 517             | 368             | 467             |
| Poly-3 test   | P=0.205         | P=0.504N        | P=0.263         | P=0.299         |
| <b>Skin: Fibroma or Sarcoma</b>                                 |                 |                 |                 |                 |
| Overall rate  | 13/48 (27.1%)   | 12/47 (25.5%)   | 16/48 (33.3%)   | 13/45 (28.9%)   |
| Adjusted rate   | 13/44.8 (29.0%) | 12/40.8 (29.4%) | 16/42.4 (37.7%) | 13/34.4 (37.8%) |
| Terminal rate   | 7/36 (19.4%)    | 4/29 (13.8%)    | 4/25 (16.0%)    | 4/12 (33.3%)    |
| First incidence (days)  | 607             | 517             | 368             | 467             |
| Poly-3 test   | P=0.221         | P=0.577         | P=0.262         | P=0.282         |
| <b>Skin: Squamous Cell Papilloma</b>                            |                 |                 |                 |                 |
| Overall rate  | 0/48 (0.0%)     | 2/47 (4.3%)     | 0/48 (0.0%)     | 6/45 (13.3%)    |
| Adjusted rate   | 0/43.9 (0.0%)   | 2/39.0 (5.1%)   | 0/37.1 (0.0%)   | 6/32.4 (18.5%)  |
| Terminal rate   | 0/36 (0.0%)     | 1/29 (3.4%)     | 0/25 (0.0%)     | 2/12 (16.7%)    |
| First incidence (days)  | —               | 662             | —               | 710             |
| Poly-3 test   | P=0.001         | P=0.211         | —               | P=0.005         |
| <b>Skin: Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                 |                 |                 |                 |
| Overall rate  | 0/48 (0.0%)     | 2/47 (4.3%)     | 0/48 (0.0%)     | 7/45 (15.6%)    |
| Adjusted rate   | 0/43.9 (0.0%)   | 2/39.0 (5.1%)   | 0/37.1 (0.0%)   | 7/32.4 (21.6%)  |
| Terminal rate   | 0/36 (0.0%)     | 1/29 (3.4%)     | 0/25 (0.0%)     | 2/12 (16.7%)    |
| First incidence (days)  | —               | 662             | —               | 710             |
| Poly-3 test   | P=0.001         | P=0.211         | —               | P=0.002         |

**TABLE C2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm         | 30 ppm         | 90 ppm          |
|--|----------------|----------------|----------------|-----------------|
| <b>Skin: Squamous Cell Papilloma, Basal Cell Adenoma, or Squamous Cell Carcinoma</b> |                |                |                |                 |
| Overall rate   | 0/48 (0.0%)    | 2/47 (4.3%)    | 0/48 (0.0%)    | 10/45 (22.2%)   |
| Adjusted rate  | 0/43.9 (0.0%)  | 2/39.0 (5.1%)  | 0/37.1 (0.0%)  | 10/32.9 (30.4%) |
| Terminal rate  | 0/36 (0.0%)    | 1/29 (3.4%)    | 0/25 (0.0%)    | 3/12 (25.0%)    |
| First incidence (days)   | —              | 662            | —              | 691             |
| Poly-3 test  | P=0.001        | P=0.211        | —              | P=0.001         |
| <b>Spleen: Histiocytic Sarcoma</b>   |                |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 0/46 (0.0%)    | 3/46 (6.5%)    | 3/45 (6.7%)     |
| Adjusted rate  | 2/44.9 (4.5%)  | 0/37.9 (0.0%)  | 3/37.1 (8.1%)  | 3/33.1 (9.1%)   |
| Terminal rate  | 0/36 (0.0%)    | 0/29 (0.0%)    | 0/25 (0.0%)    | 1/12 (8.3%)     |
| First incidence (days)   | 542            | —              | 625            | 593             |
| Poly-3 test  | P=0.155        | P=0.276N       | P=0.415        | P=0.366         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                                |                |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 2/47 (4.3%)    | 3/45 (6.7%)    | 5/48 (10.4%)    |
| Adjusted rate  | 2/43.9 (4.6%)  | 2/38.0 (5.3%)  | 3/36.6 (8.2%)  | 5/33.8 (14.8%)  |
| Terminal rate  | 2/36 (5.6%)    | 2/29 (6.9%)    | 2/25 (8.0%)    | 2/12 (16.7%)    |
| First incidence (days)   | 765 (T)        | 765 (T)        | 614            | 697             |
| Poly-3 test  | P=0.067        | P=0.641        | P=0.418        | P=0.125         |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b>     |                |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 2/47 (4.3%)    | 4/45 (8.9%)    | 5/48 (10.4%)    |
| Adjusted rate  | 2/43.9 (4.6%)  | 2/38.0 (5.3%)  | 4/36.6 (10.9%) | 5/33.8 (14.8%)  |
| Terminal rate  | 2/36 (5.6%)    | 2/29 (6.9%)    | 2/25 (8.0%)    | 2/12 (16.7%)    |
| First incidence (days)   | 765 (T)        | 765 (T)        | 614            | 697             |
| Poly-3 test  | P=0.070        | P=0.641        | P=0.257        | P=0.125         |
| <b>All Organs: Hemangioma</b>  |                |                |                |                 |
| Overall rate   | 3/48 (6.3%)    | 3/48 (6.3%)    | 2/48 (4.2%)    | 2/48 (4.2%)     |
| Adjusted rate  | 3/43.9 (6.8%)  | 3/38.7 (7.8%)  | 2/37.1 (5.4%)  | 2/33.6 (6.0%)   |
| Terminal rate  | 3/36 (8.3%)    | 3/29 (10.3%)   | 2/25 (8.0%)    | 1/12 (8.3%)     |
| First incidence (days)   | 765 (T)        | 765 (T)        | 765 (T)        | 748             |
| Poly-3 test  | P=0.508N       | P=0.603        | P=0.576N       | P=0.619N        |
| <b>All Organs: Hemangiosarcoma</b>   |                |                |                |                 |
| Overall rate   | 3/48 (6.3%)    | 3/48 (6.3%)    | 5/48 (10.4%)   | 18/48 (37.5%)   |
| Adjusted rate  | 3/44.6 (6.7%)  | 3/39.1 (7.7%)  | 5/37.4 (13.4%) | 18/36.2 (49.7%) |
| Terminal rate  | 2/36 (5.6%)    | 2/29 (6.9%)    | 4/25 (16.0%)   | 7/12 (58.3%)    |
| First incidence (days)   | 464            | 620            | 660            | 507             |
| Poly-3 test  | P=0.001        | P=0.600        | P=0.264        | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                     |                |                |                |                 |
| Overall rate   | 6/48 (12.5%)   | 6/48 (12.5%)   | 7/48 (14.6%)   | 19/48 (39.6%)   |
| Adjusted rate  | 6/44.6 (13.4%) | 6/39.1 (15.3%) | 7/37.4 (18.7%) | 19/36.3 (52.4%) |
| Terminal rate  | 5/36 (13.9%)   | 5/29 (17.2%)   | 6/25 (24.0%)   | 7/12 (58.3%)    |
| First incidence (days)   | 464            | 620            | 660            | 507             |
| Poly-3 test  | P=0.001        | P=0.526        | P=0.366        | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>   |                |                |                |                 |
| Overall rate   | 2/48 (4.2%)    | 0/48 (0.0%)    | 4/48 (8.3%)    | 5/48 (10.4%)    |
| Adjusted rate  | 2/44.9 (4.5%)  | 0/38.7 (0.0%)  | 4/37.8 (10.6%) | 5/35.2 (14.2%)  |
| Terminal rate  | 0/36 (0.0%)    | 0/29 (0.0%)    | 1/25 (4.0%)    | 1/12 (8.3%)     |
| First incidence (days)   | 542            | —              | 625            | 577             |
| Poly-3 test  | P=0.028        | P=0.272N       | P=0.262        | P=0.131         |

**TABLE C2**  
**Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |                 |
| Overall rate                                     | 12/48 (25.0%)   | 10/48 (20.8%)   | 8/48 (16.7%)    | 14/48 (29.2%)   |
| Adjusted rate                                    | 12/44.5 (27.0%) | 10/38.9 (25.7%) | 8/37.1 (21.6%)  | 14/37.1 (37.7%) |
| Terminal rate                                    | 11/36 (30.6%)   | 9/29 (31.0%)    | 8/25 (32.0%)    | 4/12 (33.3%)    |
| First incidence (days)                           | 542             | 701             | 765 (T)         | 296             |
| Poly-3 test                                      | P=0.137         | P=0.547N        | P=0.381N        | P=0.210         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |                 |
| Overall rate                                     | 30/48 (62.5%)   | 29/48 (60.4%)   | 32/48 (66.7%)   | 40/48 (83.3%)   |
| Adjusted rate                                    | 30/45.0 (66.6%) | 29/40.6 (71.4%) | 32/41.2 (77.7%) | 40/42.8 (93.5%) |
| Terminal rate                                    | 25/36 (69.4%)   | 23/29 (79.3%)   | 21/25 (84.0%)   | 12/12 (100.0%)  |
| First incidence (days)                           | 607             | 517             | 368             | 355             |
| Poly-3 test                                      | P=0.001         | P=0.401         | P=0.174         | P=0.001         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |                 |
| Overall rate                                     | 31/48 (64.6%)   | 30/48 (62.5%)   | 37/48 (77.1%)   | 45/48 (93.8%)   |
| Adjusted rate                                    | 31/47.5 (65.2%) | 30/42.9 (70.0%) | 37/44.8 (82.6%) | 45/45.5 (98.9%) |
| Terminal rate                                    | 20/36 (55.6%)   | 18/29 (62.1%)   | 18/25 (72.0%)   | 12/12 (100.0%)  |
| First incidence (days)                           | 447             | 421             | 368             | 296             |
| Poly-3 test                                      | P=0.001         | P=0.400         | P=0.046         | P=0.001         |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |                 |
| Overall rate                                     | 42/48 (87.5%)   | 41/48 (85.4%)   | 44/48 (91.7%)   | 46/48 (95.8%)   |
| Adjusted rate                                    | 42/47.5 (88.4%) | 41/43.2 (94.8%) | 44/45.2 (97.4%) | 46/46.3 (99.4%) |
| Terminal rate                                    | 31/36 (86.1%)   | 28/29 (96.6%)   | 24/25 (96.0%)   | 12/12 (100.0%)  |
| First incidence (days)                           | 447             | 421             | 368             | 296             |
| Poly-3 test                                      | P=0.023         | P=0.224         | P=0.096         | P=0.030         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol<sup>a</sup>**

|  | 0 ppm    | 10 ppm  | 30 ppm   | 90 ppm   |
|--|----------|---------|----------|----------|
| <b>Disposition Summary</b>                   |          |         |          |          |
| Animals initially in study                   | 48       | 48      | 48       | 48       |
| Early deaths                                 |          |         |          |          |
| Moribund                                     | 5        | 6       | 6        | 15       |
| Natural deaths                               | 7        | 13      | 17       | 21       |
| Survivors                                    |          |         |          |          |
| Terminal sacrifice                           | 36       | 29      | 25       | 12       |
| Animals examined microscopically             | 48       | 48      | 48       | 48       |
| <b>Alimentary System</b>                     |          |         |          |          |
| Gallbladder                                  | (42)     | (37)    | (30)     | (32)     |
| Cyst, mild, mucosa                           |          |         | 1 (3%)   |          |
| Cytoplasmic alteration, moderate, epithelium |          |         | 1 (3%)   |          |
| Inflammation, acute, minimal                 |          | 2 (5%)  |          |          |
| Inflammation, chronic, mild                  | 1 (2%)   |         |          | 1 (3%)   |
| Inflammation, chronic, minimal               | 1 (2%)   |         |          |          |
| Inflammation, subacute, minimal              |          | 1 (3%)  |          |          |
| Intestine large                              | (48)     | (47)    | (48)     | (46)     |
| Hyperplasia, mild, anus, epithelium          |          |         |          | 1 (2%)   |
| Inflammation, chronic active, mild, anus     |          |         | 1 (2%)   |          |
| Ulcer, moderate, anus                        |          |         | 1 (2%)   |          |
| Intestine large, cecum                       | (45)     | (45)    | (38)     | (39)     |
| Hyperplasia, mild, lymphoid tissue           |          | 1 (2%)  |          |          |
| Hyperplasia, moderate, lymphoid tissue       |          |         | 1 (3%)   |          |
| Intestine large, rectum                      | (47)     | (46)    | (48)     | (46)     |
| Cyst, minimal, anus                          |          | 1 (2%)  |          |          |
| Erosion, moderate                            |          |         | 1 (2%)   |          |
| Hyperplasia, mild, epithelium                |          |         |          | 1 (2%)   |
| Inflammation, acute, minimal, anus           |          | 1 (2%)  |          |          |
| Inflammation, acute, moderate                |          |         |          | 1 (2%)   |
| Inflammation, chronic active, moderate       |          |         |          | 1 (2%)   |
| Inflammation, chronic, mild                  |          |         | 1 (2%)   |          |
| Intestine small, duodenum                    | (46)     | (43)    | (36)     | (38)     |
| Hyperplasia, marked, lymphoid tissue         | 1 (2%)   |         |          |          |
| Intestine small, ileum                       | (42)     | (43)    | (36)     | (39)     |
| Inflammation, chronic, mild                  | 1 (2%)   |         |          |          |
| Liver  | (48)     | (46)    | (48)     | (48)     |
| Amyloid deposition, mild                     |          |         | 1 (2%)   |          |
| Amyloid deposition, minimal                  |          | 1 (2%)  |          |          |
| Angiectasis                                  | 1 (2%)   | 1 (2%)  | 8 (17%)  | 19 (40%) |
| Basophilic focus                             | 1 (2%)   | 4 (9%)  | 1 (2%)   |          |
| Clear cell focus                             | 2 (4%)   | 4 (9%)  | 4 (8%)   |          |
| Cyst, mild, bile duct                        | 1 (2%)   |         |          |          |
| Cyst, moderate, bile duct                    |          |         |          | 1 (2%)   |
| Eosinophilic focus                           | 10 (21%) | 9 (20%) | 18 (38%) | 25 (52%) |
| Hematopoietic cell proliferation, mild       |          |         | 2 (4%)   | 5 (10%)  |
| Hematopoietic cell proliferation, minimal    |          |         | 3 (6%)   | 8 (17%)  |
| Hematopoietic cell proliferation, moderate   | 1 (2%)   | 1 (2%)  |          |          |
| Hyperplasia, marked, Kupffer cell            | 1 (2%)   |         |          | 1 (2%)   |
| Hyperplasia, mild, bile duct                 |          |         |          | 1 (2%)   |
| Hyperplasia, mild, Kupffer cell              | 1 (2%)   | 3 (7%)  | 4 (8%)   | 5 (10%)  |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System</b> (continued)            |          |          |          |          |
| Liver (continued)                               | (48)     | (46)     | (48)     | (48)     |
| Hyperplasia, mild, oval cell                    | 1 (2%)   |          |          | 1 (2%)   |
| Hyperplasia, minimal, bile duct                 |          |          |          | 1 (2%)   |
| Hyperplasia, minimal, Kupffer cell              | 3 (6%)   | 6 (13%)  | 5 (10%)  | 2 (4%)   |
| Hyperplasia, moderate, Kupffer cell             | 2 (4%)   |          | 1 (2%)   | 5 (10%)  |
| Infarct, median lobe                            | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, minimal     |          | 2 (4%)   |          |          |
| Infiltration cellular, mixed cell, minimal      | 4 (8%)   | 3 (7%)   | 2 (4%)   |          |
| Inflammation, chronic active, marked            |          |          |          | 1 (2%)   |
| Mixed cell focus                                | 1 (2%)   | 4 (9%)   | 5 (10%)  |          |
| Necrosis, marked                                | 1 (2%)   |          |          | 2 (4%)   |
| Necrosis, mild                                  |          |          | 1 (2%)   |          |
| Necrosis, mild, hepatocyte                      | 2 (4%)   | 2 (4%)   |          | 3 (6%)   |
| Necrosis, minimal                               | 2 (4%)   |          | 2 (4%)   |          |
| Necrosis, minimal, hepatocyte                   | 5 (10%)  | 2 (4%)   | 2 (4%)   |          |
| Necrosis, moderate                              |          | 1 (2%)   |          | 2 (4%)   |
| Necrosis, moderate, hepatocyte                  |          | 1 (2%)   |          | 2 (4%)   |
| Nuclear alteration, mild, hepatocyte            | 1 (2%)   | 3 (7%)   | 3 (6%)   | 2 (4%)   |
| Nuclear alteration, minimal, hepatocyte         |          |          | 3 (6%)   |          |
| Nuclear alteration, moderate, hepatocyte        |          |          |          | 1 (2%)   |
| Regeneration                                    |          |          | 3 (6%)   | 5 (10%)  |
| Syncytial alteration, mild, hepatocyte          | 5 (10%)  | 5 (11%)  | 4 (8%)   | 4 (8%)   |
| Syncytial alteration, minimal, hepatocyte       | 10 (21%) | 8 (17%)  | 4 (8%)   | 1 (2%)   |
| Syncytial alteration, moderate, hepatocyte      | 1 (2%)   |          | 2 (4%)   |          |
| Tension lipidosis                               | 1 (2%)   |          |          |          |
| Vacuolization cytoplasmic, mild, hepatocyte     |          | 3 (7%)   | 3 (6%)   | 1 (2%)   |
| Vacuolization cytoplasmic, minimal, hepatocyte  | 2 (4%)   | 1 (2%)   |          |          |
| Vacuolization cytoplasmic, moderate, hepatocyte |          | 1 (2%)   | 1 (2%)   |          |
| Mesentery                                       | (4)      | (1)      | (2)      |          |
| Inflammation, chronic, moderate                 |          |          | 1 (50%)  |          |
| Necrosis, fat                                   | 3 (75%)  | 1 (100%) |          |          |
| Pancreas  | (48)     | (46)     | (45)     | (44)     |
| Atrophy, marked, acinar cell                    |          |          |          | 1 (2%)   |
| Atrophy, mild, acinar cell                      | 1 (2%)   |          |          |          |
| Degeneration, minimal, acinar cell              |          | 1 (2%)   |          |          |
| Dilatation, mild, duct                          |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal     | 1 (2%)   | 7 (15%)  | 4 (9%)   | 1 (2%)   |
| Inflammation, chronic active, marked            |          |          |          | 1 (2%)   |
| Necrosis, mild                                  |          |          |          | 1 (2%)   |
| Vacuolization cytoplasmic, mild, acinar cell    |          |          |          | 2 (5%)   |
| Vacuolization cytoplasmic, minimal, acinar cell |          |          | 1 (2%)   |          |
| Salivary glands                                 | (48)     | (48)     | (48)     | (48)     |
| Atrophy, mild                                   | 4 (8%)   | 2 (4%)   | 2 (4%)   | 7 (15%)  |
| Atrophy, minimal                                | 3 (6%)   |          | 1 (2%)   |          |
| Atrophy, moderate                               | 1 (2%)   |          |          | 1 (2%)   |
| Hyperplasia, moderate, duct                     | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild        | 21 (44%) | 19 (40%) | 17 (35%) | 6 (13%)  |
| Infiltration cellular, lymphocytic, minimal     | 18 (38%) | 18 (38%) | 16 (33%) | 10 (21%) |
| Infiltration cellular, lymphocytic, moderate    | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Inflammation, chronic, mild                     | 1 (2%)   |          |          |          |
| Mineralization, minimal                         |          |          | 1 (2%)   |          |
| Stomach, forestomach                            | (48)     | (47)     | (45)     | (48)     |
| Cyst, mild                                      | 1 (2%)   |          |          |          |
| Cyst, minimal                                   | 1 (2%)   |          | 1 (2%)   |          |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm  | 10 ppm | 30 ppm | 90 ppm |
|---|--------|--------|--------|--------|
| <b>Alimentary System</b> (continued)        |        |        |        |        |
| Stomach, forestomach (continued)            | (48)   | (47)   | (45)   | (48)   |
| Hyperplasia, mild, epithelium               | 1 (2%) |        |        | 2 (4%) |
| Hyperplasia, minimal, epithelium            |        |        | 1 (2%) |        |
| Hyperplasia, moderate, epithelium           |        |        | 2 (4%) |        |
| Inflammation, chronic active, mild          |        |        | 1 (2%) |        |
| Stomach, glandular                          | (48)   | (46)   | (45)   | (45)   |
| Cyst, minimal                               |        | 1 (2%) | 1 (2%) |        |
| Erosion, mild                               |        | 1 (2%) |        |        |
| Erosion, minimal                            | 1 (2%) |        |        | 1 (2%) |
| Hyperplasia, moderate, epithelium           | 1 (2%) |        |        | 1 (2%) |
| Infiltration cellular, lymphocytic, minimal | 1 (2%) |        | 1 (2%) |        |
| Inflammation, chronic, minimal              | 1 (2%) |        |        |        |
| Inflammation, subacute, minimal             | 1 (2%) |        |        |        |
| Metaplasia, squamous, minimal               | 1 (2%) |        |        |        |
| Mineralization, minimal                     |        | 1 (2%) |        |        |
| Ulcer, mild                                 |        | 1 (2%) |        |        |
| Tongue                                      | (48)   | (48)   | (48)   | (48)   |
| Foreign body                                | 1 (2%) |        |        | 2 (4%) |
| Inflammation, chronic, mild, artery         |        | 1 (2%) |        |        |
| Inflammation, chronic, minimal              | 1 (2%) |        |        | 2 (4%) |
| <b>Cardiovascular System</b>                |        |        |        |        |
| Heart                                       | (47)   | (48)   | (48)   | (48)   |
| Abscess, moderate                           |        | 1 (2%) |        |        |
| Angiectasis, mild                           |        |        |        | 2 (4%) |
| Angiectasis, minimal                        |        |        | 1 (2%) | 3 (6%) |
| Bacterium                                   |        | 3 (6%) |        |        |
| Cardiomyopathy, mild                        |        |        | 1 (2%) |        |
| Cardiomyopathy, minimal                     | 3 (6%) |        | 1 (2%) |        |
| Hyperplasia, mild, endothelium              |        |        |        | 1 (2%) |
| Hyperplasia, minimal, endothelium           |        |        |        | 1 (2%) |
| Hypertrophy, mild, parenchymal cell         |        |        |        | 1 (2%) |
| Hypertrophy, minimal, parenchymal cell      |        |        | 1 (2%) | 2 (4%) |
| Inflammation, acute, marked, valve          |        | 2 (4%) |        |        |
| Inflammation, chronic, mild, artery         |        | 1 (2%) |        |        |
| Inflammation, chronic, minimal              |        | 1 (2%) |        |        |
| Inflammation, chronic, minimal, myocardium  |        | 1 (2%) |        |        |
| Inflammation, chronic, minimal, valve       |        |        | 1 (2%) |        |
| Inflammation, subacute, minimal, epicardium |        |        | 1 (2%) |        |
| Mineralization, mild                        | 1 (2%) | 1 (2%) |        |        |
| Mineralization, minimal                     |        | 1 (2%) |        |        |
| Mineralization, moderate                    |        |        |        | 1 (2%) |
| Necrosis, mild                              |        |        |        | 1 (2%) |
| Thrombosis, mild, atrium                    |        |        |        | 1 (2%) |
| Thrombosis, moderate, atrium                |        |        | 1 (2%) |        |
| <b>Endocrine System</b>                     |        |        |        |        |
| Adrenal gland, cortex                       | (46)   | (47)   | (47)   | (45)   |
| Cyst, mild                                  |        | 1 (2%) |        |        |
| Cyst, minimal                               |        |        | 1 (2%) |        |
| Hyperplasia, focal, marked                  |        | 1 (2%) |        |        |
| Hyperplasia, focal, mild                    |        |        |        | 1 (2%) |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Endocrine System (continued)</b>         |          |          |          |          |
| Adrenal gland, cortex (continued)           | (46)     | (47)     | (47)     | (45)     |
| Hyperplasia, focal, mild, subcapsular       |          |          | 1 (2%)   |          |
| Hyperplasia, focal, minimal                 |          |          | 1 (2%)   |          |
| Hyperplasia, focal, moderate                | 1 (2%)   | 1 (2%)   |          |          |
| Hyperplasia, marked, subcapsular            | 1 (2%)   |          | 1 (2%)   |          |
| Hyperplasia, mild, subcapsular              | 11 (24%) | 17 (36%) | 9 (19%)  | 10 (22%) |
| Hyperplasia, minimal, subcapsular           | 25 (54%) | 24 (51%) | 27 (57%) | 29 (64%) |
| Hyperplasia, moderate, subcapsular          | 2 (4%)   |          | 1 (2%)   |          |
| Hypertrophy, marked                         |          |          | 1 (2%)   |          |
| Hypertrophy, mild                           | 5 (11%)  | 4 (9%)   | 1 (2%)   | 3 (7%)   |
| Hypertrophy, minimal                        | 2 (4%)   | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Hypertrophy, moderate                       | 2 (4%)   |          | 1 (2%)   | 1 (2%)   |
| Necrosis, marked                            |          |          | 1 (2%)   |          |
| Necrosis, mild                              |          | 1 (2%)   |          |          |
| Adrenal gland, medulla                      | (46)     | (46)     | (46)     | (45)     |
| Amyloid deposition, mild                    |          |          | 1 (2%)   |          |
| Hyperplasia, minimal                        |          | 1 (2%)   |          |          |
| Islets, pancreatic                          | (48)     | (46)     | (46)     | (44)     |
| Hyperplasia, marked                         |          |          |          | 1 (2%)   |
| Hyperplasia, mild                           | 1 (2%)   | 1 (2%)   | 1 (2%)   | 2 (5%)   |
| Hyperplasia, minimal                        |          | 1 (2%)   | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   |          |          |          |
| Parathyroid gland                           | (38)     | (38)     | (41)     | (37)     |
| Cyst, mild                                  |          |          | 1 (2%)   | 1 (3%)   |
| Infiltration cellular, lymphocytic, minimal |          |          |          | 1 (3%)   |
| Pituitary gland                             | (39)     | (39)     | (42)     | (42)     |
| Cyst, mild, pars distalis                   |          | 1 (3%)   |          | 1 (2%)   |
| Cyst, minimal, pars distalis                |          | 3 (8%)   |          |          |
| Thyroid gland                               | (45)     | (47)     | (48)     | (47)     |
| Crystals                                    | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Cyst, mild, follicle                        |          |          | 1 (2%)   |          |
| Hyperplasia, focal, mild, C-cell            |          |          |          | 1 (2%)   |
| Hyperplasia, minimal, follicular cell       | 1 (2%)   |          |          | 1 (2%)   |
| Hyperplasia, moderate, follicular cell      |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   | 1 (2%)   |          |          |
| Infiltration cellular, mixed cell, mild     |          |          | 1 (2%)   |          |
| Ultimobranchial cyst                        | 10 (22%) | 11 (23%) | 12 (25%) | 10 (21%) |
| <b>General Body System</b>                  |          |          |          |          |
| None  |          |          |          |          |
| <b>Genital System</b>                       |          |          |          |          |
| Coagulating gland                           | (47)     | (47)     | (48)     | (44)     |
| Atrophy, mild                               | 3 (6%)   | 4 (9%)   | 4 (8%)   | 4 (9%)   |
| Atrophy, minimal                            |          | 1 (2%)   |          | 4 (9%)   |
| Cyst, marked                                |          | 1 (2%)   |          |          |
| Dilatation, mild                            |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild    |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal | 3 (6%)   | 1 (2%)   |          |          |
| Inflammation, acute, marked                 |          |          | 1 (2%)   |          |
| Inflammation, chronic active, moderate      |          |          |          | 1 (2%)   |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm  | 90 ppm   |
|---|----------|----------|---------|----------|
| <b>Genital System (continued)</b>           |          |          |         |          |
| Epididymis                                  | (48)     | (48)     | (48)    | (47)     |
| Atrophy, mild                               |          | 1 (2%)   |         |          |
| Granuloma sperm, mild                       | 1 (2%)   |          |         | 3 (6%)   |
| Infiltration cellular, lymphocytic, mild    | 1 (2%)   | 3 (6%)   |         | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal | 3 (6%)   | 4 (8%)   | 2 (4%)  | 2 (4%)   |
| Inflammation, chronic active, mild          |          |          |         | 1 (2%)   |
| Inflammation, chronic, mild                 |          | 1 (2%)   | 2 (4%)  | 2 (4%)   |
| Inflammation, chronic, minimal              |          |          | 1 (2%)  | 1 (2%)   |
| Penis                                       |          |          | (2)     |          |
| Inflammation, chronic, mild, adventitia     |          |          | 1 (50%) |          |
| Preputial gland                             | (45)     | (46)     | (45)    | (44)     |
| Atrophy, marked                             | 1 (2%)   | 3 (7%)   | 6 (13%) | 10 (23%) |
| Atrophy, mild                               | 5 (11%)  | 7 (15%)  | 4 (9%)  | 4 (9%)   |
| Atrophy, minimal                            |          |          | 1 (2%)  | 2 (5%)   |
| Atrophy, moderate                           | 7 (16%)  | 7 (15%)  | 2 (4%)  | 13 (30%) |
| Cyst, marked                                |          |          |         | 1 (2%)   |
| Cyst, mild                                  |          |          | 2 (4%)  | 1 (2%)   |
| Cyst, minimal                               |          | 1 (2%)   |         |          |
| Dilatation, marked                          |          | 1 (2%)   | 1 (2%)  |          |
| Dilatation, mild                            | 9 (20%)  | 7 (15%)  | 9 (20%) | 6 (14%)  |
| Dilatation, minimal                         | 5 (11%)  | 3 (7%)   | 1 (2%)  | 1 (2%)   |
| Dilatation, moderate                        | 6 (13%)  | 6 (13%)  | 4 (9%)  | 5 (11%)  |
| Hyperplasia, mild                           |          | 2 (4%)   |         |          |
| Inflammation, chronic active, marked        | 2 (4%)   | 2 (4%)   | 3 (7%)  | 1 (2%)   |
| Inflammation, chronic active, mild          | 2 (4%)   | 3 (7%)   | 4 (9%)  | 3 (7%)   |
| Inflammation, chronic active, moderate      | 6 (13%)  | 2 (4%)   | 4 (9%)  | 7 (16%)  |
| Inflammation, chronic, marked               |          |          | 1 (2%)  |          |
| Inflammation, chronic, mild                 | 4 (9%)   | 3 (7%)   | 4 (9%)  |          |
| Inflammation, chronic, minimal              | 5 (11%)  | 4 (9%)   | 5 (11%) | 2 (5%)   |
| Inflammation, subacute, mild                | 1 (2%)   |          |         |          |
| Inflammation, subacute, minimal             | 3 (7%)   | 1 (2%)   |         |          |
| Prostate                                    | (46)     | (46)     | (45)    | (48)     |
| Atrophy, mild                               |          |          | 1 (2%)  | 3 (6%)   |
| Atrophy, minimal                            | 1 (2%)   | 1 (2%)   |         | 2 (4%)   |
| Hyperplasia, mild, epithelium               | 1 (2%)   |          |         |          |
| Infiltration cellular, lymphocytic, mild    | 1 (2%)   |          |         |          |
| Inflammation, acute, marked                 |          |          | 1 (2%)  |          |
| Inflammation, acute, mild                   |          |          |         | 1 (2%)   |
| Inflammation, acute, moderate               |          | 1 (2%)   |         | 1 (2%)   |
| Inflammation, chronic active, mild          | 1 (2%)   |          | 1 (2%)  | 1 (2%)   |
| Inflammation, chronic, mild                 |          |          | 1 (2%)  |          |
| Inflammation, subacute, mild                |          | 3 (7%)   | 2 (4%)  |          |
| Inflammation, subacute, minimal             | 19 (41%) | 14 (30%) | 7 (16%) | 7 (15%)  |
| Seminal vesicle                             | (47)     | (47)     | (48)    | (45)     |
| Atrophy, mild                               | 3 (6%)   | 3 (6%)   | 3 (6%)  | 4 (9%)   |
| Atrophy, minimal                            |          | 2 (4%)   |         | 6 (13%)  |
| Dilatation, mild                            |          | 1 (2%)   | 1 (2%)  | 2 (4%)   |
| Dilatation, minimal                         |          | 2 (4%)   |         |          |
| Dilatation, moderate                        |          |          | 1 (2%)  |          |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   |          | 1 (2%)  | 1 (2%)   |
| Inflammation, acute, mild                   |          |          | 1 (2%)  | 2 (4%)   |
| Inflammation, chronic active, mild          |          |          |         | 1 (2%)   |
| Inflammation, chronic, mild                 |          | 1 (2%)   |         |          |
| Inflammation, chronic, moderate             |          |          | 1 (2%)  |          |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm  | 90 ppm  |
|---|----------|----------|---------|---------|
| <b>Genital System (continued)</b>                     |          |          |         |         |
| Testes  | (48)     | (48)     | (48)    | (48)    |
| Atrophy, marked, germinal epithelium                  |          | 1 (2%)   |         |         |
| Atrophy, mild, germinal epithelium                    | 1 (2%)   | 1 (2%)   | 1 (2%)  |         |
| Atrophy, minimal, germinal epithelium                 |          |          | 3 (6%)  |         |
| Atrophy, moderate, germinal epithelium                | 1 (2%)   | 1 (2%)   |         | 2 (4%)  |
| Degeneration, mild, germinal epithelium               |          | 1 (2%)   | 1 (2%)  | 1 (2%)  |
| Degeneration, minimal, germinal epithelium            |          | 3 (6%)   | 1 (2%)  | 3 (6%)  |
| Fibrosis, marked                                      |          |          | 1 (2%)  |         |
| Mineralization, minimal                               | 1 (2%)   | 1 (2%)   | 2 (4%)  |         |
| Mineralization, moderate                              |          |          | 1 (2%)  |         |
| <b>Hematopoietic System</b>                           |          |          |         |         |
| Bone marrow   | (48)     | (46)     | (46)    | (46)    |
| Depletion, minimal                                    |          |          |         | 1 (2%)  |
| Fibrosis, mild  | 1 (2%)   |          |         |         |
| Hemorrhage, moderate                                  |          |          | 1 (2%)  |         |
| Hyperplasia, mild                                     | 3 (6%)   | 2 (4%)   |         | 1 (2%)  |
| Hyperplasia, minimal                                  | 2 (4%)   | 3 (7%)   | 3 (7%)  | 2 (4%)  |
| Hyperplasia, moderate                                 |          |          | 1 (2%)  | 2 (4%)  |
| Myelofibrosis, moderate                               |          |          | 1 (2%)  |         |
| Necrosis, mild  | 1 (2%)   |          |         | 1 (2%)  |
| Necrosis, moderate                                    |          |          |         | 1 (2%)  |
| Lymph node  | (48)     | (47)     | (48)    | (47)    |
| Hyperplasia, lymphoid, mild, inguinal                 |          |          | 1 (2%)  |         |
| Hyperplasia, lymphoid, mild, lumbar                   |          | 1 (2%)   |         |         |
| Hyperplasia, moderate, renal                          |          |          | 1 (2%)  |         |
| Infiltration cellular, histiocytic, mild, inguinal    |          | 1 (2%)   |         |         |
| Infiltration cellular, histiocytic, minimal, inguinal |          |          |         | 1 (2%)  |
| Pigmentation, mild, inguinal                          |          |          |         | 1 (2%)  |
| Lymph node, mandibular                                | (48)     | (47)     | (48)    | (47)    |
| Angiectasis, minimal                                  |          |          | 1 (2%)  |         |
| Atrophy, moderate                                     |          |          | 1 (2%)  | 1 (2%)  |
| Cyst, moderate  |          | 1 (2%)   |         |         |
| Hemorrhage, minimal                                   |          |          |         | 1 (2%)  |
| Hemorrhage, moderate                                  |          | 1 (2%)   |         |         |
| Hyperplasia, lymphoid, marked                         |          | 3 (6%)   |         |         |
| Hyperplasia, lymphoid, mild                           | 2 (4%)   | 1 (2%)   | 1 (2%)  | 1 (2%)  |
| Hyperplasia, lymphoid, minimal                        | 7 (15%)  | 5 (11%)  | 6 (13%) |         |
| Hyperplasia, lymphoid, moderate                       | 1 (2%)   | 1 (2%)   | 1 (2%)  |         |
| Infiltration cellular, histiocytic, mild              | 2 (4%)   | 1 (2%)   |         | 3 (6%)  |
| Infiltration cellular, histiocytic, minimal           |          |          |         | 1 (2%)  |
| Infiltration cellular, histiocytic, moderate          |          |          |         | 1 (2%)  |
| Inflammation, chronic, mild                           |          | 1 (2%)   |         |         |
| Pigmentation, mild                                    |          |          | 1 (2%)  |         |
| Lymph node, mesenteric                                | (46)     | (44)     | (42)    | (43)    |
| Angiectasis, marked                                   |          | 1 (2%)   |         | 1 (2%)  |
| Angiectasis, mild                                     | 10 (22%) | 11 (25%) | 9 (21%) | 9 (21%) |
| Angiectasis, minimal                                  | 12 (26%) | 6 (14%)  | 6 (14%) | 4 (9%)  |
| Angiectasis, moderate                                 | 4 (9%)   | 4 (9%)   | 2 (5%)  | 3 (7%)  |
| Depletion lymphoid, mild                              |          | 1 (2%)   |         |         |
| Hematopoietic cell proliferation, mild                | 1 (2%)   |          |         |         |
| Hematopoietic cell proliferation, minimal             |          | 1 (2%)   |         |         |
| Hematopoietic cell proliferation, moderate            |          | 1 (2%)   |         |         |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm  | 30 ppm  | 90 ppm   |
|---|----------|---------|---------|----------|
| <b>Hematopoietic System</b> (continued)     |          |         |         |          |
| Lymph node, mesenteric (continued)          | (46)     | (44)    | (42)    | (43)     |
| Hemorrhage, mild                            | 1 (2%)   |         | 1 (2%)  |          |
| Hemorrhage, moderate                        |          |         | 1 (2%)  | 1 (2%)   |
| Hyperplasia, lymphoid, marked               | 1 (2%)   | 1 (2%)  |         |          |
| Hyperplasia, lymphoid, mild                 | 3 (7%)   | 4 (9%)  | 3 (7%)  |          |
| Hyperplasia, lymphoid, minimal              | 7 (15%)  | 4 (9%)  | 3 (7%)  |          |
| Hyperplasia, lymphoid, moderate             | 1 (2%)   | 1 (2%)  |         |          |
| Infiltration cellular, histiocytic, marked  |          |         |         | 1 (2%)   |
| Infiltration cellular, histiocytic, mild    | 1 (2%)   |         |         | 1 (2%)   |
| Infiltration cellular, histiocytic, minimal | 2 (4%)   | 1 (2%)  | 1 (2%)  |          |
| Thrombosis, marked, vein                    |          |         |         | 1 (2%)   |
| Spleen                                      | (48)     | (46)    | (46)    | (45)     |
| Atrophy, mild, lymphoid follicle            |          | 1 (2%)  | 3 (7%)  | 1 (2%)   |
| Congestion, mild                            |          |         | 1 (2%)  |          |
| Hematopoietic cell proliferation, marked    | 4 (8%)   | 5 (11%) | 6 (13%) | 5 (11%)  |
| Hematopoietic cell proliferation, mild      | 5 (10%)  | 2 (4%)  | 2 (4%)  | 6 (13%)  |
| Hematopoietic cell proliferation, minimal   |          |         | 1 (2%)  | 4 (9%)   |
| Hematopoietic cell proliferation, moderate  | 5 (10%)  | 5 (11%) | 7 (15%) | 12 (27%) |
| Hyperplasia, marked, lymphoid follicle      | 3 (6%)   | 8 (17%) | 6 (13%) | 1 (2%)   |
| Hyperplasia, mild, lymphoid follicle        | 7 (15%)  | 6 (13%) | 6 (13%) | 2 (4%)   |
| Hyperplasia, minimal, lymphoid follicle     | 4 (8%)   | 4 (9%)  | 1 (2%)  | 2 (4%)   |
| Hyperplasia, moderate, lymphoid follicle    | 10 (21%) | 4 (9%)  | 6 (13%) |          |
| Metaplasia, osseous, minimal                | 1 (2%)   |         |         |          |
| Thymus                                      | (34)     | (33)    | (32)    | (35)     |
| Atrophy, marked                             | 3 (9%)   | 4 (12%) | 4 (13%) | 13 (37%) |
| Atrophy, mild                               | 5 (15%)  | 3 (9%)  | 3 (9%)  |          |
| Atrophy, minimal                            | 2 (6%)   | 4 (12%) |         | 1 (3%)   |
| Atrophy, moderate                           | 1 (3%)   | 2 (6%)  | 6 (19%) | 5 (14%)  |
| Cyst, minimal                               | 3 (9%)   | 4 (12%) | 3 (9%)  | 2 (6%)   |
| Hemorrhage, minimal                         |          |         | 1 (3%)  |          |
| <b>Integumentary System</b>                 |          |         |         |          |
| Mammary gland                               | (1)      | (1)     | (2)     | (1)      |
| Cyst, mild                                  |          |         |         | 1 (100%) |
| Skin  | (48)     | (47)    | (48)    | (45)     |
| Edema, mild                                 | 2 (4%)   | 1 (2%)  |         | 1 (2%)   |
| Edema, minimal                              |          |         | 1 (2%)  |          |
| Edema, moderate                             |          |         |         | 1 (2%)   |
| Hyperplasia, marked, epithelium             | 1 (2%)   |         |         |          |
| Hyperplasia, mild, epithelium               |          |         | 1 (2%)  | 1 (2%)   |
| Hyperplasia, minimal, epithelium            |          |         |         | 1 (2%)   |
| Hyperplasia, moderate, epithelium           |          |         |         | 1 (2%)   |
| Inflammation, acute, moderate               |          |         |         | 1 (2%)   |
| Inflammation, chronic active, marked        |          |         | 1 (2%)  |          |
| Inflammation, chronic active, mild          | 1 (2%)   |         | 1 (2%)  | 1 (2%)   |
| Inflammation, chronic active, mild, prepuce |          |         | 1 (2%)  |          |
| Inflammation, chronic active, moderate      |          |         | 1 (2%)  |          |
| Inflammation, chronic, mild                 |          | 1 (2%)  | 2 (4%)  |          |
| Inflammation, chronic, minimal              |          | 1 (2%)  | 1 (2%)  | 1 (2%)   |
| Inflammation, chronic, moderate             |          |         |         | 2 (4%)   |
| Metaplasia, osseous, marked                 |          |         | 1 (2%)  |          |
| Necrosis, moderate, fat                     |          |         | 1 (2%)  |          |
| Ulcer, mild                                 | 2 (4%)   |         | 1 (2%)  |          |
| Ulcer, moderate                             |          |         | 2 (4%)  |          |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Musculoskeletal System</b>                    |          |          |          |          |
| Bone   | (48)     | (48)     | (47)     | (48)     |
| Degeneration, marked, cartilage, sternum         |          |          |          | 1 (2%)   |
| Hyperostosis, mild, calvarium                    |          |          | 1 (2%)   |          |
| Hyperostosis, mild, cranium                      | 1 (2%)   |          |          |          |
| Hyperostosis, mild, sternum                      |          |          | 1 (2%)   |          |
| Hyperostosis, moderate, calvarium                |          |          |          | 1 (2%)   |
| Inflammation, acute, moderate, sternum           |          |          |          | 1 (2%)   |
| Inflammation, chronic, mild, periosteum, sternum |          |          |          | 1 (2%)   |
| Bone, femur                                      | (48)     | (48)     | (47)     | (47)     |
| Degeneration, mild, joint, cartilage             | 9 (19%)  | 8 (17%)  | 6 (13%)  | 7 (15%)  |
| Degeneration, minimal, joint, cartilage          | 6 (13%)  | 3 (6%)   | 2 (4%)   |          |
| Degeneration, moderate, joint, cartilage         |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Hyperostosis, mild                               |          |          | 1 (2%)   |          |
| Inflammation, chronic, mild, joint               |          |          |          | 1 (2%)   |
| Skeletal muscle                                  | (48)     | (48)     | (48)     | (47)     |
| Infiltration cellular, lymphocytic, mild         | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, minimal      | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Necrosis, mild                                   |          |          |          | 1 (2%)   |
| Necrosis, minimal                                |          |          |          | 1 (2%)   |
| Necrosis, moderate                               |          |          | 1 (2%)   |          |
| Regeneration, moderate                           |          |          | 1 (2%)   |          |
| <b>Nervous System</b>                            |          |          |          |          |
| Brain, cerebellum                                | (47)     | (48)     | (46)     | (46)     |
| Mineralization, minimal, meninges                |          | 1 (2%)   |          |          |
| Brain, cerebrum                                  | (48)     | (48)     | (48)     | (48)     |
| Inflammation, acute, marked, meninges            |          | 1 (2%)   |          |          |
| Mineralization, mild, thalamus                   | 1 (2%)   | 1 (2%)   |          | 3 (6%)   |
| Mineralization, minimal, thalamus                | 34 (71%) | 23 (48%) | 26 (54%) | 21 (44%) |
| Peripheral nerve                                 | (47)     | (48)     | (48)     | (47)     |
| Degeneration, mild                               |          |          |          | 1 (2%)   |
| Degeneration, minimal                            | 3 (6%)   | 3 (6%)   | 2 (4%)   | 3 (6%)   |
| Spinal cord, thoracic                            | (48)     | (48)     | (48)     | (48)     |
| Inflammation, acute, moderate, meninges          |          | 1 (2%)   |          |          |
| <b>Respiratory System</b>                        |          |          |          |          |
| Larynx   | (46)     | (47)     | (45)     | (47)     |
| Atrophy, mild                                    |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal      |          |          | 1 (2%)   |          |
| Inflammation, acute, mild                        |          |          |          | 1 (2%)   |
| Inflammation, acute, minimal                     |          | 1 (2%)   |          |          |
| Inflammation, subacute, minimal                  |          | 1 (2%)   |          |          |
| Lung   | (48)     | (48)     | (48)     | (48)     |
| Foreign body                                     |          | 1 (2%)   |          |          |
| Hemorrhage, mild                                 |          | 1 (2%)   |          |          |
| Hyperplasia, marked, alveolar epithelium         |          | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Hyperplasia, mild, alveolar epithelium           |          | 1 (2%)   | 4 (8%)   | 4 (8%)   |
| Hyperplasia, minimal, alveolar epithelium        | 1 (2%)   |          | 1 (2%)   |          |
| Hyperplasia, moderate, alveolar epithelium       |          | 1 (2%)   | 1 (2%)   | 6 (13%)  |
| Hyperplasia, moderate, bronchiole, epithelium    | 1 (2%)   |          |          |          |
| Infiltration cellular, histiocytic, mild         |          |          |          | 1 (2%)   |
| Infiltration cellular, histiocytic, minimal      | 1 (2%)   |          |          |          |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm  |
|---|----------|----------|----------|---------|
| <b>Respiratory System</b> (continued)                   |          |          |          |         |
| Lung (continued)  | (48)     | (48)     | (48)     | (48)    |
| Infiltration cellular, lymphocytic, mild                | 3 (6%)   | 3 (6%)   | 1 (2%)   |         |
| Infiltration cellular, lymphocytic, minimal             | 11 (23%) | 8 (17%)  | 3 (6%)   | 2 (4%)  |
| Inflammation, chronic active, minimal                   |          | 1 (2%)   |          |         |
| Inflammation, chronic, mild                             | 2 (4%)   |          |          |         |
| Inflammation, chronic, minimal                          | 2 (4%)   | 1 (2%)   | 1 (2%)   | 1 (2%)  |
| Inflammation, chronic, minimal, vein                    | 1 (2%)   |          |          |         |
| Parasite protozoan                                      | 1 (2%)   |          |          |         |
| Nose  | (48)     | (48)     | (48)     | (46)    |
| Cyst, minimal, mucosa                                   | 1 (2%)   |          |          |         |
| Cytoplasmic alteration, mild, olfactory epithelium      |          | 1 (2%)   | 1 (2%)   | 1 (2%)  |
| Cytoplasmic alteration, mild, respiratory epithelium    | 1 (2%)   | 3 (6%)   | 2 (4%)   |         |
| Cytoplasmic alteration, minimal, olfactory epithelium   | 1 (2%)   | 2 (4%)   | 2 (4%)   | 3 (7%)  |
| Cytoplasmic alteration, minimal, respiratory epithelium | 4 (8%)   | 2 (4%)   | 6 (13%)  | 1 (2%)  |
| Inflammation, acute, mild, nasolacrimal duct            | 1 (2%)   |          |          |         |
| Inflammation, chronic, mild, nasolacrimal duct          |          | 1 (2%)   |          |         |
| Inflammation, mild                                      |          |          | 1 (2%)   |         |
| <b>Special Senses System</b>                            |          |          |          |         |
| Eye   | (48)     | (48)     | (48)     | (46)    |
| Cataract, marked, lens                                  |          |          |          | 1 (2%)  |
| Cataract, mild, lens                                    |          |          | 2 (4%)   |         |
| Cataract, minimal, lens                                 |          | 1 (2%)   | 1 (2%)   | 2 (4%)  |
| Cataract, moderate, lens                                |          | 1 (2%)   |          | 1 (2%)  |
| Hyperplasia, mild, cornea                               |          |          | 1 (2%)   |         |
| Inflammation, acute, mild, cornea                       | 1 (2%)   |          |          |         |
| Inflammation, acute, mild, iris                         |          |          |          | 1 (2%)  |
| Inflammation, acute, minimal, cornea                    |          |          |          | 1 (2%)  |
| Inflammation, acute, moderate, cornea                   | 1 (2%)   |          | 1 (2%)   | 1 (2%)  |
| Inflammation, acute, moderate, optic nerve              |          | 1 (2%)   |          |         |
| Inflammation, chronic active, marked, cornea            |          |          |          | 2 (4%)  |
| Inflammation, chronic active, mild, cornea              | 1 (2%)   |          |          | 1 (2%)  |
| Inflammation, chronic active, moderate, cornea          |          |          | 1 (2%)   | 2 (4%)  |
| Inflammation, chronic, mild, cornea                     |          |          |          | 3 (7%)  |
| Inflammation, chronic, minimal, cornea                  |          |          | 1 (2%)   |         |
| Inflammation, chronic, moderate, cornea                 |          | 1 (2%)   | 1 (2%)   | 1 (2%)  |
| Harderian gland   | (47)     | (48)     | (48)     | (45)    |
| Hyperplasia, focal, mild                                |          |          | 1 (2%)   |         |
| Hyperplasia, focal, moderate                            |          |          | 1 (2%)   |         |
| Infiltration cellular, lymphocytic, mild                | 2 (4%)   |          | 2 (4%)   |         |
| Infiltration cellular, lymphocytic, minimal             | 15 (32%) | 17 (35%) | 17 (35%) | 2 (4%)  |
| Lacrimal gland  | (47)     | (47)     | (48)     | (47)    |
| Amyloid deposition, minimal                             |          |          |          | 1 (2%)  |
| Atrophy, marked   |          |          |          | 1 (2%)  |
| Atrophy, mild   | 3 (6%)   | 3 (6%)   |          | 4 (9%)  |
| Atrophy, minimal  | 3 (6%)   | 6 (13%)  | 5 (10%)  | 5 (11%) |
| Atrophy, moderate                                       |          | 2 (4%)   | 2 (4%)   |         |
| Degeneration, mild                                      |          | 1 (2%)   |          |         |
| Hyperplasia, focal, mild                                | 1 (2%)   |          |          |         |
| Hyperplasia, mild, duct                                 |          |          | 1 (2%)   |         |
| Infiltration cellular, lymphocytic, mild                | 2 (4%)   | 5 (11%)  | 2 (4%)   | 2 (4%)  |
| Infiltration cellular, lymphocytic, minimal             | 14 (30%) | 11 (23%) | 11 (23%) | 9 (19%) |
| Infiltration cellular, lymphocytic, moderate            |          |          | 1 (2%)   |         |
| Necrosis, mild  | 1 (2%)   |          |          |         |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Special Senses System (continued)</b>              |          |          |          |          |
| Zymbal's gland  | (46)     | (45)     | (47)     | (42)     |
| Hyperplasia, mild                                     |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal           | 1 (2%)   |          |          |          |
| Inflammation, subacute, minimal                       |          |          |          | 1 (2%)   |
| <b>Urinary System</b>                                 |          |          |          |          |
| Kidney  | (48)     | (47)     | (48)     | (48)     |
| Accumulation, hyaline droplet, mild, renal tubule     |          |          | 1 (2%)   | 2 (4%)   |
| Accumulation, hyaline droplet, moderate, renal tubule |          |          | 1 (2%)   |          |
| Amyloid deposition, mild                              |          | 2 (4%)   |          |          |
| Amyloid deposition, minimal                           | 4 (8%)   | 3 (6%)   | 1 (2%)   | 1 (2%)   |
| Amyloid deposition, moderate                          |          | 1 (2%)   |          |          |
| Atrophy, focal, mild                                  |          |          |          | 1 (2%)   |
| Bacterium   |          | 1 (2%)   |          |          |
| Cyst, mild  | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Cyst, minimal   | 6 (13%)  | 2 (4%)   | 4 (8%)   | 3 (6%)   |
| Degeneration, mild, renal tubule                      | 4 (8%)   | 4 (9%)   |          | 1 (2%)   |
| Degeneration, minimal, renal tubule                   | 12 (25%) | 16 (34%) | 10 (21%) | 6 (13%)  |
| Degeneration, moderate, renal tubule                  | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Dilatation, marked, pelvis                            |          | 1 (2%)   |          |          |
| Dilatation, mild, pelvis                              |          |          |          | 1 (2%)   |
| Dilatation, moderate, pelvis                          |          |          | 1 (2%)   |          |
| Glomerulosclerosis, mild                              | 12 (25%) | 10 (21%) | 8 (17%)  | 9 (19%)  |
| Glomerulosclerosis, minimal                           | 30 (63%) | 22 (47%) | 26 (54%) | 17 (35%) |
| Glomerulosclerosis, moderate                          | 2 (4%)   | 1 (2%)   |          | 3 (6%)   |
| Hyperplasia, focal, mild, renal tubule                |          |          | 1 (2%)   |          |
| Hyperplasia, focal, minimal, renal tubule             | 3 (6%)   | 1 (2%)   |          | 1 (2%)   |
| Hypoplasia, focal, mild                               | 1 (2%)   |          |          |          |
| Infarct, mild   |          | 1 (2%)   | 1 (2%)   |          |
| Infarct, minimal                                      |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild              | 12 (25%) | 7 (15%)  | 5 (10%)  |          |
| Infiltration cellular, lymphocytic, minimal           | 19 (40%) | 20 (43%) | 18 (38%) | 15 (31%) |
| Infiltration cellular, lymphocytic, moderate          |          |          | 2 (4%)   |          |
| Inflammation, acute, mild, pelvis                     |          |          | 1 (2%)   |          |
| Inflammation, chronic active, mild                    |          |          | 1 (2%)   |          |
| Inflammation, chronic active, mild, pelvis            |          |          | 1 (2%)   |          |
| Inflammation, chronic, mild                           |          |          | 1 (2%)   |          |
| Inflammation, chronic, mild, artery                   |          |          | 1 (2%)   |          |
| Inflammation, chronic, mild, pelvis                   |          |          | 1 (2%)   |          |
| Inflammation, chronic, moderate                       |          | 1 (2%)   |          |          |
| Metaplasia, osseous, minimal                          |          | 1 (2%)   |          |          |
| Mineralization, mild                                  |          | 1 (2%)   |          |          |
| Mineralization, minimal                               | 5 (10%)  | 8 (17%)  | 4 (8%)   | 2 (4%)   |
| Urethra   |          | (1)      | (3)      |          |
| Inflammation, acute, marked, bulbourethral gland      |          |          | 2 (67%)  |          |
| Urinary bladder                                       | (48)     | (47)     | (48)     | (45)     |
| Calculus gross observation                            |          |          | 1 (2%)   |          |
| Dilatation, marked                                    |          |          |          | 1 (2%)   |
| Dilatation, moderate                                  |          |          | 1 (2%)   |          |
| Edema, moderate                                       |          |          |          | 1 (2%)   |

**TABLE C3**  
**Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Urinary System</b> (continued)            |          |          |          |          |
| Urinary bladder (continued)                  | (48)     | (47)     | (48)     | (45)     |
| Infiltration cellular, lymphocytic, mild     | 6 (13%)  | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  | 19 (40%) | 22 (47%) | 15 (31%) | 22 (49%) |
| Infiltration cellular, lymphocytic, moderate | 2 (4%)   | 1 (2%)   |          |          |
| Inflammation, acute, mild                    |          |          | 2 (4%)   | 1 (2%)   |
| Inflammation, chronic active, marked         |          |          | 1 (2%)   |          |
| Inflammation, chronic active, mild           |          |          | 1 (2%)   |          |
| Ulcer, marked                                |          |          | 1 (2%)   |          |



**APPENDIX D**

**SUMMARY OF LESIONS IN FEMALE MICE**

**IN THE 2-YEAR DRINKING WATER STUDY**

**OF URETHANE, ETHANOL, AND URETHANE/ETHANOL**

|                  |   |             |
|------------------|---|-------------|
| <b>TABLE D1</b>  | <b>Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> .....             | <b>D-2</b>  |
| <b>TABLE D2a</b> | <b>Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> .....         | <b>D-8</b>  |
| <b>TABLE D2b</b> | <b>Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years</b> .....   | <b>D-14</b> |
| <b>TABLE D2c</b> | <b>Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>D-17</b> |
| <b>TABLE D2d</b> | <b>Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>D-21</b> |
| <b>TABLE D2e</b> | <b>Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years</b> .....  | <b>D-26</b> |
| <b>TABLE D3a</b> | <b>Historical Incidence of Hemangiosarcoma (All Sites) in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                           | <b>D-32</b> |
| <b>TABLE D3b</b> | <b>Historical Incidence of Hepatocellular Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                              | <b>D-32</b> |
| <b>TABLE D3c</b> | <b>Historical Incidence of Alveolar/bronchiolar Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                        | <b>D-33</b> |
| <b>TABLE D3d</b> | <b>Historical Incidence of Harderian Gland Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                             | <b>D-33</b> |
| <b>TABLE D3e</b> | <b>Historical Incidence of Mammary Gland Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                               | <b>D-34</b> |
| <b>TABLE D3f</b> | <b>Historical Incidence of Granulosa Cell Tumor in Control Female B6C3F<sub>1</sub>/Nctr BR Mice</b> .....                                  | <b>D-34</b> |
| <b>TABLE D4</b>  | <b>Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol</b> ..... | <b>D-35</b> |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol<sup>a</sup>**

|   | 0 ppm    | 10 ppm  | 30 ppm   | 90 ppm   |
|---|----------|---------|----------|----------|
| <b>Disposition Summary</b>                  |          |         |          |          |
| Animals initially in study                  | 48       | 48      | 48       | 48       |
| Early deaths                                |          |         |          |          |
| Moribund                                    | 1        | 3       | 5        | 18       |
| Natural deaths                              | 9        | 8       | 16       | 29       |
| Survivors                                   |          |         |          |          |
| Terminal sacrifice                          | 38       | 37      | 27       | 1        |
| Animals examined microscopically            | 48       | 48      | 48       | 48       |
| <b>Alimentary System</b>                    |          |         |          |          |
| Esophagus                                   | (48)     | (47)    | (47)     | (47)     |
| Lymphoma malignant                          |          | 1 (2%)  |          |          |
| Gallbladder                                 | (47)     | (45)    | (46)     | (43)     |
| Leiomyosarcoma, metastatic, uterus          |          |         | 1 (2%)   |          |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)  | 1 (2%)   |          |
| Sarcoma, metastatic, skin                   |          |         |          | 1 (2%)   |
| Intestine large, cecum                      | (48)     | (45)    | (46)     | (45)     |
| Lymphoma malignant                          |          | 1 (2%)  |          |          |
| Intestine large, colon                      | (48)     | (44)    | (46)     | (46)     |
| Lymphoma malignant                          | 1 (2%)   |         |          |          |
| Sarcoma, metastatic, skin                   |          |         |          | 1 (2%)   |
| Sarcoma, metastatic, uncertain primary site |          |         |          | 1 (2%)   |
| Sarcoma, metastatic, uterus                 |          |         | 1 (2%)   |          |
| Intestine large, rectum                     | (48)     | (45)    | (45)     | (46)     |
| Histiocytic sarcoma                         |          |         | 1 (2%)   | 1 (2%)   |
| Leiomyosarcoma, metastatic, uterus          |          |         | 1 (2%)   |          |
| Lymphoma malignant                          |          |         |          | 2 (4%)   |
| Sarcoma, metastatic, uterus                 |          |         | 1 (2%)   |          |
| Intestine small                             | (48)     | (44)    | (46)     | (44)     |
| Polyp adenomatous                           |          | 1 (2%)  |          |          |
| Intestine small, ileum                      | (48)     | (44)    | (46)     | (44)     |
| Histiocytic sarcoma                         |          |         |          | 1 (2%)   |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)  | 1 (2%)   |          |
| Intestine small, jejunum                    | (48)     | (44)    | (46)     | (44)     |
| Leiomyosarcoma, metastatic, uterus          |          |         | 1 (2%)   |          |
| Lymphoma malignant                          | 1 (2%)   |         |          |          |
| Liver                                       | (48)     | (47)    | (47)     | (47)     |
| Hemangiosarcoma                             |          |         | 1 (2%)   | 7 (15%)  |
| Hepatocellular adenoma                      | 3 (6%)   | 8 (17%) | 10 (21%) | 2 (4%)   |
| Hepatocellular adenoma, multiple            | 2 (4%)   | 2 (4%)  | 9 (19%)  | 16 (34%) |
| Hepatocellular carcinoma                    |          | 1 (2%)  | 2 (4%)   | 1 (2%)   |
| Histiocytic sarcoma                         | 1 (2%)   | 2 (4%)  | 3 (6%)   | 3 (6%)   |
| Leiomyosarcoma, metastatic, uterus          |          |         | 1 (2%)   |          |
| Lymphoma malignant                          | 11 (23%) | 3 (6%)  | 5 (11%)  | 10 (21%) |
| Sarcoma, metastatic, skin                   |          |         |          | 1 (2%)   |
| Mesentery                                   | (3)      | (4)     | (7)      | (6)      |
| Lymphoma malignant                          |          |         | 1 (14%)  |          |
| Sarcoma, metastatic, skin                   |          |         |          | 2 (33%)  |
| Pancreas                                    | (48)     | (43)    | (47)     | (44)     |
| Histiocytic sarcoma                         |          |         |          | 2 (5%)   |
| Leiomyosarcoma, metastatic, uterus          |          |         | 1 (2%)   |          |
| Lymphoma malignant                          | 7 (15%)  | 1 (2%)  | 3 (6%)   | 6 (14%)  |
| Sarcoma, metastatic, skin                   |          |         |          | 1 (2%)   |
| Sarcoma, metastatic, uncertain primary site |          |         |          | 1 (2%)   |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm  |
|---|----------|----------|----------|---------|
| <b>Alimentary System</b> (continued)        |          |          |          |         |
| Salivary glands                             | (48)     | (48)     | (48)     | (47)    |
| Lymphoma malignant                          | 7 (15%)  | 3 (6%)   | 3 (6%)   | 8 (17%) |
| Stomach, forestomach                        | (48)     | (46)     | (46)     | (46)    |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)   |          | 1 (2%)  |
| Mast cell tumor malignant                   |          |          | 1 (2%)   |         |
| Squamous cell carcinoma                     |          | 1 (2%)   |          | 1 (2%)  |
| Squamous cell papilloma                     | 2 (4%)   | 3 (7%)   | 3 (7%)   | 3 (7%)  |
| Stomach, glandular                          | (47)     | (46)     | (46)     | (47)    |
| Leiomyosarcoma, metastatic, uterus          |          |          | 1 (2%)   |         |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)   |          | 1 (2%)  |
| <b>Cardiovascular System</b>                |          |          |          |         |
| Blood vessel                                | (47)     | (47)     | (48)     | (46)    |
| Lymphoma malignant                          |          |          |          | 2 (4%)  |
| Heart                                       | (48)     | (48)     | (48)     | (48)    |
| Hemangioma                                  |          |          | 1 (2%)   |         |
| Hemangiosarcoma                             |          |          | 1 (2%)   |         |
| Histiocytic sarcoma                         | 1 (2%)   |          | 2 (4%)   | 3 (6%)  |
| Lymphoma malignant                          | 3 (6%)   | 2 (4%)   |          | 3 (6%)  |
| <b>Endocrine System</b>                     |          |          |          |         |
| Adrenal gland, cortex                       | (48)     | (45)     | (45)     | (47)    |
| Adenoma                                     |          |          |          | 1 (2%)  |
| Adenoma, bilateral                          |          |          |          | 1 (2%)  |
| Adenoma, subcapsular                        | 1 (2%)   |          | 1 (2%)   |         |
| Hemangiosarcoma                             |          |          |          | 1 (2%)  |
| Histiocytic sarcoma                         |          |          | 1 (2%)   |         |
| Lymphoma malignant                          | 1 (2%)   | 2 (4%)   | 2 (4%)   | 2 (4%)  |
| Sarcoma, metastatic, uncertain primary site |          |          |          | 1 (2%)  |
| Adrenal gland, medulla                      | (47)     | (42)     | (43)     | (47)    |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)   |          | 1 (2%)  |
| Islets, pancreatic                          | (48)     | (43)     | (47)     | (44)    |
| Adenoma                                     | 1 (2%)   |          |          |         |
| Histiocytic sarcoma                         |          |          |          | 1 (2%)  |
| Lymphoma malignant                          | 3 (6%)   | 1 (2%)   | 3 (6%)   | 2 (5%)  |
| Parathyroid gland                           | (32)     | (38)     | (31)     | (40)    |
| Lymphoma malignant                          |          | 1 (3%)   | 1 (3%)   |         |
| Pituitary gland                             | (42)     | (42)     | (40)     | (39)    |
| Adenoma, pars distalis                      | 7 (17%)  | 4 (10%)  | 5 (13%)  | 1 (3%)  |
| Lymphoma malignant                          |          |          |          | 2 (5%)  |
| Thyroid gland                               | (47)     | (47)     | (47)     | (45)    |
| Adenoma, follicular cell                    | 1 (2%)   |          | 1 (2%)   | 2 (4%)  |
| Carcinoma, follicular cell                  |          |          |          | 1 (2%)  |
| Lymphoma malignant                          | 1 (2%)   | 1 (2%)   |          |         |
| <b>General Body System</b>                  |          |          |          |         |
| Tissue NOS                                  | (1)      | (1)      | (1)      | (4)     |
| Histiocytic sarcoma                         |          |          |          | 1 (25%) |
| Lymphoma malignant                          |          | 1 (100%) |          | 1 (25%) |
| Lymphoma malignant, abdominal               | 1 (100%) |          |          | 1 (25%) |
| Sarcoma                                     |          |          |          | 1 (25%) |
| Sarcoma, abdominal                          |          |          | 1 (100%) |         |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm   | 10 ppm | 30 ppm  | 90 ppm   |
|--|---------|--------|---------|----------|
| <b>Genital System</b>                              |         |        |         |          |
| Ovary  | (48)    | (46)   | (46)    | (39)     |
| Adenoma, tubular                                   |         |        | 2 (4%)  | 1 (3%)   |
| Cystadenoma  | 2 (4%)  |        | 1 (2%)  | 1 (3%)   |
| Granulosa cell tumor benign                        |         |        | 2 (4%)  | 3 (8%)   |
| Granulosa cell tumor malignant                     |         |        |         | 3 (8%)   |
| Hemangioma   | 1 (2%)  |        |         |          |
| Histiocytic sarcoma                                | 1 (2%)  | 1 (2%) | 3 (7%)  |          |
| Luteoma  |         | 1 (2%) |         |          |
| Lymphoma malignant                                 | 4 (8%)  | 3 (7%) | 3 (7%)  | 8 (21%)  |
| Uterus   | (48)    | (47)   | (48)    | (46)     |
| Adenoma, endometrium                               |         | 1 (2%) |         | 1 (2%)   |
| Hemangioma   |         | 1 (2%) | 2 (4%)  |          |
| Hemangiosarcoma                                    |         |        |         | 2 (4%)   |
| Histiocytic sarcoma                                | 1 (2%)  | 1 (2%) | 3 (6%)  | 2 (4%)   |
| Leiomyosarcoma                                     |         |        | 1 (2%)  |          |
| Lymphoma malignant                                 | 2 (4%)  | 2 (4%) |         | 3 (7%)   |
| Polyp stromal                                      |         |        | 1 (2%)  | 1 (2%)   |
| Sarcoma  |         |        | 1 (2%)  | 1 (2%)   |
| Sarcoma stromal                                    | 1 (2%)  |        | 1 (2%)  |          |
| Vagina   | (48)    | (47)   | (46)    | (43)     |
| Basosquamous tumor benign                          |         | 1 (2%) |         |          |
| Leiomyosarcoma, metastatic, uterus                 |         |        | 1 (2%)  |          |
| Lymphoma malignant                                 | 3 (6%)  | 2 (4%) |         | 4 (9%)   |
| Sarcoma, metastatic, skin                          | 1 (2%)  |        |         |          |
| Sarcoma, metastatic, uterus                        |         |        | 1 (2%)  |          |
| Squamous cell carcinoma                            |         |        |         | 1 (2%)   |
| Squamous cell papilloma                            |         |        |         | 1 (2%)   |
| <b>Hematopoietic System</b>                        |         |        |         |          |
| Bone marrow  | (48)    | (47)   | (46)    | (47)     |
| Histiocytic sarcoma                                |         |        | 1 (2%)  |          |
| Lymphoma malignant                                 |         |        | 1 (2%)  | 1 (2%)   |
| Lymph node   | (48)    | (47)   | (47)    | (46)     |
| Histiocytic sarcoma, iliac                         |         |        | 1 (2%)  |          |
| Histiocytic sarcoma, inguinal                      |         |        | 1 (2%)  |          |
| Histiocytic sarcoma, lumbar                        |         |        | 1 (2%)  | 1 (2%)   |
| Histiocytic sarcoma, renal                         |         |        |         | 1 (2%)   |
| Leiomyosarcoma, metastatic, renal, uterus          |         |        | 1 (2%)  |          |
| Lymphangioma, renal                                |         |        |         | 1 (2%)   |
| Lymphoma malignant, axillary                       | 2 (4%)  | 1 (2%) |         |          |
| Lymphoma malignant, inguinal                       |         | 1 (2%) |         |          |
| Lymphoma malignant, lumbar                         | 3 (6%)  | 3 (6%) | 3 (6%)  | 5 (11%)  |
| Lymphoma malignant, pancreatic                     | 1 (2%)  | 1 (2%) |         |          |
| Lymphoma malignant, renal                          | 4 (8%)  | 1 (2%) | 2 (4%)  | 3 (7%)   |
| Lymphoma malignant, thoracic                       | 1 (2%)  | 2 (4%) | 1 (2%)  | 2 (4%)   |
| Lymph node, mandibular                             | (45)    | (47)   | (45)    | (42)     |
| Adenocarcinoma, metastatic, uncertain primary site |         |        |         | 1 (2%)   |
| Histiocytic sarcoma                                |         | 1 (2%) | 1 (2%)  | 1 (2%)   |
| Lymphoma malignant                                 | 9 (20%) | 4 (9%) | 5 (11%) | 11 (26%) |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm  | 30 ppm  | 90 ppm   |
|--|----------|---------|---------|----------|
| <b>Hematopoietic System</b> (continued)          |          |         |         |          |
| Lymph node, mesenteric                           | (47)     | (45)    | (42)    | (39)     |
| Histiocytic sarcoma                              |          | 2 (4%)  | 2 (5%)  | 3 (8%)   |
| Leiomyosarcoma, metastatic, uterus               |          |         | 1 (2%)  |          |
| Lymphoma malignant                               | 13 (28%) | 6 (13%) | 7 (17%) | 11 (28%) |
| Sarcoma  |          | 1 (2%)  |         |          |
| Sarcoma, metastatic, uncertain primary site      |          |         |         | 1 (3%)   |
| Spleen   | (48)     | (45)    | (47)    | (46)     |
| Hemangiosarcoma                                  |          |         | 1 (2%)  | 4 (9%)   |
| Histiocytic sarcoma                              |          |         | 2 (4%)  | 2 (4%)   |
| Leiomyosarcoma, metastatic, uterus               |          |         | 1 (2%)  |          |
| Lymphoma malignant                               | 15 (31%) | 4 (9%)  | 7 (15%) | 13 (28%) |
| Sarcoma, metastatic, lymph node                  |          | 1 (2%)  |         |          |
| Sarcoma, metastatic, skin                        |          |         |         | 1 (2%)   |
| Thymus   | (40)     | (37)    | (32)    | (38)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |          |         |         | 4 (11%)  |
| Histiocytic sarcoma                              |          | 1 (3%)  | 3 (9%)  | 1 (3%)   |
| Leiomyosarcoma, metastatic, uterus               |          |         | 1 (3%)  |          |
| Lymphoma malignant                               | 10 (25%) | 3 (8%)  | 7 (22%) | 10 (26%) |
| Sarcoma, metastatic, skin                        |          |         |         | 1 (3%)   |
| Sarcoma, metastatic, uncertain primary site      |          |         |         | 1 (3%)   |
| <b>Integumentary System</b>                      |          |         |         |          |
| Mammary gland                                    | (47)     | (46)    | (46)    | (48)     |
| Adenocanthoma                                    |          | 1 (2%)  | 1 (2%)  | 11 (23%) |
| Adenocarcinoma                                   | 4 (9%)   | 3 (7%)  | 3 (7%)  | 11 (23%) |
| Adenoma  |          |         | 2 (4%)  | 1 (2%)   |
| Basosquamous tumor malignant                     |          |         | 1 (2%)  |          |
| Fibroadenoma                                     |          |         |         | 1 (2%)   |
| Lymphoma malignant                               | 1 (2%)   |         |         | 1 (2%)   |
| Sarcoma, metastatic, skin                        |          |         |         | 1 (2%)   |
| Skin   | (48)     | (48)    | (46)    | (48)     |
| Basal cell carcinoma                             |          |         | 1 (2%)  | 1 (2%)   |
| Basosquamous tumor malignant                     |          |         | 1 (2%)  |          |
| Fibrous histiocytoma                             |          | 1 (2%)  |         |          |
| Hemangiosarcoma                                  |          |         |         | 2 (4%)   |
| Lymphoma malignant                               |          | 1 (2%)  |         | 3 (6%)   |
| Papilloma  |          | 1 (2%)  |         |          |
| Sarcoma  | 4 (8%)   | 3 (6%)  |         | 6 (13%)  |
| <b>Musculoskeletal System</b>                    |          |         |         |          |
| Bone   | (48)     | (48)    | (48)    | (48)     |
| Lymphoma malignant, sternum                      | 1 (2%)   |         |         |          |
| Osteosarcoma, right, rib                         |          |         |         | 1 (2%)   |
| Sarcoma, metastatic, sternum, skin               |          |         |         | 1 (2%)   |
| Sarcoma, sternum                                 |          |         |         | 1 (2%)   |
| Bone, femur                                      | (48)     | (48)    | (48)    | (48)     |
| Hemangioma                                       |          |         |         | 1 (2%)   |
| Lymphoma malignant                               |          |         |         | 1 (2%)   |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm   | 10 ppm   | 30 ppm   | 90 ppm   |
|--|---------|----------|----------|----------|
| <b>Musculoskeletal System (continued)</b>                |         |          |          |          |
| Skeletal muscle  | (48)    | (48)     | (48)     | (48)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung         |         |          |          | 1 (2%)   |
| Hemangiosarcoma  |         |          | 1 (2%)   |          |
| Lymphoma malignant                                       | 1 (2%)  | 2 (4%)   |          | 3 (6%)   |
| Rhabdomyosarcoma   |         | 1 (2%)   |          |          |
| Sarcoma, metastatic, diaphragm, skin                     |         |          |          | 1 (2%)   |
| Sarcoma, metastatic, skin                                | 1 (2%)  |          |          |          |
| Sarcoma, metastatic, uncertain primary site              |         |          |          | 1 (2%)   |
| <b>Nervous System</b>                                    |         |          |          |          |
| Brain, cerebrum  | (48)    | (48)     | (48)     | (48)     |
| Lymphoma malignant                                       |         |          |          | 1 (2%)   |
| <b>Respiratory System</b>                                |         |          |          |          |
| Larynx   | (48)    | (46)     | (46)     | (45)     |
| Lymphoma malignant                                       |         | 1 (2%)   |          |          |
| Lung   | (48)    | (48)     | (48)     | (47)     |
| Adenoacanthoma, metastatic, mammary gland                |         | 1 (2%)   |          | 5 (11%)  |
| Alveolar/bronchiolar adenoma                             | 4 (8%)  | 6 (13%)  | 13 (27%) | 12 (26%) |
| Alveolar/bronchiolar adenoma, multiple                   |         |          | 4 (8%)   | 17 (36%) |
| Alveolar/bronchiolar carcinoma                           | 2 (4%)  | 4 (8%)   | 10 (21%) | 6 (13%)  |
| Alveolar/bronchiolar carcinoma, multiple                 |         |          | 3 (6%)   | 13 (28%) |
| Basal cell carcinoma, metastatic, skin                   |         |          | 1 (2%)   |          |
| Basosquamous tumor malignant, metastatic, mammary gland  |         |          | 1 (2%)   |          |
| Basosquamous tumor malignant, metastatic, Zymbal's gland |         |          |          | 1 (2%)   |
| Carcinoma, metastatic, harderian gland                   |         |          |          | 1 (2%)   |
| Carcinoma, metastatic, mammary gland                     |         |          |          | 1 (2%)   |
| Granulosa cell tumor malignant, metastatic, ovary        |         |          |          | 1 (2%)   |
| Hemangiosarcoma  |         |          |          | 1 (2%)   |
| Hepatocellular carcinoma, metastatic, liver              |         |          |          | 1 (2%)   |
| Histiocytic sarcoma                                      |         | 1 (2%)   | 3 (6%)   | 1 (2%)   |
| Lymphoma malignant                                       | 8 (17%) | 3 (6%)   | 4 (8%)   | 8 (17%)  |
| <b>Special Senses System</b>                             |         |          |          |          |
| Harderian gland  | (48)    | (48)     | (48)     | (48)     |
| Adenoma  | 3 (6%)  | 10 (21%) | 8 (17%)  | 20 (42%) |
| Adenoma, bilateral                                       |         |          |          | 1 (2%)   |
| Carcinoma  |         | 1 (2%)   | 11 (23%) | 7 (15%)  |
| Carcinoma, bilateral                                     |         |          |          | 4 (8%)   |
| Lymphoma malignant                                       |         | 2 (4%)   |          | 1 (2%)   |
| Lacrimal gland   | (45)    | (47)     | (43)     | (40)     |
| Lymphoma malignant                                       | 4 (9%)  | 2 (4%)   | 3 (7%)   | 1 (3%)   |
| Zymbal's gland   | (46)    | (43)     | (46)     | (46)     |
| Basosquamous tumor malignant                             |         |          |          | 1 (2%)   |
| Lymphoma malignant                                       |         | 1 (2%)   |          | 1 (2%)   |

**TABLE D1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm   | 10 ppm | 30 ppm | 90 ppm  |
|---|---------|--------|--------|---------|
| <b>Urinary System</b>                             |         |        |        |         |
| Kidney  | (48)    | (48)   | (48)   | (48)    |
| Histiocytic sarcoma                               |         |        | 2 (4%) | 1 (2%)  |
| Lymphoma malignant                                | 6 (13%) | 2 (4%) | 2 (4%) | 8 (17%) |
| Sarcoma   |         |        |        | 1 (2%)  |
| Sarcoma, metastatic, skin                         |         |        |        | 2 (4%)  |
| Urinary bladder                                   | (48)    | (46)   | (45)   | (41)    |
| Leiomyosarcoma, metastatic, uterus                |         |        | 1 (2%) |         |
| Lymphoma malignant                                | 2 (4%)  | 1 (2%) | 1 (2%) | 5 (12%) |
| <b>Neoplasm Summary</b>                           |         |        |        |         |
| Total animals with primary neoplasms <sup>b</sup> | 37      | 35     | 45     | 47      |
| Total primary neoplasms                           | 173     | 135    | 203    | 348     |
| Total animals with benign neoplasms               | 22      | 26     | 38     | 42      |
| Total benign neoplasms                            | 27      | 39     | 65     | 88      |
| Total animals with malignant neoplasms            | 26      | 20     | 37     | 46      |
| Total malignant neoplasms                         | 146     | 96     | 138    | 260     |
| Total animals with metastatic neoplasms           | 1       | 2      | 4      | 20      |
| Total metastatic neoplasms                        | 2       | 2      | 17     | 35      |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|   | 0 ppm         | 10 ppm          | 30 ppm          | 90 ppm          |
|---|---------------|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma or Hemangiosarcoma</b> |               |                 |                 |                 |
| Overall rate <sup>a</sup>                         | 1/48 (2.1%)   | 0/45 (0.0%)     | 2/45 (4.4%)     | 3/47 (6.4%)     |
| Adjusted rate <sup>b</sup>                        | 1/45.6 (2.2%) | 0/41.3 (0.0%)   | 2/37.5 (5.3%)   | 3/28.9 (10.4%)  |
| Terminal rate <sup>c</sup>                        | 0/38 (0.0%)   | 0/35 (0.0%)     | 1/25 (4.0%)     | 0/1 (0.0%)      |
| First incidence (days)                            | 642           | — <sup>e</sup>  | 678             | 676             |
| Poly-3 test <sup>d</sup>                          | P=0.046       | P=0.520N        | P=0.432         | P=0.169         |
| <b>Harderian Gland: Adenoma</b>                   |               |                 |                 |                 |
| Overall rate                                      | 3/48 (6.3%)   | 10/48 (20.8%)   | 8/48 (16.7%)    | 21/48 (43.8%)   |
| Adjusted rate                                     | 3/45.3 (6.6%) | 10/45.0 (22.2%) | 8/41.1 (19.5%)  | 21/36.1 (58.2%) |
| Terminal rate                                     | 2/38 (5.3%)   | 7/37 (18.9%)    | 4/27 (14.8%)    | 0/1 (0.0%)      |
| First incidence (days)                            | 747           | 648             | 554             | 466             |
| Poly-3 test                                       | P=0.001       | P=0.033         | P=0.070         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>                 |               |                 |                 |                 |
| Overall rate                                      | 0/48 (0.0%)   | 1/48 (2.1%)     | 11/48 (22.9%)   | 11/48 (22.9%)   |
| Adjusted rate                                     | 0/45.2 (0.0%) | 1/44.2 (2.3%)   | 11/40.7 (27.0%) | 11/32.0 (34.3%) |
| Terminal rate                                     | 0/38 (0.0%)   | 1/37 (2.7%)     | 7/27 (25.9%)    | 1/1 (100.0%)    |
| First incidence (days)                            | —             | 765 (T)         | 616             | 548             |
| Poly-3 test                                       | P=0.001       | P=0.495         | P=0.001         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>      |               |                 |                 |                 |
| Overall rate                                      | 3/48 (6.3%)   | 11/48 (22.9%)   | 19/48 (39.6%)   | 30/48 (62.5%)   |
| Adjusted rate                                     | 3/45.3 (6.6%) | 11/45.0 (24.4%) | 19/42.3 (45.0%) | 30/39.0 (76.8%) |
| Terminal rate                                     | 2/38 (5.3%)   | 8/37 (21.6%)    | 11/27 (40.7%)   | 1/1 (100.0%)    |
| First incidence (days)                            | 747           | 648             | 554             | 466             |
| Poly-3 test                                       | P=0.001       | P=0.018         | P=0.001         | P=0.001         |
| <b>Heart: Histiocytic Sarcoma</b>                 |               |                 |                 |                 |
| Overall rate                                      | 1/48 (2.1%)   | 0/48 (0.0%)     | 2/48 (4.2%)     | 3/48 (6.3%)     |
| Adjusted rate                                     | 1/45.7 (2.2%) | 0/44.2 (0.0%)   | 2/39.8 (5.0%)   | 3/29.4 (10.2%)  |
| Terminal rate                                     | 0/38 (0.0%)   | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                            | 616           | —               | 678             | 650             |
| Poly-3 test                                       | P=0.045       | P=0.507N        | P=0.452         | P=0.173         |
| <b>Liver: Hemangiosarcoma</b>                     |               |                 |                 |                 |
| Overall rate                                      | 0/48 (0.0%)   | 0/47 (0.0%)     | 1/47 (2.1%)     | 7/47 (14.9%)    |
| Adjusted rate                                     | 0/45.2 (0.0%) | 0/43.3 (0.0%)   | 1/39.2 (2.6%)   | 7/30.3 (23.1%)  |
| Terminal rate                                     | 0/38 (0.0%)   | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                            | —             | — <sup>f</sup>  | 765 (T)         | 551             |
| Poly-3 test                                       | P=0.001       | —               | P=0.471         | P=0.001         |
| <b>Liver: Hemangioma or Hemangiosarcoma</b>       |               |                 |                 |                 |
| Overall rate                                      | 0/48 (0.0%)   | 0/47 (0.0%)     | 1/47 (2.1%)     | 7/47 (14.9%)    |
| Adjusted rate                                     | 0/45.2 (0.0%) | 0/43.3 (0.0%)   | 1/39.2 (2.6%)   | 7/30.3 (23.1%)  |
| Terminal rate                                     | 0/38 (0.0%)   | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                            | —             | —               | 765 (T)         | 551             |
| Poly-3 test                                       | P=0.001       | —               | P=0.471         | P=0.001         |
| <b>Liver: Histiocytic Sarcoma</b>                 |               |                 |                 |                 |
| Overall rate                                      | 1/48 (2.1%)   | 2/47 (4.3%)     | 3/47 (6.4%)     | 3/47 (6.4%)     |
| Adjusted rate                                     | 1/45.7 (2.2%) | 2/44.2 (4.5%)   | 3/39.5 (7.6%)   | 3/29.0 (10.3%)  |
| Terminal rate                                     | 0/38 (0.0%)   | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                            | 616           | 594             | 678             | 650             |
| Poly-3 test                                       | P=0.120       | P=0.489         | P=0.255         | P=0.169         |

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|--|----------------|-----------------|-----------------|-----------------|
| <b>Liver: Hepatocellular Adenoma</b>                   |                |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)   | 10/47 (21.3%)   | 19/47 (40.4%)   | 18/47 (38.3%)   |
| Adjusted rate  | 5/45.2 (11.1%) | 10/43.6 (22.9%) | 19/39.7 (47.8%) | 18/33.4 (54.0%) |
| Terminal rate  | 5/38 (13.2%)   | 9/37 (24.3%)    | 16/27 (59.3%)   | 0/1 (0.0%)      |
| First incidence (days)                                 | 765 (T)        | 684             | 696             | 590             |
| Poly-3 test  | P=0.001        | P=0.112         | P=0.001         | P=0.001         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)   | 11/47 (23.4%)   | 20/47 (42.6%)   | 19/47 (40.4%)   |
| Adjusted rate  | 5/45.2 (11.1%) | 11/43.7 (25.2%) | 20/39.7 (50.3%) | 19/33.7 (56.4%) |
| Terminal rate  | 5/38 (13.2%)   | 9/37 (24.3%)    | 17/27 (63.0%)   | 0/1 (0.0%)      |
| First incidence (days)                                 | 765 (T)        | 684             | 696             | 590             |
| Poly-3 test  | P=0.001        | P=0.071         | P=0.001         | P=0.001         |
| <b>Lung: Histiocytic Sarcoma</b>                       |                |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)    | 1/48 (2.1%)     | 3/48 (6.3%)     | 1/47 (2.1%)     |
| Adjusted rate  | 0/45.2 (0.0%)  | 1/44.7 (2.2%)   | 3/39.9 (7.5%)   | 1/28.5 (3.5%)   |
| Terminal rate  | 0/38 (0.0%)    | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                                 | —              | 594             | 678             | 650             |
| Poly-3 test  | P=0.267        | P=0.498         | P=0.097         | P=0.412         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)    | 6/48 (12.5%)    | 17/48 (35.4%)   | 29/47 (61.7%)   |
| Adjusted rate  | 4/45.2 (8.8%)  | 6/44.3 (13.5%)  | 17/42.4 (40.1%) | 29/38.8 (74.8%) |
| Terminal rate  | 4/38 (10.5%)   | 5/37 (13.5%)    | 9/27 (33.3%)    | 1/1 (100.0%)    |
| First incidence (days)                                 | 765 (T)        | 741             | 438             | 391             |
| Poly-3 test  | P=0.001        | P=0.356         | P=0.001         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                |                 |                 |                 |
| Overall rate   | 2/48 (4.2%)    | 4/48 (8.3%)     | 13/48 (27.1%)   | 19/47 (40.4%)   |
| Adjusted rate  | 2/45.6 (4.4%)  | 4/44.4 (9.0%)   | 13/40.5 (32.1%) | 19/32.9 (57.8%) |
| Terminal rate  | 1/38 (2.6%)    | 2/37 (5.4%)     | 9/27 (33.3%)    | 1/1 (100.0%)    |
| First incidence (days)                                 | 642            | 741             | 635             | 548             |
| Poly-3 test  | P=0.001        | P=0.324         | P=0.001         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                |                 |                 |                 |
| Overall rate   | 6/48 (12.5%)   | 8/48 (16.7%)    | 28/48 (58.3%)   | 39/47 (83.0%)   |
| Adjusted rate  | 6/45.6 (13.1%) | 8/44.4 (18.0%)  | 28/43.3 (64.6%) | 39/41.9 (93.2%) |
| Terminal rate  | 5/38 (13.2%)   | 6/37 (16.2%)    | 16/27 (59.3%)   | 1/1 (100.0%)    |
| First incidence (days)                                 | 642            | 741             | 438             | 391             |
| Poly-3 test  | P=0.001        | P=0.365         | P=0.001         | P=0.001         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 2/45 (4.4%)     | 2/42 (4.8%)     | 3/39 (7.7%)     |
| Adjusted rate  | 0/44.3 (0.0%)  | 2/43.0 (4.7%)   | 2/36.3 (5.5%)   | 3/24.7 (12.1%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)     | 0/25 (0.0%)     | 0/1 (0.0%)      |
| First incidence (days)                                 | —              | 594             | 678             | 650             |
| Poly-3 test  | P=0.043        | P=0.230         | P=0.195         | P=0.045         |
| <b>Mammary Gland: Adenoacanthoma</b>                   |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 1/46 (2.2%)     | 1/46 (2.2%)     | 11/48 (22.9%)   |
| Adjusted rate  | 0/44.2 (0.0%)  | 1/42.6 (2.3%)   | 1/39.2 (2.6%)   | 11/32.6 (33.8%) |
| Terminal rate  | 0/37 (0.0%)    | 0/36 (0.0%)     | 0/27 (0.0%)     | 0/1 (0.0%)      |
| First incidence (days)                                 | —              | 684             | 675             | 523             |
| Poly-3 test  | P=0.001        | P=0.492         | P=0.476         | P=0.001         |

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm          | 10 ppm         | 30 ppm         | 90 ppm          |
|--|----------------|----------------|----------------|-----------------|
| <b>Mammary Gland: Adenocarcinoma</b>                         |                |                |                |                 |
| Overall rate   | 4/47 (8.5%)    | 3/46 (6.5%)    | 3/46 (6.5%)    | 11/48 (22.9%)   |
| Adjusted rate  | 4/44.2 (9.0%)  | 3/42.3 (7.1%)  | 3/39.3 (7.6%)  | 11/32.8 (33.6%) |
| Terminal rate  | 4/37 (10.8%)   | 3/36 (8.3%)    | 1/27 (3.7%)    | 1/1 (100.0%)    |
| First incidence (days)                                       | 765 (T)        | 765 (T)        | 696            | 391             |
| Poly-3 test  | P=0.001        | P=0.524N       | P=0.564N       | P=0.007         |
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b>       |                |                |                |                 |
| Overall rate   | 4/47 (8.5%)    | 4/46 (8.7%)    | 4/46 (8.7%)    | 22/48 (45.8%)   |
| Adjusted rate  | 4/44.2 (9.0%)  | 4/42.6 (9.4%)  | 4/39.6 (10.1%) | 22/36.6 (60.1%) |
| Terminal rate  | 4/37 (10.8%)   | 3/36 (8.3%)    | 1/27 (3.7%)    | 1/1 (100.0%)    |
| First incidence (days)                                       | 765 (T)        | 684            | 675            | 391             |
| Poly-3 test  | P=0.001        | P=0.622        | P=0.582        | P=0.001         |
| <b>Ovary: Histiocytic Sarcoma</b>                            |                |                |                |                 |
| Overall rate   | 1/48 (2.1%)    | 1/46 (2.2%)    | 3/46 (6.5%)    | 0/39 (0.0%)     |
| Adjusted rate  | 1/45.7 (2.2%)  | 1/42.8 (2.3%)  | 3/38.8 (7.7%)  | 0/22.8 (0.0%)   |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)    | 1/27 (3.7%)    | 0/1 (0.0%)      |
| First incidence (days)                                       | 616            | 594            | 678            | —               |
| Poly-3 test  | P=0.608N       | P=0.746        | P=0.249        | P=0.628N        |
| <b>Ovary: Benign Granulosa Cell Tumor</b>                    |                |                |                |                 |
| Overall rate   | 0/48 (0.0%)    | 0/46 (0.0%)    | 2/46 (4.3%)    | 3/39 (7.7%)     |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/42.3 (0.0%)  | 2/38.5 (5.2%)  | 3/23.8 (12.6%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)    | 2/27 (7.4%)    | 0/1 (0.0%)      |
| First incidence (days)                                       | —              | —              | 765 (T)        | 576             |
| Poly-3 test  | P=0.006        | —              | P=0.203        | P=0.041         |
| <b>Ovary: Malignant Granulosa Cell Tumor</b>                 |                |                |                |                 |
| Overall rate   | 0/48 (0.0%)    | 0/46 (0.0%)    | 0/46 (0.0%)    | 3/39 (7.7%)     |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/42.3 (0.0%)  | 0/38.5 (0.0%)  | 3/23.8 (12.6%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)    | 0/27 (0.0%)    | 0/1 (0.0%)      |
| First incidence (days)                                       | —              | —              | —              | 635             |
| Poly-3 test  | P=0.002        | —              | —              | P=0.040         |
| <b>Ovary: Benign or Malignant Granulosa Cell Tumor</b>       |                |                |                |                 |
| Overall rate   | 0/48 (0.0%)    | 0/46 (0.0%)    | 2/46 (4.3%)    | 5/39 (12.8%)    |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/42.3 (0.0%)  | 2/38.5 (5.2%)  | 5/24.5 (20.4%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)    | 2/27 (7.4%)    | 0/1 (0.0%)      |
| First incidence (days)                                       | —              | —              | 765 (T)        | 576             |
| Poly-3 test  | P=0.001        | —              | P=0.203        | P=0.004         |
| <b>Pituitary Gland (Pars Distalis): Adenoma or Carcinoma</b> |                |                |                |                 |
| Overall rate   | 7/42 (16.7%)   | 4/42 (9.5%)    | 5/40 (12.5%)   | 1/39 (2.6%)     |
| Adjusted rate  | 7/40.5 (17.3%) | 4/38.3 (10.4%) | 5/33.8 (14.8%) | 1/24.0 (4.2%)   |
| Terminal rate  | 6/35 (17.1%)   | 3/31 (9.7%)    | 4/23 (17.4%)   | 0/1 (0.0%)      |
| First incidence (days)                                       | 642            | 728            | 649            | 678             |
| Poly-3 test  | P=0.158N       | P=0.291N       | P=0.510N       | P=0.136N        |
| <b>Skin: Sarcoma</b>   |                |                |                |                 |
| Overall rate   | 4/48 (8.3%)    | 3/48 (6.3%)    | 0/46 (0.0%)    | 6/48 (12.5%)    |
| Adjusted rate  | 4/45.2 (8.8%)  | 3/44.4 (6.8%)  | 0/38.8 (0.0%)  | 6/30.3 (19.8%)  |
| Terminal rate  | 4/38 (10.5%)   | 1/37 (2.7%)    | 0/27 (0.0%)    | 0/1 (0.0%)      |
| First incidence (days)                                       | 765 (T)        | 728            | —              | 590             |
| Poly-3 test  | P=0.090        | P=0.510N       | P=0.082N       | P=0.158         |

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm         | 10 ppm        | 30 ppm         | 90 ppm         |
|--|---------------|---------------|----------------|----------------|
| <b>Skin: Sarcoma or Fibrous Histiocytoma</b>                                     |               |               |                |                |
| Overall rate   | 4/48 (8.3%)   | 4/48 (8.3%)   | 0/46 (0.0%)    | 6/48 (12.5%)   |
| Adjusted rate  | 4/45.2 (8.8%) | 4/44.4 (9.0%) | 0/38.8 (0.0%)  | 6/30.3 (19.8%) |
| Terminal rate  | 4/38 (10.5%)  | 2/37 (5.4%)   | 0/27 (0.0%)    | 0/1 (0.0%)     |
| First incidence (days)   | 765 (T)       | 728           | —              | 590            |
| Poly-3 test  | P=0.124       | P=0.634       | P=0.082N       | P=0.158        |
| <b>Spleen: Hemangiosarcoma</b>   |               |               |                |                |
| Overall rate   | 0/48 (0.0%)   | 0/45 (0.0%)   | 1/47 (2.1%)    | 4/46 (8.7%)    |
| Adjusted rate  | 0/45.2 (0.0%) | 0/42.5 (0.0%) | 1/39.2 (2.6%)  | 4/28.2 (14.2%) |
| Terminal rate  | 0/38 (0.0%)   | 0/37 (0.0%)   | 1/27 (3.7%)    | 0/1 (0.0%)     |
| First incidence (days)   | —             | —             | 765 (T)        | 605            |
| Poly-3 test  | P=0.001       | —             | P=0.471        | P=0.021        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                            |               |               |                |                |
| Overall rate   | 2/48 (4.2%)   | 3/46 (6.5%)   | 3/46 (6.5%)    | 3/46 (6.5%)    |
| Adjusted rate  | 2/45.2 (4.4%) | 3/42.7 (7.0%) | 3/39.0 (7.7%)  | 3/28.6 (10.5%) |
| Terminal rate  | 2/38 (5.3%)   | 3/37 (8.1%)   | 2/27 (7.4%)    | 0/1 (0.0%)     |
| First incidence (days)   | 765 (T)       | 765 (T)       | 712            | 605            |
| Poly-3 test  | P=0.260       | P=0.474       | P=0.433        | P=0.305        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |               |               |                |                |
| Overall rate   | 2/48 (4.2%)   | 4/46 (8.7%)   | 3/46 (6.5%)    | 4/46 (8.7%)    |
| Adjusted rate  | 2/45.2 (4.4%) | 4/42.7 (9.4%) | 3/39.0 (7.7%)  | 4/29.0 (13.8%) |
| Terminal rate  | 2/38 (5.3%)   | 4/37 (10.8%)  | 2/27 (7.4%)    | 0/1 (0.0%)     |
| First incidence (days)   | 765 (T)       | 765 (T)       | 712            | 605            |
| Poly-3 test  | P=0.173       | P=0.311       | P=0.433        | P=0.165        |
| <b>Thymus: Histiocytic Sarcoma</b>   |               |               |                |                |
| Overall rate   | 0/40 (0.0%)   | 1/37 (2.7%)   | 3/32 (9.4%)    | 1/38 (2.6%)    |
| Adjusted rate  | 0/37.6 (0.0%) | 1/34.6 (2.9%) | 3/26.7 (11.3%) | 1/22.7 (4.4%)  |
| Terminal rate  | 0/31 (0.0%)   | 0/29 (0.0%)   | 1/16 (6.3%)    | 0/1 (0.0%)     |
| First incidence (days)   | —             | 594           | 678            | 744            |
| Poly-3 test  | P=0.251       | P=0.483       | P=0.064        | P=0.404        |
| <b>Thyroid Gland (Follicular Cell): Adenoma or Carcinoma</b>                     |               |               |                |                |
| Overall rate   | 1/47 (2.1%)   | 0/47 (0.0%)   | 1/47 (2.1%)    | 3/45 (6.7%)    |
| Adjusted rate  | 1/44.2 (2.3%) | 0/43.2 (0.0%) | 1/39.3 (2.5%)  | 3/27.9 (10.7%) |
| Terminal rate  | 1/37 (2.7%)   | 0/36 (0.0%)   | 0/27 (0.0%)    | 1/1 (100.0%)   |
| First incidence (days)   | 765 (T)       | —             | 719            | 466            |
| Poly-3 test  | P=0.038       | P=0.505N      | P=0.734        | P=0.167        |
| <b>Uterus: Histiocytic Sarcoma</b>   |               |               |                |                |
| Overall rate   | 1/48 (2.1%)   | 1/47 (2.1%)   | 3/48 (6.3%)    | 2/46 (4.3%)    |
| Adjusted rate  | 1/45.7 (2.2%) | 1/43.7 (2.3%) | 3/39.9 (7.5%)  | 2/28.1 (7.1%)  |
| Terminal rate  | 0/38 (0.0%)   | 0/37 (0.0%)   | 1/27 (3.7%)    | 0/1 (0.0%)     |
| First incidence (days)   | 616           | 643           | 678            | 694            |
| Poly-3 test  | P=0.193       | P=0.751       | P=0.258        | P=0.341        |
| <b>All Organs: Hemangioma</b>  |               |               |                |                |
| Overall rate   | 1/48 (2.1%)   | 1/48 (2.1%)   | 3/48 (6.3%)    | 1/48 (2.1%)    |
| Adjusted rate  | 1/45.2 (2.2%) | 1/44.2 (2.3%) | 3/39.7 (7.6%)  | 1/28.9 (3.5%)  |
| Terminal rate  | 1/38 (2.6%)   | 1/37 (2.7%)   | 2/27 (7.4%)    | 0/1 (0.0%)     |
| First incidence (days)   | 765 (T)       | 765 (T)       | 719            | 725            |
| Poly-3 test  | P=0.423       | P=0.755       | P=0.260        | P=0.651        |

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Hemangiosarcoma</b>               |                 |                 |                 |                 |
| Overall rate                                     | 0/48 (0.0%)     | 0/48 (0.0%)     | 4/48 (8.3%)     | 11/48 (22.9%)   |
| Adjusted rate                                    | 0/45.2 (0.0%)   | 0/44.2 (0.0%)   | 4/39.5 (10.1%)  | 11/31.8 (34.6%) |
| Terminal rate                                    | 0/38 (0.0%)     | 0/37 (0.0%)     | 4/27 (14.8%)    | 0/1 (0.0%)      |
| First incidence (days)                           | —               | —               | 765 (T)         | 551             |
| Poly-3 test                                      | P=0.001         | —               | P=0.045         | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                 |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 1/48 (2.1%)     | 6/48 (12.5%)    | 11/48 (22.9%)   |
| Adjusted rate                                    | 1/45.2 (2.2%)   | 1/44.2 (2.3%)   | 6/39.7 (15.1%)  | 11/31.8 (34.6%) |
| Terminal rate                                    | 1/38 (2.6%)     | 1/37 (2.7%)     | 5/27 (18.5%)    | 0/1 (0.0%)      |
| First incidence (days)                           | 765 (T)         | 765 (T)         | 719             | 551             |
| Poly-3 test                                      | P=0.001         | P=0.755         | P=0.037         | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 2/48 (4.2%)     | 3/48 (6.3%)     | 3/48 (6.3%)     |
| Adjusted rate                                    | 1/45.7 (2.2%)   | 2/45.1 (4.4%)   | 3/39.9 (7.5%)   | 3/29.4 (10.2%)  |
| Terminal rate                                    | 0/38 (0.0%)     | 0/37 (0.0%)     | 1/27 (3.7%)     | 0/1 (0.0%)      |
| First incidence (days)                           | 616             | 594             | 678             | 650             |
| Poly-3 test                                      | P=0.121         | P=0.496         | P=0.258         | P=0.173         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |                 |
| Overall rate                                     | 16/48 (33.3%)   | 6/48 (12.5%)    | 8/48 (16.7%)    | 15/48 (31.3%)   |
| Adjusted rate                                    | 16/46.0 (34.8%) | 6/45.3 (13.2%)  | 8/42.0 (19.0%)  | 15/35.1 (42.7%) |
| Terminal rate                                    | 11/38 (28.9%)   | 3/37 (8.1%)     | 2/27 (7.4%)     | 1/1 (100.0%)    |
| First incidence (days)                           | 636             | 510             | 549             | 193             |
| Poly-3 test                                      | P=0.067         | P=0.013N        | P=0.076N        | P=0.308         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |                 |
| Overall rate                                     | 22/48 (45.8%)   | 26/48 (54.2%)   | 38/48 (79.2%)   | 42/48 (87.5%)   |
| Adjusted rate                                    | 22/45.7 (48.1%) | 26/45.1 (57.6%) | 38/44.6 (85.2%) | 42/44.3 (94.9%) |
| Terminal rate                                    | 20/38 (52.6%)   | 22/37 (59.5%)   | 23/27 (85.2%)   | 1/1 (100.0%)    |
| First incidence (days)                           | 642             | 648             | 438             | 391             |
| Poly-3 test                                      | P=0.001         | P=0.241         | P=0.001         | P=0.001         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |                 |
| Overall rate                                     | 26/48 (54.2%)   | 20/48 (41.7%)   | 37/48 (77.1%)   | 46/48 (95.8%)   |
| Adjusted rate                                    | 26/46.9 (55.5%) | 20/46.9 (42.7%) | 37/46.8 (79.1%) | 46/46.8 (98.2%) |
| Terminal rate                                    | 19/38 (50.0%)   | 11/37 (29.7%)   | 18/27 (66.7%)   | 1/1 (100.0%)    |
| First incidence (days)                           | 616             | 510             | 438             | 193             |
| Poly-3 test                                      | P=0.001         | P=0.150N        | P=0.011         | P=0.001         |

**TABLE D2a**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |                 |
| Overall rate                                     | 37/48 (77.1%)   | 35/48 (72.9%)   | 45/48 (93.8%)   | 47/48 (97.9%)   |
| Adjusted rate                                    | 37/46.9 (78.8%) | 35/47.3 (74.1%) | 45/47.2 (95.4%) | 47/47.3 (99.3%) |
| Terminal rate                                    | 29/38 (76.3%)   | 25/37 (67.6%)   | 25/27 (92.6%)   | 1/1 (100.0%)    |
| First incidence (days)                           | 616             | 510             | 438             | 193             |
| Poly-3 test                                      | P=0.001         | P=0.381N        | P=0.014         | P=0.001         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE D2b**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol     |
|--|----------------|----------------|----------------|
| <b>Harderian Gland: Adenoma</b>                        |                |                |                |
| Overall rate <sup>a</sup>                              | 3/48 (6.3%)    | 2/47 (4.3%)    | 4/48 (8.3%)    |
| Adjusted rate <sup>b</sup>                             | 3/45.3 (6.6%)  | 2/44.5 (4.5%)  | 4/40.8 (9.8%)  |
| Terminal rate <sup>c</sup>                             | 2/38 (5.3%)    | 2/39 (5.1%)    | 3/31 (9.7%)    |
| First incidence (days)                                 | 747            | 765 (T)        | 718            |
| Poly-3 test <sup>d</sup>                               | P=0.825        | P=0.977        | P=0.985        |
| <b>Harderian Gland: Adenoma or Carcinoma</b>           |                |                |                |
| Overall rate   | 3/48 (6.3%)    | 3/47 (6.4%)    | 5/48 (10.4%)   |
| Adjusted rate  | 3/45.3 (6.6%)  | 3/44.5 (6.7%)  | 5/40.8 (12.3%) |
| Terminal rate  | 2/38 (5.3%)    | 3/39 (7.7%)    | 4/31 (12.9%)   |
| First incidence (days)                                 | 747            | 765 (T)        | 718            |
| Poly-3 test  | P=0.557        | P=1.000        | P=0.698        |
| <b>Liver: Histiocytic Sarcoma</b>                      |                |                |                |
| Overall rate   | 1/48 (2.1%)    | 0/47 (0.0%)    | 4/48 (8.3%)    |
| Adjusted rate  | 1/45.7 (2.2%)  | 0/44.5 (0.0%)  | 4/41.7 (9.6%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/39 (0.0%)    | 0/31 (0.0%)    |
| First incidence (days)                                 | 616            | — <sup>e</sup> | 515            |
| Poly-3 test  | P=0.160        | P=0.993        | P=0.356        |
| <b>Liver: Hepatocellular Adenoma</b>                   |                |                |                |
| Overall rate   | 5/48 (10.4%)   | 6/47 (12.8%)   | 3/48 (6.3%)    |
| Adjusted rate  | 5/45.2 (11.1%) | 6/44.5 (13.5%) | 3/40.6 (7.4%)  |
| Terminal rate  | 5/38 (13.2%)   | 6/39 (15.4%)   | 3/31 (9.7%)    |
| First incidence (days)                                 | 765 (T)        | 765 (T)        | 765 (T)        |
| Poly-3 test  | P=0.628        | P=1.000        | P=0.730        |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                |                |                |
| Overall rate   | 5/48 (10.4%)   | 7/47 (14.9%)   | 3/48 (6.3%)    |
| Adjusted rate  | 5/45.2 (11.1%) | 7/44.5 (15.7%) | 3/40.6 (7.4%)  |
| Terminal rate  | 5/38 (13.2%)   | 6/39 (15.4%)   | 3/31 (9.7%)    |
| First incidence (days)                                 | 765 (T)        | 752            | 765 (T)        |
| Poly-3 test  | P=0.641        | P=0.798        | P=0.730        |
| <b>Lung: Histiocytic Sarcoma</b>                       |                |                |                |
| Overall rate   | 0/48 (0.0%)    | 0/47 (0.0%)    | 4/48 (8.3%)    |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/44.5 (0.0%)  | 4/41.7 (9.6%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/39 (0.0%)    | 0/31 (0.0%)    |
| First incidence (days)                                 | —              | —              | 515            |
| Poly-3 test  | P=0.027        | — <sup>f</sup> | P=0.123        |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                |                |                |
| Overall rate   | 4/48 (8.3%)    | 5/47 (10.6%)   | 5/48 (10.4%)   |
| Adjusted rate  | 4/45.2 (8.8%)  | 5/44.5 (11.2%) | 5/40.6 (12.3%) |
| Terminal rate  | 4/38 (10.5%)   | 5/39 (12.8%)   | 5/31 (16.1%)   |
| First incidence (days)                                 | 765 (T)        | 765 (T)        | 765 (T)        |
| Poly-3 test  | P=0.846        | P=1.000        | P=0.980        |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                |                |                |
| Overall rate   | 6/48 (12.5%)   | 5/47 (10.6%)   | 5/48 (10.4%)   |
| Adjusted rate  | 6/45.6 (13.1%) | 5/44.5 (11.2%) | 5/40.6 (12.3%) |
| Terminal rate  | 5/38 (13.2%)   | 5/39 (12.8%)   | 5/31 (16.1%)   |
| First incidence (days)                                 | 642            | 765 (T)        | 765 (T)        |
| Poly-3 test  | P=0.906        | P=0.975        | P=1.000        |

**TABLE D2b**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol     |
|--|----------------|----------------|----------------|
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>          |                |                |                |
| Overall rate   | 0/47 (0.0%)    | 0/43 (0.0%)    | 4/45 (8.9%)    |
| Adjusted rate  | 0/44.3 (0.0%)  | 0/41.0 (0.0%)  | 4/38.8 (10.3%) |
| Terminal rate  | 0/38 (0.0%)    | 0/36 (0.0%)    | 0/29 (0.0%)    |
| First incidence (days)                                       | —              | —              | 515            |
| Poly-3 test  | P=0.026        | —              | P=0.110        |
| <b>Mammary Gland: Adenocarcinoma</b>                         |                |                |                |
| Overall rate   | 4/47 (8.5%)    | 4/47 (8.5%)    | 3/47 (6.4%)    |
| Adjusted rate  | 4/44.2 (9.0%)  | 4/44.7 (9.0%)  | 3/40.2 (7.5%)  |
| Terminal rate  | 4/37 (10.8%)   | 2/39 (5.1%)    | 2/31 (6.5%)    |
| First incidence (days)                                       | 765 (T)        | 718            | 754            |
| Poly-3 test  | P=0.851        | P=1.000        | P=1.000        |
| <b>Ovary: Histiocytic Sarcoma</b>                            |                |                |                |
| Overall rate   | 1/48 (2.1%)    | 0/47 (0.0%)    | 4/46 (8.7%)    |
| Adjusted rate  | 1/45.7 (2.2%)  | 0/44.5 (0.0%)  | 4/39.9 (10.0%) |
| Terminal rate  | 0/38 (0.0%)    | 0/39 (0.0%)    | 0/31 (0.0%)    |
| First incidence (days)                                       | 616            | —              | 515            |
| Poly-3 test  | P=0.147        | P=0.993        | P=0.332        |
| <b>Pancreas: Histiocytic Sarcoma</b>                         |                |                |                |
| Overall rate   | 0/48 (0.0%)    | 0/47 (0.0%)    | 3/47 (6.4%)    |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/44.5 (0.0%)  | 3/40.1 (7.5%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/39 (0.0%)    | 0/31 (0.0%)    |
| First incidence (days)                                       | —              | —              | 706            |
| Poly-3 test  | P=0.068        | —              | P=0.227        |
| <b>Pituitary Gland (Pars Distalis): Adenoma or Carcinoma</b> |                |                |                |
| Overall rate   | 7/42 (16.7%)   | 7/44 (15.9%)   | 7/40 (17.5%)   |
| Adjusted rate  | 7/40.5 (17.3%) | 7/42.5 (16.5%) | 7/33.8 (20.7%) |
| Terminal rate  | 6/35 (17.1%)   | 5/37 (13.5%)   | 6/25 (24.0%)   |
| First incidence (days)                                       | 642            | 677            | 718            |
| Poly-3 test  | P=0.972        | P=1.000        | P=1.000        |
| <b>Skin: Sarcoma</b>   |                |                |                |
| Overall rate   | 4/48 (8.3%)    | 2/47 (4.3%)    | 3/48 (6.3%)    |
| Adjusted rate  | 4/45.2 (8.8%)  | 2/44.5 (4.5%)  | 3/41.4 (7.2%)  |
| Terminal rate  | 4/38 (10.5%)   | 2/39 (5.1%)    | 0/31 (0.0%)    |
| First incidence (days)                                       | 765 (T)        | 765 (T)        | 571            |
| Poly-3 test  | P=0.832        | P=0.650        | P=0.997        |
| <b>Spleen: Histiocytic Sarcoma</b>                           |                |                |                |
| Overall rate   | 0/48 (0.0%)    | 0/47 (0.0%)    | 4/48 (8.3%)    |
| Adjusted rate  | 0/45.2 (0.0%)  | 0/44.5 (0.0%)  | 4/41.7 (9.6%)  |
| Terminal rate  | 0/38 (0.0%)    | 0/39 (0.0%)    | 0/31 (0.0%)    |
| First incidence (days)                                       | —              | —              | 515            |
| Poly-3 test  | P=0.027        | —              | P=0.123        |
| <b>Thymus: Histiocytic Sarcoma</b>                           |                |                |                |
| Overall rate   | 0/40 (0.0%)    | 0/41 (0.0%)    | 2/39 (5.1%)    |
| Adjusted rate  | 0/37.6 (0.0%)  | 0/39.0 (0.0%)  | 2/33.1 (6.0%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/34 (0.0%)    | 0/24 (0.0%)    |
| First incidence (days)                                       | —              | —              | 515            |
| Poly-3 test  | P=0.181        | —              | P=0.466        |

**TABLE D2b**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 0 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Uterus: Histiocytic Sarcoma</b>               |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 0/47 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate                                    | 1/45.7 (2.2%)   | 0/44.5 (0.0%)   | 3/41.5 (7.2%)   |
| Terminal rate                                    | 0/38 (0.0%)     | 0/39 (0.0%)     | 0/31 (0.0%)     |
| First incidence (days)                           | 616             | —               | 515             |
| Poly-3 test                                      | P=0.351         | P=0.993         | P=0.606         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 0/47 (0.0%)     | 4/48 (8.3%)     |
| Adjusted rate                                    | 1/45.7 (2.2%)   | 0/44.5 (0.0%)   | 4/41.7 (9.6%)   |
| Terminal rate                                    | 0/38 (0.0%)     | 0/39 (0.0%)     | 0/31 (0.0%)     |
| First incidence (days)                           | 616             | —               | 515             |
| Poly-3 test                                      | P=0.160         | P=0.993         | P=0.356         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |
| Overall rate                                     | 16/48 (33.3%)   | 9/47 (19.1%)    | 5/48 (10.4%)    |
| Adjusted rate                                    | 16/46.0 (34.8%) | 9/44.8 (20.1%)  | 5/40.8 (12.2%)  |
| Terminal rate                                    | 11/38 (28.9%)   | 7/39 (17.9%)    | 3/31 (9.7%)     |
| First incidence (days)                           | 636             | 677             | 718             |
| Poly-3 test                                      | P=0.008         | P=0.143         | P=0.012         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 22/48 (45.8%)   | 21/47 (44.7%)   | 22/48 (45.8%)   |
| Adjusted rate                                    | 22/45.7 (48.1%) | 21/45.0 (46.7%) | 22/41.1 (53.5%) |
| Terminal rate                                    | 20/38 (52.6%)   | 18/39 (46.2%)   | 18/31 (58.1%)   |
| First incidence (days)                           | 642             | 677             | 718             |
| Poly-3 test                                      | P=1.000         | P=0.904         | P=1.000         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 26/48 (54.2%)   | 14/47 (29.8%)   | 17/48 (35.4%)   |
| Adjusted rate                                    | 26/46.9 (55.5%) | 14/45.0 (31.1%) | 17/43.1 (39.5%) |
| Terminal rate                                    | 19/38 (50.0%)   | 10/39 (25.6%)   | 8/31 (25.8%)    |
| First incidence (days)                           | 616             | 677             | 515             |
| Poly-3 test                                      | P=0.069         | P=0.018         | P=0.091         |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 37/48 (77.1%)   | 29/47 (61.7%)   | 32/48 (66.7%)   |
| Adjusted rate                                    | 37/46.9 (78.8%) | 29/45.0 (64.4%) | 32/43.3 (73.8%) |
| Terminal rate                                    | 29/38 (76.3%)   | 25/39 (64.1%)   | 21/31 (67.7%)   |
| First incidence (days)                           | 616             | 677             | 515             |
| Poly-3 test                                      | P=0.290         | P=0.107         | P=0.320         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE D2c**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Harderian Gland: Adenoma</b>                        |                 |                 |                 |
| Overall rate <sup>a</sup>                              | 10/48 (20.8%)   | 3/47 (6.4%)     | 7/48 (14.6%)    |
| Adjusted rate <sup>b</sup>                             | 10/45.0 (22.2%) | 3/42.5 (7.1%)   | 7/42.0 (16.7%)  |
| Terminal rate <sup>c</sup>                             | 7/37 (18.9%)    | 3/33 (9.1%)     | 5/32 (15.6%)    |
| First incidence (days)                                 | 648             | 765 (T)         | 721             |
| Poly-3 test <sup>d</sup>                               | P=0.522         | P=0.085         | P=0.703         |
| <b>Harderian Gland: Carcinoma</b>                      |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)     | 3/47 (6.4%)     | 11/48 (22.9%)   |
| Adjusted rate  | 1/44.2 (2.3%)   | 3/42.5 (7.1%)   | 11/41.9 (26.2%) |
| Terminal rate  | 1/37 (2.7%)     | 3/33 (9.1%)     | 10/32 (31.3%)   |
| First incidence (days)                                 | 765 (T)         | 765 (T)         | 738             |
| Poly-3 test  | P=0.001         | P=0.585         | P=0.002         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>           |                 |                 |                 |
| Overall rate   | 11/48 (22.9%)   | 5/47 (10.6%)    | 18/48 (37.5%)   |
| Adjusted rate  | 11/45.0 (24.4%) | 5/42.5 (14.8%)  | 18/42.1 (42.7%) |
| Terminal rate  | 8/37 (21.6%)    | 5/33 (15.2%)    | 15/32 (46.9%)   |
| First incidence (days)                                 | 648             | 765 (T)         | 721             |
| Poly-3 test  | P=0.076         | P=0.203         | P=0.108         |
| <b>Liver: Hepatocellular Adenoma</b>                   |                 |                 |                 |
| Overall rate   | 10/47 (21.3%)   | 5/47 (10.6%)    | 6/47 (12.8%)    |
| Adjusted rate  | 10/43.6 (22.9%) | 5/42.5 (11.8%)  | 6/41.2 (14.6%)  |
| Terminal rate  | 9/37 (24.3%)    | 5/33 (15.2%)    | 4/32 (12.5%)    |
| First incidence (days)                                 | 684             | 765 (T)         | 738             |
| Poly-3 test  | P=0.356         | P=0.273         | P=0.478         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                 |                 |                 |
| Overall rate   | 11/47 (23.4%)   | 5/47 (10.6%)    | 7/47 (14.9%)    |
| Adjusted rate  | 11/43.7 (25.2%) | 5/42.5 (11.8%)  | 7/41.2 (17.0%)  |
| Terminal rate  | 9/37 (24.3%)    | 5/33 (15.2%)    | 5/32 (15.6%)    |
| First incidence (days)                                 | 684             | 765 (T)         | 738             |
| Poly-3 test  | P=0.377         | P=0.179         | P=0.510         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |
| Overall rate   | 6/48 (12.5%)    | 10/47 (21.3%)   | 10/48 (20.8%)   |
| Adjusted rate  | 6/44.3 (13.5%)  | 10/43.6 (22.9%) | 10/42.1 (23.8%) |
| Terminal rate  | 5/37 (13.5%)    | 6/33 (18.2%)    | 7/32 (21.9%)    |
| First incidence (days)                                 | 741             | 611             | 721             |
| Poly-3 test  | P=0.289         | P=0.391         | P=0.344         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)     | 2/47 (4.3%)     | 7/48 (14.6%)    |
| Adjusted rate  | 4/44.4 (9.0%)   | 2/42.5 (4.7%)   | 7/42.1 (16.6%)  |
| Terminal rate  | 2/37 (5.4%)     | 2/33 (6.1%)     | 5/32 (15.6%)    |
| First incidence (days)                                 | 741             | 765 (T)         | 703             |
| Poly-3 test  | P=0.341         | P=0.710         | P=0.460         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 8/48 (16.7%)    | 11/47 (23.4%)   | 17/48 (35.4%)   |
| Adjusted rate  | 8/44.4 (18.0%)  | 10/43.6 (25.2%) | 17/42.3 (40.2%) |
| Terminal rate  | 6/37 (16.2%)    | 7/33 (21.2%)    | 12/32 (37.5%)   |
| First incidence (days)                                 | 741             | 611             | 703             |
| Poly-3 test  | P=0.028         | P=0.580         | P=0.037         |

**TABLE D2c**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol  | 5% Ethanol     |
|--|----------------|---------------|----------------|
| <b>Lymph Node (Mandibular): Histiocytic Sarcoma</b>    |                |               |                |
| Overall rate   | 1/47 (2.1%)    | 2/44 (4.5%)   | 0/46 (0.0%)    |
| Adjusted rate  | 1/43.8 (2.3%)  | 2/41.1 (4.9%) | 0/40.0 (0.0%)  |
| Terminal rate  | 0/37 (0.0%)    | 1/33 (3.0%)   | 0/31 (0.0%)    |
| First incidence (days)                                 | 594            | 698           | — <sup>e</sup> |
| Poly-3 test  | P=0.802        | P=0.958       | P=1.000        |
| <b>Mammary Gland: Adenocarcinoma</b>                   |                |               |                |
| Overall rate   | 3/46 (6.5%)    | 3/45 (6.7%)   | 4/48 (8.3%)    |
| Adjusted rate  | 3/42.3 (7.1%)  | 3/41.0 (7.3%) | 4/42.2 (9.5%)  |
| Terminal rate  | 3/36 (8.3%)    | 3/32 (9.4%)   | 3/32 (9.4%)    |
| First incidence (days)                                 | 765 (T)        | 765 (T)       | 644            |
| Poly-3 test  | P=0.846        | P=1.000       | P=0.998        |
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b> |                |               |                |
| Overall rate   | 4/46 (8.7%)    | 3/45 (6.7%)   | 4/48 (8.3%)    |
| Adjusted rate  | 4/42.6 (9.4%)  | 3/41.0 (7.3%) | 4/42.2 (9.5%)  |
| Terminal rate  | 3/36 (8.3%)    | 3/32 (9.4%)   | 3/32 (9.4%)    |
| First incidence (days)                                 | 684            | 765 (T)       | 644            |
| Poly-3 test  | P=1.000        | P=1.000       | P=1.000        |
| <b>Pituitary Gland (Pars Distalis): Adenoma</b>        |                |               |                |
| Overall rate   | 4/42 (9.5%)    | 2/41 (4.9%)   | 6/41 (14.6%)   |
| Adjusted rate  | 4/38.3 (10.4%) | 2/37.3 (5.4%) | 6/35.5 (16.9%) |
| Terminal rate  | 3/31 (9.7%)    | 2/30 (6.7%)   | 6/27 (22.2%)   |
| First incidence (days)                                 | 728            | 765 (T)       | 765 (T)        |
| Poly-3 test  | P=0.517        | P=0.695       | P=0.640        |
| <b>Skin: Sarcoma</b>                                   |                |               |                |
| Overall rate   | 3/48 (6.3%)    | 1/47 (2.1%)   | 7/48 (14.6%)   |
| Adjusted rate  | 3/44.4 (6.8%)  | 1/42.5 (2.4%) | 7/42.2 (16.6%) |
| Terminal rate  | 1/37 (2.7%)    | 1/33 (3.0%)   | 3/32 (9.4%)    |
| First incidence (days)                                 | 728            | 765 (T)       | 721            |
| Poly-3 test  | P=0.160        | P=0.639       | P=0.272        |
| <b>Skin: Fibrous Histiocytoma or Sarcoma</b>           |                |               |                |
| Overall rate   | 4/48 (8.3%)    | 1/47 (2.1%)   | 7/48 (14.6%)   |
| Adjusted rate  | 4/44.4 (9.0%)  | 1/42.5 (2.4%) | 7/42.2 (16.6%) |
| Terminal rate  | 2/37 (5.4%)    | 1/33 (3.0%)   | 3/32 (9.4%)    |
| First incidence (days)                                 | 728            | 765 (T)       | 721            |
| Poly-3 test  | P=0.329        | P=0.381       | P=0.462        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>  |                |               |                |
| Overall rate   | 3/46 (6.5%)    | 4/46 (8.7%)   | 3/47 (6.4%)    |
| Adjusted rate  | 3/42.7 (7.0%)  | 4/42.1 (9.5%) | 3/41.1 (7.3%)  |
| Terminal rate  | 3/37 (8.1%)    | 3/33 (9.1%)   | 3/32 (9.4%)    |
| First incidence (days)                                 | 765 (T)        | 736           | 765 (T)        |
| Poly-3 test  | P=1.000        | P=0.989       | P=1.000        |

**TABLE D2c**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                 |                 |                 |
| Overall rate   | 4/46 (8.7%)     | 4/46 (8.7%)     | 3/47 (6.4%)     |
| Adjusted rate  | 4/42.7 (9.4%)   | 4/42.1 (9.5%)   | 3/41.1 (7.3%)   |
| Terminal rate  | 4/37 (10.8%)    | 3/33 (9.1%)     | 3/32 (9.4%)     |
| First incidence (days)   | 765 (T)         | 736             | 765 (T)         |
| Poly-3 test  | P=0.898         | P=1.000         | P=1.000         |
| <b>Uterus: Hemangioma or Hemangiosarcoma</b>                                     |                 |                 |                 |
| Overall rate   | 1/47 (2.1%)     | 0/47 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate  | 1/43.3 (2.3%)   | 0/42.5 (0.0%)   | 3/41.9 (7.2%)   |
| Terminal rate  | 1/37 (2.7%)     | 0/33 (0.0%)     | 2/32 (6.3%)     |
| First incidence (days)   | 765 (T)         | —               | 754             |
| Poly-3 test  | P=0.352         | P=1.000         | P=0.586         |
| <b>All Organs: Hemangiosarcoma</b>   |                 |                 |                 |
| Overall rate   | 0/48 (0.0%)     | 2/47 (4.3%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/44.2 (0.0%)   | 2/42.5 (4.7%)   | 3/41.9 (7.2%)   |
| Terminal rate  | 0/37 (0.0%)     | 2/33 (6.1%)     | 2/32 (6.3%)     |
| First incidence (days)   | —               | 765 (T)         | 754             |
| Poly-3 test  | P=0.150         | P=0.458         | P=0.218         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                 |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)     | 3/47 (6.4%)     | 4/48 (8.3%)     |
| Adjusted rate  | 1/44.2 (2.3%)   | 3/42.5 (7.1%)   | 4/41.9 (9.6%)   |
| Terminal rate  | 1/37 (2.7%)     | 3/33 (9.1%)     | 3/32 (9.4%)     |
| First incidence (days)   | 765 (T)         | 765 (T)         | 754             |
| Poly-3 test  | P=0.240         | P=0.585         | P=0.324         |
| <b>All Organs: Malignant Lymphoma</b>  |                 |                 |                 |
| Overall rate   | 6/48 (12.5%)    | 10/47 (21.3%)   | 6/48 (12.5%)    |
| Adjusted rate  | 6/45.3 (13.2%)  | 10/43.6 (22.9%) | 6/42.8 (14.0%)  |
| Terminal rate  | 3/37 (8.1%)     | 7/33 (21.2%)    | 4/32 (12.5%)    |
| First incidence (days)   | 510             | 611             | 553             |
| Poly-3 test  | P=1.000         | P=0.366         | P=1.000         |
| <b>All Organs: Benign Neoplasms</b>  |                 |                 |                 |
| Overall rate   | 26/48 (54.2%)   | 21/47 (44.7%)   | 26/48 (54.2%)   |
| Adjusted rate  | 26/45.1 (57.6%) | 21/44.4 (47.3%) | 26/42.6 (61.1%) |
| Terminal rate  | 22/37 (59.5%)   | 15/33 (45.5%)   | 20/32 (62.5%)   |
| First incidence (days)   | 648             | 529             | 662             |
| Poly-3 test  | P=0.867         | P=0.431         | P=0.913         |
| <b>All Organs: Malignant Neoplasms</b>   |                 |                 |                 |
| Overall rate   | 20/48 (41.7%)   | 22/47 (46.8%)   | 35/48 (72.9%)   |
| Adjusted rate  | 20/46.9 (42.7%) | 22/44.4 (49.6%) | 35/44.8 (78.2%) |
| Terminal rate  | 11/37 (29.7%)   | 16/33 (48.5%)   | 24/32 (75.0%)   |
| First incidence (days)   | 510             | 611             | 531             |
| Poly-3 test  | P=0.001         | P=0.666         | P=0.001         |

**TABLE D2c**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 10 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 35/48 (72.9%)   | 33/47 (70.2%)   | 43/48 (89.6%)   |
| Adjusted rate                                    | 35/47.3 (74.1%) | 33/45.2 (73.0%) | 43/45.1 (95.2%) |
| Terminal rate                                    | 25/37 (67.6%)   | 24/33 (72.7%)   | 30/32 (93.8%)   |
| First incidence (days)                           | 510             | 529             | 531             |
| Poly-3 test                                      | P=0.013         | P=1.000         | P=0.009         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

**TABLE D2d**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|   | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|---|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>                    |                 |                 |                 |
| Overall rate <sup>a</sup>                         | 1/45 (2.2%)     | 0/46 (0.0%)     | 3/47 (6.4%)     |
| Adjusted rate <sup>b</sup>                        | 1/37.2 (2.7%)   | 0/34.4 (0.0%)   | 3/39.6 (7.6%)   |
| Terminal rate <sup>c</sup>                        | 1/25 (4.0%)     | 0/18 (0.0%)     | 3/27 (11.1%)    |
| First incidence (days)                            | 765 (T)         | — <sup>e</sup>  | 765 (T)         |
| Poly-3 test <sup>d</sup>                          | P=0.375         | P=1.000         | P=0.655         |
| <b>Harderian Gland: Adenoma</b>                   |                 |                 |                 |
| Overall rate                                      | 8/48 (16.7%)    | 9/46 (19.6%)    | 6/46 (13.0%)    |
| Adjusted rate                                     | 8/41.1 (19.5%)  | 9/36.3 (24.8%)  | 6/39.5 (15.2%)  |
| Terminal rate                                     | 4/27 (14.8%)    | 3/19 (15.8%)    | 3/26 (11.5%)    |
| First incidence (days)                            | 554             | 594             | 663             |
| Poly-3 test                                       | P=0.736         | P=0.770         | P=0.833         |
| <b>Harderian Gland: Carcinoma</b>                 |                 |                 |                 |
| Overall rate                                      | 11/48 (22.9%)   | 6/46 (13.0%)    | 7/46 (15.2%)    |
| Adjusted rate                                     | 11/40.7 (27.0%) | 6/35.6 (16.8%)  | 7/38.8 (18.0%)  |
| Terminal rate                                     | 7/27 (25.9%)    | 4/19 (21.1%)    | 7/26 (26.9%)    |
| First incidence (days)                            | 616             | 584             | 765 (T)         |
| Poly-3 test                                       | P=0.380         | P=0.424         | P=0.487         |
| <b>Harderian Gland: Adenoma or Carcinoma</b>      |                 |                 |                 |
| Overall rate                                      | 19/48 (39.6%)   | 15/46 (32.6%)   | 13/46 (28.3%)   |
| Adjusted rate                                     | 19/42.3 (45.0%) | 15/37.1 (40.4%) | 13/39.5 (32.9%) |
| Terminal rate                                     | 11/27 (40.7%)   | 7/19 (36.8%)    | 10/26 (38.5%)   |
| First incidence (days)                            | 554             | 584             | 663             |
| Poly-3 test                                       | P=0.304         | P=0.855         | P=0.366         |
| <b>Liver: Histiocytic Sarcoma</b>                 |                 |                 |                 |
| Overall rate                                      | 3/47 (6.4%)     | 2/47 (4.3%)     | 3/48 (6.3%)     |
| Adjusted rate                                     | 3/39.5 (7.6%)   | 2/36.0 (5.5%)   | 3/41.0 (7.3%)   |
| Terminal rate                                     | 1/27 (3.7%)     | 0/19 (0.0%)     | 0/27 (0.0%)     |
| First incidence (days)                            | 678             | 607             | 687             |
| Poly-3 test                                       | P=1.000         | P=1.000         | P=1.000         |
| <b>Liver: Hepatocellular Adenoma</b>              |                 |                 |                 |
| Overall rate                                      | 19/47 (40.4%)   | 15/47 (31.9%)   | 16/48 (33.3%)   |
| Adjusted rate                                     | 19/39.7 (47.8%) | 15/36.2 (41.4%) | 16/41.1 (38.9%) |
| Terminal rate                                     | 16/27 (59.3%)   | 13/19 (68.4%)   | 12/27 (44.4%)   |
| First incidence (days)                            | 696             | 600             | 685             |
| Poly-3 test                                       | P=0.469         | P=0.735         | P=0.551         |
| <b>Liver: Hepatocellular Carcinoma</b>            |                 |                 |                 |
| Overall rate                                      | 2/47 (4.3%)     | 3/47 (6.4%)     | 0/48 (0.0%)     |
| Adjusted rate                                     | 2/39.2 (5.1%)   | 3/36.0 (8.3%)   | 0/40.6 (0.0%)   |
| Terminal rate                                     | 2/27 (7.4%)     | 2/19 (10.5%)    | 0/27 (0.0%)     |
| First incidence (days)                            | 765 (T)         | 584             | —               |
| Poly-3 test                                       | P=0.380         | P=0.922         | P=0.458         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate                                      | 20/47 (42.6%)   | 16/47 (34.0%)   | 16/48 (33.3%)   |
| Adjusted rate                                     | 20/39.7 (50.3%) | 16/36.8 (43.5%) | 16/41.1 (38.9%) |
| Terminal rate                                     | 17/27 (63.0%)   | 13/19 (68.4%)   | 12/27 (44.4%)   |
| First incidence (days)                            | 696             | 584             | 685             |
| Poly-3 test                                       | P=0.337         | P=0.704         | P=0.406         |

**TABLE D2d**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Lung: Histiocytic Sarcoma</b>                       |                 |                 |                 |
| Overall rate   | 3/48 (6.3%)     | 1/48 (2.1%)     | 3/48 (6.3%)     |
| Adjusted rate  | 3/39.9 (7.5%)   | 1/36.3 (2.8%)   | 3/41.0 (7.3%)   |
| Terminal rate  | 1/27 (3.7%)     | 0/19 (0.0%)     | 0/27 (0.0%)     |
| First incidence (days)                                 | 678             | 738             | 687             |
| Poly-3 test  | P=1.000         | P=0.678         | P=1.000         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |
| Overall rate   | 17/48 (35.4%)   | 16/48 (33.3%)   | 18/48 (37.5%)   |
| Adjusted rate  | 17/42.4 (40.1%) | 16/39.2 (40.8%) | 18/42.2 (42.7%) |
| Terminal rate  | 9/27 (33.3%)    | 7/19 (36.8%)    | 14/27 (51.9%)   |
| First incidence (days)                                 | 438             | 306             | 380             |
| Poly-3 test  | P=0.894         | P=1.000         | P=0.985         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |
| Overall rate   | 13/48 (27.1%)   | 6/48 (12.5%)    | 9/48 (18.8%)    |
| Adjusted rate  | 13/40.5 (32.1%) | 6/37.0 (16.2%)  | 9/40.9 (22.0%)  |
| Terminal rate  | 9/27 (33.3%)    | 3/19 (15.8%)    | 8/27 (29.6%)    |
| First incidence (days)                                 | 635             | 640             | 670             |
| Poly-3 test  | P=0.336         | P=0.167         | P=0.434         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 28/48 (58.3%)   | 21/48 (43.8%)   | 24/48 (50.0%)   |
| Adjusted rate  | 28/43.3 (64.6%) | 21/39.7 (52.9%) | 24/42.5 (56.5%) |
| Terminal rate  | 16/27 (59.3%)   | 10/19 (52.6%)   | 19/27 (70.4%)   |
| First incidence (days)                                 | 438             | 306             | 380             |
| Poly-3 test  | P=0.486         | P=0.367         | P=0.570         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                 |                 |                 |
| Overall rate   | 2/42 (4.8%)     | 1/42 (2.4%)     | 3/46 (6.5%)     |
| Adjusted rate  | 2/36.3 (5.5%)   | 1/31.5 (3.2%)   | 3/39.6 (7.6%)   |
| Terminal rate  | 0/25 (0.0%)     | 0/17 (0.0%)     | 0/26 (0.0%)     |
| First incidence (days)                                 | 678             | 738             | 687             |
| Poly-3 test  | P=0.875         | P=1.000         | P=1.000         |
| <b>Mammary Gland: Adenocarcinoma</b>                   |                 |                 |                 |
| Overall rate   | 3/46 (6.5%)     | 11/48 (22.9%)   | 6/48 (12.5%)    |
| Adjusted rate  | 3/39.3 (7.6%)   | 11/38.2 (28.8%) | 6/41.7 (14.4%)  |
| Terminal rate  | 1/27 (3.7%)     | 4/19 (21.1%)    | 2/27 (7.4%)     |
| First incidence (days)                                 | 696             | 607             | 642             |
| Poly-3 test  | P=0.526         | P=0.028         | P=0.541         |
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b> |                 |                 |                 |
| Overall rate   | 4/46 (8.7%)     | 12/48 (25.0%)   | 7/48 (14.6%)    |
| Adjusted rate  | 4/39.6 (10.1%)  | 12/38.5 (31.2%) | 7/41.7 (16.8%)  |
| Terminal rate  | 1/27 (3.7%)     | 4/19 (21.1%)    | 3/27 (11.1%)    |
| First incidence (days)                                 | 675             | 607             | 642             |
| Poly-3 test  | P=0.545         | P=0.036         | P=0.578         |
| <b>Ovary: Cystadenoma</b>                              |                 |                 |                 |
| Overall rate   | 1/46 (2.2%)     | 0/47 (0.0%)     | 3/46 (6.5%)     |
| Adjusted rate  | 1/38.5 (2.6%)   | 0/35.8 (0.0%)   | 3/38.8 (7.7%)   |
| Terminal rate  | 1/27 (3.7%)     | 0/19 (0.0%)     | 3/26 (11.5%)    |
| First incidence (days)                                 | 765 (T)         | —               | 765 (T)         |
| Poly-3 test  | P=0.348         | P=1.000         | P=0.614         |

**TABLE D2d**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol     |
|--|----------------|----------------|----------------|
| <b>Ovary: Histiocytic Sarcoma</b>                            |                |                |                |
| Overall rate   | 3/46 (6.5%)    | 1/47 (2.1%)    | 2/46 (4.3%)    |
| Adjusted rate  | 3/38.8 (7.7%)  | 1/35.9 (2.8%)  | 2/38.9 (5.1%)  |
| Terminal rate  | 1/27 (3.7%)    | 0/19 (0.0%)    | 0/26 (0.0%)    |
| First incidence (days)                                       | 678            | 738            | 745            |
| Poly-3 test  | P=0.796        | P=0.665        | P=0.998        |
| <b>Ovary: Benign Granulosa Cell Tumor</b>                    |                |                |                |
| Overall rate   | 2/46 (4.3%)    | 3/47 (6.4%)    | 5/46 (10.9%)   |
| Adjusted rate  | 2/38.5 (5.2%)  | 3/36.0 (8.3%)  | 5/39.3 (12.7%) |
| Terminal rate  | 2/27 (7.4%)    | 2/19 (10.5%)   | 3/26 (11.5%)   |
| First incidence (days)                                       | 765 (T)        | 696            | 685            |
| Poly-3 test  | P=0.323        | P=0.940        | P=0.444        |
| <b>Ovary: Benign or Malignant Granulosa Cell Tumor</b>       |                |                |                |
| Overall rate   | 2/46 (4.3%)    | 3/47 (6.4%)    | 6/46 (13.0%)   |
| Adjusted rate  | 2/38.5 (5.2%)  | 3/36.0 (8.3%)  | 6/39.5 (15.2%) |
| Terminal rate  | 2/27 (7.4%)    | 2/19 (10.5%)   | 3/26 (11.5%)   |
| First incidence (days)                                       | 765 (T)        | 696            | 685            |
| Poly-3 test  | P=0.184        | P=0.940        | P=0.278        |
| <b>Pancreatic Islets: Adenoma</b>                            |                |                |                |
| Overall rate   | 0/47 (0.0%)    | 1/46 (2.2%)    | 3/48 (6.3%)    |
| Adjusted rate  | 0/39.2 (0.0%)  | 1/35.4 (2.8%)  | 3/40.6 (7.4%)  |
| Terminal rate  | 0/27 (0.0%)    | 0/19 (0.0%)    | 2/27 (7.4%)    |
| First incidence (days)                                       | —              | 681            | 745            |
| Poly-3 test  | P=0.128        | P=0.959        | P=0.249        |
| <b>Pituitary Gland (Pars Distalis): Adenoma or Carcinoma</b> |                |                |                |
| Overall rate   | 5/40 (12.5%)   | 3/41 (7.3%)    | 5/40 (12.5%)   |
| Adjusted rate  | 5/33.8 (14.8%) | 3/30.9 (9.7%)  | 5/34.4 (14.5%) |
| Terminal rate  | 4/23 (17.4%)   | 1/15 (6.7%)    | 5/25 (20.0%)   |
| First incidence (days)                                       | 649            | 594            | 765 (T)        |
| Poly-3 test  | P=1.000        | P=0.808        | P=1.000        |
| <b>Skin: Sarcoma</b>   |                |                |                |
| Overall rate   | 0/46 (0.0%)    | 6/48 (12.5%)   | 4/48 (8.3%)    |
| Adjusted rate  | 0/38.8 (0.0%)  | 6/37.2 (16.1%) | 4/41.1 (9.7%)  |
| Terminal rate  | 0/27 (0.0%)    | 2/19 (10.5%)   | 2/27 (7.4%)    |
| First incidence (days)                                       | —              | 636            | 685            |
| Poly-3 test  | P=0.174        | P=0.025        | P=0.134        |
| <b>Spleen: Histiocytic Sarcoma</b>                           |                |                |                |
| Overall rate   | 2/47 (4.3%)    | 1/46 (2.2%)    | 3/48 (6.3%)    |
| Adjusted rate  | 2/39.5 (5.1%)  | 1/35.2 (2.8%)  | 3/41.0 (7.3%)  |
| Terminal rate  | 0/27 (0.0%)    | 0/19 (0.0%)    | 0/27 (0.0%)    |
| First incidence (days)                                       | 678            | 738            | 687            |
| Poly-3 test  | P=0.830        | P=1.000        | P=1.000        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>        |                |                |                |
| Overall rate   | 3/46 (6.5%)    | 0/47 (0.0%)    | 2/48 (4.2%)    |
| Adjusted rate  | 3/39.0 (7.7%)  | 0/35.4 (0.0%)  | 2/40.8 (4.9%)  |
| Terminal rate  | 2/27 (7.4%)    | 0/19 (0.0%)    | 1/27 (3.7%)    |
| First incidence (days)                                       | 712            | —              | 702            |
| Poly-3 test  | P=0.745        | P=0.271        | P=0.959        |

**TABLE D2d**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol    | 5% Ethanol      |
|--|----------------|-----------------|-----------------|
| <b>Thymus: Histiocytic Sarcoma</b>               |                |                 |                 |
| Overall rate                                     | 3/32 (9.4%)    | 1/34 (2.9%)     | 0/43 (0.0%)     |
| Adjusted rate                                    | 3/26.7 (11.3%) | 1/26.7 (3.7%)   | 0/36.1 (0.0%)   |
| Terminal rate                                    | 1/16 (6.3%)    | 0/14 (0.0%)     | 0/24 (0.0%)     |
| First incidence (days)                           | 678            | 738             | —               |
| Poly-3 test                                      | P=0.067        | P=0.603         | P=0.136         |
| <b>Uterus: Hemangioma or Hemangiosarcoma</b>     |                |                 |                 |
| Overall rate                                     | 2/48 (4.2%)    | 2/48 (4.2%)     | 3/47 (6.4%)     |
| Adjusted rate                                    | 2/39.5 (5.1%)  | 2/36.4 (5.5%)   | 3/40.0 (7.5%)   |
| Terminal rate                                    | 2/27 (7.4%)    | 1/19 (5.3%)     | 1/26 (3.8%)     |
| First incidence (days)                           | 765 (T)        | 696             | 675             |
| Poly-3 test                                      | P=0.824        | P=1.000         | P=1.000         |
| <b>Uterus: Histiocytic Sarcoma</b>               |                |                 |                 |
| Overall rate                                     | 3/48 (6.3%)    | 2/48 (4.2%)     | 1/47 (2.1%)     |
| Adjusted rate                                    | 3/39.9 (7.5%)  | 2/36.9 (5.4%)   | 1/39.6 (2.5%)   |
| Terminal rate                                    | 1/27 (3.7%)    | 0/19 (0.0%)     | 0/26 (0.0%)     |
| First incidence (days)                           | 678            | 607             | 746             |
| Poly-3 test                                      | P=0.447        | P=1.000         | P=0.613         |
| <b>All Organs: Hemangioma</b>                    |                |                 |                 |
| Overall rate                                     | 3/48 (6.3%)    | 2/48 (4.2%)     | 6/48 (12.5%)    |
| Adjusted rate                                    | 3/39.7 (7.6%)  | 2/36.2 (5.5%)   | 6/41.0 (14.6%)  |
| Terminal rate                                    | 2/27 (7.4%)    | 2/19 (10.5%)    | 4/27 (14.8%)    |
| First incidence (days)                           | 719            | 765 (T)         | 675             |
| Poly-3 test                                      | P=0.353        | P=1.000         | P=0.512         |
| <b>All Organs: Hemangiosarcoma</b>               |                |                 |                 |
| Overall rate                                     | 4/48 (8.3%)    | 1/48 (2.1%)     | 1/48 (2.1%)     |
| Adjusted rate                                    | 4/39.5 (10.1%) | 1/36.4 (2.7%)   | 1/40.6 (2.5%)   |
| Terminal rate                                    | 4/27 (14.8%)   | 0/19 (0.0%)     | 1/27 (3.7%)     |
| First incidence (days)                           | 765 (T)        | 696             | 765 (T)         |
| Poly-3 test                                      | P=0.191        | P=0.406         | P=0.339         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                |                 |                 |
| Overall rate                                     | 6/48 (12.5%)   | 3/48 (6.3%)     | 7/48 (14.6%)    |
| Adjusted rate                                    | 6/39.7 (15.1%) | 3/36.4 (8.2%)   | 7/41.0 (17.1%)  |
| Terminal rate                                    | 5/27 (18.5%)   | 2/19 (10.5%)    | 5/27 (18.5%)    |
| First incidence (days)                           | 719            | 696             | 675             |
| Poly-3 test                                      | P=0.910        | P=0.567         | P=1.000         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                |                 |                 |
| Overall rate                                     | 3/48 (6.3%)    | 3/48 (6.3%)     | 3/48 (6.3%)     |
| Adjusted rate                                    | 3/39.9 (7.5%)  | 3/37.0 (8.1%)   | 3/41.0 (7.3%)   |
| Terminal rate                                    | 1/27 (3.7%)    | 0/19 (0.0%)     | 0/27 (0.0%)     |
| First incidence (days)                           | 678            | 607             | 687             |
| Poly-3 test                                      | P=1.000        | P=1.000         | P=1.000         |
| <b>All Organs: Malignant Lymphoma</b>            |                |                 |                 |
| Overall rate                                     | 8/48 (16.7%)   | 11/48 (22.9%)   | 15/48 (31.3%)   |
| Adjusted rate                                    | 8/42.0 (19.0%) | 11/38.7 (28.4%) | 15/43.8 (34.3%) |
| Terminal rate                                    | 2/27 (7.4%)    | 5/19 (26.3%)    | 6/27 (22.2%)    |
| First incidence (days)                           | 549            | 593             | 285             |
| Poly-3 test                                      | P=0.134        | P=0.461         | P=0.172         |

**TABLE D2d**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 30 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 38/48 (79.2%)   | 31/48 (64.6%)   | 37/48 (77.1%)   |
| Adjusted rate                                    | 38/44.6 (85.2%) | 31/40.5 (76.6%) | 37/44.0 (84.2%) |
| Terminal rate                                    | 23/27 (85.2%)   | 18/19 (94.7%)   | 25/27 (92.6%)   |
| First incidence (days)                           | 438             | 306             | 380             |
| Poly-3 test                                      | P=1.000         | P=0.411         | P=1.000         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 37/48 (77.1%)   | 38/48 (79.2%)   | 37/48 (77.1%)   |
| Adjusted rate                                    | 37/46.8 (79.1%) | 38/44.5 (85.4%) | 37/46.2 (80.1%) |
| Terminal rate                                    | 18/27 (66.7%)   | 15/19 (78.9%)   | 20/27 (74.1%)   |
| First incidence (days)                           | 438             | 468             | 285             |
| Poly-3 test                                      | P=1.000         | P=0.601         | P=1.000         |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |
| Overall rate                                     | 45/48 (93.8%)   | 45/48 (93.8%)   | 47/48 (97.9%)   |
| Adjusted rate                                    | 45/47.2 (95.4%) | 45/46.5 (96.8%) | 47/47.5 (98.9%) |
| Terminal rate                                    | 25/27 (92.6%)   | 18/19 (94.7%)   | 27/27 (100.0%)  |
| First incidence (days)                           | 438             | 306             | 285             |
| Poly-3 test                                      | P=0.440         | P=1.000         | P=0.658         |

(T) Terminal sacrifice  
<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically  
<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality  
<sup>c</sup> Observed incidence at terminal kill  
<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.  
<sup>e</sup> Not applicable; no neoplasms in animal group

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>               |                 |                 |                 |
| Overall rate <sup>a</sup>                    | 2/47 (4.3%)     | 0/44 (0.0%)     | 3/46 (6.5%)     |
| Adjusted rate <sup>b</sup>                   | 2/28.6 (7.0%)   | 0/29.8 (0.0%)   | 3/29.7 (10.1%)  |
| Terminal rate <sup>c</sup>                   | 0/1 (0.0%)      | 0/7 (0.0%)      | 1/4 (25.0%)     |
| First incidence (days)                       | 710             | — <sup>e</sup>  | 700             |
| Poly-3 test <sup>d</sup>                     | P=0.787         | P=0.452         | P=1.000         |
| <b>Adrenal Cortex: Adenoma or Carcinoma</b>  |                 |                 |                 |
| Overall rate                                 | 2/47 (4.3%)     | 1/44 (2.3%)     | 3/46 (6.5%)     |
| Adjusted rate                                | 2/28.6 (7.0%)   | 1/30.0 (3.3%)   | 3/29.7 (10.1%)  |
| Terminal rate                                | 0/1 (0.0%)      | 0/7 (0.0%)      | 1/4 (25.0%)     |
| First incidence (days)                       | 710             | 715             | 700             |
| Poly-3 test                                  | P=0.818         | P=0.967         | P=1.000         |
| <b>Harderian Gland: Adenoma</b>              |                 |                 |                 |
| Overall rate                                 | 21/48 (43.8%)   | 19/47 (40.4%)   | 20/46 (43.5%)   |
| Adjusted rate                                | 21/36.1 (58.2%) | 19/37.9 (50.1%) | 20/36.5 (54.7%) |
| Terminal rate                                | 0/1 (0.0%)      | 2/8 (25.0%)     | 2/4 (50.0%)     |
| First incidence (days)                       | 466             | 542             | 433             |
| Poly-3 test                                  | P=0.865         | P=0.622         | P=0.949         |
| <b>Harderian Gland: Carcinoma</b>            |                 |                 |                 |
| Overall rate                                 | 11/48 (22.9%)   | 16/47 (34.0%)   | 10/46 (21.7%)   |
| Adjusted rate                                | 11/32.0 (34.3%) | 16/36.1 (44.4%) | 10/32.7 (30.5%) |
| Terminal rate                                | 1/1 (100.0%)    | 3/8 (37.5%)     | 0/4 (0.0%)      |
| First incidence (days)                       | 548             | 599             | 559             |
| Poly-3 test                                  | P=0.825         | P=0.530         | P=0.951         |
| <b>Harderian Gland: Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate                                 | 30/48 (62.5%)   | 35/47 (74.5%)   | 29/46 (63.0%)   |
| Adjusted rate                                | 30/39.0 (76.8%) | 35/41.5 (84.3%) | 29/39.7 (73.0%) |
| Terminal rate                                | 1/1 (100.0%)    | 5/8 (62.5%)     | 2/4 (50.0%)     |
| First incidence (days)                       | 466             | 542             | 433             |
| Poly-3 test                                  | P=0.739         | P=0.512         | P=0.883         |
| <b>Heart: Hemangiosarcoma</b>                |                 |                 |                 |
| Overall rate                                 | 0/48 (0.0%)     | 3/48 (6.3%)     | 6/47 (12.8%)    |
| Adjusted rate                                | 0/28.7 (0.0%)   | 3/34.2 (8.8%)   | 6/31.5 (19.1%)  |
| Terminal rate                                | 0/1 (0.0%)      | 0/8 (0.0%)      | 1/4 (25.0%)     |
| First incidence (days)                       | —               | 565             | 603             |
| Poly-3 test                                  | P=0.021         | P=0.300         | P=0.035         |
| <b>Heart: Histiocytic Sarcoma</b>            |                 |                 |                 |
| Overall rate                                 | 3/48 (6.3%)     | 0/48 (0.0%)     | 0/47 (0.0%)     |
| Adjusted rate                                | 3/29.4 (10.2%)  | 0/33.0 (0.0%)   | 0/30.0 (0.0%)   |
| Terminal rate                                | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                       | 650             | —               | —               |
| Poly-3 test                                  | P=0.069         | P=0.193         | P=0.222         |
| <b>Kidney: Hemangiosarcoma</b>               |                 |                 |                 |
| Overall rate                                 | 0/48 (0.0%)     | 3/48 (6.3%)     | 1/47 (2.1%)     |
| Adjusted rate                                | 0/28.7 (0.0%)   | 3/34.6 (8.7%)   | 1/30.4 (3.3%)   |
| Terminal rate                                | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                       | —               | 508             | 675             |
| Poly-3 test                                  | P=0.830         | P=0.306         | P=1.000         |

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Liver: Hemangiosarcoma</b>                          |                 |                 |                 |
| Overall rate   | 7/47 (14.9%)    | 7/46 (15.2%)    | 6/48 (12.5%)    |
| Adjusted rate  | 7/30.3 (23.1%)  | 7/32.6 (21.5%)  | 6/32.1 (18.7%)  |
| Terminal rate  | 0/1 (0.0%)      | 1/8 (12.5%)     | 0/4 (0.0%)      |
| First incidence (days)                                 | 551             | 677             | 485             |
| Poly-3 test  | P=0.782         | P=1.000         | P=0.901         |
| <b>Liver: Histiocytic Sarcoma</b>                      |                 |                 |                 |
| Overall rate   | 3/47 (6.4%)     | 1/46 (2.2%)     | 2/48 (4.2%)     |
| Adjusted rate  | 3/29.0 (10.3%)  | 1/31.8 (3.1%)   | 2/31.1 (6.4%)   |
| Terminal rate  | 0/1 (0.0%)      | 1/8 (12.5%)     | 0/4 (0.0%)      |
| First incidence (days)                                 | 650             | 765 (T)         | 674             |
| Poly-3 test  | P=0.760         | P=0.539         | P=0.936         |
| <b>Liver: Hepatocellular Adenoma</b>                   |                 |                 |                 |
| Overall rate   | 18/47 (38.3%)   | 23/46 (50.0%)   | 16/48 (33.3%)   |
| Adjusted rate  | 18/33.4 (54.0%) | 23/36.4 (63.2%) | 16/35.5 (45.0%) |
| Terminal rate  | 0/1 (0.0%)      | 8/8 (100.0%)    | 3/4 (75.0%)     |
| First incidence (days)                                 | 590             | 608             | 559             |
| Poly-3 test  | P=0.474         | P=0.550         | P=0.590         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                 |                 |                 |
| Overall rate   | 19/47 (40.4%)   | 23/46 (50.0%)   | 17/48 (35.4%)   |
| Adjusted rate  | 19/33.7 (56.4%) | 23/36.4 (63.2%) | 17/35.7 (47.6%) |
| Terminal rate  | 0/1 (0.0%)      | 8/8 (100.0%)    | 3/4 (75.0%)     |
| First incidence (days)                                 | 590             | 608             | 559             |
| Poly-3 test  | P=0.483         | P=0.711         | P=0.592         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                 |                 |                 |
| Overall rate   | 29/47 (61.7%)   | 28/48 (58.3%)   | 30/48 (62.5%)   |
| Adjusted rate  | 29/38.8 (74.8%) | 28/39.4 (71.1%) | 30/38.9 (77.1%) |
| Terminal rate  | 1/1 (100.0%)    | 6/8 (75.0%)     | 4/4 (100.0%)    |
| First incidence (days)                                 | 391             | 593             | 433             |
| Poly-3 test  | P=0.905         | P=0.899         | P=1.000         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                 |                 |                 |
| Overall rate   | 19/47 (40.4%)   | 23/48 (47.9%)   | 23/48 (47.9%)   |
| Adjusted rate  | 19/32.9 (57.8%) | 23/37.3 (61.7%) | 23/37.7 (61.1%) |
| Terminal rate  | 1/1 (100.0%)    | 6/8 (75.0%)     | 3/4 (75.0%)     |
| First incidence (days)                                 | 548             | 499             | 485             |
| Poly-3 test  | P=0.885         | P=0.924         | P=0.971         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                 |                 |                 |
| Overall rate   | 39/47 (83.0%)   | 38/48 (79.2%)   | 37/48 (77.1%)   |
| Adjusted rate  | 39/41.9 (93.2%) | 38/42.0 (90.6%) | 37/41.8 (88.5%) |
| Terminal rate  | 1/1 (100.0%)    | 8/8 (100.0%)    | 4/4 (100.0%)    |
| First incidence (days)                                 | 391             | 499             | 433             |
| Poly-3 test  | P=0.459         | P=0.962         | P=0.627         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                 |                 |                 |
| Overall rate   | 3/39 (7.7%)     | 2/38 (5.3%)     | 2/38 (5.3%)     |
| Adjusted rate  | 3/24.7 (12.1%)  | 2/27.0 (7.4%)   | 2/25.2 (7.9%)   |
| Terminal rate  | 0/1 (0.0%)      | 1/8 (12.5%)     | 0/4 (0.0%)      |
| First incidence (days)                                 | 650             | 762             | 674             |
| Poly-3 test  | P=0.801         | P=0.917         | P=0.981         |

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Mammary Gland: Adenoacanthoma</b>                   |                 |                 |                 |
| Overall rate   | 11/48 (22.9%)   | 3/47 (6.4%)     | 9/45 (20.0%)    |
| Adjusted rate  | 11/32.6 (33.8%) | 3/33.4 (9.0%)   | 9/32.0 (28.1%)  |
| Terminal rate  | 0/1 (0.0%)      | 0/8 (0.0%)      | 2/4 (50.0%)     |
| First incidence (days)                                 | 523             | 599             | 459             |
| Poly-3 test  | P=0.705         | P=0.023         | P=0.819         |
| <b>Mammary Gland: Adenocarcinoma</b>                   |                 |                 |                 |
| Overall rate   | 11/48 (22.9%)   | 14/47 (29.8%)   | 15/45 (33.3%)   |
| Adjusted rate  | 11/32.8 (33.6%) | 14/35.6 (39.3%) | 15/33.8 (44.3%) |
| Terminal rate  | 1/1 (100.0%)    | 2/8 (25.0%)     | 1/4 (25.0%)     |
| First incidence (days)                                 | 391             | 648             | 559             |
| Poly-3 test  | P=0.426         | P=0.800         | P=0.494         |
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b> |                 |                 |                 |
| Overall rate   | 22/48 (45.8%)   | 16/47 (34.0%)   | 23/45 (51.1%)   |
| Adjusted rate  | 22/36.6 (60.1%) | 16/36.3 (44.1%) | 23/36.9 (62.4%) |
| Terminal rate  | 1/1 (100.0%)    | 2/8 (25.0%)     | 2/4 (50.0%)     |
| First incidence (days)                                 | 391             | 599             | 459             |
| Poly-3 test  | P=0.900         | P=0.222         | P=1.000         |
| <b>Ovary: Hemangioma or Hemangiosarcoma</b>            |                 |                 |                 |
| Overall rate   | 0/39 (0.0%)     | 3/48 (6.3%)     | 0/45 (0.0%)     |
| Adjusted rate  | 0/22.8 (0.0%)   | 3/33.8 (8.9%)   | 0/28.9 (0.0%)   |
| Terminal rate  | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                                 | —               | 611             | — <sup>f</sup>  |
| Poly-3 test  | P=1.000         | P=0.396         | —               |
| <b>Ovary: Benign Granulosa Cell Tumor</b>              |                 |                 |                 |
| Overall rate   | 3/39 (7.7%)     | 3/48 (6.3%)     | 3/45 (6.7%)     |
| Adjusted rate  | 3/23.8 (12.6%)  | 3/33.9 (8.9%)   | 3/28.9 (10.4%)  |
| Terminal rate  | 0/1 (0.0%)      | 1/8 (12.5%)     | 3/4 (75.0%)     |
| First incidence (days)                                 | 576             | 614             | 765 (T)         |
| Poly-3 test  | P=1.000         | P=0.982         | P=1.000         |
| <b>Ovary: Malignant Granulosa Cell Tumor</b>           |                 |                 |                 |
| Overall rate   | 3/39 (7.7%)     | 0/48 (0.0%)     | 0/45 (0.0%)     |
| Adjusted rate  | 3/23.8 (12.6%)  | 0/33.0 (0.0%)   | 0/28.9 (0.0%)   |
| Terminal rate  | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                                 | 635             | —               | —               |
| Poly-3 test  | P=0.048         | P=0.130         | P=0.163         |
| <b>Ovary: Benign or Malignant Granulosa Cell Tumor</b> |                 |                 |                 |
| Overall rate   | 5/39 (12.8%)    | 3/48 (6.3%)     | 3/45 (6.7%)     |
| Adjusted rate  | 5/24.5 (20.4%)  | 3/33.9 (8.9%)   | 3/28.9 (10.4%)  |
| Terminal rate  | 0/1 (0.0%)      | 1/8 (12.5%)     | 3/4 (75.0%)     |
| First incidence (days)                                 | 576             | 614             | 765 (T)         |
| Poly-3 test  | P=0.406         | P=0.375         | P=0.515         |
| <b>Pancreas: Histiocytic Sarcoma</b>                   |                 |                 |                 |
| Overall rate   | 2/44 (4.5%)     | 1/44 (2.3%)     | 1/44 (2.3%)     |
| Adjusted rate  | 2/27.2 (7.4%)   | 1/30.5 (3.3%)   | 1/28.5 (3.5%)   |
| Terminal rate  | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                                 | 650             | 762             | 762             |
| Poly-3 test  | P=0.738         | P=0.918         | P=0.967         |

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol     | 2.5% Ethanol   | 5% Ethanol     |
|--|----------------|----------------|----------------|
| <b>Skin: Sarcoma</b>   |                |                |                |
| Overall rate   | 6/48 (12.5%)   | 5/47 (10.6%)   | 7/47 (14.9%)   |
| Adjusted rate  | 6/30.3 (19.8%) | 5/33.5 (14.9%) | 7/32.2 (21.7%) |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 590            | 626            | 573            |
| Poly-3 test  | P=0.955        | P=0.853        | P=1.000        |
| <b>Skin: Fibroma or Sarcoma</b>  |                |                |                |
| Overall rate   | 6/48 (12.5%)   | 6/47 (12.8%)   | 7/47 (14.9%)   |
| Adjusted rate  | 6/30.3 (19.8%) | 6/33.7 (17.8%) | 7/32.2 (21.7%) |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 590            | 626            | 573            |
| Poly-3 test  | P=0.968        | P=1.000        | P=1.000        |
| <b>Spleen: Hemangiosarcoma</b>   |                |                |                |
| Overall rate   | 4/46 (8.7%)    | 3/46 (6.5%)    | 1/45 (2.2%)    |
| Adjusted rate  | 4/28.2 (14.2%) | 3/32.7 (9.2%)  | 1/29.0 (3.4%)  |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 605            | 626            | 749            |
| Poly-3 test  | P=0.241        | P=0.835        | P=0.326        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                            |                |                |                |
| Overall rate   | 3/46 (6.5%)    | 0/46 (0.0%)    | 0/45 (0.0%)    |
| Adjusted rate  | 3/28.6 (10.5%) | 0/31.7 (0.0%)  | 0/28.8 (0.0%)  |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 605            | —              | —              |
| Poly-3 test  | P=0.069        | P=0.196        | P=0.226        |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |                |                |                |
| Overall rate   | 4/46 (8.7%)    | 1/46 (2.2%)    | 0/45 (0.0%)    |
| Adjusted rate  | 4/29.0 (13.8%) | 1/32.1 (3.1%)  | 0/28.8 (0.0%)  |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 605            | 659            | —              |
| Poly-3 test  | P=0.045        | P=0.287        | P=0.113        |
| <b>Thymus: Histiocytic Sarcoma</b>   |                |                |                |
| Overall rate   | 1/38 (2.6%)    | 0/36 (0.0%)    | 2/39 (5.1%)    |
| Adjusted rate  | 1/22.7 (4.4%)  | 0/25.0 (0.0%)  | 2/24.3 (8.2%)  |
| Terminal rate  | 0/1 (0.0%)     | 0/5 (0.0%)     | 0/2 (0.0%)     |
| First incidence (days)   | 744            | —              | 674            |
| Poly-3 test  | P=0.750        | P=0.961        | P=1.000        |
| <b>Thyroid Gland (Follicular Cell): Adenoma or Carcinoma</b>                     |                |                |                |
| Overall rate   | 3/45 (6.7%)    | 0/46 (0.0%)    | 1/46 (2.2%)    |
| Adjusted rate  | 3/27.9 (10.7%) | 0/32.2 (0.0%)  | 1/30.1 (3.3%)  |
| Terminal rate  | 1/1 (100.0%)   | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | 466            | —              | 629            |
| Poly-3 test  | P=0.330        | P=0.183        | P=0.550        |
| <b>Uterus: Hemangioma</b>  |                |                |                |
| Overall rate   | 0/46 (0.0%)    | 3/48 (6.3%)    | 1/45 (2.2%)    |
| Adjusted rate  | 0/27.8 (0.0%)  | 3/34.3 (8.7%)  | 1/29.0 (3.4%)  |
| Terminal rate  | 0/1 (0.0%)     | 0/8 (0.0%)     | 0/4 (0.0%)     |
| First incidence (days)   | —              | 608            | 751            |
| Poly-3 test  | P=0.811        | P=0.315        | P=1.000        |

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane**  
**in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol    | 5% Ethanol      |
|--|-----------------|-----------------|-----------------|
| <b>Uterus: Hemangioma or Hemangiosarcoma</b>     |                 |                 |                 |
| Overall rate                                     | 2/46 (4.3%)     | 4/48 (8.3%)     | 2/45 (4.4%)     |
| Adjusted rate                                    | 2/28.3 (7.1%)   | 4/34.3 (11.7%)  | 2/29.1 (6.9%)   |
| Terminal rate                                    | 0/1 (0.0%)      | 1/8 (12.5%)     | 0/4 (0.0%)      |
| First incidence (days)                           | 676             | 608             | 749             |
| Poly-3 test                                      | P=1.000         | P=0.854         | P=1.000         |
| <b>All Organs: Hemangioma</b>                    |                 |                 |                 |
| Overall rate                                     | 1/48 (2.1%)     | 4/48 (8.3%)     | 2/48 (4.2%)     |
| Adjusted rate                                    | 1/28.9 (3.5%)   | 4/34.5 (11.6%)  | 2/31.2 (6.4%)   |
| Terminal rate                                    | 0/1 (0.0%)      | 0/8 (0.0%)      | 0/4 (0.0%)      |
| First incidence (days)                           | 725             | 608             | 643             |
| Poly-3 test                                      | P=0.908         | P=0.466         | P=1.000         |
| <b>All Organs: Hemangiosarcoma</b>               |                 |                 |                 |
| Overall rate                                     | 11/48 (22.9%)   | 17/48 (35.4%)   | 13/48 (27.1%)   |
| Adjusted rate                                    | 11/31.8 (34.6%) | 17/37.8 (45.0%) | 13/33.8 (38.5%) |
| Terminal rate                                    | 0/1 (0.0%)      | 2/8 (25.0%)     | 2/4 (50.0%)     |
| First incidence (days)                           | 551             | 508             | 485             |
| Poly-3 test                                      | P=0.875         | P=0.508         | P=0.945         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                 |                 |                 |
| Overall rate                                     | 11/48 (22.9%)   | 21/48 (43.8%)   | 14/48 (29.2%)   |
| Adjusted rate                                    | 11/31.8 (34.6%) | 21/39.3 (53.5%) | 14/34.2 (40.9%) |
| Terminal rate                                    | 0/1 (0.0%)      | 2/8 (25.0%)     | 2/4 (50.0%)     |
| First incidence (days)                           | 551             | 508             | 485             |
| Poly-3 test                                      | P=0.750         | P=0.152         | P=0.773         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |
| Overall rate                                     | 3/48 (6.3%)     | 2/48 (4.2%)     | 2/48 (4.2%)     |
| Adjusted rate                                    | 3/29.4 (10.2%)  | 2/33.0 (6.1%)   | 2/31.1 (6.4%)   |
| Terminal rate                                    | 0/1 (0.0%)      | 1/8 (12.5%)     | 0/4 (0.0%)      |
| First incidence (days)                           | 650             | 762             | 674             |
| Poly-3 test                                      | P=0.775         | P=0.894         | P=0.950         |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |
| Overall rate                                     | 15/48 (31.3%)   | 6/48 (12.5%)    | 10/48 (20.8%)   |
| Adjusted rate                                    | 15/35.1 (42.7%) | 6/35.4 (17.0%)  | 10/35.2 (28.4%) |
| Terminal rate                                    | 1/1 (100.0%)    | 0/8 (0.0%)      | 1/4 (25.0%)     |
| First incidence (days)                           | 193             | 360             | 433             |
| Poly-3 test                                      | P=0.211         | P=0.025         | P=0.287         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |
| Overall rate                                     | 42/48 (87.5%)   | 39/48 (81.3%)   | 41/48 (85.4%)   |
| Adjusted rate                                    | 42/44.3 (94.9%) | 39/42.7 (91.4%) | 41/44.0 (93.2%) |
| Terminal rate                                    | 1/1 (100.0%)    | 8/8 (100.0%)    | 4/4 (100.0%)    |
| First incidence (days)                           | 391             | 542             | 433             |
| Poly-3 test                                      | P=0.898         | P=0.764         | P=1.000         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |
| Overall rate                                     | 46/48 (95.8%)   | 45/48 (93.8%)   | 46/48 (95.8%)   |
| Adjusted rate                                    | 46/46.8 (98.2%) | 45/46.3 (97.1%) | 46/47.0 (97.8%) |
| Terminal rate                                    | 1/1 (100.0%)    | 8/8 (100.0%)    | 3/4 (75.0%)     |
| First incidence (days)                           | 193             | 360             | 433             |
| Poly-3 test                                      | P=1.000         | P=1.000         | P=1.000         |

**TABLE D2e**  
**Statistical Analysis of Primary Neoplasms in Female Mice Exposed to Ethanol and 90 ppm Urethane in Drinking Water for 2 Years**

|  | 0% Ethanol      | 2.5% Ethanol     | 5% Ethanol      |
|--|-----------------|------------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                  |                 |
| Overall rate                                     | 47/48 (97.9%)   | 48/48 (100.0%)   | 47/48 (97.9%)   |
| Adjusted rate                                    | 47/47.3 (99.3%) | 48/48.0 (100.0%) | 47/47.0 (99.9%) |
| Terminal rate                                    | 1/1 (100.0%)    | 8/8 (100.0%)     | 4/4 (100.0%)    |
| First incidence (days)                           | 193             | 360              | 433             |
| Poly-3 test                                      | P=1.000         | P=1.000          | P=1.000         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> P values are two sided. Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE D3a**  
**Historical Incidence of Hemangiosarcoma (All Sites) in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |
|--------------------------|-----------------------|
| Chloral hydrate (gavage) | 2/144                 |
| Doxylamine               | 0/48                  |
| Fumonisin B <sub>1</sub> | 1/47                  |
| Pyrilamine               | 1/48                  |
| Sulfamethazine           | 1/184                 |
| Tripolidine              | 1/47                  |
| Total (mean)             | 6/518 (1.2%)          |
| Range                    | 0%-2%                 |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D3b**  
**Historical Incidence of Hepatocellular Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |              |                      |
|--------------------------|-----------------------|--------------|----------------------|
|                          | Adenoma               | Carcinoma    | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 5/144                 | 4/144        | 9/144                |
| Doxylamine               | 0/46                  | 0/46         | 0/46                 |
| Fumonisin B <sub>1</sub> | 5/47                  | 0/47         | 5/47                 |
| Pyrilamine               | 1/47                  | 0/47         | 1/47                 |
| Sulfamethazine           | 8/184                 | 2/184        | 10/184               |
| Tripolidine              | 2/47                  | 2/47         | 4/47                 |
| Total (mean)             | 21/515 (4.1%)         | 8/515 (1.6%) | 29/515 (5.6%)        |
| Range                    | 0%-11%                | 0%-4%        | 0%-11%               |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D3c**  
**Historical Incidence of Alveolar/bronchiolar Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |              |                      |
|--------------------------|-----------------------|--------------|----------------------|
|                          | Adenoma               | Carcinoma    | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 8/143                 | 0/143        | 8/143                |
| Doxylamine               | 3/48                  | 0/48         | 3/48                 |
| Fumonisin B <sub>1</sub> | 2/47                  | 0/47         | 2/47                 |
| Pyrilamine               | 1/48                  | 0/48         | 1/48                 |
| Sulfamethazine           | 5/182                 | 1/182        | 6/182                |
| Tripolidine              | 3/47                  | 2/47         | 5/47                 |
| Total (mean)             | 22/515 (4.3%)         | 3/515 (0.6%) | 25/515 (4.9%)        |
| Range                    | 2%-6%                 | 0%-4%        | 2%-11%               |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D3d**  
**Historical Incidence of Harderian Gland Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |              |                      |
|--------------------------|-----------------------|--------------|----------------------|
|                          | Adenoma               | Carcinoma    | Adenoma or Carcinoma |
| Chloral hydrate (gavage) | 4/140                 | 2/140        | 6/140                |
| Fumonisin B <sub>1</sub> | 4/46                  | 1/46         | 4/46                 |
| Sulfamethazine           | 13/182                | 0/182        | 13/182               |
| Total (mean)             | 21/368 (5.7%)         | 3/368 (0.8%) | 23/368 (6.3%)        |
| Range                    | 3%-9%                 | 1%-2%        | 4%-9%                |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D3e**  
**Historical Incidence of Mammary Gland Neoplasms in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |                |                                     |
|--------------------------|-----------------------|----------------|-------------------------------------|
|                          | Adenoacanthoma        | Adenocarcinoma | Adenoacanthoma<br>or Adenocarcinoma |
| Chloral hydrate (gavage) | 0/133                 | 1/133          | 1/133                               |
| Fumonisin B <sub>1</sub> | 0/46                  | 1/46           | 1/46                                |
| Total (mean)             | 0/179                 | 2/179 (1.1%)   | 2/179 (1.1%)                        |
| Range                    |                       | 1%-2%          | 1%-2%                               |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D3f**  
**Historical Incidence of Granulosa Cell Tumor in Control Female B6C3F<sub>1</sub>/Nctr BR Mice<sup>a</sup>**

| Study                    | Incidence in Controls |              |                     |
|--------------------------|-----------------------|--------------|---------------------|
|                          | Benign                | Malignant    | Benign or Malignant |
| Chloral hydrate (gavage) | 0/141                 | 0/141        | 0/141               |
| Doxylamine               | 0/47                  | 0/47         | 0/47                |
| Fumonisin B <sub>1</sub> | 0/46                  | 0/46         | 0/46                |
| Pyrimilamine             | 0/48                  | 0/48         | 0/48                |
| Sulfamethazine           | 0/177                 | 1/177        | 1/177               |
| Triprolidine             | 0/45                  | 0/45         | 0/45                |
| Total (mean)             | 0/504                 | 1/504 (0.2%) | 1/504 (0.2%)        |
| Range                    |                       | 0%-1%        | 0%-1%               |

<sup>a</sup> Data as of January 2002. Studies were conducted at the National Center for Toxicological Research in animals given NIH-31 feed.

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol<sup>a</sup>**

|  | 0 ppm   | 10 ppm | 30 ppm   | 90 ppm   |
|--|---------|--------|----------|----------|
| <b>Disposition Summary</b>                   |         |        |          |          |
| Animals initially in study                   | 48      | 48     | 48       | 48       |
| Early deaths                                 |         |        |          |          |
| Moribund                                     | 1       | 3      | 5        | 18       |
| Natural deaths                               | 9       | 8      | 16       | 29       |
| Survivors                                    |         |        |          |          |
| Terminal sacrifice                           | 38      | 37     | 27       | 1        |
| Animals examined microscopically             | 48      | 48     | 48       | 48       |
| <b>Alimentary System</b>                     |         |        |          |          |
| Esophagus                                    | (48)    | (47)   | (47)     | (47)     |
| Autolysis, marked                            |         |        |          | 1 (2%)   |
| Autolysis, moderate                          |         |        |          | 1 (2%)   |
| Gallbladder                                  | (47)    | (45)   | (46)     | (43)     |
| Autolysis, marked                            |         |        |          | 3 (7%)   |
| Autolysis, moderate                          | 7 (15%) | 1 (2%) | 2 (4%)   | 4 (9%)   |
| Cytoplasmic alteration, mild, epithelium     | 1 (2%)  |        |          |          |
| Infiltration cellular, lymphocytic, minimal  |         | 1 (2%) |          |          |
| Inflammation, chronic active, moderate       | 1 (2%)  |        |          |          |
| Intestine large, cecum                       | (48)    | (45)   | (46)     | (45)     |
| Autolysis, marked                            |         |        | 1 (2%)   | 5 (11%)  |
| Autolysis, moderate                          | 5 (10%) | 1 (2%) | 2 (4%)   | 10 (22%) |
| Hyperplasia, mild, lymphoid tissue           |         |        | 1 (2%)   |          |
| Intestine large, colon                       | (48)    | (44)   | (46)     | (46)     |
| Autolysis, marked                            |         |        | 1 (2%)   | 5 (11%)  |
| Autolysis, moderate                          | 5 (10%) | 1 (2%) | 2 (4%)   | 10 (22%) |
| Intestine large, rectum                      | (48)    | (45)   | (45)     | (46)     |
| Autolysis, marked                            |         |        |          | 4 (9%)   |
| Autolysis, moderate                          | 1 (2%)  |        | 1 (2%)   | 7 (15%)  |
| Intestine small                              | (48)    | (44)   | (46)     | (44)     |
| Intussusception                              |         | 1 (2%) |          |          |
| Intestine small, duodenum                    | (48)    | (43)   | (45)     | (44)     |
| Autolysis, marked                            |         |        | 1 (2%)   | 5 (11%)  |
| Autolysis, moderate                          | 8 (17%) | 2 (5%) | 2 (4%)   | 13 (30%) |
| Hyperplasia, moderate, lymphoid tissue       |         |        |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, moderate |         | 1 (2%) |          |          |
| Intestine small, ileum                       | (48)    | (44)   | (46)     | (44)     |
| Autolysis, marked                            |         |        | 1 (2%)   | 5 (11%)  |
| Autolysis, moderate                          | 8 (17%) | 2 (5%) | 2 (4%)   | 13 (30%) |
| Hyperplasia, marked, lymphoid tissue         |         |        | 1 (2%)   |          |
| Hyperplasia, mild, lymphoid tissue           |         | 3 (7%) | 2 (4%)   |          |
| Hyperplasia, moderate, lymphoid tissue       | 1 (2%)  | 1 (2%) | 1 (2%)   |          |
| Intestine small, jejunum                     | (48)    | (44)   | (46)     | (44)     |
| Autolysis, marked                            |         |        | 1 (2%)   | 5 (11%)  |
| Autolysis, moderate                          | 8 (17%) | 2 (5%) | 2 (4%)   | 13 (30%) |
| Hyperplasia, mild, lymphoid tissue           |         |        | 1 (2%)   |          |
| Hyperplasia, moderate, lymphoid tissue       |         | 1 (2%) |          |          |
| Liver  | (48)    | (47)   | (47)     | (47)     |
| Angiectasis                                  |         | 3 (6%) | 10 (21%) | 24 (51%) |
| Autolysis, marked                            |         |        |          | 1 (2%)   |
| Autolysis, moderate                          |         |        |          | 1 (2%)   |
| Basophilic focus                             | 1 (2%)  | 1 (2%) | 1 (2%)   |          |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System</b> (continued)                    |          |          |          |          |
| Liver (continued)                                       | (48)     | (47)     | (47)     | (47)     |
| Clear cell focus  | 1 (2%)   | 2 (4%)   |          |          |
| Clear cell focus, multiple                              |          |          |          | 1 (2%)   |
| Degeneration, cystic, minimal                           |          | 1 (2%)   |          |          |
| Eosinophilic focus                                      | 2 (4%)   | 8 (17%)  | 5 (11%)  |          |
| Eosinophilic focus, multiple                            | 1 (2%)   | 6 (13%)  | 27 (57%) | 20 (43%) |
| Granuloma, focal, minimal                               | 4 (8%)   | 1 (2%)   |          |          |
| Hematopoietic cell proliferation granulocytic, moderate |          | 1 (2%)   |          |          |
| Hematopoietic cell proliferation, marked                |          |          |          | 1 (2%)   |
| Hematopoietic cell proliferation, mild                  | 2 (4%)   | 5 (11%)  | 16 (34%) | 7 (15%)  |
| Hematopoietic cell proliferation, minimal               | 4 (8%)   | 1 (2%)   | 2 (4%)   |          |
| Hematopoietic cell proliferation, moderate              | 1 (2%)   |          | 2 (4%)   | 11 (23%) |
| Hyperplasia, mild, Kupffer cell                         |          |          | 1 (2%)   |          |
| Hyperplasia, mild, oval cell                            | 1 (2%)   |          |          |          |
| Hyperplasia, moderate, Kupffer cell                     |          | 1 (2%)   |          |          |
| Hyperplasia, moderate, oval cell                        |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild                | 1 (2%)   | 4 (9%)   | 4 (9%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal             | 11 (23%) | 12 (26%) | 5 (11%)  |          |
| Infiltration cellular, lymphocytic, moderate            |          |          | 1 (2%)   |          |
| Inflammation, chronic active, mild                      | 1 (2%)   | 2 (4%)   |          |          |
| Inflammation, chronic active, moderate                  |          |          | 1 (2%)   |          |
| Mixed cell focus  |          | 5 (11%)  | 1 (2%)   |          |
| Mixed cell focus, multiple                              |          | 1 (2%)   |          | 1 (2%)   |
| Necrosis, mild  | 1 (2%)   | 1 (2%)   | 1 (2%)   | 5 (11%)  |
| Necrosis, mild, centrilobular                           | 1 (2%)   |          |          |          |
| Necrosis, mild, hepatocyte                              | 1 (2%)   |          |          |          |
| Necrosis, minimal                                       |          |          | 2 (4%)   |          |
| Necrosis, minimal, centrilobular                        |          | 1 (2%)   |          |          |
| Necrosis, moderate                                      |          | 1 (2%)   | 2 (4%)   | 6 (13%)  |
| Necrosis, moderate, centrilobular                       |          | 1 (2%)   |          | 2 (4%)   |
| Necrosis, moderate, hepatocyte                          | 1 (2%)   |          |          |          |
| Pigmentation, mild                                      |          |          |          | 1 (2%)   |
| Regeneration  |          |          | 1 (2%)   | 2 (4%)   |
| Thrombosis  |          | 1 (2%)   | 1 (2%)   | 11 (23%) |
| Vacuolization cytoplasmic, marked, hepatocyte           |          |          |          | 3 (6%)   |
| Vacuolization cytoplasmic, mild, hepatocyte             | 3 (6%)   | 3 (6%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, minimal, hepatocyte          | 2 (4%)   | 2 (4%)   | 2 (4%)   |          |
| Vacuolization cytoplasmic, moderate, hepatocyte         | 2 (4%)   | 5 (11%)  | 1 (2%)   | 2 (4%)   |
| Mesentery   | (3)      | (4)      | (7)      | (6)      |
| Inflammation, mild, fat                                 |          |          |          | 1 (17%)  |
| Necrosis, fat   | 3 (100%) | 4 (100%) | 6 (86%)  | 3 (50%)  |
| Pancreas  | (48)     | (43)     | (47)     | (44)     |
| Atrophy, mild, acinar cell                              |          |          | 1 (2%)   |          |
| Atrophy, minimal, acinar cell                           |          | 1 (2%)   |          |          |
| Atrophy, moderate, acinar cell                          | 1 (2%)   |          | 1 (2%)   |          |
| Autolysis, marked                                       |          |          |          | 3 (7%)   |
| Autolysis, mild   |          |          |          | 1 (2%)   |
| Autolysis, moderate                                     |          |          | 1 (2%)   | 5 (11%)  |
| Infiltration cellular, lymphocytic, mild                | 1 (2%)   |          | 2 (4%)   |          |
| Infiltration cellular, lymphocytic, minimal             | 11 (23%) | 15 (35%) | 9 (19%)  | 3 (7%)   |
| Necrosis, mild  |          | 1 (2%)   |          |          |
| Vacuolization cytoplasmic, mild, acinar cell            |          |          | 1 (2%)   |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Alimentary System</b> (continued)         |          |          |          |          |
| Salivary glands                              | (48)     | (48)     | (48)     | (47)     |
| Atrophy, mild                                |          | 1 (2%)   |          | 1 (2%)   |
| Atrophy, minimal                             |          |          |          | 1 (2%)   |
| Atrophy, moderate                            |          |          |          | 1 (2%)   |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Hemorrhage, mild                             |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild     | 17 (35%) | 16 (33%) | 12 (25%) | 6 (13%)  |
| Infiltration cellular, lymphocytic, minimal  | 19 (40%) | 25 (52%) | 24 (50%) | 13 (28%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Stomach, forestomach                         | (48)     | (46)     | (46)     | (46)     |
| Autolysis, marked                            |          |          |          | 4 (9%)   |
| Autolysis, moderate                          | 1 (2%)   |          | 1 (2%)   | 5 (11%)  |
| Cyst epithelial inclusion                    |          | 1 (2%)   |          |          |
| Foreign body                                 |          |          | 2 (4%)   |          |
| Hyperkeratosis, mild                         |          |          | 2 (4%)   | 1 (2%)   |
| Hyperkeratosis, minimal                      | 2 (4%)   |          |          |          |
| Hyperplasia, mild, epithelium                | 2 (4%)   | 7 (15%)  | 7 (15%)  | 3 (7%)   |
| Hyperplasia, minimal, epithelium             | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |
| Hyperplasia, moderate, epithelium            | 3 (6%)   | 3 (7%)   | 3 (7%)   | 5 (11%)  |
| Infiltration cellular, lymphocytic, mild     |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal  |          |          |          | 1 (2%)   |
| Inflammation, mild                           | 1 (2%)   | 2 (4%)   | 6 (13%)  | 2 (4%)   |
| Inflammation, moderate                       |          |          | 1 (2%)   |          |
| Ulcer, mild                                  | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Stomach, glandular                           | (47)     | (46)     | (46)     | (47)     |
| Autolysis, marked                            |          |          |          | 4 (9%)   |
| Autolysis, moderate                          | 1 (2%)   |          | 1 (2%)   | 5 (11%)  |
| Diverticulum                                 |          |          | 1 (2%)   |          |
| Hyperplasia, minimal, epithelium             |          |          | 1 (2%)   |          |
| Hypertrophy, mild, epithelium                |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  |          |          |          | 1 (2%)   |
| Mineralization, minimal                      |          |          |          | 1 (2%)   |
| Thrombosis, minimal                          |          |          |          | 1 (2%)   |
| Tongue                                       | (48)     | (48)     | (48)     | (46)     |
| Polyarteritis, mild                          |          |          |          | 1 (2%)   |
| <b>Cardiovascular System</b>                 |          |          |          |          |
| Blood vessel                                 | (47)     | (47)     | (48)     | (46)     |
| Infiltration cellular, lymphocytic, minimal  |          |          |          | 1 (2%)   |
| Mineralization, minimal                      |          | 1 (2%)   |          |          |
| Heart  | (48)     | (48)     | (48)     | (48)     |
| Angiectasis, mild                            |          |          |          | 1 (2%)   |
| Cardiomyopathy, mild                         | 1 (2%)   |          | 2 (4%)   | 1 (2%)   |
| Cardiomyopathy, minimal                      | 1 (2%)   | 2 (4%)   | 2 (4%)   | 2 (4%)   |
| Cardiomyopathy, moderate                     |          |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild, endothelium               | 1 (2%)   |          | 2 (4%)   | 3 (6%)   |
| Hyperplasia, minimal, endothelium            |          |          | 1 (2%)   | 3 (6%)   |
| Inflammation, chronic, minimal, myocardium   |          |          |          | 1 (2%)   |
| Inflammation, mild, artery                   |          |          |          | 1 (2%)   |
| Inflammation, mild, atrioventricular valve   |          |          |          | 1 (2%)   |
| Inflammation, minimal, myocardium            |          |          | 1 (2%)   | 1 (2%)   |
| Inflammation, moderate, myocardium           |          |          |          | 1 (2%)   |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Cardiovascular System (continued)</b>    |          |          |          |          |
| Heart (continued)                           | (48)     | (48)     | (48)     | (48)     |
| Mineralization, mild                        |          |          |          | 1 (2%)   |
| Mineralization, minimal                     |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Mineralization, moderate                    |          |          |          | 2 (4%)   |
| Necrosis, minimal                           |          |          |          | 1 (2%)   |
| Necrosis, moderate                          |          |          |          | 1 (2%)   |
| Thrombosis, mild, myocardium                |          |          | 1 (2%)   |          |
| Thrombosis, moderate, atrium                |          |          |          | 2 (4%)   |
| <b>Endocrine System</b>                     |          |          |          |          |
| Adrenal gland                               | (48)     | (45)     | (45)     | (47)     |
| Hyperplasia, mild, parenchymal cell         |          |          |          | 1 (2%)   |
| Adrenal gland, cortex                       | (48)     | (45)     | (45)     | (47)     |
| Accessory adrenal cortical nodule           | 1 (2%)   |          |          |          |
| Angiectasis, mild                           |          | 1 (2%)   |          | 1 (2%)   |
| Angiectasis, minimal                        | 1 (2%)   |          |          |          |
| Atrophy, mild                               |          |          | 1 (2%)   |          |
| Atrophy, moderate                           |          |          |          | 1 (2%)   |
| Autolysis, marked                           |          |          |          | 2 (4%)   |
| Autolysis, moderate                         |          |          |          | 2 (4%)   |
| Hematopoietic cell proliferation, mild      |          |          | 1 (2%)   |          |
| Hematopoietic cell proliferation, minimal   |          |          |          | 2 (4%)   |
| Hematopoietic cell proliferation, moderate  |          | 1 (2%)   |          |          |
| Hyperplasia, mild, subcapsular              | 36 (75%) | 27 (60%) | 24 (53%) | 22 (47%) |
| Hyperplasia, minimal, subcapsular           | 7 (15%)  | 8 (18%)  | 6 (13%)  | 5 (11%)  |
| Hyperplasia, moderate, subcapsular          | 2 (4%)   | 1 (2%)   | 3 (7%)   | 2 (4%)   |
| Hypertrophy, moderate                       | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, minimal |          |          | 1 (2%)   | 3 (6%)   |
| Inflammation, acute, minimal                |          |          | 1 (2%)   |          |
| Thrombosis, moderate                        |          | 1 (2%)   |          |          |
| Adrenal gland, medulla                      | (47)     | (42)     | (43)     | (47)     |
| Angiectasis, mild                           |          |          |          | 1 (2%)   |
| Autolysis, marked                           |          |          |          | 2 (4%)   |
| Autolysis, moderate                         |          |          |          | 2 (4%)   |
| Hyperplasia, mild                           | 1 (2%)   |          | 2 (5%)   |          |
| Hyperplasia, moderate                       |          | 1 (2%)   |          |          |
| Islets, pancreatic                          | (48)     | (43)     | (47)     | (44)     |
| Autolysis, marked                           |          |          |          | 4 (9%)   |
| Autolysis, moderate                         |          |          | 1 (2%)   | 3 (7%)   |
| Hyperplasia, mild                           |          | 3 (7%)   | 1 (2%)   |          |
| Hyperplasia, minimal                        | 2 (4%)   | 3 (7%)   | 4 (9%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, minimal |          | 1 (2%)   | 1 (2%)   |          |
| Parathyroid gland                           | (32)     | (38)     | (31)     | (40)     |
| Autolysis, marked                           |          |          |          | 1 (3%)   |
| Autolysis, moderate                         |          |          |          | 1 (3%)   |
| Infiltration cellular, lymphocytic, mild    |          | 1 (3%)   |          |          |
| Inflammation, mild                          | 1 (3%)   |          |          |          |
| Pituitary gland                             | (42)     | (42)     | (40)     | (39)     |
| Angiectasis, mild                           | 3 (7%)   | 4 (10%)  |          |          |
| Angiectasis, minimal                        |          | 1 (2%)   |          |          |
| Hyperplasia, mild, pars distalis            | 1 (2%)   | 1 (2%)   | 2 (5%)   |          |
| Hyperplasia, minimal, pars distalis         | 4 (10%)  |          | 1 (3%)   |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Endocrine System (continued)</b>               |          |          |          |          |
| Thyroid gland                                     | (47)     | (47)     | (47)     | (45)     |
| Autolysis, marked                                 |          |          |          | 1 (2%)   |
| Autolysis, moderate                               |          |          |          | 3 (7%)   |
| Cyst multilocular                                 |          |          | 3 (6%)   |          |
| Hyperplasia, mild, follicular cell                | 1 (2%)   |          |          |          |
| Hyperplasia, minimal, C-cell                      | 1 (2%)   |          | 1 (2%)   |          |
| Hyperplasia, minimal, follicular cell             |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal       | 2 (4%)   |          |          | 1 (2%)   |
| Infiltration cellular, polymorphonuclear, minimal |          |          | 1 (2%)   |          |
| Inflammation, minimal                             |          |          |          | 1 (2%)   |
| <b>General Body System</b>                        |          |          |          |          |
| None  |          |          |          |          |
| <b>Genital System</b>                             |          |          |          |          |
| Clitoral gland                                    | (43)     | (41)     | (43)     | (37)     |
| Atrophy, mild                                     | 29 (67%) | 38 (93%) | 39 (91%) | 22 (59%) |
| Atrophy, minimal                                  | 1 (2%)   |          |          | 4 (11%)  |
| Atrophy, moderate                                 | 9 (21%)  | 1 (2%)   | 1 (2%)   | 6 (16%)  |
| Autolysis, moderate                               |          |          | 1 (2%)   |          |
| Ovary   | (48)     | (46)     | (46)     | (39)     |
| Angiectasis, marked                               |          |          | 1 (2%)   | 1 (3%)   |
| Angiectasis, mild                                 |          |          | 2 (4%)   | 4 (10%)  |
| Angiectasis, minimal                              | 1 (2%)   | 2 (4%)   | 1 (2%)   |          |
| Angiectasis, moderate                             | 1 (2%)   |          | 2 (4%)   | 1 (3%)   |
| Atrophy, marked                                   | 9 (19%)  | 34 (74%) | 32 (70%) | 21 (54%) |
| Atrophy, mild                                     | 13 (27%) | 1 (2%)   | 2 (4%)   | 1 (3%)   |
| Atrophy, minimal                                  | 6 (13%)  |          |          |          |
| Atrophy, moderate                                 | 14 (29%) | 5 (11%)  | 3 (7%)   | 8 (21%)  |
| Autolysis, marked                                 | 1 (2%)   |          |          | 1 (3%)   |
| Autolysis, moderate                               |          |          |          | 1 (3%)   |
| Cyst  | 10 (21%) | 11 (24%) | 12 (26%) | 2 (5%)   |
| Cyst, periovarian tissue                          | 2 (4%)   |          |          | 1 (3%)   |
| Hematocyst  | 9 (19%)  | 4 (9%)   | 3 (7%)   | 2 (5%)   |
| Hemorrhage, moderate                              |          |          | 1 (2%)   |          |
| Hyperplasia, tubular, mild                        |          |          | 3 (7%)   | 1 (3%)   |
| Hyperplasia, tubular, minimal                     |          |          |          | 2 (5%)   |
| Hyperplasia, tubular, moderate                    |          |          |          | 1 (3%)   |
| Infiltration cellular, histiocytic, marked        |          |          |          | 1 (3%)   |
| Infiltration cellular, histiocytic, moderate      |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal       |          | 1 (2%)   |          |          |
| Inflammation, moderate                            | 1 (2%)   |          |          |          |
| Mineralization, mild                              |          |          |          | 1 (3%)   |
| Mineralization, moderate                          |          |          |          | 1 (3%)   |
| Pigmentation, moderate                            |          | 1 (2%)   |          |          |
| Thrombosis, marked                                |          |          | 1 (2%)   | 1 (3%)   |
| Thrombosis, marked, periovarian tissue            |          |          |          | 1 (3%)   |
| Thrombosis, moderate                              |          |          | 3 (7%)   |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Genital System (continued)</b>                         |          |          |          |          |
| Uterus  | (48)     | (47)     | (48)     | (46)     |
| Amyloid deposition, moderate                              |          | 1 (2%)   |          |          |
| Angiectasis, marked                                       |          | 1 (2%)   | 1 (2%)   | 3 (7%)   |
| Angiectasis, mild   |          |          | 1 (2%)   | 2 (4%)   |
| Angiectasis, minimal                                      |          | 2 (4%)   |          |          |
| Angiectasis, moderate                                     |          | 1 (2%)   | 4 (8%)   | 2 (4%)   |
| Autolysis, moderate                                       |          |          |          | 1 (2%)   |
| Dilatation, minimal                                       | 1 (2%)   |          |          |          |
| Dilatation, moderate                                      | 1 (2%)   |          |          |          |
| Hemorrhage, marked  |          |          |          | 2 (4%)   |
| Hemorrhage, minimal                                       |          | 1 (2%)   |          |          |
| Hyperplasia, cystic, marked, endometrium                  |          | 1 (2%)   |          |          |
| Hyperplasia, cystic, mild, endometrium                    | 22 (46%) | 24 (51%) | 22 (46%) | 15 (33%) |
| Hyperplasia, cystic, minimal, endometrium                 | 4 (8%)   | 2 (4%)   | 4 (8%)   | 4 (9%)   |
| Hyperplasia, cystic, moderate, endometrium                | 19 (40%) | 12 (26%) | 8 (17%)  | 9 (20%)  |
| Infiltration cellular, histiocytic, mild                  |          |          | 1 (2%)   |          |
| Infiltration cellular, polymorphonuclear, mild            |          | 1 (2%)   |          |          |
| Inflammation, mild  |          |          | 1 (2%)   |          |
| Inflammation, moderate                                    |          | 1 (2%)   | 1 (2%)   |          |
| Mineralization, mild                                      |          |          | 1 (2%)   |          |
| Pigmentation, moderate                                    |          |          | 1 (2%)   |          |
| Thrombosis, marked  |          | 1 (2%)   | 1 (2%)   | 3 (7%)   |
| Thrombosis, moderate                                      |          |          | 3 (6%)   | 1 (2%)   |
| Vacuolization cytoplasmic, minimal                        | 1 (2%)   |          |          |          |
| Vagina  | (48)     | (47)     | (46)     | (43)     |
| Autolysis, marked   |          |          |          | 1 (2%)   |
| Exudate, minimal  |          | 2 (4%)   |          |          |
| Inflammation, mild  | 1 (2%)   | 1 (2%)   |          |          |
| <b>Hematopoietic System</b>                               |          |          |          |          |
| Bone marrow   | (48)     | (47)     | (46)     | (47)     |
| Angiectasis, mild   |          |          |          | 1 (2%)   |
| Angiectasis, moderate                                     |          |          |          | 1 (2%)   |
| Autolysis, marked   |          |          |          | 3 (6%)   |
| Autolysis, moderate                                       |          |          |          | 1 (2%)   |
| Hyperplasia, mild, myeloid cell                           | 6 (13%)  | 3 (6%)   | 2 (4%)   | 3 (6%)   |
| Hyperplasia, minimal, myeloid cell                        |          |          |          | 1 (2%)   |
| Hyperplasia, moderate, myeloid cell                       | 2 (4%)   | 1 (2%)   | 3 (7%)   | 3 (6%)   |
| Pigmentation, minimal                                     |          |          | 1 (2%)   |          |
| Lymph node  | (48)     | (47)     | (47)     | (46)     |
| Autolysis, moderate, lumbar                               |          |          |          | 1 (2%)   |
| Hemorrhage, mild, lumbar                                  |          |          | 1 (2%)   |          |
| Hyperplasia, mild, lumbar                                 |          |          |          | 1 (2%)   |
| Hyperplasia, mild, renal                                  |          |          | 1 (2%)   | 1 (2%)   |
| Hyperplasia, moderate, mediastinal                        |          |          | 1 (2%)   |          |
| Infiltration cellular, histiocytic, moderate, lumbar      |          |          |          | 1 (2%)   |
| Infiltration cellular, polymorphonuclear, moderate, renal |          | 1 (2%)   |          |          |
| Inflammation, mild, lumbar                                |          |          | 1 (2%)   |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Hematopoietic System</b> (continued)          |          |          |          |          |
| Lymph node, mandibular                           | (45)     | (47)     | (45)     | (42)     |
| Atrophy, mild                                    | 1 (2%)   |          |          |          |
| Atrophy, minimal                                 |          |          |          | 1 (2%)   |
| Autolysis, marked                                |          |          |          | 3 (7%)   |
| Hematopoietic cell proliferation, moderate       |          | 1 (2%)   |          |          |
| Hemorrhage, marked                               | 1 (2%)   |          |          |          |
| Hemorrhage, minimal                              |          |          |          | 2 (5%)   |
| Hemorrhage, moderate                             |          |          |          | 1 (2%)   |
| Hyperplasia, lymphoid, marked                    |          |          | 1 (2%)   |          |
| Hyperplasia, lymphoid, mild                      | 1 (2%)   | 4 (9%)   | 3 (7%)   | 2 (5%)   |
| Hyperplasia, lymphoid, moderate                  |          | 1 (2%)   |          |          |
| Hyperplasia, plasma cell, moderate               |          | 1 (2%)   |          |          |
| Infiltration cellular, histiocytic, mild         | 1 (2%)   |          |          | 2 (5%)   |
| Lymph node, mesenteric                           | (47)     | (45)     | (42)     | (39)     |
| Angiectasis, mild                                |          |          | 2 (5%)   | 1 (3%)   |
| Angiectasis, moderate                            | 1 (2%)   |          |          |          |
| Atrophy, mild                                    | 1 (2%)   |          |          | 3 (8%)   |
| Autolysis, moderate                              | 1 (2%)   |          |          | 1 (3%)   |
| Cyst   |          | 1 (2%)   |          |          |
| Hematopoietic cell proliferation, mild           | 1 (2%)   |          |          | 2 (5%)   |
| Hemorrhage, mild                                 |          |          | 1 (2%)   | 1 (3%)   |
| Hemorrhage, moderate                             | 1 (2%)   |          |          |          |
| Hyperplasia, lymphoid, marked                    |          | 2 (4%)   |          |          |
| Hyperplasia, lymphoid, mild                      | 2 (4%)   | 2 (4%)   | 1 (2%)   | 1 (3%)   |
| Infiltration cellular, histiocytic, mild         |          |          | 1 (2%)   |          |
| Infiltration cellular, histiocytic, moderate     |          |          |          | 1 (3%)   |
| Infiltration cellular, polymorphonuclear, marked |          | 1 (2%)   |          |          |
| Spleen   | (48)     | (45)     | (47)     | (46)     |
| Angiectasis, mild                                |          | 1 (2%)   |          |          |
| Angiectasis, moderate                            |          |          |          | 1 (2%)   |
| Autolysis, marked                                |          |          |          | 3 (7%)   |
| Autolysis, moderate                              |          |          |          | 4 (9%)   |
| Hematopoietic cell proliferation, marked         | 1 (2%)   |          | 3 (6%)   | 3 (7%)   |
| Hematopoietic cell proliferation, mild           | 3 (6%)   | 4 (9%)   | 5 (11%)  | 3 (7%)   |
| Hematopoietic cell proliferation, moderate       |          | 4 (9%)   | 7 (15%)  | 15 (33%) |
| Hyperplasia, marked, lymphoid follicle           |          | 1 (2%)   | 1 (2%)   |          |
| Hyperplasia, mild, lymphoid follicle             | 11 (23%) | 17 (38%) | 10 (21%) |          |
| Hyperplasia, minimal, lymphoid follicle          | 1 (2%)   | 3 (7%)   | 2 (4%)   |          |
| Hyperplasia, moderate, lymphoid follicle         | 3 (6%)   | 5 (11%)  | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, histiocytic, mild         |          |          |          | 1 (2%)   |
| Pigmentation, mild                               |          | 1 (2%)   |          |          |
| Pigmentation, moderate                           |          |          |          | 1 (2%)   |
| Polyarteritis, minimal                           |          |          |          | 1 (2%)   |
| Thrombosis, moderate                             |          |          |          | 1 (2%)   |
| Thymus   | (40)     | (37)     | (32)     | (38)     |
| Atrophy, mild                                    | 6 (15%)  | 3 (8%)   | 5 (16%)  | 8 (21%)  |
| Atrophy, moderate                                | 3 (8%)   |          |          | 1 (3%)   |
| Autolysis, marked                                |          |          |          | 1 (3%)   |
| Autolysis, moderate                              | 2 (5%)   |          |          | 2 (5%)   |
| Hyperplasia, mild                                | 1 (3%)   | 4 (11%)  | 2 (6%)   |          |
| Hyperplasia, minimal                             |          |          | 1 (3%)   |          |
| Hyperplasia, moderate                            | 2 (5%)   |          |          |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm |
|--|----------|----------|----------|--------|
| <b>Integumentary System</b>                  |          |          |          |        |
| Mammary gland                                | (47)     | (46)     | (46)     | (48)   |
| Autolysis, moderate                          |          |          | 1 (2%)   |        |
| Ectasia, mild, duct                          | 1 (2%)   |          | 1 (2%)   |        |
| Ectasia, moderate, duct                      | 1 (2%)   |          |          |        |
| Hyperplasia, mild                            | 1 (2%)   | 2 (4%)   |          | 1 (2%) |
| Hyperplasia, minimal                         | 1 (2%)   |          |          |        |
| Hyperplasia, moderate                        |          | 1 (2%)   |          |        |
| Infiltration cellular, lymphocytic, minimal  |          | 1 (2%)   | 1 (2%)   | 1 (2%) |
| Lactation, mild                              | 1 (2%)   | 2 (4%)   | 2 (4%)   |        |
| Lactation, minimal                           | 2 (4%)   |          |          |        |
| Lactation, moderate                          |          | 1 (2%)   |          |        |
| Skin   | (48)     | (48)     | (46)     | (48)   |
| Autolysis, marked                            |          |          |          | 1 (2%) |
| Autolysis, moderate                          |          |          | 1 (2%)   |        |
| Fibrosis, moderate                           |          | 1 (2%)   |          |        |
| Hemorrhage, mild                             |          |          |          | 1 (2%) |
| Inflammation, marked                         | 1 (2%)   |          |          | 1 (2%) |
| Inflammation, mild                           |          |          |          | 1 (2%) |
| Neovascularization, moderate                 |          |          |          | 1 (2%) |
| Thrombosis                                   |          |          |          | 1 (2%) |
| Ulcer  |          |          | 1 (2%)   |        |
| Ulcer, mild                                  |          | 1 (2%)   |          |        |
| <b>Musculoskeletal System</b>                |          |          |          |        |
| Bone   | (48)     | (48)     | (48)     | (48)   |
| Angiectasis, moderate, sternum               |          | 1 (2%)   |          |        |
| Degeneration, mild, cartilage, sternum       | 1 (2%)   |          |          | 1 (2%) |
| Fibrous osteodystrophy, mild, sternum        | 19 (40%) | 14 (29%) | 12 (25%) | 3 (6%) |
| Fibrous osteodystrophy, minimal, sternum     | 9 (19%)  | 3 (6%)   | 4 (8%)   | 2 (4%) |
| Fibrous osteodystrophy, moderate, sternum    | 2 (4%)   | 5 (10%)  | 6 (13%)  | 1 (2%) |
| Bone, femur                                  | (48)     | (48)     | (48)     | (48)   |
| Angiectasis, moderate                        |          | 1 (2%)   |          |        |
| Fibrous osteodystrophy, mild                 | 2 (4%)   | 1 (2%)   | 3 (6%)   | 2 (4%) |
| Fibrous osteodystrophy, minimal              | 5 (10%)  | 4 (8%)   | 1 (2%)   |        |
| Fibrous osteodystrophy, moderate             | 2 (4%)   | 3 (6%)   | 1 (2%)   | 1 (2%) |
| Skeletal muscle                              | (48)     | (48)     | (48)     | (48)   |
| Autolysis, moderate                          |          |          |          | 1 (2%) |
| Hyperplasia, lymphoid, diaphragm             |          | 1 (2%)   |          |        |
| <b>Nervous System</b>                        |          |          |          |        |
| Brain, cerebellum                            | (48)     | (48)     | (48)     | (48)   |
| Autolysis, moderate                          |          |          |          | 1 (2%) |
| Inflammation, chronic active, mild, meninges |          | 1 (2%)   |          |        |
| Mineralization, minimal, thalamus            | 1 (2%)   |          |          |        |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Nervous System (continued)</b>            |          |          |          |          |
| Brain, cerebrum                              | (48)     | (48)     | (48)     | (48)     |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Compression, moderate, hypothalamus          | 1 (2%)   |          |          |          |
| Granuloma, minimal                           |          |          |          | 2 (4%)   |
| Hemorrhage, mild                             |          |          |          | 1 (2%)   |
| Hemorrhage, minimal                          |          |          | 1 (2%)   | 1 (2%)   |
| Inflammation, chronic active, mild, meninges |          | 1 (2%)   |          |          |
| Mineralization, mild, thalamus               | 2 (4%)   | 1 (2%)   | 2 (4%)   | 3 (6%)   |
| Mineralization, minimal, thalamus            | 19 (40%) | 25 (52%) | 24 (50%) | 23 (48%) |
| Necrosis, mild                               |          |          |          | 1 (2%)   |
| Peripheral nerve                             | (48)     | (47)     | (48)     | (48)     |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Spinal cord, thoracic                        | (48)     | (48)     | (48)     | (48)     |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Hemorrhage, minimal                          |          |          | 1 (2%)   |          |
| <b>Respiratory System</b>                    |          |          |          |          |
| Larynx                                       | (48)     | (46)     | (46)     | (45)     |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Lung   | (48)     | (48)     | (48)     | (47)     |
| Congestion, moderate                         |          |          |          | 1 (2%)   |
| Hemorrhage, mild                             |          | 1 (2%)   | 2 (4%)   |          |
| Hemorrhage, minimal                          | 2 (4%)   | 4 (8%)   | 7 (15%)  |          |
| Hemorrhage, moderate                         |          |          |          | 2 (4%)   |
| Hyperplasia, mild, alveolar epithelium       |          | 1 (2%)   | 3 (6%)   | 5 (11%)  |
| Hyperplasia, minimal, alveolar epithelium    |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Hyperplasia, moderate, alveolar epithelium   |          |          |          | 1 (2%)   |
| Infiltration cellular, histiocytic, mild     |          | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, histiocytic, minimal  |          |          | 1 (2%)   |          |
| Infiltration cellular, histiocytic, moderate |          |          | 3 (6%)   | 5 (11%)  |
| Infiltration cellular, lymphocytic, mild     | 10 (21%) | 8 (17%)  | 7 (15%)  | 5 (11%)  |
| Infiltration cellular, lymphocytic, minimal  | 24 (50%) | 19 (40%) | 10 (21%) | 6 (13%)  |
| Infiltration cellular, lymphocytic, moderate |          | 1 (2%)   | 1 (2%)   |          |
| Inflammation, chronic active, mild           | 1 (2%)   |          |          |          |
| Inflammation, chronic active, minimal        |          |          | 1 (2%)   |          |
| Nose   | (48)     | (48)     | (48)     | (46)     |
| Autolysis, moderate                          |          |          |          | 2 (4%)   |
| Fibrous osteodystrophy, mild                 | 2 (4%)   |          |          |          |
| Fibrous osteodystrophy, minimal              | 6 (13%)  |          |          |          |
| Inflammation, marked                         | 1 (2%)   |          |          |          |
| Trachea                                      | (48)     | (47)     | (47)     | (46)     |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Special Senses System</b>                 |          |          |          |          |
| Eye  | (48)     | (47)     | (46)     | (48)     |
| Atrophy, mild                                |          |          | 1 (2%)   |          |
| Atrophy, moderate                            |          |          |          | 2 (4%)   |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Autolysis, moderate                          | 1 (2%)   | 1 (2%)   |          |          |
| Cataract, mild, lens                         |          |          |          | 1 (2%)   |
| Cataract, minimal, lens                      |          |          | 1 (2%)   |          |
| Inflammation, marked, cornea                 |          | 1 (2%)   |          | 1 (2%)   |
| Inflammation, mild, cornea                   |          |          | 4 (9%)   | 8 (17%)  |
| Inflammation, minimal, cornea                |          | 2 (4%)   | 1 (2%)   | 1 (2%)   |
| Inflammation, moderate, cornea               |          |          | 1 (2%)   |          |
| Phthisis bulbi                               |          | 1 (2%)   | 2 (4%)   | 3 (6%)   |
| Phthisis bulbi, bilateral                    |          |          |          | 1 (2%)   |
| Harderian gland                              | (48)     | (48)     | (48)     | (48)     |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Dilatation, mild                             |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild     | 1 (2%)   | 1 (2%)   |          | 2 (4%)   |
| Infiltration cellular, lymphocytic, minimal  | 17 (35%) | 9 (19%)  | 8 (17%)  | 2 (4%)   |
| Infiltration cellular, lymphocytic, moderate |          | 1 (2%)   |          |          |
| Lacrimal gland                               | (45)     | (47)     | (43)     | (40)     |
| Atrophy, mild                                |          |          | 1 (2%)   |          |
| Atrophy, minimal                             |          | 4 (9%)   | 1 (2%)   |          |
| Autolysis, marked                            |          |          |          | 1 (3%)   |
| Cyst   | 1 (2%)   |          |          |          |
| Dilatation, minimal, duct                    |          | 2 (4%)   | 1 (2%)   |          |
| Hemorrhage, moderate                         |          |          |          | 1 (3%)   |
| Hypertrophy, minimal, parenchymal cell       | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild     | 8 (18%)  | 15 (32%) | 1 (2%)   | 3 (8%)   |
| Infiltration cellular, lymphocytic, minimal  | 18 (40%) | 15 (32%) | 17 (40%) | 13 (33%) |
| Infiltration cellular, lymphocytic, moderate |          | 2 (4%)   | 2 (5%)   |          |
| Vacuolization cytoplasmic, minimal           |          |          | 1 (2%)   |          |
| Zymbal's gland                               | (46)     | (43)     | (46)     | (46)     |
| Atrophy, minimal                             |          |          |          | 1 (2%)   |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Hyperplasia, mild                            |          |          | 1 (2%)   |          |
| <b>Urinary System</b>                        |          |          |          |          |
| Kidney                                       | (48)     | (48)     | (48)     | (48)     |
| Accumulation, hyaline droplet, mild          |          |          | 1 (2%)   |          |
| Accumulation, hyaline droplet, moderate      |          | 1 (2%)   |          | 2 (4%)   |
| Amyloid deposition, marked                   |          |          | 1 (2%)   |          |
| Atrophy, minimal, renal tubule               |          |          |          | 1 (2%)   |
| Autolysis, marked                            |          |          |          | 1 (2%)   |
| Autolysis, mild                              | 1 (2%)   |          |          |          |
| Autolysis, moderate                          |          | 1 (2%)   | 1 (2%)   | 3 (6%)   |
| Casts, mild                                  | 1 (2%)   |          |          |          |
| Casts, minimal                               |          |          |          | 2 (4%)   |
| Congestion, mild                             |          |          | 1 (2%)   |          |
| Cyst   | 1 (2%)   |          |          |          |

**TABLE D4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Urinary System</b> (continued)              |          |          |          |          |
| Kidney (continued)                             | (48)     | (48)     | (48)     | (48)     |
| Degeneration, focal, minimal, renal tubule     | 1 (2%)   |          |          |          |
| Glomerulosclerosis, mild                       |          |          | 1 (2%)   | 1 (2%)   |
| Glomerulosclerosis, minimal                    |          |          |          | 1 (2%)   |
| Hydronephrosis, mild                           |          | 1 (2%)   |          |          |
| Hydronephrosis, moderate                       |          | 1 (2%)   |          | 1 (2%)   |
| Infarct, minimal                               | 3 (6%)   |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild       | 3 (6%)   | 8 (17%)  | 3 (6%)   | 3 (6%)   |
| Infiltration cellular, lymphocytic, minimal    | 12 (25%) | 10 (21%) | 12 (25%) | 13 (27%) |
| Infiltration cellular, lymphocytic, moderate   | 1 (2%)   | 2 (4%)   |          |          |
| Infiltration cellular, polymorphonuclear, mild |          |          | 1 (2%)   |          |
| Metaplasia, osseous, minimal                   | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Mineralization, mild                           |          |          |          | 1 (2%)   |
| Mineralization, minimal                        |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Pigmentation, moderate, renal tubule           |          |          | 1 (2%)   |          |
| Polyarteritis                                  |          |          |          | 1 (2%)   |
| Urinary bladder                                | (48)     | (46)     | (45)     | (41)     |
| Autolysis, marked                              |          |          |          | 1 (2%)   |
| Autolysis, moderate                            | 3 (6%)   | 2 (4%)   | 1 (2%)   |          |
| Distended                                      | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild       | 8 (17%)  | 7 (15%)  | 3 (7%)   | 5 (12%)  |
| Infiltration cellular, lymphocytic, minimal    | 17 (35%) | 20 (43%) | 20 (44%) | 7 (17%)  |
| Infiltration cellular, lymphocytic, moderate   |          | 1 (2%)   |          | 1 (2%)   |



**APPENDIX E**  
**SUMMARY OF LESIONS IN FEMALE MICE**  
**IN THE 2-YEAR DRINKING WATER STUDY**  
**OF URETHANE AND 2.5% ETHANOL**

**TABLE E1** Summary of the Incidence of Neoplasms in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... E-2

**TABLE E2** Statistical Analysis of Primary Neoplasms in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... E-8

**TABLE E3** Summary of the Incidence of Nonneoplastic Lesions in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol ..... E-13

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol<sup>a</sup>**

|                                     | 0 ppm  | 10 ppm  | 30 ppm  | 90 ppm   |
|-------------------------------------|--------|---------|---------|----------|
| <b>Disposition Summary</b>          |        |         |         |          |
| Animals initially in study          | 48     | 47      | 48      | 48       |
| Early deaths                        |        |         |         |          |
| Accidental deaths                   | 4      | 3       |         |          |
| Moribund                            | 1      | 4       | 11      | 9        |
| Natural deaths                      | 4      | 7       | 18      | 31       |
| Survivors                           |        |         |         |          |
| Terminal sacrifice                  | 39     | 33      | 19      | 8        |
| Animals examined microscopically    | 47     | 47      | 48      | 48       |
| <b>Alimentary System</b>            |        |         |         |          |
| Esophagus                           | (47)   | (47)    | (47)    | (47)     |
| Sarcoma, metastatic, kidney         |        |         |         | 1 (2%)   |
| Gallbladder                         | (47)   | (45)    | (46)    | (43)     |
| Lymphoma malignant                  |        |         | 1 (2%)  |          |
| Intestine large, cecum              | (47)   | (45)    | (47)    | (41)     |
| Lymphoma malignant                  |        | 1 (2%)  | 1 (2%)  | 1 (2%)   |
| Intestine large, colon              | (47)   | (45)    | (47)    | (43)     |
| Lymphoma malignant                  |        | 1 (2%)  |         | 1 (2%)   |
| Intestine large, rectum             | (47)   | (44)    | (47)    | (46)     |
| Lymphoma malignant                  | 1 (2%) |         |         | 1 (2%)   |
| Sarcoma, metastatic, uterus         |        |         |         | 1 (2%)   |
| Squamous cell carcinoma             |        |         |         | 1 (2%)   |
| Intestine small, duodenum           | (47)   | (45)    | (47)    | (39)     |
| Lymphoma malignant                  | 1 (2%) |         |         |          |
| Intestine small, ileum              | (47)   | (45)    | (47)    | (40)     |
| Lymphoma malignant                  |        | 1 (2%)  | 1 (2%)  |          |
| Intestine small, jejunum            | (47)   | (45)    | (47)    | (39)     |
| Lymphoma malignant                  |        |         | 1 (2%)  |          |
| Sarcoma stromal, metastatic, uterus |        |         | 1 (2%)  |          |
| Sarcoma, metastatic, skin           |        |         | 1 (2%)  |          |
| Liver                               | (47)   | (47)    | (47)    | (46)     |
| Hemangiosarcoma                     | 1 (2%) | 2 (4%)  |         | 7 (15%)  |
| Hepatocellular adenoma              | 4 (9%) |         | 6 (13%) | 9 (20%)  |
| Hepatocellular adenoma, multiple    | 2 (4%) | 5 (11%) | 9 (19%) | 14 (30%) |
| Hepatocellular carcinoma            | 1 (2%) |         | 3 (6%)  | 1 (2%)   |
| Histiocytic sarcoma                 |        | 2 (4%)  | 2 (4%)  | 1 (2%)   |
| Ito cell tumor malignant            | 1 (2%) |         |         |          |
| Lymphoma malignant                  | 2 (4%) | 7 (15%) | 5 (11%) | 3 (7%)   |
| Osteosarcoma, metastatic, bone      |        | 1 (2%)  | 1 (2%)  |          |
| Sarcoma stromal, metastatic, uterus |        |         | 1 (2%)  |          |
| Sarcoma, metastatic, skin           |        |         | 1 (2%)  |          |
| Mesentery                           | (2)    | (5)     | (6)     | (6)      |
| Hemangiosarcoma                     |        |         |         | 1 (17%)  |
| Lymphoma malignant                  |        | 1 (20%) | 1 (17%) |          |
| Sarcoma                             |        | 1 (20%) |         |          |
| Sarcoma, metastatic, kidney         |        |         |         | 1 (17%)  |
| Pancreas                            | (47)   | (45)    | (46)    | (44)     |
| Histiocytic sarcoma                 |        |         |         | 1 (2%)   |
| Lymphoma malignant                  | 1 (2%) | 3 (7%)  | 3 (7%)  | 1 (2%)   |
| Sarcoma                             |        | 1 (2%)  |         |          |
| Sarcoma stromal, metastatic, uterus |        |         | 1 (2%)  |          |
| Sarcoma, metastatic, kidney         |        |         |         | 1 (2%)   |
| Sarcoma, metastatic, skin           |        |         | 1 (2%)  |          |

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm | 30 ppm | 90 ppm |
|--|---------|--------|--------|--------|
| <b>Alimentary System (continued)</b>                 |         |        |        |        |
| Salivary glands                                      | (47)    | (47)   | (46)   | (48)   |
| Lymphoma malignant                                   | 2 (4%)  | 4 (9%) | 3 (7%) | 1 (2%) |
| Stomach, forestomach                                 | (47)    | (46)   | (47)   | (46)   |
| Lymphoma malignant                                   |         | 1 (2%) |        |        |
| Sarcoma stromal, metastatic, uterus                  |         |        | 1 (2%) |        |
| Sarcoma, metastatic, kidney                          |         |        |        | 1 (2%) |
| Squamous cell carcinoma                              |         |        |        | 1 (2%) |
| Squamous cell papilloma                              |         | 4 (9%) |        |        |
| Stomach, glandular                                   | (47)    | (46)   | (47)   | (45)   |
| Lymphoma malignant                                   |         | 2 (4%) |        |        |
| Tongue   | (47)    | (47)   | (48)   | (48)   |
| Lymphoma malignant                                   |         | 1 (2%) |        |        |
| <b>Cardiovascular System</b>                         |         |        |        |        |
| Blood vessel   | (47)    | (47)   | (48)   | (48)   |
| Lymphoma malignant                                   |         |        |        | 2 (4%) |
| Heart  | (47)    | (47)   | (48)   | (48)   |
| Alveolar/bronchiolar carcinoma, metastatic, lung     |         |        |        | 1 (2%) |
| Hemangiosarcoma                                      |         |        |        | 3 (6%) |
| Histiocytic sarcoma                                  |         | 1 (2%) |        |        |
| Lymphoma malignant                                   |         | 1 (2%) | 1 (2%) | 3 (6%) |
| Squamous cell carcinoma, metastatic, intestine large |         |        |        | 1 (2%) |
| <b>Endocrine System</b>                              |         |        |        |        |
| Adrenal gland  | (46)    | (47)   | (46)   | (44)   |
| Adenoma, bilateral, subcapsular                      |         |        |        | 1 (2%) |
| Adrenal gland, cortex                                | (46)    | (47)   | (46)   | (44)   |
| Adenocarcinoma, metastatic, mammary gland            | 1 (2%)  |        |        |        |
| Adenoma  | 1 (2%)  |        |        |        |
| Adenoma, subcapsular                                 |         | 1 (2%) |        |        |
| Carcinoma, subcapsular                               |         |        |        | 1 (2%) |
| Lymphoma malignant                                   |         | 3 (6%) | 1 (2%) | 1 (2%) |
| Osteosarcoma, metastatic, bone                       |         |        | 1 (2%) |        |
| Sarcoma stromal, metastatic, uterus                  |         |        | 1 (2%) |        |
| Sarcoma, metastatic, kidney                          |         |        |        | 1 (2%) |
| Sarcoma, metastatic, skin                            |         |        |        | 1 (2%) |
| Adrenal gland, medulla                               | (45)    | (47)   | (45)   | (41)   |
| Lymphoma malignant                                   |         | 1 (2%) |        | 1 (2%) |
| Pheochromocytoma benign                              | 1 (2%)  | 1 (2%) |        |        |
| Pheochromocytoma malignant                           |         |        | 1 (2%) |        |
| Islets, pancreatic                                   | (47)    | (45)   | (46)   | (44)   |
| Adenoma  | 1 (2%)  | 1 (2%) | 1 (2%) | 1 (2%) |
| Lymphoma malignant                                   |         |        | 2 (4%) | 1 (2%) |
| Parathyroid gland                                    | (34)    | (37)   | (37)   | (31)   |
| Lymphoma malignant                                   |         |        | 1 (3%) |        |
| Pituitary gland                                      | (44)    | (41)   | (41)   | (38)   |
| Adenoma, pars distalis                               | 7 (16%) | 2 (5%) | 3 (7%) | 1 (3%) |
| Lymphoma malignant                                   |         | 1 (2%) |        | 1 (3%) |
| Meningioma malignant, metastatic, brain              |         |        | 1 (2%) |        |
| Thyroid gland  | (46)    | (47)   | (45)   | (46)   |
| Adenoma, follicular cell                             | 1 (2%)  |        | 1 (2%) |        |
| Lymphoma malignant                                   |         | 1 (2%) |        |        |

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm  | 10 ppm   | 30 ppm | 90 ppm |
|---|--------|----------|--------|--------|
| <b>General Body System</b>                    |        |          |        |        |
| Tissue NOS                                    |        | (1)      | (1)    |        |
| Sarcoma, abdominal                            |        | 1 (100%) |        |        |
| <b>Genital System</b>                         |        |          |        |        |
| Clitoral gland                                | (40)   | (40)     | (34)   | (40)   |
| Lymphoma malignant                            | 1 (3%) | 1 (3%)   |        |        |
| Ovary   | (47)   | (46)     | (47)   | (48)   |
| Adenoma, tubular                              | 1 (2%) |          |        | 1 (2%) |
| Cystadenoma                                   | 1 (2%) | 2 (4%)   |        | 2 (4%) |
| Granulosa cell tumor benign                   |        |          | 3 (6%) | 3 (6%) |
| Hemangioma                                    |        |          |        | 1 (2%) |
| Hemangiosarcoma                               |        |          | 1 (2%) | 2 (4%) |
| Histiocytic sarcoma                           |        | 1 (2%)   | 1 (2%) |        |
| Lymphoma malignant                            | 1 (2%) | 4 (9%)   | 4 (9%) | 3 (6%) |
| Thecoma benign                                |        |          |        | 1 (2%) |
| Uterus  | (47)   | (47)     | (48)   | (48)   |
| Hemangioma                                    |        |          | 1 (2%) | 3 (6%) |
| Hemangiosarcoma                               |        |          | 1 (2%) | 1 (2%) |
| Histiocytic sarcoma                           |        | 1 (2%)   | 2 (4%) |        |
| Leiomyoma                                     | 1 (2%) |          |        |        |
| Leiomyosarcoma                                |        |          |        | 1 (2%) |
| Lymphoma malignant                            | 1 (2%) | 1 (2%)   | 2 (4%) | 1 (2%) |
| Polyp stromal                                 |        |          | 1 (2%) |        |
| Sarcoma                                       |        |          |        | 1 (2%) |
| Sarcoma stromal                               |        |          | 1 (2%) | 1 (2%) |
| Sarcoma, metastatic, skin                     |        |          |        | 1 (2%) |
| Vagina  | (47)   | (47)     | (47)   | (47)   |
| Hemangioma                                    |        |          |        | 1 (2%) |
| Histiocytic sarcoma                           |        | 1 (2%)   |        |        |
| Lymphoma malignant                            | 1 (2%) | 1 (2%)   |        | 1 (2%) |
| Sarcoma stromal, metastatic, uterus           |        |          | 1 (2%) |        |
| Sarcoma, metastatic, uterus                   |        |          |        | 1 (2%) |
| <b>Hematopoietic System</b>                   |        |          |        |        |
| Bone marrow                                   | (47)   | (46)     | (48)   | (48)   |
| Hemangiosarcoma                               |        |          |        | 1 (2%) |
| Histiocytic sarcoma                           |        | 1 (2%)   | 1 (2%) |        |
| Lymphoma malignant                            |        |          |        | 1 (2%) |
| Lymph node                                    | (47)   | (47)     | (47)   | (47)   |
| Histiocytic sarcoma, iliac                    |        |          |        | 1 (2%) |
| Histiocytic sarcoma, lumbar                   |        | 1 (2%)   | 1 (2%) | 1 (2%) |
| Histiocytic sarcoma, pancreatic               |        |          |        | 1 (2%) |
| Histiocytic sarcoma, renal                    |        |          |        | 1 (2%) |
| Lymphoma malignant, axillary                  |        | 1 (2%)   |        | 1 (2%) |
| Lymphoma malignant, hemal                     |        |          | 1 (2%) |        |
| Lymphoma malignant, lumbar                    |        |          | 2 (4%) | 2 (4%) |
| Lymphoma malignant, renal                     |        | 2 (4%)   | 3 (6%) | 2 (4%) |
| Lymphoma malignant, thoracic                  |        | 3 (6%)   | 2 (4%) |        |
| Sarcoma stromal, metastatic, lumbar, uterus   |        |          | 1 (2%) |        |
| Sarcoma stromal, metastatic, renal, uterus    |        |          | 1 (2%) |        |
| Sarcoma stromal, metastatic, thoracic, uterus |        |          | 1 (2%) |        |
| Sarcoma, metastatic, inguinal, skin           |        |          |        | 1 (2%) |
| Sarcoma, metastatic, lumbar, skin             |        |          |        | 1 (2%) |

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm   | 90 ppm   |
|--|---------|---------|----------|----------|
| <b>Hematopoietic System (continued)</b>              |         |         |          |          |
| Lymph node, mandibular                               | (47)    | (44)    | (43)     | (46)     |
| Histiocytic sarcoma                                  |         | 2 (5%)  | 1 (2%)   | 1 (2%)   |
| Lymphoma malignant                                   | 4 (9%)  | 4 (9%)  | 6 (14%)  | 4 (9%)   |
| Lymph node, mesenteric                               | (43)    | (42)    | (42)     | (38)     |
| Histiocytic sarcoma                                  |         | 1 (2%)  | 1 (2%)   | 2 (5%)   |
| Lymphoma malignant                                   | 5 (12%) | 6 (14%) | 8 (19%)  | 2 (5%)   |
| Sarcoma stromal, metastatic, uterus                  |         |         | 1 (2%)   |          |
| Sarcoma, metastatic, kidney                          |         |         |          | 1 (3%)   |
| Spleen   | (47)    | (46)    | (46)     | (46)     |
| Hemangioma   |         | 1 (2%)  |          |          |
| Hemangiosarcoma                                      |         |         |          | 3 (7%)   |
| Histiocytic sarcoma                                  |         | 2 (4%)  | 1 (2%)   | 2 (4%)   |
| Lymphoma malignant                                   | 6 (13%) | 8 (17%) | 8 (17%)  | 3 (7%)   |
| Sarcoma stromal, metastatic, uterus                  |         |         | 1 (2%)   |          |
| Thymus   | (41)    | (40)    | (34)     | (36)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung     |         |         | 1 (3%)   | 2 (6%)   |
| Histiocytic sarcoma                                  |         |         | 1 (3%)   |          |
| Lymphoma malignant                                   | 3 (7%)  | 5 (13%) | 7 (21%)  | 5 (14%)  |
| Sarcoma, metastatic, kidney                          |         |         |          | 1 (3%)   |
| <b>Integumentary System</b>                          |         |         |          |          |
| Mammary gland  | (47)    | (45)    | (48)     | (47)     |
| Adenoacanthoma                                       |         |         | 2 (4%)   | 3 (6%)   |
| Adenocarcinoma                                       | 4 (9%)  | 3 (7%)  | 11 (23%) | 14 (30%) |
| Lymphoma malignant                                   | 1 (2%)  | 1 (2%)  |          | 1 (2%)   |
| Skin   | (47)    | (47)    | (48)     | (47)     |
| Fibroma  |         |         |          | 1 (2%)   |
| Hemangioma   | 1 (2%)  |         | 1 (2%)   |          |
| Hemangiosarcoma                                      |         |         |          | 2 (4%)   |
| Osteosarcoma   |         |         | 1 (2%)   |          |
| Sarcoma  | 2 (4%)  | 1 (2%)  | 6 (13%)  | 5 (11%)  |
| Squamous cell carcinoma, metastatic, intestine large |         |         |          | 1 (2%)   |
| <b>Musculoskeletal System</b>                        |         |         |          |          |
| Bone   | (47)    | (47)    | (48)     | (48)     |
| Lymphoma malignant, sternum                          |         |         |          | 1 (2%)   |
| Osteosarcoma, humerus                                |         |         | 1 (2%)   |          |
| Osteosarcoma, rib                                    |         |         | 1 (2%)   |          |
| Osteosarcoma, right                                  |         | 1 (2%)  |          |          |
| Osteosarcoma, vertebra                               |         |         | 1 (2%)   |          |
| Bone, femur  | (46)    | (47)    | (48)     | (48)     |
| Hemangiosarcoma                                      |         |         |          | 1 (2%)   |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| Sarcoma, metastatic, skin                            |         |         | 1 (2%)   |          |
| Skeletal muscle                                      | (47)    | (47)    | (48)     | (48)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung     |         |         |          | 1 (2%)   |
| Hemangiosarcoma                                      |         |         |          | 1 (2%)   |
| Lymphoma malignant                                   | 2 (4%)  | 2 (4%)  | 1 (2%)   | 1 (2%)   |
| Sarcoma, metastatic, skin                            |         |         |          | 1 (2%)   |

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm   | 90 ppm   |
|--|---------|---------|----------|----------|
| <b>Nervous System</b>                                |         |         |          |          |
| Brain, cerebellum                                    | (47)    | (46)    | (47)     | (48)     |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| Brain, cerebrum                                      | (47)    | (47)    | (47)     | (48)     |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| Meningioma malignant                                 |         |         | 1 (2%)   |          |
| Peripheral nerve                                     | (47)    | (46)    | (48)     | (48)     |
| Lymphoma malignant                                   | 1 (2%)  |         |          |          |
| Spinal cord, thoracic                                | (47)    | (47)    | (47)     | (48)     |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| <b>Respiratory System</b>                            |         |         |          |          |
| Lung   | (47)    | (47)    | (48)     | (48)     |
| Adenocarcinoma, metastatic, mammary gland            |         |         | 1 (2%)   |          |
| Adenocarcinoma, metastatic, multiple, mammary gland  | 1 (2%)  |         |          |          |
| Alveolar/bronchiolar adenoma                         | 5 (11%) | 7 (15%) | 12 (25%) | 10 (21%) |
| Alveolar/bronchiolar adenoma, multiple               |         | 3 (6%)  | 4 (8%)   | 18 (38%) |
| Alveolar/bronchiolar carcinoma                       |         | 2 (4%)  | 4 (8%)   | 11 (23%) |
| Alveolar/bronchiolar carcinoma, multiple             |         |         | 2 (4%)   | 12 (25%) |
| Carcinoma, metastatic, mammary gland                 |         |         | 1 (2%)   |          |
| Carcinoma, metastatic, Zymbal's gland                |         | 1 (2%)  |          |          |
| Hepatocellular carcinoma, metastatic, liver          |         |         | 1 (2%)   |          |
| Histiocytic sarcoma                                  |         | 2 (4%)  | 1 (2%)   | 1 (2%)   |
| Lymphoma malignant                                   | 1 (2%)  | 6 (13%) | 3 (6%)   | 5 (10%)  |
| Osteosarcoma, metastatic, bone                       |         | 1 (2%)  | 1 (2%)   |          |
| Sarcoma stromal, metastatic, uterus                  |         |         |          | 1 (2%)   |
| Sarcoma, metastatic, skin                            |         |         | 1 (2%)   | 3 (6%)   |
| Squamous cell carcinoma, metastatic, intestine large |         |         |          | 1 (2%)   |
| Nose   | (47)    | (47)    | (48)     | (48)     |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| <b>Special Senses System</b>                         |         |         |          |          |
| Eye  | (47)    | (45)    | (48)     | (46)     |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |
| Harderian gland                                      | (47)    | (47)    | (46)     | (47)     |
| Adenoma  | 2 (4%)  | 3 (6%)  | 9 (20%)  | 16 (34%) |
| Adenoma, bilateral                                   |         |         |          | 3 (6%)   |
| Carcinoma  | 1 (2%)  | 3 (6%)  | 6 (13%)  | 12 (26%) |
| Carcinoma, bilateral                                 |         |         |          | 4 (9%)   |
| Lymphoma malignant                                   | 1 (2%)  |         | 1 (2%)   | 1 (2%)   |
| Lacrimal gland                                       | (45)    | (45)    | (44)     | (43)     |
| Lymphoma malignant                                   | 2 (4%)  | 3 (7%)  | 1 (2%)   | 1 (2%)   |
| Zymbal's gland                                       | (46)    | (43)    | (41)     | (44)     |
| Carcinoma  |         | 1 (2%)  |          |          |
| Lymphoma malignant                                   |         |         |          | 1 (2%)   |

**TABLE E1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|   | 0 ppm  | 10 ppm  | 30 ppm | 90 ppm |
|---|--------|---------|--------|--------|
| <b>Urinary System</b>                             |        |         |        |        |
| Kidney  | (47)   | (47)    | (48)   | (48)   |
| Hemangiosarcoma                                   |        |         |        | 2 (4%) |
| Hemangiosarcoma, perirenal tissue                 |        |         |        | 1 (2%) |
| Histiocytic sarcoma                               |        | 1 (2%)  |        |        |
| Lymphoma malignant                                | 1 (2%) | 6 (13%) | 3 (6%) | 3 (6%) |
| Osteosarcoma, metastatic, bone                    |        |         | 1 (2%) |        |
| Sarcoma   |        | 1 (2%)  |        | 1 (2%) |
| Sarcoma, metastatic, skin                         |        |         | 1 (2%) |        |
| Urinary bladder                                   | (45)   | (43)    | (47)   | (45)   |
| Lymphoma malignant                                | 1 (2%) | 1 (2%)  | 3 (6%) | 1 (2%) |
| <b>Neoplasm Summary</b>                           |        |         |        |        |
| Total animals with primary neoplasms <sup>b</sup> | 29     | 32      | 45     | 48     |
| Total primary neoplasms                           | 77     | 148     | 182    | 255    |
| Total animals with benign neoplasms               | 21     | 20      | 31     | 39     |
| Total benign neoplasms                            | 28     | 29      | 51     | 86     |
| Total animals with malignant neoplasms            | 14     | 22      | 38     | 45     |
| Total malignant neoplasms                         | 49     | 119     | 131    | 169    |
| Total animals with metastatic neoplasms           | 1      | 2       | 10     | 10     |
| Total metastatic neoplasms                        | 2      | 3       | 26     | 25     |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE E2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm          | 10 ppm         | 30 ppm          | 90 ppm          |
|--|----------------|----------------|-----------------|-----------------|
| <b>Harderian Gland: Adenoma</b>              |                |                |                 |                 |
| Overall rate <sup>a</sup>                    | 2/47 (4.3%)    | 3/47 (6.4%)    | 9/46 (19.6%)    | 19/47 (40.4%)   |
| Adjusted rate <sup>b</sup>                   | 2/44.5 (4.5%)  | 3/42.5 (7.1%)  | 9/36.3 (24.8%)  | 19/37.9 (50.1%) |
| Terminal rate <sup>c</sup>                   | 2/39 (5.1%)    | 3/33 (9.1%)    | 3/19 (15.8%)    | 2/8 (25.0%)     |
| First incidence (days)                       | 765 (T)        | 765 (T)        | 594             | 542             |
| Poly-3 test <sup>d</sup>                     | P=0.001        | P=0.461        | P=0.007         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>            |                |                |                 |                 |
| Overall rate                                 | 1/47 (2.1%)    | 3/47 (6.4%)    | 6/46 (13.0%)    | 16/47 (34.0%)   |
| Adjusted rate                                | 1/44.5 (2.2%)  | 3/42.5 (7.1%)  | 6/35.6 (16.8%)  | 16/36.1 (44.4%) |
| Terminal rate                                | 1/39 (2.6%)    | 3/33 (9.1%)    | 4/19 (21.1%)    | 3/8 (37.5%)     |
| First incidence (days)                       | 765 (T)        | 765 (T)        | 584             | 599             |
| Poly-3 test                                  | P=0.001        | P=0.276        | P=0.024         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b> |                |                |                 |                 |
| Overall rate                                 | 3/47 (6.4%)    | 5/47 (10.6%)   | 15/46 (32.6%)   | 35/47 (74.5%)   |
| Adjusted rate                                | 3/44.5 (6.7%)  | 5/42.5 (11.8%) | 15/37.1 (40.4%) | 35/41.5 (84.3%) |
| Terminal rate                                | 3/39 (7.7%)    | 5/33 (15.2%)   | 7/19 (36.8%)    | 5/8 (62.5%)     |
| First incidence (days)                       | 765 (T)        | 765 (T)        | 584             | 542             |
| Poly-3 test                                  | P=0.001        | P=0.311        | P=0.001         | P=0.001         |
| <b>Heart: Hemangiosarcoma</b>                |                |                |                 |                 |
| Overall rate                                 | 0/47 (0.0%)    | 0/47 (0.0%)    | 0/48 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate                                | 0/44.5 (0.0%)  | 0/42.5 (0.0%)  | 0/36.2 (0.0%)   | 3/34.2 (8.8%)   |
| Terminal rate                                | 0/39 (0.0%)    | 0/33 (0.0%)    | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                       | — <sup>e</sup> | — <sup>f</sup> | —               | 565             |
| Poly-3 test                                  | P=0.005        | —              | —               | P=0.074         |
| <b>Kidney: Hemangiosarcoma</b>               |                |                |                 |                 |
| Overall rate                                 | 0/47 (0.0%)    | 0/47 (0.0%)    | 0/48 (0.0%)     | 3/48 (6.3%)     |
| Adjusted rate                                | 0/44.5 (0.0%)  | 0/42.5 (0.0%)  | 0/36.2 (0.0%)   | 3/34.6 (8.7%)   |
| Terminal rate                                | 0/39 (0.0%)    | 0/33 (0.0%)    | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                       | —              | —              | —               | 508             |
| Poly-3 test                                  | P=0.005        | —              | —               | P=0.075         |
| <b>Liver: Hemangiosarcoma</b>                |                |                |                 |                 |
| Overall rate                                 | 1/47 (2.1%)    | 2/47 (4.3%)    | 0/47 (0.0%)     | 7/46 (15.2%)    |
| Adjusted rate                                | 1/44.5 (2.2%)  | 2/42.5 (4.7%)  | 0/35.4 (0.0%)   | 7/32.6 (21.5%)  |
| Terminal rate                                | 1/39 (2.6%)    | 2/33 (6.1%)    | 0/19 (0.0%)     | 1/8 (12.5%)     |
| First incidence (days)                       | 765 (T)        | 765 (T)        | —               | 677             |
| Poly-3 test                                  | P=0.001        | P=0.470        | P=0.553N        | P=0.007         |
| <b>Liver: Hepatocellular Adenoma</b>         |                |                |                 |                 |
| Overall rate                                 | 6/47 (12.8%)   | 5/47 (10.6%)   | 15/47 (31.9%)   | 23/46 (50.0%)   |
| Adjusted rate                                | 6/44.5 (13.5%) | 5/42.5 (11.8%) | 15/36.2 (41.4%) | 23/36.4 (63.2%) |
| Terminal rate                                | 6/39 (15.4%)   | 5/33 (15.2%)   | 13/19 (68.4%)   | 8/8 (100.0%)    |
| First incidence (days)                       | 765 (T)        | 765 (T)        | 600             | 608             |
| Poly-3 test                                  | P=0.001        | P=0.559N       | P=0.003         | P=0.001         |
| <b>Liver: Hepatocellular Carcinoma</b>       |                |                |                 |                 |
| Overall rate                                 | 1/47 (2.1%)    | 0/47 (0.0%)    | 3/47 (6.4%)     | 1/46 (2.2%)     |
| Adjusted rate                                | 1/44.5 (2.2%)  | 0/42.5 (0.0%)  | 3/36.0 (8.3%)   | 1/32.2 (3.1%)   |
| Terminal rate                                | 0/39 (0.0%)    | 0/33 (0.0%)    | 2/19 (10.5%)    | 0/8 (0.0%)      |
| First incidence (days)                       | 752            | —              | 584             | 646             |
| Poly-3 test                                  | P=0.397        | P=0.517N       | P=0.221         | P=0.672         |

**TABLE E2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|--|----------------|-----------------|-----------------|-----------------|
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                |                 |                 |                 |
| Overall rate   | 7/47 (14.9%)   | 5/47 (10.6%)    | 16/47 (34.0%)   | 23/46 (50.0%)   |
| Adjusted rate  | 7/44.5 (15.7%) | 5/42.5 (11.8%)  | 16/36.8 (43.5%) | 23/36.4 (63.2%) |
| Terminal rate  | 6/39 (15.4%)   | 5/33 (15.2%)    | 13/19 (68.4%)   | 8/8 (100.0%)    |
| First incidence (days)                                 | 752            | 765 (T)         | 584             | 608             |
| Poly-3 test  | P=0.001        | P=0.441N        | P=0.003         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                |                 |                 |                 |
| Overall rate   | 5/47 (10.6%)   | 10/47 (21.3%)   | 16/48 (33.3%)   | 28/48 (58.3%)   |
| Adjusted rate  | 5/44.5 (11.2%) | 10/43.6 (22.9%) | 16/39.2 (40.8%) | 28/39.4 (71.1%) |
| Terminal rate  | 5/39 (12.8%)   | 6/33 (18.2%)    | 7/19 (36.8%)    | 6/8 (75.0%)     |
| First incidence (days)                                 | 765 (T)        | 611             | 306             | 593             |
| Poly-3 test  | P=0.001        | P=0.103         | P=0.001         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 2/47 (4.3%)     | 6/48 (12.5%)    | 23/48 (47.9%)   |
| Adjusted rate  | 0/44.5 (0.0%)  | 2/42.5 (4.7%)   | 6/37.0 (16.2%)  | 23/37.3 (61.7%) |
| Terminal rate  | 0/39 (0.0%)    | 2/33 (6.1%)     | 3/19 (15.8%)    | 6/8 (75.0%)     |
| First incidence (days)                                 | —              | 765 (T)         | 640             | 499             |
| Poly-3 test  | P=0.001        | P=0.219         | P=0.007         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                |                 |                 |                 |
| Overall rate   | 5/47 (10.6%)   | 11/47 (23.4%)   | 21/48 (43.8%)   | 38/48 (79.2%)   |
| Adjusted rate  | 5/44.5 (11.2%) | 11/43.6 (25.2%) | 21/39.7 (52.9%) | 38/42.0 (90.6%) |
| Terminal rate  | 5/39 (12.8%)   | 7/33 (21.2%)    | 10/19 (52.6%)   | 8/8 (100.0%)    |
| First incidence (days)                                 | 765 (T)        | 611             | 306             | 499             |
| Poly-3 test  | P=0.001        | P=0.064         | P=0.001         | P=0.001         |
| <b>Lymph Node (Mandibular): Histiocytic Sarcoma</b>    |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 2/44 (4.5%)     | 1/43 (2.3%)     | 1/46 (2.2%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 2/41.1 (4.9%)   | 1/32.6 (3.1%)   | 1/31.7 (3.2%)   |
| Terminal rate  | 0/39 (0.0%)    | 1/33 (3.0%)     | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                                 | —              | 698             | 738             | 762             |
| Poly-3 test  | P=0.465        | P=0.211         | P=0.431         | P=0.426         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                |                 |                 |                 |
| Overall rate   | 0/43 (0.0%)    | 1/42 (2.4%)     | 1/42 (2.4%)     | 2/38 (5.3%)     |
| Adjusted rate  | 0/41.0 (0.0%)  | 1/38.8 (2.6%)   | 1/31.5 (3.2%)   | 2/27.0 (7.4%)   |
| Terminal rate  | 0/36 (0.0%)    | 0/31 (0.0%)     | 0/17 (0.0%)     | 1/8 (12.5%)     |
| First incidence (days)                                 | —              | 698             | 738             | 762             |
| Poly-3 test  | P=0.101        | P=0.482         | P=0.442         | P=0.150         |
| <b>Mammary Gland: Adenoacanthoma</b>                   |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/45 (0.0%)     | 2/48 (4.2%)     | 3/47 (6.4%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 0/41.0 (0.0%)   | 2/36.4 (5.5%)   | 3/33.4 (9.0%)   |
| Terminal rate  | 0/39 (0.0%)    | 0/32 (0.0%)     | 1/19 (5.3%)     | 0/8 (0.0%)      |
| First incidence (days)                                 | —              | —               | 690             | 599             |
| Poly-3 test  | P=0.017        | —               | P=0.188         | P=0.071         |
| <b>Mammary Gland: Adenocarcinoma</b>                   |                |                 |                 |                 |
| Overall rate   | 4/47 (8.5%)    | 3/45 (6.7%)     | 11/48 (22.9%)   | 14/47 (29.8%)   |
| Adjusted rate  | 4/44.7 (9.0%)  | 3/41.0 (7.3%)   | 11/38.2 (28.8%) | 14/35.6 (39.3%) |
| Terminal rate  | 2/39 (5.1%)    | 3/32 (9.4%)     | 4/19 (21.1%)    | 2/8 (25.0%)     |
| First incidence (days)                                 | 718            | 765 (T)         | 607             | 648             |
| Poly-3 test  | P=0.001        | P=0.568N        | P=0.015         | P=0.001         |

**TABLE E2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm          | 10 ppm        | 30 ppm          | 90 ppm          |
|--|----------------|---------------|-----------------|-----------------|
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b>       |                |               |                 |                 |
| Overall rate   | 4/47 (8.5%)    | 3/45 (6.7%)   | 12/48 (25.0%)   | 16/47 (34.0%)   |
| Adjusted rate  | 4/44.7 (9.0%)  | 3/41.0 (7.3%) | 12/38.2 (31.2%) | 16/36.3 (44.1%) |
| Terminal rate  | 2/39 (5.1%)    | 3/32 (9.4%)   | 4/19 (21.1%)    | 2/8 (25.0%)     |
| First incidence (days)                                       | 718            | 765 (T)       | 607             | 599             |
| Poly-3 test  | P=0.001        | P=0.568N      | P=0.007         | P=0.001         |
| <b>Ovary: Hemangioma or Hemangiosarcoma</b>                  |                |               |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/46 (0.0%)   | 1/47 (2.1%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 0/41.5 (0.0%) | 1/36.0 (2.8%)   | 3/33.8 (8.9%)   |
| Terminal rate  | 0/39 (0.0%)    | 0/33 (0.0%)   | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                                       | —              | —             | 696             | 611             |
| Poly-3 test  | P=0.011        | —             | P=0.450         | P=0.073         |
| <b>Ovary: Benign Granulosa Cell Tumor</b>                    |                |               |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/46 (0.0%)   | 3/47 (6.4%)     | 3/48 (6.3%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 0/41.5 (0.0%) | 3/36.0 (8.3%)   | 3/33.9 (8.9%)   |
| Terminal rate  | 0/39 (0.0%)    | 0/33 (0.0%)   | 2/19 (10.5%)    | 1/8 (12.5%)     |
| First incidence (days)                                       | —              | —             | 696             | 614             |
| Poly-3 test  | P=0.023        | —             | P=0.080         | P=0.073         |
| <b>Pituitary Gland (Pars Distalis): Adenoma or Carcinoma</b> |                |               |                 |                 |
| Overall rate   | 7/44 (15.9%)   | 2/41 (4.9%)   | 3/41 (7.3%)     | 1/38 (2.6%)     |
| Adjusted rate  | 7/42.5 (16.5%) | 2/37.3 (5.4%) | 3/30.9 (9.7%)   | 1/26.5 (3.8%)   |
| Terminal rate  | 5/37 (13.5%)   | 2/30 (6.7%)   | 1/15 (6.7%)     | 0/8 (0.0%)      |
| First incidence (days)                                       | 677            | 765 (T)       | 594             | 646             |
| Poly-3 test  | P=0.142N       | P=0.123N      | P=0.336N        | P=0.130N        |
| <b>Skin: Sarcoma</b>   |                |               |                 |                 |
| Overall rate   | 2/47 (4.3%)    | 1/47 (2.1%)   | 6/48 (12.5%)    | 5/47 (10.6%)    |
| Adjusted rate  | 2/44.5 (4.5%)  | 1/42.5 (2.4%) | 6/37.2 (16.1%)  | 5/33.5 (14.9%)  |
| Terminal rate  | 2/39 (5.1%)    | 1/33 (3.0%)   | 2/19 (10.5%)    | 0/8 (0.0%)      |
| First incidence (days)                                       | 765 (T)        | 765 (T)       | 636             | 626             |
| Poly-3 test  | P=0.035        | P=0.530N      | P=0.074         | P=0.108         |
| <b>Skin: Fibroma or Sarcoma</b>                              |                |               |                 |                 |
| Overall rate   | 2/47 (4.3%)    | 1/47 (2.1%)   | 6/48 (12.5%)    | 6/47 (12.8%)    |
| Adjusted rate  | 2/44.5 (4.7%)  | 1/42.5 (2.4%) | 6/37.2 (16.1%)  | 6/33.7 (17.8%)  |
| Terminal rate  | 2/39 (5.1%)    | 1/33 (3.0%)   | 2/19 (10.5%)    | 0/8 (0.0%)      |
| First incidence (days)                                       | 765 (T)        | 765 (T)       | 636             | 626             |
| Poly-3 test  | P=0.013        | P=0.530N      | P=0.074         | P=0.055         |
| <b>Spleen: Hemangiosarcoma</b>                               |                |               |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/46 (0.0%)   | 0/46 (0.0%)     | 3/46 (6.5%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 0/42.0 (0.0%) | 0/35.1 (0.0%)   | 3/32.7 (9.2%)   |
| Terminal rate  | 0/39 (0.0%)    | 0/33 (0.0%)   | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                                       | —              | —             | —               | 626             |
| Poly-3 test  | P=0.005        | —             | —               | P=0.069         |
| <b>Spleen: Hemangioma or Hemangiosarcoma</b>                 |                |               |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 1/46 (2.2%)   | 0/46 (0.0%)     | 3/46 (6.5%)     |
| Adjusted rate  | 0/44.5 (0.0%)  | 1/42.0 (2.4%) | 0/35.1 (0.0%)   | 3/32.7 (9.2%)   |
| Terminal rate  | 0/39 (0.0%)    | 1/33 (3.0%)   | 0/19 (0.0%)     | 0/8 (0.0%)      |
| First incidence (days)                                       | —              | 765 (T)       | —               | 626             |
| Poly-3 test  | P=0.023        | P=0.481       | —               | P=0.069         |

**TABLE E2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm          |
|--|---------------|---------------|---------------|-----------------|
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>                            |               |               |               |                 |
| Overall rate   | 0/47 (0.0%)   | 4/46 (8.7%)   | 0/47 (0.0%)   | 0/46 (0.0%)     |
| Adjusted rate  | 0/44.5 (0.0%) | 4/42.0 (9.5%) | 0/35.4 (0.0%) | 0/31.7 (0.0%)   |
| Terminal rate  | 0/39 (0.0%)   | 3/33 (9.1%)   | 0/19 (0.0%)   | 0/8 (0.0%)      |
| First incidence (days)   | —             | 736           | —             | —               |
| Poly-3 test  | P=0.280N      | P=0.049       | —             | —               |
| <b>Stomach (Forestomach): Squamous Cell Papilloma or Squamous Cell Carcinoma</b> |               |               |               |                 |
| Overall rate   | 0/47 (0.0%)   | 4/46 (8.7%)   | 0/47 (0.0%)   | 1/46 (2.2%)     |
| Adjusted rate  | 0/44.5 (0.0%) | 4/42.1 (9.5%) | 0/35.4 (0.0%) | 1/32.1 (3.1%)   |
| Terminal rate  | 0/39 (0.0%)   | 3/33 (9.1%)   | 0/19 (0.0%)   | 0/8 (0.0%)      |
| First incidence (days)   | —             | 736           | —             | 659             |
| Poly-3 test  | P=0.606N      | P=0.049       | —             | P=0.428         |
| <b>Uterus: Hemangioma</b>  |               |               |               |                 |
| Overall rate   | 0/47 (0.0%)   | 0/47 (0.0%)   | 1/48 (2.1%)   | 3/48 (6.3%)     |
| Adjusted rate  | 0/44.5 (0.0%) | 0/42.5 (0.0%) | 1/36.2 (2.8%) | 3/34.3 (8.7%)   |
| Terminal rate  | 0/39 (0.0%)   | 0/33 (0.0%)   | 1/19 (5.3%)   | 0/8 (0.0%)      |
| First incidence (days)   | —             | —             | 765 (T)       | 608             |
| Poly-3 test  | P=0.011       | —             | P=0.451       | P=0.074         |
| <b>Uterus: Hemangioma or Hemangiosarcoma</b>                                     |               |               |               |                 |
| Overall rate   | 0/47 (0.0%)   | 0/44 (0.0%)   | 2/48 (4.2%)   | 4/48 (8.3%)     |
| Adjusted rate  | 0/44.5 (0.0%) | 0/42.5 (0.0%) | 2/36.4 (5.5%) | 4/34.3 (11.7%)  |
| Terminal rate  | 0/39 (0.0%)   | 0/33 (0.0%)   | 1/19 (5.3%)   | 1/8 (12.5%)     |
| First incidence (days)   | —             | —             | 696           | 608             |
| Poly-3 test  | P=0.004       | —             | P=0.188       | P=0.031         |
| <b>All Organs: Hemangioma</b>  |               |               |               |                 |
| Overall rate   | 1/47 (2.1%)   | 1/47 (2.1%)   | 2/48 (4.2%)   | 4/48 (8.3%)     |
| Adjusted rate  | 1/44.5 (2.2%) | 1/42.5 (2.4%) | 2/36.2 (5.5%) | 4/34.5 (11.6%)  |
| Terminal rate  | 1/39 (2.6%)   | 1/33 (3.0%)   | 2/19 (10.5%)  | 0/8 (0.0%)      |
| First incidence (days)   | 765 (T)       | 765 (T)       | 765 (T)       | 608             |
| Poly-3 test  | P=0.038       | P=0.741       | P=0.414       | P=0.104         |
| <b>All Organs: Hemangiosarcoma</b>   |               |               |               |                 |
| Overall rate   | 1/47 (2.1%)   | 2/47 (4.3%)   | 1/48 (2.1%)   | 17/48 (35.4%)   |
| Adjusted rate  | 1/44.5 (2.2%) | 2/42.5 (4.7%) | 1/36.4 (2.7%) | 17/37.8 (45.0%) |
| Terminal rate  | 1/39 (2.6%)   | 2/33 (6.1%)   | 0/19 (0.0%)   | 2/8 (25.0%)     |
| First incidence (days)   | 765 (T)       | 765 (T)       | 696           | 508             |
| Poly-3 test  | P=0.001       | P=0.470       | P=0.703       | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b>                                 |               |               |               |                 |
| Overall rate   | 2/47 (4.3%)   | 3/47 (6.4%)   | 3/48 (6.3%)   | 21/48 (43.8%)   |
| Adjusted rate  | 2/44.5 (4.5%) | 3/42.5 (7.1%) | 3/36.4 (8.2%) | 21/39.3 (53.5%) |
| Terminal rate  | 2/39 (5.1%)   | 3/33 (9.1%)   | 2/19 (10.5%)  | 2/8 (25.0%)     |
| First incidence (days)   | 765 (T)       | 765 (T)       | 696           | 508             |
| Poly-3 test  | P=0.001       | P=0.461       | P=0.391       | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>   |               |               |               |                 |
| Overall rate   | 0/47 (0.0%)   | 2/47 (4.3%)   | 3/48 (6.3%)   | 2/48 (4.2%)     |
| Adjusted rate  | 0/44.5 (0.0%) | 2/42.7 (4.7%) | 3/37.0 (8.1%) | 2/33.0 (6.1%)   |
| Terminal rate  | 0/39 (0.0%)   | 1/33 (3.0%)   | 0/19 (0.0%)   | 1/8 (12.5%)     |
| First incidence (days)   | —             | 698           | 607           | 762             |
| Poly-3 test  | P=0.199       | P=0.220       | P=0.084       | P=0.171         |

**TABLE E2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm           |
|--|-----------------|-----------------|-----------------|------------------|
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |                  |
| Overall rate                                     | 9/47 (19.1%)    | 10/47 (21.3%)   | 11/48 (22.9%)   | 6/48 (12.5%)     |
| Adjusted rate                                    | 9/44.8 (20.1%)  | 10/43.6 (22.9%) | 11/38.7 (28.4%) | 6/35.4 (17.0%)   |
| Terminal rate                                    | 7/39 (17.9%)    | 7/33 (21.2%)    | 5/19 (26.3%)    | 0/8 (0.0%)       |
| First incidence (days)                           | 677             | 611             | 593             | 360              |
| Poly-3 test                                      | P=0.429N        | P=0.437         | P=0.230         | P=0.509N         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |                  |
| Overall rate                                     | 21/47 (44.7%)   | 21/47 (44.7%)   | 31/48 (64.6%)   | 39/48 (81.3%)    |
| Adjusted rate                                    | 21/45.0 (46.7%) | 21/44.4 (47.3%) | 31/40.5 (76.6%) | 39/42.7 (91.4%)  |
| Terminal rate                                    | 18/39 (46.2%)   | 15/33 (45.5%)   | 18/19 (94.7%)   | 8/8 (100.0%)     |
| First incidence (days)                           | 677             | 529             | 306             | 542              |
| Poly-3 test                                      | P=0.001         | P=0.490N        | P=0.001         | P=0.001          |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |                  |
| Overall rate                                     | 14/47 (29.8%)   | 22/47 (46.8%)   | 38/48 (79.2%)   | 45/48 (93.8%)    |
| Adjusted rate                                    | 14/45.0 (31.1%) | 22/44.4 (49.6%) | 38/44.5 (85.4%) | 45/46.3 (97.1%)  |
| Terminal rate                                    | 10/39 (25.6%)   | 16/33 (48.5%)   | 15/19 (78.9%)   | 8/8 (100.0%)     |
| First incidence (days)                           | 677             | 611             | 468             | 360              |
| Poly-3 test                                      | P=0.001         | P=0.042         | P=0.001         | P=0.001          |
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |                  |
| Overall rate                                     | 29/47 (61.7%)   | 33/47 (70.2%)   | 45/48 (93.8%)   | 48/48 (100.0%)   |
| Adjusted rate                                    | 29/45.0 (67.4%) | 33/45.2 (73.0%) | 45/46.5 (96.8%) | 48/48.0 (100.0%) |
| Terminal rate                                    | 25/39 (64.1%)   | 24/33 (72.7%)   | 18/19 (94.7%)   | 8/8 (100.0%)     |
| First incidence (days)                           | 677             | 529             | 306             | 360              |
| Poly-3 test                                      | P=0.001         | P=0.180         | P=0.001         | P=0.001          |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol<sup>a</sup>**

|   | 0 ppm  | 10 ppm | 30 ppm | 90 ppm  |
|---|--------|--------|--------|---------|
| <b>Disposition Summary</b>                  |        |        |        |         |
| Animals initially in study                  | 48     | 47     | 48     | 48      |
| Early deaths                                |        |        |        |         |
| Accidental deaths                           | 4      | 3      |        |         |
| Moribund                                    | 1      | 4      | 11     | 9       |
| Natural deaths                              | 4      | 7      | 18     | 31      |
| Survivors                                   |        |        |        |         |
| Terminal sacrifice                          | 39     | 33     | 19     | 8       |
| Animals examined microscopically            | 47     | 47     | 48     | 48      |
| <b>Alimentary System</b>                    |        |        |        |         |
| Esophagus                                   | (47)   | (47)   | (47)   | (47)    |
| Autolysis, marked                           |        |        | 1 (2%) |         |
| Gallbladder                                 | (47)   | (45)   | (46)   | (43)    |
| Autolysis, marked                           |        |        |        | 1 (2%)  |
| Autolysis, moderate                         |        | 2 (4%) | 2 (4%) | 3 (7%)  |
| Infiltration cellular, lymphocytic, mild    |        |        | 1 (2%) |         |
| Infiltration cellular, lymphocytic, minimal | 1 (2%) |        |        |         |
| Intestine large, cecum                      | (47)   | (45)   | (47)   | (41)    |
| Autolysis, marked                           |        |        | 1 (2%) | 2 (5%)  |
| Autolysis, mild                             | 1 (2%) |        |        |         |
| Autolysis, moderate                         |        | 1 (2%) | 2 (4%) | 8 (20%) |
| Hyperplasia, mild, lymphoid tissue          | 1 (2%) | 1 (2%) |        |         |
| Hyperplasia, minimal, lymphoid tissue       |        |        | 1 (2%) |         |
| Intestine large, colon                      | (47)   | (45)   | (47)   | (43)    |
| Autolysis, marked                           |        |        | 1 (2%) | 2 (5%)  |
| Autolysis, mild                             | 1 (2%) |        |        |         |
| Autolysis, moderate                         |        | 1 (2%) | 2 (4%) | 8 (19%) |
| Hyperplasia, mild, lymphoid tissue          |        | 1 (2%) |        |         |
| Hyperplasia, minimal, lymphoid tissue       |        |        | 1 (2%) |         |
| Inflammation, chronic active, marked        |        |        | 1 (2%) |         |
| Inflammation, chronic, moderate             |        | 1 (2%) |        |         |
| Intestine large, rectum                     | (47)   | (44)   | (47)   | (46)    |
| Autolysis, marked                           |        |        | 1 (2%) |         |
| Autolysis, mild                             | 1 (2%) |        |        | 1 (2%)  |
| Autolysis, moderate                         |        | 1 (2%) | 1 (2%) | 6 (13%) |
| Intestine small, duodenum                   | (47)   | (45)   | (47)   | (39)    |
| Autolysis, marked                           |        |        | 1 (2%) | 2 (5%)  |
| Autolysis, mild                             | 1 (2%) |        |        |         |
| Autolysis, moderate                         | 1 (2%) | 1 (2%) | 3 (6%) | 6 (15%) |
| Hyperplasia, moderate, lymphoid tissue      |        | 1 (2%) |        |         |
| Intestine small, ileum                      | (47)   | (45)   | (47)   | (40)    |
| Autolysis, marked                           |        |        | 1 (2%) | 2 (5%)  |
| Autolysis, mild                             | 1 (2%) |        |        |         |
| Autolysis, moderate                         | 1 (2%) | 1 (2%) | 3 (6%) | 7 (18%) |
| Hyperplasia, mild, lymphoid tissue          | 2 (4%) | 1 (2%) | 1 (2%) |         |
| Intestine small, jejunum                    | (47)   | (45)   | (47)   | (39)    |
| Angiectasis, minimal                        |        |        |        | 1 (3%)  |
| Autolysis, marked                           |        |        | 1 (2%) | 2 (5%)  |
| Autolysis, mild                             | 1 (2%) |        |        |         |
| Autolysis, moderate                         | 1 (2%) | 1 (2%) | 2 (4%) | 6 (15%) |
| Hyperplasia, marked, lymphoid tissue        |        |        | 1 (2%) |         |
| Hyperplasia, mild, lymphoid tissue          | 1 (2%) | 1 (2%) |        |         |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System (continued)</b>            |          |          |          |          |
| Liver   | (47)     | (47)     | (47)     | (46)     |
| Accessory spleen                                | 1 (2%)   |          |          |          |
| Angiectasis                                     | 2 (4%)   | 5 (11%)  | 7 (15%)  | 20 (43%) |
| Autolysis, marked                               |          |          | 1 (2%)   |          |
| Autolysis, mild                                 | 1 (2%)   |          |          |          |
| Autolysis, moderate                             | 2 (4%)   | 1 (2%)   |          |          |
| Basophilic focus                                | 2 (4%)   |          |          |          |
| Clear cell focus                                |          |          | 1 (2%)   |          |
| Clear cell focus, multiple                      |          |          | 1 (2%)   |          |
| Eosinophilic focus                              | 2 (4%)   | 10 (21%) | 1 (2%)   | 6 (13%)  |
| Eosinophilic focus, multiple                    |          | 10 (21%) | 20 (43%) | 22 (48%) |
| Fatty change, focal, minimal                    |          | 1 (2%)   |          |          |
| Fatty change, moderate                          |          |          |          | 1 (2%)   |
| Fibrosis, mild                                  |          | 1 (2%)   |          |          |
| Granuloma, focal, mild                          |          |          | 1 (2%)   |          |
| Granuloma, focal, minimal                       | 2 (4%)   |          | 1 (2%)   |          |
| Hematopoietic cell proliferation, marked        |          |          |          | 1 (2%)   |
| Hematopoietic cell proliferation, mild          |          | 12 (26%) | 6 (13%)  | 18 (39%) |
| Hematopoietic cell proliferation, minimal       | 2 (4%)   | 3 (6%)   |          |          |
| Hematopoietic cell proliferation, moderate      | 1 (2%)   | 1 (2%)   | 7 (15%)  | 7 (15%)  |
| Hyperplasia, mild, kupffer cell                 |          | 1 (2%)   |          |          |
| Infarct, caudate lobe                           | 1 (2%)   |          | 1 (2%)   |          |
| Infarct, median lobe                            |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild        | 3 (6%)   | 2 (4%)   | 2 (4%)   | 2 (4%)   |
| Infiltration cellular, lymphocytic, minimal     | 11 (23%) | 9 (19%)  | 3 (6%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, moderate    | 1 (2%)   | 1 (2%)   |          |          |
| Inflammation, chronic active, mild              | 1 (2%)   |          |          |          |
| Inflammation, chronic active, minimal           | 1 (2%)   |          |          |          |
| Inflammation, chronic active, moderate          |          | 1 (2%)   |          | 1 (2%)   |
| Inflammation, granulomatous, marked             | 1 (2%)   |          |          |          |
| Inflammation, mild                              |          | 1 (2%)   |          |          |
| Mixed cell focus                                |          | 1 (2%)   |          |          |
| Mixed cell focus, multiple                      |          | 5 (11%)  | 5 (11%)  | 3 (7%)   |
| Necrosis, marked                                |          |          |          | 1 (2%)   |
| Necrosis, mild                                  | 2 (4%)   |          | 2 (4%)   | 9 (20%)  |
| Necrosis, mild, hepatocyte                      |          | 1 (2%)   |          |          |
| Necrosis, minimal                               | 3 (6%)   | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Necrosis, moderate                              |          |          | 1 (2%)   | 6 (13%)  |
| Necrosis, moderate, hepatocyte                  |          |          | 1 (2%)   |          |
| Pigmentation, mild                              |          | 1 (2%)   |          |          |
| Regeneration                                    |          |          |          | 2 (4%)   |
| Thrombosis                                      | 1 (2%)   |          | 4 (9%)   | 9 (20%)  |
| Vacuolization cytoplasmic, marked, hepatocyte   |          |          | 1 (2%)   |          |
| Vacuolization cytoplasmic, mild, hepatocyte     | 7 (15%)  | 7 (15%)  | 3 (6%)   |          |
| Vacuolization cytoplasmic, minimal, hepatocyte  | 2 (4%)   | 1 (2%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, moderate, hepatocyte | 2 (4%)   |          | 2 (4%)   | 5 (11%)  |
| Mesentery                                       | (2)      | (5)      | (6)      | (6)      |
| Necrosis, fat                                   | 2 (100%) | 3 (60%)  | 5 (83%)  | 4 (67%)  |
| Pancreas  | (47)     | (45)     | (46)     | (44)     |
| Angiectasis, mild                               | 1 (2%)   |          | 1 (2%)   |          |
| Angiectasis, minimal                            |          |          | 1 (2%)   |          |
| Atrophy, moderate, acinar cell                  |          |          | 1 (2%)   |          |
| Autolysis, moderate                             |          |          | 2 (4%)   | 6 (14%)  |
| Cyst  | 1 (2%)   |          |          |          |
| Cyst, duct                                      |          | 1 (2%)   |          |          |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Alimentary System (continued)</b>         |          |          |          |          |
| Pancreas (continued)                         | (47)     | (45)     | (46)     | (44)     |
| Hemorrhage, mild                             |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild     | 2 (4%)   | 1 (2%)   | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal  | 12 (26%) | 17 (38%) | 7 (15%)  | 2 (5%)   |
| Inflammation, chronic, moderate              |          | 1 (2%)   |          |          |
| Salivary glands                              | (47)     | (47)     | (46)     | (48)     |
| Fibrosis, minimal                            |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild     | 11 (23%) | 12 (26%) | 15 (33%) | 10 (21%) |
| Infiltration cellular, lymphocytic, minimal  | 31 (66%) | 25 (53%) | 17 (37%) | 21 (44%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Inflammation, mild                           |          |          | 1 (2%)   |          |
| Stomach, forestomach                         | (47)     | (46)     | (47)     | (46)     |
| Autolysis, marked                            |          |          | 1 (2%)   |          |
| Autolysis, mild                              | 1 (2%)   |          |          | 1 (2%)   |
| Autolysis, moderate                          |          | 1 (2%)   | 1 (2%)   | 4 (9%)   |
| Foreign body                                 |          |          | 2 (4%)   |          |
| Hyperkeratosis, mild                         |          |          |          | 2 (4%)   |
| Hyperplasia, marked, epithelium              | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild, epithelium                | 2 (4%)   | 1 (2%)   | 6 (13%)  | 3 (7%)   |
| Hyperplasia, minimal, epithelium             |          | 1 (2%)   | 1 (2%)   | 3 (7%)   |
| Hyperplasia, moderate, epithelium            | 1 (2%)   | 1 (2%)   |          | 2 (4%)   |
| Infiltration cellular, lymphocytic, mild     |          | 1 (2%)   |          |          |
| Inflammation, mild                           | 1 (2%)   | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Inflammation, minimal                        |          |          |          | 1 (2%)   |
| Ulcer, mild                                  | 1 (2%)   |          |          |          |
| Ulcer, minimal                               |          | 1 (2%)   |          |          |
| Stomach, glandular                           | (47)     | (46)     | (47)     | (45)     |
| Autolysis, marked                            |          |          | 1 (2%)   |          |
| Autolysis, mild                              | 1 (2%)   |          |          | 1 (2%)   |
| Autolysis, moderate                          |          | 1 (2%)   | 1 (2%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, mild     |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal  |          |          | 1 (2%)   |          |
| Inflammation, mild                           |          |          | 1 (2%)   |          |
| Mineralization, minimal                      |          |          |          | 1 (2%)   |
| Tongue                                       | (47)     | (47)     | (48)     | (48)     |
| Polyarteritis, mild                          | 1 (2%)   |          |          |          |
| <b>Cardiovascular System</b>                 |          |          |          |          |
| Heart  | (47)     | (47)     | (48)     | (48)     |
| Abscess                                      |          | 1 (2%)   |          |          |
| Angiectasis, mild                            |          |          |          | 2 (4%)   |
| Angiectasis, minimal                         |          |          | 1 (2%)   | 2 (4%)   |
| Cardiomyopathy, mild                         |          | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Cardiomyopathy, minimal                      | 2 (4%)   | 3 (6%)   | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild, endothelium               |          |          |          | 3 (6%)   |
| Hyperplasia, minimal, endothelium            |          |          | 3 (6%)   | 4 (8%)   |
| Hyperplasia, moderate, endothelium           |          |          |          | 1 (2%)   |
| Hypertrophy, minimal, artery                 | 1 (2%)   |          |          |          |
| Inflammation, chronic, mild, epicardium      | 1 (2%)   |          |          |          |
| Inflammation, chronic, minimal, epicardium   |          |          |          | 1 (2%)   |
| Inflammation, mild, myocardium               |          |          | 2 (4%)   |          |
| Inflammation, minimal, myocardium            |          |          |          | 1 (2%)   |
| Inflammation, moderate, atrium               |          |          | 1 (2%)   |          |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Cardiovascular System</b> (continued)    |          |          |          |          |
| Heart (continued)                           | (47)     | (47)     | (48)     | (48)     |
| Mineralization, minimal                     |          | 1 (2%)   | 2 (4%)   |          |
| Necrosis, mild                              |          |          | 1 (2%)   |          |
| Thrombosis, mild, atrium                    |          |          | 1 (2%)   |          |
| Thrombosis, minimal, myocardium             |          |          | 1 (2%)   |          |
| Thrombosis, moderate, atrium                |          | 1 (2%)   |          |          |
| <b>Endocrine System</b>                     |          |          |          |          |
| Adrenal gland, cortex                       | (46)     | (47)     | (46)     | (44)     |
| Angiectasis, mild                           |          | 1 (2%)   | 3 (7%)   | 1 (2%)   |
| Angiectasis, moderate                       | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| Atrophy, moderate                           |          |          | 1 (2%)   |          |
| Cyst  |          | 1 (2%)   |          | 1 (2%)   |
| Hematopoietic cell proliferation, mild      |          |          | 1 (2%)   |          |
| Hematopoietic cell proliferation, minimal   |          |          |          | 1 (2%)   |
| Hyperplasia, mild, subcapsular              | 26 (57%) | 20 (43%) | 22 (48%) | 23 (52%) |
| Hyperplasia, minimal, subcapsular           | 15 (33%) | 13 (28%) | 7 (15%)  | 5 (11%)  |
| Hyperplasia, moderate, subcapsular          | 1 (2%)   | 4 (9%)   | 6 (13%)  | 2 (5%)   |
| Infarct, mild                               |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal |          |          |          | 1 (2%)   |
| Inflammation, mild                          |          |          | 1 (2%)   |          |
| Thrombosis, moderate                        | 1 (2%)   |          |          |          |
| Adrenal gland, medulla                      | (45)     | (47)     | (45)     | (41)     |
| Hyperplasia, mild                           |          |          | 1 (2%)   |          |
| Hyperplasia, minimal                        |          | 1 (2%)   |          |          |
| Islets, pancreatic                          | (47)     | (45)     | (46)     | (44)     |
| Autolysis, moderate                         |          |          | 2 (4%)   | 4 (9%)   |
| Hyperplasia, mild                           | 1 (2%)   | 2 (4%)   |          |          |
| Hyperplasia, minimal                        | 6 (13%)  |          | 3 (7%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, minimal | 2 (4%)   | 2 (4%)   |          |          |
| Inflammation, minimal                       |          | 1 (2%)   |          |          |
| Parathyroid gland                           | (34)     | (37)     | (37)     | (31)     |
| Autolysis, marked                           |          |          | 1 (3%)   |          |
| Cyst  |          |          |          | 1 (3%)   |
| Pituitary gland                             | (44)     | (41)     | (41)     | (38)     |
| Angiectasis, mild                           |          |          | 2 (5%)   |          |
| Angiectasis, minimal                        | 1 (2%)   |          |          |          |
| Angiectasis, moderate                       |          | 1 (2%)   |          |          |
| Cyst  |          | 2 (5%)   |          |          |
| Hemorrhage, mild                            |          |          |          | 1 (3%)   |
| Hyperplasia, mild, pars distalis            | 1 (2%)   | 2 (5%)   | 1 (2%)   | 1 (3%)   |
| Hyperplasia, minimal, pars distalis         |          |          | 1 (2%)   |          |
| Hyperplasia, moderate, pars distalis        |          |          | 1 (2%)   |          |
| Thyroid gland                               | (46)     | (47)     | (45)     | (46)     |
| Autolysis, marked                           |          |          | 1 (2%)   |          |
| Cyst multilocular                           | 2 (4%)   |          | 1 (2%)   | 1 (2%)   |
| Depletion secretory                         |          |          |          | 1 (2%)   |
| Hyperplasia, minimal, C-cell                | 1 (2%)   |          | 1 (2%)   |          |
| Hyperplasia, minimal, follicular cell       | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild    |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>General Body System</b>                                       |          |          |          |          |
| Tissue NOS   |          | (1)      | (1)      |          |
| Cyst, abdominal  |          |          | 1 (100%) |          |
| Inflammation, moderate, abdominal                                |          |          | 1 (100%) |          |
| <b>Genital System</b>  |          |          |          |          |
| Clitoral gland   | (40)     | (40)     | (34)     | (40)     |
| Atrophy, mild  | 37 (93%) | 35 (88%) | 26 (76%) | 34 (85%) |
| Atrophy, minimal   |          |          | 3 (9%)   | 2 (5%)   |
| Atrophy, moderate  |          | 3 (8%)   | 1 (3%)   | 1 (3%)   |
| Autolysis, moderate  |          |          |          | 1 (3%)   |
| Pigmentation   |          | 1 (3%)   |          |          |
| Ovary  | (47)     | (46)     | (47)     | (48)     |
| Angiectasis, mild  |          | 1 (2%)   | 3 (6%)   | 3 (6%)   |
| Angiectasis, moderate  |          | 1 (2%)   | 1 (2%)   | 3 (6%)   |
| Atrophy, marked  | 20 (43%) | 34 (74%) | 33 (70%) | 36 (75%) |
| Atrophy, mild  | 6 (13%)  | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Atrophy, minimal   | 4 (9%)   |          |          |          |
| Atrophy, moderate  | 15 (32%) | 4 (9%)   | 2 (4%)   | 5 (10%)  |
| Cyst   | 14 (30%) | 12 (26%) | 7 (15%)  | 4 (8%)   |
| Cyst, periovarian tissue   | 1 (2%)   |          |          | 1 (2%)   |
| Hematocyst   | 6 (13%)  | 6 (13%)  |          | 2 (4%)   |
| Hemorrhage, marked   |          | 1 (2%)   |          |          |
| Hemorrhage, mild   |          |          | 2 (4%)   |          |
| Hyperplasia, tubular, mild                                       |          |          |          | 2 (4%)   |
| Hyperplasia, tubular, minimal                                    |          |          |          | 1 (2%)   |
| Hyperplasia, tubular, moderate                                   |          | 1 (2%)   |          | 2 (4%)   |
| Infiltration cellular, histiocytic, moderate                     |          | 1 (2%)   | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, moderate, periovarian tissue |          |          | 1 (2%)   |          |
| Metaplasia, osseous, mild  | 1 (2%)   |          |          |          |
| Mineralization, moderate   |          | 1 (2%)   | 1 (2%)   |          |
| Pigmentation, moderate   |          | 1 (2%)   | 1 (2%)   |          |
| Thrombosis, marked   |          | 2 (4%)   |          |          |
| Uterus   | (47)     | (47)     | (48)     | (48)     |
| Angiectasis, marked  |          |          | 1 (2%)   | 1 (2%)   |
| Angiectasis, mild  | 1 (2%)   | 2 (4%)   | 2 (4%)   | 5 (10%)  |
| Angiectasis, moderate  |          |          | 4 (8%)   | 3 (6%)   |
| Atrophy, mild  |          |          | 1 (2%)   |          |
| Autolysis, marked  |          |          | 1 (2%)   |          |
| Hemorrhage, mild   |          |          | 1 (2%)   |          |
| Hemorrhage, moderate   |          |          | 2 (4%)   | 1 (2%)   |
| Hemorrhage, moderate, cervix                                     |          |          | 1 (2%)   |          |
| Hyperplasia, cystic, marked, endometrium                         | 2 (4%)   |          | 1 (2%)   |          |
| Hyperplasia, cystic, mild, endometrium                           | 24 (51%) | 26 (55%) | 14 (29%) | 21 (44%) |
| Hyperplasia, cystic, minimal, endometrium                        | 1 (2%)   | 4 (9%)   | 8 (17%)  | 6 (13%)  |
| Hyperplasia, cystic, moderate, endometrium                       | 15 (32%) | 10 (21%) | 15 (31%) | 6 (13%)  |
| Inflammation, moderate   |          | 1 (2%)   |          |          |
| Inflammation, suppurative, marked                                |          |          |          | 1 (2%)   |
| Thrombosis, marked   |          |          | 1 (2%)   | 2 (4%)   |
| Thrombosis, mild   |          |          | 2 (4%)   |          |
| Thrombosis, moderate   |          |          | 2 (4%)   | 4 (8%)   |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm  | 10 ppm | 30 ppm | 90 ppm  |
|--|--------|--------|--------|---------|
| <b>Genital System (continued)</b>                          |        |        |        |         |
| Vagina   | (47)   | (47)   | (47)   | (47)    |
| Exudate, mild  |        | 2 (4%) |        | 1 (2%)  |
| Exudate, minimal   | 1 (2%) |        |        |         |
| Exudate, moderate  | 1 (2%) |        |        |         |
| Hemorrhage, moderate                                       |        |        |        | 1 (2%)  |
| Inflammation, mild   | 1 (2%) | 1 (2%) |        |         |
| <b>Hematopoietic System</b>                                |        |        |        |         |
| Bone marrow  | (47)   | (46)   | (48)   | (48)    |
| Angiectasis, mild  |        |        |        | 2 (4%)  |
| Autolysis, marked  |        |        | 1 (2%) |         |
| Autolysis, moderate  |        |        |        | 1 (2%)  |
| Hyperplasia, mild, myeloid cell                            |        | 1 (2%) | 1 (2%) | 5 (10%) |
| Hyperplasia, moderate, myeloid cell                        |        | 1 (2%) | 2 (4%) | 1 (2%)  |
| Infiltration cellular, histiocytic, mild                   |        |        | 1 (2%) |         |
| Pigmentation, mild   | 1 (2%) |        |        |         |
| Lymph node   | (47)   | (47)   | (47)   | (47)    |
| Autolysis, marked, thoracic                                |        |        | 1 (2%) |         |
| Hemorrhage, mild, lumbar                                   | 1 (2%) |        |        |         |
| Hemorrhage, moderate, lumbar                               |        |        | 1 (2%) | 1 (2%)  |
| Hyperplasia, mild, lumbar                                  | 1 (2%) |        | 1 (2%) | 1 (2%)  |
| Hyperplasia, mild, renal                                   |        | 1 (2%) |        |         |
| Hyperplasia, moderate, lumbar                              |        |        | 1 (2%) | 1 (2%)  |
| Hyperplasia, moderate, renal                               |        |        |        | 1 (2%)  |
| Hyperplasia, moderate, thoracic                            |        |        | 2 (4%) |         |
| Infiltration cellular, plasma cell, moderate, lumbar       |        |        | 1 (2%) |         |
| Infiltration cellular, polymorphonuclear, moderate, lumbar |        |        | 1 (2%) | 1 (2%)  |
| Lymph node, mandibular                                     | (47)   | (44)   | (43)   | (46)    |
| Hemorrhage, mild   | 1 (2%) |        | 1 (2%) |         |
| Hyperplasia, lymphoid, marked                              |        | 1 (2%) |        |         |
| Hyperplasia, lymphoid, mild                                | 3 (6%) | 1 (2%) | 1 (2%) | 4 (9%)  |
| Hyperplasia, lymphoid, minimal                             | 1 (2%) |        | 1 (2%) |         |
| Hyperplasia, lymphoid, moderate                            |        | 3 (7%) | 2 (5%) | 2 (4%)  |
| Infiltration cellular, histiocytic, mild                   |        |        |        | 1 (2%)  |
| Infiltration cellular, histiocytic, minimal                |        |        |        | 1 (2%)  |
| Infiltration cellular, plasma cell, moderate               |        |        |        | 1 (2%)  |
| Inflammation, mild   |        |        | 1 (2%) |         |
| Lymph node, mesenteric                                     | (43)   | (42)   | (42)   | (38)    |
| Angiectasis, mild  |        | 1 (2%) | 1 (2%) | 2 (5%)  |
| Angiectasis, minimal                                       | 1 (2%) |        |        |         |
| Atrophy, mild  |        |        | 1 (2%) | 1 (3%)  |
| Autolysis, marked  |        |        | 1 (2%) | 1 (3%)  |
| Autolysis, moderate  |        |        |        | 1 (3%)  |
| Hematopoietic cell proliferation, mild                     |        |        |        | 1 (3%)  |
| Hemorrhage, marked   |        |        |        | 1 (3%)  |
| Hemorrhage, mild   |        |        | 1 (2%) | 1 (3%)  |
| Hyperplasia, lymphoid, marked                              |        | 1 (2%) |        |         |
| Hyperplasia, lymphoid, mild                                | 4 (9%) |        | 1 (2%) |         |
| Hyperplasia, lymphoid, moderate                            | 1 (2%) | 1 (2%) |        |         |
| Infiltration cellular, polymorphonuclear, mild             |        |        |        | 1 (3%)  |
| Inflammation, granulomatous, moderate                      | 1 (2%) |        |        |         |
| Pigmentation, mild   |        |        | 1 (2%) |         |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm  | 90 ppm   |
|---|----------|----------|---------|----------|
| <b>Hematopoietic System (continued)</b>                 |          |          |         |          |
| Spleen  | (47)     | (46)     | (46)    | (46)     |
| Angiectasis, mild                                       | 1 (2%)   |          |         | 2 (4%)   |
| Angiectasis, moderate                                   | 1 (2%)   | 1 (2%)   |         |          |
| Atrophy, mild, red pulp                                 |          |          | 1 (2%)  |          |
| Autolysis, moderate                                     |          |          | 1 (2%)  | 4 (9%)   |
| Hematopoietic cell proliferation granulocytic, moderate |          | 1 (2%)   |         |          |
| Hematopoietic cell proliferation, marked                |          |          | 1 (2%)  | 2 (4%)   |
| Hematopoietic cell proliferation, mild                  | 1 (2%)   | 3 (7%)   | 7 (15%) | 6 (13%)  |
| Hematopoietic cell proliferation, moderate              | 1 (2%)   | 5 (11%)  | 7 (15%) | 17 (37%) |
| Hemorrhage, mild  |          |          |         | 1 (2%)   |
| Hyperplasia, marked, lymphoid follicle                  | 2 (4%)   | 1 (2%)   | 1 (2%)  |          |
| Hyperplasia, mild, lymphoid follicle                    | 14 (30%) | 11 (24%) | 8 (17%) | 4 (9%)   |
| Hyperplasia, minimal, lymphoid follicle                 | 3 (6%)   |          | 1 (2%)  |          |
| Hyperplasia, moderate, lymphoid follicle                | 6 (13%)  | 4 (9%)   | 2 (4%)  | 1 (2%)   |
| Inflammation, mild, capsule                             |          | 1 (2%)   |         |          |
| Pigmentation, mild                                      | 2 (4%)   |          | 1 (2%)  | 1 (2%)   |
| Pigmentation, minimal                                   | 1 (2%)   | 1 (2%)   |         |          |
| Thrombosis, marked                                      |          |          |         | 1 (2%)   |
| Thymus  | (41)     | (40)     | (34)    | (36)     |
| Atrophy, mild   | 2 (5%)   | 6 (15%)  | 8 (24%) | 11 (31%) |
| Atrophy, minimal  |          |          | 1 (3%)  | 1 (3%)   |
| Atrophy, moderate                                       |          |          |         | 3 (8%)   |
| Autolysis, marked                                       |          |          | 1 (3%)  |          |
| Autolysis, moderate                                     |          |          | 1 (3%)  | 2 (6%)   |
| Hyperplasia, mild                                       | 3 (7%)   | 6 (15%)  | 3 (9%)  | 2 (6%)   |
| Hyperplasia, minimal                                    | 1 (2%)   |          |         |          |
| <b>Integumentary System</b>                             |          |          |         |          |
| Mammary gland   | (47)     | (45)     | (48)    | (47)     |
| Autolysis, marked                                       |          |          | 1 (2%)  |          |
| Ectasia, mild, duct                                     |          |          | 1 (2%)  |          |
| Ectasia, moderate, duct                                 | 1 (2%)   |          |         |          |
| Hyperplasia, mild                                       | 2 (4%)   |          | 1 (2%)  | 1 (2%)   |
| Hyperplasia, minimal                                    |          |          | 1 (2%)  | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal             |          |          |         | 1 (2%)   |
| Lactation, mild   | 2 (4%)   | 1 (2%)   | 2 (4%)  |          |
| Lactation, minimal                                      | 1 (2%)   | 1 (2%)   | 4 (8%)  | 3 (6%)   |
| Skin  | (47)     | (47)     | (48)    | (47)     |
| Autolysis, marked                                       |          |          | 1 (2%)  |          |
| Cyst epithelial inclusion                               |          |          |         | 1 (2%)   |
| Inflammation, mild                                      |          |          |         | 1 (2%)   |
| Ulcer, moderate   |          |          | 1 (2%)  |          |
| <b>Musculoskeletal System</b>                           |          |          |         |          |
| Bone  | (47)     | (47)     | (48)    | (48)     |
| Autolysis, marked, sternum                              |          |          | 1 (2%)  |          |
| Fibrous osteodystrophy, mild, sternum                   | 8 (17%)  | 10 (21%) | 8 (17%) | 1 (2%)   |
| Fibrous osteodystrophy, minimal, sternum                | 9 (19%)  | 10 (21%) | 6 (13%) | 3 (6%)   |
| Fibrous osteodystrophy, moderate, sternum               | 2 (4%)   |          | 1 (2%)  |          |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Musculoskeletal System (continued)</b>    |          |          |          |          |
| Bone, femur                                  | (46)     | (47)     | (48)     | (48)     |
| Fibrous osteodystrophy, mild                 | 2 (4%)   | 2 (4%)   |          | 1 (2%)   |
| Fibrous osteodystrophy, minimal              | 3 (7%)   | 3 (6%)   | 1 (2%)   |          |
| Fibrous osteodystrophy, moderate             | 2 (4%)   |          | 2 (4%)   |          |
| Skeletal muscle                              | (47)     | (47)     | (48)     | (48)     |
| Degeneration, moderate                       |          |          |          | 1 (2%)   |
| Mineralization, moderate                     |          |          |          | 1 (2%)   |
| <b>Nervous System</b>                        |          |          |          |          |
| Brain, cerebellum                            | (47)     | (46)     | (47)     | (48)     |
| Abscess, moderate                            |          |          |          | 1 (2%)   |
| Autolysis, moderate                          |          |          | 1 (2%)   |          |
| Hemorrhage, mild                             |          | 1 (2%)   |          |          |
| Brain, cerebrum                              | (47)     | (47)     | (47)     | (48)     |
| Autolysis, moderate                          |          |          | 1 (2%)   |          |
| Hemorrhage, moderate                         |          |          | 1 (2%)   |          |
| Mineralization, mild, thalamus               |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Mineralization, minimal, thalamus            | 29 (62%) | 28 (60%) | 22 (47%) | 17 (35%) |
| Spinal cord, thoracic                        | (47)     | (47)     | (47)     | (48)     |
| Autolysis, moderate                          |          |          | 1 (2%)   |          |
| Hemorrhage, mild                             |          |          |          | 1 (2%)   |
| <b>Respiratory System</b>                    |          |          |          |          |
| Larynx                                       | (47)     | (46)     | (47)     | (46)     |
| Autolysis, marked                            |          |          | 1 (2%)   |          |
| Hemorrhage, mild                             |          |          | 1 (2%)   |          |
| Inflammation, mild                           |          |          | 1 (2%)   |          |
| Lung   | (47)     | (47)     | (48)     | (48)     |
| Autolysis, mild                              | 2 (4%)   |          |          |          |
| Autolysis, moderate                          | 1 (2%)   |          |          |          |
| Congestion, moderate                         |          | 3 (6%)   |          |          |
| Crystals, mild                               |          | 1 (2%)   |          |          |
| Exudate, mild, alveolus                      |          |          |          | 1 (2%)   |
| Hemorrhage, mild                             | 4 (9%)   | 6 (13%)  | 1 (2%)   | 1 (2%)   |
| Hemorrhage, minimal                          | 3 (6%)   | 6 (13%)  | 1 (2%)   |          |
| Hyperplasia, mild, alveolar epithelium       | 1 (2%)   |          | 2 (4%)   | 2 (4%)   |
| Hyperplasia, minimal, alveolar epithelium    |          |          | 3 (6%)   | 1 (2%)   |
| Infiltration cellular, histiocytic, mild     |          | 1 (2%)   |          | 6 (13%)  |
| Infiltration cellular, histiocytic, minimal  |          |          | 1 (2%)   |          |
| Infiltration cellular, histiocytic, moderate | 1 (2%)   |          | 1 (2%)   | 3 (6%)   |
| Infiltration cellular, lymphocytic, mild     | 4 (9%)   | 5 (11%)  | 4 (8%)   | 6 (13%)  |
| Infiltration cellular, lymphocytic, minimal  | 18 (38%) | 21 (45%) | 19 (40%) | 10 (21%) |
| Infiltration cellular, lymphocytic, moderate | 2 (4%)   |          | 2 (4%)   |          |
| Inflammation, chronic active, minimal        |          | 1 (2%)   |          |          |
| Inflammation, suppurative, moderate          |          |          | 1 (2%)   |          |
| Pigmentation, mild                           | 1 (2%)   |          |          |          |
| Nose   | (47)     | (47)     | (48)     | (48)     |
| Hemorrhage, moderate                         |          |          | 1 (2%)   |          |
| Inflammation, moderate                       |          |          |          | 1 (2%)   |
| Trachea                                      | (47)     | (47)     | (46)     | (47)     |
| Autolysis, marked                            |          |          | 1 (2%)   |          |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Special Senses System</b>                 |          |          |          |          |
| Eye  | (47)     | (45)     | (48)     | (46)     |
| Atrophy, mild                                |          |          |          | 2 (4%)   |
| Atrophy, moderate                            |          |          |          | 1 (2%)   |
| Cataract, mild, lens                         |          |          |          | 2 (4%)   |
| Cataract, minimal, lens                      |          |          |          | 1 (2%)   |
| Hemorrhage, moderate                         |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild     |          |          | 1 (2%)   |          |
| Inflammation, marked, cornea                 |          |          |          | 1 (2%)   |
| Inflammation, mild, cornea                   |          | 1 (2%)   | 2 (4%)   | 5 (11%)  |
| Inflammation, minimal, cornea                | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Inflammation, moderate, cornea               |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Phthisis bulbi                               | 1 (2%)   |          |          | 1 (2%)   |
| Harderian gland                              | (47)     | (47)     | (46)     | (47)     |
| Atrophy, mild                                |          | 1 (2%)   |          |          |
| Hyperplasia, mild                            | 2 (4%)   |          | 1 (2%)   |          |
| Hyperplasia, minimal                         |          |          |          | 2 (4%)   |
| Infiltration cellular, lymphocytic, mild     | 1 (2%)   |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal  | 9 (19%)  | 10 (21%) | 8 (17%)  | 1 (2%)   |
| Inflammation, mild                           |          | 1 (2%)   |          |          |
| Inflammation, moderate                       |          |          |          | 1 (2%)   |
| Necrosis, marked                             |          | 1 (2%)   |          |          |
| Lacrimal gland                               | (45)     | (45)     | (44)     | (43)     |
| Atrophy, mild                                |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Atrophy, minimal                             | 4 (9%)   | 3 (7%)   | 2 (5%)   | 1 (2%)   |
| Cyst   |          | 1 (2%)   |          |          |
| Dilatation, minimal, duct                    | 1 (2%)   | 4 (9%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild     | 6 (13%)  | 8 (18%)  | 11 (25%) | 5 (12%)  |
| Infiltration cellular, lymphocytic, minimal  | 19 (42%) | 19 (42%) | 15 (34%) | 15 (35%) |
| Infiltration cellular, lymphocytic, moderate |          | 1 (2%)   | 1 (2%)   |          |
| Inflammation, mild                           |          |          | 1 (2%)   |          |
| Zymbal's gland                               | (46)     | (43)     | (41)     | (44)     |
| Infiltration cellular, lymphocytic, minimal  |          | 1 (2%)   |          |          |
| Inflammation, chronic, minimal               |          | 1 (2%)   |          |          |
| <b>Urinary System</b>                        |          |          |          |          |
| Kidney                                       | (47)     | (47)     | (48)     | (48)     |
| Accumulation, hyaline droplet, moderate      |          | 1 (2%)   |          | 1 (2%)   |
| Amyloid deposition, moderate                 | 1 (2%)   |          |          | 1 (2%)   |
| Autolysis, marked                            |          |          | 2 (4%)   |          |
| Autolysis, mild                              | 2 (4%)   |          |          |          |
| Embolus bacterial, moderate                  |          | 1 (2%)   |          |          |
| Glomerulosclerosis, mild                     | 1 (2%)   |          | 1 (2%)   | 3 (6%)   |
| Glomerulosclerosis, minimal                  | 1 (2%)   |          | 1 (2%)   |          |
| Hydronephrosis, mild                         |          |          |          | 2 (4%)   |
| Infarct, minimal                             |          |          | 1 (2%)   |          |
| Infarct, moderate                            |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild     | 3 (6%)   | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  | 15 (32%) | 12 (26%) | 17 (35%) | 9 (19%)  |
| Infiltration cellular, lymphocytic, moderate |          |          | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, plasma cell, mild     |          |          | 1 (2%)   |          |
| Infiltration cellular, plasma cell, moderate |          |          |          | 1 (2%)   |
| Inflammation, minimal                        |          | 1 (2%)   |          |          |

**TABLE E3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Urinary System</b> (continued)           |          |          |          |          |
| Kidney (continued)                          | (47)     | (47)     | (48)     | (48)     |
| Metaplasia, osseous, minimal                | 1 (2%)   |          |          | 1 (2%)   |
| Mineralization, mild                        |          |          |          | 1 (2%)   |
| Nephropathy, mild                           |          | 1 (2%)   |          | 1 (2%)   |
| Regeneration, minimal                       |          |          |          | 1 (2%)   |
| Urinary bladder                             | (45)     | (43)     | (47)     | (45)     |
| Autolysis, marked                           |          |          | 1 (2%)   |          |
| Autolysis, moderate                         |          |          |          | 3 (7%)   |
| Infiltration cellular, lymphocytic, mild    | 4 (9%)   | 3 (7%)   | 4 (9%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, minimal | 25 (56%) | 17 (40%) | 23 (49%) | 15 (33%) |

**APPENDIX F**  
**SUMMARY OF LESIONS IN FEMALE MICE**  
**IN THE 2-YEAR DRINKING WATER STUDY**  
**OF URETHANE AND 5% ETHANOL**

**TABLE F1** Summary of the Incidence of Neoplasms in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... F-2

**TABLE F2** Statistical Analysis of Primary Neoplasms in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... F-8

**TABLE F3** Summary of the Incidence of Nonneoplastic Lesions in Female Mice  
in the 2-Year Drinking Water Study of Urethane and 5% Ethanol ..... F-14

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol<sup>a</sup>**

|                                       | 0 ppm   | 10 ppm | 30 ppm   | 90 ppm   |
|---------------------------------------|---------|--------|----------|----------|
| <b>Disposition Summary</b>            |         |        |          |          |
| Animals initially in study            | 48      | 48     | 48       | 48       |
| Early deaths                          |         |        |          |          |
| Accidental deaths                     | 4       |        |          |          |
| Moribund                              | 6       | 4      | 4        | 11       |
| Natural deaths                        | 7       | 12     | 17       | 33       |
| Survivors                             |         |        |          |          |
| Terminal sacrifice                    | 31      | 32     | 27       | 4        |
| Animals examined microscopically      | 48      | 48     | 48       | 48       |
| <b>Alimentary System</b>              |         |        |          |          |
| Esophagus                             | (47)    | (48)   | (47)     | (46)     |
| Lymphoma malignant                    |         |        | 1 (2%)   |          |
| Gallbladder                           | (47)    | (44)   | (47)     | (45)     |
| Lymphoma malignant                    | 1 (2%)  |        | 2 (4%)   | 1 (2%)   |
| Intestine large, cecum                | (47)    | (44)   | (48)     | (42)     |
| Lymphoma malignant                    |         |        | 1 (2%)   |          |
| Mast cell tumor malignant             |         | 1 (2%) |          |          |
| Intestine large, colon                | (47)    | (45)   | (48)     | (42)     |
| Sarcoma, metastatic, skin             |         |        |          | 1 (2%)   |
| Intestine large, rectum               | (48)    | (47)   | (46)     | (44)     |
| Lymphoma malignant                    |         |        | 1 (2%)   |          |
| Sarcoma, metastatic, skin             |         | 1 (2%) |          |          |
| Intestine small, duodenum             | (47)    | (44)   | (46)     | (40)     |
| Adenoma                               | 1 (2%)  |        |          |          |
| Lymphoma malignant                    |         | 1 (2%) | 1 (2%)   |          |
| Intestine small, ileum                | (47)    | (44)   | (47)     | (40)     |
| Lymphoma malignant                    | 1 (2%)  |        | 1 (2%)   | 1 (3%)   |
| Intestine small, jejunum              | (47)    | (44)   | (47)     | (40)     |
| Hemangioma                            |         |        |          | 1 (3%)   |
| Liver                                 | (48)    | (47)   | (48)     | (48)     |
| Hemangiosarcoma                       |         |        |          | 6 (13%)  |
| Hepatocellular adenoma                | 3 (6%)  | 4 (9%) | 5 (10%)  | 2 (4%)   |
| Hepatocellular adenoma, multiple      |         | 2 (4%) | 11 (23%) | 14 (29%) |
| Hepatocellular carcinoma              |         | 1 (2%) |          |          |
| Hepatocellular carcinoma, multiple    |         |        |          | 1 (2%)   |
| Histiocytic sarcoma                   | 4 (8%)  |        | 3 (6%)   | 2 (4%)   |
| Lymphoma malignant                    | 4 (8%)  | 3 (6%) | 9 (19%)  | 6 (13%)  |
| Mast cell tumor malignant             |         | 1 (2%) |          |          |
| Sarcoma stromal, metastatic, uterus   |         |        | 1 (2%)   | 1 (2%)   |
| Sarcoma, metastatic, skin             |         | 1 (2%) |          | 1 (2%)   |
| Mesentery                             | (3)     | (3)    | (5)      | (4)      |
| Hemangiosarcoma                       |         |        |          | 2 (50%)  |
| Lymphoma malignant                    | 1 (33%) |        |          |          |
| Pancreas                              | (47)    | (45)   | (48)     | (44)     |
| Histiocytic sarcoma                   | 3 (6%)  |        | 1 (2%)   | 1 (2%)   |
| Lymphoma malignant                    |         |        | 5 (10%)  | 1 (2%)   |
| Sarcoma stromal, metastatic, uterus   |         |        | 1 (2%)   | 1 (2%)   |
| Sarcoma, metastatic, skin             |         | 1 (2%) |          | 1 (2%)   |
| Teratoma malignant, metastatic, ovary |         | 1 (2%) |          |          |

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm   | 10 ppm  | 30 ppm  | 90 ppm  |
|--|---------|---------|---------|---------|
| <b>Alimentary System</b> (continued)             |         |         |         |         |
| Salivary glands                                  | (48)    | (47)    | (48)    | (47)    |
| Histiocytic sarcoma                              | 1 (2%)  |         |         |         |
| Lymphoma malignant                               | 1 (2%)  |         | 5 (10%) | 1 (2%)  |
| Mast cell tumor malignant                        |         | 1 (2%)  |         |         |
| Stomach, forestomach                             | (48)    | (47)    | (48)    | (45)    |
| Lymphoma malignant                               |         |         |         | 1 (2%)  |
| Mast cell tumor malignant                        |         |         |         | 1 (2%)  |
| Squamous cell papilloma                          | 2 (4%)  | 3 (6%)  | 2 (4%)  |         |
| Stomach, glandular                               | (48)    | (46)    | (48)    | (45)    |
| Lymphoma malignant                               |         |         |         | 1 (2%)  |
| Mast cell tumor malignant                        |         | 1 (2%)  |         |         |
| Sarcoma, metastatic, skin                        |         |         |         | 1 (2%)  |
| <b>Cardiovascular System</b>                     |         |         |         |         |
| Blood vessel                                     | (47)    | (48)    | (46)    | (45)    |
| Lymphoma malignant                               |         |         | 1 (2%)  | 1 (2%)  |
| Heart  | (47)    | (48)    | (48)    | (47)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung |         |         | 1 (2%)  | 1 (2%)  |
| Hemangioma                                       |         |         | 2 (4%)  |         |
| Hemangiosarcoma                                  |         |         |         | 6 (13%) |
| Lymphoma malignant                               |         | 1 (2%)  | 2 (4%)  | 2 (4%)  |
| <b>Endocrine System</b>                          |         |         |         |         |
| Adrenal gland, cortex                            | (46)    | (46)    | (47)    | (46)    |
| Adenoma  |         |         | 1 (2%)  |         |
| Adenoma, subcapsular                             |         |         | 2 (4%)  | 3 (7%)  |
| Carcinoma, subcapsular                           |         | 1 (2%)  |         |         |
| Histiocytic sarcoma                              | 1 (2%)  |         |         |         |
| Lymphoma malignant                               | 1 (2%)  |         |         | 2 (4%)  |
| Sarcoma, metastatic, skin                        |         |         |         | 1 (2%)  |
| Adrenal gland, medulla                           | (44)    | (44)    | (46)    | (46)    |
| Alveolar/bronchiolar carcinoma, metastatic, lung |         |         | 1 (2%)  |         |
| Pheochromocytoma malignant                       |         | 1 (2%)  |         |         |
| Islets, pancreatic                               | (47)    | (45)    | (48)    | (44)    |
| Adenoma  |         | 1 (2%)  | 3 (6%)  |         |
| Histiocytic sarcoma                              |         |         | 1 (2%)  |         |
| Lymphoma malignant                               |         |         | 2 (4%)  | 1 (2%)  |
| Sarcoma, metastatic, skin                        |         | 1 (2%)  |         |         |
| Parathyroid gland                                | (35)    | (41)    | (41)    | (36)    |
| Lymphoma malignant                               |         |         |         | 1 (3%)  |
| Pituitary gland                                  | (40)    | (41)    | (40)    | (38)    |
| Adenoma, pars distalis                           | 6 (15%) | 6 (15%) | 5 (13%) | 1 (3%)  |
| Carcinoma, pars distalis                         | 1 (3%)  |         |         |         |
| Histiocytic sarcoma                              | 1 (3%)  |         |         |         |
| Lymphoma malignant                               | 1 (3%)  |         |         |         |
| Thyroid gland                                    | (45)    | (48)    | (45)    | (46)    |
| Adenoma, follicular cell                         | 2 (4%)  |         | 1 (2%)  | 1 (2%)  |

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm  | 10 ppm   | 30 ppm  | 90 ppm  |
|--|--------|----------|---------|---------|
| <b>General Body System</b>                                 |        |          |         |         |
| Tissue NOS   |        | (1)      |         | (2)     |
| Alveolar/bronchiolar carcinoma, metastatic, thoracic, lung |        | 1 (100%) |         |         |
| Histiocytic sarcoma, abdominal                             |        |          |         | 1 (50%) |
| <b>Genital System</b>                                      |        |          |         |         |
| Ovary  | (46)   | (47)     | (46)    | (45)    |
| Adenoma, tubular   |        |          | 1 (2%)  | 2 (4%)  |
| Cystadenoma  | 2 (4%) | 1 (2%)   | 3 (7%)  | 2 (4%)  |
| Granulosa cell tumor benign                                |        |          | 5 (11%) | 3 (7%)  |
| Granulosa cell tumor malignant                             |        |          | 1 (2%)  |         |
| Hemangioma   |        |          | 1 (2%)  |         |
| Histiocytic sarcoma  | 4 (9%) |          | 2 (4%)  | 2 (4%)  |
| Lymphoma malignant   |        | 1 (2%)   | 5 (11%) | 2 (4%)  |
| Sarcoma stromal, metastatic, uterus                        |        |          |         | 1 (2%)  |
| Sarcoma, metastatic, skin                                  |        |          |         | 1 (2%)  |
| Teratoma malignant   |        | 1 (2%)   |         |         |
| Uterus   | (48)   | (48)     | (47)    | (45)    |
| Adenoma, endometrium                                       |        | 1 (2%)   |         |         |
| Alveolar/bronchiolar carcinoma, metastatic, lung           |        |          | 1 (2%)  |         |
| Hemangioma   |        | 1 (2%)   | 2 (4%)  | 1 (2%)  |
| Hemangiosarcoma  |        | 2 (4%)   | 1 (2%)  | 1 (2%)  |
| Histiocytic sarcoma  | 3 (6%) |          | 1 (2%)  | 1 (2%)  |
| Leiomyoma  |        |          | 2 (4%)  |         |
| Lymphoma malignant   |        |          | 1 (2%)  |         |
| Polyp stromal  | 2 (4%) | 1 (2%)   |         |         |
| Sarcoma stromal  |        |          | 1 (2%)  | 2 (4%)  |
| Sarcoma, metastatic, skin                                  |        |          |         | 1 (2%)  |
| Vagina   | (48)   | (48)     | (46)    | (44)    |
| Histiocytic sarcoma  | 1 (2%) |          |         |         |
| Lymphoma malignant   |        |          | 2 (4%)  | 1 (2%)  |
| Sarcoma stromal, metastatic, uterus                        |        |          | 1 (2%)  |         |
| Sarcoma, metastatic, skin                                  |        | 1 (2%)   |         |         |
| Squamous cell carcinoma                                    |        |          | 1 (2%)  |         |
| <b>Hematopoietic System</b>                                |        |          |         |         |
| Bone marrow  | (48)   | (46)     | (48)    | (47)    |
| Histiocytic sarcoma  | 2 (4%) |          | 1 (2%)  | 1 (2%)  |
| Lymphoma malignant   |        |          | 1 (2%)  | 1 (2%)  |
| Lymph node   | (48)   | (47)     | (48)    | (47)    |
| Alveolar/bronchiolar carcinoma, metastatic, lumbar, lung   |        |          | 1 (2%)  |         |
| Histiocytic sarcoma, lumbar                                | 1 (2%) |          |         | 1 (2%)  |
| Histiocytic sarcoma, renal                                 |        |          |         | 1 (2%)  |
| Lymphoma malignant, axillary                               |        |          | 1 (2%)  |         |
| Lymphoma malignant, iliac                                  |        |          | 1 (2%)  |         |
| Lymphoma malignant, inguinal                               |        |          | 4 (8%)  |         |
| Lymphoma malignant, lumbar                                 | 1 (2%) | 1 (2%)   | 5 (10%) | 1 (2%)  |
| Lymphoma malignant, renal                                  | 1 (2%) | 1 (2%)   | 4 (8%)  | 1 (2%)  |
| Lymphoma malignant, thoracic                               |        |          | 1 (2%)  | 1 (2%)  |
| Sarcoma stromal, metastatic, renal, uterus                 |        |          | 1 (2%)  | 1 (2%)  |

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm  | 10 ppm  | 30 ppm   | 90 ppm   |
|--|--------|---------|----------|----------|
| <b>Hematopoietic System</b> (continued)          |        |         |          |          |
| Lymph node (continued)                           | (48)   | (47)    | (48)     | (47)     |
| Sarcoma, metastatic, axillary, skin              | 1 (2%) | 1 (2%)  |          |          |
| Sarcoma, metastatic, lumbar, skin                |        | 1 (2%)  |          |          |
| Sarcoma, metastatic, renal, skin                 |        | 1 (2%)  |          |          |
| Lymph node, mandibular                           | (48)   | (46)    | (45)     | (47)     |
| Histiocytic sarcoma                              | 2 (4%) |         |          |          |
| Lymphoma malignant                               | 2 (4%) | 3 (7%)  | 9 (20%)  | 2 (4%)   |
| Mast cell tumor malignant                        |        | 1 (2%)  |          | 1 (2%)   |
| Lymph node, mesenteric                           | (45)   | (42)    | (46)     | (38)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |        |         |          | 1 (3%)   |
| Histiocytic sarcoma                              | 4 (9%) |         | 3 (7%)   | 2 (5%)   |
| Lymphoma malignant                               | 4 (9%) | 5 (12%) | 10 (22%) | 4 (11%)  |
| Mast cell tumor malignant                        |        | 1 (2%)  |          |          |
| Sarcoma stromal, metastatic, uterus              |        |         | 1 (2%)   | 1 (3%)   |
| Sarcoma, metastatic, skin                        |        |         |          | 1 (3%)   |
| Spleen   | (48)   | (47)    | (48)     | (45)     |
| Hemangioma                                       |        |         | 1 (2%)   |          |
| Hemangiosarcoma                                  |        | 1 (2%)  |          | 1 (2%)   |
| Histiocytic sarcoma                              | 4 (8%) |         | 3 (6%)   | 2 (4%)   |
| Lymphoma malignant                               | 3 (6%) | 4 (9%)  | 9 (19%)  | 6 (13%)  |
| Mast cell tumor malignant                        |        | 1 (2%)  |          |          |
| Sarcoma stromal, metastatic, uterus              |        |         | 1 (2%)   |          |
| Sarcoma, metastatic, skin                        |        | 2 (4%)  |          | 1 (2%)   |
| Thymus   | (39)   | (38)    | (43)     | (39)     |
| Adenocarcinoma, metastatic, mammary gland        |        |         |          | 1 (3%)   |
| Alveolar/bronchiolar carcinoma, metastatic, lung |        |         | 1 (2%)   | 3 (8%)   |
| Histiocytic sarcoma                              | 2 (5%) |         |          | 2 (5%)   |
| Lymphoma malignant                               | 2 (5%) | 1 (3%)  | 11 (26%) | 6 (15%)  |
| Sarcoma, metastatic, skin                        |        | 1 (3%)  |          | 1 (3%)   |
| <b>Integumentary System</b>                      |        |         |          |          |
| Mammary gland                                    | (47)   | (48)    | (48)     | (45)     |
| Adenoacanthoma                                   |        |         | 1 (2%)   | 9 (20%)  |
| Adenocarcinoma                                   | 3 (6%) | 4 (8%)  | 6 (13%)  | 15 (33%) |
| Lymphoma malignant                               |        |         | 1 (2%)   | 1 (2%)   |
| Mast cell tumor malignant, lymphatic             |        |         |          | 1 (2%)   |
| Skin   | (48)   | (48)    | (48)     | (47)     |
| Lymphoma malignant                               |        |         | 1 (2%)   |          |
| Osteosarcoma                                     | 1 (2%) |         |          |          |
| Sarcoma  | 3 (6%) | 7 (15%) | 4 (8%)   | 7 (15%)  |
| <b>Musculoskeletal System</b>                    |        |         |          |          |
| Bone   | (48)   | (48)    | (48)     | (47)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung |        |         |          | 1 (2%)   |
| Lymphoma malignant, sternum                      |        |         |          | 1 (2%)   |
| Bone, femur                                      | (48)   | (48)    | (48)     | (47)     |
| Lymphoma malignant                               |        |         |          | 1 (2%)   |

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm  | 10 ppm   | 30 ppm   | 90 ppm   |
|--|--------|----------|----------|----------|
| <b>Musculoskeletal System (continued)</b>                      |        |          |          |          |
| Skeletal muscle  | (48)   | (48)     | (48)     | (47)     |
| Adenocarcinoma, metastatic, diaphragm,<br>mammary gland        |        |          |          | 1 (2%)   |
| Alveolar/bronchiolar carcinoma, metastatic,<br>diaphragm, lung |        |          |          | 1 (2%)   |
| Lymphoma malignant   |        |          | 4 (8%)   |          |
| Mast cell tumor malignant                                      |        | 1 (2%)   |          |          |
| Sarcoma  |        |          |          | 2 (4%)   |
| Sarcoma, metastatic, skin                                      |        | 1 (2%)   |          | 1 (2%)   |
| Teratoma malignant, metastatic, diaphragm, ovary               |        | 1 (2%)   |          |          |
| <b>Nervous System</b>  |        |          |          |          |
| Brain, cerebrum  | (48)   | (48)     | (48)     | (47)     |
| Carcinoma, deep invasion                                       | 1 (2%) |          |          |          |
| Lymphoma malignant   |        |          |          | 2 (4%)   |
| <b>Respiratory System</b>                                      |        |          |          |          |
| Lung   | (48)   | (48)     | (48)     | (48)     |
| Adenoacanthoma, metastatic, mammary gland                      |        |          |          | 1 (2%)   |
| Adenocarcinoma, metastatic, mammary gland                      |        | 1 (2%)   |          | 1 (2%)   |
| Alveolar/bronchiolar adenoma                                   | 4 (8%) | 8 (17%)  | 15 (31%) | 8 (17%)  |
| Alveolar/bronchiolar adenoma, multiple                         | 1 (2%) | 2 (4%)   | 3 (6%)   | 22 (46%) |
| Alveolar/bronchiolar carcinoma                                 | 1 (2%) | 5 (10%)  | 7 (15%)  | 8 (17%)  |
| Alveolar/bronchiolar carcinoma, multiple                       |        | 2 (4%)   | 2 (4%)   | 15 (31%) |
| Carcinoma, metastatic, mammary gland                           |        |          |          | 1 (2%)   |
| Granulosa cell tumor malignant, metastatic, ovary              |        |          | 1 (2%)   |          |
| Hepatocellular carcinoma, metastatic, liver                    |        |          | 1 (2%)   |          |
| Histiocytic sarcoma  | 4 (8%) |          | 3 (6%)   | 1 (2%)   |
| Leukemia   |        | 1 (2%)   |          |          |
| Lymphoma malignant   | 1 (2%) | 1 (2%)   | 5 (10%)  | 4 (8%)   |
| Osteosarcoma, metastatic, skin                                 | 1 (2%) |          |          |          |
| Sarcoma, metastatic, skin                                      | 1 (2%) | 4 (8%)   |          | 3 (6%)   |
| Sarcoma, metastatic, uncertain primary site                    |        |          |          | 1 (2%)   |
| Nose   | (47)   | (48)     | (48)     | (47)     |
| Carcinoma, metastatic, harderian gland                         |        |          |          | 1 (2%)   |
| <b>Special Senses System</b>                                   |        |          |          |          |
| Ear  |        |          | (1)      |          |
| Squamous cell papilloma  |        |          | 1 (100%) |          |
| Eye  | (48)   | (48)     | (47)     | (45)     |
| Alveolar/bronchiolar carcinoma, metastatic, lung               |        |          |          | 1 (2%)   |
| Harderian gland  | (48)   | (48)     | (46)     | (46)     |
| Adenoma  | 4 (8%) | 7 (15%)  | 6 (13%)  | 14 (30%) |
| Adenoma, bilateral   |        |          |          | 6 (13%)  |
| Carcinoma  | 1 (2%) | 10 (21%) | 6 (13%)  | 10 (22%) |
| Carcinoma, bilateral   |        | 1 (2%)   | 1 (2%)   |          |
| Histiocytic sarcoma  | 1 (2%) |          |          |          |
| Lymphoma malignant   |        |          | 3 (7%)   |          |

**TABLE F1**  
**Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|   | 0 ppm  | 10 ppm | 30 ppm  | 90 ppm |
|---|--------|--------|---------|--------|
| <b>Special Senses System</b> (continued)          |        |        |         |        |
| Lacrimal gland                                    | (45)   | (45)   | (45)    | (43)   |
| Histiocytic sarcoma                               | 1 (2%) |        |         |        |
| Lymphoma malignant                                |        |        | 3 (7%)  | 1 (2%) |
| Mast cell tumor malignant                         |        | 1 (2%) |         |        |
| Zymbal's gland                                    | (48)   | (46)   | (43)    | (40)   |
| Atrophy, minimal                                  |        |        | 1 (2%)  |        |
| Infiltration cellular, lymphocytic, minimal       |        |        |         | 1 (3%) |
| <b>Urinary System</b>                             |        |        |         |        |
| Kidney  | (48)   | (48)   | (48)    | (47)   |
| Alveolar/bronchiolar carcinoma, metastatic, lung  |        |        |         | 1 (2%) |
| Hemangiosarcoma                                   |        |        |         | 1 (2%) |
| Histiocytic sarcoma                               | 1 (2%) |        |         | 1 (2%) |
| Lymphoma malignant                                | 2 (4%) |        | 5 (10%) | 3 (6%) |
| Mast cell tumor malignant                         |        | 1 (2%) |         | 1 (2%) |
| Osteosarcoma, metastatic, skin                    | 1 (2%) |        |         |        |
| Sarcoma, metastatic, skin                         |        | 2 (4%) |         |        |
| Urinary bladder                                   | (46)   | (46)   | (47)    | (45)   |
| Histiocytic sarcoma                               | 1 (2%) |        |         |        |
| Lymphoma malignant                                | 1 (2%) |        | 4 (9%)  |        |
| <b>Neoplasm Summary</b>                           |        |        |         |        |
| Total animals with primary neoplasms <sup>b</sup> | 32     | 43     | 47      | 47     |
| Total primary neoplasms                           | 106    | 106    | 242     | 245    |
| Total animals with benign neoplasms               | 22     | 26     | 37      | 41     |
| Total benign neoplasms                            | 27     | 37     | 72      | 80     |
| Total animals with malignant neoplasms            | 17     | 35     | 37      | 46     |
| Total malignant neoplasms                         | 79     | 69     | 170     | 165    |
| Total animals with metastatic neoplasms           | 3      | 8      | 4       | 12     |
| Total metastatic neoplasms                        | 4      | 23     | 13      | 35     |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm

<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|--|----------------|-----------------|-----------------|-----------------|
| <b>Adrenal Cortex: Adenoma</b>               |                |                 |                 |                 |
| Overall rate <sup>a</sup>                    | 0/46 (0.0%)    | 0/46 (0.0%)     | 3/47 (6.4%)     | 3/46 (6.5%)     |
| Adjusted rate <sup>b</sup>                   | 0/38.9 (0.0%)  | 0/40.0 (0.0%)   | 3/39.6 (7.6%)   | 3/29.7 (10.1%)  |
| Terminal rate <sup>c</sup>                   | 0/31 (0.0%)    | 0/32 (0.0%)     | 3/27 (11.1%)    | 1/4 (25.0%)     |
| First incidence (days) <sup>d</sup>          | — <sup>e</sup> | — <sup>f</sup>  | 765 (T)         | 700             |
| Poly-3 test <sup>d</sup>                     | P=0.018        | — <sup>f</sup>  | P=0.105         | P=0.067         |
| <b>Adrenal Cortex: Adenoma or Carcinoma</b>  |                |                 |                 |                 |
| Overall rate                                 | 0/46 (0.0%)    | 1/46 (2.2%)     | 3/47 (6.4%)     | 3/46 (6.5%)     |
| Adjusted rate                                | 0/38.9 (0.0%)  | 1/40.0 (2.5%)   | 3/39.6 (7.6%)   | 3/29.7 (10.1%)  |
| Terminal rate                                | 0/31 (0.0%)    | 1/32 (3.1%)     | 3/27 (11.1%)    | 1/4 (25.0%)     |
| First incidence (days)                       | —              | 765 (T)         | 765 (T)         | 700             |
| Poly-3 test                                  | P=0.041        | P=0.486         | P=0.105         | P=0.067         |
| <b>Harderian Gland: Adenoma</b>              |                |                 |                 |                 |
| Overall rate                                 | 4/48 (8.3%)    | 7/48 (14.6%)    | 6/46 (13.0%)    | 20/46 (43.5%)   |
| Adjusted rate                                | 4/40.8 (9.8%)  | 7/42.0 (16.7%)  | 6/39.5 (15.2%)  | 20/36.5 (54.7%) |
| Terminal rate                                | 3/31 (9.7%)    | 5/32 (15.6%)    | 3/26 (11.5%)    | 2/4 (50.0%)     |
| First incidence (days)                       | 718            | 721             | 663             | 433             |
| Poly-3 test                                  | P=0.001        | P=0.226         | P=0.294         | P=0.001         |
| <b>Harderian Gland: Carcinoma</b>            |                |                 |                 |                 |
| Overall rate                                 | 1/48 (2.1%)    | 11/48 (22.9%)   | 7/46 (15.2%)    | 10/46 (21.7%)   |
| Adjusted rate                                | 1/40.6 (2.5%)  | 11/41.9 (26.2%) | 7/38.8 (18.0%)  | 10/32.7 (30.5%) |
| Terminal rate                                | 1/31 (3.2%)    | 10/32 (31.3%)   | 7/26 (26.9%)    | 0/4 (0.0%)      |
| First incidence (days)                       | 765 (T)        | 738             | 765 (T)         | 559             |
| Poly-3 test                                  | P=0.011        | P=0.001         | P=0.017         | P=0.001         |
| <b>Harderian Gland: Adenoma or Carcinoma</b> |                |                 |                 |                 |
| Overall rate                                 | 5/48 (10.4%)   | 18/48 (37.5%)   | 13/46 (28.3%)   | 29/46 (63.0%)   |
| Adjusted rate                                | 5/40.8 (12.3%) | 18/42.1 (42.7%) | 13/39.5 (32.9%) | 29/39.7 (73.0%) |
| Terminal rate                                | 4/31 (12.9%)   | 15/32 (46.9%)   | 10/26 (38.5%)   | 2/4 (50.0%)     |
| First incidence (days)                       | 718            | 721             | 663             | 433             |
| Poly-3 test                                  | P=0.001        | P=0.001         | P=0.013         | P=0.001         |
| <b>Heart: Hemangiosarcoma</b>                |                |                 |                 |                 |
| Overall rate                                 | 0/47 (0.0%)    | 0/48 (0.0%)     | 0/48 (0.0%)     | 6/47 (12.8%)    |
| Adjusted rate                                | 0/39.8 (0.0%)  | 0/41.8 (0.0%)   | 0/40.6 (0.0%)   | 6/31.5 (19.1%)  |
| Terminal rate                                | 0/31 (0.0%)    | 0/32 (0.0%)     | 0/27 (0.0%)     | 1/4 (25.0%)     |
| First incidence (days)                       | —              | —               | —               | 603             |
| Poly-3 test                                  | P=0.001        | —               | —               | P=0.004         |
| <b>Liver: Hemangiosarcoma</b>                |                |                 |                 |                 |
| Overall rate                                 | 0/48 (0.0%)    | 0/47 (0.0%)     | 0/48 (0.0%)     | 6/48 (12.5%)    |
| Adjusted rate                                | 0/40.6 (0.0%)  | 0/41.1 (0.0%)   | 0/40.6 (0.0%)   | 6/32.1 (18.7%)  |
| Terminal rate                                | 0/31 (0.0%)    | 0/32 (0.0%)     | 0/27 (0.0%)     | 0/4 (0.0%)      |
| First incidence (days)                       | —              | —               | —               | 485             |
| Poly-3 test                                  | P=0.001        | —               | —               | P=0.004         |
| <b>Liver: Histiocytic Sarcoma</b>            |                |                 |                 |                 |
| Overall rate                                 | 4/48 (8.3%)    | 0/47 (0.0%)     | 3/48 (6.3%)     | 2/48 (4.2%)     |
| Adjusted rate                                | 4/41.7 (9.6%)  | 0/41.1 (0.0%)   | 3/41.0 (7.3%)   | 2/31.1 (6.4%)   |
| Terminal rate                                | 0/31 (0.0%)    | 0/32 (0.0%)     | 0/27 (0.0%)     | 0/4 (0.0%)      |
| First incidence (days)                       | 515            | —               | 687             | 674             |
| Poly-3 test                                  | P=0.548        | P=0.074N        | P=0.558N        | P=0.523N        |

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm          | 30 ppm          | 90 ppm          |
|--|----------------|-----------------|-----------------|-----------------|
| <b>Liver: Hepatocellular Adenoma</b>                   |                |                 |                 |                 |
| Overall rate   | 3/48 (6.3%)    | 6/47 (12.8%)    | 16/48 (33.3%)   | 16/48 (33.3%)   |
| Adjusted rate  | 3/40.6 (7.4%)  | 6/41.2 (14.6%)  | 16/41.1 (38.9%) | 16/35.5 (45.0%) |
| Terminal rate  | 3/31 (9.7%)    | 4/32 (12.5%)    | 12/27 (44.4%)   | 3/4 (75.0%)     |
| First incidence (days)                                 | 765 (T)        | 738             | 685             | 559             |
| Poly-3 test  | P=0.001        | P=0.205         | P=0.001         | P=0.001         |
| <b>Liver: Hepatocellular Adenoma or Carcinoma</b>      |                |                 |                 |                 |
| Overall rate   | 3/48 (6.3%)    | 7/47 (14.9%)    | 16/48 (33.3%)   | 17/48 (35.4%)   |
| Adjusted rate  | 3/40.6 (7.4%)  | 7/41.2 (17.0%)  | 16/41.1 (38.9%) | 17/35.7 (47.6%) |
| Terminal rate  | 3/31 (9.7%)    | 5/32 (15.6%)    | 12/27 (44.4%)   | 3/4 (75.0%)     |
| First incidence (days)                                 | 765 (T)        | 738             | 685             | 559             |
| Poly-3 test  | P=0.001        | P=0.127         | P=0.001         | P=0.001         |
| <b>Lung: Histiocytic Sarcoma</b>                       |                |                 |                 |                 |
| Overall rate   | 4/48 (8.3%)    | 0/48 (0.0%)     | 3/48 (6.3%)     | 1/48 (2.1%)     |
| Adjusted rate  | 4/41.7 (9.6%)  | 0/41.8 (0.0%)   | 3/41.0 (7.3%)   | 1/31.0 (3.2%)   |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)     | 0/27 (0.0%)     | 0/4 (0.0%)      |
| First incidence (days)                                 | 515            | —               | 687             | 674             |
| Poly-3 test  | P=0.422N       | P=0.072N        | P=0.558N        | P=0.317N        |
| <b>Lung: Alveolar/bronchiolar Adenoma</b>              |                |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)   | 10/48 (20.8%)   | 18/48 (37.5%)   | 30/48 (62.5%)   |
| Adjusted rate  | 5/40.6 (12.3%) | 10/42.1 (23.8%) | 18/42.2 (42.7%) | 30/38.9 (77.1%) |
| Terminal rate  | 5/31 (16.1%)   | 7/32 (21.9%)    | 14/27 (51.9%)   | 4/4 (100.0%)    |
| First incidence (days)                                 | 765 (T)        | 721             | 380             | 433             |
| Poly-3 test  | P=0.001        | P=0.103         | P=0.001         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Carcinoma</b>            |                |                 |                 |                 |
| Overall rate   | 1/48 (2.1%)    | 7/48 (14.6%)    | 9/48 (18.8%)    | 23/48 (47.9%)   |
| Adjusted rate  | 1/40.6 (2.5%)  | 7/42.1 (16.6%)  | 9/40.9 (22.0%)  | 23/37.7 (61.1%) |
| Terminal rate  | 1/31 (3.2%)    | 5/32 (15.6%)    | 8/27 (29.6%)    | 3/4 (75.0%)     |
| First incidence (days)                                 | 765 (T)        | 703             | 670             | 485             |
| Poly-3 test  | P=0.001        | P=0.024         | P=0.005         | P=0.001         |
| <b>Lung: Alveolar/bronchiolar Adenoma or Carcinoma</b> |                |                 |                 |                 |
| Overall rate   | 5/48 (10.4%)   | 17/48 (35.4%)   | 24/48 (50.0%)   | 37/48 (77.1%)   |
| Adjusted rate  | 5/40.6 (12.3%) | 17/42.3 (40.2%) | 24/42.5 (56.5%) | 37/41.8 (88.5%) |
| Terminal rate  | 5/31 (16.1%)   | 12/32 (37.5%)   | 19/27 (70.4%)   | 4/4 (100.0%)    |
| First incidence (days)                                 | 765 (T)        | 703             | 380             | 433             |
| Poly-3 test  | P=0.001        | P=0.001         | P=0.001         | P=0.001         |
| <b>Lymph Node (Mesenteric): Histiocytic Sarcoma</b>    |                |                 |                 |                 |
| Overall rate   | 4/45 (8.9%)    | 0/42 (0.0%)     | 3/46 (6.5%)     | 2/38 (5.3%)     |
| Adjusted rate  | 4/38.8 (10.3%) | 0/37.3 (0.0%)   | 3/39.6 (7.6%)   | 2/25.2 (7.9%)   |
| Terminal rate  | 0/29 (0.0%)    | 0/31 (0.0%)     | 0/26 (0.0%)     | 0/4 (0.0%)      |
| First incidence (days)                                 | 515            | —               | 687             | 674             |
| Poly-3 test  | P=0.496        | P=0.078N        | P=0.541N        | P=0.591N        |
| <b>Mammary Gland: Adenoacanthoma</b>                   |                |                 |                 |                 |
| Overall rate   | 0/47 (0.0%)    | 0/48 (0.0%)     | 1/48 (2.1%)     | 9/45 (20.0%)    |
| Adjusted rate  | 0/40.2 (0.0%)  | 0/41.8 (0.0%)   | 1/40.6 (2.5%)   | 9/32.0 (28.1%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)     | 1/27 (3.7%)     | 2/4 (50.0%)     |
| First incidence (days)                                 | —              | —               | 765 (T)         | 459             |
| Poly-3 test  | P=0.001        | —               | P=0.483         | P=0.001         |

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm        | 30 ppm         | 90 ppm          |
|--|----------------|---------------|----------------|-----------------|
| <b>Mammary Gland: Adenocarcinoma</b>                   |                |               |                |                 |
| Overall rate   | 3/47 (6.4%)    | 4/48 (8.3%)   | 6/48 (12.5%)   | 15/45 (33.3%)   |
| Adjusted rate  | 3/40.2 (7.5%)  | 4/42.2 (9.5%) | 6/41.7 (14.4%) | 15/33.8 (44.3%) |
| Terminal rate  | 2/31 (6.5%)    | 3/32 (9.4%)   | 2/27 (7.4%)    | 1/4 (25.0%)     |
| First incidence (days)                                 | 754            | 644           | 642            | 559             |
| Poly-3 test  | P=0.001        | P=0.476       | P=0.214        | P=0.001         |
| <b>Mammary Gland: Adenoacanthoma or Adenocarcinoma</b> |                |               |                |                 |
| Overall rate   | 3/47 (6.4%)    | 4/48 (8.3%)   | 7/48 (14.6%)   | 23/45 (51.1%)   |
| Adjusted rate  | 3/40.2 (7.5%)  | 4/42.2 (9.5%) | 7/41.7 (16.8%) | 23/36.9 (62.4%) |
| Terminal rate  | 2/31 (6.5%)    | 3/32 (9.4%)   | 3/27 (11.1%)   | 2/4 (50.0%)     |
| First incidence (days)                                 | 754            | 644           | 642            | 459             |
| Poly-3 test  | P=0.001        | P=0.476       | P=0.134        | P=0.001         |
| <b>Ovary: Histiocytic Sarcoma</b>                      |                |               |                |                 |
| Overall rate   | 4/46 (8.7%)    | 0/47 (0.0%)   | 2/46 (4.3%)    | 2/45 (4.4%)     |
| Adjusted rate  | 4/39.9 (10.0%) | 0/41.1 (0.0%) | 2/38.9 (5.1%)  | 2/29.3 (6.8%)   |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)   | 0/26 (0.0%)    | 0/4 (0.0%)      |
| First incidence (days)                                 | 515            | —             | 745            | 674             |
| Poly-3 test  | P=0.567        | P=0.068N      | P=0.393N       | P=0.532N        |
| <b>Ovary: Cystadenoma</b>                              |                |               |                |                 |
| Overall rate   | 2/46 (4.3%)    | 1/47 (2.1%)   | 3/46 (6.5%)    | 2/45 (4.4%)     |
| Adjusted rate  | 2/38.8 (5.2%)  | 1/41.1 (2.4%) | 3/38.8 (7.7%)  | 2/29.5 (6.8%)   |
| Terminal rate  | 2/31 (6.5%)    | 1/32 (3.1%)   | 3/26 (11.5%)   | 0/4 (0.0%)      |
| First incidence (days)                                 | 765 (T)        | 765 (T)       | 765 (T)        | 661             |
| Poly-3 test  | P=0.359        | P=0.513N      | P=0.456        | P=0.553         |
| <b>Ovary: Benign Granulosa Cell Tumor</b>              |                |               |                |                 |
| Overall rate   | 0/46 (0.0%)    | 0/47 (0.0%)   | 5/46 (10.9%)   | 3/45 (6.7%)     |
| Adjusted rate  | 0/38.8 (0.0%)  | 0/41.1 (0.0%) | 5/39.3 (12.7%) | 3/28.9 (10.4%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)   | 3/26 (11.5%)   | 3/4 (75.0%)     |
| First incidence (days)                                 | —              | —             | 685            | 765 (T)         |
| Poly-3 test  | P=0.021        | —             | P=0.023        | P=0.064         |
| <b>Ovary: Benign or Malignant Granulosa Cell Tumor</b> |                |               |                |                 |
| Overall rate   | 0/46 (0.0%)    | 0/47 (0.0%)   | 6/46 (13.0%)   | 3/45 (6.7%)     |
| Adjusted rate  | 0/38.8 (0.0%)  | 0/41.1 (0.0%) | 6/39.5 (15.2%) | 3/28.9 (10.4%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)   | 3/26 (11.5%)   | 3/4 (75.0%)     |
| First incidence (days)                                 | —              | —             | 685            | 765 (T)         |
| Poly-3 test  | P=0.022        | —             | P=0.011        | P=0.064         |
| <b>Pancreas: Histiocytic Sarcoma</b>                   |                |               |                |                 |
| Overall rate   | 3/47 (6.4%)    | 0/45 (0.0%)   | 1/48 (2.1%)    | 1/44 (2.3%)     |
| Adjusted rate  | 3/40.1 (7.5%)  | 0/39.8 (0.0%) | 1/40.6 (2.5%)  | 1/28.5 (3.5%)   |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)   | 0/27 (0.0%)    | 0/4 (0.0%)      |
| First incidence (days)                                 | 706            | —             | 746            | 762             |
| Poly-3 test  | P=0.508N       | P=0.138N      | P=0.334N       | P=0.471N        |
| <b>Pancreatic Islets: Adenoma</b>                      |                |               |                |                 |
| Overall rate   | 0/47 (0.0%)    | 1/45 (2.2%)   | 3/48 (6.3%)    | 0/44 (0.0%)     |
| Adjusted rate  | 0/39.7 (0.0%)  | 1/40.1 (2.5%) | 3/40.6 (7.4%)  | 0/28.5 (0.0%)   |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)   | 2/27 (7.4%)    | 0/4 (0.0%)      |
| First incidence (days)                                 | —              | 662           | 745            | —               |
| Poly-3 test  | P=0.619        | P=0.483       | P=0.106        | —               |

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm          | 10 ppm         | 30 ppm         | 90 ppm         |
|--|----------------|----------------|----------------|----------------|
| <b>Pituitary Gland (Pars Distalis): Adenoma or Carcinoma</b> |                |                |                |                |
| Overall rate   | 7/40 (17.5%)   | 6/41 (14.6%)   | 5/40 (12.5%)   | 1/38 (2.6%)    |
| Adjusted rate  | 7/33.8 (20.7%) | 6/35.5 (16.9%) | 5/34.4 (14.5%) | 1/25.1 (4.0%)  |
| Terminal rate  | 6/25 (24.0%)   | 6/27 (22.2%)   | 5/25 (20.0%)   | 0/4 (0.0%)     |
| First incidence (days)                                       | 718            | 765 (T)        | 765 (T)        | 726            |
| Poly-3 test  | P=0.076N       | P=0.527N       | P=0.424N       | P=0.092N       |
| <b>Skin: Sarcoma</b>   |                |                |                |                |
| Overall rate   | 3/48 (6.3%)    | 7/48 (14.6%)   | 4/48 (8.3%)    | 7/47 (14.9%)   |
| Adjusted rate  | 3/41.4 (7.2%)  | 7/42.2 (16.6%) | 4/41.1 (9.7%)  | 7/32.2 (21.7%) |
| Terminal rate  | 0/31 (0.0%)    | 3/32 (9.4%)    | 2/27 (7.4%)    | 0/4 (0.0%)     |
| First incidence (days)                                       | 571            | 721            | 685            | 573            |
| Poly-3 test  | P=0.090        | P=0.129        | P=0.446        | P=0.055        |
| <b>Spleen: Histiocytic Sarcoma</b>                           |                |                |                |                |
| Overall rate   | 4/48 (8.3%)    | 0/47 (0.0%)    | 3/48 (6.3%)    | 2/45 (4.4%)    |
| Adjusted rate  | 4/41.7 (9.6%)  | 0/41.1 (0.0%)  | 3/41.0 (7.3%)  | 2/29.3 (6.8%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)    | 0/27 (0.0%)    | 0/4 (0.0%)     |
| First incidence (days)                                       | 515            | —              | 687            | 674            |
| Poly-3 test  | P=0.524        | P=0.074N       | P=0.558N       | P=0.551N       |
| <b>Stomach (Forestomach): Squamous Cell Papilloma</b>        |                |                |                |                |
| Overall rate   | 2/48 (4.2%)    | 3/47 (6.4%)    | 2/48 (4.2%)    | 0/45 (0.0%)    |
| Adjusted rate  | 2/40.7 (4.9%)  | 3/41.1 (7.3%)  | 2/40.8 (4.9%)  | 0/28.8 (0.0%)  |
| Terminal rate  | 1/31 (3.2%)    | 3/32 (9.4%)    | 1/27 (3.7%)    | 0/4 (0.0%)     |
| First incidence (days)                                       | 737            | 765 (T)        | 702            | —              |
| Poly-3 test  | P=0.219N       | P=0.463        | P=0.661N       | P=0.344N       |
| <b>Thymus: Histiocytic Sarcoma</b>                           |                |                |                |                |
| Overall rate   | 2/39 (5.1%)    | 0/38 (0.0%)    | 0/43 (0.0%)    | 2/39 (5.1%)    |
| Adjusted rate  | 2/33.1 (6.0%)  | 0/32.1 (0.0%)  | 0/36.1 (0.0%)  | 2/24.3 (8.2%)  |
| Terminal rate  | 0/24 (0.0%)    | 0/24 (0.0%)    | 0/24 (0.0%)    | 0/2 (0.0%)     |
| First incidence (days)                                       | 515            | —              | —              | 674            |
| Poly-3 test  | P=0.337        | P=0.270N       | P=0.243N       | P=0.534        |
| <b>Uterus: Histiocytic Sarcoma</b>                           |                |                |                |                |
| Overall rate   | 3/48 (6.3%)    | 0/48 (0.0%)    | 1/47 (2.1%)    | 1/45 (2.2%)    |
| Adjusted rate  | 3/41.5 (7.2%)  | 0/41.8 (0.0%)  | 1/39.6 (2.5%)  | 1/29.0 (3.5%)  |
| Terminal rate  | 0/31 (0.0%)    | 0/32 (0.0%)    | 0/26 (0.0%)    | 0/4 (0.0%)     |
| First incidence (days)                                       | 515            | —              | 746            | 762            |
| Poly-3 test  | P=0.512N       | P=0.134N       | P=0.355N       | P=0.477N       |
| <b>Uterus: Hemangioma or Hemangiosarcoma</b>                 |                |                |                |                |
| Overall rate   | 0/48 (0.0%)    | 3/48 (6.3%)    | 3/47 (6.4%)    | 2/45 (4.4%)    |
| Adjusted rate  | 0/40.6 (0.0%)  | 3/41.9 (7.2%)  | 3/40.0 (7.5%)  | 2/29.1 (6.9%)  |
| Terminal rate  | 0/31 (0.0%)    | 2/32 (6.3%)    | 1/26 (3.8%)    | 0/4 (0.0%)     |
| First incidence (days)                                       | —              | 754            | 675            | 749            |
| Poly-3 test  | P=0.238        | P=0.108        | P=0.100        | P=0.156        |

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Hemangioma</b>                    |                 |                 |                 |                 |
| Overall rate                                     | 0/48 (0.0%)     | 1/48 (2.1%)     | 6/48 (12.5%)    | 2/48 (4.2%)     |
| Adjusted rate                                    | 0/40.6 (0.0%)   | 1/41.8 (2.4%)   | 6/41.0 (14.6%)  | 2/31.2 (6.4%)   |
| Terminal rate                                    | 0/31 (0.0%)     | 1/32 (3.1%)     | 4/27 (14.8%)    | 0/4 (0.0%)      |
| First incidence (days)                           | —               | 765 (T)         | 675             | 643             |
| Poly-3 test                                      | P=0.123         | P=0.488         | P=0.011         | P=0.168         |
| <b>All Organs: Hemangiosarcoma</b>               |                 |                 |                 |                 |
| Overall rate                                     | 0/48 (0.0%)     | 3/48 (6.3%)     | 1/48 (2.1%)     | 13/48 (27.1%)   |
| Adjusted rate                                    | 0/40.6 (0.0%)   | 3/41.9 (7.2%)   | 1/40.6 (2.5%)   | 13/33.8 (38.5%) |
| Terminal rate                                    | 0/31 (0.0%)     | 2/32 (6.3%)     | 1/27 (3.7%)     | 2/4 (50.0%)     |
| First incidence (days)                           | —               | 754             | 765 (T)         | 485             |
| Poly-3 test                                      | P=0.001         | P=0.108         | P=0.481         | P=0.001         |
| <b>All Organs: Hemangioma or Hemangiosarcoma</b> |                 |                 |                 |                 |
| Overall rate                                     | 0/48 (0.0%)     | 4/48 (8.3%)     | 7/48 (14.6%)    | 14/48 (29.2%)   |
| Adjusted rate                                    | 0/40.6 (0.0%)   | 4/41.9 (9.6%)   | 7/41.0 (17.1%)  | 14/34.2 (40.9%) |
| Terminal rate                                    | 0/31 (0.0%)     | 3/32 (9.4%)     | 5/27 (18.5%)    | 2/4 (50.0%)     |
| First incidence (days)                           | —               | 754             | 675             | 485             |
| Poly-3 test                                      | P=0.001         | P=0.052         | P=0.005         | P=0.001         |
| <b>All Organs: Histiocytic Sarcoma</b>           |                 |                 |                 |                 |
| Overall rate                                     | 4/48 (8.3%)     | 0/48 (0.0%)     | 3/48 (6.3%)     | 2/48 (4.2%)     |
| Adjusted rate                                    | 4/41.7 (9.6%)   | 0/41.8 (0.0%)   | 3/41.0 (7.3%)   | 2/31.1 (6.4%)   |
| Terminal rate                                    | 0/31 (0.0%)     | 0/32 (0.0%)     | 0/27 (0.0%)     | 0/4 (0.0%)      |
| First incidence (days)                           | 515             | —               | 687             | 674             |
| Poly-3 test                                      | P=0.546         | P=0.072N        | P=0.558N        | P=0.523N        |
| <b>All Organs: Malignant Lymphoma</b>            |                 |                 |                 |                 |
| Overall rate                                     | 5/48 (10.4%)    | 6/48 (12.5%)    | 15/48 (31.3%)   | 10/48 (20.8%)   |
| Adjusted rate                                    | 5/40.8 (12.2%)  | 6/42.8 (14.0%)  | 15/43.8 (34.3%) | 10/35.2 (28.4%) |
| Terminal rate                                    | 3/31 (9.7%)     | 4/32 (12.5%)    | 6/27 (22.2%)    | 1/4 (25.0%)     |
| First incidence (days)                           | 718             | 553             | 285             | 433             |
| Poly-3 test                                      | P=0.028         | P=0.468         | P=0.008         | P=0.046         |
| <b>All Organs: Benign Neoplasms</b>              |                 |                 |                 |                 |
| Overall rate                                     | 22/48 (45.8%)   | 26/48 (54.2%)   | 37/48 (77.1%)   | 41/48 (85.4%)   |
| Adjusted rate                                    | 22/41.1 (53.5%) | 26/42.6 (61.1%) | 37/44.0 (84.2%) | 41/44.0 (93.2%) |
| Terminal rate                                    | 18/31 (58.1%)   | 20/32 (62.5%)   | 25/27 (92.6%)   | 4/4 (100.0%)    |
| First incidence (days)                           | 718             | 662             | 380             | 433             |
| Poly-3 test                                      | P=0.001         | P=0.171         | P=0.001         | P=0.001         |
| <b>All Organs: Malignant Neoplasms</b>           |                 |                 |                 |                 |
| Overall rate                                     | 17/48 (35.4%)   | 35/48 (72.9%)   | 37/48 (77.1%)   | 46/48 (95.8%)   |
| Adjusted rate                                    | 17/43.1 (39.5%) | 35/44.8 (78.2%) | 37/46.2 (80.1%) | 46/47.0 (97.8%) |
| Terminal rate                                    | 8/31 (25.8%)    | 24/32 (75.0%)   | 20/27 (74.1%)   | 3/4 (75.0%)     |
| First incidence (days)                           | 515             | 531             | 285             | 433             |
| Poly-3 test                                      | P=0.001         | P=0.001         | P=0.001         | P=0.001         |

**TABLE F2**  
**Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm           | 10 ppm          | 30 ppm          | 90 ppm          |
|--|-----------------|-----------------|-----------------|-----------------|
| <b>All Organs: Benign or Malignant Neoplasms</b> |                 |                 |                 |                 |
| Overall rate                                     | 32/48 (66.7%)   | 43/48 (89.6%)   | 47/48 (97.9%)   | 47/48 (97.9%)   |
| Adjusted rate                                    | 32/43.3 (73.8%) | 43/45.1 (95.2%) | 47/47.5 (98.9%) | 47/47.0 (99.9%) |
| Terminal rate                                    | 21/31 (67.7%)   | 30/32 (93.8%)   | 27/27 (100.0%)  | 4/4 (100.0%)    |
| First incidence (days)                           | 515             | 531             | 285             | 433             |
| Poly-3 test                                      | P=0.001         | P=0.001         | P=0.001         | P=0.001         |

(T) Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals with tissue examined microscopically

<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for the differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposed group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>f</sup> Value of statistic cannot be computed.

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol<sup>a</sup>**

|   | 0 ppm  | 10 ppm   | 30 ppm   | 90 ppm   |
|---|--------|----------|----------|----------|
| <b>Disposition Summary</b>                  |        |          |          |          |
| Animals initially in study                  | 48     | 48       | 48       | 48       |
| Early deaths                                |        |          |          |          |
| Accidental deaths                           | 4      |          |          |          |
| Moribund                                    | 6      | 4        | 4        | 11       |
| Natural deaths                              | 7      | 12       | 17       | 33       |
| Survivors                                   |        |          |          |          |
| Terminal sacrifice                          | 31     | 32       | 27       | 4        |
| Animals examined microscopically            | 48     | 48       | 48       | 48       |
| <b>Alimentary System</b>                    |        |          |          |          |
| Esophagus                                   | (47)   | (48)     | (47)     | (46)     |
| Autolysis, moderate                         |        | 1 (2%)   |          |          |
| Gallbladder                                 | (47)   | (44)     | (47)     | (45)     |
| Autolysis, marked                           |        |          |          | 1 (2%)   |
| Autolysis, mild                             |        |          | 1 (2%)   |          |
| Autolysis, moderate                         | 2 (4%) | 1 (2%)   | 1 (2%)   | 3 (7%)   |
| Infiltration cellular, lymphocytic, minimal | 1 (2%) | 1 (2%)   |          |          |
| Intestine large                             | (48)   | (47)     | (48)     | (44)     |
| Inflammation, mild                          | 1 (2%) |          |          |          |
| Intestine large, cecum                      | (47)   | (44)     | (48)     | (42)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 2 (4%) | 1 (2%)   | 5 (10%)  | 4 (10%)  |
| Intestine large, colon                      | (47)   | (45)     | (48)     | (42)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 2 (4%) | 1 (2%)   | 4 (8%)   | 4 (10%)  |
| Intestine large, rectum                     | (48)   | (47)     | (46)     | (44)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 2 (4%) | 2 (4%)   | 3 (7%)   | 3 (7%)   |
| Inflammation, mild                          |        |          | 1 (2%)   |          |
| Polyarteritis, moderate                     |        | 1 (2%)   |          |          |
| Intestine small, duodenum                   | (47)   | (44)     | (46)     | (40)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 4 (9%) | 1 (2%)   | 6 (13%)  | 5 (13%)  |
| Intestine small, ileum                      | (47)   | (44)     | (47)     | (40)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 4 (9%) | 1 (2%)   | 6 (13%)  | 6 (15%)  |
| Hyperplasia, mild, lymphoid tissue          |        |          | 1 (2%)   |          |
| Hyperplasia, moderate, lymphoid tissue      |        |          | 1 (2%)   |          |
| Intussusception                             |        | 1 (2%)   |          |          |
| Intestine small, jejunum                    | (47)   | (44)     | (47)     | (40)     |
| Autolysis, marked                           | 1 (2%) | 1 (2%)   |          |          |
| Autolysis, moderate                         | 4 (9%) | 1 (2%)   | 6 (13%)  | 6 (15%)  |
| Hyperplasia, mild, lymphoid tissue          |        |          | 1 (2%)   | 1 (3%)   |
| Hyperplasia, moderate, lymphoid tissue      |        | 2 (5%)   |          |          |
| Liver                                       | (48)   | (47)     | (48)     | (48)     |
| Angiectasis                                 | 2 (4%) | 1 (2%)   | 5 (10%)  | 22 (46%) |
| Autolysis, marked                           |        | 1 (2%)   |          |          |
| Autolysis, moderate                         | 1 (2%) |          | 2 (4%)   | 1 (2%)   |
| Basophilic focus                            | 1 (2%) |          |          |          |
| Eosinophilic focus                          | 2 (4%) | 12 (26%) | 4 (8%)   | 1 (2%)   |
| Eosinophilic focus, multiple                |        | 14 (30%) | 21 (44%) | 20 (42%) |

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System</b> (continued)                    |          |          |          |          |
| Liver (continued)                                       | (48)     | (47)     | (48)     | (48)     |
| Granuloma, focal, minimal                               | 2 (4%)   | 1 (2%)   |          |          |
| Hematopoietic cell proliferation, marked                |          |          | 1 (2%)   | 3 (6%)   |
| Hematopoietic cell proliferation, mild                  | 2 (4%)   | 6 (13%)  | 11 (23%) | 14 (29%) |
| Hematopoietic cell proliferation, minimal               |          | 3 (6%)   | 3 (6%)   |          |
| Hematopoietic cell proliferation, moderate              | 1 (2%)   | 2 (4%)   | 3 (6%)   | 10 (21%) |
| Hepatodiaphragmatic nodule                              | 1 (2%)   |          |          |          |
| Hyperplasia, moderate, Kupffer cell                     |          | 1 (2%)   |          |          |
| Infarct, caudate lobe                                   |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild                | 3 (6%)   | 3 (6%)   | 3 (6%)   | 2 (4%)   |
| Infiltration cellular, lymphocytic, minimal             | 10 (21%) | 5 (11%)  | 1 (2%)   | 2 (4%)   |
| Infiltration cellular, lymphocytic, moderate            | 1 (2%)   |          |          |          |
| Inflammation, chronic active, mild                      |          |          |          | 1 (2%)   |
| Inflammation, chronic, mild                             |          | 1 (2%)   |          |          |
| Inflammation, mild                                      |          |          | 1 (2%)   |          |
| Leukocytosis, moderate                                  |          |          |          | 1 (2%)   |
| Mixed cell focus  | 1 (2%)   | 1 (2%)   |          |          |
| Mixed cell focus, multiple                              |          | 4 (9%)   | 9 (19%)  | 2 (4%)   |
| Necrosis, marked  |          |          |          | 1 (2%)   |
| Necrosis, mild  |          |          | 2 (4%)   | 7 (15%)  |
| Necrosis, mild, centrilobular                           |          | 1 (2%)   |          | 1 (2%)   |
| Necrosis, minimal                                       |          | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Necrosis, moderate                                      |          |          |          | 5 (10%)  |
| Necrosis, moderate, centrilobular                       |          |          |          | 1 (2%)   |
| Pigmentation, mild                                      | 1 (2%)   |          |          |          |
| Pigmentation, moderate, centrilobular                   |          |          | 1 (2%)   |          |
| Regeneration  |          |          |          | 3 (6%)   |
| Thrombosis  |          |          | 1 (2%)   | 8 (17%)  |
| Vacuolization cytoplasmic, mild, hepatocyte             |          | 5 (11%)  | 5 (10%)  | 2 (4%)   |
| Vacuolization cytoplasmic, mild, hepatocyte, acanthosis |          | 1 (2%)   |          |          |
| Vacuolization cytoplasmic, minimal, hepatocyte          |          | 1 (2%)   | 1 (2%)   |          |
| Vacuolization cytoplasmic, moderate, hepatocyte         |          |          | 4 (8%)   | 1 (2%)   |
| Mesentery   | (3)      | (3)      | (5)      | (4)      |
| Fibrosis, mild  | 1 (33%)  |          |          |          |
| Necrosis, fat   | 2 (67%)  | 3 (100%) | 5 (100%) | 3 (75%)  |
| Pancreas  | (47)     | (45)     | (48)     | (44)     |
| Atrophy, marked, acinar cell                            |          |          | 1 (2%)   |          |
| Atrophy, minimal, acinar cell                           | 1 (2%)   |          |          | 1 (2%)   |
| Autolysis, moderate                                     | 2 (4%)   | 1 (2%)   | 1 (2%)   | 3 (7%)   |
| Infiltration cellular, lymphocytic, mild                | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal             | 10 (21%) | 8 (18%)  | 6 (13%)  | 4 (9%)   |
| Infiltration cellular, lymphocytic, moderate            |          |          |          | 1 (2%)   |
| Salivary glands   | (48)     | (47)     | (48)     | (47)     |
| Hypertrophy, minimal, parenchymal cell                  |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild                | 15 (31%) | 12 (26%) | 12 (25%) | 10 (21%) |
| Infiltration cellular, lymphocytic, minimal             | 18 (38%) | 26 (55%) | 25 (52%) | 29 (62%) |
| Infiltration cellular, lymphocytic, moderate            |          | 1 (2%)   |          |          |
| Stomach, forestomach                                    | (48)     | (47)     | (48)     | (45)     |
| Autolysis, marked                                       | 1 (2%)   | 1 (2%)   |          |          |
| Autolysis, moderate                                     | 1 (2%)   | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Foreign body  |          | 1 (2%)   | 2 (4%)   |          |
| Hyperkeratosis, mild                                    |          | 1 (2%)   | 2 (4%)   | 5 (11%)  |
| Hyperplasia, marked, epithelium                         | 1 (2%)   | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Hyperplasia, mild, epithelium                           | 1 (2%)   |          | 3 (6%)   | 4 (9%)   |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Alimentary System</b> (continued)        |          |          |          |          |
| Stomach, forestomach (continued)            | (48)     | (47)     | (48)     | (45)     |
| Hyperplasia, minimal, epithelium            | 1 (2%)   |          | 2 (4%)   | 2 (4%)   |
| Hyperplasia, moderate, epithelium           | 1 (2%)   | 1 (2%)   | 4 (8%)   |          |
| Inflammation, mild                          | 2 (4%)   | 1 (2%)   |          |          |
| Inflammation, minimal                       |          | 1 (2%)   |          |          |
| Ulcer, mild                                 |          |          |          | 1 (2%)   |
| Ulcer, moderate                             |          |          | 1 (2%)   |          |
| Stomach, glandular                          | (48)     | (46)     | (48)     | (45)     |
| Autolysis, marked                           | 1 (2%)   | 1 (2%)   |          |          |
| Autolysis, moderate                         | 1 (2%)   | 1 (2%)   | 1 (2%)   | 2 (4%)   |
| Cyst  |          |          | 1 (2%)   |          |
| Metaplasia, squamous, mild                  |          |          |          | 1 (2%)   |
| Mineralization, mild                        |          |          |          | 1 (2%)   |
| Mineralization, minimal                     | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |
| <b>Cardiovascular System</b>                |          |          |          |          |
| Blood vessel                                | (47)     | (48)     | (46)     | (45)     |
| Inflammation, minimal                       |          |          |          | 1 (2%)   |
| Mineralization, moderate                    | 1 (2%)   |          |          |          |
| Heart                                       | (47)     | (48)     | (48)     | (47)     |
| Angiectasis, mild                           |          |          | 2 (4%)   | 3 (6%)   |
| Angiectasis, minimal                        |          |          | 1 (2%)   | 1 (2%)   |
| Cardiomyopathy, mild                        |          |          | 4 (8%)   | 2 (4%)   |
| Cardiomyopathy, minimal                     |          |          | 2 (4%)   |          |
| Embolus tumor                               |          |          | 1 (2%)   |          |
| Hyperplasia, mild, endothelium              |          |          | 1 (2%)   | 7 (15%)  |
| Hyperplasia, minimal, endothelium           |          |          | 2 (4%)   | 5 (11%)  |
| Hyperplasia, moderate, endothelium          |          | 1 (2%)   |          | 2 (4%)   |
| Inflammation, chronic, mild, epicardium     |          |          | 1 (2%)   |          |
| Inflammation, chronic, minimal, epicardium  |          |          |          | 2 (4%)   |
| Inflammation, minimal, myocardium           |          |          | 1 (2%)   |          |
| Mineralization, mild                        |          |          | 2 (4%)   | 1 (2%)   |
| Mineralization, minimal                     | 2 (4%)   | 1 (2%)   |          | 1 (2%)   |
| Thrombosis, mild, myocardium                |          |          | 1 (2%)   | 1 (2%)   |
| <b>Endocrine System</b>                     |          |          |          |          |
| Adrenal gland, cortex                       | (46)     | (46)     | (47)     | (46)     |
| Accessory adrenal cortical nodule           |          |          |          | 1 (2%)   |
| Angiectasis, mild                           |          |          | 1 (2%)   |          |
| Angiectasis, minimal                        | 1 (2%)   |          |          |          |
| Autolysis, moderate                         |          | 1 (2%)   |          | 1 (2%)   |
| Hematopoietic cell proliferation, mild      |          |          |          | 1 (2%)   |
| Hematopoietic cell proliferation, minimal   |          |          |          | 1 (2%)   |
| Hemorrhage, mild                            |          |          |          | 1 (2%)   |
| Hyperplasia, marked, subcapsular            | 1 (2%)   |          |          |          |
| Hyperplasia, mild, subcapsular              | 25 (54%) | 27 (59%) | 32 (68%) | 25 (54%) |
| Hyperplasia, minimal, subcapsular           | 9 (20%)  | 3 (7%)   | 3 (6%)   | 4 (9%)   |
| Hyperplasia, moderate, subcapsular          | 1 (2%)   | 3 (7%)   | 2 (4%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, minimal |          |          |          | 3 (7%)   |
| Inflammation, acute, minimal                |          |          |          | 1 (2%)   |
| Pigmentation, minimal                       |          |          |          | 1 (2%)   |
| Vacuolization cytoplasmic, minimal          | 1 (2%)   |          |          |          |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Endocrine System (continued)</b>         |          |          |          |          |
| Adrenal gland, medulla                      | (44)     | (44)     | (46)     | (46)     |
| Autolysis, moderate                         |          | 1 (2%)   |          | 1 (2%)   |
| Hemorrhage, mild                            |          |          |          | 1 (2%)   |
| Hyperplasia, mild                           | 1 (2%)   | 1 (2%)   |          |          |
| Hyperplasia, minimal                        |          | 1 (2%)   |          |          |
| Islets, pancreatic                          | (47)     | (45)     | (48)     | (44)     |
| Autolysis, moderate                         | 2 (4%)   | 1 (2%)   | 1 (2%)   | 2 (5%)   |
| Hyperplasia, mild                           | 3 (6%)   | 1 (2%)   | 3 (6%)   | 2 (5%)   |
| Hyperplasia, minimal                        | 5 (11%)  | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Hyperplasia, moderate                       |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal | 1 (2%)   |          |          |          |
| Parathyroid gland                           | (35)     | (41)     | (41)     | (36)     |
| Autolysis, moderate                         |          | 1 (2%)   |          |          |
| Cyst  |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild    |          |          | 1 (2%)   |          |
| Pituitary gland                             | (40)     | (41)     | (40)     | (38)     |
| Angiectasis, mild                           | 1 (3%)   | 1 (2%)   |          | 1 (3%)   |
| Angiectasis, minimal                        |          |          | 1 (3%)   |          |
| Angiectasis, moderate                       | 1 (3%)   |          |          |          |
| Hyperplasia, mild, pars distalis            |          |          |          | 1 (3%)   |
| Hyperplasia, minimal, pars distalis         |          | 2 (5%)   | 1 (3%)   |          |
| Hyperplasia, moderate, pars distalis        | 1 (3%)   | 1 (2%)   |          |          |
| Thyroid gland                               | (45)     | (48)     | (45)     | (46)     |
| Autolysis, marked                           |          |          |          | 1 (2%)   |
| Autolysis, moderate                         |          | 1 (2%)   |          |          |
| Cyst multilocular                           |          |          | 1 (2%)   |          |
| Cyst, minimal                               |          |          |          | 1 (2%)   |
| Hyperplasia, minimal, C-cell                |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal |          | 1 (2%)   | 1 (2%)   |          |
| <b>General Body System</b>                  |          |          |          |          |
| Tissue NOS                                  |          | (1)      |          | (2)      |
| Necrosis, moderate, abdominal, fat          |          |          |          | 1 (50%)  |
| <b>Genital System</b>                       |          |          |          |          |
| Clitoral gland                              | (38)     | (41)     | (41)     | (35)     |
| Atrophy, mild                               | 27 (71%) | 35 (85%) | 33 (80%) | 22 (63%) |
| Atrophy, minimal                            | 2 (5%)   |          |          | 5 (14%)  |
| Atrophy, moderate                           | 2 (5%)   | 1 (2%)   | 4 (10%)  | 2 (6%)   |
| Dilatation, mild                            |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, mild    | 1 (3%)   |          |          |          |
| Ovary                                       | (46)     | (47)     | (46)     | (45)     |
| Angiectasis, mild                           |          | 2 (4%)   | 2 (4%)   | 3 (7%)   |
| Angiectasis, minimal                        |          | 1 (2%)   |          | 1 (2%)   |
| Angiectasis, moderate                       |          | 1 (2%)   | 2 (4%)   | 2 (4%)   |
| Atrophy, marked                             | 11 (24%) | 35 (74%) | 36 (78%) | 30 (67%) |
| Atrophy, mild                               | 6 (13%)  | 2 (4%)   |          | 1 (2%)   |
| Atrophy, minimal                            | 3 (7%)   |          |          |          |
| Atrophy, moderate                           | 13 (28%) | 2 (4%)   | 1 (2%)   | 5 (11%)  |
| Congestion, minimal                         |          | 1 (2%)   |          |          |
| Cyst  | 12 (26%) | 12 (26%) | 7 (15%)  | 6 (13%)  |
| Cyst, periovarian tissue                    |          |          |          | 2 (4%)   |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Genital System (continued)</b>                                |          |          |          |          |
| Ovary (continued)  | (46)     | (47)     | (46)     | (45)     |
| Hematocyst   | 6 (13%)  | 1 (2%)   |          |          |
| Hemorrhage, marked   |          |          | 1 (2%)   |          |
| Hyperplasia, tubular, mild                                       |          |          |          | 1 (2%)   |
| Hyperplasia, tubular, moderate                                   |          |          | 1 (2%)   | 3 (7%)   |
| Infiltration cellular, histiocytic, moderate                     | 1 (2%)   | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild                         | 1 (2%)   |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, moderate, periovarian tissue |          | 1 (2%)   |          |          |
| Inflammation, marked, periovarian tissue                         |          |          |          | 1 (2%)   |
| Mineralization, minimal  | 1 (2%)   |          |          |          |
| Mineralization, moderate   | 1 (2%)   | 1 (2%)   | 1 (2%)   |          |
| Pigmentation, mild   | 1 (2%)   |          |          |          |
| Pigmentation, moderate   | 1 (2%)   | 1 (2%)   |          |          |
| Polyarteritis, moderate  |          | 1 (2%)   |          |          |
| Thrombosis, marked   | 1 (2%)   | 1 (2%)   | 2 (4%)   | 1 (2%)   |
| Thrombosis, mild   |          |          | 1 (2%)   |          |
| Thrombosis, moderate   |          |          |          | 2 (4%)   |
| Uterus   | (48)     | (48)     | (47)     | (45)     |
| Angiectasis, marked  | 2 (4%)   | 2 (4%)   |          | 1 (2%)   |
| Angiectasis, mild  | 1 (2%)   |          | 6 (13%)  | 2 (4%)   |
| Angiectasis, moderate  | 1 (2%)   |          | 2 (4%)   | 3 (7%)   |
| Hemorrhage, marked   |          |          | 1 (2%)   |          |
| Hemorrhage, mild   |          |          | 1 (2%)   |          |
| Hyperplasia, cystic, mild, endometrium                           | 18 (38%) | 22 (46%) | 19 (40%) | 18 (40%) |
| Hyperplasia, cystic, minimal, endometrium                        |          | 4 (8%)   | 5 (11%)  | 2 (4%)   |
| Hyperplasia, cystic, moderate, endometrium                       | 18 (38%) | 12 (25%) | 11 (23%) | 11 (24%) |
| Thrombosis, marked   | 1 (2%)   | 2 (4%)   |          | 1 (2%)   |
| Thrombosis, moderate   |          |          | 2 (4%)   | 3 (7%)   |
| Vagina   | (48)     | (48)     | (46)     | (44)     |
| Exudate, mild  |          | 1 (2%)   |          |          |
| Exudate, moderate  |          |          | 1 (2%)   |          |
| Inflammation, mild   |          |          | 1 (2%)   |          |
| Polyarteritis, moderate  |          | 1 (2%)   |          |          |
| <b>Hematopoietic System</b>                                      |          |          |          |          |
| Bone marrow  | (48)     | (46)     | (48)     | (47)     |
| Autolysis, marked  |          |          |          | 1 (2%)   |
| Autolysis, mild  |          |          |          | 1 (2%)   |
| Autolysis, moderate  |          |          |          | 1 (2%)   |
| Hyperplasia, marked, myeloid cell                                |          |          |          | 2 (4%)   |
| Hyperplasia, mild, myeloid cell                                  |          | 2 (4%)   | 4 (8%)   | 5 (11%)  |
| Hyperplasia, moderate, myeloid cell                              | 1 (2%)   |          | 1 (2%)   | 5 (11%)  |
| Lymph node   | (48)     | (47)     | (48)     | (47)     |
| Hematocyst, mild   | 1 (2%)   |          |          |          |
| Hematopoietic cell proliferation, marked, renal                  |          |          |          | 1 (2%)   |
| Hematopoietic cell proliferation, moderate, lumbar               |          |          | 1 (2%)   |          |
| Hemorrhage, moderate, lumbar                                     |          |          |          | 1 (2%)   |
| Hyperplasia, lymphoid, mild, renal                               |          |          |          | 1 (2%)   |
| Hyperplasia, moderate, lumbar                                    |          | 1 (2%)   |          |          |
| Infiltration cellular, histiocytic, mild, lumbar                 |          |          | 1 (2%)   |          |
| Inflammation, mild, lumbar                                       |          |          | 1 (2%)   |          |
| Pigmentation, moderate   | 1 (2%)   |          |          |          |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm  | 90 ppm   |
|--|----------|----------|---------|----------|
| <b>Hematopoietic System</b> (continued)            |          |          |         |          |
| Lymph node, mandibular                             | (48)     | (46)     | (45)    | (47)     |
| Autolysis, moderate                                |          |          |         | 1 (2%)   |
| Hyperplasia, lymphoid, mild                        | 5 (10%)  | 2 (4%)   | 4 (9%)  | 2 (4%)   |
| Hyperplasia, lymphoid, minimal                     |          |          |         | 1 (2%)   |
| Hyperplasia, lymphoid, moderate                    |          | 1 (2%)   |         | 3 (6%)   |
| Infiltration cellular, histiocytic, minimal        |          |          |         | 3 (6%)   |
| Lymph node, mesenteric                             | (45)     | (42)     | (46)    | (38)     |
| Angiectasis, mild                                  |          |          |         | 1 (3%)   |
| Angiectasis, moderate                              | 1 (2%)   | 1 (2%)   |         |          |
| Atrophy, moderate                                  |          |          |         | 1 (3%)   |
| Autolysis, moderate                                | 2 (4%)   | 1 (2%)   |         | 2 (5%)   |
| Hematopoietic cell proliferation, mild             |          |          |         | 1 (3%)   |
| Hematopoietic cell proliferation, moderate         |          |          |         | 1 (3%)   |
| Hemorrhage, mild                                   |          |          |         | 1 (3%)   |
| Hemorrhage, moderate                               | 1 (2%)   |          |         |          |
| Hyperplasia, lymphoid, marked                      |          |          | 2 (4%)  |          |
| Hyperplasia, lymphoid, mild                        | 2 (4%)   | 3 (7%)   | 1 (2%)  | 3 (8%)   |
| Hyperplasia, lymphoid, minimal                     |          |          | 1 (2%)  |          |
| Hyperplasia, lymphoid, moderate                    |          |          |         | 1 (3%)   |
| Infiltration cellular, histiocytic, minimal        | 1 (2%)   |          |         |          |
| Infiltration cellular, polymorphonuclear, moderate |          |          |         | 1 (3%)   |
| Spleen   | (48)     | (47)     | (48)    | (45)     |
| Angiectasis, mild                                  |          |          | 1 (2%)  | 1 (2%)   |
| Autolysis, moderate                                |          | 2 (4%)   | 1 (2%)  | 2 (4%)   |
| Hematopoietic cell proliferation, marked           |          |          |         | 6 (13%)  |
| Hematopoietic cell proliferation, mild             |          | 7 (15%)  | 2 (4%)  | 4 (9%)   |
| Hematopoietic cell proliferation, moderate         | 3 (6%)   | 3 (6%)   | 7 (15%) | 19 (42%) |
| Hemorrhage, moderate                               |          |          | 1 (2%)  |          |
| Hyperplasia, marked, lymphoid follicle             | 3 (6%)   | 2 (4%)   |         |          |
| Hyperplasia, mild, lymphoid follicle               | 10 (21%) | 11 (23%) | 8 (17%) | 3 (7%)   |
| Hyperplasia, minimal, lymphoid follicle            | 5 (10%)  |          | 1 (2%)  |          |
| Hyperplasia, moderate, lymphoid follicle           | 5 (10%)  | 6 (13%)  | 4 (8%)  | 2 (4%)   |
| Pigmentation, moderate                             |          |          | 1 (2%)  |          |
| Thrombosis, mild                                   |          |          |         | 1 (2%)   |
| Thrombosis, moderate                               | 1 (2%)   |          |         |          |
| Thymus   | (39)     | (38)     | (43)    | (39)     |
| Atrophy, mild                                      | 3 (8%)   | 8 (21%)  | 7 (16%) | 13 (33%) |
| Atrophy, minimal                                   |          |          |         | 1 (3%)   |
| Atrophy, moderate                                  |          | 2 (5%)   | 1 (2%)  |          |
| Autolysis, moderate                                | 1 (3%)   | 1 (3%)   |         | 3 (8%)   |
| Cyst, minimal                                      |          | 1 (3%)   |         |          |
| Hemorrhage, mild                                   |          | 1 (3%)   |         |          |
| Hyperplasia, mild                                  | 2 (5%)   | 3 (8%)   | 3 (7%)  | 1 (3%)   |
| Hyperplasia, minimal                               | 1 (3%)   |          |         |          |
| Hyperplasia, moderate                              | 1 (3%)   |          |         |          |
| <b>Integumentary System</b>                        |          |          |         |          |
| Mammary gland                                      | (47)     | (48)     | (48)    | (45)     |
| Autolysis, marked                                  | 1 (2%)   |          |         |          |
| Autolysis, moderate                                |          | 1 (2%)   |         |          |
| Hyperplasia, mild                                  | 1 (2%)   | 1 (2%)   | 2 (4%)  | 2 (4%)   |
| Hyperplasia, minimal                               | 1 (2%)   | 1 (2%)   |         |          |
| Hyperplasia, moderate                              | 2 (4%)   | 1 (2%)   |         |          |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|   | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|---|----------|----------|----------|----------|
| <b>Integumentary System (continued)</b>                   |          |          |          |          |
| Mammary gland (continued)                                 | (47)     | (48)     | (48)     | (45)     |
| Infiltration cellular, lymphocytic, mild                  |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal               |          |          |          | 1 (2%)   |
| Lactation, mild   | 3 (6%)   |          | 2 (4%)   |          |
| Lactation, minimal  | 1 (2%)   |          | 2 (4%)   | 1 (2%)   |
| Skin  | (48)     | (48)     | (48)     | (47)     |
| Autolysis, marked   | 1 (2%)   |          |          | 2 (4%)   |
| Autolysis, moderate                                       |          | 1 (2%)   |          |          |
| Distended, sebaceous gland                                |          |          | 1 (2%)   |          |
| Inflammation, chronic, moderate                           |          |          | 1 (2%)   |          |
| Necrosis, fat   |          |          | 1 (2%)   |          |
| <b>Musculoskeletal System</b>                             |          |          |          |          |
| Bone  | (48)     | (48)     | (48)     | (47)     |
| Fibrous osteodystrophy, mild, sternum                     | 10 (21%) | 7 (15%)  | 5 (10%)  | 1 (2%)   |
| Fibrous osteodystrophy, minimal, sternum                  | 5 (10%)  | 11 (23%) | 6 (13%)  | 2 (4%)   |
| Fibrous osteodystrophy, moderate, sternum                 |          |          | 1 (2%)   |          |
| Bone, femur   | (48)     | (48)     | (48)     | (47)     |
| Fibrous osteodystrophy, mild                              | 1 (2%)   | 2 (4%)   |          |          |
| Fibrous osteodystrophy, minimal                           |          | 4 (8%)   | 1 (2%)   |          |
| Fibrous osteodystrophy, moderate                          |          | 1 (2%)   | 2 (4%)   |          |
| Skeletal muscle   | (48)     | (48)     | (48)     | (47)     |
| Degeneration, minimal                                     |          | 1 (2%)   |          |          |
| Infiltration cellular, lymphocytic, mild                  |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal               |          |          |          | 1 (2%)   |
| <b>Nervous System</b>                                     |          |          |          |          |
| Brain   | (48)     | (48)     | (48)     | (47)     |
| Hemorrhage, minimal, brain stem                           |          |          | 1 (2%)   |          |
| Brain, cerebellum   | (48)     | (48)     | (47)     | (47)     |
| Hemorrhage, mild  |          |          | 1 (2%)   | 1 (2%)   |
| Hemorrhage, minimal                                       |          | 1 (2%)   | 1 (2%)   |          |
| Brain, cerebrum   | (48)     | (48)     | (48)     | (47)     |
| Hemorrhage, mild  |          |          | 1 (2%)   | 1 (2%)   |
| Hemorrhage, minimal                                       |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal, perivascular |          |          | 1 (2%)   |          |
| Inflammation, mild  |          |          |          | 1 (2%)   |
| Inflammation, moderate, meninges                          |          |          | 1 (2%)   |          |
| Mineralization, mild, thalamus                            |          | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Mineralization, minimal, thalamus                         | 29 (60%) | 26 (54%) | 25 (52%) | 26 (55%) |
| Necrosis, mild  |          |          |          | 1 (2%)   |
| Spinal cord, thoracic                                     | (48)     | (48)     | (48)     | (47)     |
| Hemorrhage, mild  |          |          |          | 1 (2%)   |
| Hemorrhage, minimal                                       |          | 1 (2%)   |          |          |
| <b>Respiratory System</b>                                 |          |          |          |          |
| Larynx  | (45)     | (47)     | (47)     | (47)     |
| Autolysis, moderate                                       |          | 1 (2%)   |          |          |
| Lung  | (48)     | (48)     | (48)     | (48)     |
| Hemorrhage, marked  |          |          | 1 (2%)   |          |
| Hemorrhage, mild  |          | 2 (4%)   | 1 (2%)   | 1 (2%)   |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Respiratory System (continued)</b>        |          |          |          |          |
| Lung (continued)                             | (48)     | (48)     | (48)     | (48)     |
| Hemorrhage, minimal                          | 3 (6%)   | 4 (8%)   | 2 (4%)   | 2 (4%)   |
| Hemorrhage, moderate                         |          |          |          | 1 (2%)   |
| Hyperplasia, mild, alveolar epithelium       |          | 2 (4%)   | 1 (2%)   | 4 (8%)   |
| Hyperplasia, minimal, alveolar epithelium    |          | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Hyperplasia, moderate, alveolar epithelium   |          |          |          | 1 (2%)   |
| Hypertrophy, mild, arteriole                 | 1 (2%)   |          |          |          |
| Infiltration cellular, histiocytic, marked   |          |          |          | 1 (2%)   |
| Infiltration cellular, histiocytic, mild     | 1 (2%)   | 1 (2%)   | 4 (8%)   | 3 (6%)   |
| Infiltration cellular, histiocytic, moderate |          | 2 (4%)   | 1 (2%)   | 2 (4%)   |
| Infiltration cellular, lymphocytic, mild     | 8 (17%)  | 8 (17%)  | 2 (4%)   | 4 (8%)   |
| Infiltration cellular, lymphocytic, minimal  | 19 (40%) | 12 (25%) | 15 (31%) | 17 (35%) |
| Infiltration cellular, lymphocytic, moderate |          | 2 (4%)   | 2 (4%)   |          |
| Inflammation, chronic active, minimal        |          | 1 (2%)   |          |          |
| Leukocytosis, marked                         |          |          |          | 1 (2%)   |
| Leukocytosis, moderate                       |          |          |          | 1 (2%)   |
| Trachea                                      | (47)     | (48)     | (47)     | (45)     |
| Autolysis, moderate                          |          | 1 (2%)   |          |          |
| Ectasia, mild, glands                        |          |          |          | 1 (2%)   |
| <b>Special Senses System</b>                 |          |          |          |          |
| Eye  | (48)     | (48)     | (47)     | (45)     |
| Atrophy, marked                              |          |          |          | 2 (4%)   |
| Atrophy, mild                                |          |          |          | 1 (2%)   |
| Atrophy, moderate                            |          |          |          | 2 (4%)   |
| Autolysis, moderate                          | 2 (4%)   |          |          | 1 (2%)   |
| Cataract, moderate, lens                     |          | 1 (2%)   | 1 (2%)   | 1 (2%)   |
| Inflammation, marked, cornea                 | 1 (2%)   |          |          | 2 (4%)   |
| Inflammation, mild, cornea                   |          | 2 (4%)   | 2 (4%)   | 1 (2%)   |
| Inflammation, minimal, cornea                | 1 (2%)   | 3 (6%)   | 1 (2%)   |          |
| Inflammation, moderate, cornea               |          | 1 (2%)   |          |          |
| Phthisis bulbi                               |          |          | 1 (2%)   | 1 (2%)   |
| Harderian gland                              | (48)     | (48)     | (46)     | (46)     |
| Autolysis, moderate                          |          |          |          | 1 (2%)   |
| Hyperplasia, mild                            |          |          |          | 2 (4%)   |
| Hyperplasia, moderate                        |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  | 7 (15%)  | 3 (6%)   | 8 (17%)  | 3 (7%)   |
| Inflammation, chronic, moderate              |          |          |          | 1 (2%)   |
| Inflammation, moderate                       |          |          | 1 (2%)   |          |
| Lacrimal gland                               | (45)     | (45)     | (45)     | (43)     |
| Atrophy, mild                                |          | 2 (4%)   | 1 (2%)   |          |
| Atrophy, minimal                             | 2 (4%)   | 4 (9%)   | 1 (2%)   |          |
| Atrophy, moderate                            | 1 (2%)   |          |          |          |
| Dilatation, minimal, duct                    | 2 (4%)   | 2 (4%)   | 1 (2%)   |          |
| Dilatation, moderate, duct                   | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, marked   | 1 (2%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild     | 6 (13%)  | 11 (24%) | 9 (20%)  | 2 (5%)   |
| Infiltration cellular, lymphocytic, minimal  | 17 (38%) | 14 (31%) | 16 (36%) | 24 (56%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   |          |          |          |
| Zymbal's gland                               | (48)     | (46)     | (43)     | (40)     |
| Atrophy, minimal                             |          |          | 1 (2%)   |          |
| Infiltration cellular, lymphocytic, minimal  |          |          |          | 1 (3%)   |

**TABLE F3**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol**

|  | 0 ppm    | 10 ppm   | 30 ppm   | 90 ppm   |
|--|----------|----------|----------|----------|
| <b>Urinary System</b>                        |          |          |          |          |
| Kidney                                       | (48)     | (48)     | (48)     | (47)     |
| Accumulation, hyaline droplet, mild          |          | 1 (2%)   |          | 1 (2%)   |
| Accumulation, hyaline droplet, moderate      | 1 (2%)   | 1 (2%)   | 3 (6%)   | 2 (4%)   |
| Amyloid deposition, moderate                 |          |          |          | 1 (2%)   |
| Autolysis, marked                            |          | 1 (2%)   |          |          |
| Autolysis, moderate                          |          | 1 (2%)   | 1 (2%)   |          |
| Casts, mild                                  |          |          |          | 1 (2%)   |
| Casts, minimal                               |          |          | 1 (2%)   |          |
| Cyst   |          | 1 (2%)   |          |          |
| Glomerulosclerosis, mild                     | 1 (2%)   | 1 (2%)   |          | 2 (4%)   |
| Glomerulosclerosis, minimal                  |          |          | 1 (2%)   |          |
| Hematopoietic cell proliferation, mild       |          |          |          | 1 (2%)   |
| Hydronephrosis, moderate                     | 1 (2%)   |          |          |          |
| Infarct, mild                                | 1 (2%)   |          |          |          |
| Infarct, minimal                             | 2 (4%)   |          |          |          |
| Infiltration cellular, lymphocytic, mild     | 4 (8%)   | 1 (2%)   | 1 (2%)   | 4 (9%)   |
| Infiltration cellular, lymphocytic, minimal  | 14 (29%) | 20 (42%) | 17 (35%) | 18 (38%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   |          |          | 2 (4%)   |
| Metaplasia, osseous, minimal                 | 1 (2%)   |          |          |          |
| Mineralization, mild                         | 1 (2%)   |          |          |          |
| Mineralization, minimal                      |          |          | 1 (2%)   | 2 (4%)   |
| Necrosis, minimal, papilla                   |          |          | 1 (2%)   |          |
| Nephropathy, mild                            |          |          | 1 (2%)   |          |
| Nephropathy, moderate                        |          | 1 (2%)   |          |          |
| Pigmentation, moderate, renal tubule         |          | 1 (2%)   |          |          |
| Urinary bladder                              | (46)     | (46)     | (47)     | (45)     |
| Autolysis, marked                            |          |          |          | 2 (4%)   |
| Autolysis, moderate                          | 2 (4%)   | 3 (7%)   |          | 2 (4%)   |
| Fibrosis, moderate                           |          |          |          | 1 (2%)   |
| Infiltration cellular, lymphocytic, mild     | 2 (4%)   | 6 (13%)  | 7 (15%)  | 1 (2%)   |
| Infiltration cellular, lymphocytic, minimal  | 22 (48%) | 16 (35%) | 14 (30%) | 16 (36%) |
| Infiltration cellular, lymphocytic, moderate | 1 (2%)   |          | 2 (4%)   |          |
| Polyarteritis, moderate                      |          | 1 (2%)   |          |          |

## APPENDIX G

### 4-WEEK STUDY RESULTS

|                 |  |             |
|-----------------|--|-------------|
| <b>TABLE G1</b> | <b>Body Weights of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>  | <b>G-2</b>  |
| <b>TABLE G2</b> | <b>Water Consumption by Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>   | <b>G-3</b>  |
| <b>TABLE G3</b> | <b>Feed Consumption by Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>  | <b>G-4</b>  |
| <b>TABLE G4</b> | <b>Serum Concentrations of Urethane in Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>  | <b>G-5</b>  |
| <b>TABLE G5</b> | <b>Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>                                     | <b>G-6</b>  |
| <b>TABLE G6</b> | <b>Cell Cycle Distribution and Percent Apoptosis in the Liver of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>                                | <b>G-8</b>  |
| <b>TABLE G7</b> | <b>PCNA-Labeling Index in the Lung of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>   | <b>G-10</b> |
| <b>TABLE G8</b> | <b>Total Cytochrome P450, Cytochrome P450 2E1 Activity, and Glutathione Content in the Liver of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b> | <b>G-11</b> |
| <b>TABLE G9</b> | <b>Etheno-DNA Adducts in the Liver and Lung of Male and Female Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol .....</b>                                  | <b>G-12</b> |

**TABLE G1**  
**Body Weights of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|               | % Ethanol | Urethane     |              |              |              |
|---------------|-----------|--------------|--------------|--------------|--------------|
|               |           | 0 ppm        | 10 ppm       | 30 ppm       | 90 ppm       |
| n             |           | 8            | 8            | 8            | 8            |
| <b>Male</b>   |           |              |              |              |              |
| Week 1        | 0         | 22.89 ± 0.57 | 22.01 ± 0.63 | 22.74 ± 0.57 | 23.53 ± 0.56 |
|               | 2.5       | 22.17 ± 0.99 | 22.29 ± 0.65 | 22.91 ± 0.71 | 22.05 ± 0.70 |
|               | 5         | 22.55 ± 0.69 | 23.05 ± 0.47 | 22.61 ± 0.78 | 21.99 ± 0.87 |
| Week 2        | 0         | 25.43 ± 0.58 | 24.08 ± 0.64 | 24.71 ± 0.58 | 25.70 ± 0.43 |
|               | 2.5       | 24.46 ± 1.05 | 24.44 ± 0.68 | 24.89 ± 0.70 | 24.21 ± 0.65 |
|               | 5         | 24.90 ± 0.74 | 24.98 ± 0.43 | 25.16 ± 0.57 | 24.06 ± 0.77 |
| Week 3        | 0         | 26.86 ± 0.41 | 25.74 ± 0.61 | 26.23 ± 0.51 | 27.15 ± 0.29 |
|               | 2.5       | 26.24 ± 0.92 | 26.19 ± 0.64 | 26.88 ± 0.64 | 26.01 ± 0.63 |
|               | 5         | 26.65 ± 0.63 | 26.68 ± 0.42 | 27.03 ± 0.49 | 26.46 ± 0.75 |
| Week 4        | 0         | 27.94 ± 0.44 | 27.04 ± 0.68 | 27.31 ± 0.52 | 28.09 ± 0.26 |
|               | 2.5       | 27.35 ± 0.80 | 27.19 ± 0.69 | 28.16 ± 0.59 | 26.81 ± 0.58 |
|               | 5         | 27.14 ± 0.72 | 27.64 ± 0.28 | 28.20 ± 0.59 | 27.46 ± 0.85 |
| <b>Female</b> |           |              |              |              |              |
| Week 1        | 0         | 18.63 ± 0.49 | 17.81 ± 0.37 | 17.79 ± 0.37 | 18.53 ± 0.45 |
|               | 2.5       | 18.69 ± 0.43 | 18.41 ± 0.43 | 18.74 ± 0.68 | 18.19 ± 0.51 |
|               | 5         | 18.53 ± 0.35 | 18.15 ± 0.51 | 18.53 ± 0.49 | 17.56 ± 0.45 |
| Week 2        | 0         | 18.94 ± 0.45 | 18.70 ± 0.52 | 18.30 ± 0.35 | 19.40 ± 0.45 |
|               | 2.5       | 19.65 ± 0.48 | 18.76 ± 0.44 | 19.61 ± 0.45 | 18.66 ± 0.44 |
|               | 5         | 18.90 ± 0.48 | 19.00 ± 0.51 | 19.15 ± 0.40 | 18.69 ± 0.42 |
| Week 3        | 0         | 20.09 ± 0.32 | 19.10 ± 0.41 | 19.04 ± 0.33 | 19.76 ± 0.45 |
|               | 2.5       | 20.75 ± 0.48 | 19.87 ± 0.41 | 20.25 ± 0.50 | 19.17 ± 0.53 |
|               | 5         | 19.79 ± 0.43 | 19.99 ± 0.47 | 20.21 ± 0.40 | 19.81 ± 0.31 |
| Week 4        | 0         | 20.29 ± 0.37 | 19.36 ± 0.48 | 19.78 ± 0.27 | 20.50 ± 0.46 |
|               | 2.5       | 20.88 ± 0.49 | 20.19 ± 0.45 | 21.01 ± 0.56 | 19.74 ± 0.43 |
|               | 5         | 20.29 ± 0.32 | 20.64 ± 0.86 | 20.50 ± 0.45 | 20.34 ± 0.37 |

<sup>a</sup> Data are given in grams (mean ± standard error). Neither urethane nor ethanol had any effect on body weights.

**TABLE G2**  
**Water Consumption by Mice in the 4-Week Drinking Water Study of Urethane, Ethanol,**  
**and Urethane/Ethanol<sup>a</sup>**

|               | % Ethanol | Urethane          |                   |                   |                   |
|---------------|-----------|-------------------|-------------------|-------------------|-------------------|
|               |           | 0 ppm             | 10 ppm            | 30 ppm            | 90 ppm            |
| n             |           | 8                 | 8                 | 8                 | 8                 |
| <b>Male</b>   |           |                   |                   |                   |                   |
| Week 1        | 0         | 4.00 ± 0.08       | 3.87 ± 0.63       | 3.70 ± 0.03       | 4.08 ± 0.42       |
|               | 2.5       | 2.64 <sup>b</sup> | 3.41 <sup>b</sup> | 3.43 ± 0.09       | 3.11 ± 0.13       |
|               | 5         | 3.06 ± 0.12       | 3.02 ± 0.88       | 3.19 <sup>b</sup> | 3.00 ± 0.18       |
| Week 2        | 0         | 4.71 ± 0.90       | 3.02 ± 0.02*      | 3.45 ± 0.20*      | 3.27 ± 1.25*      |
|               | 2.5       | 2.99 ± 0.10*      | 3.58 ± 0.34       | 3.30 ± 0.23*      | 3.40 <sup>b</sup> |
|               | 5         | 2.87 ± 0.16*      | 2.95 ± 0.16*      | 3.67 ± 0.04       | 3.12 ± 0.15*      |
| Week 3        | 0         | 4.79 ± 0.47       | 3.81 ± 0.02       | 3.82 ± 0.17       | 4.17 ± 0.54       |
|               | 2.5       | 3.23 ± 0.04*      | 4.08 ± 0.29       | 3.41 ± 0.27*      | 3.42 ± 0.29*      |
|               | 5         | 3.04 ± 0.18*      | 3.25 ± 0.25*      | 4.18 ± 0.13       | 3.33 ± 0.07*      |
| Week 4        | 0         | 4.77 ± 0.37       | 4.32 ± 0.11       | 4.04 ± 0.13       | 4.23 ± 0.70       |
|               | 2.5       | 3.61 ± 0.18       | 4.42 ± 0.57       | 3.29 ± 0.01*      | 3.19 ± 0.33*      |
|               | 5         | 3.18 ± 0.35*      | 3.67 ± 0.64       | 4.31 ± 0.15       | 3.51 ± 0.19*      |
| <b>Female</b> |           |                   |                   |                   |                   |
| Week 1        | 0         | 2.89 ± 0.33       | 2.42 ± 0.27       | 2.09 ± 0.08       | 2.41 ± 0.20       |
|               | 2.5       | 2.44 ± 0.03       | 2.61 ± 0.25       | 2.54 ± 0.00       | 2.56 ± 0.05       |
|               | 5         | 2.39 ± 0.02       | 2.38 ± 0.01       | 2.51 ± 0.08       | 2.21 ± 0.18       |
| Week 2        | 0         | 3.23 ± 0.27       | 2.61 ± 0.08       | 2.41 ± 0.08       | 2.93 ± 0.03       |
|               | 2.5       | 2.98 ± 0.54       | 2.66 ± 0.03       | 2.62 ± 0.00       | 2.82 ± 0.02       |
|               | 5         | 2.70 ± 0.01       | 2.71 ± 0.02       | 2.74 ± 0.12       | 2.54 ± 0.20       |
| Week 3        | 0         | 3.07 ± 0.51       | 2.73 ± 0.02       | 2.96 ± 0.13       | 3.02 ± 0.42       |
|               | 2.5       | 2.77 ± 0.16       | 2.71 ± 0.15       | 2.79 ± 0.15       | 2.64 ± 0.02       |
|               | 5         | 2.66 ± 0.24       | 2.75 ± 0.13       | 2.78 ± 0.22       | 2.71 ± 0.02       |
| Week 4        | 0         | 2.81 ± 0.51       | 2.76 ± 0.02       | 2.78 ± 0.21       | 3.27 ± 0.53       |
|               | 2.5       | 2.90 ± 0.18       | 2.72 ± 0.00       | 2.83 ± 0.05       | 2.99 <sup>b</sup> |
|               | 5         | 2.58 ± 0.39       | 2.86 ± 0.09       | 2.67 ± 0.14       | 2.71 ± 0.09       |

\* Significantly different ( $P \leq 0.05$ ) from the control group (0 ppm urethane/0% ethanol) at the same time point by Dunnett's test

<sup>a</sup> Data are given in grams per animal per day (mean ± standard error). Increasing the urethane concentration had no effect on water consumption by males or females. Increasing the ethanol concentration caused a significant decrease in water consumption by males ( $P=0.009$ ), but not females.

<sup>b</sup> Data are for one cage.

**TABLE G3**  
**Feed Consumption by Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|               | % Ethanol | Urethane          |                          |                   |                   |
|---------------|-----------|-------------------|--------------------------|-------------------|-------------------|
|               |           | 0 ppm             | 10 ppm                   | 30 ppm            | 90 ppm            |
| n             |           | 8                 | 8                        | 8                 | 8                 |
| <b>Male</b>   |           |                   |                          |                   |                   |
| Week 1        | 0         | 3.76 ± 0.13       | 3.76 ± 0.41              | 3.75 ± 0.07       | 3.89 ± 0.38       |
|               | 2.5       | 3.05 ± 0.33       | 3.05 <sub>b</sub> ± 0.24 | 3.29 ± 0.22       | 3.12 ± 0.35       |
|               | 5         | 2.85 ± 0.48       | 4.34 <sup>b</sup>        | 2.54 ± 0.97       | 2.74 ± 0.34       |
| Week 2        | 0         | 4.15 ± 0.32       | 3.19 ± 0.45              | 4.09 ± 0.22       | 3.23 ± 0.85       |
|               | 2.5       | 3.53 ± 0.04       | 3.61 ± 0.37              | 3.63 ± 0.12       | 3.51 ± 0.22       |
|               | 5         | 3.44 ± 0.11       | 2.88 ± 0.30              | 3.67 ± 0.08       | 3.28 ± 0.08       |
| Week 3        | 0         | 4.65 ± 0.71       | 3.91 ± 0.03              | 4.94 ± 0.92       | 5.11 ± 0.46       |
|               | 2.5       | 4.20 ± 0.37       | 3.92 ± 0.34              | 4.38 ± 0.44       | 3.98 ± 0.44       |
|               | 5         | 4.01 ± 0.15       | 4.08 ± 0.75              | 4.41 ± 0.15       | 3.89 ± 0.05       |
| Week 4        | 0         | 5.64 <sup>b</sup> | 3.93 ± 0.21              | 4.41 ± 0.47       | 4.48 ± 0.32       |
|               | 2.5       | 4.35 ± 0.38       | 4.27 ± 0.45              | 4.66 ± 0.27       | 4.28 ± 0.58       |
|               | 5         | 3.70 ± 0.06       | 3.90 ± 0.34              | 5.49 ± 0.69       | 3.84 ± 0.30       |
| <b>Female</b> |           |                   |                          |                   |                   |
| Week 1        | 0         | 2.79 <sup>b</sup> | 2.54 ± 0.25              | 2.70 <sup>b</sup> | 3.04 <sup>b</sup> |
|               | 2.5       | 2.70 ± 0.07       | 2.65 <sup>b</sup>        | 3.86 <sup>b</sup> | 2.86 <sup>b</sup> |
|               | 5         | 2.71 <sup>b</sup> | 2.74 <sup>b</sup>        | 2.68 <sup>b</sup> | 2.44 ± 0.21       |
| Week 2        | 0         | 3.09 ± 0.17       | 3.01 ± 0.33              | 2.87 ± 0.08       | 3.06 ± 0.12       |
|               | 2.5       | 2.95 ± 0.07       | 2.83 ± 0.01              | 2.91 ± 0.02       | 2.81 ± 0.04       |
|               | 5         | 2.90 ± 0.16       | 2.88 ± 0.04              | 2.78 ± 0.03       | 2.63 ± 0.28       |
| Week 3        | 0         | 3.26 ± 0.22       | 3.06 ± 0.16              | 3.08 ± 0.02       | 3.21 ± 0.10       |
|               | 2.5       | 3.27 ± 0.09       | 3.10 ± 0.02              | 3.18 ± 0.11       | 2.91 ± 0.01       |
|               | 5         | 3.08 ± 0.25       | 3.01 ± 0.12              | 3.02 ± 0.10       | 3.26 ± 0.33       |
| Week 4        | 0         | 3.31 ± 0.22       | 3.06 ± 0.23              | 3.14 ± 0.10       | 3.39 ± 0.14       |
|               | 2.5       | 3.33 ± 0.06       | 3.18 ± 0.12              | 3.47 ± 0.11       | 3.04 ± 0.02       |
|               | 5         | 3.76 ± 0.40       | 3.21 ± 0.04              | 3.15 ± 0.08       | 3.03 ± 0.02       |

<sup>a</sup> Data are given in grams per animal per day (mean ± standard error). Increasing the urethane concentration had no effect on feed consumption by males or females. Increasing the ethanol concentration caused a significant exposure-related decrease in feed consumption by males (P=0.023) but not by females. Pairwise comparisons at each week (Dunnett's test) indicated no significant differences from the control groups (0 ppm urethane/0% ethanol).

<sup>b</sup> Data are for one cage.

**TABLE G4**  
**Serum Concentrations of Urethane in Mice in the 4-Week Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|               | % Ethanol | Urethane     |              |              |              |
|---------------|-----------|--------------|--------------|--------------|--------------|
|               |           | 0 ppm        | 10 ppm       | 30 ppm       | 90 ppm       |
| n             |           | 4            | 4            | 4            | 4            |
| <b>Male</b>   |           |              |              |              |              |
|               | 0         | 0.01 ± 0.002 | 0.01 ± 0.002 | 0.02 ± 0.01  | 0.02 ± 0.003 |
|               | 2.5       | 0.01 ± 0.004 | 0.02 ± 0.004 | 0.03 ± 0.01  | 0.04 ± 0.02  |
|               | 5         | 0.01 ± 0.003 | 0.05 ± 0.003 | 2.75 ± 0.95* | 0.43 ± 0.38  |
| <b>Female</b> |           |              |              |              |              |
|               | 0         | 0.01 ± 0.002 | 0.01 ± 0.003 | 0.05 ± 0.007 | 0.07 ± 0.01  |
|               | 2.5       | 0.01 ± 0.003 | 0.11 ± 0.03  | 0.12 ± 0.05  | 0.04 ± 0.007 |
|               | 5         | 0.01 ± 0.005 | 0.17 ± 0.12  | 1.67 ± 0.86* | 1.56 ± 1.05* |

\* Significantly different ( $P \leq 0.05$ ) from the control group (0 ppm urethane/0% ethanol) by Dunnett's test

<sup>a</sup> Data are given in ppm (mean ± standard error).

**TABLE G5**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice**  
**in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|                  | % Ethanol | Urethane      |               |               |               |
|------------------|-----------|---------------|---------------|---------------|---------------|
|                  |           | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm        |
| n                |           | 4             | 4             | 4             | 4             |
| <b>Male</b>      |           |               |               |               |               |
| Necropsy body wt | 0         | 25.3 ± 0.41   | 23.3 ± 0.38   | 23.8 ± 0.28   | 24.9 ± 0.49   |
|                  | 2.5       | 24.0 ± 0.27   | 24.6 ± 0.72   | 24.7 ± 0.35   | 23.9 ± 0.21   |
|                  | 5         | 24.2 ± 1.10   | 24.5 ± 0.22   | 24.9 ± 0.76   | 23.7 ± 0.93   |
| Liver            |           |               |               |               |               |
| Absolute         | 0         | 1.250 ± 0.035 | 1.135 ± 0.057 | 1.218 ± 0.022 | 1.309 ± 0.057 |
|                  | 0         | 4.94 ± 0.082  | 4.87 ± 0.208  | 5.12 ± 0.046  | 5.26 ± 0.225  |
| Relative         | 2.5       | 1.187 ± 0.018 | 1.186 ± 0.030 | 1.188 ± 0.049 | 1.237 ± 0.042 |
|                  | 2.5       | 4.95 ± 0.033  | 4.82 ± 0.123  | 4.81 ± 0.152  | 5.16 ± 0.136  |
| Absolute         | 5         | 1.290 ± 0.087 | 1.316 ± 0.029 | 1.239 ± 0.036 | 1.188 ± 0.064 |
|                  | 5         | 5.31 ± 0.170  | 5.36 ± 0.089  | 4.97 ± 0.014  | 5.01 ± 0.115  |
| Lung             |           |               |               |               |               |
| Absolute         | 0         | 216 ± 23      | 210 ± 5       | 212 ± 24      | 229 ± 27      |
|                  | 0         | 8.58 ± 1.03   | 9.00 ± 0.23   | 8.91 ± 0.99   | 9.16 ± 1.00   |
| Relative         | 2.5       | 209 ± 29      | 204 ± 11      | 224 ± 8       | 210 ± 26      |
|                  | 2.5       | 8.75 ± 1.32   | 8.32 ± 0.62   | 9.05 ± 0.35   | 8.77 ± 1.06   |
| Absolute         | 5         | 243 ± 26      | 254 ± 22      | 188 ± 10      | 190 ± 13      |
|                  | 5         | 10.0 ± 1.03   | 10.3 ± 0.86   | 7.55 ± 0.40   | 8.02 ± 0.59   |

**TABLE G5**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice**  
**in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|                  | % Ethanol | Urethane      |               |               |               |
|------------------|-----------|---------------|---------------|---------------|---------------|
|                  |           | 0 ppm         | 10 ppm        | 30 ppm        | 90 ppm        |
| n                |           | 4             | 4             | 4             | 4             |
| <b>Female</b>    |           |               |               |               |               |
| Necropsy body wt | 0         | 18.1 ± 0.56   | 16.5 ± 0.18   | 17.8 ± 0.53   | 18.2 ± 0.35   |
|                  | 2.5       | 19.2 ± 0.53   | 18.2 ± 0.68   | 19.3 ± 1.04   | 17.5 ± 0.28   |
|                  | 5         | 18.0 ± 0.27   | 17.7 ± 0.73   | 18.2 ± 0.79   | 18.0 ± 0.50   |
| <b>Liver</b>     |           |               |               |               |               |
| Absolute         | 0         | 0.878 ± 0.017 | 0.747 ± 0.029 | 0.797 ± 0.016 | 0.911 ± 0.012 |
|                  | Relative  | 0             | 4.86 ± 0.10   | 4.51 ± 0.14   | 4.48 ± 0.14   |
| Absolute         | 2.5       | 0.851 ± 0.047 | 0.859 ± 0.053 | 0.875 ± 0.013 | 0.798 ± 0.037 |
|                  | Relative  | 2.5           | 4.42 ± 0.17   | 4.71 ± 0.15   | 4.56 ± 0.21   |
| Absolute         | 5         | 0.867 ± 0.029 | 0.879 ± 0.074 | 0.832 ± 0.049 | 0.781 ± 0.021 |
|                  | Relative  | 5             | 4.80 ± 0.10   | 4.93 ± 0.20   | 4.57 ± 0.12   |
| <b>Lung</b>      |           |               |               |               |               |
| Absolute         | 0         | 157 ± 16      | 158 ± 10      | 179 ± 16      | 178 ± 5       |
|                  | Relative  | 0             | 8.66 ± 0.78   | 9.53 ± 0.47   | 10.1 ± 1.09   |
| Absolute         | 2.5       | 192 ± 20      | 183 ± 12      | 197 ± 15      | 177 ± 10      |
|                  | Relative  | 2.5           | 9.92 ± 0.87   | 10.0 ± 0.42   | 10.1 ± 0.39   |
| Absolute         | 5         | 173 ± 8       | 208 ± 46      | 184 ± 13      | 164 ± 3       |
|                  | Relative  | 5             | 9.59 ± 0.36   | 11.5 ± 2.03   | 10.1 ± 0.48   |

<sup>a</sup> Liver weights (absolute weights) and body weights are given in grams; lung weights (absolute weights) are given in milligrams; organ-weight-to-body-weight ratios (relative weights) are given as g liver weight/g body weight as a percent or mg lung weight/g body weight (mean ± standard error). Terminal body weights and liver and lung weights were not affected by either urethane or ethanol in male or female mice.

**TABLE G6**  
**Cell Cycle Distribution and Percent Apoptosis in the Liver of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|                  | % Ethanol | Urethane     |              |              |              |
|------------------|-----------|--------------|--------------|--------------|--------------|
|                  |           | 0 ppm        | 10 ppm       | 30 ppm       | 90 ppm       |
| n                |           | 4            | 4            | 4            | 4            |
| <b>Male</b>      |           |              |              |              |              |
| Cell Cycle Phase |           |              |              |              |              |
| G <sub>0</sub>   | 0         | 99.47 ± 0.46 | 99.83 ± 0.08 | 99.84 ± 0.07 | 99.87 ± 0.06 |
|                  | 2.5       | 99.87 ± 0.06 | 99.83 ± 0.09 | 99.03 ± 0.15 | 99.69 ± 0.12 |
|                  | 5         | 99.55 ± 0.11 | 99.74 ± 0.05 | 99.93 ± 0.06 | 99.82 ± 0.08 |
| G <sub>1</sub>   | 0         | 0.13 ± 0.10  | 0.07 ± 0.04  | 0.05 ± 0.03  | 0.07 ± 0.04  |
|                  | 2.5       | 0.06 ± 0.04  | 0.01 ± 0.01  | 0.26 ± 0.06  | 0.05 ± 0.04  |
|                  | 5         | 0.14 ± 0.04  | 0.13 ± 0.03  | 0.05 ± 0.03  | 0.05 ± 0.03  |
| G <sub>2</sub>   | 0         | 0.06 ± 0.06  | 0.00 ± 0.00  | 0.02 ± 0.02  | 0.00 ± 0.00  |
|                  | 2.5       | 0.04 ± 0.04  | 0.02 ± 0.02  | 0.11 ± 0.04  | 0.07 ± 0.04  |
|                  | 5         | 0.14 ± 0.06  | 0.06 ± 0.01  | 0.00 ± 0.00  | 0.00 ± 0.00  |
| S                | 0         | 0.22 ± 0.18  | 0.09 ± 0.04  | 0.05 ± 0.02  | 0.06 ± 0.02  |
|                  | 2.5       | 0.04 ± 0.04  | 0.10 ± 0.05  | 0.23 ± 0.08  | 0.15 ± 0.07  |
|                  | 5         | 0.12 ± 0.03  | 0.06 ± 0.04  | 0.02 ± 0.02  | 0.13 ± 0.07  |
| M                | 0         | 0.12 ± 0.12  | 0.01 ± 0.01  | 0.04 ± 0.02  | 0.00 ± 0.00  |
|                  | 2.5       | 0.00 ± 0.00  | 0.04 ± 0.04  | 0.38 ± 0.04  | 0.04 ± 0.02  |
|                  | 5         | 0.05 ± 0.02  | 0.00 ± 0.00  | 0.00 ± 0.00  | 0.00 ± 0.00  |
| Apoptosis        | 0         | 0.11 ± 0.04  | 0.65 ± 0.06  | 0.33 ± 0.07  | 0.31 ± 0.11  |
|                  | 2.5       | 0.25 ± 0.15  | 0.11 ± 0.04  | 0.36 ± 0.08  | 0.28 ± 0.08  |
|                  | 5         | 0.12 ± 0.01  | 0.33 ± 0.13  | 0.66 ± 0.13  | 0.12 ± 0.01  |

**TABLE G6**  
**Cell Cycle Distribution and Percent Apoptosis in the Liver of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|                  | % Ethanol | Urethane     |              |              |              |
|------------------|-----------|--------------|--------------|--------------|--------------|
|                  |           | 0 ppm        | 10 ppm       | 30 ppm       | 90 ppm       |
| n                |           | 4            | 4            | 4            | 4            |
| <b>Female</b>    |           |              |              |              |              |
| Cell Cycle Phase |           |              |              |              |              |
| G <sub>0</sub>   | 0         | 99.69 ± 0.09 | 99.33 ± 0.09 | 99.57 ± 0.51 | 99.29 ± 0.19 |
|                  | 2.5       | 99.30 ± 0.19 | 99.46 ± 0.19 | 99.12 ± 0.32 | 98.67 ± 0.22 |
|                  | 5         | 99.44 ± 0.14 | 99.54 ± 0.06 | 99.18 ± 0.11 | 98.93 ± 0.16 |
| G <sub>1</sub>   | 0         | 0.11 ± 0.02  | 0.22 ± 0.03  | 0.46 ± 0.11  | 0.40 ± 0.10  |
|                  | 2.5       | 0.29 ± 0.05  | 0.20 ± 0.05  | 0.40 ± 0.20  | 0.85 ± 0.20  |
|                  | 5         | 0.24 ± 0.08  | 0.22 ± 0.06  | 0.44 ± 0.11  | 0.71 ± 0.14  |
| G <sub>2</sub>   | 0         | 0.07 ± 0.14  | 0.20 ± 0.10  | 0.33 ± 0.23  | 0.21 ± 0.06  |
|                  | 2.5       | 0.24 ± 0.11  | 0.10 ± 0.02  | 0.08 ± 0.04  | 0.17 ± 0.08  |
|                  | 5         | 0.17 ± 0.06  | 0.10 ± 0.03  | 0.29 ± 0.07  | 0.07 ± 0.05  |
| S                | 0         | 0.10 ± 0.07  | 0.22 ± 0.05  | 0.61 ± 0.21  | 0.10 ± 0.03  |
|                  | 2.5       | 0.16 ± 0.05  | 0.24 ± 0.04  | 0.30 ± 0.16  | 0.24 ± 0.06  |
|                  | 5         | 0.13 ± 0.03  | 0.13 ± 0.04  | 0.09 ± 0.02  | 0.26 ± 0.08  |
| M                | 0         | 0.02 ± 0.01  | 0.02 ± 0.01  | 0.03 ± 0.02  | 0.00 ± 0.00  |
|                  | 2.5       | 0.00 ± 0.00  | 0.00 ± 0.00  | 0.09 ± 0.06  | 0.06 ± 0.01  |
|                  | 5         | 0.01 ± 0.01  | 0.00 ± 0.00  | 0.00 ± 0.00  | 0.02 ± 0.01  |
| Apoptosis        | 0         | 0.16 ± 0.02  | 0.15 ± 0.06  | 0.11 ± 0.05  | 0.18 ± 0.09  |
|                  | 2.5       | 0.13 ± 0.01  | 0.31 ± 0.11  | 0.15 ± 0.05  | 0.41 ± 0.02  |
|                  | 5         | 0.39 ± 0.11  | 0.16 ± 0.10  | 0.06 ± 0.02  | 0.50 ± 0.08  |

<sup>a</sup> Data are given as percentage of cells in each cell cycle phase or apoptotic (mean ± standard error). Approximately 2,000 cells were counted per liver. Increasing the ethanol concentration had no effect on the cell cycle distribution in the liver of males or females. The percentage of G<sub>0</sub> cells was decreased and the percentage of G<sub>1</sub> cells was increased in females exposed to 30 or 90 ppm urethane (P≤0.05); the percentages were unchanged in males. The extent of apoptosis was affected by urethane in males, but not females, and the difference was significant in males exposed to 10 or 30 ppm urethane; the extent of apoptosis was not affected by ethanol in either sex.

**TABLE G7**  
**PCNA-Labeling Index in the Lung of Mice in the 4-Week Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|               | % Ethanol | Urethane   |            |           |           |
|---------------|-----------|------------|------------|-----------|-----------|
|               |           | 0 ppm      | 10 ppm     | 30 ppm    | 90 ppm    |
| n             |           | 4          | 4          | 4         | 4         |
| <b>Male</b>   |           |            |            |           |           |
|               | 0         | 10.7 ± 1.4 | 7.5 ± 1.0  | 5.7 ± 1.4 | 5.0 ± 0.9 |
|               | 2.5       | 9.2 ± 0.6  | 8.7 ± 0.9  | 2.7 ± 1.2 | 6.2 ± 1.2 |
|               | 5         | 10.5 ± 2.2 | 7.2 ± 2.1  | 7.2 ± 1.7 | 3.7 ± 0.6 |
| <b>Female</b> |           |            |            |           |           |
|               | 0         | 10.5 ± 1.6 | 9.5 ± 2.1  | 5.0 ± 1.5 | 6.5 ± 0.6 |
|               | 2.5       | 12.0 ± 2.0 | 8.7 ± 1.5  | 4.0 ± 0.9 | 6.5 ± 1.8 |
|               | 5         | 11.2 ± 1.7 | 11.0 ± 1.6 | 4.0 ± 0.9 | 7.7 ± 3.1 |

\* Significantly different ( $P \leq 0.05$ ) from the control group (0 ppm urethane/0% ethanol) by Dunnett's test

<sup>a</sup> Data are given as percentage of PCNA-labeled cells (mean ± standard error). Approximately 2,000 cells were counted per lung. The percentage of PCNA labeling was decreased in the lung of mice exposed to 30 or 90 ppm urethane ( $P \leq 0.05$ ). Increasing the ethanol concentration had no effect on the extent of PCNA labeling in the lung of males or females.

**TABLE G8**  
**Total Cytochrome P450, Cytochrome P450 2E1 Activity, and Glutathione Content in the Liver of Mice in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|  | % Ethanol | Urethane                |                          |                         |              |
|--|-----------|-------------------------|--------------------------|-------------------------|--------------|
|  |           | 0 ppm                   | 10 ppm                   | 30 ppm                  | 90 ppm       |
| n  |           | 4                       | 4                        | 4                       | 4            |
| <b>Male</b>  |           |                         |                          |                         |              |
| Cytochrome P450 (nmol/g liver)                                   |           |                         |                          |                         |              |
|  | 0         | 11.6 ± 0.3              | ND                       | 12.6 ± 0.2 <sup>b</sup> | 13.3 ± 0.5   |
|  | 2.5       | 12.6 ± 0.8              | 11.0 ± 1.6               | 13.9 ± 1.1              | 11.1 ± 0.6   |
|  | 5         | 12.3 ± 0.9 <sup>c</sup> | 13.0 ± 1.0               | 11.1 ± 2.3              | 14.7 ± 0.6   |
| Cytochrome P450 2E1 (nmol 4-nitrocatechol/mg protein per minute) |           |                         |                          |                         |              |
|  | 0         | 4.5 ± 0.1               | ND                       | 4.9 ± 0.1 <sup>b</sup>  | 4.0 ± 0.3    |
|  | 2.5       | 4.0 ± 0.1               | 4.3 ± 0.3                | 3.7 ± 0.2               | 3.9 ± 0.3    |
|  | 5         | 5.0 ± 0.2 <sup>c</sup>  | 4.4 ± 0.3                | 5.0 ± 0.4               | 5.0 ± 0.2    |
| Glutathione (absorbance; relative units)                         |           |                         |                          |                         |              |
|  | 0         | 0.31 ± 0.01             | 0.30 ± 0.02              | 0.28 ± 0.02             | 0.30 ± 0.02  |
|  | 2.5       | 0.50 ± 0.05             | 0.33 ± 0.05              | 0.44 ± 0.04             | 0.32 ± 0.02  |
|  | 5         | 0.24 ± 0.03             | 0.26 ± 0.01              | 0.23 ± 0.04             | 0.29 ± 0.02  |
| <b>Female</b>  |           |                         |                          |                         |              |
| Cytochrome P450 (nmol/g liver)                                   |           |                         |                          |                         |              |
|  | 0         | 14.4 ± 0.6              | 13.8 ± 0.6 <sup>d</sup>  | 12.7 ± 0.4              | 14.3 ± 0.2   |
|  | 2.5       | 13.8 ± 0.1              | 12.9 ± 0.2               | 12.1 ± 1.0              | 14.6 ± 1.7   |
|  | 5         | 14.2 ± 1.3              | 12.9 ± 0.6               | 11.2 ± 1.5              | 13.6 ± 0.9   |
| Cytochrome P450 2E1 (nmol 4-nitrocatechol/mg protein per minute) |           |                         |                          |                         |              |
|  | 0         | 3.5 ± 0.3               | 3.5 ± 0.1                | 4.0 ± 0.3               | 3.5 ± 0.2    |
|  | 2.5       | 4.4 ± 0.5               | 5.4 ± 0.2                | 4.8 ± 0.2               | 3.9 ± 0.2    |
|  | 5         | 5.4 ± 0.2               | 6.1 ± 0.4                | 6.0 ± 0.4               | 5.8 ± 0.2    |
| Glutathione (absorbance; relative units)                         |           |                         |                          |                         |              |
|  | 0         | 0.30 ± 0.02             | 0.28 ± 0.02 <sup>d</sup> | 0.23 ± 0.04             | 0.32 ± 0.003 |
|  | 2.5       | 0.23 ± 0.003            | 0.20 ± 0.01              | 0.22 ± 0.01             | 0.28 ± 0.02  |
|  | 5         | 0.21 ± 0.01             | 0.19 ± 0.02              | 0.17 ± 0.02             | 0.25 ± 0.03  |

<sup>a</sup> Data are given as mean ± standard error. Total cytochrome P450 content was not affected by either urethane or ethanol in males or females. Urethane did not affect the cytochrome P450 2E1 activity in males or females. Ethanol caused an exposure-related increase in cytochrome P450 2E1 activity in the liver of females, and the levels in females exposed to 2.5% or 5% ethanol were significantly increased ( $P \leq 0.05$ ); this trend did not occur in males. Ethanol caused an exposure-related decrease in glutathione content in the females, and the levels in the 2.5% and 5% ethanol groups were significantly less ( $P \leq 0.05$ ) than those of the controls; this trend did not occur in males. Urethane did not affect the glutathione content. ND=not determined

<sup>b</sup> n=2

<sup>c</sup> n=3

<sup>d</sup> n=8

**TABLE G9**  
**Etheno-DNA Adducts in the Liver and Lung of Male and Female Mice**  
**in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|                                       | % Ethanol | Urethane    |             |
|---------------------------------------|-----------|-------------|-------------|
|                                       |           | 0 ppm       | 90 ppm      |
| n                                     |           | 8           | 8           |
| Liver                                 |           |             |             |
| Etheno-dA/10 <sup>8</sup> nucleotides | 0         | 1.19 ± 0.07 | 1.48 ± 0.14 |
|                                       | 5         | 0.81 ± 0.06 | 1.10 ± 0.20 |
| Lung                                  |           |             |             |
| Etheno-dA/10 <sup>8</sup> nucleotides | 0         | 0.97 ± 0.18 | 1.12 ± 0.13 |
|                                       | 5         | 0.92 ± 0.15 | 1.06 ± 0.10 |
| Etheno-dC/10 <sup>8</sup> nucleotides | 0         | 0.92 ± 0.21 | 0.97 ± 0.18 |
|                                       | 5         | 1.16 ± 0.15 | 0.76 ± 0.16 |

<sup>a</sup> Data are given as mean ± standard error. The levels of hepatic DNA etheno-dA adducts were increased (P<0.05) by exposure to 90 ppm urethane and decreased (P<0.05) by exposure to 5% ethanol.

# APPENDIX H ORGAN WEIGHTS AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS

**TABLE H1** Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice  
in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol . . . . . H-2

**TABLE H1**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol<sup>a</sup>**

|                     | Urethane     |                           |              |               |
|---------------------|--------------|---------------------------|--------------|---------------|
|                     | 0 ppm        | 10 ppm                    | 30 ppm       | 90 ppm        |
| <b>Male</b>         |              |                           |              |               |
| <b>0% Ethanol</b>   |              |                           |              |               |
| n                   | 26           | 26                        | 24           | 8             |
| Necropsy body wt    | 39.5 ± 1.2   | 39.3 ± 0.9                | 37.1 ± 1.3   | 34.8 ± 1.9*   |
| Liver               |              |                           |              |               |
| Absolute            | 2.33 ± 0.22  | 2.09 ± 0.12               | 2.38 ± 0.19  | 2.65 ± 0.58   |
| Relative            | 61.43 ± 7.3  | 54.15 ± 3.92              | 65.6 ± 5.68  | 72.81 ± 12.4  |
| Lung                |              |                           |              |               |
| Absolute            | 0.36 ± 0.03  | 0.32 ± 0.01               | 0.39 ± 0.04  | 0.55 ± 0.19*  |
| Relative            | 9.07 ± 0.72  | 8.28 ± 0.26               | 10.93 ± 1.46 | 16.83 ± 6.4** |
| <b>2.5% Ethanol</b> |              |                           |              |               |
| n                   | 31           | 30                        | 25           | 16            |
| Necropsy body wt    | 37.7 ± 1.1   | 36.8 ± 0.9                | 37.8 ± 1.0   | 32.9 ± 0.7**  |
| Liver               |              |                           |              |               |
| Absolute            | 2.01 ± 0.15  | 2.16 ± 0.14 <sup>b</sup>  | 2.29 ± 0.16  | 2.19 ± 0.25   |
| Relative            | 55.95 ± 5.87 | 60.37 ± 5.03 <sup>b</sup> | 61.73 ± 4.95 | 65.9 ± 6.66   |
| Lung                |              |                           |              |               |
| Absolute            | 0.38 ± 0.03  | 0.37 ± 0.04               | 0.41 ± 0.04  | 0.42 ± 0.05   |
| Relative            | 10.24 ± 0.93 | 10.33 ± 1.37              | 11.12 ± 1.23 | 13.1 ± 1.87   |
| <b>5% Ethanol</b>   |              |                           |              |               |
| n                   | 36           | 29                        | 21           | 12            |
| Necropsy body wt    | 39.0 ± 0.5   | 37.9 ± 0.9                | 38.7 ± 1.0   | 31.5 ± 1.0**  |
| Liver               |              |                           |              |               |
| Absolute            | 2.24 ± 0.11  | 2.31 ± 0.19               | 2.02 ± 0.09  | 1.86 ± 0.16   |
| Relative            | 58.04 ± 3.37 | 63.67 ± 6.78              | 52.46 ± 2.11 | 60.23 ± 5.93  |
| Lung                |              |                           |              |               |
| Absolute            | 0.37 ± 0.03  | 0.32 ± 0.02               | 0.36 ± 0.02  | 0.47 ± 0.09   |
| Relative            | 9.58 ± 0.77  | 8.62 ± 0.49               | 9.34 ± 0.7   | 15.05 ± 2.97* |

**TABLE H1**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice**  
**in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

|                     | Urethane                 |              |                           |                |
|---------------------|--------------------------|--------------|---------------------------|----------------|
|                     | 0 ppm                    | 10 ppm       | 30 ppm                    | 90 ppm         |
| <b>Female</b>       |                          |              |                           |                |
| <b>0% Ethanol</b>   |                          |              |                           |                |
| n                   | 37                       | 36           | 27                        | 0 <sup>c</sup> |
| Necropsy body wt    | 47.3 ± 1.7               | 47.0 ± 1.4   | 43.7 ± 1.6                |                |
| Liver               |                          |              |                           |                |
| Absolute            | 2.19 ± 0.14              | 1.97 ± 0.07  | 2.13 ± 0.01 <sup>d</sup>  |                |
| Relative            | 48.09 ± 4.05             | 42.67 ± 1.55 | 49.72 ± 2.69 <sup>d</sup> |                |
| Lung                |                          |              |                           |                |
| Absolute            | 0.28 ± 0.01              | 0.27 ± 0.01  | 0.36 ± 0.04               |                |
| Relative            | 6.33 ± 0.37              | 5.88 ± 0.23  | 8.86 ± 1.16               |                |
| <b>2.5% Ethanol</b> |                          |              |                           |                |
| n                   | 39                       | 33           | 19                        | 8              |
| Necropsy body wt    | 46.9 ± 1.5               | 43.8 ± 1.6   | 39.6 ± 1.7**              | 30.4 ± 2.4**   |
| Liver               |                          |              |                           |                |
| Absolute            | 1.98 ± 0.08              | 2.12 ± 0.1   | 2.06 ± 0.14               | 1.73 ± 0.21    |
| Relative            | 42.65 ± 1.53             | 50.51 ± 3.22 | 52.45 ± 3.17              | 57.8 ± 7.04    |
| Lung                |                          |              |                           |                |
| Absolute            | 0.27 ± 0.01              | 0.29 ± 0.01  | 0.33 ± 0.05               | 0.61 ± 0.18**  |
| Relative            | 5.99 ± 0.24              | 6.97 ± 0.45  | 9.4 ± 2.32                | 23.36 ± 8.36** |
| <b>5% Ethanol</b>   |                          |              |                           |                |
| n                   | 31                       | 32           | 26                        | 4              |
| Necropsy body wt    | 44.2 ± 1.2               | 42.4 ± 1.2   | 41.2 ± 1.6                | 34.2 ± 4.7     |
| Liver               |                          |              |                           |                |
| Absolute            | 1.95 ± 0.09              | 2.01 ± 0.08  | 2.21 ± 0.16*              | 1.95 ± 0.38    |
| Relative            | 44.37 ± 1.92             | 48.5 ± 2.55  | 56.25 ± 5.96              | 55.81 ± 4.2    |
| Lung                |                          |              |                           |                |
| Absolute            | 0.27 ± 0.01 <sup>e</sup> | 0.3 ± 0.01   | 0.34 ± 0.03 <sup>f</sup>  | 0.37 ± 0.09    |
| Relative            | 6.27 ± 0.23 <sup>e</sup> | 7.12 ± 0.37  | 8.5 ± 0.69 <sup>f</sup>   | 10.91 ± 2.23   |

\* Significantly different ( $P \leq 0.05$ ) from the control group (0 ppm urethane/0%, 2.5%, or 5% ethanol) by Dunnett's test

\*\*  $P \leq 0.01$

<sup>a</sup> Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error).

<sup>b</sup> n=29

<sup>c</sup> No data were available for the 90 ppm group because only one animal survived in this group.

<sup>d</sup> n=26

<sup>e</sup> n=30

<sup>f</sup> n=25



# APPENDIX I

## CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

|   |  |             |
|---|--|-------------|
| <b>PROCUREMENT AND CHARACTERIZATION OF URETHANE AND ETHANOL</b> |  | <b>I-2</b>  |
| <b>PREPARATION AND ANALYSIS OF DOSE FORMULATIONS</b>            |  | <b>I-2</b>  |
| <b>FIGURE I1</b>  | <b><sup>1</sup>H-Nuclear Magnetic Resonance Spectrum of Urethane</b>   | <b>I-4</b>  |
| <b>FIGURE I2</b>  | <b><sup>13</sup>C-Nuclear Magnetic Resonance Spectrum of Urethane</b>  | <b>I-5</b>  |
| <b>FIGURE I3</b>  | <b><sup>1</sup>H-Nuclear Magnetic Resonance Spectrum of Ethanol</b>  | <b>I-6</b>  |
| <b>FIGURE I4</b>  | <b><sup>13</sup>C-Nuclear Magnetic Resonance Spectrum of Ethanol</b>   | <b>I-7</b>  |
| <b>TABLE I1</b>   | <b>Preparation and Storage of Dose Formulations<br/>in the 4-Week and 2-Year Drinking Water Studies<br/>of Urethane, Ethanol, and Urethane/Ethanol</b> | <b>I-8</b>  |
| <b>TABLE I2</b>   | <b>Results of Analyses of Dose Formulations Administered to Mice<br/>in the 4-Week Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b> | <b>I-9</b>  |
| <b>TABLE I3</b>   | <b>Results of Analyses of Dose Formulations Administered to Mice<br/>in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol</b> | <b>I-12</b> |

# CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

## PROCUREMENT AND CHARACTERIZATION OF URETHANE AND ETHANOL

Urethane was obtained from Aldrich Chemical Company (Milwaukee, WI) in one lot (09101PN), and ethanol was obtained from AAPER Alcohol (Shelbyville, KY) in one lot (961730BB); both lots were used during the 4-week and 2-year studies. Identity, purity, and stability analyses were conducted by the study laboratory.

Lot 09101PN, a white crystalline solid, was identified as urethane by <sup>1</sup>H- and <sup>13</sup>C-nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Lot 961730BB, a clear liquid, was identified as ethanol by <sup>1</sup>H- and <sup>13</sup>C-NMR spectroscopy. All spectra were consistent with the structures of urethane or ethanol. The NMR spectra are presented in Figures I1 to I4.

The purity of lots 09101PN and 961730BB were determined by <sup>1</sup>H- and <sup>13</sup>C-NMR spectroscopy and gas chromatography (GC)/MS (lot 09101PN). The water content of urethane and ethanol were determined by Karl Fischer titration. For urethane, the results of <sup>1</sup>H- and <sup>13</sup>C-NMR spectroscopy indicated a purity of 99% or greater, and GC/MS indicated a purity of greater than 95% with no minor impurity peaks detected. For ethanol, no impurities other than water were detected; <sup>1</sup>H-NMR spectroscopy indicated 92.6% ethanol and 7.4% water. Karl Fischer titration indicated 0.1% water in urethane and 7.4% water in ethanol.

The bulk urethane was stored in sealed plastic bags in glass desiccators under phosphorus pentoxide at ambient temperature. The bulk ethanol was stored in glass containers at ambient temperature. Stability of urethane and ethanol in aqueous solutions was monitored for 56 (urethane) or 35 (ethanol) days using GC with a flame ionization detector and a GP 60/80 Carbowax 20M column (6 ft × 2 mm) (Supelco, Bellefonte, PA) with helium as the carrier gas at 57 mL/minute and an oven temperature of 80° C for 0.5 minutes, then 80° C to 180° C at 40° C per minute with a 5-minute hold. Concentrations of 10 ppm urethane and 0%, 2.5%, and 5% ethanol and 1% urethane were used to monitor the stability of urethane; concentrations of 2.5% ethanol and water and 2.5% ethanol and 90 ppm urethane were used to monitor the stability of ethanol. No degradation of the bulk chemical was detected.

## PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

The dose formulations were prepared once weekly during the 4-week study and approximately every 8 weeks during the 2-year study by mixing urethane with deionized water, ethanol with Millipore-filtered tap water, and then urethane with Millipore-filtered tap water or Millipore-filtered tap water containing ethanol (Table I1).

Stability studies of the dose formulations were performed by the study laboratory with GC using the methods and concentrations described for the bulk chemical analyses. Stability was confirmed for at least 56 (urethane) or 35 (ethanol) days.

Periodic analyses of the dose formulations were conducted by the study laboratory using GC as described above. The dose formulations were analyzed once weekly during the 4-week study (Table I2) and approximately every 8 weeks during the 2-year study (Table I3). During the 2-year study, animal room samples of the dose formulations were analyzed approximately every 6 months. Of the urethane dose formulations used during the 4-week study, 90 of 90 were within the target concentrations ( $\pm 20\%$  for the 10 ppm or  $\pm 10\%$  for the 30 and 90 ppm dose formulations); of the ethanol dose formulations, 80 of 80 were within the target concentrations ( $\pm 20\%$

for the 2.5% or  $\pm 10\%$  for the 5% dose formulations). Of the urethane dose formulations used during the 2-year study, 223 of 228 were within the target concentrations; of the animal room samples analyzed, 35 of 36 were within the target concentrations. Of the ethanol dose formulations, 200 of 203 were within the target concentrations; of the animal room samples analyzed, 31 of 32 were within the target concentrations.




FIGURE I1  
1H-Nuclear Magnetic Resonance Spectrum of Urethane




FIGURE I2  
13C-Nuclear Magnetic Resonance Spectrum of Urethane




FIGURE I3  
1H-Nuclear Magnetic Resonance Spectrum of Ethanol




FIGURE I4  
<sup>13</sup>C-Nuclear Magnetic Resonance Spectrum of Ethanol

**TABLE II**  
**Preparation and Storage of Dose Formulations in the 4-Week and 2-Year Drinking Water Studies of Urethane, Ethanol, and Urethane/Ethanol**

---

**Preparation**

The urethane dose formulations were prepared by mixing urethane with distilled water and then filtering the solutions through sterile 0.45  $\mu\text{m}$  nylon filters. The ethanol dose formulations were prepared by adding ethanol to Millipore-filtered tap water. The urethane solutions were added to Millipore-filtered tap water or to Millipore-filtered tap water containing ethanol. Dose formulations were prepared once weekly (4-week study) or approximately every 8 weeks (2-year study).

**Chemical Lot Numbers**

Urethane: 09101PN

Ethanol: 961730BB

**Maximum Storage Time**

56 (urethane) or 35 (ethanol) days

**Study Laboratory**

National Center for Toxicological Research (Jefferson, AR)

---

**TABLE I2**  
**Results of Analyses of Dose Formulations Administered to Mice in the 4-Week Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared    | Date Analyzed    | Urethane                   |   |                            | Ethanol                  |   |                            |
|------------------|------------------|----------------------------|---|----------------------------|--------------------------|---|----------------------------|
|                  |                  | Target Concentration (ppm) | Determined Concentration <sup>a</sup> (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration <sup>a</sup> (%) | Difference from Target (%) |
| October 9, 1996  | October 28, 1996 | 0                          | 0.00  | 0                          | 2.5                      | 2.36                                      | -6                         |
|                  |                  | 0                          | 0.00  | 0                          | 5                        | 4.75                                      | -5                         |
|                  |                  | 10                         | 9.47  | -5                         | 0                        | 0.01                                      | 0                          |
|                  |                  | 10                         | 9.47  | -5                         | 2.5                      | 2.37                                      | -5                         |
|                  |                  | 10                         | 9.45  | -5                         | 5                        | 4.84                                      | -3                         |
|                  |                  | 30                         | 29.24                                       | -3                         | 0                        | 0.02                                      | 0                          |
|                  |                  | 30                         | 29.30                                       | -2                         | 2.5                      | 2.35                                      | -6                         |
|                  |                  | 30                         | 29.03                                       | -3                         | 5                        | 4.71                                      | -6                         |
|                  |                  | 90                         | 94.32                                       | +5                         | 0                        | 0.01                                      | 0                          |
|                  |                  | 90                         | 93.13                                       | +3                         | 2.5                      | 2.40                                      | -4                         |
|                  |                  | 90                         | 92.82                                       | +3                         | 5                        | 4.82                                      | -4                         |
| October 16, 1996 | October 28, 1996 | 0                          | 0.00  | 0                          | 2.5                      | 2.34                                      | -6                         |
|                  |                  | 0                          | 0.00  | 0                          | 5                        | 4.80                                      | -4                         |
|                  |                  | 10                         | 9.87  | -1                         | 0                        | 0.01                                      | 0                          |
|                  |                  | 10                         | 9.32  | -7                         | 2.5                      | 2.38                                      | -5                         |
|                  |                  | 10                         | 9.51  | -5                         | 5                        | 4.89                                      | -2                         |
|                  |                  | 30                         | 30.89                                       | +3                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 30                         | 28.90                                       | -4                         | 2.5                      | 2.39                                      | -4                         |
|                  |                  | 30                         | 29.66                                       | -1                         | 5                        | 4.94                                      | -1                         |
|                  |                  | 90                         | 93.72                                       | +4                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 90                         | 93.64                                       | +4                         | 2.5                      | 2.37                                      | -5                         |
|                  |                  | 90                         | 97.00                                       | +8                         | 5                        | 4.94                                      | -1                         |
| October 23, 1996 | October 28, 1996 | 0                          | 0.00  | 0                          | 2.5                      | 2.42                                      | -3                         |
|                  |                  | 0                          | 0.00  | 0                          | 5                        | 4.69                                      | -6                         |
|                  |                  | 10                         | 9.14  | -9                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 10                         | 9.28  | -7                         | 2.5                      | 2.40                                      | -4                         |
|                  |                  | 10                         | 9.53  | -5                         | 5                        | 4.73                                      | -5                         |
|                  |                  | 30                         | 28.04                                       | -7                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 30                         | 28.63                                       | -5                         | 2.5                      | 2.41                                      | -4                         |
|                  |                  | 30                         | 28.29                                       | -6                         | 5                        | 4.83                                      | -3                         |
|                  |                  | 90                         | 93.90                                       | +4                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 90                         | 94.52                                       | +5                         | 2.5                      | 2.42                                      | -3                         |
|                  |                  | 90                         | 91.67                                       | +2                         | 5                        | 4.85                                      | -3                         |
| October 30, 1996 | October 31, 1996 | 0                          | 0.00  | 0                          | 2.5                      | 2.39                                      | -4                         |
|                  |                  | 0                          | 0.00  | 0                          | 5                        | 4.69                                      | -6                         |
|                  |                  | 10                         | 9.11  | -9                         | 0                        | 0.00                                      | 0                          |
|                  |                  | 10                         | 9.06  | -9                         | 2.5                      | 2.41                                      | -4                         |
|                  |                  | 10                         | 9.15  | -8                         | 5                        | 4.79                                      | -4                         |
|                  |                  | 30                         | 28.56                                       | -5                         | 0                        | 0.01                                      | 0                          |
|                  |                  | 30                         | 28.26                                       | -6                         | 2.5                      | 2.45                                      | -2                         |
|                  |                  | 30                         | 28.30                                       | -6                         | 5                        | 4.84                                      | -3                         |
|                  |                  | 90                         | 93.09                                       | +3                         | 0                        | 0.01                                      | 0                          |
|                  |                  | 90                         | 92.95                                       | +3                         | 2.5                      | 2.43                                      | -3                         |
|                  |                  | 90                         | 93.11                                       | +3                         | 5                        | 4.88                                      | -2                         |

**TABLE I2**  
**Results of Analyses of Dose Formulations Administered to Mice in the 4-Week Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared     | Date Analyzed     | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|-------------------|-------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                   |                   | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| November 2, 1996  | November 4, 1996  | 0                          | 0.00                           | 0                          | 2.5                      | 2.49                         | 0                          |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 5.23                         | +5                         |
|                   |                   | 10                         | 10.58                          | +6                         | 0                        | 0.01                         | 0                          |
|                   |                   | 10                         | 9.92                           | -1                         | 2.5                      | 2.55                         | +2                         |
|                   |                   | 10                         | 9.61                           | -4                         | 5                        | 4.62                         | -8                         |
|                   |                   | 30                         | 32.49                          | +8                         | 0                        | 0.01                         | 0                          |
|                   |                   | 30                         | 31.24                          | +4                         | 2.5                      | 2.50                         | 0                          |
|                   |                   | 30                         | 29.96                          | 0                          | 5                        | 4.78                         | -4                         |
|                   |                   | 90                         | 91.51                          | +2                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 92.61                          | +3                         | 2.5                      | 2.50                         | 0                          |
|                   |                   | 90                         | 91.64                          | +2                         | 5                        | 4.65                         | -7                         |
| November 6, 1996  | November 8, 1996  | 0                          | 0.00                           | 0                          | 2.5                      | 2.38                         | -5                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 4.75                         | -5                         |
|                   |                   | 10                         | 9.11                           | -9                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.17                           | -8                         | 2.5                      | 2.44                         | -2                         |
|                   |                   | 10                         | 9.17                           | -8                         | 5                        | 4.79                         | -4                         |
|                   |                   | 30                         | 29.60                          | -1                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 29.40                          | -2                         | 2.5                      | 2.41                         | -4                         |
|                   |                   | 30                         | 29.52                          | -2                         | 5                        | 4.88                         | -2                         |
|                   |                   | 90                         | 92.76                          | +3                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 94.11                          | +5                         | 2.5                      | 2.42                         | -3                         |
|                   |                   | 90                         | 84.74                          | -6                         | 5                        | 4.89                         | -2                         |
| November 13, 1996 | November 15, 1996 | 0                          | 0.00                           | 0                          | 2.5                      | 2.39                         | -4                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 4.89                         | -2                         |
|                   |                   | 10                         | 9.67                           | -3                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.52                           | -5                         | 2.5                      | 2.37                         | -5                         |
|                   |                   | 10                         | 9.34                           | -7                         | 5                        | 4.81                         | -4                         |
|                   |                   | 30                         | 28.93                          | -4                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 28.33                          | -6                         | 2.5                      | 2.31                         | -8                         |
|                   |                   | 30                         | 29.98                          | 0                          | 5                        | 4.76                         | -5                         |
|                   |                   | 90                         | 93.60                          | +4                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 92.35                          | +3                         | 2.5                      | 2.41                         | -4                         |
|                   |                   | 90                         | 92.69                          | +3                         | 5                        | 4.84                         | -3                         |
| November 20, 1996 | November 21, 1996 | 0                          | 0.00                           | 0                          | 2.5                      | 2.28                         | -9                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 4.90                         | -2                         |
|                   |                   | 10                         | 9.57                           | -4                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.71                           | -3                         | 2.5                      | 2.25                         | -10                        |
|                   |                   | 10                         | 9.75                           | -2                         | 5                        | 5.14                         | +3                         |
|                   |                   | 30                         | 28.99                          | -3                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 29.04                          | -3                         | 2.5                      | 2.35                         | -6                         |
|                   |                   | 30                         | 28.78                          | -4                         | 5                        | 4.98                         | 0                          |
|                   |                   | 90                         | 94.30                          | +5                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 91.77                          | +2                         | 2.5                      | 2.32                         | -7                         |
|                   |                   | 90                         | 94.56                          | +5                         | 5                        | 5.00                         | 0                          |

**TABLE I2**  
**Results of Analyses of Dose Formulations Administered to Mice in the 4-Week Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared     | Date Analyzed     | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|-------------------|-------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                   |                   | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| November 25, 1996 | November 26, 1996 | 0                          | 0.00                           | 0                          | 2.5                      | 2.40                         | -4                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 4.93                         | -1                         |
|                   |                   | 10                         | 9.52                           | -5                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.59                           | -4                         | 2.5                      | 2.42                         | -3                         |
|                   |                   | 10                         | 9.58                           | -4                         | 5                        | 4.88                         | -2                         |
|                   |                   | 30                         | 29.32                          | -2                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 29.51                          | -2                         | 2.5                      | 2.43                         | -3                         |
|                   |                   | 30                         | 29.58                          | -1                         | 5                        | 4.89                         | -2                         |
|                   |                   | 90                         | 94.58                          | +5                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 94.51                          | +5                         | 2.5                      | 2.41                         | -4                         |
|                   |                   | 90                         | 93.07                          | +3                         | 5                        | 4.98                         | 0                          |
| December 4, 1996  | December 5, 1996  | 0                          | 0.00                           | 0                          | 2.5                      | 2.38                         | -5                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 4.94                         | -1                         |
|                   |                   | 10                         | 9.80                           | -2                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.94                           | -1                         | 2.5                      | 2.47                         | -1                         |
|                   |                   | 10                         | 9.90                           | -1                         | 5                        | 4.99                         | 0                          |
|                   |                   | 30                         | 29.70                          | -1                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 29.87                          | 0                          | 2.5                      | 2.43                         | -3                         |
|                   |                   | 30                         | 29.77                          | -1                         | 5                        | 4.90                         | -2                         |
|                   |                   | 90                         | 95.98                          | +7                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 95.16                          | +6                         | 2.5                      | 2.44                         | -2                         |
|                   |                   | 90                         | 95.63                          | +6                         | 5                        | 4.91                         | -2                         |

<sup>a</sup> Results of duplicate analyses

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared  | Date Analyzed  | Urethane                   |   |                            | Ethanol                  |   |                            |
|----------------|----------------|----------------------------|---|----------------------------|--------------------------|---|----------------------------|
|                |                | Target Concentration (ppm) | Determined Concentration <sup>a</sup> (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration <sup>a</sup> (%) | Difference from Target (%) |
| March 10, 1997 | March 10, 1997 | 0                          | 0.00  | 0                          | 2.5                      | 2.39                                      | -4                         |
|                |                | 0                          | 0.00  | 0                          | 5                        | 4.84                                      | -3                         |
|                |                | 10                         | 9.18  | -8                         | 0                        | 0.00                                      | 0                          |
|                |                | 10                         | 9.46  | -5                         | 2.5                      | 2.39                                      | -4                         |
|                |                | 10                         | 9.34  | -7                         | 5                        | 4.80                                      | -4                         |
|                |                | 30                         | 30.37                                       | +1                         | 0                        | 0.00                                      | 0                          |
|                |                | 30                         | 30.57                                       | +2                         | 2.5                      | 2.42                                      | -3                         |
|                |                | 30                         | 30.16                                       | +1                         | 5                        | 4.72                                      | -6                         |
|                |                | 90                         | 90.96                                       | +1                         | 0                        | 0.00                                      | 0                          |
|                |                | 90                         | 93.94                                       | +4                         | 2.5                      | 2.37                                      | -5                         |
|                |                | 90                         | 91.56                                       | +2                         | 5                        | 4.76                                      | -5                         |
| March 13, 1997 | March 17, 1997 | 0                          | 0.00  | 0                          | 2.5                      | 2.47                                      | -1                         |
|                |                | 0                          | 0.00  | 0                          | 5                        | 4.95                                      | -1                         |
|                |                | 10                         | 9.57  | -4                         | 0                        | 0.00                                      | 0                          |
|                |                | 10                         | 9.79  | -2                         | 2.5                      | 2.47                                      | -1                         |
|                |                | 10                         | 10.11                                       | +1                         | 5                        | 4.82                                      | -4                         |
|                |                | 30                         | 31.29                                       | +4                         | 0                        | 0.00                                      | 0                          |
|                |                | 30                         | 31.05                                       | +4                         | 2.5                      | 2.47                                      | -1                         |
|                |                | 30                         | 30.70                                       | +2                         | 5                        | 4.81                                      | -4                         |
|                |                | 90                         | 85.80                                       | -5                         | 0                        | 0.00                                      | 0                          |
|                |                | 90                         | 90.02                                       | 0                          | 2.5                      | 2.46                                      | -2                         |
|                |                | 90                         | 87.87                                       | -2                         | 5                        | 4.76                                      | -5                         |
| March 19, 1997 | March 21, 1997 | 0                          | 0.00  | 0                          | 2.5                      | 2.47                                      | -1                         |
|                |                | 0                          | 0.00  | 0                          | 5                        | 5.03                                      | +1                         |
|                |                | 10                         | 9.03  | -10                        | 0                        | 0.00                                      | 0                          |
|                |                | 10                         | 9.33  | -7                         | 2.5                      | 2.52                                      | +1                         |
|                |                | 10                         | 9.16  | -8                         | 5                        | 5.07                                      | +1                         |
|                |                | 30                         | 28.48                                       | -5                         | 0                        | 0.00                                      | 0                          |
|                |                | 30                         | 28.22                                       | -6                         | 2.5                      | 2.44                                      | -2                         |
|                |                | 30                         | 28.58                                       | -5                         | 5                        | 5.03                                      | +1                         |
|                |                | 90                         | 88.36                                       | -2                         | 0                        | 0.00                                      | 0                          |
|                |                | 90                         | 87.85                                       | -2                         | 2.5                      | 2.46                                      | -2                         |
|                |                | 90                         | 88.24                                       | -2                         | 5                        | 5.14                                      | +3                         |
| March 27, 1997 | April 1, 1997  | 0                          | 0.00  | 0                          | 2.5                      | 2.42                                      | -3                         |
|                |                | 0                          | 0.00  | 0                          | 5                        | 4.86                                      | -3                         |
|                |                | 10                         | 9.53  | -5                         | 0                        | 0.00                                      | 0                          |
|                |                | 10                         | 9.29  | -7                         | 2.5                      | 2.41                                      | -4                         |
|                |                | 10                         | 8.80  | -12                        | 5                        | 5.01                                      | 0                          |
|                |                | 30                         | 28.16                                       | -6                         | 0                        | 0.00                                      | 0                          |
|                |                | 30                         | 28.48                                       | -5                         | 2.5                      | 2.40                                      | -4                         |
|                |                | 30                         | 28.29                                       | -6                         | 5                        | 4.97                                      | -1                         |
|                |                | 90                         | 86.78                                       | -4                         | 0                        | 0.00                                      | 0                          |
|                |                | 90                         | 87.39                                       | -3                         | 2.5                      | 2.41                                      | -4                         |
|                |                | 90                         | 85.53                                       | -5                         | 5                        | 5.01                                      | 0                          |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared      | Date Analyzed      | Urethane                           |                                |                            | Ethanol                  |                              |                            |   |
|--------------------|--------------------|------------------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|---|
|                    |                    | Target Concentration (ppm)         | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |   |
| May 30, 1997       | June 3, 1997       | 0                                  | 0.00                           | 0                          | 2.5                      | 2.42                         | -3                         |   |
|                    |                    | 0                                  | 0.00                           | 0                          | 5                        | 4.96                         | -1                         |   |
|                    |                    | 10                                 | 9.15                           | -9                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 10                                 | 9.50                           | -5                         | 2.5                      | 2.48                         | -1                         |   |
|                    |                    | 10                                 | 9.52                           | -5                         | 5                        | 5.03                         | +1                         |   |
|                    |                    | 30                                 | 29.07                          | -3                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 30                                 | 29.08                          | -3                         | 2.5                      | 2.50                         | 0                          |   |
|                    |                    | 30                                 | 29.67                          | -1                         | 5                        | 5.03                         | +1                         |   |
|                    |                    | 90                                 | 87.90                          | -2                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 90                                 | 86.58                          | -4                         | 2.5                      | 2.42                         | -3                         |   |
|                    |                    | 90                                 | 88.01                          | -2                         | 5                        | 5.08                         | +2                         |   |
| July 23, 1997      | July 28, 1997      | 0                                  | 0.00                           | 0                          | 2.5                      | 2.55                         | +2                         |   |
|                    |                    | 0                                  | 0.00                           | 0                          | 5                        | 4.96                         | -1                         |   |
|                    |                    | 10                                 | 8.81                           | -12                        | 0                        | 0.00                         | 0                          |   |
|                    |                    | 10                                 | 9.16                           | -8                         | 2.5                      | 2.48                         | -1                         |   |
|                    |                    | 10                                 | 8.60                           | -14                        | 5                        | 4.79                         | -4                         |   |
|                    |                    | 30                                 | 27.07                          | -10                        | 0                        | 0.00                         | 0                          |   |
|                    |                    | 30                                 | 27.70                          | -8                         | 2.5                      | 2.47                         | -1                         |   |
|                    |                    | 30                                 | 28.46                          | -5                         | 5                        | 5.10                         | +2                         |   |
|                    |                    | 90                                 | 89.04                          | -1                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 90                                 | 85.27                          | -5                         | 2.5                      | 2.42                         | -3                         |   |
|                    |                    | 90                                 | 88.65                          | -2                         | 5                        | 5.01                         | 0                          |   |
| September 17, 1997 | September 23, 1997 | 0                                  | 0.00                           | 0                          | 2.5                      | 2.47                         | -1                         |   |
|                    |                    | 0                                  | 0.00                           | 0                          | 5                        | 5.00                         | 0                          |   |
|                    |                    | 10                                 | 9.41                           | -6                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 10                                 | 9.57                           | -4                         | 2.5                      | 2.41                         | -4                         |   |
|                    |                    | 10                                 | 9.71                           | -3                         | 5                        | 5.10                         | +2                         |   |
|                    |                    | 30                                 | 28.7                           | -4                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 30                                 | 28.7                           | -4                         | 2.5                      | 2.49                         | 0                          |   |
|                    |                    | 30                                 | 28.5                           | -5                         | 5                        | 5.04                         | +1                         |   |
|                    |                    | 90                                 | 87.5                           | -3                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 90                                 | 86.8                           | -4                         | 2.5                      | 2.45                         | -2                         |   |
|                    |                    | 90                                 | 88.4                           | -2                         | 5                        | 5.10                         | +2                         |   |
|                    |                    | September 17-23, 1997 <sup>b</sup> | 0                              | 0.00                       | 0                        | 2.5                          | 2.50                       | 0 |
|                    |                    |                                    | 0                              | 0.00                       | 0                        | 5                            | 5.00                       | 0 |
|                    |                    |                                    | 10                             | 9.21                       | -8                       | 0                            | 0.00                       | 0 |
|                    | 10                 |                                    | 9.33                           | -7                         | 2.5                      | 2.46                         | -2                         |   |
|                    | 10                 |                                    | 9.45                           | -6                         | 5                        | 5.00                         | 0                          |   |
|                    |                    | 30                                 | 27.8                           | -7                         | 0                        | 0.00                         | 0                          |   |
|                    |                    | 30                                 | 28.0                           | -7                         | 2.5                      | 2.48                         | -1                         |   |
|                    |                    | 30                                 | 27.9                           | -7                         | 5                        | 4.98                         | 0                          |   |
|                    | 90                 | 87.5                               | -3                             | 0                          | 0.00                     | 0                            |                            |   |
|                    | 90                 | 87.3                               | -3                             | 2.5                        | 2.46                     | -2                           |                            |   |
|                    | 90                 | 87.5                               | -3                             | 5                          | 5.00                     | 0                            |                            |   |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared     | Date Analyzed     | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|-------------------|-------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                   |                   | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| November 13, 1997 | November 18, 1997 | 0                          | 0.00                           | 0                          | 2.5                      | 2.48                         | -1                         |
|                   |                   | 0                          | 0.00                           | 0                          | 5                        | 5.03                         | +1                         |
|                   |                   | 10                         | 9.54                           | -5                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.66                           | -3                         | 2.5                      | 2.45                         | -2                         |
|                   |                   | 10                         | 9.58                           | -4                         | 5                        | 5.00                         | 0                          |
|                   |                   | 30                         | 29.7                           | -1                         | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 34.8                           | +16                        | 2.5                      | 2.50                         | 0                          |
|                   |                   | 30                         | 31.9                           | +6                         | 5                        | 5.04                         | +1                         |
|                   |                   | 90                         | 84.1                           | -7                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 87.0                           | -3                         | 2.5                      | 2.49                         | 0                          |
|                   |                   | 90                         | 86.1                           | -4                         | 5                        | 5.07                         | +1                         |
| January 8, 1998   | January 14, 1998  | 0                          | 0.0                            | 0                          | 2.5                      | 2.50                         | 0                          |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 5.10                         | +2                         |
|                   |                   | 10                         | 9.5                            | -5                         | 0                        | 0.00                         | 0                          |
|                   |                   | 10                         | 9.5                            | -5                         | 2.5                      | 2.50                         | 0                          |
|                   |                   | 10                         | 9.6                            | -4                         | 5                        | 5.00                         | 0                          |
|                   |                   | 30                         | 19.0                           | -37 <sup>c</sup>           | 0                        | 0.00                         | 0                          |
|                   |                   | 30                         | 49.5                           | +65 <sup>c</sup>           | 2.5                      | 2.30 <sup>c</sup>            | -8                         |
|                   |                   | 30                         | 18.8                           | -37 <sup>c</sup>           | 5                        | 5.20 <sup>c</sup>            | +4                         |
|                   |                   | 90                         | 86.6                           | -4                         | 0                        | 0.00                         | 0                          |
|                   |                   | 90                         | 85.3                           | -5                         | 2.5                      | 2.50                         | 0                          |
|                   |                   | 90                         | 85.9                           | -5                         | 5                        | 5.10                         | +2                         |
| January 15, 1998  | January 16, 1998  | 30                         | 28.2 <sup>d</sup>              | -6                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 28.3 <sup>d</sup>              | -6                         | 2.5                      | 2.5                          | 0                          |
|                   |                   | 30                         | 27.5 <sup>d</sup>              | -8                         | 5                        | 4.9                          | -2                         |
| January 26, 1998  | February 3, 1998  | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                   |                   | 10                         | 9.8                            | -2                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 10.4                           | +4                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 10                         | 9.8                            | -2                         | 5                        | 4.9                          | -2                         |
|                   |                   | 30                         | 29.8                           | -1                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 28.6                           | -5                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 30                         | 29.6                           | -1                         | 5                        | 5.1                          | +2                         |
|                   |                   | 90                         | 92.5                           | +3                         | 0                        | 0.0                          | 0                          |
|                   |                   | 90                         | 94.1                           | +5                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 90                         | 89.3                           | -1                         | 5                        | 5.0                          | 0                          |
| January 27, 1998  | February 3, 1998  | 0                          | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 4.8                          | -4                         |
|                   |                   | 10                         | 10.3                           | +3                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 10.1                           | +1                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 10                         | 10.0                           | 0                          | 5                        | 5.0                          | 0                          |
|                   |                   | 30                         | 29.3                           | -2                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 29.2                           | -3                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 30                         | 28.8                           | -4                         | 5                        | 5.0                          | 0                          |
|                   |                   | 90                         | 90.7                           | +1                         | 0                        | 0.0                          | 0                          |
|                   |                   | 90                         | 87.6                           | -3                         | 2.5                      | 2.3                          | -8                         |
|                   |                   | 90                         | 89.6                           | 0                          | 5                        | 5.1                          | +2                         |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared     | Date Analyzed     | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|-------------------|-------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                   |                   | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| February 3, 1998  | February 8, 1998  | 0                          | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 4.9                          | -2                         |
|                   |                   | 10                         | 9.4                            | -6                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 9.3                            | -7                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 10                         | 9.3                            | -7                         | 5                        | 4.9                          | -2                         |
|                   |                   | 30                         | 27.0                           | -10                        | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 27.0                           | -10                        | 2.5                      | 2.4                          | -4                         |
|                   |                   | 30                         | 27.0                           | -10                        | 5                        | 4.9                          | -2                         |
|                   |                   | 90                         | 83.0                           | -8                         |                          |                              |                            |
|                   |                   | 90                         | 84.0                           | -7                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 90                         | 84.0                           | -7                         | 5                        | 5.0                          | 0                          |
| February 10, 1998 | February 12, 1998 | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                   |                   | 10                         | 9.3                            | -7                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 9.3                            | -7                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 10                         | 9.2                            | -8                         | 5                        | 4.9                          | -2                         |
|                   |                   | 30                         | 27.4                           | -9                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 27.3                           | -9                         | 2.5                      | 2.5                          | 0                          |
|                   |                   | 30                         | 27.4                           | -9                         | 5                        | 5.1                          | +2                         |
|                   |                   | 90                         | 85.4                           | -5                         | 0                        | 0.0                          | 0                          |
|                   |                   | 90                         | 85.2                           | -5                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 90                         | 84.6                           | -6                         | 5                        | 5.1                          | +2                         |
| February 17, 1998 | February 18, 1998 | 0                          | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                   |                   | 10                         | 9.4                            | -6                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 9.6                            | -4                         | 2.5                      | 2.5                          | 0                          |
|                   |                   | 10                         | 9.6                            | -4                         | 5                        | 5.1                          | +2                         |
|                   |                   | 30                         | 28.8                           | -4                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 28.7                           | -4                         | 2.5                      | 2.5                          | 0                          |
|                   |                   | 30                         | 28.9                           | -4                         | 5                        | 5.0                          | 0                          |
|                   |                   | 90                         | 85.5                           | -5                         | 0                        | 0.0                          | 0                          |
|                   |                   | 90                         | 85.7                           | -5                         | 2.5                      | 2.5                          | 0                          |
|                   |                   | 90                         | 85.6                           | -5                         | 5                        | 5.1                          | +2                         |
| February 24, 1998 | February 25, 1998 | 0                          | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |
|                   |                   | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                   |                   | 10                         | 9.2                            | -8                         | 0                        | 0.0                          | 0                          |
|                   |                   | 10                         | 9.2                            | -8                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 10                         | 9.3                            | -7                         | 5                        | 4.9                          | -2                         |
|                   |                   | 30                         | 27.6                           | -8                         | 0                        | 0.0                          | 0                          |
|                   |                   | 30                         | 27.8                           | -7                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 30                         | 28.3                           | -6                         | 5                        | 5.1                          | +2                         |
|                   |                   | 90                         | 83.6                           | -7                         | 0                        | 0.0                          | 0                          |
|                   |                   | 90                         | 83.6                           | -7                         | 2.5                      | 2.4                          | -4                         |
|                   |                   | 90                         | 83.4                           | -7                         | 5                        | 5.0                          | 0                          |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared  | Date Analyzed  | Urethane                     |                                |                            | Ethanol                  |                              |                            |     |    |
|----------------|----------------|------------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|-----|----|
|                |                | Target Concentration (ppm)   | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |     |    |
| March 3, 1998  | March 4, 1998  | 0                            | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |     |    |
|                |                | 0                            | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |     |    |
|                |                | 10                           | 9.2                            | -8                         | 0                        | 0.0                          | 0                          |     |    |
|                |                | 10                           | 9.3                            | -7                         | 2.5                      | 2.5                          | 0                          |     |    |
|                |                | 10                           | 9.4                            | -6                         | 5                        | 5.2                          | +4                         |     |    |
|                |                | 30                           | 27.8                           | -7                         | 0                        | 0.0                          | 0                          |     |    |
|                |                | 30                           | 27.8                           | -7                         | 2.5                      | 2.5                          | 0                          |     |    |
|                |                | 30                           | 28.4                           | -5                         | 5                        | 5.1                          | +2                         |     |    |
|                |                | 90                           | 86.7                           | -4                         | 0                        | 0.0                          | 0                          |     |    |
|                |                | 90                           | 86.7                           | -4                         | 2.5                      | 2.5                          | 0                          |     |    |
|                |                | 90                           | 87.3                           | -3                         | 5                        | 5.0                          | 0                          |     |    |
|                |                | March 4-5, 1998 <sup>b</sup> | 0                              | 0.0                        | 0                        | 2.5                          | 2.5                        | 0   |    |
|                |                |                              | 0                              | 0.0                        | 0                        | 5                            | 5.0                        | 0   |    |
|                | 10             |                              | 9.2                            | -8                         | 0                        | 0.0                          | 0                          |     |    |
|                | 10             |                              | 9.5                            | -5                         | 2.5                      | 2.5                          | 0                          |     |    |
|                | 10             |                              | 9.4                            | -6                         | 5                        | 4.9                          | -2                         |     |    |
|                | 30             |                              | 27.6                           | -8                         | 0                        | 0.0                          | 0                          |     |    |
|                | 30             |                              | 28.5                           | -5                         | 2.5                      | 2.5                          | 0                          |     |    |
|                | March 10, 1998 | March 12, 1998               | 0                              | 0.0                        | 0                        | 2.5                          | 2.5                        | 0   |    |
|                |                |                              | 0                              | 0.0                        | 0                        | 5                            | 5.2                        | +4  |    |
| 10             |                |                              | 10.0                           | 0                          | 0                        | 0.0                          | 0                          |     |    |
| 10             |                |                              | 10.1                           | +1                         | 2.5                      | 2.5                          | 0                          |     |    |
| 10             |                |                              | 10.0                           | 0                          | 5                        | 5.2                          | +4                         |     |    |
| 30             |                |                              | 30.7                           | +2                         | 0                        | 0.0                          | 0                          |     |    |
| 30             |                |                              | 30.7                           | +2                         | 2.5                      | 2.5                          | 0                          |     |    |
| 30             |                |                              | 30.6                           | +2                         | 5                        | 5.2                          | +4                         |     |    |
| 90             |                |                              | 87.8                           | -2                         | 0                        | 0.0                          | 0                          |     |    |
| 90             |                |                              | 87.3                           | -3                         | 2.5                      | 2.4                          | -4                         |     |    |
| 90             |                |                              | 87.8                           | -2                         | 5                        | 5.0                          | 0                          |     |    |
| April 29, 1998 |                |                              | April 30, 1998                 | 0                          | 0.0                      | 0                            | 2.5                        | 2.5 | 0  |
|                |                |                              |                                | 0                          | 0.0                      | 0                            | 5                          | 5.2 | +4 |
|                |                |                              |                                | 10                         | 10.0                     | 0                            | 0                          | 0.0 | 0  |
|                |                |                              |                                | 10                         | 10.3                     | +3                           | 2.5                        | 2.5 | 0  |
|                | 10             | 10.5                         |                                | +5                         | 5                        | 5.2                          | +4                         |     |    |
|                | 30             | 31.9                         |                                | +6                         | 0                        | 0.0                          | 0                          |     |    |
|                | 30             | 31.7                         |                                | +6                         | 2.5                      | 2.4                          | -4                         |     |    |
|                | 30             | 32.1                         |                                | +7                         | 5                        | 5.5                          | +10                        |     |    |
|                | 90             | 89.2                         |                                | -1                         | 0                        | 0.0                          | 0                          |     |    |
|                | 90             | 90.6                         |                                | +1                         | 2.5                      | 2.4                          | -4                         |     |    |
|                | 90             | 90.8                         | +1                             | 5                          | 5.4                      | +8                           |                            |     |    |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared                   | Date Analyzed    | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|---------------------------------|------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                                 |                  | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| June 24, 1998                   | June 26, 1998    | 0                          | 0.0                            | 0                          | 2.5                      | 2.4                          | -4                         |
|                                 |                  | 0                          | 0.0                            | 0                          | 5                        | 5.1                          | +2                         |
|                                 |                  | 10                         | 9.2                            | -8                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 10                         | 9.3                            | -7                         | 2.5                      | 2.4                          | -4                         |
|                                 |                  | 10                         | 9.5                            | -5                         | 5                        | 4.9                          | -2                         |
|                                 |                  | 30                         | 31.8                           | +6                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 30                         | 31.4                           | +5                         | 2.5                      | 2.4                          | -4                         |
|                                 |                  | 30                         | 31.9                           | +6                         | 5                        | 5.0                          | 0                          |
|                                 |                  | 90                         | 88.3                           | -2                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 90                         | 89.7                           | 0                          | 2.5                      | 2.5                          | 0                          |
|                                 |                  | 90                         | 90.2                           | 0                          | 5                        | 5.1                          | +2                         |
|                                 |                  | August 19, 1998            | August 20, 1998                | 0                          | 0.0                      | 0                            | 2.5                        |
| 0                               | 0.0              |                            |                                | 0                          | 5                        | 5.1                          | +2                         |
| 10                              | 10.3             |                            |                                | +3                         | 0                        | 0.0                          | 0                          |
| 10                              | 9.6              |                            |                                | -4                         | 2.5                      | 2.5                          | 0                          |
| 10                              | 9.9              |                            |                                | -1                         | 5                        | 5.1                          | +2                         |
| 30                              | 32.0             |                            |                                | +7                         | 0                        | 0.0                          | 0                          |
| 30                              | 31.9             |                            |                                | +6                         | 2.5                      | 2.5                          | 0                          |
| 30                              | 31.7             |                            |                                | +6                         | 5                        | 5.0                          | 0                          |
| 90                              | 90.3             |                            |                                | 0                          | 0                        | 0.0                          | 0                          |
| 90                              | 91.1             |                            |                                | +1                         | 2.5                      | 2.4                          | -4                         |
| 90                              | 91.4             |                            |                                | +2                         | 5                        | 5.0                          | 0                          |
| August 19-21, 1998 <sup>b</sup> | 0                |                            |                                | 0.0                        | 0                        | 2.5                          | 2.3                        |
|                                 | 0                |                            | 0.0                            | 0                          | 5                        | 4.9                          | -2                         |
|                                 | 10               |                            | 10.4                           | +4                         | 0                        | 0.0                          | 0                          |
|                                 | 10               |                            | 10.3                           | +3                         | 2.5                      | 2.3                          | -8                         |
|                                 | 10               |                            | 10.4                           | +4                         | 5                        | 5.0                          | 0                          |
|                                 | 30               |                            | 31.1                           | +4                         | 0                        | 0.0                          | 0                          |
|                                 | 30               |                            | 32.5                           | +8                         | 2.5                      | 2.4                          | -4                         |
|                                 | 30               |                            | 32.2                           | +7                         | 5                        | 4.9                          | -2                         |
| 90                              | 88.1             |                            | -2                             | 0                          | 0.0                      | 0                            |                            |
| 90                              | 90.6             | +1                         | 2.5                            | 2.3                        | -8                       |                              |                            |
| 90                              | 90.6             | +1                         | 5                              | 4.8                        | -4                       |                              |                            |
| October 14, 1998                | October 19, 1998 | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |
|                                 |                  | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                                 |                  | 10                         | 9.2                            | -8                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 10                         | 9.3                            | -7                         | 2.5                      | 2.5                          | 0                          |
|                                 |                  | 10                         | 9.6                            | -4                         | 5                        | 5.2                          | +4                         |
|                                 |                  | 30                         | 30.9                           | +3                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 30                         | 30.9                           | +3                         | 2.5                      | 2.5                          | 0                          |
|                                 |                  | 30                         | 30.3                           | +1                         | 5                        | 5.1                          | +2                         |
|                                 |                  | 90                         | 88.6                           | -2                         | 0                        | 0.0                          | 0                          |
|                                 |                  | 90                         | 87.7                           | -3                         | 2.5                      | 2.5                          | 0                          |
|                                 |                  | 90                         | 87.2                           | -3                         | 5                        | 5.0                          | 0                          |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study**  
**of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared                   | Date Analyzed     | Urethane                   |                                |                            | Ethanol                  |                              |                            |     |
|---------------------------------|-------------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|-----|
|                                 |                   | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |     |
| December 9, 1998                | December 14, 1998 | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |     |
|                                 |                   | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |     |
|                                 |                   | 10                         | 8.9                            | -11                        | 0                        | 0.0                          | 0                          |     |
|                                 |                   | 10                         | 9.4                            | -6                         | 2.5                      | 2.6                          | +4                         |     |
|                                 |                   | 10                         | 9.4                            | -6                         | 5                        | 5.1                          | +2                         |     |
|                                 |                   | 30                         | 28.2                           | -6                         | 0                        | 0.0                          | 0                          |     |
|                                 |                   | 30                         | 32.8                           | +9                         | 2.5                      | 2.6                          | +4                         |     |
|                                 |                   | 30                         | 28.3                           | -6                         | 5                        | 4.5                          | -10                        |     |
|                                 |                   | 90                         | 97.8                           | +9                         | 0                        | 0.0                          | 0                          |     |
|                                 |                   | 90                         | 90.2                           | 0                          | 2.5                      | 2.6                          | +4                         |     |
|                                 |                   | 90                         | 89.0                           | -1                         | 5                        | 5.2                          | +4                         |     |
|                                 |                   | February 3, 1999           | February 5, 1999               | 0                          | 0.0                      | 0                            | 2.5                        | 2.5 |
| 0                               | 0.0               |                            |                                | 0                          | 5                        | 5.0                          | 0                          |     |
| 10                              | 9.3               |                            |                                | -7                         | 0                        | 0.0                          | 0                          |     |
| 10                              | 9.3               |                            |                                | -7                         | 2.5                      | 2.5                          | 0                          |     |
| 10                              | 9.6               |                            |                                | -4                         | 5                        | 5.0                          | 0                          |     |
| 30                              | 29.1              |                            |                                | -3                         | 0                        | 0.0                          | 0                          |     |
| 30                              | 30.8              |                            |                                | +3                         | 2.5                      | 2.5                          | 0                          |     |
| 30                              | 30.4              |                            |                                | +1                         | 5                        | 5.1                          | +2                         |     |
| 90                              | 82.4              |                            |                                | -8                         | 0                        | 0.0                          | 0                          |     |
| 90                              | 82.4              |                            |                                | -8                         | 2.5                      | 2.4                          | -4                         |     |
| 90                              | 82.8              |                            |                                | -8                         | 5                        | 5.0                          | 0                          |     |
| February 3-8, 1999 <sup>b</sup> | 0                 |                            |                                | 0.0                        | 0                        | 2.5                          | 2.6                        | +4  |
|                                 | 0                 |                            |                                | 0.0                        | 0                        | 5                            | 4.9                        | -2  |
|                                 | 10                |                            |                                | 8.8                        | -12                      | 0                            | 0.0                        | 0   |
|                                 | 10                |                            | 9.2                            | -8                         | 2.5                      | 2.6                          | +4                         |     |
|                                 | 10                |                            | 9.5                            | -5                         | 5                        | 1.7                          | -66                        |     |
|                                 | 30                |                            | 28.7                           | -4                         | 0                        | 0.0                          | 0                          |     |
|                                 | 30                |                            | 30.3                           | +1                         | 2.5                      | 2.5                          | 0                          |     |
| February 11, 1999               | February 16, 1999 |                            | 30                             | 29.9                       | 0                        | 5                            | 5.2                        | +4  |
|                                 |                   |                            | 90                             | 93.0                       | +3                       | 0                            | 0.0                        | 0   |
|                                 |                   |                            | 90                             | 78.7                       | -13                      | 2.5                          | 2.6                        | +4  |
|                                 |                   | 90                         | 81.8                           | -9                         | 5                        | 5.1                          | +2                         |     |
|                                 |                   | 90                         | 91.5                           | +2                         | 5                        | 5.2                          | +4                         |     |

**TABLE I3**  
**Results of Analyses of Dose Formulations Administered to Mice in the 2-Year Drinking Water Study of Urethane, Ethanol, and Urethane/Ethanol**

| Date Prepared  | Date Analyzed | Urethane                   |                                |                            | Ethanol                  |                              |                            |
|----------------|---------------|----------------------------|--------------------------------|----------------------------|--------------------------|------------------------------|----------------------------|
|                |               | Target Concentration (ppm) | Determined Concentration (ppm) | Difference from Target (%) | Target Concentration (%) | Determined Concentration (%) | Difference from Target (%) |
| March 31, 1999 | April 1, 1999 | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |
|                |               | 0                          | 0.0                            | 0                          | 5                        | 5.0                          | 0                          |
|                |               | 10                         | 9.7                            | -3                         | 0                        | 0.0                          | 0                          |
|                |               | 10                         | 9.9                            | -1                         | 2.5                      | 2.5 <sup>e</sup>             | 0                          |
|                |               | 10                         | 9.8 <sup>c</sup>               | -2                         | 5                        | 4.3 <sup>e</sup>             | -14                        |
|                |               | 30                         | 32.3                           | +8                         | 0                        | 0.0                          | 0                          |
|                |               | 30                         | 32.8                           | +9                         | 2.5                      | 2.5                          | 0                          |
|                |               | 30                         | 33.7 <sup>e</sup>              | +12                        | 5                        | 2.8 <sup>e</sup>             | -44                        |
|                |               | 90                         | 93.9                           | +4                         | 0                        | 0.0                          | 0                          |
|                |               | 90                         | 94.3                           | +5                         | 2.5                      | 2.5                          | 0                          |
|                |               | 90                         | 95.3 <sup>e</sup>              | +6                         | 5                        | 3.6 <sup>e</sup>             | -28                        |
| April 2, 1999  | April 2, 1999 | 10                         | 9.3 <sup>d</sup>               | -7                         | 5                        | 5.1 <sup>d</sup>             | +2                         |
|                |               | 30                         | 29.8 <sup>d</sup>              | -1                         | 5                        | 5.0 <sup>d</sup>             | 0                          |
|                |               | 90                         | 85.3 <sup>d</sup>              | -5                         | 5                        | 4.9 <sup>d</sup>             | -2                         |
| May 25, 1999   | May 27, 1999  | 0                          | 0.0                            | 0                          | 2.5                      | 2.5                          | 0                          |
|                |               | 0                          | 0.0                            | 0                          | 5                        | 5.1                          | +2                         |
|                |               | 10                         | 9.0                            | -10                        | 0                        | 0.0                          | 0                          |
|                |               | 10                         | 9.3                            | -7                         | 2.5                      | 2.3                          | -8                         |
|                |               | 10                         | 9.4                            | -6                         | 5                        | 5.1                          | +2                         |
|                |               | 30                         | 30.9                           | +3                         | 0                        | 0.0                          | 0                          |
|                |               | 30                         | 30.0                           | 0                          | 2.5                      | 2.2                          | -12                        |
|                |               | 30                         | 30.9                           | +3                         | 5                        | 4.2                          | -16                        |
|                |               | 90                         | 84.2                           | -6                         | 0                        | 0.0                          | 0                          |
|                |               | 90                         | 83.8                           | -7                         | 2.5                      | 2.4                          | -4                         |
|                |               | 90                         | 86.5                           | -4                         | 5                        | 4.2                          | -16                        |
| May 28, 1999   | May 31, 1999  | 30                         | 30.8                           | +3                         | 5                        | 5.1                          | +2                         |
|                |               | 90                         | 88.4                           | -2                         | 5                        | 5.1                          | +2                         |

<sup>a</sup> Results of duplicate analyses

<sup>b</sup> Animal room samples

<sup>c</sup> Remixed; mice received dose formulation for no more than 2 days

<sup>d</sup> Results of remix

<sup>e</sup> Remixed; not used in study



**APPENDIX J  
 WATER AND URETHANE CONSUMPTION  
 IN THE 2-YEAR DRINKING WATER STUDY  
 OF URETHANE, ETHANOL,  
 AND URETHANE/ETHANOL**

|                 |  |            |
|-----------------|--|------------|
| <b>TABLE J1</b> | <b>Water and Urethane Consumption by Male Mice<br/>in the 2-Year Drinking Water Study of Urethane and 0% Ethanol .....</b>     | <b>J-2</b> |
| <b>TABLE J2</b> | <b>Water and Urethane Consumption by Male Mice<br/>in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol .....</b>   | <b>J-3</b> |
| <b>TABLE J3</b> | <b>Water and Urethane Consumption by Male Mice<br/>in the 2-Year Drinking Water Study of Urethane and 5% Ethanol .....</b>     | <b>J-4</b> |
| <b>TABLE J4</b> | <b>Water and Urethane Consumption by Female Mice<br/>in the 2-Year Drinking Water Study of Urethane and 0% Ethanol .....</b>   | <b>J-5</b> |
| <b>TABLE J5</b> | <b>Water and Urethane Consumption by Female Mice<br/>in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol .....</b> | <b>J-6</b> |
| <b>TABLE J6</b> | <b>Water and Urethane Consumption by Female Mice<br/>in the 2-Year Drinking Water Study of Urethane and 5% Ethanol .....</b>   | <b>J-7</b> |

**TABLE J1**  
**Water and Urethane Consumption by Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 3.97                      | 23.56                 | 3.92         | 24.05                 | 1.63                         | 3.47         | 22.90                 | 4.55            | 3.58         | 24.02                 | 13.40           |
| 3                     | 3.97                      | 25.35                 | 3.95         | 26.25                 | 1.50                         | 3.64         | 26.27                 | 4.15            | 3.79         | 26.12                 | 13.06           |
| 4                     | 4.27                      | 27.30                 | 3.97         | 27.52                 | 1.44                         | 3.87         | 26.25                 | 4.43            | 4.19         | 27.52                 | 13.71           |
| 5                     | 4.42                      | 28.51                 | 4.34         | 28.81                 | 1.51                         | 4.25         | 27.64                 | 4.61            | 4.11         | 28.89                 | 12.82           |
| 6                     | 4.45                      | 29.25                 | 4.59         | 29.93                 | 1.53                         | 4.60         | 28.70                 | 4.80            | 4.22         | 30.06                 | 12.63           |
| 7                     | 4.71                      | 30.60                 | 4.57         | 30.83                 | 1.48                         | 4.80         | 30.12                 | 4.78            | 4.33         | 31.08                 | 12.54           |
| 8                     | 4.63                      | 31.19                 | 4.67         | 31.87                 | 1.46                         | 4.73         | 31.10                 | 4.57            | 4.67         | 32.05                 | 13.12           |
| 9                     | 4.65                      | 31.65                 | 4.67         | 32.90                 | 1.42                         | 4.77         | 31.84                 | 4.50            | 4.73         | 33.12                 | 12.85           |
| 10                    | 4.86                      | 33.04                 | 4.82         | 33.65                 | 1.43                         | 4.91         | 32.85                 | 4.49            | 4.72         | 33.99                 | 12.51           |
| 11                    | 4.56                      | 33.80                 | 4.81         | 34.47                 | 1.39                         | 4.95         | 33.36                 | 4.45            | 4.85         | 34.61                 | 12.61           |
| 12                    | 4.85                      | 35.02                 | 4.75         | 35.58                 | 1.34                         | 5.33         | 34.08                 | 4.69            | 4.68         | 35.49                 | 11.86           |
| 16                    | 4.45                      | 37.82                 | 4.56         | 38.00                 | 1.20                         | 4.98         | 36.66                 | 4.08            | 4.53         | 37.60                 | 10.85           |
| 20                    | 4.74                      | 39.55                 | 4.80         | 39.42                 | 1.22                         | 5.21         | 38.02                 | 4.11            | 5.05         | 39.06                 | 11.63           |
| 24                    | 5.03                      | 40.73                 | 5.02         | 40.66                 | 1.24                         | 5.05         | 39.18                 | 3.87            | 5.05         | 40.22                 | 11.30           |
| 28                    | 4.65                      | 41.87                 | 5.08         | 41.46                 | 1.23                         | 4.95         | 40.31                 | 3.68            | 4.79         | 41.55                 | 10.38           |
| 32                    | 4.89                      | 43.16                 | 5.29         | 42.52                 | 1.24                         | 5.06         | 42.09                 | 3.61            | 4.78         | 42.80                 | 10.05           |
| 36                    | 4.64                      | 44.73                 | 4.90         | 43.90                 | 1.12                         | 4.43         | 43.79                 | 3.04            | 4.59         | 43.71                 | 9.45            |
| 40                    | 4.62                      | 45.14                 | 4.80         | 44.70                 | 1.07                         | 4.43         | 44.93                 | 2.96            | 4.46         | 44.60                 | 8.99            |
| 44                    | 4.67                      | 45.59                 | 4.79         | 44.83                 | 1.07                         | 4.25         | 45.00                 | 2.83            | 4.21         | 45.28                 | 8.37            |
| 48                    | 4.77                      | 45.77                 | 4.97         | 44.80                 | 1.11                         | 4.59         | 44.85                 | 3.07            | 4.21         | 45.58                 | 8.31            |
| 52                    | 4.52                      | 46.56                 | 4.80         | 45.58                 | 1.05                         | 4.53         | 44.99                 | 3.02            | 4.50         | 45.46                 | 8.91            |
| 56                    | 4.53                      | 46.82                 | 5.15         | 45.67                 | 1.13                         | 4.42         | 45.93                 | 2.88            | 4.52         | 45.86                 | 8.87            |
| 60                    | 4.48                      | 47.37                 | 5.18         | 45.44                 | 1.14                         | 4.17         | 46.07                 | 2.72            | 4.68         | 46.09                 | 9.15            |
| 64                    | 4.43                      | 47.04                 | 5.01         | 46.08                 | 1.09                         | 4.22         | 45.92                 | 2.76            | 4.25         | 46.22                 | 8.29            |
| 68                    | 4.65                      | 48.06                 | 4.51         | 46.17                 | 0.98                         | 4.07         | 46.30                 | 2.64            | 4.21         | 46.43                 | 8.16            |
| 72                    | 4.47                      | 47.84                 | 4.77         | 46.38                 | 1.03                         | 4.20         | 46.64                 | 2.70            | 4.12         | 46.57                 | 7.96            |
| 76                    | 4.43                      | 47.97                 | 4.74         | 46.54                 | 1.02                         | 4.23         | 46.60                 | 2.73            | 4.33         | 45.96                 | 8.48            |
| 80                    | 4.64                      | 47.79                 | 5.03         | 46.22                 | 1.09                         | 4.19         | 46.38                 | 2.71            | 4.04         | 45.44                 | 8.00            |
| 84                    | 4.80                      | 47.19                 | 4.87         | 45.82                 | 1.06                         | 4.07         | 46.38                 | 2.64            | 4.56         | 45.32                 | 9.06            |
| 88                    | 4.89                      | 46.84                 | 4.46         | 45.33                 | 0.98                         | 4.37         | 45.22                 | 2.90            | 5.16         | 43.90                 | 10.58           |
| 92                    | 5.31                      | 46.42                 | 4.87         | 44.87                 | 1.09                         | 4.37         | 44.64                 | 2.94            | 5.20         | 41.98                 | 11.15           |
| 96                    | 5.95                      | 44.39                 | 5.09         | 44.90                 | 1.13                         | 4.34         | 42.81                 | 3.04            | 5.60         | 39.47                 | 12.77           |
| 100                   | 5.50                      | 43.07                 | 4.88         | 44.28                 | 1.10                         | 4.95         | 42.80                 | 3.47            | 5.07         | 37.73                 | 12.10           |
| 104                   | 5.61                      | 42.19                 | 5.20         | 43.25                 | 1.20                         | 4.92         | 41.27                 | 3.57            | 5.39         | 38.36                 | 12.64           |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 4.49                      | 29.20                 | 4.46         | 29.77                 | 1.50                         | 4.48         | 28.78                 | 4.67            | 4.35         | 29.90                 | 13.10           |
| 14-52                 | 4.70                      | 43.09                 | 4.90         | 42.59                 | 1.15                         | 4.75         | 41.98                 | 3.39            | 4.62         | 42.59                 | 9.76            |
| 53-104                | 4.90                      | 46.38                 | 4.90         | 45.46                 | 1.08                         | 4.35         | 45.15                 | 2.89            | 4.70         | 43.79                 | 9.67            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day

**TABLE J2**  
**Water and Urethane Consumption by Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 3.83                      | 24.03                 | 3.63         | 23.30                 | 1.56                         | 3.54         | 23.10                 | 4.60            | 3.36         | 23.46                 | 12.88           |
| 3                     | 3.97                      | 25.71                 | 3.66         | 25.24                 | 1.45                         | 3.61         | 25.07                 | 4.33            | 3.43         | 25.13                 | 12.28           |
| 4                     | 4.12                      | 27.51                 | 3.99         | 26.76                 | 1.49                         | 3.88         | 27.02                 | 4.31            | 3.93         | 26.77                 | 13.22           |
| 5                     | 4.28                      | 28.89                 | 3.97         | 27.99                 | 1.42                         | 4.04         | 28.08                 | 4.31            | 4.01         | 28.51                 | 12.65           |
| 6                     | 4.47                      | 29.95                 | 4.27         | 29.08                 | 1.47                         | 4.26         | 29.48                 | 4.34            | 4.20         | 29.87                 | 12.65           |
| 7                     | 4.71                      | 30.91                 | 4.16         | 30.23                 | 1.38                         | 4.19         | 30.32                 | 4.14            | 4.33         | 30.93                 | 12.59           |
| 8                     | 4.74                      | 32.10                 | 4.30         | 31.22                 | 1.38                         | 4.22         | 31.48                 | 4.02            | 4.30         | 31.92                 | 12.13           |
| 9                     | 4.79                      | 33.37                 | 4.35         | 32.06                 | 1.36                         | 4.28         | 32.11                 | 4.00            | 4.36         | 32.96                 | 11.91           |
| 10                    | 4.56                      | 34.01                 | 4.37         | 32.89                 | 1.33                         | 4.21         | 33.06                 | 3.82            | 4.17         | 33.62                 | 11.17           |
| 11                    | 4.43                      | 34.79                 | 4.34         | 33.68                 | 1.29                         | 4.29         | 33.59                 | 3.83            | 4.42         | 34.52                 | 11.54           |
| 12                    | 4.57                      | 35.48                 | 4.31         | 35.09                 | 1.23                         | 4.45         | 34.21                 | 3.90            | 4.31         | 35.30                 | 10.98           |
| 16                    | 4.58                      | 37.76                 | 4.31         | 37.13                 | 1.16                         | 4.39         | 36.44                 | 3.62            | 4.15         | 37.75                 | 9.90            |
| 20                    | 4.88                      | 39.75                 | 4.21         | 39.55                 | 1.06                         | 4.46         | 38.40                 | 3.48            | 4.18         | 39.67                 | 9.49            |
| 24                    | 4.59                      | 41.01                 | 4.39         | 40.87                 | 1.07                         | 4.35         | 39.87                 | 3.28            | 4.30         | 41.04                 | 9.43            |
| 28                    | 4.96                      | 42.33                 | 4.37         | 41.50                 | 1.05                         | 4.59         | 40.98                 | 3.36            | 4.33         | 41.34                 | 9.42            |
| 32                    | 4.78                      | 43.12                 | 4.20         | 43.33                 | 0.97                         | 4.50         | 41.88                 | 3.22            | 4.43         | 42.57                 | 9.37            |
| 36                    | 4.78                      | 43.44                 | 3.91         | 44.50                 | 0.88                         | 4.49         | 43.07                 | 3.13            | 4.00         | 43.92                 | 8.20            |
| 40                    | 4.49                      | 44.38                 | 3.82         | 45.02                 | 0.85                         | 4.21         | 43.92                 | 2.87            | 3.79         | 45.34                 | 7.52            |
| 44                    | 4.35                      | 44.63                 | 3.66         | 45.74                 | 0.80                         | 4.19         | 44.48                 | 2.82            | 4.01         | 45.54                 | 7.93            |
| 48                    | 4.47                      | 44.80                 | 3.67         | 45.59                 | 0.80                         | 4.00         | 44.97                 | 2.67            | 4.00         | 45.78                 | 7.86            |
| 52                    | 4.35                      | 45.24                 | 3.82         | 45.58                 | 0.84                         | 4.08         | 45.55                 | 2.69            | 3.82         | 46.20                 | 7.44            |
| 56                    | 4.11                      | 45.26                 | 3.74         | 46.33                 | 0.81                         | 4.12         | 45.66                 | 2.71            | 3.85         | 46.39                 | 7.46            |
| 60                    | 3.97                      | 45.55                 | 3.64         | 46.57                 | 0.78                         | 4.09         | 46.02                 | 2.67            | 3.68         | 46.62                 | 7.11            |
| 64                    | 3.92                      | 45.23                 | 3.72         | 46.32                 | 0.80                         | 4.00         | 46.42                 | 2.58            | 3.63         | 47.34                 | 6.89            |
| 68                    | 4.03                      | 45.48                 | 3.43         | 46.12                 | 0.74                         | 4.30         | 46.63                 | 2.77            | 3.74         | 46.80                 | 7.20            |
| 72                    | 3.65                      | 45.63                 | 3.46         | 45.84                 | 0.75                         | 3.77         | 46.67                 | 2.42            | 3.49         | 47.12                 | 6.66            |
| 76                    | 3.86                      | 45.26                 | 3.42         | 45.62                 | 0.75                         | 3.89         | 46.66                 | 2.50            | 3.74         | 46.41                 | 7.25            |
| 80                    | 3.60                      | 45.53                 | 3.86         | 45.29                 | 0.85                         | 3.81         | 46.27                 | 2.47            | 3.52         | 44.61                 | 7.10            |
| 84                    | 3.85                      | 44.41                 | 3.87         | 44.60                 | 0.87                         | 4.33         | 45.67                 | 2.85            | 3.46         | 43.73                 | 7.12            |
| 88                    | 4.01                      | 44.18                 | 4.08         | 44.05                 | 0.93                         | 3.58         | 45.66                 | 2.35            | 3.87         | 42.47                 | 8.20            |
| 92                    | 4.05                      | 44.16                 | 4.06         | 43.07                 | 0.94                         | 3.73         | 45.05                 | 2.49            | 4.22         | 41.52                 | 9.15            |
| 96                    | 4.04                      | 43.31                 | 4.12         | 42.95                 | 0.96                         | 4.07         | 43.70                 | 2.79            | 4.24         | 40.24                 | 9.48            |
| 100                   | 4.44                      | 42.80                 | 4.19         | 41.68                 | 1.00                         | 4.08         | 42.60                 | 2.87            | 4.52         | 37.65                 | 10.81           |
| 104                   | 4.42                      | 41.71                 | 4.35         | 40.46                 | 1.07                         | 4.73         | 41.98                 | 3.38            | 4.99         | 37.31                 | 12.03           |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 4.41                      | 29.87                 | 4.12         | 29.01                 | 1.42                         | 4.09         | 29.07                 | 4.22            | 4.07         | 29.49                 | 12.43           |
| 14-52                 | 4.62                      | 42.65                 | 4.04         | 42.88                 | 0.94                         | 4.33         | 41.96                 | 3.09            | 4.10         | 42.92                 | 8.60            |
| 53-104                | 4.00                      | 44.50                 | 3.84         | 44.53                 | 0.86                         | 4.04         | 45.31                 | 2.67            | 3.92         | 43.71                 | 8.07            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day

**TABLE J3**  
**Water and Urethane Consumption by Male Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 2.99                      | 23.40                 | 3.23         | 23.15                 | 1.40                         | 3.21         | 23.53                 | 4.09            | 3.60         | 23.79                 | 13.62           |
| 3                     | 3.46                      | 25.32                 | 3.34         | 25.04                 | 1.33                         | 3.30         | 25.33                 | 3.90            | 3.46         | 25.87                 | 12.04           |
| 4                     | 3.69                      | 26.93                 | 3.51         | 26.51                 | 1.32                         | 3.67         | 26.69                 | 4.13            | 3.69         | 27.01                 | 12.28           |
| 5                     | 3.61                      | 28.22                 | 3.63         | 28.04                 | 1.29                         | 3.82         | 28.15                 | 4.07            | 3.79         | 28.56                 | 11.94           |
| 6                     | 3.89                      | 29.24                 | 3.78         | 29.30                 | 1.29                         | 3.75         | 29.33                 | 3.84            | 3.73         | 29.90                 | 11.23           |
| 7                     | 4.07                      | 30.44                 | 3.84         | 30.20                 | 1.27                         | 4.10         | 30.52                 | 4.03            | 4.09         | 31.14                 | 11.83           |
| 8                     | 4.15                      | 31.42                 | 4.00         | 31.33                 | 1.28                         | 4.20         | 31.61                 | 3.99            | 3.98         | 31.93                 | 11.21           |
| 9                     | 4.24                      | 32.35                 | 4.01         | 32.03                 | 1.25                         | 3.92         | 32.49                 | 3.62            | 3.99         | 33.11                 | 10.83           |
| 10                    | 4.25                      | 33.34                 | 4.22         | 33.34                 | 1.26                         | 4.20         | 33.37                 | 3.78            | 3.86         | 34.09                 | 10.18           |
| 11                    | 4.17                      | 34.10                 | 4.11         | 33.86                 | 1.21                         | 3.86         | 34.40                 | 3.37            | 3.87         | 35.16                 | 9.90            |
| 12                    | 4.24                      | 34.81                 | 4.01         | 35.05                 | 1.14                         | 4.04         | 35.25                 | 3.44            | 4.07         | 35.72                 | 10.26           |
| 16                    | 4.33                      | 37.26                 | 3.86         | 36.96                 | 1.04                         | 4.03         | 37.17                 | 3.25            | 3.86         | 38.53                 | 9.01            |
| 20                    | 4.08                      | 39.70                 | 3.88         | 39.13                 | 0.99                         | 4.05         | 39.13                 | 3.10            | 4.23         | 40.81                 | 9.32            |
| 24                    | 3.94                      | 41.35                 | 3.87         | 40.58                 | 0.95                         | 3.98         | 40.61                 | 2.94            | 4.12         | 41.68                 | 8.90            |
| 28                    | 4.01                      | 42.32                 | 3.73         | 41.66                 | 0.89                         | 3.75         | 42.03                 | 2.68            | 3.97         | 42.83                 | 8.35            |
| 32                    | 3.93                      | 43.23                 | 3.68         | 43.13                 | 0.85                         | 4.19         | 42.54                 | 2.95            | 3.91         | 43.77                 | 8.05            |
| 36                    | 3.76                      | 44.43                 | 3.59         | 44.06                 | 0.82                         | 3.87         | 43.78                 | 2.65            | 3.85         | 44.42                 | 7.79            |
| 40                    | 3.52                      | 44.88                 | 3.83         | 44.27                 | 0.87                         | 3.58         | 44.71                 | 2.40            | 3.73         | 45.12                 | 7.44            |
| 44                    | 3.43                      | 45.54                 | 3.50         | 44.71                 | 0.78                         | 3.60         | 44.21                 | 2.44            | 3.79         | 45.45                 | 7.51            |
| 48                    | 3.21                      | 45.58                 | 3.42         | 44.69                 | 0.76                         | 3.62         | 44.73                 | 2.42            | 3.55         | 46.22                 | 6.92            |
| 52                    | 3.22                      | 45.92                 | 3.36         | 45.64                 | 0.74                         | 3.82         | 45.20                 | 2.54            | 3.80         | 46.07                 | 7.43            |
| 56                    | 3.14                      | 46.28                 | 3.20         | 45.44                 | 0.71                         | 3.45         | 45.64                 | 2.27            | 3.73         | 46.40                 | 7.24            |
| 60                    | 3.17                      | 46.73                 | 3.16         | 45.50                 | 0.70                         | 3.52         | 45.14                 | 2.34            | 3.54         | 46.26                 | 6.88            |
| 64                    | 3.31                      | 46.07                 | 3.35         | 45.67                 | 0.73                         | 3.59         | 45.40                 | 2.37            | 3.51         | 46.26                 | 6.84            |
| 68                    | 3.18                      | 46.41                 | 3.26         | 45.76                 | 0.71                         | 3.31         | 45.22                 | 2.19            | 3.37         | 46.16                 | 6.58            |
| 72                    | 3.15                      | 46.66                 | 3.15         | 45.19                 | 0.70                         | 3.44         | 45.74                 | 2.25            | 3.30         | 46.22                 | 6.43            |
| 76                    | 3.09                      | 46.30                 | 3.17         | 45.40                 | 0.70                         | 3.39         | 45.26                 | 2.24            | 3.39         | 45.93                 | 6.65            |
| 80                    | 3.10                      | 46.19                 | 3.37         | 45.15                 | 0.75                         | 3.42         | 45.21                 | 2.27            | 3.38         | 44.74                 | 6.79            |
| 84                    | 3.12                      | 45.85                 | 3.31         | 45.08                 | 0.73                         | 3.52         | 44.81                 | 2.35            | 3.34         | 43.78                 | 6.87            |
| 88                    | 3.10                      | 45.16                 | 3.57         | 44.92                 | 0.79                         | 3.60         | 44.76                 | 2.41            | 3.96         | 42.25                 | 8.43            |
| 92                    | 3.25                      | 44.73                 | 3.77         | 43.99                 | 0.86                         | 3.51         | 44.63                 | 2.36            | 4.35         | 41.28                 | 9.48            |
| 96                    | 3.54                      | 43.60                 | 3.47         | 42.82                 | 0.81                         | 3.22         | 43.39                 | 2.22            | 4.26         | 38.15                 | 10.05           |
| 100                   | 3.63                      | 43.27                 | 4.15         | 42.50                 | 0.98                         | 3.50         | 43.41                 | 2.42            | 5.41         | 37.72                 | 12.90           |
| 104                   | 3.52                      | 42.97                 | 3.84         | 42.08                 | 0.91                         | 3.84         | 42.30                 | 2.72            | 5.39         | 37.05                 | 13.09           |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 3.89                      | 29.25                 | 3.79         | 29.08                 | 1.30                         | 3.82         | 29.29                 | 3.92            | 3.83         | 29.84                 | 11.55           |
| 14-52                 | 3.74                      | 43.02                 | 3.67         | 42.48                 | 0.86                         | 3.85         | 42.41                 | 2.72            | 3.88         | 43.49                 | 8.03            |
| 53-104                | 3.26                      | 45.40                 | 3.44         | 44.58                 | 0.77                         | 3.48         | 44.69                 | 2.34            | 3.92         | 43.25                 | 8.15            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day

**TABLE J4**  
**Water and Urethane Consumption by Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 0% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 2.72                      | 18.51                 | 2.73         | 18.88                 | 1.45                         | 2.75         | 18.52                 | 4.45            | 2.72         | 18.73                 | 13.09           |
| 3                     | 2.96                      | 19.30                 | 2.91         | 19.56                 | 1.49                         | 2.76         | 18.79                 | 4.41            | 2.86         | 19.02                 | 13.53           |
| 4                     | 3.12                      | 20.18                 | 2.91         | 20.34                 | 1.43                         | 3.05         | 19.66                 | 4.65            | 2.93         | 20.14                 | 13.11           |
| 5                     | 3.12                      | 20.85                 | 3.09         | 20.92                 | 1.47                         | 2.98         | 20.31                 | 4.40            | 3.08         | 20.55                 | 13.49           |
| 6                     | 3.23                      | 21.31                 | 3.01         | 21.72                 | 1.39                         | 2.98         | 21.39                 | 4.17            | 3.14         | 21.23                 | 13.31           |
| 7                     | 3.05                      | 21.66                 | 3.20         | 22.20                 | 1.44                         | 3.07         | 21.85                 | 4.21            | 3.08         | 22.02                 | 12.58           |
| 8                     | 3.32                      | 22.32                 | 3.21         | 22.81                 | 1.41                         | 3.17         | 22.49                 | 4.22            | 3.22         | 22.85                 | 12.68           |
| 9                     | 3.30                      | 22.85                 | 3.16         | 23.07                 | 1.37                         | 3.16         | 22.75                 | 4.17            | 3.06         | 22.99                 | 11.97           |
| 10                    | 3.26                      | 23.43                 | 3.22         | 23.53                 | 1.37                         | 3.24         | 23.18                 | 4.19            | 3.19         | 23.49                 | 12.21           |
| 11                    | 3.31                      | 23.72                 | 3.18         | 23.84                 | 1.34                         | 3.14         | 23.37                 | 4.03            | 3.24         | 23.80                 | 12.26           |
| 12                    | 3.17                      | 24.02                 | 3.12         | 24.67                 | 1.27                         | 3.29         | 24.02                 | 4.11            | 3.20         | 24.29                 | 11.85           |
| 16                    | 3.17                      | 25.61                 | 3.15         | 26.32                 | 1.20                         | 3.20         | 25.82                 | 3.72            | 3.16         | 25.90                 | 10.98           |
| 20                    | 3.28                      | 26.99                 | 3.29         | 27.39                 | 1.20                         | 3.22         | 26.65                 | 3.63            | 3.15         | 26.93                 | 10.54           |
| 24                    | 3.29                      | 27.76                 | 3.19         | 28.09                 | 1.13                         | 3.11         | 27.63                 | 3.37            | 3.10         | 28.27                 | 9.87            |
| 28                    | 3.22                      | 29.12                 | 3.31         | 29.42                 | 1.12                         | 3.31         | 28.91                 | 3.43            | 3.23         | 29.64                 | 9.81            |
| 32                    | 3.38                      | 30.87                 | 3.24         | 31.48                 | 1.03                         | 3.34         | 30.64                 | 3.27            | 3.26         | 31.93                 | 9.20            |
| 36                    | 3.21                      | 32.72                 | 3.33         | 33.24                 | 1.00                         | 3.31         | 32.61                 | 3.05            | 3.18         | 33.24                 | 8.60            |
| 40                    | 3.27                      | 34.37                 | 3.42         | 34.45                 | 0.99                         | 3.14         | 34.35                 | 2.74            | 3.15         | 35.44                 | 8.00            |
| 44                    | 3.48                      | 35.44                 | 3.27         | 35.99                 | 0.91                         | 3.38         | 36.27                 | 2.79            | 3.33         | 37.30                 | 8.03            |
| 48                    | 3.33                      | 36.85                 | 3.24         | 37.51                 | 0.87                         | 3.28         | 37.18                 | 2.65            | 3.22         | 40.11                 | 7.22            |
| 52                    | 3.33                      | 38.73                 | 3.16         | 39.22                 | 0.81                         | 3.37         | 38.23                 | 2.65            | 3.11         | 42.83                 | 6.54            |
| 56                    | 3.22                      | 40.64                 | 3.12         | 41.03                 | 0.76                         | 3.43         | 41.22                 | 2.50            | 3.23         | 44.54                 | 6.52            |
| 60                    | 3.22                      | 42.34                 | 3.17         | 41.88                 | 0.76                         | 3.12         | 42.92                 | 2.18            | 3.07         | 46.52                 | 5.94            |
| 64                    | 3.31                      | 44.15                 | 3.03         | 43.60                 | 0.70                         | 3.39         | 44.73                 | 2.27            | 3.31         | 48.40                 | 6.16            |
| 68                    | 3.02                      | 44.97                 | 3.08         | 45.19                 | 0.68                         | 3.38         | 47.11                 | 2.15            | 3.14         | 49.12                 | 5.76            |
| 72                    | 3.06                      | 46.26                 | 3.07         | 47.06                 | 0.65                         | 3.39         | 48.88                 | 2.08            | 3.28         | 49.04                 | 6.01            |
| 76                    | 3.11                      | 47.73                 | 3.23         | 48.43                 | 0.67                         | 3.71         | 50.24                 | 2.22            | 3.64         | 48.21                 | 6.79            |
| 80                    | 3.13                      | 48.51                 | 3.17         | 49.52                 | 0.64                         | 3.72         | 50.72                 | 2.20            | 3.57         | 48.77                 | 6.59            |
| 84                    | 3.10                      | 49.93                 | 3.44         | 49.45                 | 0.70                         | 3.59         | 51.69                 | 2.08            | 3.62         | 49.40                 | 6.60            |
| 88                    | 3.24                      | 50.90                 | 3.62         | 51.00                 | 0.71                         | 3.49         | 52.01                 | 2.01            | 3.83         | 47.09                 | 7.33            |
| 92                    | 3.44                      | 52.12                 | 3.61         | 52.36                 | 0.69                         | 3.62         | 51.80                 | 2.09            | 3.89         | 43.38                 | 8.08            |
| 96                    | 3.48                      | 51.90                 | 3.55         | 52.63                 | 0.67                         | 3.75         | 51.08                 | 2.21            | 3.59         | 40.52                 | 7.97            |
| 100                   | 3.53                      | 52.30                 | 3.47         | 51.86                 | 0.67                         | 3.79         | 49.61                 | 2.29            | 3.04         | 38.15                 | 7.18            |
| 104                   | 3.62                      | 50.74                 | 3.60         | 50.34                 | 0.72                         | 3.97         | 47.55                 | 2.50            | 3.29         | 39.40                 | 7.52            |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 3.14                      | 21.32                 | 3.07         | 21.57                 | 1.42                         | 3.05         | 21.09                 | 4.34            | 3.07         | 21.34                 | 12.93           |
| 14-52                 | 3.30                      | 31.85                 | 3.26         | 32.31                 | 1.01                         | 3.27         | 31.83                 | 3.08            | 3.19         | 33.16                 | 8.66            |
| 53-104                | 3.27                      | 47.88                 | 3.32         | 48.03                 | 0.69                         | 3.56         | 48.43                 | 2.21            | 3.42         | 45.58                 | 6.76            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day

**TABLE J5**  
**Water and Urethane Consumption by Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 2.5% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 2.72                      | 19.15                 | 2.78         | 18.79                 | 1.48                         | 2.62         | 18.61                 | 4.23            | 2.60         | 18.35                 | 12.76           |
| 3                     | 2.78                      | 19.74                 | 2.84         | 19.38                 | 1.47                         | 2.76         | 19.37                 | 4.27            | 2.77         | 19.03                 | 13.09           |
| 4                     | 3.18                      | 20.50                 | 3.28         | 20.21                 | 1.62                         | 2.97         | 20.35                 | 4.38            | 2.88         | 20.09                 | 12.91           |
| 5                     | 3.18                      | 21.56                 | 3.07         | 21.02                 | 1.46                         | 2.92         | 20.66                 | 4.25            | 2.94         | 20.72                 | 12.75           |
| 6                     | 3.24                      | 22.19                 | 3.15         | 21.78                 | 1.45                         | 3.07         | 21.56                 | 4.27            | 2.97         | 21.26                 | 12.56           |
| 7                     | 3.22                      | 22.87                 | 3.14         | 22.16                 | 1.42                         | 3.04         | 21.85                 | 4.18            | 3.08         | 22.05                 | 12.59           |
| 8                     | 3.20                      | 23.47                 | 3.16         | 22.61                 | 1.40                         | 3.21         | 22.15                 | 4.34            | 3.15         | 22.43                 | 12.66           |
| 9                     | 3.28                      | 23.63                 | 3.21         | 23.07                 | 1.39                         | 3.12         | 23.27                 | 4.02            | 3.12         | 22.68                 | 12.37           |
| 10                    | 3.38                      | 24.13                 | 3.32         | 23.43                 | 1.42                         | 3.12         | 23.29                 | 4.02            | 3.18         | 23.38                 | 12.23           |
| 11                    | 3.32                      | 24.60                 | 3.38         | 23.90                 | 1.42                         | 3.04         | 23.73                 | 3.85            | 3.19         | 23.92                 | 11.98           |
| 12                    | 3.24                      | 25.22                 | 3.32         | 24.30                 | 1.37                         | 3.20         | 24.45                 | 3.93            | 3.26         | 24.10                 | 12.17           |
| 16                    | 3.33                      | 26.91                 | 3.30         | 26.01                 | 1.27                         | 3.06         | 25.61                 | 3.58            | 3.19         | 25.64                 | 11.20           |
| 20                    | 3.21                      | 28.32                 | 3.24         | 27.27                 | 1.19                         | 2.94         | 26.94                 | 3.27            | 3.19         | 26.83                 | 10.69           |
| 24                    | 3.18                      | 29.80                 | 3.35         | 29.32                 | 1.14                         | 3.15         | 28.40                 | 3.33            | 3.06         | 27.96                 | 9.87            |
| 28                    | 3.33                      | 31.74                 | 3.38         | 30.10                 | 1.12                         | 3.23         | 29.71                 | 3.26            | 3.06         | 29.35                 | 9.38            |
| 32                    | 3.38                      | 33.95                 | 3.42         | 31.81                 | 1.08                         | 3.13         | 31.34                 | 3.00            | 3.11         | 30.97                 | 9.05            |
| 36                    | 3.03                      | 35.89                 | 3.44         | 33.63                 | 1.02                         | 3.27         | 33.41                 | 2.94            | 3.16         | 32.54                 | 8.74            |
| 40                    | 3.13                      | 37.28                 | 3.19         | 35.17                 | 0.91                         | 3.30         | 34.45                 | 2.87            | 3.07         | 34.55                 | 8.00            |
| 44                    | 3.06                      | 39.11                 | 3.29         | 36.77                 | 0.89                         | 3.11         | 36.00                 | 2.60            | 3.02         | 36.71                 | 7.41            |
| 48                    | 3.09                      | 40.32                 | 3.18         | 38.07                 | 0.84                         | 3.15         | 37.65                 | 2.51            | 3.07         | 38.61                 | 7.16            |
| 52                    | 3.09                      | 41.61                 | 3.10         | 39.28                 | 0.79                         | 3.33         | 39.10                 | 2.55            | 3.06         | 40.96                 | 6.71            |
| 56                    | 3.20                      | 43.80                 | 3.08         | 41.11                 | 0.75                         | 3.08         | 40.56                 | 2.28            | 2.98         | 43.39                 | 6.19            |
| 60                    | 2.98                      | 45.25                 | 3.05         | 42.26                 | 0.72                         | 3.00         | 42.44                 | 2.12            | 2.86         | 44.91                 | 5.73            |
| 64                    | 2.85                      | 46.35                 | 3.06         | 43.98                 | 0.70                         | 3.03         | 43.88                 | 2.07            | 2.87         | 45.88                 | 5.63            |
| 68                    | 2.77                      | 47.30                 | 2.93         | 46.06                 | 0.64                         | 3.03         | 44.94                 | 2.02            | 2.85         | 46.55                 | 5.51            |
| 72                    | 2.76                      | 48.28                 | 2.97         | 47.01                 | 0.63                         | 3.10         | 46.62                 | 1.99            | 2.88         | 47.66                 | 5.44            |
| 76                    | 2.80                      | 48.92                 | 3.08         | 47.98                 | 0.64                         | 3.11         | 48.43                 | 1.93            | 2.84         | 48.55                 | 5.27            |
| 80                    | 2.88                      | 48.51                 | 3.13         | 48.51                 | 0.65                         | 3.07         | 48.99                 | 1.88            | 2.86         | 48.06                 | 5.36            |
| 84                    | 2.91                      | 49.99                 | 3.05         | 49.04                 | 0.62                         | 3.06         | 49.72                 | 1.85            | 3.15         | 46.18                 | 6.13            |
| 88                    | 2.91                      | 50.26                 | 3.05         | 49.00                 | 0.62                         | 3.40         | 48.60                 | 2.10            | 2.91         | 44.60                 | 5.88            |
| 92                    | 2.84                      | 50.44                 | 3.13         | 49.44                 | 0.63                         | 3.31         | 46.61                 | 2.13            | 3.10         | 43.18                 | 6.46            |
| 96                    | 2.92                      | 50.78                 | 3.25         | 48.59                 | 0.67                         | 3.38         | 45.60                 | 2.22            | 3.33         | 39.64                 | 7.56            |
| 100                   | 2.98                      | 50.69                 | 3.26         | 48.06                 | 0.68                         | 3.68         | 44.15                 | 2.50            | 3.43         | 36.31                 | 8.49            |
| 104                   | 2.89                      | 50.06                 | 3.37         | 47.22                 | 0.71                         | 3.95         | 43.37                 | 2.73            | 3.10         | 33.46                 | 8.33            |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 3.16                      | 22.07                 | 3.15         | 21.51                 | 1.46                         | 3.01         | 21.36                 | 4.22            | 3.01         | 21.24                 | 12.76           |
| 14-52                 | 3.18                      | 34.49                 | 3.29         | 32.74                 | 1.00                         | 3.17         | 32.26                 | 2.95            | 3.10         | 32.41                 | 8.61            |
| 53-104                | 2.90                      | 48.51                 | 3.11         | 46.79                 | 0.66                         | 3.25         | 45.68                 | 2.13            | 3.01         | 43.72                 | 6.20            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day

**TABLE J6**  
**Water and Urethane Consumption by Female Mice in the 2-Year Drinking Water Study**  
**of Urethane and 5% Ethanol**

| Week                  | 0 ppm                     |                       | 10 ppm       |                       |                              | 30 ppm       |                       |                 | 90 ppm       |                       |                 |
|-----------------------|---------------------------|-----------------------|--------------|-----------------------|------------------------------|--------------|-----------------------|-----------------|--------------|-----------------------|-----------------|
|                       | Water<br>(g) <sup>a</sup> | Body<br>Weight<br>(g) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) <sup>b</sup> | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) | Water<br>(g) | Body<br>Weight<br>(g) | Dose<br>(mg/kg) |
| 2                     | 2.49                      | 18.48                 | 2.59         | 18.57                 | 1.40                         | 2.55         | 18.54                 | 4.13            | 2.60         | 18.75                 | 12.46           |
| 3                     | 2.75                      | 19.10                 | 2.90         | 19.05                 | 1.52                         | 2.73         | 19.44                 | 4.21            | 2.86         | 19.08                 | 13.48           |
| 4                     | 2.87                      | 19.84                 | 2.97         | 20.03                 | 1.48                         | 2.99         | 20.30                 | 4.41            | 2.81         | 20.10                 | 12.58           |
| 5                     | 2.89                      | 20.43                 | 3.09         | 21.10                 | 1.47                         | 3.06         | 21.02                 | 4.37            | 3.04         | 20.84                 | 13.15           |
| 6                     | 2.95                      | 21.25                 | 3.05         | 21.44                 | 1.42                         | 3.10         | 21.70                 | 4.28            | 2.99         | 21.49                 | 12.54           |
| 7                     | 3.02                      | 22.14                 | 3.27         | 21.76                 | 1.50                         | 3.05         | 22.04                 | 4.16            | 3.22         | 22.00                 | 13.18           |
| 8                     | 3.21                      | 22.35                 | 3.34         | 22.66                 | 1.48                         | 3.32         | 22.61                 | 4.40            | 3.18         | 22.64                 | 12.63           |
| 9                     | 3.10                      | 22.80                 | 3.31         | 23.10                 | 1.43                         | 3.32         | 22.99                 | 4.33            | 3.37         | 23.32                 | 13.01           |
| 10                    | 3.23                      | 23.36                 | 3.30         | 23.52                 | 1.40                         | 3.24         | 23.74                 | 4.09            | 3.17         | 23.65                 | 12.05           |
| 11                    | 3.16                      | 23.83                 | 3.27         | 23.71                 | 1.38                         | 3.36         | 24.29                 | 4.15            | 3.21         | 24.35                 | 11.86           |
| 12                    | 3.33                      | 24.37                 | 3.51         | 24.23                 | 1.45                         | 3.17         | 24.46                 | 3.88            | 3.33         | 24.77                 | 12.12           |
| 16                    | 3.29                      | 25.93                 | 3.34         | 25.53                 | 1.31                         | 3.28         | 26.07                 | 3.77            | 3.27         | 26.18                 | 11.24           |
| 20                    | 3.34                      | 26.80                 | 3.35         | 26.92                 | 1.24                         | 3.28         | 27.17                 | 3.62            | 3.26         | 27.65                 | 10.62           |
| 24                    | 3.19                      | 27.95                 | 3.35         | 28.22                 | 1.19                         | 3.30         | 28.25                 | 3.50            | 3.15         | 28.50                 | 9.94            |
| 28                    | 3.31                      | 29.41                 | 3.50         | 29.37                 | 1.19                         | 3.24         | 29.68                 | 3.28            | 3.29         | 29.93                 | 9.88            |
| 32                    | 3.19                      | 31.00                 | 3.52         | 31.29                 | 1.12                         | 3.43         | 30.94                 | 3.33            | 3.31         | 31.52                 | 9.45            |
| 36                    | 3.23                      | 32.38                 | 3.31         | 33.36                 | 0.99                         | 3.22         | 32.31                 | 2.99            | 3.31         | 32.98                 | 9.03            |
| 40                    | 3.13                      | 33.58                 | 3.31         | 34.85                 | 0.95                         | 3.28         | 34.18                 | 2.88            | 3.14         | 35.16                 | 8.04            |
| 44                    | 3.24                      | 35.28                 | 3.32         | 35.34                 | 0.94                         | 3.05         | 35.15                 | 2.60            | 3.26         | 37.57                 | 7.82            |
| 48                    | 3.15                      | 37.54                 | 3.51         | 36.80                 | 0.95                         | 3.04         | 36.53                 | 2.50            | 3.11         | 39.59                 | 7.07            |
| 52                    | 3.03                      | 38.44                 | 3.24         | 38.32                 | 0.85                         | 3.17         | 38.79                 | 2.45            | 3.08         | 41.85                 | 6.63            |
| 56                    | 3.08                      | 39.32                 | 3.22         | 39.42                 | 0.82                         | 3.15         | 40.98                 | 2.30            | 3.04         | 43.77                 | 6.24            |
| 60                    | 3.16                      | 40.56                 | 3.17         | 40.81                 | 0.78                         | 3.15         | 43.02                 | 2.20            | 3.02         | 45.42                 | 5.98            |
| 64                    | 2.86                      | 41.81                 | 3.19         | 42.29                 | 0.75                         | 2.96         | 44.75                 | 1.98            | 3.02         | 46.68                 | 5.83            |
| 68                    | 2.88                      | 43.64                 | 3.05         | 43.98                 | 0.69                         | 2.83         | 46.84                 | 1.81            | 2.85         | 48.34                 | 5.31            |
| 72                    | 2.80                      | 44.84                 | 3.11         | 45.88                 | 0.68                         | 3.12         | 48.41                 | 1.93            | 2.89         | 48.93                 | 5.32            |
| 76                    | 2.85                      | 45.52                 | 3.03         | 47.47                 | 0.64                         | 2.90         | 48.60                 | 1.79            | 2.91         | 48.97                 | 5.34            |
| 80                    | 2.88                      | 46.47                 | 3.07         | 48.35                 | 0.64                         | 2.98         | 49.00                 | 1.82            | 3.06         | 48.38                 | 5.69            |
| 84                    | 2.82                      | 46.32                 | 3.16         | 49.45                 | 0.64                         | 3.10         | 48.94                 | 1.90            | 2.99         | 47.68                 | 5.65            |
| 88                    | 2.86                      | 47.33                 | 3.15         | 50.07                 | 0.63                         | 3.39         | 49.02                 | 2.08            | 3.23         | 47.03                 | 6.19            |
| 92                    | 2.90                      | 48.20                 | 2.96         | 49.24                 | 0.60                         | 3.38         | 48.10                 | 2.11            | 3.68         | 43.99                 | 7.53            |
| 96                    | 2.97                      | 48.21                 | 2.97         | 49.16                 | 0.60                         | 3.60         | 48.15                 | 2.25            | 3.84         | 41.30                 | 8.38            |
| 100                   | 3.02                      | 47.13                 | 3.15         | 47.31                 | 0.67                         | 3.42         | 46.69                 | 2.20            | 3.62         | 38.20                 | 8.53            |
| 104                   | 3.18                      | 47.33                 | 2.95         | 45.88                 | 0.64                         | 3.60         | 44.97                 | 2.40            | 3.81         | 42.52                 | 8.07            |
| <b>Mean for weeks</b> |                           |                       |              |                       |                              |              |                       |                 |              |                       |                 |
| 1-13                  | 3.00                      | 21.24                 | 3.15         | 21.35                 | 1.47                         | 3.08         | 21.54                 | 4.29            | 3.07         | 21.54                 | 12.83           |
| 14-52                 | 3.21                      | 31.83                 | 3.38         | 32.00                 | 1.05                         | 3.23         | 31.91                 | 3.04            | 3.22         | 33.09                 | 8.75            |
| 53-104                | 2.94                      | 45.13                 | 3.09         | 46.10                 | 0.67                         | 3.20         | 46.73                 | 2.05            | 3.23         | 45.48                 | 6.39            |

<sup>a</sup> Grams of water consumed per animal per day

<sup>b</sup> Milligrams of urethane consumed per kilogram body weight per day



**APPENDIX K  
FEED CONSUMPTION  
IN THE 2-YEAR DRINKING WATER STUDY  
OF URETHANE, ETHANOL,  
AND URETHANE/ETHANOL**

|                 |  |            |
|-----------------|--|------------|
| <b>TABLE K1</b> | <b>Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol .....</b>     | <b>K-2</b> |
| <b>TABLE K2</b> | <b>Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol .....</b>   | <b>K-3</b> |
| <b>TABLE K3</b> | <b>Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol .....</b>     | <b>K-4</b> |
| <b>TABLE K4</b> | <b>Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol .....</b>   | <b>K-5</b> |
| <b>TABLE K5</b> | <b>Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol .....</b> | <b>K-6</b> |
| <b>TABLE K6</b> | <b>Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol .....</b>   | <b>K-7</b> |

**TABLE K1**  
**Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 4.18  | 4.15   | 3.91   | 4.06   |
| 3                     | 4.25  | 4.35   | 4.07   | 4.18   |
| 4                     | 4.58  | 4.67   | 4.35   | 4.41   |
| 5                     | 4.73  | 5.20   | 4.64   | 4.90   |
| 6                     | 4.94  | 5.11   | 5.05   | 5.08   |
| 7                     | 5.17  | 5.59   | 5.06   | 4.96   |
| 8                     | 5.30  | 5.49   | 5.33   | 5.31   |
| 9                     | 5.44  | 5.78   | 5.14   | 5.37   |
| 10                    | 5.58  | 5.92   | 5.62   | 5.45   |
| 11                    | 5.71  | 6.03   | 5.59   | 5.47   |
| 12                    | 5.84  | 5.50   | 6.00   | 5.53   |
| 16                    | 5.81  | 5.89   | 5.79   | 5.59   |
| 20                    | 5.91  | 5.67   | 5.80   | 5.80   |
| 24                    | 5.93  | 5.75   | 5.81   | 5.66   |
| 28                    | 5.71  | 5.98   | 5.82   | 5.80   |
| 32                    | 5.73  | 5.61   | 5.54   | 5.63   |
| 36                    | 5.82  | 5.81   | 5.56   | 5.52   |
| 40                    | 5.82  | 5.63   | 5.53   | 5.48   |
| 44                    | 5.92  | 5.75   | 5.66   | 5.91   |
| 48                    | 5.88  | 5.89   | 5.71   | 5.78   |
| 52                    | 6.14  | 5.93   | 5.62   | 5.64   |
| 56                    | 5.92  | 5.86   | 5.60   | 5.76   |
| 60                    | 5.66  | 6.07   | 5.65   | 5.76   |
| 64                    | 5.63  | 5.96   | 5.52   | 5.53   |
| 68                    | 5.94  | 5.87   | 5.79   | 5.39   |
| 72                    | 6.38  | 6.12   | 6.00   | 5.55   |
| 76                    | 5.84  | 6.64   | 5.97   | 5.58   |
| 80                    | 6.71  | 6.43   | 5.49   | 5.78   |
| 84                    | 6.59  | 6.14   | 5.67   | 5.61   |
| 88                    | 6.51  | 6.16   | 5.83   | 5.88   |
| 92                    | 6.30  | 6.01   | 5.37   | 6.11   |
| 96                    | 6.61  | 5.97   | 5.40   | 6.23   |
| 100                   | 6.51  | 5.75   | 5.77   | 6.57   |
| 104                   | 5.67  | 6.10   | 5.44   | 7.06   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 5.06  | 5.25   | 4.98   | 4.97   |
| 14-52                 | 5.87  | 5.79   | 5.68   | 5.68   |
| 53-104                | 6.17  | 6.08   | 5.65   | 5.91   |

<sup>a</sup> Grams of feed consumed per animal per day

**TABLE K2**  
**Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 4.00  | 3.88   | 3.97   | 3.88   |
| 3                     | 4.21  | 4.06   | 4.15   | 4.13   |
| 4                     | 4.57  | 4.46   | 4.47   | 4.43   |
| 5                     | 4.70  | 4.95   | 4.53   | 4.57   |
| 6                     | 5.33  | 5.07   | 4.84   | 4.70   |
| 7                     | 4.99  | 4.96   | 5.15   | 5.28   |
| 8                     | 5.67  | 5.55   | 5.24   | 5.75   |
| 9                     | 5.58  | 5.04   | 5.22   | 4.89   |
| 10                    | 5.76  | 5.43   | 5.22   | 5.47   |
| 11                    | 5.63  | 5.21   | 5.22   | 5.21   |
| 12                    | 5.55  | 5.45   | 5.16   | 5.38   |
| 16                    | 5.63  | 5.65   | 5.29   | 5.52   |
| 20                    | 5.62  | 5.36   | 5.48   | 5.58   |
| 24                    | 5.44  | 5.74   | 5.35   | 5.52   |
| 28                    | 5.82  | 5.33   | 5.21   | 5.29   |
| 32                    | 5.67  | 5.41   | 5.40   | 5.30   |
| 36                    | 5.43  | 5.32   | 5.54   | 5.41   |
| 40                    | 5.84  | 5.63   | 5.55   | 5.14   |
| 44                    | 5.96  | 5.45   | 5.44   | 5.38   |
| 48                    | 5.76  | 5.55   | 5.48   | 5.45   |
| 52                    | 5.47  | 5.64   | 5.61   | 5.39   |
| 56                    | 5.52  | 5.42   | 5.49   | 5.35   |
| 60                    | 5.59  | 5.34   | 5.41   | 5.35   |
| 64                    | 5.71  | 5.56   | 5.45   | 5.44   |
| 68                    | 5.72  | 5.63   | 5.39   | 5.78   |
| 72                    | 5.84  | 5.38   | 6.06   | 5.24   |
| 76                    | 6.18  | 5.58   | 6.03   | 5.15   |
| 80                    | 5.38  | 5.39   | 5.48   | 4.89   |
| 84                    | 5.04  | 5.34   | 5.73   | 4.91   |
| 88                    | 5.15  | 5.21   | 5.50   | 4.92   |
| 92                    | 5.45  | 5.13   | 5.53   | 5.18   |
| 96                    | 5.17  | 5.20   | 5.58   | 5.29   |
| 100                   | 5.49  | 5.78   | 5.48   | 5.70   |
| 104                   | 5.12  | 5.57   | 5.78   | 5.65   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 5.09  | 4.91   | 4.83   | 4.88   |
| 14-52                 | 5.66  | 5.51   | 5.43   | 5.40   |
| 53-104                | 5.49  | 5.43   | 5.61   | 5.30   |

<sup>a</sup> Grams of feed consumed per animal per day

**TABLE K3**  
**Feed Consumption by Male Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 3.53  | 3.65   | 3.76   | 3.78   |
| 3                     | 3.85  | 3.80   | 4.01   | 4.21   |
| 4                     | 4.09  | 4.05   | 4.16   | 4.04   |
| 5                     | 4.43  | 4.68   | 4.61   | 4.42   |
| 6                     | 4.87  | 5.03   | 4.60   | 4.71   |
| 7                     | 5.14  | 4.96   | 4.84   | 4.89   |
| 8                     | 5.11  | 4.81   | 5.25   | 4.78   |
| 9                     | 5.12  | 4.79   | 4.82   | 4.99   |
| 10                    | 5.50  | 4.95   | 4.92   | 5.03   |
| 11                    | 5.54  | 5.08   | 5.16   | 5.24   |
| 12                    | 5.36  | 5.28   | 5.01   | 4.94   |
| 16                    | 5.44  | 5.14   | 5.04   | 5.53   |
| 20                    | 5.31  | 5.08   | 5.67   | 5.30   |
| 24                    | 5.64  | 5.10   | 5.27   | 5.51   |
| 28                    | 5.33  | 5.12   | 5.19   | 5.38   |
| 32                    | 5.09  | 5.16   | 5.16   | 5.33   |
| 36                    | 5.06  | 4.95   | 5.24   | 5.12   |
| 40                    | 5.16  | 5.13   | 5.24   | 5.43   |
| 44                    | 5.31  | 5.27   | 5.16   | 5.39   |
| 48                    | 5.27  | 5.18   | 5.15   | 5.61   |
| 52                    | 5.12  | 5.18   | 5.28   | 5.48   |
| 56                    | 5.18  | 5.07   | 5.58   | 5.45   |
| 60                    | 5.25  | 5.25   | 5.61   | 5.61   |
| 64                    | 5.29  | 4.85   | 5.22   | 5.58   |
| 68                    | 5.26  | 5.06   | 5.12   | 5.73   |
| 72                    | 5.71  | 5.25   | 5.47   | 5.73   |
| 76                    | 5.31  | 5.32   | 5.23   | 5.30   |
| 80                    | 5.67  | 5.29   | 5.66   | 5.64   |
| 84                    | 5.34  | 5.28   | 5.04   | 5.43   |
| 88                    | 5.32  | 4.77   | 4.96   | 5.67   |
| 92                    | 5.71  | 5.47   | 4.86   | 4.77   |
| 96                    | 5.33  | 5.18   | 4.93   | 5.10   |
| 100                   | 5.37  | 5.48   | 5.29   | 5.64   |
| 104                   | 5.38  | 5.40   | 5.33   | 5.67   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 4.78  | 4.64   | 4.65   | 4.64   |
| 14-52                 | 5.27  | 5.13   | 5.24   | 5.41   |
| 53-104                | 5.39  | 5.20   | 5.25   | 5.49   |

<sup>a</sup> Grams of feed consumed per animal per day

**TABLE K4**  
**Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 0% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 3.06  | 3.32   | 3.09   | 3.05   |
| 3                     | 3.33  | 3.48   | 3.43   | 3.21   |
| 4                     | 3.53  | 3.44   | 3.49   | 3.43   |
| 5                     | 3.76  | 3.61   | 3.74   | 3.53   |
| 6                     | 3.87  | 3.81   | 4.14   | 3.75   |
| 7                     | 4.08  | 3.96   | 4.12   | 3.85   |
| 8                     | 4.22  | 4.04   | 4.20   | 3.95   |
| 9                     | 4.22  | 4.03   | 4.18   | 4.09   |
| 10                    | 4.30  | 4.12   | 4.30   | 4.11   |
| 11                    | 4.39  | 4.26   | 4.20   | 4.07   |
| 12                    | 4.53  | 4.17   | 4.30   | 4.20   |
| 16                    | 4.50  | 4.36   | 4.56   | 4.21   |
| 20                    | 4.63  | 4.42   | 4.56   | 4.23   |
| 24                    | 4.49  | 4.25   | 4.26   | 4.35   |
| 28                    | 4.29  | 4.45   | 4.39   | 4.31   |
| 32                    | 4.49  | 4.41   | 4.31   | 4.32   |
| 36                    | 4.51  | 4.59   | 4.26   | 4.41   |
| 40                    | 4.73  | 4.74   | 4.50   | 4.69   |
| 44                    | 5.10  | 4.85   | 4.95   | 4.69   |
| 48                    | 5.23  | 4.77   | 4.93   | 4.97   |
| 52                    | 5.03  | 4.72   | 5.08   | 4.78   |
| 56                    | 5.17  | 4.75   | 5.12   | 4.62   |
| 60                    | 5.30  | 4.61   | 5.05   | 4.96   |
| 64                    | 5.36  | 4.76   | 5.11   | 5.39   |
| 68                    | 5.36  | 4.66   | 5.52   | 5.01   |
| 72                    | 5.54  | 5.17   | 5.56   | 4.81   |
| 76                    | 5.49  | 5.17   | 5.72   | 5.00   |
| 80                    | 5.43  | 5.16   | 5.41   | 5.27   |
| 84                    | 5.38  | 5.22   | 5.76   | 5.44   |
| 88                    | 5.43  | 5.37   | 5.56   | 4.95   |
| 92                    | 5.67  | 5.34   | 5.77   | 5.07   |
| 96                    | 5.55  | 5.34   | 5.63   | 5.01   |
| 100                   | 5.38  | 5.21   | 6.06   | 5.42   |
| 104                   | 5.81  | 5.49   | 5.79   | 7.78   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 3.93  | 3.84   | 3.93   | 3.75   |
| 14-52                 | 4.70  | 4.55   | 4.58   | 4.50   |
| 53-104                | 5.45  | 5.10   | 5.54   | 5.29   |

<sup>a</sup> Grams of feed consumed per animal per day

**TABLE K5**  
**Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 2.5% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 3.03  | 2.95   | 2.94   | 3.09   |
| 3                     | 3.10  | 3.19   | 3.03   | 3.11   |
| 4                     | 3.49  | 3.39   | 3.30   | 3.42   |
| 5                     | 3.54  | 3.52   | 3.42   | 3.60   |
| 6                     | 3.73  | 3.68   | 3.59   | 3.77   |
| 7                     | 3.86  | 3.77   | 3.66   | 3.82   |
| 8                     | 4.07  | 4.02   | 3.74   | 3.88   |
| 9                     | 4.07  | 3.91   | 3.96   | 4.16   |
| 10                    | 4.00  | 3.94   | 3.92   | 4.07   |
| 11                    | 4.04  | 4.02   | 4.07   | 4.18   |
| 12                    | 4.28  | 3.98   | 4.17   | 4.09   |
| 16                    | 4.27  | 4.26   | 4.08   | 4.18   |
| 20                    | 4.47  | 4.32   | 4.15   | 4.00   |
| 24                    | 4.31  | 4.28   | 4.31   | 4.37   |
| 28                    | 4.37  | 4.30   | 4.26   | 4.27   |
| 32                    | 4.49  | 4.16   | 4.35   | 4.28   |
| 36                    | 4.46  | 4.28   | 4.32   | 4.23   |
| 40                    | 4.51  | 4.27   | 4.40   | 4.52   |
| 44                    | 4.65  | 4.53   | 4.40   | 4.53   |
| 48                    | 4.84  | 4.52   | 4.62   | 4.62   |
| 52                    | 4.78  | 4.56   | 4.57   | 4.74   |
| 56                    | 4.88  | 4.60   | 4.54   | 4.87   |
| 60                    | 4.79  | 4.61   | 4.69   | 4.77   |
| 64                    | 4.98  | 4.90   | 4.94   | 4.74   |
| 68                    | 5.03  | 5.09   | 4.92   | 5.49   |
| 72                    | 5.39  | 4.93   | 5.20   | 4.88   |
| 76                    | 5.16  | 4.81   | 5.51   | 5.08   |
| 80                    | 5.14  | 4.99   | 5.09   | 5.10   |
| 84                    | 5.00  | 5.04   | 5.21   | 4.80   |
| 88                    | 5.22  | 4.64   | 5.07   | 5.20   |
| 92                    | 5.31  | 5.32   | 5.32   | 5.17   |
| 96                    | 5.28  | 4.85   | 5.19   | 4.82   |
| 100                   | 5.38  | 5.34   | 5.38   | 5.34   |
| 104                   | 5.18  | 5.22   | 5.85   | 4.53   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 3.75  | 3.67   | 3.62   | 3.75   |
| 14-52                 | 4.52  | 4.35   | 4.34   | 4.37   |
| 53-104                | 5.13  | 4.95   | 5.15   | 4.98   |

<sup>a</sup> Grams of feed consumed per animal per day

**TABLE K6**  
**Feed Consumption by Female Mice in the 2-Year Drinking Water Study of Urethane and 5% Ethanol<sup>a</sup>**

| Week                  | 0 ppm | 10 ppm | 30 ppm | 90 ppm |
|-----------------------|-------|--------|--------|--------|
| 2                     | 2.81  | 2.76   | 2.80   | 2.90   |
| 3                     | 2.94  | 2.95   | 3.02   | 3.08   |
| 4                     | 3.21  | 3.23   | 3.41   | 3.20   |
| 5                     | 3.28  | 3.44   | 3.40   | 3.37   |
| 6                     | 3.44  | 3.51   | 3.57   | 3.47   |
| 7                     | 3.66  | 3.61   | 3.47   | 3.51   |
| 8                     | 3.64  | 3.75   | 3.66   | 3.70   |
| 9                     | 3.69  | 3.79   | 3.82   | 3.94   |
| 10                    | 3.82  | 3.83   | 3.90   | 3.94   |
| 11                    | 3.86  | 3.88   | 4.09   | 4.09   |
| 12                    | 4.00  | 3.85   | 4.21   | 3.96   |
| 16                    | 4.07  | 4.06   | 4.16   | 4.05   |
| 20                    | 4.01  | 4.06   | 4.32   | 4.56   |
| 24                    | 4.16  | 4.15   | 4.41   | 4.13   |
| 28                    | 4.00  | 4.07   | 3.99   | 4.07   |
| 32                    | 4.00  | 4.11   | 4.13   | 4.11   |
| 36                    | 4.03  | 4.39   | 4.10   | 4.27   |
| 40                    | 4.14  | 4.29   | 4.33   | 4.31   |
| 44                    | 4.24  | 4.29   | 4.60   | 4.80   |
| 48                    | 4.57  | 4.50   | 4.89   | 4.64   |
| 52                    | 4.51  | 4.82   | 4.66   | 4.81   |
| 56                    | 3.99  | 4.47   | 4.58   | 4.48   |
| 60                    | 4.51  | 4.59   | 4.68   | 4.74   |
| 64                    | 4.68  | 4.65   | 4.60   | 4.61   |
| 68                    | 4.90  | 4.74   | 5.03   | 4.80   |
| 72                    | 4.71  | 4.84   | 5.14   | 5.39   |
| 76                    | 4.70  | 4.74   | 5.08   | 5.25   |
| 80                    | 4.34  | 5.02   | 5.18   | 4.99   |
| 84                    | 4.54  | 5.21   | 4.87   | 4.95   |
| 88                    | 4.70  | 5.18   | 5.26   | 4.80   |
| 92                    | 4.77  | 4.85   | 5.04   | 4.31   |
| 96                    | 4.77  | 4.96   | 5.39   | 5.03   |
| 100                   | 4.89  | 5.39   | 5.01   | 5.28   |
| 104                   | 5.07  | 4.97   | 5.37   | 5.19   |
| <b>Mean for weeks</b> |       |        |        |        |
| 1-13                  | 3.49  | 3.51   | 3.58   | 3.56   |
| 14-52                 | 4.17  | 4.27   | 4.36   | 4.38   |
| 53-104                | 4.66  | 4.89   | 5.02   | 4.91   |

<sup>a</sup> Grams of feed consumed per animal per day



**APPENDIX L**  
**INGREDIENTS, NUTRIENT COMPOSITION,**  
**AND CONTAMINANT LEVELS**  
**IN NIH-31 RAT AND MOUSE RATION**

|                 |   |            |
|-----------------|---|------------|
| <b>TABLE L1</b> | <b>Ingredients of NIH-31 Rat and Mouse Ration .....</b>           | <b>L-2</b> |
| <b>TABLE L2</b> | <b>Vitamins and Minerals in NIH-31 Rat and Mouse Ration .....</b> | <b>L-2</b> |
| <b>TABLE L3</b> | <b>Nutrient Composition of NIH-31 Rat and Mouse Ration .....</b>  | <b>L-3</b> |
| <b>TABLE L4</b> | <b>Contaminant Levels in NIH-31 Rat and Mouse Ration .....</b>    | <b>L-3</b> |

**TABLE L1**  
**Ingredients of NIH-31 Rat and Mouse Ration**

| Ingredients <sup>a</sup>         | Percent by Weight |
|----------------------------------|-------------------|
| Ground #2 yellow shelled corn    | 21.0              |
| Ground whole hard wheat          | 35.5              |
| Ground whole oats                | 10.0              |
| Soybean meal (49% protein)       | 5.0               |
| Fish meal (60% protein)          | 9.0               |
| Wheat middlings                  | 10.0              |
| Alfalfa meal (17% protein)       | 2.0               |
| Corn gluten meal (60% protein)   | 2.0               |
| Soy oil                          | 1.5               |
| Dried brewer's yeast             | 1.0               |
| Dicalcium phosphate (food grade) | 1.5               |
| Ground limestone                 | 0.5               |
| Salt                             | 0.5               |
| Premixes (vitamin and mineral)   | 0.5               |

<sup>a</sup> Ingredients were ground to pass through a U.S. Standard Screen No. 16 before being mixed.

**TABLE L2**  
**Vitamins and Minerals in NIH-31 Rat and Mouse Ration<sup>a</sup>**

|   | Amount        | Source                         |
|---|---------------|--------------------------------|
| <b>Vitamins</b>                         |               |                                |
| A                                       | 22,000,000 IU | Vitamin A palmitate or acetate |
| D <sub>3</sub>                          | 3,800,000 IU  | D-activated animal sterol      |
| K <sub>3</sub>                          | 20 g          | Menadione activity             |
| <i>d</i> - $\alpha$ -Tocopheryl acetate | 15 g          |                                |
| Choline                                 | 700 g         | Choline chloride               |
| Folic acid                              | 1 g           |                                |
| Niacin                                  | 20 g          |                                |
| <i>d</i> -Pantothenic acid              | 25 g          | <i>d</i> -Calcium pantothenate |
| Riboflavin                              | 5 g           |                                |
| Thiamine                                | 65 g          | Thiamine mononitrate           |
| B <sub>12</sub>                         | 14 g          |                                |
| Pyridoxine                              | 2 g           | Pyridoxine hydrochloride       |
| Biotin                                  | 0.120 g       | <i>d</i> -Biotin               |
| <b>Minerals</b>                         |               |                                |
| Iron                                    | 60 g          | Iron sulfate                   |
| Magnesium                               | 400 g         | Magnesium oxide                |
| Manganese                               | 100 g         | Manganous oxide                |
| Zinc                                    | 10 g          | Zinc oxide                     |
| Copper                                  | 4 g           | Copper sulfate                 |
| Iodine                                  | 1.5 g         | Calcium iodate                 |
| Cobalt                                  | 0.4 g         | Cobalt carbonate               |

<sup>a</sup> Per ton (2,000 lb) of finished product

**TABLE L3**  
**Nutrient Composition of NIH-31 Rat and Mouse Ration<sup>a</sup>**

| Nutrient                      | Mean ± Standard<br>Deviation <sup>b</sup> |
|-------------------------------|---|
| Crude protein (% by weight)   | 19.2 ± 1.0                                |
| Crude fat (% by weight)       | 5.55 ± 0.92                               |
| <b>Vitamins</b>               |   |
| Vitamin A (µg/g)              | 11.7 ± 1.2                                |
| Vitamin B <sub>1</sub> (mg/g) | 0.094 ± 0.019                             |
| Vitamin E (ppm)               | 60.4 ± 5.6                                |
| <b>Minerals</b>               |   |
| Selenium (ppm)                | 0.36 ± 0.11                               |

<sup>a</sup> Prior to autoclaving

<sup>b</sup> Average of 37 diet production lots

**TABLE L4**  
**Contaminant Levels in NIH-31 Rat and Mouse Ration<sup>a</sup>**

| Contaminants                   | Mean ± Standard<br>Deviation <sup>b</sup> |
|--------------------------------|---|
| Arsenic (ppb)                  | 107 ± 48                                  |
| Cadmium (ppb)                  | 62 ± 37                                   |
| Lead (ppm)                     | 0.39 ± 0.15                               |
| Aflatoxin B <sub>1</sub> (ppb) | <0.25                                     |
| Aflatoxin B <sub>2</sub> (ppb) | <0.25                                     |
| Aflatoxin G <sub>1</sub> (ppb) | <0.25                                     |
| Aflatoxin G <sub>2</sub> (ppb) | <0.12                                     |
| Fumonisin B <sub>1</sub> (ppb) | 31.6 ± 24.3                               |
| Total fumonisin (ppb)          | 50.4 ± 22.7                               |
| Volatiles (%)                  | 6.68 ± 0.96                               |
| <b>Pesticides (ppb)</b>        |   |
| Heptachlor                     | <10                                       |
| DDT, total <sup>c</sup>        | <5  |
| Dieldrin                       | <5  |
| PCB                            | 26 ± 34                                   |
| Malathion                      | 86 ± 53                                   |
| Lindane                        | <1  |

<sup>a</sup> Prior to autoclaving

<sup>b</sup> Average of 8, 9, 10, 25, or 37 diet production lots; for values less than the limit of detection, the detection limit is given as the mean.

<sup>c</sup> DDE+DDT+DDD



# APPENDIX M

## SENTINEL ANIMAL PROGRAM

**METHODS** ..... **M-2**  
**RESULTS** ..... **M-2**

## SENTINEL ANIMAL PROGRAM

### METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Serum samples were collected from randomly selected mice during the 2-year study. Blood from each animal was collected and allowed to clot, and the serum was separated. The samples were processed appropriately and sent to the Surveillance/Diagnostic Program, Division of Microbiology, at the NCTR for determination of antibody titers. In addition to the serology testing, all sentinel animals were examined for ectoparasites, endoparasites, and bacterial pathogens. The laboratory serology methods and viral agents for which testing was performed are tabulated below; the times at which blood was collected during the study are also listed.

#### Method and Test

#### Time of Analysis

##### ELISA

|  |   |
|--|---|
| Ectromelia virus                         | 6, 12, and 18 months, study termination |
| GDVII (mouse encephalomyelitis virus)    | 6, 12, and 18 months, study termination |
| LCM (lymphocytic choriomeningitis virus) | 6, 12, and 18 months, study termination |
| MVM (minute virus of mice)               | 6, 12, and 18 months, study termination |
| MHV (mouse hepatitis virus)              | 6, 12, and 18 months, study termination |
| <i>Mycoplasma arthritidis</i>            | 6, 12, and 18 months, study termination |
| <i>Mycoplasma pulmonis</i>               | 6, 12, and 18 months, study termination |
| PVM (pneumonia virus of mice)            | 6, 12, and 18 months, study termination |
| Polyoma virus                            | 6, 12, and 18 months, study termination |
| Reovirus 3                               | 6, 12, and 18 months, study termination |
| Sendai                                   | 6, 12, and 18 months, study termination |

### RESULTS

Six of eight mice at 6 months and three of eight mice at 18 months had positive titers for MHV. Mice used in this study were loaded from a breeding colony that had previously tested positive for MHV antibodies. Colon samples from the breeder colony were sent to Yale University School of Medicine, Section of Comparative Medicine, for molecular characterization of the virus. The conclusion was that the virus was likely a coronavirus intermediate to known MHV and rat coronavirus strains and was considered only mildly or nonpathogenic to the mice.

All other test results were negative.